致病菌<|>RELATION_NOE 中<|>RELATION_NOE 金黄色<|>RELATION_NOE 葡萄<|>RELATION_NOE 球菌<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 57.14%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 光滑念珠菌<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 28.5<|>RELATION_NOE 7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 微球菌<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 14.2<|>RELATION_NOE 9%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
细胞<|>RELATION_NOE 分为<|>RELATION_NOE 未<|>RELATION_NOE 处理<|>RELATION_NOE (<|>RELATION_NOE N-DC<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 加<|>RELATION_NOE 抗原<|>RELATION_NOE 未<|>RELATION_NOE 感染<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE A-DC<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 加<|>RELATION_NOE 抗原<|>RELATION_NOE 感染<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE G-A-DC<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
自体<|>RELATION_NOE 和<|>RELATION_NOE 半<|>RELATION_NOE 相<|>RELATION_NOE 合异<|>RELATION_NOE 体细胞<|>RELATION_NOE 因子<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE
观察<|>RELATION_S 自体<|>RELATION_NOE 和<|>RELATION_NOE 异体<|>RELATION_NOE CIK<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE (<|>RELATION_NOE FCM<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_NOE 比较<|>RELATION_NOE 各<|>RELATION_NOE 治疗组<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 体内<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 3组<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE 观察<|>RELATION_NOE 自体<|>RELATION_NOE 和<|>RELATION_NOE 异体<|>RELATION_NOE CIK<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE (<|>RELATION_NOE FCM<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_B 比较<|>RELATION_E 各<|>RELATION_NOE 治疗组<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 体内<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 3组<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
临床<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 自体<|>RELATION_NOE 及<|>RELATION_NOE 异体<|>RELATION_NOE CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗组<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 和<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 35.7%<|>RELATION_NOE 、<|>RELATION_NOE 28.6%<|>RELATION_NOE 和<|>RELATION_NOE 64.3%<|>RELATION_NOE 、<|>RELATION_NOE 7t<|>RELATION_NOE .<|>RELATION_NOE
自体<|>RELATION_NOE 或<|>RELATION_NOE 半相合<|>RELATION_NOE 异体<|>RELATION_NOE CIK<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 治疗<|>RELATION_NOE 安全性<|>RELATION_NOE 好<|>RELATION_NOE 、<|>RELATION_NOE 毒副作用<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_NOE 延缓<|>RELATION_S 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 推广<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 模式<|>RELATION_NOE 。<|>RELATION_NOE
影响<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 影响<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S 与<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE
检测<|>RELATION_S 以<|>RELATION_NOE 铂类<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 联合化疗<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 核苷酸<|>RELATION_NOE 切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE ERCC1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 敏感<|>RELATION_NOE 蛋白<|>RELATION_NOE 1型<|>RELATION_NOE (<|>RELATION_NOE BRCA1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE 微管蛋白<|>RELATION_NOE (<|>RELATION_NOE β<|>RELATION_NOE -tubulin<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE K-ras<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 136<|>RELATION_NOE 例<|>RELATION_NOE 以<|>RELATION_NOE 铂类<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 联合化疗<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE BRCA1<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE -tubulin<|>RELATION_NOE 和<|>RELATION_NOE K-ras<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 表达<|>RELATION_NOE 状况<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 预后<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 放化<|>RELATION_NOE 疗<|>RELATION_NOE 不同<|>RELATION_NOE 联合<|>RELATION_NOE 模式<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_B 反应<|>RELATION_I 分析<|>RELATION_E
探讨<|>RELATION_NOE 放化<|>RELATION_NOE 疗<|>RELATION_NOE 不同<|>RELATION_NOE 联合<|>RELATION_NOE 模式<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 影响<|>RELATION_NOE 其<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 各种<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 及<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE ,<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗组<|>RELATION_NOE 及<|>RELATION_NOE 序贯<|>RELATION_NOE 放化<|>RELATION_NOE 疗组<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 念珠菌<|>RELATION_NOE 临床<|>RELATION_NOE 分离<|>RELATION_NOE 株<|>RELATION_NOE 的<|>RELATION_NOE 药物<|>RELATION_B 敏感性<|>RELATION_E 研究<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE 氟康唑<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 总<|>RELATION_NOE 符合率<|>RELATION_NOE 为<|>RELATION_NOE 93.0%<|>RELATION_NOE (<|>RELATION_NOE 146<|>RELATION_NOE /<|>RELATION_NOE 157<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 2005<|>RELATION_NOE —<|>RELATION_NOE 2009年<|>RELATION_NOE 氟胞嘧啶<|>RELATION_NOE 、<|>RELATION_NOE 两性<|>RELATION_NOE 霉素<|>RELATION_NOE B<|>RELATION_NOE 、<|>RELATION_NOE 氟康唑<|>RELATION_NOE 、<|>RELATION_NOE 伊曲康唑<|>RELATION_NOE 、<|>RELATION_NOE 伏立康唑<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE 分离<|>RELATION_NOE 念珠菌<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 敏感率<|>RELATION_NOE 分别<|>RELATION_NOE 由<|>RELATION_NOE 97.9%<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 0.0%<|>RELATION_NOE 、<|>RELATION_NOE 72.9%<|>RELATION_NOE 、<|>RELATION_NOE 68.8%<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 0.0%<|>RELATION_NOE 下降<|>RELATION_S 至<|>RELATION_NOE 82.9%<|>RELATION_NOE 、<|>RELATION_NOE 84.4%<|>RELATION_NOE 、<|>RELATION_NOE 51.8%<|>RELATION_NOE 、<|>RELATION_NOE 50.3%<|>RELATION_NOE 、<|>RELATION_NOE 91.4%<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE 氟康唑<|>RELATION_NOE 检测<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 符合率<|>RELATION_NOE ,<|>RELATION_NOE 2005<|>RELATION_NOE —<|>RELATION_NOE 2009年<|>RELATION_NOE 常<|>RELATION_NOE 用<|>RELATION_NOE 抗真菌<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE 念珠菌<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 敏感率<|>RELATION_NOE 变化<|>RELATION_NOE 呈<|>RELATION_NOE 下降<|>RELATION_S 趋势<|>RELATION_NOE 。<|>RELATION_NOE
阻断<|>RELATION_S Sp1<|>RELATION_NOE 蛋白<|>RELATION_NOE 对<|>RELATION_NOE Ki-67<|>RELATION_NOE 基因<|>RELATION_NOE 转录<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
观察<|>RELATION_NOE 阻断<|>RELATION_NOE 转录因子<|>RELATION_NOE Sp1<|>RELATION_NOE 蛋白<|>RELATION_NOE 及其<|>RELATION_NOE 和<|>RELATION_NOE 顺式<|>RELATION_NOE 作用<|>RELATION_NOE 元件<|>RELATION_NOE 的<|>RELATION_NOE 结合<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE Ki-67<|>RELATION_NOE 基因<|>RELATION_NOE 转录<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_S 作用<|>RELATION_NOE 。<|>RELATION_NOE
Sp1<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE Sp1-siRNA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Sp1<|>RELATION_NOE 蛋白<|>RELATION_NOE 竞争剂<|>RELATION_NOE 光神<|>RELATION_NOE 霉素<|>RELATION_NOE 分别<|>RELATION_NOE 作用<|>RELATION_B 于<|>RELATION_E 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE Hela<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 人<|>RELATION_NOE 肾癌<|>RELATION_NOE OS-RC-2<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE Sp1<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE Sp1-siRNA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Sp1<|>RELATION_NOE 蛋白<|>RELATION_NOE 竞争剂<|>RELATION_NOE 光神<|>RELATION_NOE 霉素<|>RELATION_NOE 分别<|>RELATION_NOE 作用<|>RELATION_B 于<|>RELATION_E 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE Hela<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 人<|>RELATION_NOE 肾癌<|>RELATION_NOE OS-RC-2<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
细胞免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检测<|>RELATION_S 3种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE Ki<|>RELATION_NOE .<|>RELATION_NOE
Sp1-siRNA<|>RELATION_NOE 或<|>RELATION_NOE 光神<|>RELATION_NOE 霉素<|>RELATION_NOE 与<|>RELATION_NOE Ki-67<|>RELATION_NOE 基因<|>RELATION_NOE 核心<|>RELATION_NOE 启动子<|>RELATION_NOE pGLBK235<|>RELATION_NOE 共<|>RELATION_NOE 转染<|>RELATION_NOE 上述<|>RELATION_NOE 3<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 双<|>RELATION_NOE 荧光素<|>RELATION_NOE 酶<|>RELATION_NOE 报告基因<|>RELATION_NOE 系统<|>RELATION_NOE 检测<|>RELATION_S 启动子<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
光神<|>RELATION_NOE 霉素<|>RELATION_NOE 共<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE pGLBK235<|>RELATION_NOE 启动子<|>RELATION_NOE 活性<|>RELATION_NOE 随着<|>RELATION_NOE 药物<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 升高<|>RELATION_NOE 而<|>RELATION_NOE 降低<|>RELATION_S ,<|>RELATION_NOE 其中<|>RELATION_NOE 药物<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE 500nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 时<|>RELATION_NOE 其<|>RELATION_NOE 活性<|>RELATION_NOE 最低<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE Hela<|>RELATION_NOE 、<|>RELATION_NOE OS-RC<|>RELATION_NOE 一<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 分别<|>RELATION_NOE 降<|>RELATION_NOE 至<|>RELATION_NOE 单独<|>RELATION_NOE 转染<|>RELATION_NOE pGLBK235<|>RELATION_NOE 的<|>RELATION_NOE 34.7%<|>RELATION_NOE 、<|>RELATION_NOE 44.2%<|>RELATION_NOE 、<|>RELATION_NOE 29.8%<|>RELATION_NOE 。<|>RELATION_NOE
RNA<|>RELATION_NOE 干扰<|>RELATION_B 抑制<|>RELATION_E CD44<|>RELATION_NOE 和<|>RELATION_NOE CD133<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 抑制<|>RELATION_NOE CD44<|>RELATION_NOE 和<|>RELATION_NOE CD133<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
筛选<|>RELATION_NOE 得到<|>RELATION_NOE 沉默<|>RELATION_NOE 效果<|>RELATION_NOE 最佳<|>RELATION_NOE 的<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 片段<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 其<|>RELATION_NOE 转染<|>RELATION_S 各组<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE MTS<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 干扰<|>RELATION_NOE 前后<|>RELATION_NOE 筛选<|>RELATION_NOE 得到<|>RELATION_NOE 沉默<|>RELATION_NOE 效果<|>RELATION_NOE 最佳<|>RELATION_NOE 的<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 片段<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 其<|>RELATION_NOE 转染<|>RELATION_NOE 各组<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE MTS<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_B 并<|>RELATION_I 比较<|>RELATION_E 干扰<|>RELATION_NOE 前后<|>RELATION_NOE 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 对<|>RELATION_NOE 移植性<|>RELATION_NOE lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
用<|>RELATION_NOE 清洁级<|>RELATION_NOE 雄性<|>RELATION_NOE C57BL<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 小鼠<|>RELATION_NOE 50<|>RELATION_NOE 只<|>RELATION_NOE 制作<|>RELATION_NOE lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 体重<|>RELATION_NOE 将<|>RELATION_NOE 小鼠<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_S 模型<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆组<|>RELATION_NOE 、<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 联合<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE (<|>RELATION_NOE 联合<|>RELATION_NOE 用药1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 中<|>RELATION_NOE 剂量<|>RELATION_NOE 联合<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE (<|>RELATION_NOE 联合<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 5组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 10<|>RELATION_NOE 只<|>RELATION_NOE 。<|>RELATION_NOE
给<|>RELATION_NOE 药<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 取瘤<|>RELATION_NOE 组织<|>RELATION_NOE 石蜡包埋<|>RELATION_B 、<|>RELATION_I 切片<|>RELATION_I ,<|>RELATION_I HE<|>RELATION_I 染色<|>RELATION_E ,<|>RELATION_NOE 光镜<|>RELATION_NOE 下<|>RELATION_NOE 观察<|>RELATION_NOE 组织<|>RELATION_NOE 形态<|>RELATION_NOE ;<|>RELATION_NOE
取<|>RELATION_NOE 上述<|>RELATION_NOE 5组<|>RELATION_NOE 切片<|>RELATION_NOE 以<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染色法<|>RELATION_NOE 观察<|>RELATION_S VEGF<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE VEGF<|>RELATION_NOE 表达<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 伍<|>RELATION_NOE 用<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 不<|>RELATION_NOE 会<|>RELATION_NOE 影响<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE VEGF<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 下调<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE VEGF<|>RELATION_NOE 表达<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 伍用<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 不<|>RELATION_B 会<|>RELATION_I 影响<|>RELATION_E 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE VEGF<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 下调<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 抗<|>RELATION_NOE 死亡<|>RELATION_NOE 受体<|>RELATION_NOE 5<|>RELATION_NOE 人<|>RELATION_NOE -<|>RELATION_NOE 鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 抗体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 活性<|>RELATION_NOE 研究<|>RELATION_S
鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 抗体<|>RELATION_NOE 的<|>RELATION_NOE 重链<|>RELATION_NOE 和<|>RELATION_NOE 轻链<|>RELATION_NOE ,<|>RELATION_NOE 形成<|>RELATION_NOE 一个<|>RELATION_NOE 开放<|>RELATION_NOE 阅读框<|>RELATION_NOE (<|>RELATION_NOE ORF<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 插入<|>RELATION_S 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE pWPXL<|>RELATION_NOE ,<|>RELATION_NOE 构建<|>RELATION_NOE 重组<|>RELATION_NOE 抗<|>RELATION_NOE DR5<|>RELATION_NOE 全长<|>RELATION_NOE 人<|>RELATION_NOE -<|>RELATION_NOE 鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 抗体<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE pWPXL-HF2AL<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE Western<|>RELATION_NOE 印迹<|>RELATION_NOE 测定<|>RELATION_S 该<|>RELATION_NOE 嵌合<|>RELATION_NOE 抗体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE
鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 抗体<|>RELATION_NOE 可<|>RELATION_NOE 在<|>RELATION_NOE F<|>RELATION_NOE /<|>RELATION_NOE 2A<|>RELATION_NOE 处<|>RELATION_NOE 自我<|>RELATION_NOE 剪切<|>RELATION_NOE ,<|>RELATION_NOE 人<|>RELATION_NOE -<|>RELATION_NOE 鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 抗体<|>RELATION_NOE 的<|>RELATION_NOE 轻<|>RELATION_NOE 、<|>RELATION_NOE 重链<|>RELATION_NOE 表达<|>RELATION_B 对称<|>RELATION_E 并<|>RELATION_NOE 具有<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 母<|>RELATION_NOE 本<|>RELATION_NOE 鼠源<|>RELATION_NOE 抗体<|>RELATION_NOE 相似<|>RELATION_NOE 的<|>RELATION_NOE 亲和力<|>RELATION_NOE 和<|>RELATION_NOE 杀伤<|>RELATION_NOE 多种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE HRM<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 循环<|>RELATION_NOE DNA<|>RELATION_NOE 中<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE
探讨<|>RELATION_NOE 高<|>RELATION_NOE 分辨<|>RELATION_NOE 熔解<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE HRM<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 循环<|>RELATION_NOE DNA<|>RELATION_NOE 中<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE HRM<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE 含<|>RELATION_NOE 不同<|>RELATION_NOE 比例<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 型<|>RELATION_NOE 质粒<|>RELATION_NOE 的<|>RELATION_NOE 系列<|>RELATION_NOE 混合<|>RELATION_NOE 样本<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_S ,<|>RELATION_NOE 以<|>RELATION_NOE 评价<|>RELATION_NOE 其<|>RELATION_NOE 灵敏度<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE HRM<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 2009年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 96<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 循环<|>RELATION_NOE DNA<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 基因<|>RELATION_NOE 测序法<|>RELATION_NOE 的<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE HRM<|>RELATION_NOE 法<|>RELATION_NOE 可<|>RELATION_B 检<|>RELATION_I 出<|>RELATION_E 系列<|>RELATION_NOE 混合<|>RELATION_NOE 样本<|>RELATION_NOE 中<|>RELATION_NOE 突变<|>RELATION_NOE 型<|>RELATION_NOE 质粒<|>RELATION_NOE 比例<|>RELATION_NOE 为<|>RELATION_NOE 5%<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 检测<|>RELATION_NOE 灵敏度<|>RELATION_NOE 达<|>RELATION_NOE 5%<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE H<|>RELATION_NOE RM<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 96<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 检测<|>RELATION_B 出<|>RELATION_E 17<|>RELATION_NOE 例<|>RELATION_NOE 发生<|>RELATION_NOE 了<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 17.7%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 突变<|>RELATION_NOE 分别<|>RELATION_NOE 占<|>RELATION_NOE 88.2%<|>RELATION_NOE (<|>RELATION_NOE 15<|>RELATION_NOE /<|>RELATION_NOE 17<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 11.8%<|>RELATION_NOE (<|>RELATION_NOE 2/17<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 致<|>RELATION_NOE 心电图<|>RELATION_NOE 与<|>RELATION_NOE 心肌<|>RELATION_NOE 酶<|>RELATION_NOE 谱<|>RELATION_NOE 异常<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 观察<|>RELATION_E
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 对<|>RELATION_NOE 心脏<|>RELATION_NOE 的<|>RELATION_NOE 损伤<|>RELATION_S 。<|>RELATION_NOE
对<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 6月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 中和<|>RELATION_NOE 放疗<|>RELATION_NOE 结束<|>RELATION_NOE 时<|>RELATION_NOE 分别<|>RELATION_NOE 做<|>RELATION_NOE 心电图<|>RELATION_B 检查<|>RELATION_E 和<|>RELATION_NOE 心肌<|>RELATION_NOE 酶<|>RELATION_NOE 谱<|>RELATION_NOE 检查.<|>RELATION_NOE 对<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 6月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 中和<|>RELATION_NOE 放疗<|>RELATION_NOE 结束<|>RELATION_NOE 时<|>RELATION_NOE 分别<|>RELATION_NOE 做<|>RELATION_NOE 心电图<|>RELATION_NOE 检查<|>RELATION_NOE 和<|>RELATION_NOE 心肌<|>RELATION_B 酶<|>RELATION_I 谱<|>RELATION_I 检查<|>RELATION_E .<|>RELATION_NOE
放疗<|>RELATION_NOE 期间<|>RELATION_NOE 可<|>RELATION_NOE 发生<|>RELATION_S 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 心脏损伤<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 损伤<|>RELATION_NOE 程度<|>RELATION_NOE 与<|>RELATION_NOE 心脏<|>RELATION_NOE 受<|>RELATION_NOE 照射<|>RELATION_NOE 体积<|>RELATION_NOE 、<|>RELATION_NOE 放射<|>RELATION_NOE 剂量<|>RELATION_NOE 有关<|>RELATION_NOE .<|>RELATION_NOE
厄洛替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 化疗<|>RELATION_NOE 失败<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 观察<|>RELATION_E
厄洛替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 总<|>RELATION_NOE 有效率<|>RELATION_NOE 为<|>RELATION_NOE 42%<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 为<|>RELATION_NOE 77.8%<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 总<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 15<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
厄洛替尼<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 化疗<|>RELATION_NOE 失败<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_B 药物<|>RELATION_E ,<|>RELATION_NOE 对于<|>RELATION_NOE 我国<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 状态<|>RELATION_NOE 不明<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 仍然<|>RELATION_NOE 能够<|>RELATION_NOE 达到<|>RELATION_NOE 很<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 无<|>RELATION_NOE 严重<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 化疗<|>RELATION_NOE 失败<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 药物<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 我国<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 状态<|>RELATION_NOE 不明<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 仍然<|>RELATION_NOE 能够<|>RELATION_NOE 达到<|>RELATION_NOE 很<|>RELATION_B 好<|>RELATION_I 的<|>RELATION_I 疗效<|>RELATION_E ,<|>RELATION_NOE 并且<|>RELATION_NOE 无<|>RELATION_NOE 严重<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 化疗<|>RELATION_NOE 失败<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 药物<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 我国<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 状态<|>RELATION_NOE 不明<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 仍然<|>RELATION_NOE 能够<|>RELATION_NOE 达到<|>RELATION_NOE 很<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 无<|>RELATION_B 严重<|>RELATION_I 不良<|>RELATION_I 反应<|>RELATION_E 。<|>RELATION_NOE
影响<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 治疗效果<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 因素<|>RELATION_I 分析<|>RELATION_E
分别<|>RELATION_NOE 以<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 卡氏<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 部位<|>RELATION_NOE 数目<|>RELATION_NOE 、<|>RELATION_NOE 是否<|>RELATION_NOE 综合治疗<|>RELATION_NOE 为<|>RELATION_NOE 变量<|>RELATION_NOE 进行<|>RELATION_NOE 分层<|>RELATION_B 分析<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 各<|>RELATION_NOE 变量<|>RELATION_NOE 对<|>RELATION_NOE 远期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TUBB3<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE EGFR<|>RELATION_NOE (<|>RELATION_NOE E19<|>RELATION_NOE /<|>RELATION_NOE E21<|>RELATION_NOE )<|>RELATION_NOE 突变率<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标本<|>RELATION_NOE 进行<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TUBB3<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE EGFR<|>RELATION_NOE (<|>RELATION_NOE E19<|>RELATION_NOE /<|>RELATION_NOE E21<|>RELATION_NOE )<|>RELATION_NOE 突变率<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S ,<|>RELATION_NOE 揭示<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 铂类<|>RELATION_NOE 药物<|>RELATION_NOE 、<|>RELATION_NOE 第三<|>RELATION_NOE 代<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE (<|>RELATION_NOE 吉西他滨<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 、<|>RELATION_NOE 培<|>RELATION_NOE 美曲赛<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 耐药性<|>RELATION_NOE 以及<|>RELATION_NOE 靶向<|>RELATION_NOE 药物治疗<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 。<|>RELATION_NOE 探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标本<|>RELATION_NOE 进行<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TUBB3<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE EGFR<|>RELATION_NOE (<|>RELATION_NOE E19<|>RELATION_NOE /<|>RELATION_NOE E21<|>RELATION_NOE )<|>RELATION_NOE 突变率<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 揭示<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 铂类<|>RELATION_NOE 药物<|>RELATION_NOE 、<|>RELATION_NOE 第三<|>RELATION_NOE 代<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE (<|>RELATION_NOE 吉西他滨<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 、<|>RELATION_NOE 培美<|>RELATION_NOE 曲赛<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 耐药性<|>RELATION_S 以及<|>RELATION_NOE 靶向<|>RELATION_NOE 药物治疗<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 。<|>RELATION_NOE 探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标本<|>RELATION_NOE 进行<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TUBB3<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE EGFR<|>RELATION_NOE (<|>RELATION_NOE E19<|>RELATION_NOE /<|>RELATION_NOE E21<|>RELATION_NOE )<|>RELATION_NOE 突变率<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 揭示<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 铂类<|>RELATION_NOE 药物<|>RELATION_NOE 、<|>RELATION_NOE 第三<|>RELATION_NOE 代<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE (<|>RELATION_NOE 吉西他滨<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 、<|>RELATION_NOE 培<|>RELATION_NOE 美曲赛<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 耐药性<|>RELATION_NOE 以及<|>RELATION_NOE 靶向<|>RELATION_NOE 药物治疗<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_S 的<|>RELATION_NOE 不同<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 本院<|>RELATION_NOE 2009年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 8月<|>RELATION_NOE 91<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 完全<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标本<|>RELATION_NOE 进行<|>RELATION_NOE 个体化<|>RELATION_NOE 治疗<|>RELATION_NOE 靶标<|>RELATION_NOE 检测<|>RELATION_NOE ——<|>RELATION_NOE 以<|>RELATION_NOE 分支<|>RELATION_NOE DNA-<|>RELATION_NOE 液相<|>RELATION_NOE 芯片法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TUBB3<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 其<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TUBB3<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 之间<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 差异<|>RELATION_E ,<|>RELATION_NOE 但<|>RELATION_NOE 各组<|>RELATION_NOE 中<|>RELATION_NOE ERCC1<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 较<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TUBB3<|>RELATION_NOE 和<|>RELATION_NOE RRM1<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 低<|>RELATION_NOE ;<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 及<|>RELATION_NOE 非<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 35.3%<|>RELATION_NOE 、<|>RELATION_NOE 42.8%<|>RELATION_NOE 、<|>RELATION_NOE 42.9%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_S 非腺癌<|>RELATION_NOE 、<|>RELATION_NOE 男性<|>RELATION_NOE 及<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 2.5%<|>RELATION_NOE 、<|>RELATION_NOE 11.1%<|>RELATION_NOE 、<|>RELATION_NOE 7.1%<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 差别<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 对<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TUBB3<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE EGFR<|>RELATION_NOE (<|>RELATION_NOE E19<|>RELATION_NOE /<|>RELATION_NOE E21<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 体细胞<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 个体化<|>RELATION_NOE 治疗<|>RELATION_NOE 靶标<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 发现<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 耐药性<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 是<|>RELATION_NOE 各<|>RELATION_NOE 不<|>RELATION_B 相同<|>RELATION_E 的<|>RELATION_NOE 。<|>RELATION_NOE 通过<|>RELATION_NOE 对<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TUBB3<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE EGFR<|>RELATION_NOE (<|>RELATION_NOE E19<|>RELATION_NOE /<|>RELATION_NOE E21<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 体细胞<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 个体化<|>RELATION_NOE 治疗<|>RELATION_NOE 靶标<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 发现<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 耐药性<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 是<|>RELATION_NOE 各<|>RELATION_NOE 不<|>RELATION_B 相同<|>RELATION_E 的<|>RELATION_NOE 。<|>RELATION_NOE
新疆<|>RELATION_NOE 维吾尔<|>RELATION_NOE 自治区<|>RELATION_NOE 少数民族<|>RELATION_NOE 地区<|>RELATION_NOE 肺癌<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 分析<|>RELATION_S
纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 是<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 主要<|>RELATION_B 确诊<|>RELATION_I 手段<|>RELATION_E ;<|>RELATION_NOE
少数民族<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病率<|>RELATION_NOE 相对<|>RELATION_NOE 较<|>RELATION_B 低<|>RELATION_E ,<|>RELATION_NOE 由于<|>RELATION_NOE 生活<|>RELATION_NOE 习俗<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 环境<|>RELATION_NOE 、<|>RELATION_NOE 文化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 宗教<|>RELATION_NOE 信仰<|>RELATION_NOE 、<|>RELATION_NOE 求医<|>RELATION_NOE 观点<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 上<|>RELATION_NOE 与<|>RELATION_NOE 一般<|>RELATION_NOE 人群<|>RELATION_NOE 有<|>RELATION_NOE 差别<|>RELATION_NOE ,<|>RELATION_NOE 加之<|>RELATION_NOE 经济<|>RELATION_NOE 相对<|>RELATION_NOE 落后<|>RELATION_NOE ,<|>RELATION_NOE 制约<|>RELATION_NOE 了<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 及时<|>RELATION_NOE 诊治<|>RELATION_NOE 及<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
立体<|>RELATION_NOE 定向<|>RELATION_NOE 放疗<|>RELATION_NOE +<|>RELATION_NOE 中药<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 可<|>RELATION_NOE 稳定<|>RELATION_S 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病情<|>RELATION_NOE 及<|>RELATION_NOE 改善<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 提高<|>RELATION_NOE Kamofsky<|>RELATION_NOE 评分<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_NOE 降低<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE PPN<|>RELATION_NOE /<|>RELATION_NOE MG61<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE PPN<|>RELATION_NOE /<|>RELATION_NOE MG61<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE Ⅲ<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 治疗<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE 立体<|>RELATION_NOE 定向<|>RELATION_NOE 放疗<|>RELATION_NOE +<|>RELATION_NOE 中药<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 可<|>RELATION_NOE 稳定<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病情<|>RELATION_NOE 及<|>RELATION_NOE 改善<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 提高<|>RELATION_S Kamofsky<|>RELATION_NOE 评分<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_NOE 降低<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE PPN<|>RELATION_NOE /<|>RELATION_NOE MG61<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE PPN<|>RELATION_NOE /<|>RELATION_NOE MG61<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE Ⅲ<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 治疗<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 126<|>RELATION_NOE 例<|>RELATION_NOE 疗效<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE
126<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 划分<|>RELATION_B 为<|>RELATION_E 同期<|>RELATION_NOE 化放疗<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 序贯<|>RELATION_NOE 化放疗<|>RELATION_NOE (<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 治疗组<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 为<|>RELATION_NOE 含<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 卡铂<|>RELATION_NOE 的<|>RELATION_NOE 两<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 联合<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 67<|>RELATION_NOE 例<|>RELATION_NOE
观察<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE (<|>RELATION_NOE YH-16<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE 商品名<|>RELATION_NOE :<|>RELATION_NOE 恩度<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 探讨<|>RELATION_NOE 血清<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨单<|>RELATION_NOE 药<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE
观察<|>RELATION_S 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨单<|>RELATION_NOE 药<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 分别<|>RELATION_NOE 按<|>RELATION_NOE 实体瘤<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 标准<|>RELATION_NOE (<|>RELATION_NOE RECIST<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 美国<|>RELATION_NOE 国立<|>RELATION_NOE 癌症<|>RELATION_NOE 研究所<|>RELATION_NOE (<|>RELATION_NOE NCI<|>RELATION_NOE )<|>RELATION_NOE 常见<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 标准<|>RELATION_NOE 评价<|>RELATION_S 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 评估<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 改善<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 分别<|>RELATION_NOE 按<|>RELATION_NOE 实体瘤<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 标准<|>RELATION_NOE (<|>RELATION_NOE RECIST<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 美国<|>RELATION_NOE 国立<|>RELATION_NOE 癌症<|>RELATION_NOE 研究所<|>RELATION_NOE (<|>RELATION_NOE NCI<|>RELATION_NOE )<|>RELATION_NOE 常见<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 标准<|>RELATION_NOE 评价<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 评估<|>RELATION_S 生活<|>RELATION_NOE 质量<|>RELATION_NOE 改善<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 主要<|>RELATION_NOE 表现<|>RELATION_B 为<|>RELATION_E 以<|>RELATION_NOE 白细胞<|>RELATION_NOE 和<|>RELATION_NOE 血小板减少<|>RELATION_NOE 为主<|>RELATION_NOE 的<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE ,<|>RELATION_NOE 白细胞减少<|>RELATION_NOE I<|>RELATION_NOE －Ⅱ度<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 44.4%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE －<|>RELATION_NOE Ⅳ<|>RELATION_NOE 度<|>RELATION_NOE 11.1%<|>RELATION_NOE (<|>RELATION_NOE 4/36<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
一线<|>RELATION_NOE 化疗<|>RELATION_NOE 后吉非替尼<|>RELATION_NOE 维持<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 观察<|>RELATION_E
腺癌<|>RELATION_NOE 及<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 0S<|>RELATION_NOE (<|>RELATION_NOE 16.0<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 亦<|>RELATION_NOE 显著<|>RELATION_B 长于<|>RELATION_E 鳞状细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 10.2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 4.6<|>RELATION_NOE 38<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 不良<|>RELATION_B 反应<|>RELATION_E 以<|>RELATION_NOE 皮疹<|>RELATION_NOE 、<|>RELATION_NOE 腹泻<|>RELATION_NOE 、<|>RELATION_NOE 皮肤<|>RELATION_NOE 干燥<|>RELATION_NOE 瘙痒<|>RELATION_NOE 及<|>RELATION_NOE 乏力<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 为<|>RELATION_NOE I<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 度<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 术后<|>RELATION_NOE 胸壁<|>RELATION_NOE 缺损<|>RELATION_NOE 重建<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 探讨<|>RELATION_S
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 直接<|>RELATION_NOE 侵犯<|>RELATION_NOE 胸壁<|>RELATION_NOE 的<|>RELATION_NOE 根治性<|>RELATION_NOE 手术<|>RELATION_NOE 和<|>RELATION_NOE 胸壁<|>RELATION_NOE 重建<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_S
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_B 总结<|>RELATION_E 27<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 直接<|>RELATION_NOE 侵犯<|>RELATION_NOE 胸壁<|>RELATION_NOE 根治<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 全<|>RELATION_NOE 肺<|>RELATION_NOE 切除<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 中<|>RELATION_NOE 同时<|>RELATION_NOE 切除<|>RELATION_NOE 肺癌<|>RELATION_NOE 直接<|>RELATION_NOE 侵犯<|>RELATION_NOE 的<|>RELATION_NOE 胸壁<|>RELATION_NOE ,<|>RELATION_NOE 胸壁<|>RELATION_NOE 切除<|>RELATION_NOE 范围<|>RELATION_NOE 从<|>RELATION_NOE 6.5<|>RELATION_NOE cm<|>RELATION_NOE ×<|>RELATION_NOE 5.4<|>RELATION_NOE cm<|>RELATION_NOE ×<|>RELATION_NOE 5.0<|>RELATION_NOE cm<|>RELATION_NOE 至<|>RELATION_NOE 15.5<|>RELATION_NOE cm<|>RELATION_NOE ×<|>RELATION_NOE 12.5<|>RELATION_NOE cm<|>RELATION_NOE ×<|>RELATION_NOE 10.0<|>RELATION_NOE cm<|>RELATION_NOE ,<|>RELATION_NOE 切除<|>RELATION_NOE 肿瘤<|>RELATION_NOE 所<|>RELATION_NOE 侵犯<|>RELATION_NOE 的<|>RELATION_NOE 肋骨<|>RELATION_NOE 1－<|>RELATION_NOE 4<|>RELATION_NOE 根<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 涤纶布<|>RELATION_NOE 修复<|>RELATION_NOE 胸膜<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 有机<|>RELATION_NOE 玻璃<|>RELATION_NOE 、<|>RELATION_NOE 钢丝<|>RELATION_NOE 编网<|>RELATION_NOE 、<|>RELATION_NOE 网格状钛<|>RELATION_NOE 合金<|>RELATION_NOE 板<|>RELATION_NOE 修复<|>RELATION_NOE 骨性<|>RELATION_NOE 胸廓<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 邻近<|>RELATION_NOE 肌肉<|>RELATION_NOE 瓣<|>RELATION_NOE 和<|>RELATION_NOE 带蒂<|>RELATION_NOE 肌肉<|>RELATION_NOE 瓣<|>RELATION_NOE 修补<|>RELATION_NOE 缺损<|>RELATION_NOE 胸壁<|>RELATION_NOE 肌肉<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 均<|>RELATION_B 为<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 鳞癌<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 5例.<|>RELATION_NOE
术后<|>RELATION_NOE 出现<|>RELATION_S 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 胸壁<|>RELATION_NOE 出血<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 胸壁<|>RELATION_NOE 感染<|>RELATION_NOE 1例<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 直接<|>RELATION_NOE 侵犯<|>RELATION_NOE 胸壁<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 上<|>RELATION_NOE 应<|>RELATION_NOE 积极<|>RELATION_B 采取<|>RELATION_E 根治性<|>RELATION_NOE 外科手术<|>RELATION_NOE ,<|>RELATION_NOE 要<|>RELATION_NOE 以<|>RELATION_NOE 缺损<|>RELATION_NOE 面积<|>RELATION_NOE 大小<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 不同<|>RELATION_NOE 重建<|>RELATION_NOE 方法<|>RELATION_NOE 和<|>RELATION_NOE 修补<|>RELATION_NOE 材料<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 辅<|>RELATION_NOE 以<|>RELATION_NOE 其他<|>RELATION_NOE 方法<|>RELATION_NOE 进行<|>RELATION_NOE 综合治疗<|>RELATION_NOE .<|>RELATION_NOE
5-<|>RELATION_NOE 杂氮<|>RELATION_NOE -2<|>RELATION_NOE '<|>RELATION_NOE -<|>RELATION_NOE 脱氧胞苷<|>RELATION_NOE 对<|>RELATION_NOE 三阴性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 细胞肺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_S 作用<|>RELATION_NOE
探讨<|>RELATION_NOE 5-<|>RELATION_NOE 杂氮<|>RELATION_NOE -2<|>RELATION_NOE '<|>RELATION_NOE -<|>RELATION_NOE 脱氧胞苷<|>RELATION_NOE (<|>RELATION_NOE 5-Aza-CdR<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 三阴性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE (<|>RELATION_NOE TNBC<|>RELATION_NOE )<|>RELATION_NOE MDA-MB-231<|>RELATION_NOE 细胞<|>RELATION_NOE 实验性<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
PCR<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 乳腺癌<|>RELATION_NOE 转移<|>RELATION_NOE 抑制基因<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE BRMSl<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CXC<|>RELATION_NOE 趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体<|>RELATION_NOE -4<|>RELATION_NOE (<|>RELATION_NOE CXCR4<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 甲基化<|>RELATION_NOE 状况<|>RELATION_NOE 。<|>RELATION_NOE
然后<|>RELATION_NOE 通过<|>RELATION_NOE 边缘尾<|>RELATION_NOE 静脉<|>RELATION_NOE 将<|>RELATION_NOE 2×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 细胞<|>RELATION_NOE 注射<|>RELATION_NOE 到<|>RELATION_NOE 每<|>RELATION_NOE 只<|>RELATION_NOE BALB<|>RELATION_NOE /<|>RELATION_NOE Cnu<|>RELATION_NOE /<|>RELATION_NOE nu<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE (<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 5<|>RELATION_NOE 只<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5周<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE RT-PCR<|>RELATION_NOE (<|>RELATION_NOE FqRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 裸鼠<|>RELATION_NOE 肺<|>RELATION_NOE 组织<|>RELATION_NOE 内<|>RELATION_NOE 目的<|>RELATION_NOE :<|>RELATION_NOE 基因<|>RELATION_NOE HPRTmRNA<|>RELATION_NOE 丰度<|>RELATION_NOE 来<|>RELATION_NOE 确定<|>RELATION_NOE 癌细胞肺<|>RELATION_NOE 转移<|>RELATION_NOE 程度<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 与<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE BRMSl<|>RELATION_NOE 相对<|>RELATION_NOE 灰度值<|>RELATION_NOE (<|>RELATION_NOE IDV<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE 与<|>RELATION_NOE 0.3<|>RELATION_NOE 90<|>RELATION_NOE ±<|>RELATION_NOE 0.001<|>RELATION_NOE ,<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE BRMSlmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_NOE 上调<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5-Aza-CdR<|>RELATION_NOE 使<|>RELATION_NOE BRMS1<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE B<|>RELATION_NOE 完全<|>RELATION_B 去<|>RELATION_I 甲基化<|>RELATION_E ;<|>RELATION_NOE
5-Aza-CdR<|>RELATION_NOE 通过<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 机制<|>RELATION_NOE 重新<|>RELATION_NOE 激活<|>RELATION_S 了<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 抑制基因<|>RELATION_NOE BRMSI<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 了<|>RELATION_NOE TNBCMDA-MB-231<|>RELATION_NOE 细胞<|>RELATION_NOE 实验性<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE 5-Aza-CdR<|>RELATION_NOE 通过<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 机制<|>RELATION_NOE 重新<|>RELATION_NOE 激活<|>RELATION_NOE 了<|>RELATION_NOE 肿瘤<|>RELATION_NOE 转移<|>RELATION_NOE 抑制基因<|>RELATION_NOE BRMSI<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_S 了<|>RELATION_NOE TNBCMDA-MB-231<|>RELATION_NOE 细胞<|>RELATION_NOE 实验性<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
肾母细胞瘤<|>RELATION_NOE 合并<|>RELATION_NOE 肾母细胞瘤<|>RELATION_NOE 病<|>RELATION_NOE 6例<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_S
行瘤<|>RELATION_NOE 肾切除术<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 保留<|>RELATION_NOE 肾脏<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 对<|>RELATION_NOE 侧肾<|>RELATION_NOE 上下<|>RELATION_NOE 极<|>RELATION_NOE 结节<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 瘤肾<|>RELATION_NOE 切除<|>RELATION_NOE 十<|>RELATION_NOE 对<|>RELATION_NOE 侧<|>RELATION_NOE 保留<|>RELATION_NOE 肾脏<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 切除术<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 保留<|>RELATION_NOE 肾脏<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 同<|>RELATION_NOE 侧结节<|>RELATION_NOE 切除术<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
1例术<|>RELATION_NOE 后<|>RELATION_NOE 化疗<|>RELATION_NOE 15<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 33<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 后<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 再次<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 继续<|>RELATION_NOE 化疗<|>RELATION_NOE 11<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 后<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肝脏<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
表面<|>RELATION_NOE 增强<|>RELATION_NOE 激光<|>RELATION_NOE 解析<|>RELATION_NOE 电离<|>RELATION_NOE 飞行<|>RELATION_NOE 时间<|>RELATION_NOE 质谱法<|>RELATION_NOE 筛选<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE 肺泡灌洗液<|>RELATION_NOE 中<|>RELATION_NOE 标志<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
应用<|>RELATION_NOE 表面<|>RELATION_NOE 增强<|>RELATION_NOE 激光<|>RELATION_NOE 解析<|>RELATION_NOE 电离<|>RELATION_NOE 飞行<|>RELATION_NOE 时间<|>RELATION_NOE 质谱<|>RELATION_NOE (<|>RELATION_NOE SELDI-TOF-MS<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 筛选<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE BALF<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 差异性<|>RELATION_NOE 表达<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 是否<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE SELDI-TOF-MS<|>RELATION_NOE 技术<|>RELATION_NOE 通过<|>RELATION_NOE 弱<|>RELATION_NOE 阳离子交换<|>RELATION_NOE 蛋白<|>RELATION_NOE 芯片<|>RELATION_NOE (<|>RELATION_NOE WCX-2<|>RELATION_NOE 芯片<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_S 35<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE BALF<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 蛋白质<|>RELATION_NOE 质谱<|>RELATION_NOE 图<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE Biomarker<|>RELATION_NOE Pattern<|>RELATION_NOE 软件<|>RELATION_NOE 分析<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白<|>RELATION_NOE 并<|>RELATION_NOE 初步<|>RELATION_NOE 建立<|>RELATION_NOE 诊断<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 盲筛<|>RELATION_NOE 进一步<|>RELATION_NOE 验证<|>RELATION_NOE 诊断<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 发现<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 蛋白质<|>RELATION_NOE 波峰<|>RELATION_NOE ,<|>RELATION_NOE 选用<|>RELATION_NOE 其中<|>RELATION_NOE 质<|>RELATION_NOE 荷比<|>RELATION_NOE 为<|>RELATION_NOE 56<|>RELATION_NOE 39<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白<|>RELATION_NOE 波峰<|>RELATION_NOE 建立<|>RELATION_S 分类树<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 为<|>RELATION_NOE 80%<|>RELATION_NOE (<|>RELATION_NOE 28<|>RELATION_NOE /<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 特异度<|>RELATION_NOE 为<|>RELATION_NOE 78%<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE /<|>RELATION_NOE 18<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
SELDI-TOF-MS<|>RELATION_NOE 技术<|>RELATION_NOE 可<|>RELATION_NOE 筛选<|>RELATION_S 出<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE BALF<|>RELATION_NOE 中<|>RELATION_NOE 差异性<|>RELATION_NOE 表达<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 作为<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 诊断<|>RELATION_NOE 敏感度<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 特异度<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE BALF<|>RELATION_NOE 中<|>RELATION_NOE 差异性<|>RELATION_NOE 表达<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 测定<|>RELATION_NOE 可能<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 前景<|>RELATION_NOE .<|>RELATION_NOE
吉西他滨<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 双<|>RELATION_NOE 路径<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 125<|>RELATION_NOE Ⅰ<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_B 治疗<|>RELATION_E Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE
顺铂<|>RELATION_NOE 100<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 灌注<|>RELATION_NOE 时<|>RELATION_NOE 取<|>RELATION_NOE 总量<|>RELATION_NOE 的<|>RELATION_NOE 1/<|>RELATION_NOE 3.<|>RELATION_NOE 余量<|>RELATION_NOE 顺铂<|>RELATION_NOE 于<|>RELATION_NOE 第2<|>RELATION_NOE 天<|>RELATION_NOE 和<|>RELATION_NOE 第3<|>RELATION_NOE 大<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注.<|>RELATION_NOE
吉西他滨<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 双<|>RELATION_NOE 路径<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 明显<|>RELATION_NOE 优于<|>RELATION_S 单纯<|>RELATION_NOE 同<|>RELATION_NOE 方案<|>RELATION_NOE 双路径<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE .<|>RELATION_NOE
恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 18<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE 构成<|>RELATION_NOE 情况<|>RELATION_NOE 分析<|>RELATION_S
18<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 前<|>RELATION_NOE 6<|>RELATION_NOE 位<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE [<|>RELATION_NOE 23.6%<|>RELATION_NOE (<|>RELATION_NOE 437<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 13.1%<|>RELATION_NOE (<|>RELATION_NOE 243<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 12.0%<|>RELATION_NOE (<|>RELATION_NOE 223<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 11.4%<|>RELATION_NOE (<|>RELATION_NOE 211<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 8.9%<|>RELATION_NOE (<|>RELATION_NOE 165<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 7.6%<|>RELATION_NOE (<|>RELATION_NOE 140<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ;<|>RELATION_NOE
前<|>RELATION_NOE 6<|>RELATION_NOE 位<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 以<|>RELATION_NOE 70<|>RELATION_NOE —<|>RELATION_NOE 79<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 最高<|>RELATION_S ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 以<|>RELATION_NOE 60<|>RELATION_NOE —<|>RELATION_NOE 69<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 前<|>RELATION_NOE 6<|>RELATION_NOE 位<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 以<|>RELATION_NOE 70<|>RELATION_NOE —<|>RELATION_NOE 79<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 以<|>RELATION_NOE 60<|>RELATION_NOE —<|>RELATION_NOE 69<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 最高<|>RELATION_S ,<|>RELATION_NOE 而<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 以<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 49<|>RELATION_NOE 岁<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 前<|>RELATION_NOE 6<|>RELATION_NOE 位<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 以<|>RELATION_NOE 70<|>RELATION_NOE —<|>RELATION_NOE 79<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 以<|>RELATION_NOE 60<|>RELATION_NOE —<|>RELATION_NOE 69<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 以<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 49<|>RELATION_NOE 岁<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 最高<|>RELATION_S 。<|>RELATION_NOE
超声<|>RELATION_NOE 引导<|>RELATION_NOE 胸膜<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE 在<|>RELATION_NOE 胸膜<|>RELATION_NOE 病变<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E
对<|>RELATION_NOE 我院<|>RELATION_NOE 自<|>RELATION_NOE 2006年<|>RELATION_NOE 2月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 3月<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 胸膜疾病<|>RELATION_NOE 并行<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 胸膜<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE 109<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_B 分析<|>RELATION_E 。<|>RELATION_NOE
术后<|>RELATION_NOE 并发症<|>RELATION_NOE 包括<|>RELATION_S 气胸<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜<|>RELATION_NOE 反应<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 出血<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
Fascin<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 探讨<|>RELATION_NOE
对<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 和<|>RELATION_NOE 不同<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 以及<|>RELATION_NOE 92<|>RELATION_NOE 例<|>RELATION_NOE 其它<|>RELATION_NOE 部位<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 进行<|>RELATION_NOE Fascin<|>RELATION_B 免疫<|>RELATION_I 组化<|>RELATION_I 染色<|>RELATION_E ,<|>RELATION_NOE 分别<|>RELATION_NOE 计算<|>RELATION_NOE Fascin<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 以及<|>RELATION_NOE 肺癌<|>RELATION_NOE 与<|>RELATION_NOE 肺正常<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 其他<|>RELATION_NOE 肿瘤<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
Fascin<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_S 其<|>RELATION_NOE 在<|>RELATION_NOE 肺正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 有关<|>RELATION_NOE ;<|>RELATION_NOE
Fascin<|>RELATION_NOE 在<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_S 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE
自<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术前<|>RELATION_B 评估<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
探讨<|>RELATION_NOE 自<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE AFB<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 术前<|>RELATION_B 评估<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE K-ras<|>RELATION_NOE 突变<|>RELATION_NOE 小<|>RELATION_NOE 分子<|>RELATION_NOE 对<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 耐药<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
观察<|>RELATION_NOE 针对<|>RELATION_NOE K-ras<|>RELATION_NOE 突变<|>RELATION_NOE 小<|>RELATION_NOE 分子<|>RELATION_NOE NSC-741909<|>RELATION_NOE 是否<|>RELATION_NOE 可<|>RELATION_NOE 特异性<|>RELATION_B 杀伤<|>RELATION_E 吉非替尼<|>RELATION_NOE 原<|>RELATION_NOE 发耐<|>RELATION_NOE 药<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 抗存<|>RELATION_NOE 活素<|>RELATION_NOE 抗体<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 肺部良<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 对照<|>RELATION_B 研究<|>RELATION_E
比较<|>RELATION_S 血清<|>RELATION_NOE 抗存<|>RELATION_NOE 活素<|>RELATION_NOE 抗体<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 肺部良<|>RELATION_NOE 、<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 之间<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 将<|>RELATION_NOE 抗<|>RELATION_NOE 存活素<|>RELATION_NOE 抗体<|>RELATION_NOE 作为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 筛查<|>RELATION_NOE 指标<|>RELATION_NOE 提供<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE ELISA<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 60<|>RELATION_NOE 名<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺良<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 肺良性<|>RELATION_NOE 病变组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌组<|>RELATION_NOE )<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 抗存<|>RELATION_NOE 活素<|>RELATION_NOE 抗体<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
抗存<|>RELATION_NOE 活素<|>RELATION_NOE 抗体<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE 11.7%<|>RELATION_NOE (<|>RELATION_NOE 7/60<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 中<|>RELATION_NOE 几乎<|>RELATION_B 不<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 肺良<|>RELATION_NOE 性病<|>RELATION_NOE 变组<|>RELATION_NOE 中<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE [<|>RELATION_NOE 20.0%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 之间<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
抗存<|>RELATION_NOE 活素<|>RELATION_NOE 抗体<|>RELATION_NOE 在<|>RELATION_NOE 健康<|>RELATION_NOE 人群<|>RELATION_NOE 及<|>RELATION_NOE 肺良性<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 不<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 提供<|>RELATION_NOE 重要<|>RELATION_NOE 依据<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 筛查<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE 抗存<|>RELATION_NOE 活素<|>RELATION_NOE 抗体<|>RELATION_NOE 在<|>RELATION_NOE 健康<|>RELATION_NOE 人群<|>RELATION_NOE 及<|>RELATION_NOE 肺良性<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 不<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 为<|>RELATION_NOE
复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE +<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE (<|>RELATION_NOE CE<|>RELATION_NOE 方案<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_S 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 64<|>RELATION_NOE 例<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 住院<|>RELATION_NOE 先后<|>RELATION_NOE 顺序<|>RELATION_NOE 分为<|>RELATION_NOE 2<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 给予<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE CE<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 单纯<|>RELATION_NOE 给予<|>RELATION_NOE CE<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 诊治<|>RELATION_NOE 分析<|>RELATION_S
对<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE ,<|>RELATION_NOE 一般<|>RELATION_NOE 主张<|>RELATION_S 积极<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 根据<|>RELATION_NOE 肿块<|>RELATION_NOE 的<|>RELATION_NOE 数目<|>RELATION_NOE 、<|>RELATION_NOE 分布<|>RELATION_NOE 及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 食道癌<|>RELATION_NOE 远<|>RELATION_NOE 端骨<|>RELATION_NOE 转移<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_B 研究<|>RELATION_E
[<|>RELATION_NOE 摘要<|>RELATION_NOE ]<|>RELATION_NOE 目的<|>RELATION_NOE 对比<|>RELATION_B 研究<|>RELATION_E 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 食道癌<|>RELATION_NOE 患者<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 分布<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 食道癌<|>RELATION_NOE 患者<|>RELATION_NOE 454<|>RELATION_NOE 例<|>RELATION_NOE 进行<|>RELATION_S ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-<|>RELATION_NOE 亚甲基<|>RELATION_NOE 二膦酸盐<|>RELATION_NOE (<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-MDP<|>RELATION_NOE )<|>RELATION_NOE SPECT<|>RELATION_NOE 全身<|>RELATION_NOE 骨<|>RELATION_NOE 显像<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 上肢<|>RELATION_NOE 中远端<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE 1骨盆<|>RELATION_NOE 、<|>RELATION_NOE 下肢<|>RELATION_NOE 部位<|>RELATION_NOE 发生<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 为<|>RELATION_NOE 纳入<|>RELATION_NOE 条件<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 特点<|>RELATION_NOE 及其<|>RELATION_NOE 在<|>RELATION_NOE 病种<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE 区别<|>RELATION_NOE 。<|>RELATION_NOE
结论<|>RELATION_NOE :<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-MDP<|>RELATION_NOE 全身<|>RELATION_NOE 骨<|>RELATION_NOE 显像<|>RELATION_NOE 显示<|>RELATION_S ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 食道癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 部位<|>RELATION_NOE 有所不同<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 靶向<|>RELATION_NOE 经皮<|>RELATION_NOE 冷冻<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_B 分析<|>RELATION_E
采用<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 靶向<|>RELATION_NOE 经皮<|>RELATION_NOE 冷冻<|>RELATION_NOE 治疗<|>RELATION_S 816<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 1年<|>RELATION_NOE 和<|>RELATION_NOE 2年<|>RELATION_NOE 生存率<|>RELATION_NOE 、<|>RELATION_NOE
其中<|>RELATION_NOE 4例<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘及<|>RELATION_NOE 血气胸<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 患者<|>RELATION_NOE 并发症<|>RELATION_NOE 程度<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 均<|>RELATION_NOE 恢复<|>RELATION_NOE 良好<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 靶向<|>RELATION_NOE 经皮<|>RELATION_NOE 冷冻<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 具有<|>RELATION_NOE 微创<|>RELATION_NOE 、<|>RELATION_NOE 适形<|>RELATION_NOE 、<|>RELATION_NOE 高效<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_S ,<|>RELATION_NOE 并发症<|>RELATION_NOE 相对<|>RELATION_NOE 较<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 选择<|>RELATION_NOE 。<|>RELATION_NOE
全身<|>RELATION_NOE MRI<|>RELATION_NOE 与<|>RELATION_NOE 核素骨<|>RELATION_NOE 扫描<|>RELATION_NOE 对<|>RELATION_NOE 骨<|>RELATION_NOE 转移瘤<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE 对照<|>RELATION_B 研究<|>RELATION_E
33<|>RELATION_NOE 例<|>RELATION_NOE 肺炎型<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
病理<|>RELATION_NOE 证实<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞<|>RELATION_NOE 癌3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 肺部<|>RELATION_NOE 肿块<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 是<|>RELATION_S 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 检查<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 结合<|>RELATION_NOE 可以<|>RELATION_NOE 获得<|>RELATION_NOE 更为<|>RELATION_NOE 准确<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 结果<|>RELATION_NOE 。<|>RELATION_NOE
中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 内灌<|>RELATION_NOE 注化<|>RELATION_NOE 疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_S
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 内灌<|>RELATION_NOE 注化<|>RELATION_NOE 疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE Seldinger<|>RELATION_NOE 技术<|>RELATION_NOE 进行<|>RELATION_NOE 选择性<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 插管<|>RELATION_NOE 对<|>RELATION_NOE 61<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 支气管动脉<|>RELATION_B 灌注<|>RELATION_I 化疗<|>RELATION_E 。<|>RELATION_NOE
缓解率<|>RELATION_NOE 为<|>RELATION_NOE 78.6<|>RELATION_NOE 8%<|>RELATION_NOE (<|>RELATION_NOE 48<|>RELATION_NOE /<|>RELATION_NOE 61<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 有<|>RELATION_NOE 轻度<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 等<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 和<|>RELATION_NOE 胸闷<|>RELATION_NOE 等<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 均<|>RELATION_NOE 好转<|>RELATION_NOE 。<|>RELATION_NOE
支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 抗<|>RELATION_NOE 癌药<|>RELATION_NOE 治疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_S 临床<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 并<|>RELATION_NOE 延长<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 抗<|>RELATION_NOE 癌药<|>RELATION_NOE 治疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 并<|>RELATION_NOE 延长<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 抗<|>RELATION_NOE 癌药<|>RELATION_NOE 治疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 并<|>RELATION_NOE 延长<|>RELATION_S 生存<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
结合<|>RELATION_NOE 临床<|>RELATION_NOE 实践<|>RELATION_NOE 经验<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_S 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 急性<|>RELATION_NOE 呼吸窘迫<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE ARDS<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
2000年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 12月<|>RELATION_NOE ,<|>RELATION_NOE 我院<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE ARDS<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 以此<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 总结<|>RELATION_NOE 回顾<|>RELATION_NOE 分析<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病历<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 资料<|>RELATION_NOE 等<|>RELATION_NOE 搜集<|>RELATION_NOE 整理<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 经治医生<|>RELATION_NOE 、<|>RELATION_NOE 责任<|>RELATION_NOE 护士<|>RELATION_NOE 共同<|>RELATION_NOE 探讨<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 总结<|>RELATION_S 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 并发<|>RELATION_NOE ARDS<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE 。<|>RELATION_NOE
本组<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 采用<|>RELATION_NOE 鼻导管<|>RELATION_NOE 吸氧<|>RELATION_NOE 、<|>RELATION_NOE 面罩<|>RELATION_NOE 吸氧<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 气管<|>RELATION_NOE 内<|>RELATION_NOE 插管<|>RELATION_NOE 高频<|>RELATION_NOE 喷射<|>RELATION_NOE 通气<|>RELATION_NOE ,<|>RELATION_NOE 7例<|>RELATION_NOE 气管<|>RELATION_NOE 内<|>RELATION_NOE 插管<|>RELATION_NOE 呼吸机<|>RELATION_NOE 辅助<|>RELATION_NOE 呼吸<|>RELATION_NOE ,<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 行<|>RELATION_NOE 气管<|>RELATION_NOE 切开<|>RELATION_NOE 呼吸机<|>RELATION_NOE 辅助<|>RELATION_NOE 呼吸.<|>RELATION_NOE
护理<|>RELATION_NOE 人员<|>RELATION_NOE 应<|>RELATION_NOE 了解<|>RELATION_NOE 早期<|>RELATION_NOE ARDS<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 严密<|>RELATION_NOE 观察<|>RELATION_NOE 患者<|>RELATION_NOE 病情<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 及时<|>RELATION_NOE 将<|>RELATION_NOE 呼吸道<|>RELATION_NOE 阻塞<|>RELATION_NOE 排除<|>RELATION_NOE ,<|>RELATION_NOE 保持<|>RELATION_NOE 呼吸<|>RELATION_NOE 的<|>RELATION_NOE 通畅<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 做到<|>RELATION_NOE 勤<|>RELATION_NOE 观察<|>RELATION_NOE 、<|>RELATION_NOE 勤<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 勤<|>RELATION_NOE 巡视<|>RELATION_NOE 、<|>RELATION_NOE 勤<|>RELATION_NOE 报告<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 各种<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_S 手术<|>RELATION_NOE 后<|>RELATION_NOE 合并<|>RELATION_NOE ARDS<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 死亡率<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE 护理<|>RELATION_NOE 人员<|>RELATION_NOE 应<|>RELATION_NOE 了解<|>RELATION_NOE 早期<|>RELATION_NOE ARDS<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 严密<|>RELATION_NOE 观察<|>RELATION_NOE 患者<|>RELATION_NOE 病情<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 及时<|>RELATION_NOE 将<|>RELATION_NOE 呼吸道<|>RELATION_NOE 阻塞<|>RELATION_NOE 排除<|>RELATION_NOE ,<|>RELATION_NOE 保持<|>RELATION_NOE 呼吸<|>RELATION_NOE 的<|>RELATION_NOE 通畅<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 做到<|>RELATION_NOE 勤<|>RELATION_NOE 观察<|>RELATION_NOE 、<|>RELATION_NOE 勤<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 勤<|>RELATION_NOE 巡视<|>RELATION_NOE 、<|>RELATION_NOE 勤<|>RELATION_NOE 报告<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 各种<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 合并<|>RELATION_NOE ARDS<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 死亡率<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_S 患者<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 片断<|>RELATION_NOE 21-1<|>RELATION_NOE 、<|>RELATION_NOE 癌抗原<|>RELATION_NOE 153<|>RELATION_NOE 和<|>RELATION_NOE 神经<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 的<|>RELATION_NOE 测定<|>RELATION_S 及<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 片断<|>RELATION_NOE 21-1<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 癌抗原<|>RELATION_NOE 153<|>RELATION_NOE (<|>RELATION_NOE CA153<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 神经<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 放射<|>RELATION_NOE 免疫法<|>RELATION_NOE 单项<|>RELATION_B 和<|>RELATION_I 联合<|>RELATION_I 测定<|>RELATION_E 60<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE CA153<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 治疗<|>RELATION_S 老年人<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 探讨<|>RELATION_S
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 癌灶<|>RELATION_NOE 个数<|>RELATION_NOE ><|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 、<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 放射性<|>RELATION_NOE 碘治疗<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 相关<|>RELATION_S .<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 独立性<|>RELATION_B 危险因素<|>RELATION_E ,<|>RELATION_NOE 使<|>RELATION_NOE 肿瘤<|>RELATION_NOE 局部<|>RELATION_NOE 复发率<|>RELATION_NOE 增加<|>RELATION_NOE 2.5<|>RELATION_NOE 倍<|>RELATION_NOE 。<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 独立性<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 使<|>RELATION_NOE 肿瘤<|>RELATION_NOE 局部<|>RELATION_NOE 复发率<|>RELATION_NOE 增加<|>RELATION_S 2.5<|>RELATION_NOE 倍<|>RELATION_NOE 。<|>RELATION_NOE
170<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 随机化<|>RELATION_NOE 原则<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 85<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 按<|>RELATION_NOE 临床<|>RELATION_NOE 护理<|>RELATION_NOE 路径<|>RELATION_NOE 设定<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 程序<|>RELATION_NOE 进行<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 平均<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 自行<|>RELATION_NOE 排痰<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 自行<|>RELATION_NOE 排痰<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 短<|>RELATION_B 于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.49<|>RELATION_NOE ,<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 4.29<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 94<|>RELATION_NOE 、<|>RELATION_NOE 0.03<|>RELATION_NOE 95<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 自行<|>RELATION_NOE 排痰<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 短<|>RELATION_NOE 于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.49<|>RELATION_NOE ,<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 4.29<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 94<|>RELATION_NOE 、<|>RELATION_NOE 0.03<|>RELATION_NOE 95<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 3.18<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.03<|>RELATION_NOE 83<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 28<|>RELATION_NOE 天<|>RELATION_NOE 时<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 自行<|>RELATION_NOE 排痰<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 短<|>RELATION_NOE 于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.49<|>RELATION_NOE ,<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 4.29<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 94<|>RELATION_NOE 、<|>RELATION_NOE 0.03<|>RELATION_NOE 95<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 3.18<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.03<|>RELATION_NOE 83<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 28<|>RELATION_NOE 天<|>RELATION_NOE 时<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 成<|>RELATION_NOE 形术<|>RELATION_NOE 治疗<|>RELATION_S 老年人<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
失访<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 余<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 平均<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 40.6<|>RELATION_NOE ±<|>RELATION_NOE 15.2<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 1<|>RELATION_NOE 年<|>RELATION_NOE 、<|>RELATION_NOE 3年<|>RELATION_NOE 及<|>RELATION_NOE 5年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 71.4%<|>RELATION_NOE 、<|>RELATION_NOE 52.4%<|>RELATION_NOE 和<|>RELATION_NOE 28.6%<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 37.4<|>RELATION_NOE ±<|>RELATION_NOE 11.6<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 呼<|>RELATION_NOE 出气<|>RELATION_NOE 冷凝液<|>RELATION_NOE 中<|>RELATION_NOE p53<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_S 的<|>RELATION_NOE 研究<|>RELATION_NOE
采用<|>RELATION_NOE PCR<|>RELATION_NOE 结合<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 53<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE )<|>RELATION_NOE EBC<|>RELATION_NOE 中<|>RELATION_NOE p53<|>RELATION_NOE 基因<|>RELATION_NOE 第5<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 、<|>RELATION_NOE 8外显子<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 32<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE EBC<|>RELATION_NOE 标本<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE )<|>RELATION_NOE EBC<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 扩<|>RELATION_NOE 增<|>RELATION_NOE 到<|>RELATION_NOE p53<|>RELATION_NOE 基因<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 检测<|>RELATION_B 到<|>RELATION_E p53<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 38.5%<|>RELATION_NOE ;<|>RELATION_NOE
正常<|>RELATION_NOE 对照组<|>RELATION_NOE EBC<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 扩<|>RELATION_NOE 增<|>RELATION_NOE 到<|>RELATION_NOE p53<|>RELATION_NOE 基因<|>RELATION_NOE 15<|>RELATION_NOE 名<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_B 检测<|>RELATION_I 到<|>RELATION_E p53<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ;<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 呼<|>RELATION_NOE 出气<|>RELATION_NOE 冷凝液<|>RELATION_NOE 中<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 检测<|>RELATION_S 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
收集<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE EBC<|>RELATION_NOE 和<|>RELATION_NOE 血浆<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 双<|>RELATION_NOE 抗体<|>RELATION_NOE 夹心<|>RELATION_NOE ABC-ELISA<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S EBC<|>RELATION_NOE 和<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 98<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 对照者<|>RELATION_NOE 测定值<|>RELATION_NOE 比较<|>RELATION_NOE .<|>RELATION_NOE
比较<|>RELATION_S 肺癌<|>RELATION_NOE 组中<|>RELATION_NOE 不同<|>RELATION_NOE 分型<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 以及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史者<|>RELATION_NOE EBC<|>RELATION_NOE 和<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 和<|>RELATION_NOE 癌组织<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE .<|>RELATION_NOE
应用<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 分析<|>RELATION_S 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 血浆<|>RELATION_NOE 及<|>RELATION_NOE EBC<|>RELATION_NOE 的<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 及<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 血浆<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 测定<|>RELATION_NOE 值<|>RELATION_NOE 高于<|>RELATION_S 健康<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE 2.58<|>RELATION_NOE ±<|>RELATION_NOE 8.79<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE vs<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 1.66<|>RELATION_NOE ±<|>RELATION_NOE 3.33<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE ]<|>RELATION_NOE .<|>RELATION_NOE
⑥<|>RELATION_NOE 血浆<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 对于<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 95.90%<|>RELATION_NOE .<|>RELATION_NOE
EBC<|>RELATION_NOE p53<|>RELATION_NOE 蛋白埘<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 92.90%<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 79.5<|>RELATION_NOE 9%<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 诊断<|>RELATION_NOE 最佳<|>RELATION_NOE 参考<|>RELATION_NOE 临界<|>RELATION_NOE 值<|>RELATION_NOE 血浆<|>RELATION_NOE 为<|>RELATION_NOE 17<|>RELATION_NOE 5.68<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE EBC<|>RELATION_NOE 为<|>RELATION_NOE 166.26<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE Dickkopf-1<|>RELATION_NOE (<|>RELATION_NOE DKK-1<|>RELATION_NOE )<|>RELATION_NOE 自身抗体<|>RELATION_NOE 潜在<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
应用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 方法<|>RELATION_NOE 获得<|>RELATION_NOE DKK-1<|>RELATION_NOE cDNA<|>RELATION_NOE ,<|>RELATION_NOE 构建<|>RELATION_NOE 原<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE pET30a<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE /<|>RELATION_NOE DKK-1<|>RELATION_NOE ,<|>RELATION_NOE 亲和<|>RELATION_NOE 层析<|>RELATION_NOE 方法<|>RELATION_NOE 纯化<|>RELATION_S 蛋白<|>RELATION_NOE ,<|>RELATION_NOE SDS<|>RELATION_NOE PAGE<|>RELATION_NOE 电泳<|>RELATION_NOE 及<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 鉴定<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 间接<|>RELATION_NOE ELISA<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE 38<|>RELATION_NOE 名<|>RELATION_NOE 键康<|>RELATION_NOE 志愿者<|>RELATION_NOE 和<|>RELATION_NOE 97<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE DKK-1<|>RELATION_NOE 自身<|>RELATION_NOE 抗体<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_NOE 。<|>RELATION_NOE 应用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 方法<|>RELATION_NOE 获得<|>RELATION_NOE DKK-1<|>RELATION_NOE cDNA<|>RELATION_NOE ,<|>RELATION_NOE 构建<|>RELATION_NOE 原<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE pET30a<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE /<|>RELATION_NOE DKK-1<|>RELATION_NOE ,<|>RELATION_NOE 亲和<|>RELATION_NOE 层析<|>RELATION_NOE 方法<|>RELATION_NOE 纯化<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE SDS<|>RELATION_NOE PAGE<|>RELATION_NOE 电泳<|>RELATION_NOE 及<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 鉴定<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 间接<|>RELATION_NOE ELISA<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE 38<|>RELATION_NOE 名<|>RELATION_NOE 键康<|>RELATION_NOE 志愿者<|>RELATION_NOE 和<|>RELATION_NOE 97<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE DKK-1<|>RELATION_NOE 自身<|>RELATION_NOE 抗体<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_S 。<|>RELATION_NOE
DKK-1<|>RELATION_NOE 自身<|>RELATION_NOE 抗体<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 34.0%<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 84.2%<|>RELATION_NOE ;<|>RELATION_NOE
DKK-1<|>RELATION_NOE 自身<|>RELATION_NOE 抗体<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 存在<|>RELATION_NOE 相关<|>RELATION_S 性(<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.006<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
DKK-1<|>RELATION_NOE 自身抗体<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志<|>RELATION_NOE 物痛<|>RELATION_NOE 胚<|>RELATION_NOE 抗原<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_S 癌胚抗原<|>RELATION_NOE 与<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 、<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 抗原<|>RELATION_NOE 进行<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 。<|>RELATION_NOE
该<|>RELATION_NOE 研究<|>RELATION_NOE 成功<|>RELATION_NOE 构建<|>RELATION_NOE 原<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE pET30a<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE /<|>RELATION_NOE DKK<|>RELATION_NOE 1.<|>RELATION_NOE 并<|>RELATION_NOE 建立<|>RELATION_NOE 检测<|>RELATION_NOE DKK-1<|>RELATION_NOE 自身<|>RELATION_NOE 抗体<|>RELATION_NOE 的<|>RELATION_NOE ELISA<|>RELATION_NOE 方法.<|>RELATION_NOE
DKK-1<|>RELATION_NOE 自身<|>RELATION_NOE 抗体<|>RELATION_NOE 可能<|>RELATION_NOE 成为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 有用<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_B 标志物<|>RELATION_E 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 或<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 治疗<|>RELATION_S 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 失败<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE ERCCI<|>RELATION_NOE mRNA<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0003<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 低于<|>RELATION_S 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE ERCCI<|>RELATION_NOE mRNA<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0003<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 低于<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 低于<|>RELATION_S 无<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 49<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 分级<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 生存率<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE ERCCI<|>RELATION_NOE mRNA<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0003<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 低于<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 低于<|>RELATION_NOE 无<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 49<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 分级<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 生存率<|>RELATION_NOE 低于<|>RELATION_S 病理<|>RELATION_NOE 分级<|>RELATION_NOE 低<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
20<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 5-Aza-dc<|>RELATION_NOE (<|>RELATION_NOE 无毒剂量组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 40<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L5-Aza-dc<|>RELATION_NOE (<|>RELATION_NOE 低毒<|>RELATION_NOE 剂量组<|>RELATION_NOE )<|>RELATION_NOE 干预<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE R1<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.82<|>RELATION_NOE 和<|>RELATION_NOE 4.42.MSP<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE hMLH1<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 呈<|>RELATION_S 部分<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE ;<|>RELATION_NOE
经<|>RELATION_NOE 无毒<|>RELATION_NOE 和<|>RELATION_NOE 低毒<|>RELATION_NOE 剂量<|>RELATION_NOE 5-Aza-dc<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE hMLH1<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 发生<|>RELATION_S DNA<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE .<|>RELATION_NOE
原<|>RELATION_NOE 发涎腺型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_S
回顾性<|>RELATION_B 分析<|>RELATION_E 经<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 原<|>RELATION_NOE 发涎腺型<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE 黏液<|>RELATION_NOE 表皮样癌<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 腺样囊性癌<|>RELATION_NOE 5例<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE cT<|>RELATION_NOE 表现<|>RELATION_NOE 。<|>RELATION_NOE
8例<|>RELATION_NOE 黏液<|>RELATION_NOE 表皮样癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 位于<|>RELATION_NOE 主<|>RELATION_NOE 支气管<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 位于<|>RELATION_NOE 段<|>RELATION_NOE 支气管<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE I<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 周围型<|>RELATION_NOE ,<|>RELATION_NOE 位于<|>RELATION_NOE 肺内<|>RELATION_NOE 。<|>RELATION_NOE
5例腺样<|>RELATION_NOE 囊腺癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 3例侵<|>RELATION_NOE 及<|>RELATION_NOE 气管<|>RELATION_NOE ,<|>RELATION_NOE 2例侵<|>RELATION_NOE 及<|>RELATION_NOE 主<|>RELATION_NOE 支气管<|>RELATION_NOE 及<|>RELATION_NOE 叶<|>RELATION_NOE 支气管<|>RELATION_NOE 。<|>RELATION_NOE
其<|>RELATION_NOE 主要<|>RELATION_NOE cT<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 气管<|>RELATION_NOE 或<|>RELATION_NOE 支气管<|>RELATION_NOE 壁<|>RELATION_NOE 弥漫<|>RELATION_NOE 或<|>RELATION_NOE 环形<|>RELATION_NOE 不规则<|>RELATION_NOE 增<|>RELATION_NOE 厚<|>RELATION_NOE ,<|>RELATION_NOE 管腔<|>RELATION_NOE 变形<|>RELATION_NOE ,<|>RELATION_NOE 可见<|>RELATION_NOE 结节<|>RELATION_NOE 突出<|>RELATION_B 于<|>RELATION_E 管腔<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 长径<|>RELATION_NOE 大于<|>RELATION_NOE 横径<|>RELATION_NOE 。<|>RELATION_NOE 其<|>RELATION_NOE 主要<|>RELATION_NOE cT<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 气管<|>RELATION_NOE 或<|>RELATION_NOE 支气管<|>RELATION_NOE 壁<|>RELATION_NOE 弥漫<|>RELATION_NOE 或<|>RELATION_NOE 环形<|>RELATION_NOE 不规则<|>RELATION_NOE 增<|>RELATION_NOE 厚<|>RELATION_NOE ,<|>RELATION_NOE 管腔<|>RELATION_NOE 变形<|>RELATION_NOE ,<|>RELATION_NOE 可见<|>RELATION_NOE 结节<|>RELATION_NOE 突出<|>RELATION_NOE 于<|>RELATION_NOE 管腔<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 长径<|>RELATION_NOE 大于<|>RELATION_S 横径<|>RELATION_NOE 。<|>RELATION_NOE
动态<|>RELATION_NOE 增强<|>RELATION_NOE CT<|>RELATION_NOE 鉴别诊断<|>RELATION_S 孤立性<|>RELATION_NOE 肺结节<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
应用<|>RELATION_NOE Toshiba<|>RELATION_NOE Aquilion16<|>RELATION_NOE 层<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 扫描机<|>RELATION_NOE 对<|>RELATION_NOE SPN<|>RELATION_NOE 行<|>RELATION_NOE 平扫<|>RELATION_NOE 和<|>RELATION_NOE 增强<|>RELATION_NOE 后<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 30<|>RELATION_NOE 、<|>RELATION_NOE 45<|>RELATION_NOE 、<|>RELATION_NOE 60<|>RELATION_NOE 、<|>RELATION_NOE 75<|>RELATION_NOE 、<|>RELATION_NOE 90<|>RELATION_NOE 、<|>RELATION_NOE 120<|>RELATION_NOE 、<|>RELATION_NOE 180<|>RELATION_NOE 、<|>RELATION_NOE 300<|>RELATION_NOE 、<|>RELATION_NOE 540<|>RELATION_NOE 、<|>RELATION_NOE 720<|>RELATION_NOE 、<|>RELATION_NOE 900<|>RELATION_NOE 、<|>RELATION_NOE 1200S<|>RELATION_NOE 等<|>RELATION_NOE 13<|>RELATION_NOE 个<|>RELATION_NOE 序列<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 结节<|>RELATION_NOE 增强<|>RELATION_NOE 参数<|>RELATION_NOE 、<|>RELATION_NOE 观察<|>RELATION_NOE 结节<|>RELATION_NOE 形态学<|>RELATION_NOE 征象<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 差异<|>RELATION_NOE 统计学<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 筛选<|>RELATION_NOE 有<|>RELATION_NOE 诊断<|>RELATION_NOE 意义<|>RELATION_NOE 的<|>RELATION_NOE 参数<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 鉴别诊断<|>RELATION_S 恶性结节<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 形态学<|>RELATION_NOE 征象<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 良恶<|>RELATION_NOE 性结节<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 类圆形<|>RELATION_NOE 、<|>RELATION_NOE 类三<|>RELATION_NOE 角形<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 角形<|>RELATION_NOE 、<|>RELATION_NOE 毛刺<|>RELATION_NOE 、<|>RELATION_NOE 浅<|>RELATION_NOE 分叶<|>RELATION_NOE 、<|>RELATION_NOE 边缘<|>RELATION_NOE 锐利<|>RELATION_NOE 、<|>RELATION_NOE 清楚<|>RELATION_NOE 、<|>RELATION_NOE 模糊<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 集束征<|>RELATION_NOE 、<|>RELATION_NOE 空泡<|>RELATION_NOE 征<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 充气征<|>RELATION_NOE 、<|>RELATION_NOE 典型<|>RELATION_NOE 胸膜<|>RELATION_NOE 凹陷征<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 截断<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 穿过<|>RELATION_NOE 和<|>RELATION_NOE 支气管<|>RELATION_NOE 压迫<|>RELATION_NOE 等<|>RELATION_NOE 征象<|>RELATION_NOE 的<|>RELATION_NOE 表现率<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_S 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE 或<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
动态<|>RELATION_NOE 增强<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 可以<|>RELATION_NOE 同时<|>RELATION_NOE 观察<|>RELATION_S 结节<|>RELATION_NOE 的<|>RELATION_NOE 形态<|>RELATION_NOE 和<|>RELATION_NOE 强化<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 形态学<|>RELATION_NOE 特征<|>RELATION_NOE 在<|>RELATION_NOE 鉴刖<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 重要<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 综合<|>RELATION_NOE 运用<|>RELATION_NOE 动态<|>RELATION_NOE 增强<|>RELATION_NOE 参数<|>RELATION_NOE 和<|>RELATION_NOE 形态学<|>RELATION_NOE 征象<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_NOE 恶性<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效率<|>RELATION_NOE 。<|>RELATION_NOE 动态<|>RELATION_NOE 增强<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 可以<|>RELATION_NOE 同时<|>RELATION_NOE 观察<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 形态<|>RELATION_NOE 和<|>RELATION_NOE 强化<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 形态学<|>RELATION_NOE 特征<|>RELATION_NOE 在<|>RELATION_NOE 鉴刖<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 重要<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 综合<|>RELATION_NOE 运用<|>RELATION_NOE 动态<|>RELATION_NOE 增强<|>RELATION_NOE 参数<|>RELATION_NOE 和<|>RELATION_NOE 形态学<|>RELATION_NOE 征象<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_S 恶性结节<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效率<|>RELATION_NOE 。<|>RELATION_NOE
中心型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
评价<|>RELATION_S 经<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE (<|>RELATION_NOE BAI<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 中心型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
大<|>RELATION_NOE 剂量<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 有效性<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE
采用<|>RELATION_NOE 非随机<|>RELATION_NOE 病例<|>RELATION_NOE 对照<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 选取<|>RELATION_NOE 有<|>RELATION_NOE 明确<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 胃肠道<|>RELATION_NOE 肿瘤<|>RELATION_NOE 带瘤<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 依据<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE (<|>RELATION_NOE 20ml<|>RELATION_NOE /<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE 应用<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 的<|>RELATION_NOE 中药<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 化疗组<|>RELATION_NOE 各<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
中药<|>RELATION_NOE 治疗组<|>RELATION_NOE 仅<|>RELATION_NOE 有<|>RELATION_NOE 1例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 轻度<|>RELATION_NOE 皮肤<|>RELATION_NOE 刺激<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_B 发现<|>RELATION_E 其他<|>RELATION_NOE 与<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 应用<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 有关<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
同时性<|>RELATION_NOE 食管癌<|>RELATION_NOE 伴发<|>RELATION_NOE 肺癌<|>RELATION_NOE 同期<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 观察<|>RELATION_E
对<|>RELATION_NOE 同时性<|>RELATION_NOE 食管癌<|>RELATION_NOE 伴发<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 特性<|>RELATION_NOE 、<|>RELATION_NOE 同期<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 治疗效果<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 进行<|>RELATION_NOE 探讨<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2003年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 7月<|>RELATION_NOE 期间<|>RELATION_NOE 中国<|>RELATION_NOE 医学<|>RELATION_NOE 科学院<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 同时性<|>RELATION_NOE 食管癌<|>RELATION_NOE 伴发<|>RELATION_NOE 肺癌<|>RELATION_NOE 同期<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 行<|>RELATION_NOE 回顾性<|>RELATION_B 分析<|>RELATION_E 。<|>RELATION_NOE
通过<|>RELATION_NOE 腺体<|>RELATION_NOE 相关<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE adeno-associated<|>RELATION_NOE virusAAV<|>RELATION_NOE )<|>RELATION_NOE 载体<|>RELATION_NOE 把<|>RELATION_NOE p53N15<|>RELATION_NOE 融合<|>RELATION_NOE 肽<|>RELATION_NOE 高效<|>RELATION_NOE 导入<|>RELATION_NOE p53<|>RELATION_NOE 缺<|>RELATION_NOE 失<|>RELATION_NOE 肺腺癌<|>RELATION_NOE H1299<|>RELATION_NOE 细胞系<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 相差<|>RELATION_NOE 倒置<|>RELATION_NOE 显微镜<|>RELATION_NOE 观察<|>RELATION_NOE 、<|>RELATION_NOE MTf<|>RELATION_NOE 细胞<|>RELATION_NOE 活性<|>RELATION_NOE 试验<|>RELATION_NOE 及<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 技术<|>RELATION_NOE 分析<|>RELATION_S p53N15<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
p53N15<|>RELATION_NOE 融合肽<|>RELATION_NOE 在<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 得到<|>RELATION_NOE 了<|>RELATION_NOE 高效<|>RELATION_B 表达<|>RELATION_I 并<|>RELATION_I 发挥<|>RELATION_I 明显<|>RELATION_I 效应<|>RELATION_E ,<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 显微镜<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 病毒<|>RELATION_NOE 转染<|>RELATION_NOE 72h<|>RELATION_NOE 可见<|>RELATION_NOE 大片<|>RELATION_NOE 细胞死亡<|>RELATION_NOE 。<|>RELATION_NOE
MTF<|>RELATION_NOE 试验<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 病毒<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 活性<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_S 。<|>RELATION_NOE
流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 技术<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 病毒<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 可见<|>RELATION_NOE 大量<|>RELATION_NOE 死亡<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
临床<|>RELATION_NOE Ⅰ<|>RELATION_NOE A<|>RELATION_NOE 期<|>RELATION_NOE 周围型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 危险因素<|>RELATION_S
行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 或<|>RELATION_NOE 肺局<|>RELATION_NOE 限性<|>RELATION_NOE 切除<|>RELATION_NOE 加<|>RELATION_NOE 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 病人<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 及<|>RELATION_NOE 吸烟量<|>RELATION_NOE 、<|>RELATION_NOE 既<|>RELATION_NOE 往<|>RELATION_NOE 肿瘤史<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 钙化<|>RELATION_NOE 、<|>RELATION_NOE 毛刺<|>RELATION_NOE 、<|>RELATION_NOE 分叶<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 牵<|>RELATION_NOE 拉<|>RELATION_NOE 征<|>RELATION_NOE 、<|>RELATION_NOE 边界<|>RELATION_NOE 清楚<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 集束征<|>RELATION_NOE 、<|>RELATION_NOE 空洞<|>RELATION_NOE 等<|>RELATION_NOE 16<|>RELATION_NOE 项<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 逻辑<|>RELATION_NOE 回归<|>RELATION_NOE 分析<|>RELATION_B 筛选<|>RELATION_E 与<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
经过<|>RELATION_NOE Ldgistic<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE 筛选<|>RELATION_S NSCLC<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 共有<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 指标<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 关联<|>RELATION_NOE ,<|>RELATION_NOE 是否<|>RELATION_NOE 消瘦<|>RELATION_NOE (<|>RELATION_NOE 比值比<|>RELATION_NOE 22.2<|>RELATION_NOE 62<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 既往<|>RELATION_NOE 是否<|>RELATION_NOE 有<|>RELATION_NOE 肿瘤史<|>RELATION_NOE (<|>RELATION_NOE 比值比<|>RELATION_NOE 5.4<|>RELATION_NOE 85<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 结节<|>RELATION_NOE 大小<|>RELATION_NOE (<|>RELATION_NOE 比值比<|>RELATION_NOE 3.7<|>RELATION_NOE 88<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 是否<|>RELATION_NOE 密度<|>RELATION_NOE 均匀<|>RELATION_NOE (<|>RELATION_NOE 比值比<|>RELATION_NOE 5.8<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 是否<|>RELATION_NOE 胸膜<|>RELATION_NOE 牵拉征<|>RELATION_NOE (<|>RELATION_NOE 比值比<|>RELATION_NOE 1.3<|>RELATION_NOE 71<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 界限<|>RELATION_NOE 是否<|>RELATION_NOE 清楚<|>RELATION_NOE (<|>RELATION_NOE 比值比<|>RELATION_NOE 8.2<|>RELATION_NOE 59<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 是否<|>RELATION_NOE 有<|>RELATION_NOE 空泡<|>RELATION_NOE 征<|>RELATION_NOE (<|>RELATION_NOE 比值比<|>RELATION_NOE 7.1<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对于<|>RELATION_NOE 临床<|>RELATION_NOE Ⅰ<|>RELATION_NOE A<|>RELATION_NOE 期<|>RELATION_NOE 的<|>RELATION_NOE 周围型<|>RELATION_NOE NSCLC<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 越<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 风险性<|>RELATION_NOE 越<|>RELATION_B 高<|>RELATION_E ;<|>RELATION_NOE
而<|>RELATION_NOE 既<|>RELATION_NOE 往<|>RELATION_NOE 有<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病史<|>RELATION_NOE ,<|>RELATION_NOE 影像<|>RELATION_NOE 上<|>RELATION_NOE 出现<|>RELATION_NOE 密度<|>RELATION_NOE 不<|>RELATION_NOE 均匀<|>RELATION_NOE ,<|>RELATION_NOE 周围<|>RELATION_NOE 毛刺症<|>RELATION_NOE ,<|>RELATION_NOE 空泡症<|>RELATION_NOE ,<|>RELATION_NOE 界限<|>RELATION_NOE 不<|>RELATION_NOE 清<|>RELATION_NOE ,<|>RELATION_NOE 胸膜<|>RELATION_NOE 牵拉<|>RELATION_NOE ,<|>RELATION_NOE 体征<|>RELATION_NOE 出现<|>RELATION_NOE 消瘦者<|>RELATION_NOE 尽管<|>RELATION_NOE 肿瘤<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 出现<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 加强<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 清扫<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE 腺癌<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 类癌<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 黏液<|>RELATION_NOE 表皮样癌<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞<|>RELATION_NOE 癌3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 4例<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 肺不张<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 发生率<|>RELATION_NOE 5.0<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 剖胸<|>RELATION_NOE 探查组<|>RELATION_NOE 术后<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 死亡<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
青少年<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治性<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 5年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 35%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 普通<|>RELATION_NOE 肺癌<|>RELATION_NOE 人群<|>RELATION_NOE 相当<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 积极<|>RELATION_B 采取<|>RELATION_E 以<|>RELATION_NOE 手术<|>RELATION_NOE 为主<|>RELATION_NOE 的<|>RELATION_NOE 综合治疗<|>RELATION_NOE 。<|>RELATION_NOE
酶<|>RELATION_NOE 切<|>RELATION_NOE 富集<|>RELATION_NOE 联合<|>RELATION_NOE DHPLC<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE EGFR<|>RELATION_NOE 和<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 及其<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE
建立<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE REDE-DHPLC<|>RELATION_NOE 检测<|>RELATION_S 外周<|>RELATION_NOE 血肿<|>RELATION_NOE 瘤游<|>RELATION_NOE 离<|>RELATION_NOE 核酸<|>RELATION_NOE EGFR<|>RELATION_NOE 、<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 采用<|>RELATION_NOE 限制性<|>RELATION_NOE 内切<|>RELATION_NOE 酶<|>RELATION_NOE Mse<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Msc<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE BstN<|>RELATION_NOE Ⅰ<|>RELATION_NOE 和<|>RELATION_NOE Bgl<|>RELATION_NOE Ⅰ<|>RELATION_NOE 分别<|>RELATION_NOE 切断<|>RELATION_S EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第19<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 和<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 第12<|>RELATION_NOE 、<|>RELATION_NOE 13<|>RELATION_NOE 号<|>RELATION_NOE 密码子<|>RELATION_NOE 的<|>RELATION_NOE 野生<|>RELATION_NOE 型片<|>RELATION_NOE 段<|>RELATION_NOE 以<|>RELATION_NOE 富集<|>RELATION_NOE 突变<|>RELATION_NOE 片段<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 检测<|>RELATION_NOE 血浆<|>RELATION_NOE EGFR<|>RELATION_NOE 和<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 采用<|>RELATION_NOE 50%<|>RELATION_NOE 、<|>RELATION_NOE 10%<|>RELATION_NOE 、<|>RELATION_NOE 5%<|>RELATION_NOE 、<|>RELATION_NOE 1%<|>RELATION_NOE 和<|>RELATION_NOE 0.1%<|>RELATION_NOE 稀释<|>RELATION_NOE 度<|>RELATION_NOE 的<|>RELATION_NOE 质粒<|>RELATION_NOE 标准品<|>RELATION_NOE 评价<|>RELATION_NOE REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE 传统<|>RELATION_NOE DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 灵敏<|>RELATION_NOE 度.<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 采用<|>RELATION_NOE 限制性<|>RELATION_NOE 内切<|>RELATION_NOE 酶<|>RELATION_NOE Mse<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Msc<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE BstN<|>RELATION_NOE Ⅰ<|>RELATION_NOE 和<|>RELATION_NOE Bgl<|>RELATION_NOE Ⅰ<|>RELATION_NOE 分别<|>RELATION_NOE 切断<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第19<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 和<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 第12<|>RELATION_NOE 、<|>RELATION_NOE 13<|>RELATION_NOE 号<|>RELATION_NOE 密码子<|>RELATION_NOE 的<|>RELATION_NOE 野生<|>RELATION_NOE 型片<|>RELATION_NOE 段<|>RELATION_NOE 以<|>RELATION_NOE 富集<|>RELATION_NOE 突变<|>RELATION_NOE 片段<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 检测<|>RELATION_NOE 血浆<|>RELATION_NOE EGFR<|>RELATION_NOE 和<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 采用<|>RELATION_NOE 50%<|>RELATION_NOE 、<|>RELATION_NOE 10%<|>RELATION_NOE 、<|>RELATION_NOE 5%<|>RELATION_NOE 、<|>RELATION_NOE 1%<|>RELATION_NOE 和<|>RELATION_NOE 0.1%<|>RELATION_NOE 稀释<|>RELATION_NOE 度<|>RELATION_NOE 的<|>RELATION_NOE 质粒<|>RELATION_NOE 标准品<|>RELATION_NOE 评价<|>RELATION_S REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE 传统<|>RELATION_NOE DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 灵敏度<|>RELATION_NOE .<|>RELATION_NOE
然后<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 120<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 和<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 和<|>RELATION_NOE 石蜡<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 和<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE .<|>RELATION_NOE
同时<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 传统<|>RELATION_NOE DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE 测序法<|>RELATION_NOE 进行<|>RELATION_NOE 平行<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 评价<|>RELATION_S REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE NSCLC<|>RELATION_NOE 和<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效能<|>RELATION_NOE 。<|>RELATION_NOE
REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE EGFR<|>RELATION_NOE 和<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 突变<|>RELATION_NOE 位<|>RELATION_NOE 点<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 均<|>RELATION_NOE 达<|>RELATION_NOE 0.1%<|>RELATION_NOE ,<|>RELATION_NOE 传统<|>RELATION_NOE DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 灵敏度<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 1.0%<|>RELATION_NOE ,<|>RELATION_NOE REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE 含<|>RELATION_NOE 0.1%<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 质粒<|>RELATION_NOE 标准品<|>RELATION_NOE 重复<|>RELATION_NOE 2－<|>RELATION_NOE 3<|>RELATION_NOE 次<|>RELATION_NOE 检测<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 阳性<|>RELATION_NOE .<|>RELATION_NOE
REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 、<|>RELATION_NOE 传统<|>RELATION_NOE DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 总<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 27.5%<|>RELATION_NOE 、<|>RELATION_NOE 16.7%<|>RELATION_NOE 和<|>RELATION_NOE 12.5%<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 总<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 38.3%<|>RELATION_NOE 、<|>RELATION_NOE 25.8%<|>RELATION_NOE 和<|>RELATION_NOE 16.7%<|>RELATION_NOE .<|>RELATION_NOE
REDE-DHPLC<|>RELATION_NOE 检测<|>RELATION_NOE 血浆<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 和<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 总<|>RELATION_NOE 突变<|>RELATION_NOE 符合率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 91.7%<|>RELATION_NOE (<|>RELATION_NOE 33<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE Kappa<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 39<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 90.2%<|>RELATION_NOE (<|>RELATION_NOE 46<|>RELATION_NOE /<|>RELATION_NOE 51<|>RELATION_NOE ,<|>RELATION_NOE Kappa<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 14<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
REDE-DHPLC<|>RELATION_NOE 法<|>RELATION_NOE 灵敏度<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE 高<|>RELATION_S ,<|>RELATION_NOE 结果<|>RELATION_NOE 易<|>RELATION_NOE 判读<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_NOE 避免<|>RELATION_NOE 纯合<|>RELATION_NOE 点突变<|>RELATION_NOE 漏检<|>RELATION_NOE ,<|>RELATION_NOE 有望<|>RELATION_NOE 成为<|>RELATION_NOE 临床<|>RELATION_NOE 实验室<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE EGFR<|>RELATION_NOE 和<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 推广<|>RELATION_NOE 方法.<|>RELATION_NOE
肿瘤骨<|>RELATION_NOE 转移<|>RELATION_NOE 疼痛<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE ^<|>RELATION_NOE 188Re-HEDP<|>RELATION_NOE 的<|>RELATION_NOE 耐受性<|>RELATION_S 研究<|>RELATION_NOE
评价<|>RELATION_S ^<|>RELATION_NOE 188Re-1<|>RELATION_NOE -<|>RELATION_NOE 羟基<|>RELATION_NOE -1<|>RELATION_NOE ,<|>RELATION_NOE 1-<|>RELATION_NOE 二膦酸钠<|>RELATION_NOE 乙烷<|>RELATION_NOE (<|>RELATION_NOE 即<|>RELATION_NOE 依替<|>RELATION_NOE 膦酸盐<|>RELATION_NOE ,<|>RELATION_NOE HEDP<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 疼痛<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
符合<|>RELATION_NOE 入选<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 肝癌<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 直肠癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 食管癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肾癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 随<|>RELATION_NOE 时间<|>RELATION_NOE 顺序<|>RELATION_NOE 人选<|>RELATION_NOE )<|>RELATION_NOE 知情<|>RELATION_NOE 同意<|>RELATION_NOE 后<|>RELATION_NOE 接受<|>RELATION_NOE 了<|>RELATION_NOE 按<|>RELATION_NOE 体质<|>RELATION_NOE 量肘<|>RELATION_NOE 静脉<|>RELATION_NOE 单次<|>RELATION_NOE 注射<|>RELATION_NOE ^<|>RELATION_NOE 188ReHEDP<|>RELATION_NOE ,<|>RELATION_NOE 据<|>RELATION_NOE 药物<|>RELATION_NOE 递增<|>RELATION_NOE 剂量<|>RELATION_NOE 分为<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 20<|>RELATION_NOE MBq<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 组<|>RELATION_NOE 6例<|>RELATION_NOE 、<|>RELATION_NOE 30<|>RELATION_NOE MBq<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 组<|>RELATION_NOE 6例<|>RELATION_NOE 、<|>RELATION_NOE 40<|>RELATION_NOE MBq<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 组<|>RELATION_NOE 9例<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE MBq<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 组<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE .<|>RELATION_NOE
观察<|>RELATION_NOE 指标<|>RELATION_NOE 包括<|>RELATION_NOE 给<|>RELATION_NOE 药前<|>RELATION_NOE 及<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 8<|>RELATION_NOE 周<|>RELATION_NOE 内<|>RELATION_NOE 每<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生命体征<|>RELATION_NOE (<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 6<|>RELATION_NOE ,<|>RELATION_NOE 12<|>RELATION_NOE ,<|>RELATION_NOE 24<|>RELATION_NOE ,<|>RELATION_NOE 48<|>RELATION_NOE ,<|>RELATION_NOE 72h<|>RELATION_NOE 和<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 2,3<|>RELATION_NOE ,<|>RELATION_NOE 4<|>RELATION_NOE ,<|>RELATION_NOE 6<|>RELATION_NOE ,<|>RELATION_NOE 8周<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血细胞计数<|>RELATION_NOE (<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 2,3<|>RELATION_NOE ,<|>RELATION_NOE 4<|>RELATION_NOE ,<|>RELATION_NOE 6<|>RELATION_NOE 和<|>RELATION_NOE 8周<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 心电图<|>RELATION_NOE ,<|>RELATION_NOE 肝<|>RELATION_NOE 、<|>RELATION_NOE 肾<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE ALP<|>RELATION_NOE (<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 4<|>RELATION_NOE ,<|>RELATION_NOE 8周<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE "<|>RELATION_NOE 反<|>RELATION_NOE 跳痛<|>RELATION_NOE "<|>RELATION_NOE 以及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 等<|>RELATION_NOE .<|>RELATION_NOE
30<|>RELATION_NOE MBq<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 组<|>RELATION_NOE 5例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 2例<|>RELATION_NOE 白细胞<|>RELATION_NOE 出现<|>RELATION_NOE WHO<|>RELATION_NOE Ⅰ级<|>RELATION_NOE 毒性<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 1例<|>RELATION_NOE 合并<|>RELATION_NOE 血小板<|>RELATION_NOE Ⅲ<|>RELATION_NOE 级<|>RELATION_NOE 毒性<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 8周<|>RELATION_NOE 白细胞<|>RELATION_NOE 和<|>RELATION_NOE 血小板<|>RELATION_NOE 均<|>RELATION_NOE 恢复<|>RELATION_NOE 正常<|>RELATION_NOE ;<|>RELATION_NOE
40<|>RELATION_NOE MBq<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 组<|>RELATION_NOE 8例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 2例<|>RELATION_NOE 白细胞<|>RELATION_NOE 和<|>RELATION_NOE 血小板<|>RELATION_NOE 同时<|>RELATION_NOE 出现<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE WHO<|>RELATION_NOE Ⅰ级<|>RELATION_NOE 和<|>RELATION_NOE Ⅱ级<|>RELATION_NOE ,<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 白细胞<|>RELATION_NOE 和<|>RELATION_NOE 血小板<|>RELATION_NOE 同时<|>RELATION_NOE 、<|>RELATION_NOE 同级<|>RELATION_NOE 减<|>RELATION_NOE 低<|>RELATION_NOE ;<|>RELATION_NOE
白细胞<|>RELATION_NOE 均<|>RELATION_NOE 在<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 6周达<|>RELATION_NOE 最低<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 5.4<|>RELATION_NOE ×<|>RELATION_NOE 109/<|>RELATION_NOE L<|>RELATION_NOE (<|>RELATION_NOE 两者<|>RELATION_NOE 与<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 前<|>RELATION_NOE 基线值<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.13<|>RELATION_NOE 25<|>RELATION_NOE 和<|>RELATION_NOE 3.3<|>RELATION_NOE 156<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 8周<|>RELATION_NOE 自<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 血小板<|>RELATION_NOE 均<|>RELATION_NOE 恢复<|>RELATION_NOE 到<|>RELATION_NOE 基线<|>RELATION_NOE 水平<|>RELATION_NOE ;<|>RELATION_NOE
按体<|>RELATION_NOE 质量<|>RELATION_NOE 注射<|>RELATION_NOE 188Re-HEDP<|>RELATION_NOE 20<|>RELATION_NOE ,<|>RELATION_NOE 30<|>RELATION_NOE ,<|>RELATION_NOE 40<|>RELATION_NOE 和<|>RELATION_NOE 50<|>RELATION_NOE MBq<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤骨<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 毒性<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 随着<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 剂量<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 188Re-HEDP<|>RELATION_NOE 对<|>RELATION_NOE 骨髓<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 有<|>RELATION_NOE 增加<|>RELATION_S 趋势.<|>RELATION_NOE
应用<|>RELATION_NOE 四维<|>RELATION_NOE CT<|>RELATION_NOE 评价<|>RELATION_S 肺癌<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 随<|>RELATION_NOE 呼吸运动<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE 及<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE
肺肿瘤<|>RELATION_NOE 运动<|>RELATION_NOE 规律<|>RELATION_NOE 及其<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
搜集<|>RELATION_NOE 射波刀<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 原发<|>RELATION_NOE 或<|>RELATION_NOE 转移<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE 共<|>RELATION_NOE 83<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 7例<|>RELATION_NOE 患者<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 侵犯<|>RELATION_NOE 胸壁<|>RELATION_NOE 。<|>RELATION_NOE
相关<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE z<|>RELATION_NOE 、<|>RELATION_NOE Y<|>RELATION_NOE 、<|>RELATION_NOE z<|>RELATION_NOE 轴<|>RELATION_NOE 方向<|>RELATION_NOE 移动<|>RELATION_NOE 距离<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 身高<|>RELATION_NOE 、<|>RELATION_NOE 体重<|>RELATION_NOE 和<|>RELATION_NOE 1S<|>RELATION_NOE 呼吸率<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE -0.001<|>RELATION_NOE －0.1<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
呼吸<|>RELATION_NOE 导致<|>RELATION_NOE 的<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 移动<|>RELATION_NOE 距离<|>RELATION_NOE 主要<|>RELATION_NOE 受<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 和<|>RELATION_NOE 是否<|>RELATION_NOE 侵犯<|>RELATION_NOE 胸壁<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 了解<|>RELATION_NOE 其<|>RELATION_NOE 运动<|>RELATION_NOE 规律<|>RELATION_NOE 及<|>RELATION_NOE
56<|>RELATION_NOE 例<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 加<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 长期<|>RELATION_B 疗效<|>RELATION_I 分析<|>RELATION_E
分析<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE 3DCRT<|>RELATION_NOE )<|>RELATION_NOE 疗效<|>RELATION_B 和<|>RELATION_I 不良<|>RELATION_I 反应<|>RELATION_E ,<|>RELATION_NOE 以及<|>RELATION_NOE 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
Logrank<|>RELATION_NOE 检验<|>RELATION_NOE 显示<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 卡氏<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 模式<|>RELATION_NOE 、<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 显著<|>RELATION_B 影响<|>RELATION_E 生存率<|>RELATION_NOE ,<|>RELATION_NOE Cox<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 模式<|>RELATION_NOE 和<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 为<|>RELATION_NOE 独立<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 2级<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 3级<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 晚期<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 2级<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 3级<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
3DCRT<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 较<|>RELATION_NOE 早<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 剂量<|>RELATION_NOE ≥<|>RELATION_NOE 60Gy<|>RELATION_NOE 的<|>RELATION_NOE 化放疗<|>RELATION_NOE 、<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 生存率<|>RELATION_NOE 较<|>RELATION_B 好<|>RELATION_E ,<|>RELATION_NOE 放射性<|>RELATION_NOE 损伤<|>RELATION_NOE 在<|>RELATION_NOE 可<|>RELATION_NOE 接受<|>RELATION_NOE 范围<|>RELATION_NOE 。<|>RELATION_NOE
适合<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE 3DCRT<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE ,<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位于<|>RELATION_NOE 肺上叶<|>RELATION_NOE 为<|>RELATION_NOE 肺上叶组<|>RELATION_NOE ,<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位于<|>RELATION_NOE 肺中下叶<|>RELATION_NOE 为<|>RELATION_NOE 肺中下叶组<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 于<|>RELATION_NOE 同<|>RELATION_NOE 次<|>RELATION_NOE CT<|>RELATION_NOE 模拟<|>RELATION_NOE 定位<|>RELATION_NOE 时<|>RELATION_NOE 序贯<|>RELATION_NOE 完成<|>RELATION_NOE 胸部<|>RELATION_NOE 常规<|>RELATION_NOE 3D-CT<|>RELATION_NOE 轴位<|>RELATION_NOE 扫描<|>RELATION_NOE 和<|>RELATION_NOE 4D-CT<|>RELATION_NOE 扫描<|>RELATION_NOE 。<|>RELATION_NOE
X<|>RELATION_NOE 射线<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE Pokemon<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
研究<|>RELATION_NOE 不同<|>RELATION_NOE 剂量<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 及<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 点<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE Pokemon<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
用<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 和<|>RELATION_NOE 8Gy<|>RELATION_NOE 的<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48<|>RELATION_NOE 和<|>RELATION_NOE 72h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 其中<|>RELATION_NOE 的<|>RELATION_NOE PokemonmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 未<|>RELATION_NOE 照射组<|>RELATION_NOE 为<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
较<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 在<|>RELATION_NOE 早期<|>RELATION_NOE 可<|>RELATION_NOE 下调<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE Pokemon<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 诱导<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ;<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 在<|>RELATION_NOE 早期<|>RELATION_NOE 可<|>RELATION_NOE 下调<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE Pokemon<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 诱导<|>RELATION_S 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ;<|>RELATION_NOE
2006<|>RELATION_NOE －<|>RELATION_NOE 2009年<|>RELATION_NOE 瓦房店市<|>RELATION_NOE 红沿河<|>RELATION_NOE 核电站<|>RELATION_NOE 周围<|>RELATION_NOE 居民<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡<|>RELATION_B 基线<|>RELATION_I 调查<|>RELATION_E
选取<|>RELATION_NOE 对<|>RELATION_NOE 辐射<|>RELATION_NOE 敏感<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE (<|>RELATION_NOE 白血病<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 死亡<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
瓦房店市<|>RELATION_NOE 2006-2009<|>RELATION_NOE 年<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 15<|>RELATION_NOE 1.97<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5<|>RELATION_NOE (<|>RELATION_NOE 标化率<|>RELATION_NOE 97.76<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 18<|>RELATION_NOE 8.28<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5<|>RELATION_NOE (<|>RELATION_NOE 标化率<|>RELATION_NOE 11<|>RELATION_NOE 6.76<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 11<|>RELATION_NOE 3.47<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5<|>RELATION_NOE (<|>RELATION_NOE 标化率<|>RELATION_NOE 75.89<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 性别<|>RELATION_NOE 比值<|>RELATION_NOE 为<|>RELATION_NOE 1.71<|>RELATION_NOE 。<|>RELATION_NOE
恶性肿瘤<|>RELATION_NOE 死亡<|>RELATION_NOE 顺位<|>RELATION_B 前<|>RELATION_I 5<|>RELATION_I 位<|>RELATION_E 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 和<|>RELATION_NOE 食管癌<|>RELATION_NOE ;<|>RELATION_NOE
与<|>RELATION_NOE 核辐射<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 白血病<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 的<|>RELATION_NOE 死亡率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.57<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 4.06<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5和<|>RELATION_NOE 0.26<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 5<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 前后<|>RELATION_NOE 肺功能<|>RELATION_NOE 的<|>RELATION_NOE 动态<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 研究<|>RELATION_NOE
68<|>RELATION_NOE 例<|>RELATION_NOE 未<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 男<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 年龄<|>RELATION_NOE 52<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE KPS<|>RELATION_NOE 评分<|>RELATION_NOE ≥<|>RELATION_NOE 80<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE ,<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 及<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 检查<|>RELATION_NOE 肺功能<|>RELATION_NOE 主要<|>RELATION_NOE 参数<|>RELATION_NOE 用力肺活量<|>RELATION_NOE (<|>RELATION_NOE FVC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 1S<|>RELATION_NOE 用力呼气量<|>RELATION_NOE (<|>RELATION_NOE FEV1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 一氧化碳<|>RELATION_NOE 弥散量<|>RELATION_NOE (<|>RELATION_NOE CLCO<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 观察<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 及<|>RELATION_NOE 程度<|>RELATION_NOE 。<|>RELATION_NOE
小细胞肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE DLCO<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE FEVl<|>RELATION_NOE 和<|>RELATION_NOE DLCO<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE DLCO<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE FEVl<|>RELATION_NOE 和<|>RELATION_NOE DLCO<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E 。<|>RELATION_NOE
伊利<|>RELATION_NOE 替<|>RELATION_NOE 康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_NOE 盐酸<|>RELATION_NOE 伊利<|>RELATION_NOE 替<|>RELATION_NOE 康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 采用<|>RELATION_NOE 盐酸<|>RELATION_NOE 伊利<|>RELATION_NOE 替<|>RELATION_NOE 康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 评定<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
毒副反应<|>RELATION_NOE 主要<|>RELATION_B 有<|>RELATION_E 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 腹泻<|>RELATION_NOE 、<|>RELATION_NOE 肝功能<|>RELATION_NOE 受损<|>RELATION_NOE 及<|>RELATION_NOE 粒缺<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 发热<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
49<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 白细胞<|>RELATION_NOE 减少<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 46.9%<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 恶心<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 22.4%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 10.0%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肝功能<|>RELATION_NOE 异常<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 8.o<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
PET-CT<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 精确<|>RELATION_NOE 放疗<|>RELATION_NOE 靶区<|>RELATION_NOE 勾画<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 体层<|>RELATION_NOE 显像<|>RELATION_NOE (<|>RELATION_NOE PET<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE CT<|>RELATION_NOE 同机<|>RELATION_NOE 融合<|>RELATION_NOE 图像<|>RELATION_NOE (<|>RELATION_NOE PET-CT<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 靶区<|>RELATION_NOE (<|>RELATION_NOE GTV<|>RELATION_NOE )<|>RELATION_NOE 勾画<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
选取<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 具有<|>RELATION_NOE 典型<|>RELATION_NOE 影像<|>RELATION_NOE 表现<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE PET-CT<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 其<|>RELATION_NOE 影像学<|>RELATION_NOE 特点<|>RELATION_NOE 将<|>RELATION_NOE 所有<|>RELATION_NOE 病例<|>RELATION_NOE 分为<|>RELATION_NOE 3组<|>RELATION_NOE ,<|>RELATION_NOE 肺不张<|>RELATION_NOE 组<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 纵隔<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 外<|>RELATION_NOE 周型<|>RELATION_NOE 单纯<|>RELATION_NOE 肺内病<|>RELATION_NOE 灶组<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
伴<|>RELATION_NOE 肺门<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 使用<|>RELATION_NOE PET-CT<|>RELATION_NOE 勾画<|>RELATION_NOE 靶区<|>RELATION_NOE 可<|>RELATION_NOE 获得<|>RELATION_B 更<|>RELATION_I 大<|>RELATION_I 受益<|>RELATION_E ,<|>RELATION_NOE 其次<|>RELATION_NOE 为<|>RELATION_NOE 肺不张<|>RELATION_NOE ,<|>RELATION_NOE 外<|>RELATION_NOE 周型<|>RELATION_NOE 单纯<|>RELATION_NOE 肺内病<|>RELATION_NOE 灶<|>RELATION_NOE 受益<|>RELATION_NOE 最<|>RELATION_NOE 小<|>RELATION_NOE 。<|>RELATION_NOE
吉西他滨<|>RELATION_NOE 、<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE
采用<|>RELATION_NOE 随机<|>RELATION_NOE 对照<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 随机表法<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE GC<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨+<|>RELATION_NOE 卡铂<|>RELATION_NOE )<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE NC<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE +<|>RELATION_NOE 卡铂<|>RELATION_NOE )<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
给<|>RELATION_NOE 药<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 吉西<|>RELATION_NOE 他滨<|>RELATION_NOE 1000mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 在<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 卡铂<|>RELATION_NOE AUC<|>RELATION_NOE =<|>RELATION_NOE 5<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 微<|>RELATION_NOE 转移<|>RELATION_NOE 分子<|>RELATION_NOE 标志物<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CK19<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 外周<|>RELATION_NOE 血肺<|>RELATION_NOE 组织<|>RELATION_NOE 特异性<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE Lunx<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 对于<|>RELATION_NOE 肿瘤微转移<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 反转录<|>RELATION_NOE 一<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CK19<|>RELATION_NOE 、<|>RELATION_NOE LunxmRNA<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_S 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE Lunx<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CK19<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 52.2%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 43.5%<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 41.3%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE I<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE LunxmRNA<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 为<|>RELATION_NOE 16.6%<|>RELATION_NOE (<|>RELATION_NOE 1/6<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 44.4%<|>RELATION_NOE (<|>RELATION_NOE 4/9<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 50.0%<|>RELATION_NOE (<|>RELATION_NOE 7/14<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 70.6%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 17<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CEAmRNA<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 为<|>RELATION_NOE 16.6%<|>RELATION_NOE (<|>RELATION_NOE 1/6<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 33<|>RELATION_NOE _<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 3/9<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 50.0%<|>RELATION_NOE (<|>RELATION_NOE 7/14<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 52.9%<|>RELATION_NOE (<|>RELATION_NOE 9/17<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CKl9mRNA<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE (<|>RELATION_NOE 0/6<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 22.2%<|>RELATION_NOE (<|>RELATION_NOE 2/9<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 42.9%<|>RELATION_NOE (<|>RELATION_NOE 6/14<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 64.7%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 17<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE Fisher<|>RELATION_NOE 精确<|>RELATION_NOE 概率<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_B 抑制<|>RELATION_E 作用<|>RELATION_NOE
选择<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE SPC-A-1<|>RELATION_NOE 细胞株<|>RELATION_NOE ,<|>RELATION_NOE PI<|>RELATION_NOE 标记<|>RELATION_NOE 后<|>RELATION_NOE 应用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 观察<|>RELATION_S 细胞凋亡<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE Transweu<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 情况<|>RELATION_NOE ;<|>RELATION_NOE 选择<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE SPC-A-1<|>RELATION_NOE 细胞株<|>RELATION_NOE ,<|>RELATION_NOE PI<|>RELATION_NOE 标记<|>RELATION_NOE 后<|>RELATION_NOE 应用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 观察<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE Transweu<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 情况<|>RELATION_NOE ;<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 能<|>RELATION_NOE 抑制<|>RELATION_S 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 诱导<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 作用<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 下调<|>RELATION_NOE 活化<|>RELATION_NOE 的<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 信号<|>RELATION_NOE 转导<|>RELATION_NOE 通路<|>RELATION_NOE 关键<|>RELATION_NOE 酶<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 能<|>RELATION_NOE 抑制<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 诱导<|>RELATION_S 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 作用<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 下调<|>RELATION_NOE 活化<|>RELATION_NOE 的<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 信号<|>RELATION_NOE 转导<|>RELATION_NOE 通路<|>RELATION_NOE 关键<|>RELATION_NOE 酶<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE Foxp<|>RELATION_NOE ^<|>RELATION_NOE 3+<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 月龄<|>RELATION_NOE 小鼠<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_S 及<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 关系<|>RELATION_NOE
探讨<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE Foxp<|>RELATION_NOE ^<|>RELATION_NOE 3+<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE (<|>RELATION_NOE Treg<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 衰老<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_S 及<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 36<|>RELATION_NOE 只<|>RELATION_NOE C57BL<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 小鼠<|>RELATION_NOE 分成<|>RELATION_NOE 6组<|>RELATION_NOE ,<|>RELATION_NOE 青年<|>RELATION_NOE 健康组<|>RELATION_NOE 、<|>RELATION_NOE 中年<|>RELATION_NOE 健康组<|>RELATION_NOE 、<|>RELATION_NOE 老年<|>RELATION_NOE 健康组<|>RELATION_NOE 以及<|>RELATION_NOE 青年<|>RELATION_NOE 肿瘤组<|>RELATION_NOE 、<|>RELATION_NOE 中年<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 老年<|>RELATION_NOE 肿瘤组<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 流式<|>RELATION_NOE 细胞<|>RELATION_NOE 分析法<|>RELATION_NOE 测定<|>RELATION_S 6组<|>RELATION_NOE 小鼠<|>RELATION_NOE 脾脏<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE Foxp<|>RELATION_NOE ^<|>RELATION_NOE 3+<|>RELATION_NOE Treg<|>RELATION_NOE 占<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 百分比<|>RELATION_NOE 来<|>RELATION_NOE 反映<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE Foxp<|>RELATION_NOE ^<|>RELATION_NOE 3+<|>RELATION_NOE Treg<|>RELATION_NOE 细胞<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 通过<|>RELATION_NOE 流式<|>RELATION_NOE 细胞<|>RELATION_NOE 分析法<|>RELATION_NOE 测定<|>RELATION_NOE 6组<|>RELATION_NOE 小鼠<|>RELATION_NOE 脾脏<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE Foxp<|>RELATION_NOE ^<|>RELATION_NOE 3+<|>RELATION_NOE Treg<|>RELATION_NOE 占<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 百分比<|>RELATION_NOE 来<|>RELATION_NOE 反映<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE Foxp<|>RELATION_NOE ^<|>RELATION_NOE 3+<|>RELATION_NOE Treg<|>RELATION_NOE 细胞<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S Foxp3mRNA<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 健康组<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 年龄段<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE Foxp<|>RELATION_NOE ^<|>RELATION_NOE 3+/<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 47.70<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Foxp3mRNA<|>RELATION_NOE (<|>RELATION_NOE F6.56<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.009<|>RELATION_NOE )<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 老年<|>RELATION_NOE 鼠<|>RELATION_NOE 脾脏<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 含有<|>RELATION_NOE 高<|>RELATION_NOE 数量<|>RELATION_NOE 的<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE Foxp<|>RELATION_NOE ^<|>RELATION_NOE 3+<|>RELATION_NOE '<|>RELATION_NOE Treg<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE Foxp3mRNA<|>RELATION_NOE ,<|>RELATION_NOE 最高组<|>RELATION_NOE 是<|>RELATION_NOE 老年<|>RELATION_NOE 肺肿<|>RELATION_NOE 瘤鼠<|>RELATION_NOE 。<|>RELATION_NOE
甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE 误诊<|>RELATION_NOE 原因<|>RELATION_B 及<|>RELATION_I 对策<|>RELATION_I 分析<|>RELATION_E
术前<|>RELATION_NOE B<|>RELATION_NOE 超<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 冰冻<|>RELATION_NOE 检查<|>RELATION_NOE 、<|>RELATION_NOE 必要<|>RELATION_NOE 时<|>RELATION_NOE 行<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE CKl9<|>RELATION_NOE 、<|>RELATION_NOE Galectin-3<|>RELATION_NOE 有助于<|>RELATION_NOE 提高<|>RELATION_S TMC<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 及时<|>RELATION_NOE 选择<|>RELATION_NOE 合理<|>RELATION_NOE 的<|>RELATION_NOE 外科术式<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 减少<|>RELATION_NOE 并发症<|>RELATION_NOE ;<|>RELATION_NOE 术前<|>RELATION_NOE B<|>RELATION_NOE 超<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 冰冻<|>RELATION_NOE 检查<|>RELATION_NOE 、<|>RELATION_NOE 必要<|>RELATION_NOE 时行<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE CKl9<|>RELATION_NOE 、<|>RELATION_NOE Galectin-3<|>RELATION_NOE 有助于<|>RELATION_NOE 提高<|>RELATION_S TMC<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 及时<|>RELATION_NOE 选择<|>RELATION_NOE 合理<|>RELATION_NOE 的<|>RELATION_NOE 外科术式<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 减少<|>RELATION_NOE 并发症<|>RELATION_NOE ;<|>RELATION_NOE
晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 联合<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 效果<|>RELATION_B 分析<|>RELATION_E
所有<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 放疗<|>RELATION_NOE 期间<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_NOE 完成<|>RELATION_NOE 放疗<|>RELATION_NOE 联合<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 腹泻<|>RELATION_NOE ,<|>RELATION_NOE 8例<|>RELATION_NOE 伴发<|>RELATION_NOE 呕吐<|>RELATION_NOE ,<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 合并<|>RELATION_NOE 有<|>RELATION_NOE 皮疹<|>RELATION_NOE 。<|>RELATION_NOE
针对<|>RELATION_NOE Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE ,<|>RELATION_NOE 姑息性<|>RELATION_NOE 放疗<|>RELATION_NOE 联合<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 是<|>RELATION_NOE 有效<|>RELATION_B 而<|>RELATION_I 安全<|>RELATION_I 的<|>RELATION_I 治疗<|>RELATION_I 方法<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 需要<|>RELATION_NOE 进一步<|>RELATION_NOE 观察<|>RELATION_NOE 。<|>RELATION_NOE
复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 联合<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 对<|>RELATION_NOE 移植性<|>RELATION_NOE 小鼠<|>RELATION_NOE lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 抑瘤率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 联合<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 对<|>RELATION_NOE 移植性<|>RELATION_NOE 小鼠<|>RELATION_NOE lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 抑瘤率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
构建<|>RELATION_NOE lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 体重<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 模型<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE CTX<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆组<|>RELATION_NOE 、<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 联合<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 联合<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 1组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 中<|>RELATION_NOE 剂量<|>RELATION_NOE 联合<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 联合<|>RELATION_NOE 用药<|>RELATION_NOE 2组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 小<|>RELATION_NOE 剂量<|>RELATION_NOE 联合<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 联合<|>RELATION_NOE 用药<|>RELATION_NOE 3组<|>RELATION_NOE )<|>RELATION_NOE 共<|>RELATION_NOE 6组<|>RELATION_NOE 各<|>RELATION_NOE 10<|>RELATION_NOE 只<|>RELATION_NOE 。<|>RELATION_NOE
联合<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 1组<|>RELATION_NOE 给予<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 原液<|>RELATION_NOE 0.4ml<|>RELATION_NOE 灌胃<|>RELATION_NOE 、<|>RELATION_NOE 隔日<|>RELATION_NOE 腹腔<|>RELATION_NOE 注射<|>RELATION_NOE CTX0.2ml<|>RELATION_NOE :<|>RELATION_NOE 联合<|>RELATION_NOE 用药<|>RELATION_NOE 2组<|>RELATION_NOE 给予<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 原液<|>RELATION_NOE 0.2ml<|>RELATION_NOE 加<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 0.2ml<|>RELATION_NOE 混合<|>RELATION_NOE 后<|>RELATION_NOE 灌胃<|>RELATION_NOE 、<|>RELATION_NOE 隔日<|>RELATION_NOE 腹腔<|>RELATION_NOE 注射<|>RELATION_NOE CTX0.2ml<|>RELATION_NOE ;<|>RELATION_NOE
联合<|>RELATION_NOE 用药<|>RELATION_NOE 与<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制率<|>RELATION_NOE 均<|>RELATION_NOE 在<|>RELATION_NOE 50%<|>RELATION_NOE 以上<|>RELATION_NOE ,<|>RELATION_NOE 复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制率<|>RELATION_NOE 为<|>RELATION_NOE 25.8<|>RELATION_NOE 8%<|>RELATION_NOE 。<|>RELATION_NOE
缓激肽<|>RELATION_NOE 促进<|>RELATION_S 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 及其<|>RELATION_NOE 机制<|>RELATION_NOE
观察<|>RELATION_NOE 缓激肽<|>RELATION_NOE (<|>RELATION_NOE BK<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE A549<|>RELATION_NOE 迁移<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
dsRNA<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE PTEN<|>RELATION_NOE 基因表达<|>RELATION_NOE 上调<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
观察<|>RELATION_NOE 以<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 非<|>RELATION_NOE CpG<|>RELATION_NOE 岛序<|>RELATION_NOE 列为<|>RELATION_NOE 靶点<|>RELATION_NOE 的<|>RELATION_NOE dsRNA<|>RELATION_NOE 促进<|>RELATION_NOE PTEN<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE RNAa<|>RELATION_NOE 现象<|>RELATION_NOE 对<|>RELATION_NOE PTEN<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE DNA<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
将<|>RELATION_NOE 与<|>RELATION_NOE P<|>RELATION_NOE TEN<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 非<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE DNA<|>RELATION_NOE 序列<|>RELATION_NOE 互补<|>RELATION_NOE 的<|>RELATION_NOE 双链<|>RELATION_NOE RNA<|>RELATION_NOE 分子<|>RELATION_NOE (<|>RELATION_NOE dsPTEN<|>RELATION_NOE )<|>RELATION_NOE 转染<|>RELATION_S 入<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE H292<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE real-time<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE PTEN<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 筛选<|>RELATION_NOE 能够<|>RELATION_NOE 促进<|>RELATION_NOE PTEN<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE dsRNA<|>RELATION_NOE 序列<|>RELATION_NOE 。<|>RELATION_NOE 将<|>RELATION_NOE 与<|>RELATION_NOE PTEN<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 非<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE DNA<|>RELATION_NOE 序列<|>RELATION_NOE 互补<|>RELATION_NOE 的<|>RELATION_NOE 双链<|>RELATION_NOE RNA<|>RELATION_NOE 分子<|>RELATION_NOE (<|>RELATION_NOE dsPTEN<|>RELATION_NOE )<|>RELATION_NOE 转染<|>RELATION_NOE 入<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE H292<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE real-time<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S PTEN<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 筛选<|>RELATION_NOE 能够<|>RELATION_NOE 促进<|>RELATION_NOE PTEN<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE dsRNA<|>RELATION_NOE 序列<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 产物<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S dsRNA<|>RELATION_NOE 转染<|>RELATION_NOE 前后<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 甲基化<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 多<|>RELATION_NOE 条<|>RELATION_NOE dsRNA<|>RELATION_NOE 分别<|>RELATION_NOE 转染<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 证实<|>RELATION_NOE 针对<|>RELATION_NOE PTEN<|>RELATION_NOE 基因<|>RELATION_NOE -57<|>RELATION_NOE 到<|>RELATION_NOE -38<|>RELATION_NOE 的<|>RELATION_NOE 序列<|>RELATION_NOE (<|>RELATION_NOE dsPTEN2—2<|>RELATION_NOE )<|>RELATION_NOE 转染<|>RELATION_NOE H292<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 出现<|>RELATION_NOE PTEN<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 明显<|>RELATION_B 上调<|>RELATION_E ,<|>RELATION_NOE 上调<|>RELATION_NOE 最高<|>RELATION_NOE 达<|>RELATION_NOE 5.1<|>RELATION_NOE 倍<|>RELATION_NOE (<|>RELATION_NOE 与<|>RELATION_NOE 对照<|>RELATION_NOE dsRNA<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 证实<|>RELATION_NOE 了<|>RELATION_NOE RNAa<|>RELATION_NOE 现象<|>RELATION_NOE 的<|>RELATION_NOE 存在<|>RELATION_NOE ;<|>RELATION_NOE
使用<|>RELATION_NOE 5-Aza<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE H292<|>RELATION_NOE 细胞<|>RELATION_NOE 与<|>RELATION_NOE 空白<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE CpG<|>RELATION_NOE 点<|>RELATION_NOE 甲基化<|>RELATION_NOE 明显<|>RELATION_B 减少<|>RELATION_E (<|>RELATION_NOE 5<|>RELATION_NOE ±<|>RELATION_NOE 3<|>RELATION_NOE 比<|>RELATION_NOE 10<|>RELATION_NOE ±<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE ±<|>RELATION_NOE 3比9<|>RELATION_NOE ±<|>RELATION_NOE 3<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 转染<|>RELATION_NOE PTEN2—2dsRNA<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE 细胞株<|>RELATION_NOE
dsRNA<|>RELATION_NOE 可以<|>RELATION_NOE 促进<|>RELATION_S PTEN<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 上调<|>RELATION_NOE ,<|>RELATION_NOE RNAa<|>RELATION_NOE 现象<|>RELATION_NOE 并<|>RELATION_NOE 不<|>RELATION_NOE 改变<|>RELATION_NOE PTEN<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 甲基化<|>RELATION_NOE 程度<|>RELATION_NOE 。<|>RELATION_NOE dsRNA<|>RELATION_NOE 可以<|>RELATION_NOE 促进<|>RELATION_NOE PTEN<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 上调<|>RELATION_NOE ,<|>RELATION_NOE RNAa<|>RELATION_NOE 现象<|>RELATION_NOE 并<|>RELATION_NOE 不<|>RELATION_B 改变<|>RELATION_E PTEN<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 甲基化<|>RELATION_NOE 程度<|>RELATION_NOE 。<|>RELATION_NOE
生理性<|>RELATION_NOE 雌激素<|>RELATION_NOE 对<|>RELATION_NOE 大鼠<|>RELATION_NOE 肝癌<|>RELATION_NOE 生成<|>RELATION_NOE 的<|>RELATION_NOE 保护<|>RELATION_B 作用<|>RELATION_E
观察<|>RELATION_NOE 生理性<|>RELATION_NOE 雌激素<|>RELATION_NOE 在<|>RELATION_NOE 化学性<|>RELATION_NOE 诱导<|>RELATION_NOE 大鼠<|>RELATION_NOE 肝癌<|>RELATION_NOE 生成<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 。<|>RELATION_NOE
联合<|>RELATION_NOE 应用<|>RELATION_NOE 二乙基<|>RELATION_NOE 亚硝胺<|>RELATION_NOE (<|>RELATION_NOE DEN<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE N-<|>RELATION_NOE 亚硝基吗啉<|>RELATION_NOE (<|>RELATION_NOE NMOR<|>RELATION_NOE )<|>RELATION_NOE 建立<|>RELATION_NOE 诱导性<|>RELATION_NOE 大鼠<|>RELATION_NOE 高<|>RELATION_NOE 转移<|>RELATION_NOE 肝癌<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 去<|>RELATION_NOE 卵巢<|>RELATION_NOE +<|>RELATION_NOE 雌激素组<|>RELATION_NOE 大鼠<|>RELATION_NOE 使用<|>RELATION_NOE 生理<|>RELATION_NOE 剂量<|>RELATION_NOE 雌激素<|>RELATION_NOE 进行<|>RELATION_NOE 干预<|>RELATION_S 。<|>RELATION_NOE
诱癌<|>RELATION_NOE 20<|>RELATION_NOE 周<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 各组<|>RELATION_NOE 大鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生成<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
诱癌<|>RELATION_NOE 20<|>RELATION_NOE 周<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 去<|>RELATION_NOE 卵巢<|>RELATION_NOE +<|>RELATION_NOE 雌激素组<|>RELATION_NOE 大鼠<|>RELATION_NOE 肝癌<|>RELATION_NOE 生成率<|>RELATION_NOE (<|>RELATION_NOE 44.44%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺转移率<|>RELATION_NOE (<|>RELATION_NOE 20.00%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肝肿瘤<|>RELATION_NOE 平均<|>RELATION_NOE 直径<|>RELATION_NOE (<|>RELATION_NOE 0.39<|>RELATION_NOE ±<|>RELATION_NOE 0.24<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_S 去<|>RELATION_NOE 卵巢<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 92.59%<|>RELATION_NOE 、<|>RELATION_NOE 65.2<|>RELATION_NOE 1%<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 0.95<|>RELATION_NOE ±<|>RELATION_NOE 1.22<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
实验<|>RELATION_NOE 终点<|>RELATION_NOE 前<|>RELATION_NOE 去<|>RELATION_NOE 卵巢<|>RELATION_NOE +<|>RELATION_NOE 雌激素组<|>RELATION_NOE 死亡<|>RELATION_NOE 大鼠<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE 79.54<|>RELATION_NOE ±<|>RELATION_NOE 4.14<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 也<|>RELATION_NOE 显著<|>RELATION_NOE 长于<|>RELATION_S 去<|>RELATION_NOE 卵巢<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 59.54<|>RELATION_NOE ±<|>RELATION_NOE 8.31<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
生理性<|>RELATION_NOE 雌激素<|>RELATION_NOE 抑制<|>RELATION_S 大鼠<|>RELATION_NOE 肝癌<|>RELATION_NOE 的<|>RELATION_NOE 生成<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 亚甲蓝<|>RELATION_NOE 与<|>RELATION_NOE Hookwire<|>RELATION_NOE 联合术<|>RELATION_NOE 前<|>RELATION_NOE 定位<|>RELATION_NOE 在<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 孤立性<|>RELATION_NOE 肺小结节<|>RELATION_NOE 切除术<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
2008年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 共<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 25<|>RELATION_NOE 枚<|>RELATION_NOE 小结节<|>RELATION_NOE ,<|>RELATION_NOE 先行<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 亚甲蓝<|>RELATION_NOE 与<|>RELATION_NOE Hookwire<|>RELATION_NOE 联合<|>RELATION_NOE 定位<|>RELATION_NOE ,<|>RELATION_NOE 后<|>RELATION_NOE 行<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 肺楔形<|>RELATION_NOE 切除<|>RELATION_NOE 术.<|>RELATION_NOE
联合<|>RELATION_NOE 定位<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE 21.64<|>RELATION_NOE ±<|>RELATION_NOE 4.76<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 成功率<|>RELATION_NOE 100%<|>RELATION_NOE ,<|>RELATION_NOE 失败率<|>RELATION_NOE 为<|>RELATION_NOE 0.<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 33.3%<|>RELATION_NOE :<|>RELATION_NOE 其中<|>RELATION_NOE 少量<|>RELATION_NOE 气胸<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 20.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胸膜<|>RELATION_NOE 反应<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 8.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 轻度<|>RELATION_NOE 咯血<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 4.2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 血胸<|>RELATION_NOE 或<|>RELATION_NOE 血气胸<|>RELATION_NOE .<|>RELATION_NOE
SPNs<|>RELATION_NOE 术后<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 诊断<|>RELATION_NOE 结果<|>RELATION_NOE :<|>RELATION_NOE 14<|>RELATION_NOE 枚<|>RELATION_NOE 为<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 11<|>RELATION_NOE 枚<|>RELATION_NOE 为<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 。<|>RELATION_NOE
SPNs<|>RELATION_NOE 术前<|>RELATION_NOE 运用<|>RELATION_NOE 亚甲蓝<|>RELATION_NOE 与<|>RELATION_NOE Hookwire<|>RELATION_NOE 联合<|>RELATION_NOE 定位<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 准确率<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 并发症<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S VATS<|>RELATION_NOE 肺楔形<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 成功率<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE SPNs<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE 具有<|>RELATION_NOE 很<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 运用<|>RELATION_NOE 。<|>RELATION_NOE
晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 回顾性研究<|>RELATION_S
研究<|>RELATION_NOE 157<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 和<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 影响<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 回顾性<|>RELATION_NOE 调查<|>RELATION_NOE 研究<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 收集<|>RELATION_NOE 2006年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 大连<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 第二<|>RELATION_NOE 医院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 经<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE SPSS<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 的<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 绘制<|>RELATION_S 生存<|>RELATION_NOE 曲线<|>RELATION_NOE .<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 胸水<|>RELATION_NOE 和<|>RELATION_NOE 多发<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 均<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
含<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 血钠<|>RELATION_B 分析<|>RELATION_E
观察<|>RELATION_NOE 既<|>RELATION_NOE 往<|>RELATION_NOE 含<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 每<|>RELATION_NOE 周期<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血<|>RELATION_NOE 钠值<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 、<|>RELATION_NOE 神志<|>RELATION_NOE 等<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 做<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 自身<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
40<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 出现<|>RELATION_NOE 低钠血症<|>RELATION_NOE 者<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 重度<|>RELATION_NOE 低钠血症<|>RELATION_NOE 者<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 中度<|>RELATION_NOE 低钠血症<|>RELATION_NOE 者<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 轻度<|>RELATION_NOE 低钠血症<|>RELATION_NOE 者<|>RELATION_NOE 7例.<|>RELATION_NOE
经<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 血钠<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_NOE 有所<|>RELATION_NOE 下降<|>RELATION_S ,<|>RELATION_NOE 降低<|>RELATION_NOE 原因<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 以下<|>RELATION_NOE 因素<|>RELATION_NOE 有关<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 使用<|>RELATION_NOE 顺铂<|>RELATION_NOE 时<|>RELATION_NOE 水化<|>RELATION_NOE 造成<|>RELATION_NOE 液体<|>RELATION_NOE 输入<|>RELATION_NOE 过<|>RELATION_NOE 多<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE 分泌<|>RELATION_NOE 综合征<|>RELATION_NOE .<|>RELATION_NOE
脑转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 观察<|>RELATION_S
其中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 9例<|>RELATION_NOE (<|>RELATION_NOE 26.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 35.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 大肠癌<|>RELATION_NOE 8例<|>RELATION_NOE (<|>RELATION_NOE 23.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 肿瘤<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 14.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 原发灶<|>RELATION_NOE 不明<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 2.9%<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
构建<|>RELATION_NOE Survivin<|>RELATION_NOE T34A<|>RELATION_NOE 质粒<|>RELATION_NOE /<|>RELATION_NOE 脂质体<|>RELATION_NOE 复合物<|>RELATION_NOE (<|>RELATION_NOE Lip-mS<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 空载<|>RELATION_NOE 质粒<|>RELATION_NOE /<|>RELATION_NOE 脂质体<|>RELATION_NOE 复合物<|>RELATION_NOE (<|>RELATION_NOE Lip-null<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
体外<|>RELATION_NOE 分别<|>RELATION_NOE 以<|>RELATION_NOE Lip-mS<|>RELATION_NOE 及<|>RELATION_NOE Lip-null<|>RELATION_NOE 转染<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 空白<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE NS<|>RELATION_NOE )<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡率<|>RELATION_NOE ;<|>RELATION_NOE
流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 体外<|>RELATION_NOE 转染<|>RELATION_NOE 不同<|>RELATION_NOE 质粒<|>RELATION_NOE 后<|>RELATION_NOE 各组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE :<|>RELATION_NOE NS<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 8.7<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE Lip-null<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 9.0<|>RELATION_NOE ±<|>RELATION_NOE 1.0)%<|>RELATION_NOE 、<|>RELATION_NOE Lip-mS<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 41.6<|>RELATION_NOE ±<|>RELATION_NOE 1.7<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE Lip-mS<|>RELATION_NOE 组<|>RELATION_NOE 相对<|>RELATION_NOE 于<|>RELATION_NOE 其他<|>RELATION_NOE 各组<|>RELATION_NOE 诱导<|>RELATION_NOE 凋亡<|>RELATION_NOE 作用<|>RELATION_NOE 显著<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
C57<|>RELATION_NOE BL<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 模型<|>RELATION_NOE 接受<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 各组<|>RELATION_NOE 小鼠<|>RELATION_NOE 抑瘤率<|>RELATION_NOE (<|>RELATION_NOE TIR<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Lip-null<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 负值<|>RELATION_NOE ,<|>RELATION_NOE Lip-mS<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 71.1%<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 小鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE Lip-mS<|>RELATION_NOE 组<|>RELATION_NOE 较<|>RELATION_NOE 其他<|>RELATION_NOE 各组<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_NOE 抑瘤<|>RELATION_NOE 作用<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 凋亡<|>RELATION_NOE 染色<|>RELATION_NOE (<|>RELATION_NOE TUNEL<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE Lip-mS<|>RELATION_NOE 组<|>RELATION_NOE 凋亡<|>RELATION_NOE 系数<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 40.0±<|>RELATION_NOE 2.3<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE NS<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 11.8<|>RELATION_NOE ±<|>RELATION_NOE 2.4<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE Lip-null<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 12.8<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 比较<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CD31<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染色<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE :<|>RELATION_NOE Lip-mS<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 6.3<|>RELATION_NOE ±<|>RELATION_NOE 0.76<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 小于<|>RELATION_NOE NS<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 47.1<|>RELATION_NOE ±<|>RELATION_NOE 1.37<|>RELATION_NOE 和<|>RELATION_NOE Lip-null<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 45.8<|>RELATION_NOE ±<|>RELATION_NOE 1.18<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
力<|>RELATION_NOE 比<|>RELATION_NOE 泰<|>RELATION_NOE 与<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
对照组<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛用量<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 配伍<|>RELATION_NOE 卡铂<|>RELATION_NOE AUC5mg<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE —<|>RELATION_NOE 28<|>RELATION_NOE 天<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 疗程<|>RELATION_NOE 。<|>RELATION_NOE
2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 6月<|>RELATION_NOE 期间<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE VATS<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE SPT<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 在<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 胸管<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 常见<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 早期<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE SPT<|>RELATION_NOE 组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE VATS<|>RELATION_NOE 组<|>RELATION_NOE 术后<|>RELATION_B 疼痛<|>RELATION_I 明显<|>RELATION_I 减轻<|>RELATION_I 、<|>RELATION_I 住院时间<|>RELATION_I 减少<|>RELATION_I 、<|>RELATION_I 围手术期<|>RELATION_I 出血量<|>RELATION_I 明显<|>RELATION_I 减少<|>RELATION_I 、<|>RELATION_I 术后<|>RELATION_I 早期<|>RELATION_I 生存<|>RELATION_I 质量<|>RELATION_I 明显<|>RELATION_I 受益<|>RELATION_E ;<|>RELATION_NOE
免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 转运<|>RELATION_NOE 蛋白1<|>RELATION_NOE 和<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE 1<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
评价<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 转运<|>RELATION_NOE 蛋白1<|>RELATION_NOE (<|>RELATION_NOE GLUT-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE TTF-1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
选择<|>RELATION_NOE 经<|>RELATION_NOE 组织学<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 继发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 恶性<|>RELATION_NOE 间皮瘤<|>RELATION_NOE 8例<|>RELATION_NOE 为<|>RELATION_NOE 恶性组<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 良性<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S GLUT-1<|>RELATION_NOE 及<|>RELATION_NOE TTF-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
1<|>RELATION_NOE 诊断<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 94.2<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 49<|>RELATION_NOE /<|>RELATION_NOE 52<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 97.3<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE 37<|>RELATION_NOE ,<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
恶性组<|>RELATION_NOE TTF-1<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 42.3<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 52<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 良性<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 0<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE TTF-1<|>RELATION_NOE 诊断<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 42.3<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 52<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 0.00%<|>RELATION_NOE (<|>RELATION_NOE 38<|>RELATION_NOE /<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
GLUT-1<|>RELATION_NOE 在<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE 鉴别<|>RELATION_S 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 可靠<|>RELATION_NOE 标记<|>RELATION_NOE 。<|>RELATION_NOE
吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨+<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 胸腔<|>RELATION_NOE 灌注羟<|>RELATION_NOE 喜树碱<|>RELATION_NOE 治疗<|>RELATION_S 肺腺<|>RELATION_NOE 癌伴<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
32<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌伴<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 胸腔<|>RELATION_NOE 置<|>RELATION_NOE 人<|>RELATION_NOE 小<|>RELATION_NOE 口径<|>RELATION_NOE 导管<|>RELATION_NOE 引流<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 后<|>RELATION_NOE 注入<|>RELATION_NOE 羟<|>RELATION_NOE 喜树碱<|>RELATION_NOE 30mg<|>RELATION_NOE 行<|>RELATION_NOE 胸腔<|>RELATION_NOE 灌注<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 给予<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 行<|>RELATION_NOE 全身<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 每<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 重复<|>RELATION_NOE 1次<|>RELATION_NOE 。<|>RELATION_NOE
GP<|>RELATION_NOE 方案<|>RELATION_NOE 全身<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 胸腔<|>RELATION_NOE 灌注羟<|>RELATION_NOE 喜树碱<|>RELATION_NOE 治疗<|>RELATION_S 肺腺<|>RELATION_NOE 癌伴<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
p27<|>RELATION_NOE 、<|>RELATION_NOE C-mye<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 35<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE p27<|>RELATION_NOE 及<|>RELATION_NOE C-mye<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
p27<|>RELATION_NOE 蛋白阳<|>RELATION_NOE 性率<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 中<|>RELATION_NOE 比较<|>RELATION_B 差异<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
p27<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_B 明显<|>RELATION_I 降低<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 变<|>RELATION_NOE 差<|>RELATION_NOE 而<|>RELATION_NOE 降低<|>RELATION_NOE 。<|>RELATION_NOE
C-myc<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 无<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_B 明显<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE
提示<|>RELATION_NOE C-mye<|>RELATION_NOE 蛋白<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 评价<|>RELATION_NOE 肿瘤<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE 之一<|>RELATION_NOE 。<|>RELATION_NOE
帕瑞昔布钠<|>RELATION_NOE 超前<|>RELATION_NOE 镇痛<|>RELATION_NOE 对<|>RELATION_NOE 胸科<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 镇痛<|>RELATION_NOE 及<|>RELATION_NOE 肾功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
③<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 后<|>RELATION_NOE 肾<|>RELATION_NOE 功能<|>RELATION_NOE [<|>RELATION_NOE 血<|>RELATION_NOE 肌苷<|>RELATION_NOE (<|>RELATION_NOE Ser<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血尿素氮<|>RELATION_NOE (<|>RELATION_NOE BUN<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
肺炎性假瘤<|>RELATION_NOE 的<|>RELATION_NOE 影像学<|>RELATION_NOE 诊断<|>RELATION_S 12<|>RELATION_NOE 例<|>RELATION_NOE
探讨<|>RELATION_NOE 肺炎性假瘤<|>RELATION_NOE 的<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺结核球<|>RELATION_NOE 的<|>RELATION_NOE 鉴别<|>RELATION_B 诊断<|>RELATION_I 要点<|>RELATION_E 。<|>RELATION_NOE
桃尖征<|>RELATION_NOE 及<|>RELATION_NOE 肿块<|>RELATION_NOE 与<|>RELATION_NOE 胸膜<|>RELATION_NOE 紧贴<|>RELATION_NOE 或<|>RELATION_NOE 有<|>RELATION_NOE 粘连<|>RELATION_NOE ,<|>RELATION_NOE 粗<|>RELATION_NOE 长<|>RELATION_NOE 毛刺索<|>RELATION_NOE 条影<|>RELATION_NOE 等<|>RELATION_NOE 征象<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺炎性假瘤<|>RELATION_NOE 诊断<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_B 意义<|>RELATION_E 。<|>RELATION_NOE
癌性<|>RELATION_NOE Lambert-Eaton<|>RELATION_NOE 肌无力<|>RELATION_NOE 综合征<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 分析<|>RELATION_S
癌性<|>RELATION_NOE Lambert-Eaton<|>RELATION_NOE 肌无力<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE LEMS<|>RELATION_NOE )<|>RELATION_NOE 临床<|>RELATION_NOE 少见<|>RELATION_NOE ,<|>RELATION_NOE 此<|>RELATION_NOE 报道<|>RELATION_NOE 旨在<|>RELATION_NOE 增进<|>RELATION_NOE 临床<|>RELATION_NOE 对<|>RELATION_NOE 这<|>RELATION_NOE 一<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 认识<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S LEMS<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 发病<|>RELATION_NOE 年龄<|>RELATION_NOE 39<|>RELATION_NOE —<|>RELATION_NOE 72<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 肢体<|>RELATION_NOE 无力<|>RELATION_NOE ,<|>RELATION_NOE 全部<|>RELATION_NOE 病例<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肌无力<|>RELATION_NOE 症状<|>RELATION_NOE 早<|>RELATION_NOE 于<|>RELATION_NOE 癌症状<|>RELATION_NOE 出现<|>RELATION_NOE 的<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
心包<|>RELATION_NOE 置管<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 心包<|>RELATION_NOE 转移<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 不同<|>RELATION_NOE 心包<|>RELATION_NOE 内<|>RELATION_NOE 置管<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 伴<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 心包填塞<|>RELATION_NOE 的<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_B 疗效<|>RELATION_I 和<|>RELATION_I 安全性<|>RELATION_E 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_NOE 相同<|>RELATION_NOE 的<|>RELATION_NOE 心包<|>RELATION_NOE 注射<|>RELATION_NOE 和<|>RELATION_NOE 全身<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 药物<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 观察6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 内<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 复发率<|>RELATION_NOE 、<|>RELATION_NOE 生存率<|>RELATION_NOE 及<|>RELATION_NOE 置管<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_B 发现<|>RELATION_E 心包<|>RELATION_NOE 化脓<|>RELATION_NOE 感染<|>RELATION_NOE 、<|>RELATION_NOE 窦道<|>RELATION_NOE 形成<|>RELATION_NOE 及<|>RELATION_NOE 严重<|>RELATION_NOE 粘连<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
适当<|>RELATION_NOE 延长<|>RELATION_NOE 心包<|>RELATION_NOE 置管<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 安全性<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 首要<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
抑癌<|>RELATION_NOE 蛋白<|>RELATION_NOE 维生素<|>RELATION_NOE D3<|>RELATION_NOE 上调<|>RELATION_NOE 蛋白1<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 意义<|>RELATION_E
应用<|>RELATION_NOE RTPCR<|>RELATION_NOE 及<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_S 35<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患行<|>RELATION_NOE 的<|>RELATION_NOE 癌组织<|>RELATION_NOE 及<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE VDUP1mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 进一步<|>RELATION_NOE 按照<|>RELATION_NOE 癌细胞<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 肺癌<|>RELATION_NOE TNM<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 进行<|>RELATION_NOE 分层<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
VDUP1mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 肺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE VDUP1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 细胞<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 无关<|>RELATION_NOE 。<|>RELATION_NOE
VDUP1<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 低<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE
Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术前<|>RELATION_NOE C<|>RELATION_NOE 反应<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
研究<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 术前<|>RELATION_NOE C<|>RELATION_NOE 反应<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE CRP<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S ,<|>RELATION_NOE 以及<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 评价<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 治疗<|>RELATION_NOE 进展<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
研究<|>RELATION_NOE 使用<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE EGFR-TKIs<|>RELATION_NOE )<|>RELATION_NOE 前后<|>RELATION_NOE 进展<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 预测<|>RELATION_NOE 患者<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 免疫法<|>RELATION_NOE 检测<|>RELATION_S 75<|>RELATION_NOE 例<|>RELATION_NOE 应用<|>RELATION_NOE EGFR-TKIs<|>RELATION_NOE 前后<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 下降<|>RELATION_NOE ≥<|>RELATION_NOE 32%<|>RELATION_NOE 、<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 下降<|>RELATION_NOE ><|>RELATION_NOE 161%<|>RELATION_NOE 、<|>RELATION_NOE DC<|>RELATION_NOE 和<|>RELATION_NOE Ps<|>RELATION_NOE 评分<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_S 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE OR<|>RELATION_NOE 则<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE
外<|>RELATION_NOE 周血<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 蛋白<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
探讨<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S ,<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 直接<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第19<|>RELATION_NOE 号<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 外<|>RELATION_NOE 周血<|>RELATION_NOE EGFR<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
99<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 存在<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 35.4%<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 获益率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 65.7%<|>RELATION_NOE 和<|>RELATION_NOE 94.3%<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 43.8%<|>RELATION_NOE 和<|>RELATION_NOE 71.9%<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 23<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 12.9<|>RELATION_NOE －3<|>RELATION_NOE 3.0<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 长于<|>RELATION_E 无<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 7.3-12.6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ;<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 和<|>RELATION_NOE 心肌<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 结构<|>RELATION_NOE 及<|>RELATION_NOE 血管<|>RELATION_NOE 生成<|>RELATION_NOE 相关<|>RELATION_NOE 因子<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 心肌<|>RELATION_NOE 中<|>RELATION_NOE 微血管<|>RELATION_NOE 影响<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_S 。<|>RELATION_NOE
40<|>RELATION_NOE 只<|>RELATION_NOE 小鼠<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 未<|>RELATION_NOE 荷瘤<|>RELATION_NOE ,<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 100ml<|>RELATION_NOE /<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 药物<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 未<|>RELATION_NOE 荷瘤<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 400<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 模型<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 荷瘤<|>RELATION_NOE ,<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 100<|>RELATION_NOE μ<|>RELATION_NOE l<|>RELATION_NOE /<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 实验组<|>RELATION_NOE (<|>RELATION_NOE 荷瘤<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 400<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 处理<|>RELATION_NOE 28d<|>RELATION_NOE 。<|>RELATION_NOE
实验<|>RELATION_NOE 前后<|>RELATION_NOE 称量<|>RELATION_NOE 小鼠<|>RELATION_NOE 体重<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_NOE 移植<|>RELATION_NOE 瘤体<|>RELATION_NOE 积<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_S 小鼠<|>RELATION_NOE 心脏<|>RELATION_NOE 和<|>RELATION_NOE 移植瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE (<|>RELATION_NOE MMP<|>RELATION_NOE )<|>RELATION_NOE -2<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 、<|>RELATION_NOE 缺氧<|>RELATION_NOE 诱导<|>RELATION_NOE 因子1<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 计数<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 移植瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE MMP-9<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE 以及<|>RELATION_NOE 心肌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 、<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 显著<|>RELATION_NOE 变化<|>RELATION_NOE ;<|>RELATION_NOE
移植瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 胶原<|>RELATION_NOE 覆盖<|>RELATION_NOE 血管<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 心肌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 移植瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 显著<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 胶原<|>RELATION_NOE 覆盖<|>RELATION_NOE 血管<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 升高<|>RELATION_S ,<|>RELATION_NOE 而<|>RELATION_NOE 心肌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 和<|>RELATION_NOE 结构<|>RELATION_NOE 几乎<|>RELATION_NOE 无<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 可<|>RELATION_NOE 通过<|>RELATION_NOE 下调<|>RELATION_NOE 移植瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE MMPs<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE MVD<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_B 移植瘤<|>RELATION_I 的<|>RELATION_I 生长<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 使<|>RELATION_NOE 移植<|>RELATION_NOE 瘤血管<|>RELATION_NOE 趋向<|>RELATION_NOE 成熟<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 不能<|>RELATION_NOE 降低<|>RELATION_NOE 心肌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE MMPs<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 成熟<|>RELATION_NOE 血管<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 。<|>RELATION_NOE
125<|>RELATION_NOE ↑<|>RELATION_NOE I-103<|>RELATION_NOE ↑<|>RELATION_NOE Pd<|>RELATION_NOE 复合型<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_S 小鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_NOE
体外<|>RELATION_NOE 培养<|>RELATION_NOE 肺腺癌<|>RELATION_NOE GLC-82<|>RELATION_NOE 细胞<|>RELATION_NOE 及<|>RELATION_NOE 大细胞癌<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I-103<|>RELATION_NOE ↑<|>RELATION_NOE Pd<|>RELATION_NOE .<|>RELATION_NOE
125<|>RELATION_NOE ↑<|>RELATION_NOE I<|>RELATION_NOE 、<|>RELATION_NOE 103<|>RELATION_NOE ↑<|>RELATION_NOE Pd<|>RELATION_NOE 及<|>RELATION_NOE 空白<|>RELATION_NOE 粒子<|>RELATION_NOE 置于<|>RELATION_NOE 细胞培养<|>RELATION_NOE 皿中<|>RELATION_NOE 照射<|>RELATION_NOE 48h<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 粒子<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 效应.<|>RELATION_NOE
将<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I-103<|>RELATION_NOE ↑<|>RELATION_NOE pd<|>RELATION_NOE 、<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I<|>RELATION_NOE 、<|>RELATION_NOE 103<|>RELATION_NOE ↑<|>RELATION_NOE Pd<|>RELATION_NOE 及<|>RELATION_NOE 空白<|>RELATION_NOE 粒子<|>RELATION_NOE 分别<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 裸鼠<|>RELATION_NOE 的<|>RELATION_NOE 移植<|>RELATION_NOE 瘤内<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 5<|>RELATION_NOE 天<|>RELATION_NOE 定期<|>RELATION_NOE 测量<|>RELATION_NOE 移植<|>RELATION_NOE 瘤大<|>RELATION_NOE 小<|>RELATION_NOE 及<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体重变化<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 61d<|>RELATION_NOE 。<|>RELATION_NOE
粒子<|>RELATION_NOE 照射<|>RELATION_NOE 细胞<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I<|>RELATION_NOE 、<|>RELATION_NOE 103<|>RELATION_NOE ↑<|>RELATION_NOE Pd<|>RELATION_NOE 及<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I-103<|>RELATION_NOE ↑<|>RELATION_NOE Pd<|>RELATION_NOE 粒子<|>RELATION_NOE 周围<|>RELATION_NOE 约<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 粒子<|>RELATION_NOE 直径<|>RELATION_NOE 范围<|>RELATION_NOE 内<|>RELATION_NOE 的<|>RELATION_NOE GLC-82<|>RELATION_NOE 细胞<|>RELATION_NOE 明显<|>RELATION_NOE 肿胀<|>RELATION_NOE 、<|>RELATION_NOE 变形<|>RELATION_NOE ,<|>RELATION_NOE 生长<|>RELATION_NOE 抑制<|>RELATION_NOE ;<|>RELATION_NOE
125<|>RELATION_NOE ↑<|>RELATION_NOE I<|>RELATION_NOE 粒子<|>RELATION_NOE 周围<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 牛长<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 103<|>RELATION_NOE ↑<|>RELATION_NOE Pd<|>RELATION_NOE 及<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I-103<|>RELATION_NOE ↑<|>RELATION_NOE Pd<|>RELATION_NOE 粒子<|>RELATION_NOE 周围<|>RELATION_NOE 约<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 粒子<|>RELATION_NOE 直径<|>RELATION_NOE 内<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 稀少.<|>RELATION_NOE
体内<|>RELATION_NOE 实验小鼠<|>RELATION_NOE 无<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE H460<|>RELATION_NOE 移植<|>RELATION_NOE 瘤较<|>RELATION_NOE GLC-82<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 快<|>RELATION_NOE ,<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 对<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 移植瘤<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 抑制<|>RELATION_S ,<|>RELATION_NOE 抑瘤<|>RELATION_NOE 效果<|>RELATION_NOE :<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I-103<|>RELATION_NOE ↑<|>RELATION_NOE pd<|>RELATION_NOE 粒子<|>RELATION_NOE ><|>RELATION_NOE 103<|>RELATION_NOE ↑<|>RELATION_NOE Pd<|>RELATION_NOE 粒子<|>RELATION_NOE ≈<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I<|>RELATION_NOE 粒子<|>RELATION_NOE ><|>RELATION_NOE 空白<|>RELATION_NOE 粒子<|>RELATION_NOE ;<|>RELATION_NOE
水冷式<|>RELATION_NOE 单针<|>RELATION_NOE 射频<|>RELATION_NOE 热消融<|>RELATION_NOE 系统<|>RELATION_NOE 可<|>RELATION_NOE 消融<|>RELATION_NOE 范围<|>RELATION_NOE 测定<|>RELATION_S 的<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE
采用<|>RELATION_NOE 水冷式<|>RELATION_NOE 单针<|>RELATION_NOE 射频<|>RELATION_NOE 消融<|>RELATION_NOE 系统<|>RELATION_NOE 分别<|>RELATION_NOE 对<|>RELATION_NOE 新鲜牛<|>RELATION_NOE 肝脏<|>RELATION_NOE 、<|>RELATION_NOE 健康<|>RELATION_NOE 成年<|>RELATION_NOE 新西兰<|>RELATION_NOE 白兔<|>RELATION_NOE 的<|>RELATION_NOE 肝脏<|>RELATION_NOE 和<|>RELATION_NOE 肌肉<|>RELATION_NOE 组织<|>RELATION_NOE 实施<|>RELATION_B 射频<|>RELATION_I 消融<|>RELATION_I 处理<|>RELATION_E ,<|>RELATION_NOE 经<|>RELATION_NOE 多<|>RELATION_NOE 路<|>RELATION_NOE 测温<|>RELATION_NOE 系统<|>RELATION_NOE 实时<|>RELATION_NOE 采集<|>RELATION_NOE 消融<|>RELATION_NOE 区域<|>RELATION_NOE 的<|>RELATION_NOE 温度<|>RELATION_NOE 场<|>RELATION_NOE 数据<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 50<|>RELATION_NOE ℃<|>RELATION_NOE 为<|>RELATION_NOE 温度<|>RELATION_NOE 区域<|>RELATION_NOE 边界<|>RELATION_NOE 确定<|>RELATION_NOE 实际<|>RELATION_NOE 达到<|>RELATION_NOE 的<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 消融<|>RELATION_NOE 范围<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 计算<|>RELATION_NOE 离体<|>RELATION_NOE 肝脏<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 比<|>RELATION_NOE 吸收率<|>RELATION_NOE (<|>RELATION_NOE SAR<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 140<|>RELATION_NOE －<|>RELATION_NOE 170V<|>RELATION_NOE 治疗<|>RELATION_NOE 电压<|>RELATION_NOE 范围<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 短<|>RELATION_NOE 时间<|>RELATION_NOE 即可<|>RELATION_NOE 达到<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 消融<|>RELATION_NOE 范围<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 之后<|>RELATION_NOE 阻抗<|>RELATION_NOE 开始<|>RELATION_NOE 上升<|>RELATION_NOE ,<|>RELATION_NOE 组织<|>RELATION_NOE 消融<|>RELATION_NOE 范围<|>RELATION_NOE 不再<|>RELATION_NOE 继续<|>RELATION_NOE 扩大<|>RELATION_NOE 。<|>RELATION_NOE
病理学<|>RELATION_NOE 观察<|>RELATION_NOE 证实<|>RELATION_NOE 肝脏<|>RELATION_NOE 、<|>RELATION_NOE 肌肉<|>RELATION_NOE 组织<|>RELATION_NOE 发生<|>RELATION_S 了<|>RELATION_NOE 典型<|>RELATION_NOE 的<|>RELATION_NOE 凝固性<|>RELATION_NOE 坏死<|>RELATION_NOE 。<|>RELATION_NOE
双<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 外科<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
同时<|>RELATION_NOE 双<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 72<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 144<|>RELATION_NOE 个<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 包括<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 双<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 全<|>RELATION_NOE 肺<|>RELATION_NOE 切除<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 并<|>RELATION_NOE 楔形<|>RELATION_NOE 切除<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 双楔形<|>RELATION_NOE 切除<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 双<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 并<|>RELATION_NOE 楔形<|>RELATION_NOE 切除<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
异时<|>RELATION_NOE 双<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 52<|>RELATION_NOE 个<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 包括<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 31<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 双<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 1次<|>RELATION_NOE ,<|>RELATION_NOE 楔形<|>RELATION_NOE 切除<|>RELATION_NOE 10<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 全<|>RELATION_NOE 肺<|>RELATION_NOE 切除<|>RELATION_NOE 8次<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 易感<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE BRCA1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE 微管蛋白<|>RELATION_NOE Ⅲ<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 采用<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE TP<|>RELATION_NOE )<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE BRCA1<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE 微管蛋白<|>RELATION_NOE Ⅲ<|>RELATION_NOE 表达<|>RELATION_NOE .<|>RELATION_NOE
根据<|>RELATION_NOE BRCA1<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE 微管蛋白<|>RELATION_NOE Ⅲ<|>RELATION_NOE 表达<|>RELATION_NOE 高低<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE BRCA1<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE 微管蛋白<|>RELATION_NOE Ⅲ<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE BRCA1<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE 微管蛋白<|>RELATION_NOE Ⅲ<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE BRCA1<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE β<|>RELATION_NOE 微管蛋白<|>RELATION_NOE Ⅲ<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE BRCA1<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 微管蛋白<|>RELATION_NOE Ⅲ<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
评价<|>RELATION_NOE 疗效<|>RELATION_NOE 指标<|>RELATION_NOE :<|>RELATION_NOE 客观<|>RELATION_NOE 反应率<|>RELATION_NOE (<|>RELATION_NOE RR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 总<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE OS<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 至<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
腺病毒<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 抑制<|>RELATION_NOE 因子4<|>RELATION_NOE 和<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -24<|>RELATION_NOE 双<|>RELATION_NOE 基因<|>RELATION_NOE 共<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 增敏<|>RELATION_S 的<|>RELATION_NOE 体内外<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE
应用<|>RELATION_NOE 抽签<|>RELATION_NOE 法<|>RELATION_NOE 将<|>RELATION_NOE 25<|>RELATION_NOE 只<|>RELATION_NOE 裸鼠<|>RELATION_NOE 随机<|>RELATION_NOE 均<|>RELATION_NOE 分为<|>RELATION_NOE 5组<|>RELATION_NOE :<|>RELATION_NOE PBS<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 腺病毒<|>RELATION_NOE (<|>RELATION_NOE Ad<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 双<|>RELATION_NOE 基因组<|>RELATION_NOE 、<|>RELATION_NOE 放疗组<|>RELATION_NOE 及<|>RELATION_NOE 联合组<|>RELATION_NOE ,<|>RELATION_NOE 除<|>RELATION_NOE 放疗组<|>RELATION_NOE 外<|>RELATION_NOE 其余<|>RELATION_NOE 各组<|>RELATION_NOE 均<|>RELATION_NOE 采用<|>RELATION_NOE 瘤体内<|>RELATION_NOE 注射<|>RELATION_NOE 干预<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE ,<|>RELATION_NOE 隔<|>RELATION_NOE 日<|>RELATION_NOE 1<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 注射<|>RELATION_NOE 6<|>RELATION_NOE 次<|>RELATION_NOE 。<|>RELATION_NOE
Westernblot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 目的<|>RELATION_NOE :<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE SPC-A-1<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 成功<|>RELATION_B 表达<|>RELATION_E ;<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE Ad-ING4-IL-24<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_B 上调<|>RELATION_E Bax<|>RELATION_NOE 和<|>RELATION_NOE Caspase-3<|>RELATION_NOE 基因表达<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_NOE Bel-2<|>RELATION_NOE 及<|>RELATION_NOE VECF<|>RELATION_NOE 基因表达<|>RELATION_NOE 。<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE Ad-ING4-IL-24<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_NOE 上调<|>RELATION_NOE Bax<|>RELATION_NOE 和<|>RELATION_NOE Caspase-3<|>RELATION_NOE 基因表达<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_S Bel-2<|>RELATION_NOE 及<|>RELATION_NOE VECF<|>RELATION_NOE 基因表达<|>RELATION_NOE 。<|>RELATION_NOE
24<|>RELATION_NOE 具有<|>RELATION_NOE 放疗<|>RELATION_NOE 增敏<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 理想<|>RELATION_NOE 的<|>RELATION_NOE 放疗<|>RELATION_NOE 增敏剂<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 诱导<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 和<|>RELATION_NOE 抑制<|>RELATION_NOE 血管<|>RELATION_NOE 形成<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
功能<|>RELATION_NOE 肺<|>RELATION_NOE DVH<|>RELATION_NOE 参数<|>RELATION_NOE 预测<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE
行<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE /<|>RELATION_NOE SPECT<|>RELATION_NOE 融合<|>RELATION_NOE 影像<|>RELATION_NOE 引导<|>RELATION_NOE 胸部<|>RELATION_NOE 精确<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE PhilipsPinnacle<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 肺<|>RELATION_NOE V5<|>RELATION_NOE －<|>RELATION_NOE V40<|>RELATION_NOE ,<|>RELATION_NOE 同<|>RELATION_NOE 侧肺<|>RELATION_NOE V5-V20<|>RELATION_NOE ,<|>RELATION_NOE 功能<|>RELATION_NOE 肺<|>RELATION_NOE V5<|>RELATION_NOE －<|>RELATION_NOE V50<|>RELATION_NOE 与<|>RELATION_NOE ≥<|>RELATION_NOE 2<|>RELATION_NOE 级<|>RELATION_NOE RILT<|>RELATION_NOE 发生<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE 双侧肺<|>RELATION_NOE V15<|>RELATION_NOE 、<|>RELATION_NOE 功能<|>RELATION_NOE 肺<|>RELATION_NOE V20<|>RELATION_NOE 与<|>RELATION_NOE RILT<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.005<|>RELATION_NOE ,<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
X<|>RELATION_NOE 射线<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE CCR7<|>RELATION_NOE 表达<|>RELATION_NOE 影响<|>RELATION_S 的<|>RELATION_NOE 研究<|>RELATION_NOE
研究<|>RELATION_NOE 不同<|>RELATION_NOE 剂量<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 及<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 点<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE CC-<|>RELATION_NOE 趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体7<|>RELATION_NOE (<|>RELATION_NOE CCR7<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
体外<|>RELATION_NOE 培养<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 采用<|>RELATION_NOE 直线<|>RELATION_NOE 加速器<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 一次性<|>RELATION_NOE 照射<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 和<|>RELATION_NOE 8Gy<|>RELATION_NOE (<|>RELATION_NOE 源皮<|>RELATION_NOE 距<|>RELATION_NOE 100em<|>RELATION_NOE ;<|>RELATION_NOE
剂量率<|>RELATION_NOE 442.89cGy<|>RELATION_NOE /<|>RELATION_NOE min<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48<|>RELATION_NOE 和<|>RELATION_NOE 72h<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 技术<|>RELATION_NOE 及<|>RELATION_NOE Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 分别<|>RELATION_NOE 进行<|>RELATION_NOE CCR7mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白质<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 检测<|>RELATION_S ;<|>RELATION_NOE 剂量率<|>RELATION_NOE 442.89cGy<|>RELATION_NOE /<|>RELATION_NOE min<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48<|>RELATION_NOE 和<|>RELATION_NOE 72h<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 技术<|>RELATION_NOE 及<|>RELATION_NOE Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 分别<|>RELATION_NOE 进行<|>RELATION_NOE CCR7mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白质<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 检测<|>RELATION_S ;<|>RELATION_NOE
72h<|>RELATION_NOE 后<|>RELATION_NOE 6<|>RELATION_NOE 和<|>RELATION_NOE 8Gy<|>RELATION_NOE 组<|>RELATION_NOE mRNA<|>RELATION_NOE 表达量<|>RELATION_NOE 仍<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 6.75-7.26<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE 和<|>RELATION_NOE 6Gy<|>RELATION_NOE 组<|>RELATION_NOE 蛋白质<|>RELATION_NOE 表达量<|>RELATION_NOE 72h<|>RELATION_NOE 后6<|>RELATION_NOE 和<|>RELATION_NOE 8Gy<|>RELATION_NOE 组<|>RELATION_NOE mRNA<|>RELATION_NOE 表达量<|>RELATION_NOE 仍<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 6.75-7.26<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE 和<|>RELATION_NOE 6Gy<|>RELATION_NOE 组<|>RELATION_NOE 蛋白质<|>RELATION_NOE 表达量<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 11.13-14.17<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 4<|>RELATION_NOE 和<|>RELATION_NOE 8Gy<|>RELATION_NOE 组<|>RELATION_NOE 蛋白质<|>RELATION_NOE 表达量<|>RELATION_NOE 在<|>RELATION_NOE 48<|>RELATION_NOE 和<|>RELATION_NOE 72h<|>RELATION_NOE 已<|>RELATION_NOE 降<|>RELATION_NOE 至<|>RELATION_NOE
2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 和<|>RELATION_NOE 8Gy<|>RELATION_NOE 的<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE CCR7mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白质<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 一定<|>RELATION_NOE 剂量<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 辐射<|>RELATION_NOE 促进<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
基因<|>RELATION_NOE 芯片<|>RELATION_NOE 筛选<|>RELATION_S 榄香烯<|>RELATION_NOE 乳增强<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE
MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 榄香烯<|>RELATION_NOE 乳对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 抑制<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE 求得<|>RELATION_NOE IC50<|>RELATION_NOE 值<|>RELATION_NOE ;<|>RELATION_NOE
实验<|>RELATION_NOE 分为<|>RELATION_NOE 照射组<|>RELATION_NOE 及<|>RELATION_NOE 榄香烯<|>RELATION_NOE 乳联合<|>RELATION_NOE 照射组<|>RELATION_NOE ,<|>RELATION_NOE 寡核苷酸<|>RELATION_NOE 基因<|>RELATION_NOE 芯片<|>RELATION_NOE 筛选<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 基因<|>RELATION_NOE ;<|>RELATION_NOE
基因<|>RELATION_NOE 芯片<|>RELATION_NOE 共<|>RELATION_NOE 检测<|>RELATION_NOE 出<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 基因<|>RELATION_NOE 122<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 上调<|>RELATION_NOE 基因<|>RELATION_NOE 89<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_NOE 基因<|>RELATION_NOE 33<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 功能<|>RELATION_NOE 参与<|>RELATION_NOE 维持<|>RELATION_NOE 细胞结构<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 代谢<|>RELATION_NOE 、<|>RELATION_NOE 增殖<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 信号传导<|>RELATION_NOE 、<|>RELATION_NOE 物质<|>RELATION_NOE 转运<|>RELATION_NOE 、<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 、<|>RELATION_NOE DNA<|>RELATION_NOE 修复<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 应答<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
RT-PER<|>RELATION_NOE 结果<|>RELATION_NOE :<|>RELATION_NOE 上调<|>RELATION_NOE 基因<|>RELATION_NOE Egr-1<|>RELATION_NOE 及<|>RELATION_NOE 下调<|>RELATION_NOE 基因<|>RELATION_NOE CyclinD1<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 基因<|>RELATION_NOE 芯片<|>RELATION_NOE 结果<|>RELATION_B 一致<|>RELATION_E 。<|>RELATION_NOE
榄香烯<|>RELATION_NOE 乳对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_NOE 增敏<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE 是<|>RELATION_NOE 多<|>RELATION_NOE 基因<|>RELATION_NOE 参与<|>RELATION_NOE 、<|>RELATION_NOE 协同<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_S ,<|>RELATION_NOE 对于<|>RELATION_NOE 新<|>RELATION_NOE 发现<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 进一步<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 有助于<|>RELATION_NOE 发现<|>RELATION_NOE 榄香烯<|>RELATION_NOE 乳对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射<|>RELATION_NOE 增敏<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE 靶点<|>RELATION_NOE 。<|>RELATION_NOE
新型<|>RELATION_NOE MR<|>RELATION_NOE 对比剂<|>RELATION_NOE 长循环<|>RELATION_NOE 超<|>RELATION_NOE 顺磁<|>RELATION_NOE 氧化铁<|>RELATION_NOE 脂质体<|>RELATION_NOE 纳米<|>RELATION_NOE 微粒<|>RELATION_NOE 的<|>RELATION_NOE 体<|>RELATION_B 内外<|>RELATION_I 实验<|>RELATION_I 研究<|>RELATION_E
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 吞噬<|>RELATION_NOE 实验<|>RELATION_NOE :<|>RELATION_NOE 将<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 株<|>RELATION_NOE RAW264.7<|>RELATION_NOE 经<|>RELATION_NOE 复苏<|>RELATION_NOE 、<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 达到<|>RELATION_NOE 80%<|>RELATION_NOE －<|>RELATION_NOE 90%<|>RELATION_NOE 融合<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 每孔<|>RELATION_NOE 2.5<|>RELATION_NOE ×<|>RELATION_NOE 10<|>RELATION_NOE '<|>RELATION_NOE 个<|>RELATION_NOE 细胞<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 培养<|>RELATION_NOE 板<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 实验组<|>RELATION_NOE 细胞<|>RELATION_NOE 与<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 药物<|>RELATION_NOE 孵化<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 测定<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE Fe<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE Fe<|>RELATION_NOE 染色<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 析<|>RELATION_NOE 因<|>RELATION_NOE 设计<|>RELATION_NOE 的<|>RELATION_NOE 方差分析<|>RELATION_NOE 对<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 小鼠<|>RELATION_NOE 体内<|>RELATION_NOE 药物<|>RELATION_NOE 分布<|>RELATION_NOE 实验<|>RELATION_NOE :<|>RELATION_NOE C57BL<|>RELATION_NOE /<|>RELATION_NOE 6J<|>RELATION_NOE 雄性<|>RELATION_NOE 小鼠<|>RELATION_NOE 6<|>RELATION_NOE 只<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 2<|>RELATION_NOE 只<|>RELATION_NOE ,<|>RELATION_NOE 设<|>RELATION_NOE 为<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 实验组<|>RELATION_NOE ,<|>RELATION_NOE 经尾<|>RELATION_NOE 静脉<|>RELATION_NOE 分别<|>RELATION_NOE 注射<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 、<|>RELATION_NOE SPIO<|>RELATION_NOE 以及<|>RELATION_NOE 长循环<|>RELATION_NOE SPIO<|>RELATION_NOE 脂质体<|>RELATION_NOE 后<|>RELATION_NOE 牺牲<|>RELATION_NOE 动物<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 观察<|>RELATION_NOE 2组<|>RELATION_NOE 药物<|>RELATION_NOE 在<|>RELATION_NOE 体内<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 荷<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE MR<|>RELATION_NOE 成<|>RELATION_NOE 像<|>RELATION_NOE 实验<|>RELATION_NOE :<|>RELATION_NOE 建立<|>RELATION_NOE 20<|>RELATION_NOE 只<|>RELATION_NOE BALB<|>RELATION_NOE /<|>RELATION_NOE c<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植型<|>RELATION_NOE 肺癌<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 实验组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 10<|>RELATION_NOE 只<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 经尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注入<|>RELATION_NOE SPIO<|>RELATION_NOE 和<|>RELATION_NOE 长循环<|>RELATION_NOE SPIO<|>RELATION_NOE 脂质体<|>RELATION_NOE 纳米<|>RELATION_NOE 微粒<|>RELATION_NOE 后行<|>RELATION_NOE MR<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_NOE 增强<|>RELATION_NOE 前后<|>RELATION_NOE 2组<|>RELATION_NOE 实验动物<|>RELATION_NOE 各<|>RELATION_NOE 时间点<|>RELATION_NOE 肝脏<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE ROI<|>RELATION_NOE 的<|>RELATION_NOE 信号<|>RELATION_NOE 强度<|>RELATION_NOE ,<|>RELATION_NOE 绘制<|>RELATION_S 信噪比<|>RELATION_NOE (<|>RELATION_NOE SNR<|>RELATION_NOE )<|>RELATION_NOE 时间<|>RELATION_NOE 动态<|>RELATION_NOE 变化<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 协<|>RELATION_NOE 方差分析<|>RELATION_NOE 比较<|>RELATION_NOE 2组<|>RELATION_NOE 动物<|>RELATION_NOE 肝脏<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 增强<|>RELATION_NOE 12h<|>RELATION_NOE 后<|>RELATION_NOE SNR<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 毒性<|>RELATION_NOE 实验<|>RELATION_NOE (<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 检查<|>RELATION_NOE 2种<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肝细胞株<|>RELATION_NOE HL-7702<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 毒性作用<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 析<|>RELATION_NOE 因<|>RELATION_NOE 设计<|>RELATION_NOE 的<|>RELATION_NOE 方差分析<|>RELATION_NOE 对<|>RELATION_NOE 结果<|>RELATION_NOE 进行<|>RELATION_NOE 统计学<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 实验<|>RELATION_NOE :<|>RELATION_NOE 析因<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 表明<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE Fe<|>RELATION_NOE 含量<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 实验组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 29<|>RELATION_NOE 683<|>RELATION_NOE 9.9<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 小鼠<|>RELATION_NOE 体内<|>RELATION_NOE 药物<|>RELATION_NOE 分布<|>RELATION_NOE 实验<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 肝<|>RELATION_NOE 、<|>RELATION_NOE 脾<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 、<|>RELATION_NOE 肾组织<|>RELATION_NOE 内<|>RELATION_NOE 蓝染<|>RELATION_NOE 颗粒<|>RELATION_NOE 多于<|>RELATION_S 实验组<|>RELATION_NOE 。<|>RELATION_NOE
长循环<|>RELATION_NOE SPIO<|>RELATION_NOE 脂质体<|>RELATION_NOE 纳米<|>RELATION_NOE 微粒<|>RELATION_NOE 在<|>RELATION_NOE 体内外<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_B 巨噬<|>RELATION_I 系统<|>RELATION_I 吞噬<|>RELATION_I 功能<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 体内<|>RELATION_NOE 实现<|>RELATION_NOE 了<|>RELATION_NOE 长<|>RELATION_NOE 循环<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 非网状<|>RELATION_NOE 内皮<|>RELATION_NOE 系统<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 也<|>RELATION_NOE 具有<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE T2<|>RELATION_NOE 负性<|>RELATION_NOE 被动<|>RELATION_NOE 靶向<|>RELATION_NOE 强化<|>RELATION_NOE 效果<|>RELATION_NOE ;<|>RELATION_NOE
TMPRSS2-ERG<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 转移性<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
检测<|>RELATION_S 转移性<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 中<|>RELATION_NOE TMPRSS2-ERG<|>RELATION_NOE 基因融合<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE ERG<|>RELATION_NOE 基因重排<|>RELATION_NOE 在<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 进展<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE 检测<|>RELATION_NOE 转移性<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 中<|>RELATION_NOE TMPRSS2-ERG<|>RELATION_NOE 基因融合<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE ERG<|>RELATION_NOE 基因重排<|>RELATION_NOE 在<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 进展<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 由<|>RELATION_NOE 细针<|>RELATION_NOE 穿刺<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 转移性<|>RELATION_NOE 前列腺癌<|>RELATION_NOE ,<|>RELATION_NOE 穿刺<|>RELATION_NOE 部位<|>RELATION_NOE 包括<|>RELATION_NOE 盆腔<|>RELATION_NOE 及<|>RELATION_NOE 远处<|>RELATION_NOE 淋巴结<|>RELATION_NOE 、<|>RELATION_NOE 肝<|>RELATION_NOE 、<|>RELATION_NOE 骨<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 回顾<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 病理学<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 采用<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE 标记<|>RELATION_S 前列腺<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE 、<|>RELATION_NOE 突触素<|>RELATION_NOE 和<|>RELATION_NOE 嗜<|>RELATION_NOE 铬粒素<|>RELATION_NOE A<|>RELATION_NOE 。<|>RELATION_NOE
运用<|>RELATION_NOE ERG<|>RELATION_NOE 分离<|>RELATION_NOE 断裂<|>RELATION_NOE 探针<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE (<|>RELATION_NOE FISH<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 学<|>RELATION_NOE 蜡块<|>RELATION_NOE 中<|>RELATION_NOE 转移性<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 的<|>RELATION_NOE TMPRSS2-ERG<|>RELATION_NOE 基因融合<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE 67<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 有<|>RELATION_NOE 经<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 病史<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 6例<|>RELATION_NOE 以<|>RELATION_NOE 转移<|>RELATION_NOE 性病<|>RELATION_NOE 灶<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE 。<|>RELATION_NOE
11<|>RELATION_NOE 例<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 形态<|>RELATION_NOE 上<|>RELATION_NOE 提示<|>RELATION_NOE 为<|>RELATION_NOE 前列腺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 突触素<|>RELATION_NOE (<|>RELATION_NOE 9/9<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 嗜铬<|>RELATION_NOE 粒素<|>RELATION_NOE A<|>RELATION_NOE (<|>RELATION_NOE 7/8<|>RELATION_NOE )<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 前列腺<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE 7/7<|>RELATION_NOE )<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE
FISH<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 共有<|>RELATION_NOE 31.3%<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE 转移性<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 存在<|>RELATION_NOE TMPRSS2-ERG<|>RELATION_NOE 基因融合<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 6例<|>RELATION_NOE 为<|>RELATION_NOE ERG<|>RELATION_NOE 基因<|>RELATION_NOE 5'<|>RELATION_NOE 端缺<|>RELATION_NOE 失性<|>RELATION_NOE 重排<|>RELATION_NOE ;<|>RELATION_NOE
11<|>RELATION_NOE 例<|>RELATION_NOE 转移性<|>RELATION_NOE 前列腺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 显示<|>RELATION_NOE TMPRSS2-ERG<|>RELATION_NOE 基因融合<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 为<|>RELATION_NOE 5'<|>RELATION_NOE 端缺<|>RELATION_NOE 失性<|>RELATION_NOE 重<|>RELATION_NOE 排伴<|>RELATION_NOE 拷贝数<|>RELATION_NOE 增加<|>RELATION_NOE 。<|>RELATION_NOE
TMPRSS2-ERG<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 区分<|>RELATION_S 前列腺<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 原发性<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 分析<|>RELATION_S
组织<|>RELATION_NOE 学除<|>RELATION_NOE 经典<|>RELATION_NOE 普通型<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 以<|>RELATION_NOE 恶性<|>RELATION_NOE 梭形<|>RELATION_NOE 细胞<|>RELATION_NOE 为<|>RELATION_NOE 主要<|>RELATION_NOE 成分<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 以<|>RELATION_NOE 软骨<|>RELATION_NOE 为<|>RELATION_NOE 主要<|>RELATION_NOE 成分<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 髓内<|>RELATION_NOE 高<|>RELATION_NOE 分化<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE (<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE 染色<|>RELATION_NOE 没有<|>RELATION_S 特异性<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
除<|>RELATION_NOE 3例失<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 9例<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 跟踪<|>RELATION_NOE 随访<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 到<|>RELATION_NOE 6年<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 2.8年<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肺转移<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 因<|>RELATION_NOE 心脑<|>RELATION_NOE 血管疾病<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 仍<|>RELATION_NOE 存活<|>RELATION_NOE 。<|>RELATION_NOE
人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 表型<|>RELATION_NOE CDl33<|>RELATION_NOE 、<|>RELATION_NOE CD34<|>RELATION_NOE 、<|>RELATION_NOE CD44<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_B 研究<|>RELATION_E
采集<|>RELATION_NOE 新鲜<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 扩增<|>RELATION_S 出<|>RELATION_NOE 贴壁<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 悬浮<|>RELATION_NOE 细胞球<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 检测<|>RELATION_NOE 比较<|>RELATION_NOE CDl33<|>RELATION_NOE 、<|>RELATION_NOE CD34<|>RELATION_NOE 和<|>RELATION_NOE CD44<|>RELATION_NOE 在<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 培养<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE 采集<|>RELATION_NOE 新鲜<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 扩增<|>RELATION_NOE 出<|>RELATION_NOE 贴壁<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 悬浮<|>RELATION_NOE 细胞球<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 检测<|>RELATION_B 比较<|>RELATION_E CDl33<|>RELATION_NOE 、<|>RELATION_NOE CD34<|>RELATION_NOE 和<|>RELATION_NOE CD44<|>RELATION_NOE 在<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 培养<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
表现<|>RELATION_NOE 为<|>RELATION_NOE 局限<|>RELATION_NOE 性磨<|>RELATION_NOE 玻璃影<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE MSCT<|>RELATION_NOE 诊断<|>RELATION_B 体会<|>RELATION_E
胸段<|>RELATION_NOE 硬膜<|>RELATION_NOE 外<|>RELATION_NOE 阻滞<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 胸科<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 苏醒期<|>RELATION_NOE 躁动<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
A<|>RELATION_NOE 组<|>RELATION_NOE 在<|>RELATION_NOE 全麻<|>RELATION_NOE 诱导<|>RELATION_NOE 前行<|>RELATION_NOE 硬膜<|>RELATION_NOE 外<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE ,<|>RELATION_NOE 间隙<|>RELATION_NOE 选择<|>RELATION_NOE T5-6<|>RELATION_NOE 或<|>RELATION_NOE T6-7<|>RELATION_NOE 之间<|>RELATION_NOE ,<|>RELATION_NOE 局<|>RELATION_NOE 麻药<|>RELATION_NOE 选用<|>RELATION_NOE 1.5%<|>RELATION_NOE 的<|>RELATION_NOE 利多卡因<|>RELATION_NOE ,<|>RELATION_NOE 确定<|>RELATION_NOE 硬膜外麻醉<|>RELATION_NOE 有效<|>RELATION_NOE 后<|>RELATION_NOE 再行<|>RELATION_NOE 全麻<|>RELATION_NOE 诱导<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 全麻<|>RELATION_NOE 诱导<|>RELATION_NOE 均<|>RELATION_NOE 采用<|>RELATION_NOE 静注<|>RELATION_NOE 依托咪酯<|>RELATION_NOE 0.2mg<|>RELATION_NOE /<|>RELATION_NOE kg-0.3mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 、<|>RELATION_NOE 芬太尼<|>RELATION_NOE 3μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE kg-4<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 、<|>RELATION_NOE 顺式<|>RELATION_NOE 阿曲库铵<|>RELATION_NOE 0.15mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE 诱导<|>RELATION_NOE 成功<|>RELATION_NOE 后<|>RELATION_NOE 插入<|>RELATION_NOE 双腔<|>RELATION_NOE 支气管<|>RELATION_NOE 导管<|>RELATION_NOE ,<|>RELATION_NOE 维持<|>RELATION_NOE 采用<|>RELATION_NOE 吸入<|>RELATION_NOE l<|>RELATION_NOE %<|>RELATION_NOE -3<|>RELATION_NOE %<|>RELATION_NOE 七<|>RELATION_NOE 氟烷<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 泵注<|>RELATION_NOE 丙泊酚<|>RELATION_NOE 4mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1.h<|>RELATION_NOE ^<|>RELATION_NOE -1-6mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1.h<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE 、<|>RELATION_NOE 瑞芬太尼<|>RELATION_NOE 5<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1.h<|>RELATION_NOE ^<|>RELATION_NOE -1-10<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE 1.h<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE 和<|>RELATION_NOE 顺式<|>RELATION_NOE 阿曲库铵<|>RELATION_NOE 0.1mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE ·<|>RELATION_NOE h<|>RELATION_NOE ^<|>RELATION_NOE -1-0.2mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1.h<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE 。<|>RELATION_NOE
B<|>RELATION_NOE 组<|>RELATION_NOE 单纯<|>RELATION_NOE 用<|>RELATION_NOE 全麻<|>RELATION_NOE ,<|>RELATION_NOE 全麻<|>RELATION_NOE 诱导<|>RELATION_NOE 和<|>RELATION_NOE 维持<|>RELATION_NOE 方案<|>RELATION_NOE 与<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 相同<|>RELATION_NOE ,<|>RELATION_NOE 维持<|>RELATION_NOE 采用<|>RELATION_NOE 吸入<|>RELATION_NOE 1%<|>RELATION_NOE -3<|>RELATION_NOE %<|>RELATION_NOE 七<|>RELATION_NOE 氟烷<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 泵注<|>RELATION_NOE 丙泊酚<|>RELATION_NOE 4mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1.h<|>RELATION_NOE ^<|>RELATION_NOE -1-6mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1.h<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE 瑞<|>RELATION_NOE 芬太尼<|>RELATION_NOE 10<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1.h<|>RELATION_NOE ^<|>RELATION_NOE -1-20<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE ·<|>RELATION_NOE h<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE 和<|>RELATION_NOE 顺式<|>RELATION_NOE 阿曲库铵<|>RELATION_NOE 0.1mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE ·<|>RELATION_NOE h<|>RELATION_NOE ^<|>RELATION_NOE -1-0.2mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE ·<|>RELATION_NOE h<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术中<|>RELATION_NOE 出血<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 500ml<|>RELATION_NOE ,<|>RELATION_NOE 手术时间<|>RELATION_NOE <<|>RELATION_NOE 3h<|>RELATION_NOE ,<|>RELATION_NOE 维持<|>RELATION_NOE 输液<|>RELATION_NOE 以<|>RELATION_NOE 乳酸钠<|>RELATION_NOE 林格氏液<|>RELATION_NOE 和<|>RELATION_NOE 中<|>RELATION_NOE 分子<|>RELATION_NOE 羟乙基淀粉<|>RELATION_NOE ,<|>RELATION_NOE 保持<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血流动力学<|>RELATION_NOE 平稳<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 肌松<|>RELATION_NOE 监测仪<|>RELATION_NOE 监测<|>RELATION_NOE 使<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 都<|>RELATION_NOE 达到<|>RELATION_NOE 相同<|>RELATION_NOE 的<|>RELATION_NOE 肌松<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 结束<|>RELATION_NOE 前<|>RELATION_NOE 5min<|>RELATION_NOE 给予<|>RELATION_NOE 芬太尼<|>RELATION_NOE 2μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 静脉<|>RELATION_NOE 接<|>RELATION_NOE 镇痛<|>RELATION_NOE 泵作术<|>RELATION_NOE 后<|>RELATION_NOE 镇痛<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 未<|>RELATION_NOE 使用<|>RELATION_NOE 催醒药<|>RELATION_NOE 。<|>RELATION_NOE
硬膜<|>RELATION_NOE 外<|>RELATION_NOE 阻滞<|>RELATION_NOE 复合<|>RELATION_NOE 全麻<|>RELATION_NOE 可以<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E 老年<|>RELATION_NOE 胸科<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 麻醉<|>RELATION_NOE 后<|>RELATION_NOE EA<|>RELATION_NOE 特别<|>RELATION_NOE 是<|>RELATION_NOE 危险性<|>RELATION_NOE 躁动<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 有利<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 康复<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 诊断<|>RELATION_S 艾滋病<|>RELATION_NOE 合并<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
探讨<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 在<|>RELATION_NOE 艾滋病<|>RELATION_NOE 合并<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 诊断<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 与<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
确诊<|>RELATION_NOE 马尔尼菲<|>RELATION_NOE 青霉菌<|>RELATION_NOE 感染<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 马红球菌<|>RELATION_NOE 感染<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺结核<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肺腺样囊性癌<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
CT<|>RELATION_NOE 能<|>RELATION_NOE 清晰<|>RELATION_NOE 地<|>RELATION_NOE 显示<|>RELATION_NOE 脏器<|>RELATION_NOE 内部<|>RELATION_NOE 的<|>RELATION_NOE 病变<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 又<|>RELATION_NOE 能<|>RELATION_NOE 明确<|>RELATION_NOE 病灶<|>RELATION_NOE 与<|>RELATION_NOE 周围<|>RELATION_NOE 组织<|>RELATION_NOE 结构<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 因此<|>RELATION_NOE 在<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 获取<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 为<|>RELATION_NOE 各种<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 病因<|>RELATION_NOE 诊断<|>RELATION_NOE 提供<|>RELATION_NOE 重要<|>RELATION_NOE 依据<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 存活率<|>RELATION_NOE 具有<|>RELATION_NOE 十分<|>RELATION_NOE 重要<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
中<|>RELATION_NOE 位<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 38<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE －<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 全<|>RELATION_NOE 组<|>RELATION_NOE 共<|>RELATION_NOE 出现<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE 8例肺<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 5例骨<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 1例肝<|>RELATION_NOE 转移<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 9例<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 剂量<|>RELATION_NOE 为<|>RELATION_NOE 66Gy<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 放疗<|>RELATION_NOE 同时<|>RELATION_NOE 予<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 联合化疗<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
疼痛<|>RELATION_NOE 缓解率<|>RELATION_NOE 为<|>RELATION_NOE 87.5%<|>RELATION_NOE (<|>RELATION_NOE 21<|>RELATION_NOE /<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疼痛<|>RELATION_NOE 缓解<|>RELATION_NOE 中位<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 3－<|>RELATION_NOE 23<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CD8<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 自然<|>RELATION_NOE 杀伤<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 受体<|>RELATION_NOE NKG2D<|>RELATION_NOE 和<|>RELATION_NOE NKG2A<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
选择<|>RELATION_NOE 95<|>RELATION_NOE 例<|>RELATION_NOE 原发<|>RELATION_NOE 未<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S CD8<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE NKT<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 受体<|>RELATION_NOE NKG2D<|>RELATION_NOE 和<|>RELATION_NOE NKG2A<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 50<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 人为<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE CD8<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE NKT<|>RELATION_NOE 细胞<|>RELATION_NOE NKG2D<|>RELATION_NOE +<|>RELATION_NOE 表达率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 77.07<|>RELATION_NOE ±<|>RELATION_NOE 5.77<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 84.13<|>RELATION_NOE ±<|>RELATION_NOE 4.49<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 8.<|>RELATION_NOE 14<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE CD8<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE NKT<|>RELATION_NOE 细胞<|>RELATION_NOE NKG2A<|>RELATION_NOE +<|>RELATION_NOE 表达率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 33.58<|>RELATION_NOE ±<|>RELATION_NOE 8.82<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 25.31<|>RELATION_NOE ±<|>RELATION_NOE 8.38<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.46<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE CD8<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE NKT<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE NKG2A<|>RELATION_NOE 和<|>RELATION_NOE NKG2D<|>RELATION_NOE 表达<|>RELATION_NOE 失衡<|>RELATION_NOE 可能<|>RELATION_NOE 抑制<|>RELATION_S 该<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 这<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 肿瘤<|>RELATION_NOE 免疫<|>RELATION_NOE 逃逸<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 之一<|>RELATION_NOE 。<|>RELATION_NOE
抑制<|>RELATION_NOE Src<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 对<|>RELATION_NOE 人类<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 小鼠<|>RELATION_NOE 皮下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E 及其<|>RELATION_NOE 机制<|>RELATION_NOE
探讨<|>RELATION_NOE 抑制<|>RELATION_NOE Src<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 对<|>RELATION_NOE 人类<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 小鼠<|>RELATION_NOE 皮下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 雄性<|>RELATION_NOE 严重<|>RELATION_NOE 联合<|>RELATION_NOE 免疫<|>RELATION_NOE 缺陷<|>RELATION_NOE (<|>RELATION_NOE SCID<|>RELATION_NOE )<|>RELATION_NOE 小鼠<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 肺腺癌<|>RELATION_NOE PC-9<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 皮下<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 动物模型<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 研究<|>RELATION_S 抑制<|>RELATION_NOE Src<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 皮下<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 增生<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE PI<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE Ki-67<|>RELATION_NOE 染色<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE CD34<|>RELATION_NOE 染色<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
PC-9<|>RELATION_NOE 细胞<|>RELATION_NOE 皮下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 对<|>RELATION_NOE Src<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 非常<|>RELATION_B 敏感<|>RELATION_E ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE PC-9<|>RELATION_NOE 细胞<|>RELATION_NOE 皮下<|>RELATION_NOE 移植<|>RELATION_NOE 瘤中<|>RELATION_NOE ,<|>RELATION_NOE 50mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE ·<|>RELATION_NOE d<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE Src<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE PI<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE PC-9<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 皮下<|>RELATION_NOE 移植<|>RELATION_NOE 瘤中<|>RELATION_NOE ,<|>RELATION_NOE 50mg<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE ·<|>RELATION_NOE d<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE Src<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE MVD<|>RELATION_NOE 均<|>RELATION_B 显著<|>RELATION_I 降低<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
抑制<|>RELATION_NOE Src<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 通过<|>RELATION_B 直接<|>RELATION_I 抑制<|>RELATION_I 肺腺<|>RELATION_I 癌细胞增生<|>RELATION_I 和<|>RELATION_I 间接<|>RELATION_I 抑制<|>RELATION_I 血管<|>RELATION_I 新生<|>RELATION_E ,<|>RELATION_NOE 进而<|>RELATION_NOE 抑制<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 皮下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 。<|>RELATION_NOE
中介素<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
研究<|>RELATION_NOE 中介素<|>RELATION_NOE (<|>RELATION_NOE IMD<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 及<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 研究<|>RELATION_NOE 中介素<|>RELATION_NOE (<|>RELATION_NOE IMD<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 及<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 测定<|>RELATION_S 88<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE IMD<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 为<|>RELATION_NOE 对照<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 测定<|>RELATION_S 36<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE IMD<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 统计学<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 血浆<|>RELATION_NOE IMD<|>RELATION_NOE 含量<|>RELATION_NOE (<|>RELATION_NOE 81.61<|>RELATION_NOE ±<|>RELATION_NOE 30.78<|>RELATION_NOE )<|>RELATION_NOE Pg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 38.68<|>RELATION_NOE ±<|>RELATION_NOE 12.65<|>RELATION_NOE )<|>RELATION_NOE Pg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -5.818<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
IMD<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE [<|>RELATION_NOE 23<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE (<|>RELATION_NOE 63.9%<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 高于<|>RELATION_S 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE [<|>RELATION_NOE 5<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE (<|>RELATION_NOE 23.8%<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^2<|>RELATION_NOE =<|>RELATION_NOE 8.5<|>RELATION_NOE 25<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE [<|>RELATION_NOE 14<|>RELATION_NOE /<|>RELATION_NOE 17<|>RELATION_NOE (<|>RELATION_NOE 82.4%<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 显著<|>RELATION_NOE IMD<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE [<|>RELATION_NOE 23<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE (<|>RELATION_NOE 63.9%<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 高于<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE [<|>RELATION_NOE 5<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE (<|>RELATION_NOE 23.8%<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^2<|>RELATION_NOE =<|>RELATION_NOE 8.5<|>RELATION_NOE 25<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE [<|>RELATION_NOE 14<|>RELATION_NOE /<|>RELATION_NOE 17<|>RELATION_NOE (<|>RELATION_NOE 82.4%<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E Ⅰ期<|>RELATION_NOE [<|>RELATION_NOE 1/5<|>RELATION_NOE (<|>RELATION_NOE 20.0%<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^2<|>RELATION_NOE =<|>RELATION_NOE 6.9<|>RELATION_NOE 24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.009<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
IMD<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
解剖性<|>RELATION_NOE 肺切除<|>RELATION_NOE 治疗<|>RELATION_S 80<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 老年人<|>RELATION_NOE 肺癌<|>RELATION_NOE
探讨<|>RELATION_NOE 经<|>RELATION_NOE 不<|>RELATION_NOE 损伤<|>RELATION_NOE 肌肉<|>RELATION_NOE 切口<|>RELATION_NOE 行<|>RELATION_NOE 解剖性<|>RELATION_NOE 肺切除<|>RELATION_NOE 治疗<|>RELATION_S 80<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 老年人<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE 和<|>RELATION_NOE
对<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 80<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_S 外科<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 腋下<|>RELATION_NOE 保留<|>RELATION_NOE 胸部<|>RELATION_NOE 肌肉<|>RELATION_NOE 和<|>RELATION_NOE 肋间神经<|>RELATION_NOE 的<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 完成<|>RELATION_NOE 解剖性<|>RELATION_NOE 肺切除<|>RELATION_NOE 加<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清除<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
需<|>RELATION_NOE 机械通气<|>RELATION_NOE 者<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 机械通气<|>RELATION_NOE 时间<|>RELATION_NOE 3－<|>RELATION_NOE 18h<|>RELATION_NOE ;<|>RELATION_NOE
前<|>RELATION_NOE 3<|>RELATION_NOE 位<|>RELATION_NOE 并发症<|>RELATION_NOE 分别<|>RELATION_B 为<|>RELATION_E 心律失常<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 和<|>RELATION_NOE 低氧血症<|>RELATION_NOE 。<|>RELATION_NOE
胚胎<|>RELATION_NOE 干细胞<|>RELATION_NOE 抗<|>RELATION_NOE Lewis<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 体内<|>RELATION_B 研究<|>RELATION_E
研究<|>RELATION_NOE 胚胎<|>RELATION_NOE 干细胞<|>RELATION_NOE 动物<|>RELATION_NOE 体内<|>RELATION_NOE 抗<|>RELATION_NOE Lewis<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 及<|>RELATION_NOE 初步<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 模型<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 实验组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 小鼠<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 情况<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 胚胎<|>RELATION_NOE 干细胞<|>RELATION_NOE 在<|>RELATION_NOE 体内<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 作用<|>RELATION_NOE 及其<|>RELATION_NOE 初步<|>RELATION_NOE 分子<|>RELATION_NOE 免疫<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 小鼠<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 小鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE 明显<|>RELATION_B 减慢<|>RELATION_E ,<|>RELATION_NOE 从<|>RELATION_NOE 实验<|>RELATION_NOE 的<|>RELATION_NOE 第5<|>RELATION_NOE 天<|>RELATION_NOE 开始<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 小鼠<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
小鼠<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE T<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 小鼠<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 小鼠<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE 、<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 比例<|>RELATION_B 增加<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE 、<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE ,<|>RELATION_NOE CD19<|>RELATION_NOE +<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 比例<|>RELATION_NOE 下降<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 细胞<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE IL-2<|>RELATION_NOE 、<|>RELATION_NOE IL-4<|>RELATION_NOE 和<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 小鼠<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血中<|>RELATION_NOE IL-2<|>RELATION_NOE 和<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE 细胞<|>RELATION_NOE 因子<|>RELATION_NOE 水平<|>RELATION_NOE 增高<|>RELATION_S ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE IL-4<|>RELATION_NOE 略<|>RELATION_NOE 有<|>RELATION_NOE
胚胎<|>RELATION_NOE 干细胞<|>RELATION_NOE 不仅<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 具有<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 动物<|>RELATION_NOE 体内<|>RELATION_NOE 胚胎<|>RELATION_NOE 干细胞<|>RELATION_NOE 也<|>RELATION_NOE 能<|>RELATION_NOE 通过<|>RELATION_B 激活<|>RELATION_I 免疫系统<|>RELATION_E 从而<|>RELATION_NOE 产生<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE 或<|>RELATION_NOE 延缓<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 形成<|>RELATION_NOE 和<|>RELATION_NOE 发展<|>RELATION_NOE 。<|>RELATION_NOE
70<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 并发症<|>RELATION_NOE 及<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_S
Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_NOE 术后<|>RELATION_NOE 总体<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 危险因素<|>RELATION_E 为<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 体重<|>RELATION_NOE 下降<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE ASA<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE MVV<|>RELATION_NOE (<|>RELATION_NOE %<|>RELATION_NOE 预测值<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫数<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
重视<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 体重<|>RELATION_NOE 下降<|>RELATION_NOE 及<|>RELATION_NOE 术中<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 对<|>RELATION_NOE 70<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 病人<|>RELATION_NOE 手术<|>RELATION_NOE 安全性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ;<|>RELATION_NOE
血清<|>RELATION_NOE IGF-1<|>RELATION_NOE 及<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊治<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
研究<|>RELATION_NOE 血清<|>RELATION_NOE 胰岛素<|>RELATION_NOE 样<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE IGF-1<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 角质素<|>RELATION_NOE 片断<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊治<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 价值<|>RELATION_E ,<|>RELATION_NOE 以<|>RELATION_NOE 筛选<|>RELATION_NOE 理想<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 组合<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 分析法<|>RELATION_NOE 检测<|>RELATION_S 30<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 、<|>RELATION_NOE 91<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE IGF-1<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 应用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 免疫<|>RELATION_NOE 分析法<|>RELATION_NOE 测定<|>RELATION_NOE 同一<|>RELATION_NOE 批<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Kruskal-Wallis<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 方差分析<|>RELATION_NOE Mann-Whitney<|>RELATION_NOE 秩和检验<|>RELATION_NOE 进行<|>RELATION_NOE 统计学<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE 应用<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 分析<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 30<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 、<|>RELATION_NOE 91<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE IGF-1<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 应用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 免疫<|>RELATION_NOE 分析法<|>RELATION_NOE 测定<|>RELATION_S 同一<|>RELATION_NOE 批<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Kruskal-Wallis<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 方差分析<|>RELATION_NOE Mann-Whitney<|>RELATION_NOE 秩和检验<|>RELATION_NOE 进行<|>RELATION_NOE 统计学<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 对<|>RELATION_NOE 各项<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效能<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_B 和<|>RELATION_I 评价<|>RELATION_E ,<|>RELATION_NOE 曲线下面积<|>RELATION_NOE (<|>RELATION_NOE AUC<|>RELATION_NOE )<|>RELATION_NOE 采用<|>RELATION_NOE Wileoxon<|>RELATION_NOE 检验<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE IGF-1<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 3<|>RELATION_NOE 种<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 健康<|>RELATION_NOE 人<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE IGF-1<|>RELATION_NOE :<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 26.95<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE ;<|>RELATION_NOE
血清<|>RELATION_NOE 中<|>RELATION_NOE IGF-1<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
IGF-1<|>RELATION_NOE 与<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 提高<|>RELATION_E 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 和<|>RELATION_NOE 效能<|>RELATION_NOE ,<|>RELATION_NOE IGF-1<|>RELATION_NOE +<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 与<|>RELATION_NOE IGF-1<|>RELATION_NOE +<|>RELATION_NOE CEA<|>RELATION_NOE +<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 是<|>RELATION_NOE 诊断<|>RELATION_NOE 肺痛<|>RELATION_NOE 较为<|>RELATION_NOE 理想<|>RELATION_NOE 的<|>RELATION_NOE 组合<|>RELATION_NOE 。<|>RELATION_NOE
联合<|>RELATION_NOE 组Ⅲ<|>RELATION_NOE －Ⅳ级<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 及<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 总<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 13.94<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
保留<|>RELATION_NOE 上肢<|>RELATION_NOE 的<|>RELATION_NOE 肩胛<|>RELATION_NOE 带<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_S 肩胛<|>RELATION_NOE 带<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE
8例<|>RELATION_NOE 起源<|>RELATION_NOE 于<|>RELATION_NOE 肩胛骨<|>RELATION_NOE ,<|>RELATION_NOE 软骨肉瘤<|>RELATION_NOE 4例<|>RELATION_NOE 、<|>RELATION_NOE Ewing<|>RELATION_NOE 肉瘤<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 癌3<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
5例<|>RELATION_NOE 起源<|>RELATION_NOE 于<|>RELATION_NOE 肩部<|>RELATION_NOE 软<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 滑膜肉瘤<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 纤维肉瘤<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 外皮瘤<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 高<|>RELATION_NOE 分化<|>RELATION_NOE 脂肪肉瘤<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
3例<|>RELATION_NOE 起源<|>RELATION_NOE 于<|>RELATION_NOE 肱骨<|>RELATION_NOE 近端<|>RELATION_NOE ,<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 转移癌<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
1例<|>RELATION_NOE 肱骨<|>RELATION_NOE 近<|>RELATION_NOE 端<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 肺转移<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 肩胛<|>RELATION_NOE 带<|>RELATION_NOE 离<|>RELATION_NOE 断术<|>RELATION_NOE 后<|>RELATION_NOE 18<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 累及<|>RELATION_NOE 肩关节<|>RELATION_NOE 的<|>RELATION_NOE 肩部<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 采用<|>RELATION_NOE Tikhoff-Linberg<|>RELATION_NOE 手术<|>RELATION_NOE 可<|>RELATION_NOE 达到<|>RELATION_B 肿瘤<|>RELATION_I 广泛<|>RELATION_I 切除<|>RELATION_E ,<|>RELATION_NOE 保留<|>RELATION_NOE 上肢<|>RELATION_NOE 肢体<|>RELATION_NOE 及<|>RELATION_NOE 部分<|>RELATION_NOE 功能<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血细胞计数<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
研究<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 白细胞<|>RELATION_NOE 及<|>RELATION_NOE 血小板计数<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_B 关系<|>RELATION_E 。<|>RELATION_NOE
观察<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 228<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 白细胞<|>RELATION_NOE 及<|>RELATION_NOE 血小板计数<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 生存期<|>RELATION_NOE 长短<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 白细胞<|>RELATION_NOE 及<|>RELATION_NOE 血小板计数<|>RELATION_NOE 升高<|>RELATION_NOE 与其<|>RELATION_NOE 生存期<|>RELATION_NOE 呈<|>RELATION_NOE 负<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 白细胞<|>RELATION_NOE 及<|>RELATION_NOE 血小板计数<|>RELATION_NOE 升高<|>RELATION_NOE 提示<|>RELATION_S 预后<|>RELATION_NOE 不<|>RELATION_NOE 佳<|>RELATION_NOE ,<|>RELATION_NOE 生存期<|>RELATION_NOE 短<|>RELATION_NOE 。<|>RELATION_NOE
拓<|>RELATION_NOE 扑<|>RELATION_NOE 异构<|>RELATION_NOE 酶<|>RELATION_NOE Ⅰ<|>RELATION_NOE 抑制剂<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 杀伤<|>RELATION_B 和<|>RELATION_I 诱导<|>RELATION_I 凋亡<|>RELATION_I 作用<|>RELATION_E 的<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_NOE 拓<|>RELATION_NOE 扑<|>RELATION_NOE 异构<|>RELATION_NOE 酶<|>RELATION_NOE Ⅰ<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE 拓扑<|>RELATION_NOE 替康<|>RELATION_NOE ,<|>RELATION_NOE TPT<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 杀伤<|>RELATION_B 和<|>RELATION_I 诱导<|>RELATION_I 凋亡<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 、<|>RELATION_NOE AnnexinV<|>RELATION_NOE 染色<|>RELATION_NOE 、<|>RELATION_NOE 梯状<|>RELATION_NOE DNA<|>RELATION_NOE 电泳<|>RELATION_NOE 与<|>RELATION_NOE 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE 观察<|>RELATION_NOE 等<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S TPT<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 作用<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE
螺旋<|>RELATION_NOE 藻多糖<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E
对照组<|>RELATION_NOE 每<|>RELATION_NOE 只<|>RELATION_NOE 小鼠<|>RELATION_NOE 右<|>RELATION_NOE 后肢<|>RELATION_NOE 背部<|>RELATION_NOE 皮下<|>RELATION_NOE 接种<|>RELATION_NOE 1×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 6Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 待<|>RELATION_NOE 瘤体<|>RELATION_NOE 直径<|>RELATION_NOE 达<|>RELATION_NOE 5<|>RELATION_NOE 删<|>RELATION_NOE 时<|>RELATION_NOE 瘤内<|>RELATION_NOE 多<|>RELATION_NOE 点<|>RELATION_NOE 注射<|>RELATION_NOE 0.9%<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 100ms<|>RELATION_NOE /<|>RELATION_NOE ks<|>RELATION_NOE ,<|>RELATION_NOE 每天<|>RELATION_NOE 1<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 3w<|>RELATION_NOE ;<|>RELATION_NOE
预防组<|>RELATION_NOE 给<|>RELATION_NOE 小鼠<|>RELATION_NOE 接种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 前<|>RELATION_NOE 1w<|>RELATION_NOE 每天<|>RELATION_NOE 腹腔<|>RELATION_NOE 注射<|>RELATION_NOE PSP100ms<|>RELATION_NOE /<|>RELATION_NOE ks<|>RELATION_NOE ,<|>RELATION_NOE 每天<|>RELATION_NOE 1<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 1W<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 只<|>RELATION_NOE 小鼠<|>RELATION_NOE 右<|>RELATION_NOE 后肢<|>RELATION_NOE 背部<|>RELATION_NOE 皮下<|>RELATION_NOE 接种<|>RELATION_NOE 1×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 6Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 待<|>RELATION_NOE 瘤体<|>RELATION_NOE 直径<|>RELATION_NOE 达<|>RELATION_NOE 5inIll<|>RELATION_NOE 时<|>RELATION_NOE 瘤内<|>RELATION_NOE 多<|>RELATION_NOE 点<|>RELATION_NOE 注射<|>RELATION_NOE PSP100mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE 每天<|>RELATION_NOE 1<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 3w<|>RELATION_NOE ;<|>RELATION_NOE
PSP<|>RELATION_NOE 组<|>RELATION_NOE 首先<|>RELATION_NOE 于<|>RELATION_NOE 右<|>RELATION_NOE 后肢<|>RELATION_NOE 背部<|>RELATION_NOE 皮下<|>RELATION_NOE 接种<|>RELATION_NOE 1×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 6Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 待<|>RELATION_NOE 瘤体<|>RELATION_NOE 直径<|>RELATION_NOE 达<|>RELATION_NOE 5mill<|>RELATION_NOE 时<|>RELATION_NOE 瘤内<|>RELATION_NOE 多<|>RELATION_NOE 点<|>RELATION_NOE 注射<|>RELATION_NOE PSP100ms<|>RELATION_NOE /<|>RELATION_NOE ks<|>RELATION_NOE ,<|>RELATION_NOE 每天<|>RELATION_NOE 1<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 3W<|>RELATION_NOE 。<|>RELATION_NOE
螺旋<|>RELATION_NOE 藻多糖<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 分析<|>RELATION_E
探讨<|>RELATION_NOE 淋巴结<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE (<|>RELATION_NOE LNR<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 预测<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
结合<|>RELATION_NOE 现有<|>RELATION_NOE N<|>RELATION_NOE 分期<|>RELATION_NOE 对<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 预后<|>RELATION_B 危险<|>RELATION_I 组别<|>RELATION_I 的<|>RELATION_I 划分<|>RELATION_E 。<|>RELATION_NOE
高<|>RELATION_NOE LNR<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE 低<|>RELATION_NOE LNR<|>RELATION_NOE 组<|>RELATION_NOE 在<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 隆突<|>RELATION_NOE 下<|>RELATION_NOE 淋巴结<|>RELATION_NOE 是否<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 阳性<|>RELATION_NOE 个数<|>RELATION_NOE 、<|>RELATION_NOE 清扫<|>RELATION_NOE 个数<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 站数<|>RELATION_NOE 存在<|>RELATION_B 明显<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
LNR<|>RELATION_NOE 是<|>RELATION_NOE 独立<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE LNR<|>RELATION_NOE 的<|>RELATION_NOE 高低<|>RELATION_NOE 明显<|>RELATION_NOE 影响<|>RELATION_S 总<|>RELATION_NOE 生存期<|>RELATION_NOE (<|>RELATION_NOE OS<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 无病生存<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE DFS<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE LNR<|>RELATION_NOE 越<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 死亡<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE =<|>RELATION_NOE 2.<|>RELATION_NOE 507<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE =<|>RELATION_NOE 1.8<|>RELATION_NOE 72<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.008<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 风险性<|>RELATION_NOE 越<|>RELATION_NOE 大<|>RELATION_NOE ;<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 16<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 探讨<|>RELATION_S
结合<|>RELATION_NOE 2009TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 分析<|>RELATION_B 探讨<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 及其<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 2001年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2005年<|>RELATION_NOE 1月<|>RELATION_NOE 接受<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 16<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 预后<|>RELATION_NOE 及<|>RELATION_NOE 影响<|>RELATION_NOE 其<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 因素<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_B 因素<|>RELATION_I 分析<|>RELATION_I 显示<|>RELATION_E 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 为<|>RELATION_NOE 支气管<|>RELATION_NOE 断端<|>RELATION_NOE 是否<|>RELATION_NOE 阳性<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 、<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 个数<|>RELATION_NOE (<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE －<|>RELATION_NOE 及<|>RELATION_NOE ><|>RELATION_NOE 20<|>RELATION_NOE 个<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 组数<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_B 回归<|>RELATION_I 多<|>RELATION_I 因素<|>RELATION_I 分析<|>RELATION_I 提示<|>RELATION_E ,<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 个数<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 13<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 独立<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 总体<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_S 。<|>RELATION_NOE
抑制<|>RELATION_NOE 乙肝<|>RELATION_NOE 病毒<|>RELATION_NOE X<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 上皮<|>RELATION_NOE 一<|>RELATION_NOE 间<|>RELATION_NOE 质<|>RELATION_NOE 转化<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 乙肝<|>RELATION_NOE 病毒<|>RELATION_NOE x<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE HBx<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE Transwell<|>RELATION_NOE 小室<|>RELATION_NOE 和<|>RELATION_NOE 裸鼠肺<|>RELATION_NOE 转移<|>RELATION_NOE 模型<|>RELATION_NOE 实验<|>RELATION_NOE 比较<|>RELATION_S HBx<|>RELATION_NOE 抑制<|>RELATION_NOE 前后<|>RELATION_NOE MHCC97H<|>RELATION_NOE 细胞<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE Hgx-siRNA<|>RELATION_NOE 导入<|>RELATION_NOE MHCC97H<|>RELATION_NOE 细胞<|>RELATION_NOE 可以<|>RELATION_NOE 抑制<|>RELATION_S HBx<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 下调<|>RELATION_NOE EMT<|>RELATION_NOE 相关<|>RELATION_NOE 分子<|>RELATION_NOE Twist<|>RELATION_NOE 和<|>RELATION_NOE N-cadherin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 上调<|>RELATION_NOE E-cad-herin<|>RELATION_NOE 表达<|>RELATION_NOE 而<|>RELATION_NOE 将<|>RELATION_NOE Hgx-siRNA<|>RELATION_NOE 导入<|>RELATION_NOE MHCC97H<|>RELATION_NOE 细胞<|>RELATION_NOE 可以<|>RELATION_NOE 抑制<|>RELATION_NOE HBx<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 下调<|>RELATION_S EMT<|>RELATION_NOE 相关<|>RELATION_NOE 分子<|>RELATION_NOE Twist<|>RELATION_NOE 和<|>RELATION_NOE N-cadherin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 上调<|>RELATION_NOE E-cad-herin<|>RELATION_NOE 表达<|>RELATION_NOE 而<|>RELATION_NOE 抑制<|>RELATION_NOE EMT<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 还<|>RELATION_NOE 可<|>RELATION_NOE 通过<|>RELATION_NOE Twist-P53<|>RELATION_NOE 途径<|>RELATION_NOE 诱发<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 。<|>RELATION_NOE 将<|>RELATION_NOE Hgx-siRNA<|>RELATION_NOE 导入<|>RELATION_NOE MHCC97H<|>RELATION_NOE 细胞<|>RELATION_NOE 可以<|>RELATION_NOE 抑制<|>RELATION_NOE HBx<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 下调<|>RELATION_NOE EMT<|>RELATION_NOE 相关<|>RELATION_NOE 分子<|>RELATION_NOE Twist<|>RELATION_NOE 和<|>RELATION_NOE N-cadherin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 上调<|>RELATION_S E-cad-herin<|>RELATION_NOE 表达<|>RELATION_NOE 而<|>RELATION_NOE 抑制<|>RELATION_NOE EMT<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 还<|>RELATION_NOE 可<|>RELATION_NOE 通过<|>RELATION_NOE Twist-P53<|>RELATION_NOE 途径<|>RELATION_NOE 诱发<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 。<|>RELATION_NOE
抑制<|>RELATION_NOE HBx<|>RELATION_NOE 表达<|>RELATION_NOE 可以<|>RELATION_NOE 通过<|>RELATION_NOE 改变<|>RELATION_NOE 上皮<|>RELATION_NOE 一<|>RELATION_NOE 间<|>RELATION_NOE 质<|>RELATION_NOE 转化<|>RELATION_NOE 和<|>RELATION_NOE 诱发<|>RELATION_NOE 凋亡<|>RELATION_NOE 而<|>RELATION_NOE 减弱<|>RELATION_S 高<|>RELATION_NOE 侵袭<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE MHCC7H<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 样<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 病<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 表型<|>RELATION_NOE 及<|>RELATION_NOE 基因重排<|>RELATION_NOE 研究<|>RELATION_S
观察<|>RELATION_S 肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 样<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 病<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 组成<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 表型<|>RELATION_NOE 和<|>RELATION_NOE 分子<|>RELATION_NOE 生物学<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE EnVision<|>RELATION_NOE 法染色<|>RELATION_NOE (<|>RELATION_NOE 抗体<|>RELATION_NOE 包括<|>RELATION_NOE CD20<|>RELATION_NOE 、<|>RELATION_NOE CD3<|>RELATION_NOE 、<|>RELATION_NOE CD56<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 原位杂交<|>RELATION_NOE 检测<|>RELATION_S EB<|>RELATION_NOE 病毒<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE 进行<|>RELATION_NOE Ig<|>RELATION_NOE 和<|>RELATION_NOE TCR<|>RELATION_NOE 基因重排<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 显示<|>RELATION_NOE 以<|>RELATION_NOE CD3<|>RELATION_NOE 阳性<|>RELATION_NOE 的<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 占<|>RELATION_NOE 绝对<|>RELATION_NOE 优势<|>RELATION_NOE ,<|>RELATION_NOE 散<|>RELATION_NOE 在<|>RELATION_NOE 不等<|>RELATION_NOE 数量<|>RELATION_NOE 的<|>RELATION_NOE CD20<|>RELATION_NOE 阳性<|>RELATION_NOE 的<|>RELATION_NOE B<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE CD56<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE
8例行<|>RELATION_NOE EB<|>RELATION_NOE 病毒<|>RELATION_NOE 原位杂交<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞数<|>RELATION_NOE <<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE ><|>RELATION_NOE 20%<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 15%<|>RELATION_NOE 。<|>RELATION_NOE
随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 0.5<|>RELATION_NOE －<|>RELATION_NOE 6.5<|>RELATION_NOE 年<|>RELATION_NOE 不等<|>RELATION_NOE ,<|>RELATION_NOE 9例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 存活<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 失访<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE PICC<|>RELATION_NOE 相关<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_B 分析<|>RELATION_I 及<|>RELATION_I 护理<|>RELATION_E
恩度<|>RELATION_NOE 联合<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE
探讨<|>RELATION_NOE 肿瘤<|>RELATION_NOE 靶<|>RELATION_NOE 向<|>RELATION_NOE 治疗<|>RELATION_NOE 药物<|>RELATION_NOE 恩度<|>RELATION_NOE 联合<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 初诊<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 优势<|>RELATION_NOE ,<|>RELATION_NOE 寻找<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 探讨<|>RELATION_NOE 肿瘤<|>RELATION_NOE 靶<|>RELATION_NOE 向<|>RELATION_NOE 治疗<|>RELATION_NOE 药物<|>RELATION_NOE 恩度<|>RELATION_NOE 联合<|>RELATION_NOE 放化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 初诊<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 优势<|>RELATION_NOE ,<|>RELATION_NOE 寻找<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 组合<|>RELATION_NOE 模式<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 及<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 2009年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 2月<|>RELATION_NOE 收<|>RELATION_NOE 住<|>RELATION_NOE 的<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 初诊<|>RELATION_NOE 为<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 实验组<|>RELATION_NOE (<|>RELATION_NOE 含<|>RELATION_NOE 恩度<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 不<|>RELATION_NOE 含<|>RELATION_NOE 恩度<|>RELATION_NOE )<|>RELATION_NOE 各<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 诱导<|>RELATION_NOE 化疗<|>RELATION_NOE 并<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 2组<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 缓解率<|>RELATION_NOE 、<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 做好<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 及<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 77.8%<|>RELATION_NOE 和<|>RELATION_NOE 66.7%<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 缓解率<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_B 无<|>RELATION_I 显著<|>RELATION_I 差异<|>RELATION_E ,<|>RELATION_NOE 2组<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 护理<|>RELATION_NOE 人员<|>RELATION_NOE 的<|>RELATION_NOE 整体<|>RELATION_NOE 护理<|>RELATION_NOE 和<|>RELATION_NOE 系统<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 顺利<|>RELATION_NOE 完成<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
恩度<|>RELATION_NOE 联合<|>RELATION_NOE 放化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 初诊<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_S 疗效<|>RELATION_NOE 及<|>RELATION_NOE 生存率<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 虽<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 经<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 处理<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 能<|>RELATION_NOE 缓解<|>RELATION_NOE 。<|>RELATION_NOE 恩度<|>RELATION_NOE 联合<|>RELATION_NOE 放化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 初诊<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 生存率<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_S 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 虽<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 经<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 处理<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 能<|>RELATION_NOE 缓解<|>RELATION_NOE 。<|>RELATION_NOE
支气管动脉<|>RELATION_NOE 介入<|>RELATION_NOE 栓塞<|>RELATION_NOE 治疗<|>RELATION_S 大<|>RELATION_NOE 咳血<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE
32<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 支气管动脉栓塞<|>RELATION_NOE 后<|>RELATION_NOE 立即<|>RELATION_NOE 停止<|>RELATION_B 使用<|>RELATION_E 止血<|>RELATION_NOE 药物治疗<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 再<|>RELATION_NOE 出血<|>RELATION_NOE 情况<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE
随<|>RELATION_NOE 访<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 2例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 再<|>RELATION_NOE 发<|>RELATION_NOE 咳<|>RELATION_NOE 血<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 因<|>RELATION_NOE 肺癌<|>RELATION_NOE 晚期<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 咳<|>RELATION_NOE 血<|>RELATION_NOE 症状<|>RELATION_NOE 复发<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE 医生<|>RELATION_NOE 的<|>RELATION_NOE 抢救<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 短<|>RELATION_NOE 时间<|>RELATION_NOE 内<|>RELATION_NOE 提供<|>RELATION_NOE 可<|>RELATION_NOE 供<|>RELATION_NOE 医生<|>RELATION_NOE 选择<|>RELATION_NOE 的<|>RELATION_NOE 配套<|>RELATION_NOE 介入<|>RELATION_NOE 抢救<|>RELATION_NOE 器材<|>RELATION_NOE 和<|>RELATION_NOE 护理<|>RELATION_NOE 配合<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 护士<|>RELATION_NOE 必须<|>RELATION_NOE 掌握<|>RELATION_NOE 熟练<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 操作<|>RELATION_NOE 技能<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 提高<|>RELATION_S 抢救<|>RELATION_NOE 成功率<|>RELATION_NOE 。<|>RELATION_NOE
护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 125<|>RELATION_NOE Ⅰ<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 心理<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
选取<|>RELATION_NOE 2009年<|>RELATION_NOE 1月<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 间<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 骨癌<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 24<|>RELATION_NOE 例.<|>RELATION_NOE
观察组<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 临床<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 加入<|>RELATION_S 了<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 了<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
血小板活化<|>RELATION_NOE 分子<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_B 相关性<|>RELATION_I 研究<|>RELATION_E
研究<|>RELATION_NOE 血小板活化<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 病情<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 放射<|>RELATION_NOE 免疫法<|>RELATION_NOE 和<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫法<|>RELATION_NOE 测定<|>RELATION_S 168<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 80<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 血浆<|>RELATION_NOE 血栓<|>RELATION_NOE 烷<|>RELATION_NOE B2<|>RELATION_NOE (<|>RELATION_NOE TXB2<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 11-<|>RELATION_NOE 去<|>RELATION_NOE 氢<|>RELATION_NOE -<|>RELATION_NOE 血栓<|>RELATION_NOE 烷<|>RELATION_NOE B2<|>RELATION_NOE (<|>RELATION_NOE DH-TXB2<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 凝血酶<|>RELATION_NOE 敏感<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE TSP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 血小板球<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE β<|>RELATION_NOE -TG<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血小板<|>RELATION_NOE α<|>RELATION_NOE -<|>RELATION_NOE 颗粒膜<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE GMP-140<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血清<|>RELATION_NOE 纤维<|>RELATION_NOE 结合<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE FN<|>RELATION_NOE )<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
抗<|>RELATION_NOE 前胃<|>RELATION_NOE 泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE 的<|>RELATION_NOE 纯化<|>RELATION_NOE 及<|>RELATION_NOE 体外<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_S
探讨<|>RELATION_NOE 亲和层<|>RELATION_NOE 析法<|>RELATION_NOE 纯化<|>RELATION_S 抗<|>RELATION_NOE 前胃<|>RELATION_NOE 泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽<|>RELATION_NOE (<|>RELATION_NOE PGRP<|>RELATION_NOE )<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE (<|>RELATION_NOE MAb<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 该法<|>RELATION_NOE
采用<|>RELATION_NOE 蛋白<|>RELATION_NOE A-<|>RELATION_NOE 琼脂糖<|>RELATION_NOE 亲和层<|>RELATION_NOE 析法<|>RELATION_NOE 纯化<|>RELATION_S 含有<|>RELATION_NOE MAb<|>RELATION_NOE 的<|>RELATION_NOE 腹腔<|>RELATION_NOE 积液<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE SDS-PAGE<|>RELATION_NOE 和<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_NOE 其<|>RELATION_NOE 纯度<|>RELATION_NOE 和<|>RELATION_NOE 效价<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE NCI-H446<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 切片<|>RELATION_NOE 的<|>RELATION_NOE 生物<|>RELATION_NOE 功能<|>RELATION_NOE 。<|>RELATION_NOE 采用<|>RELATION_NOE 蛋白<|>RELATION_NOE A-<|>RELATION_NOE 琼脂糖<|>RELATION_NOE 亲和层<|>RELATION_NOE 析法<|>RELATION_NOE 纯化<|>RELATION_NOE 含有<|>RELATION_NOE MAb<|>RELATION_NOE 的<|>RELATION_NOE 腹腔<|>RELATION_NOE 积液<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE SDS-PAGE<|>RELATION_NOE 和<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_S 其<|>RELATION_NOE 纯度<|>RELATION_NOE 和<|>RELATION_NOE 效价<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE
亲和层<|>RELATION_NOE 析法<|>RELATION_NOE 纯化<|>RELATION_NOE 前<|>RELATION_NOE 小鼠<|>RELATION_NOE 腹腔<|>RELATION_NOE 积液<|>RELATION_NOE 蛋白质<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 23.62mg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ;<|>RELATION_NOE
蛋白<|>RELATION_NOE A-<|>RELATION_NOE 琼脂糖<|>RELATION_NOE 亲和层<|>RELATION_NOE 析法<|>RELATION_NOE 可<|>RELATION_NOE 快速<|>RELATION_NOE 、<|>RELATION_NOE 高效<|>RELATION_NOE 地<|>RELATION_NOE 从<|>RELATION_NOE 小鼠<|>RELATION_NOE 腹腔<|>RELATION_NOE 积液<|>RELATION_NOE 中<|>RELATION_NOE 纯化<|>RELATION_S 抗<|>RELATION_NOE PGRPMAb<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 抗体<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 纯度<|>RELATION_NOE ,<|>RELATION_NOE 免疫学活性<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 选择性<|>RELATION_NOE 的<|>RELATION_NOE 和<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE PGRP<|>RELATION_NOE 结合<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 及<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 及<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CD<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 4CD<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 25<|>RELATION_NOE 调节<|>RELATION_S T<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_NOE 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 表达<|>RELATION_B 比例<|>RELATION_I 不同<|>RELATION_E ,<|>RELATION_NOE 其中<|>RELATION_NOE Ⅰ<|>RELATION_NOE +<|>RELATION_NOE Ⅱ<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CDIcD<|>RELATION_NOE 击<|>RELATION_NOE 细胞<|>RELATION_NOE 占<|>RELATION_NOE cD<|>RELATION_NOE 刍细胞<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 19.52<|>RELATION_NOE ±<|>RELATION_NOE 3.32<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 27.28<|>RELATION_NOE ±<|>RELATION_NOE 8.26<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 32.31<|>RELATION_NOE ±<|>RELATION_NOE 15.60<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 11.12<|>RELATION_NOE ±<|>RELATION_NOE 3.32<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 31.00<|>RELATION_NOE 40<|>RELATION_NOE 、<|>RELATION_NOE -7.9688<|>RELATION_NOE 、<|>RELATION_NOE -4.9770<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <005<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
合并<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 及<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CD<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 4细胞<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 25.32<|>RELATION_NOE ±<|>RELATION_NOE 13.45<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 及<|>RELATION_NOE (<|>RELATION_NOE 34.68<|>RELATION_NOE ±<|>RELATION_NOE 12.34<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_S 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 43.24<|>RELATION_NOE ±<|>RELATION_NOE 8.68<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 7.3<|>RELATION_NOE 104<|>RELATION_NOE 、<|>RELATION_NOE 4.88<|>RELATION_NOE 18<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CD<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 56<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 8.24<|>RELATION_NOE ±<|>RELATION_NOE 7.38<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 及<|>RELATION_NOE (<|>RELATION_NOE 11.23<|>RELATION_NOE ±<|>RELATION_NOE 7.65<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 及<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CD<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 4CD<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 25T<|>RELATION_NOE 细胞<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_S ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 低下<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE
半乳糖<|>RELATION_NOE 凝集<|>RELATION_NOE 素1<|>RELATION_NOE 在<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 和<|>RELATION_I 功能<|>RELATION_E
观察<|>RELATION_NOE 肺腺癌<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 半乳糖<|>RELATION_NOE 凝集<|>RELATION_NOE 素1<|>RELATION_NOE (<|>RELATION_NOE Galeetin-1<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 和<|>RELATION_I 功能<|>RELATION_E 。<|>RELATION_NOE
磁珠分<|>RELATION_NOE 选出<|>RELATION_NOE 9例<|>RELATION_NOE 患者<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 分选<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE fqRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Westernblot<|>RELATION_NOE 和<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 磁珠分<|>RELATION_NOE 选出<|>RELATION_NOE 9例<|>RELATION_NOE 患者<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE 分选<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE fqRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Westernblot<|>RELATION_NOE 和<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 或<|>RELATION_NOE 上<|>RELATION_NOE 清液<|>RELATION_NOE 中<|>RELATION_NOE Galectin-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Galeetin-1<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 转染<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 磁珠分<|>RELATION_NOE 选出<|>RELATION_NOE 9例<|>RELATION_NOE 患者<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE 分选<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE fqRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Westernblot<|>RELATION_NOE 和<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 或<|>RELATION_NOE 上<|>RELATION_NOE 清液<|>RELATION_NOE 中<|>RELATION_NOE Galectin-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Galeetin-1<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 转染<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 检测<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 以及<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
予<|>RELATION_NOE 裸鼠<|>RELATION_NOE 皮下注射<|>RELATION_NOE Galeetin-1<|>RELATION_NOE siRNA<|>RELATION_NOE 转染<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 并<|>RELATION_NOE 观察<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 。<|>RELATION_NOE
1<|>RELATION_NOE 表达<|>RELATION_NOE 后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖率<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 36.75<|>RELATION_NOE ±<|>RELATION_NOE 1.35<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 92.31<|>RELATION_NOE ±<|>RELATION_NOE 0.78<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Galeetin-1<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 干细胞<|>RELATION_NOE 中<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 能<|>RELATION_NOE 促进<|>RELATION_NOE Galeetin-1<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 干细胞<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 能<|>RELATION_NOE 促进<|>RELATION_S 肺腺癌<|>RELATION_NOE 干细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 增殖<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE -<|>RELATION_NOE β<|>RELATION_NOE (<|>RELATION_NOE TGF-<|>RELATION_NOE β<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 对<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 抑制组<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 促进<|>RELATION_NOE 组<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE 方面<|>RELATION_NOE 验证<|>RELATION_NOE TGF-<|>RELATION_NOE β<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 促<|>RELATION_NOE 增殖<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 测定<|>RELATION_S 细胞增殖<|>RELATION_NOE 速率<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 早晚<|>RELATION_NOE 期<|>RELATION_NOE 凋亡<|>RELATION_NOE 和<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE 通过<|>RELATION_NOE 抑制组<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 促进<|>RELATION_NOE 组<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE 方面<|>RELATION_NOE 验证<|>RELATION_NOE TGF-<|>RELATION_NOE β<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 促<|>RELATION_NOE 增殖<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 测定<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 速率<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 的<|>RELATION_NOE 早晚<|>RELATION_NOE 期<|>RELATION_NOE 凋亡<|>RELATION_NOE 和<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
兔肺<|>RELATION_NOE VX2<|>RELATION_NOE 肿瘤<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 模型<|>RELATION_NOE 中<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_B 和<|>RELATION_I 意义<|>RELATION_E
观察<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 兔肺<|>RELATION_NOE VX2<|>RELATION_NOE 肿瘤<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 模型<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_S 。<|>RELATION_NOE
手术<|>RELATION_NOE 切除<|>RELATION_NOE 兔肺<|>RELATION_NOE VX2<|>RELATION_NOE 肿瘤<|>RELATION_NOE 后<|>RELATION_NOE 15d<|>RELATION_NOE 和<|>RELATION_NOE 30d<|>RELATION_NOE ,<|>RELATION_NOE 实验兔<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 水平<|>RELATION_NOE 较术<|>RELATION_NOE 前<|>RELATION_NOE 下降<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 不<|>RELATION_NOE 进行<|>RELATION_NOE 肿瘤<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 实验兔<|>RELATION_NOE
手术<|>RELATION_NOE 切除<|>RELATION_NOE 肿瘤<|>RELATION_NOE 可<|>RELATION_NOE 减少<|>RELATION_S 肿瘤负荷<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_NOE 机体<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 恢复<|>RELATION_NOE 。<|>RELATION_NOE
抑制<|>RELATION_NOE 骨桥<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 降低<|>RELATION_S 肺癌<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 增殖<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE
与<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 1.20<|>RELATION_NOE ±<|>RELATION_NOE 0.15<|>RELATION_NOE )<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE 72h<|>RELATION_NOE 后<|>RELATION_NOE pINF-1<|>RELATION_NOE 组<|>RELATION_NOE OPN<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.15<|>RELATION_NOE ±<|>RELATION_NOE 0.04<|>RELATION_NOE )<|>RELATION_NOE 下降<|>RELATION_NOE 87%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_S 比<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 早期<|>RELATION_NOE 显影<|>RELATION_NOE 与<|>RELATION_NOE ^<|>RELATION_NOE 131I<|>RELATION_NOE 疗效<|>RELATION_NOE 关系<|>RELATION_B 分析<|>RELATION_E
探讨<|>RELATION_NOE DTC<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 应用<|>RELATION_NOE ^<|>RELATION_NOE 131I<|>RELATION_NOE 清除<|>RELATION_NOE 甲状腺<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE 简称<|>RELATION_NOE 清甲<|>RELATION_NOE )<|>RELATION_NOE 时<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 显像<|>RELATION_NOE 与<|>RELATION_NOE ^<|>RELATION_NOE 131I<|>RELATION_NOE 治疗效果<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S ,<|>RELATION_NOE 及<|>RELATION_NOE 影响<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 早期<|>RELATION_NOE 显影<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
83%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 行<|>RELATION_NOE 甲状腺<|>RELATION_NOE 全切<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 清甲<|>RELATION_NOE 治疗<|>RELATION_NOE 时<|>RELATION_NOE 即<|>RELATION_NOE 有<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 显影<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 行<|>RELATION_NOE 甲状腺<|>RELATION_NOE 部分<|>RELATION_NOE 切除<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 仅<|>RELATION_NOE 有<|>RELATION_NOE 42%<|>RELATION_NOE (<|>RELATION_NOE 5/12<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 与<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 早期<|>RELATION_NOE 显影<|>RELATION_NOE 有<|>RELATION_NOE 相关性<|>RELATION_S (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.4<|>RELATION_NOE 11<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
146<|>RELATION_NOE 例<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-MDP1110MBq<|>RELATION_NOE ,<|>RELATION_NOE 3－<|>RELATION_NOE 6h<|>RELATION_NOE 后<|>RELATION_NOE 按<|>RELATION_NOE 常规<|>RELATION_NOE 方法<|>RELATION_NOE 行<|>RELATION_NOE 全身<|>RELATION_NOE 骨<|>RELATION_NOE 显像<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 或<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 获得<|>RELATION_NOE 正确<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 计算<|>RELATION_NOE 全身<|>RELATION_NOE 骨<|>RELATION_NOE 显像<|>RELATION_NOE 、<|>RELATION_NOE SPECT<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 融合<|>RELATION_NOE 图像<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 能<|>RELATION_NOE 正确<|>RELATION_NOE (<|>RELATION_NOE 肿瘤骨<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 无肿<|>RELATION_NOE 瘤骨<|>RELATION_NOE 转移<|>RELATION_NOE )<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 正确<|>RELATION_NOE 诊断<|>RELATION_NOE (<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 确定<|>RELATION_NOE 和<|>RELATION_NOE 诊断<|>RELATION_NOE 错误<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 百分率<|>RELATION_NOE 及其<|>RELATION_NOE 95%<|>RELATION_NOE 可信<|>RELATION_NOE 区间<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分别<|>RELATION_NOE 计算<|>RELATION_S 其<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 最终<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 符合率<|>RELATION_NOE 及其<|>RELATION_NOE 95%<|>RELATION_NOE 可信<|>RELATION_NOE 区间<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 能谱<|>RELATION_NOE 成像<|>RELATION_NOE 在<|>RELATION_NOE 诊断<|>RELATION_NOE 肿瘤<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 性质<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
通过<|>RELATION_NOE 对<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 、<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 及<|>RELATION_NOE 胆管癌<|>RELATION_NOE 的<|>RELATION_NOE 转移性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 行<|>RELATION_NOE 能<|>RELATION_NOE 谱<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 能<|>RELATION_NOE 谱<|>RELATION_NOE 成像<|>RELATION_NOE 在<|>RELATION_NOE 鉴别<|>RELATION_NOE 不同<|>RELATION_NOE 肿瘤<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 性肿大<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 12月<|>RELATION_NOE 间<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 28<|>RELATION_NOE 个<|>RELATION_NOE 淋巴结<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 30<|>RELATION_NOE 个<|>RELATION_NOE 淋巴结<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 淋巴结<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 胆管癌<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 淋巴结<|>RELATION_NOE )<|>RELATION_NOE 行<|>RELATION_NOE 能谱<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_S 混合<|>RELATION_NOE 能量<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 各个<|>RELATION_NOE 淋巴结<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 能量<|>RELATION_NOE 水平<|>RELATION_NOE 下<|>RELATION_NOE (<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 140keV<|>RELATION_NOE ,<|>RELATION_NOE 间隔<|>RELATION_NOE 10keV<|>RELATION_NOE )<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 值<|>RELATION_NOE 及<|>RELATION_NOE 碘基图<|>RELATION_NOE 和<|>RELATION_NOE 水基图<|>RELATION_NOE 各个<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 碘<|>RELATION_NOE 和<|>RELATION_NOE 水<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 对<|>RELATION_NOE 不同<|>RELATION_NOE 肿瘤转移性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE keV<|>RELATION_NOE 下<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 值<|>RELATION_NOE 、<|>RELATION_NOE 碘<|>RELATION_NOE 和<|>RELATION_NOE 水<|>RELATION_NOE 含量<|>RELATION_NOE 进行<|>RELATION_NOE 方差分析<|>RELATION_NOE 和<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_S 肿大<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 最佳<|>RELATION_NOE 对比<|>RELATION_NOE 噪声<|>RELATION_NOE 比<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 单<|>RELATION_NOE 能量<|>RELATION_NOE 水平<|>RELATION_NOE 是<|>RELATION_NOE 70keV<|>RELATION_NOE 。<|>RELATION_NOE
70keV<|>RELATION_NOE 下<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 、<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 及<|>RELATION_NOE 胆管癌<|>RELATION_NOE CT<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE (<|>RELATION_NOE 81.36<|>RELATION_NOE ±<|>RELATION_NOE 9.81<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 58.33<|>RELATION_NOE ±<|>RELATION_NOE 21.55<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 56.47<|>RELATION_NOE ±<|>RELATION_NOE 10.62<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 73.57<|>RELATION_NOE ±<|>RELATION_NOE 4.43<|>RELATION_NOE )<|>RELATION_NOE HU<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 17.29<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 及<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 与<|>RELATION_NOE 胆管癌<|>RELATION_NOE 在<|>RELATION_NOE CT<|>RELATION_NOE 值<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 与<|>RELATION_NOE 胆管癌<|>RELATION_NOE 及<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 与<|>RELATION_NOE 胆管癌<|>RELATION_NOE
CT<|>RELATION_NOE 能谱<|>RELATION_NOE 成像<|>RELATION_NOE 通过<|>RELATION_NOE 应用<|>RELATION_NOE 碘<|>RELATION_NOE 含量<|>RELATION_NOE 及<|>RELATION_NOE 低<|>RELATION_NOE 能量<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 值<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 不同<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE 转移性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 鉴别<|>RELATION_S 有<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 70keV<|>RELATION_NOE 单<|>RELATION_NOE 能量<|>RELATION_NOE 图像<|>RELATION_NOE 显示<|>RELATION_NOE 肿大<|>RELATION_NOE 转移性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 最<|>RELATION_NOE 清楚<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE ASPPl<|>RELATION_NOE 和<|>RELATION_NOE ASPP2<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE ASPPl<|>RELATION_NOE 和<|>RELATION_NOE ASPP2<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE 和<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 及<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 水平<|>RELATION_NOE 和<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE ASPP<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 90<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE 癌旁肺<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ASPPl<|>RELATION_NOE 、<|>RELATION_NOE ASPP2<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 证实<|>RELATION_NOE 其<|>RELATION_NOE 甲基化<|>RELATION_NOE 位点<|>RELATION_NOE ;<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ASPPl<|>RELATION_NOE 、<|>RELATION_NOE ASPP2<|>RELATION_NOE 和<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
ASPPl<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 无<|>RELATION_B 相关性<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 存在<|>RELATION_NOE 相关性<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 31<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE ASPPl<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 无<|>RELATION_NOE 相关性<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 存在<|>RELATION_NOE 相关性<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 31<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
90<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ASPPl<|>RELATION_NOE 甲基化<|>RELATION_NOE 者<|>RELATION_NOE 其<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达率<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E ASPPl<|>RELATION_NOE 未<|>RELATION_NOE 甲基化<|>RELATION_NOE 者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
90<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 和<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_B 检测<|>RELATION_I 到<|>RELATION_E ASPP2<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE ;<|>RELATION_NOE
NSCLC<|>RELATION_NOE 中<|>RELATION_NOE ASPPl<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE ASPPl<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_S ,<|>RELATION_NOE 高<|>RELATION_NOE 甲基化<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 恶性<|>RELATION_NOE 进展<|>RELATION_NOE 有关<|>RELATION_NOE .<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE ASPPl<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE ASPPl<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 高<|>RELATION_NOE 甲基化<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 恶性<|>RELATION_NOE 进展<|>RELATION_NOE 有关<|>RELATION_S .<|>RELATION_NOE
肺原发性<|>RELATION_NOE ALCL<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 特点<|>RELATION_E 以<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咯痰<|>RELATION_NOE 、<|>RELATION_NOE 胸痛<|>RELATION_NOE 伴气<|>RELATION_NOE 促<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 病变<|>RELATION_NOE 多<|>RELATION_NOE 发生<|>RELATION_NOE 于<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 支气管<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组化<|>RELATION_NOE 示<|>RELATION_NOE 肺原发性<|>RELATION_NOE ALCL<|>RELATION_NOE 表达<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 抗原<|>RELATION_NOE 、<|>RELATION_NOE CD30<|>RELATION_NOE 及<|>RELATION_NOE ALK<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺原发性<|>RELATION_NOE ALCL<|>RELATION_NOE 非常<|>RELATION_NOE 罕见<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 检查<|>RELATION_NOE 无<|>RELATION_B 特异性<|>RELATION_E ,<|>RELATION_NOE 容易<|>RELATION_NOE 误诊<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 诊断<|>RELATION_NOE 需要<|>RELATION_NOE 依靠<|>RELATION_NOE 病理<|>RELATION_NOE 活检<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE ,<|>RELATION_NOE 该病<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE 。<|>RELATION_NOE
提高<|>RELATION_S 对<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 消化道<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 认识<|>RELATION_NOE 。<|>RELATION_NOE
报道<|>RELATION_NOE 1例<|>RELATION_NOE 原发性<|>RELATION_NOE 肺鳞<|>RELATION_NOE 癌回<|>RELATION_NOE 盲部<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 胃肠道<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE 文献<|>RELATION_NOE 进行<|>RELATION_NOE 复习<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE “<|>RELATION_NOE 急腹症<|>RELATION_NOE ”<|>RELATION_NOE 为首<|>RELATION_NOE 症<|>RELATION_NOE 就诊<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 回<|>RELATION_NOE 盲部<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 癌性<|>RELATION_NOE 穿孔<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 支气管镜<|>RELATION_NOE 活检<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 合并<|>RELATION_NOE 多<|>RELATION_NOE 部位<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 胃肠道<|>RELATION_NOE 转移<|>RELATION_NOE 较为<|>RELATION_NOE 少见<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 困难<|>RELATION_NOE ,<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE 。<|>RELATION_NOE
HE<|>RELATION_NOE 染色<|>RELATION_NOE 结合<|>RELATION_NOE TTF-1<|>RELATION_NOE 、<|>RELATION_NOE CK7<|>RELATION_NOE 、<|>RELATION_NOE CK20<|>RELATION_NOE 等<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_B 鉴别<|>RELATION_E 肿瘤<|>RELATION_NOE 是<|>RELATION_NOE 肺<|>RELATION_NOE 来源<|>RELATION_NOE 还是<|>RELATION_NOE 消化道<|>RELATION_NOE 来源<|>RELATION_NOE 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 与<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 二线<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
将<|>RELATION_NOE 既<|>RELATION_NOE 往<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 失败<|>RELATION_NOE 的<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_B 分为<|>RELATION_E 吉非替尼组<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉<|>RELATION_NOE 醇组<|>RELATION_NOE 进行<|>RELATION_NOE 治疗<|>RELATION_NOE 观察<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤标记物<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9<|>RELATION_NOE 和<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 鉴别<|>RELATION_S 良恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE (<|>RELATION_NOE ES<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_B 及其<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE ELISA<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 了<|>RELATION_NOE 176<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE MMP-9<|>RELATION_NOE 和<|>RELATION_NOE ES<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 95<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 结核性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 心衰<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 漏出性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE MMP-9<|>RELATION_NOE 和<|>RELATION_NOE ES<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 结核性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 及<|>RELATION_NOE 漏出性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE MMP-9<|>RELATION_NOE 、<|>RELATION_NOE ES<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE MMP-9<|>RELATION_NOE 水平<|>RELATION_NOE 还<|>RELATION_NOE 与<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 胸膜<|>RELATION_NOE 之外<|>RELATION_NOE 的<|>RELATION_NOE 远<|>RELATION_NOE 隔<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE
MMP-9<|>RELATION_NOE 、<|>RELATION_NOE ES<|>RELATION_NOE 诊断<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 67.9%<|>RELATION_NOE 和<|>RELATION_NOE 82.1%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 88.1%<|>RELATION_NOE 和<|>RELATION_NOE 64.3%<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE MMP-9<|>RELATION_NOE 和<|>RELATION_NOE ES<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_S 它们<|>RELATION_NOE 参与<|>RELATION_NOE 了<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 形成<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 敏感度<|>RELATION_NOE 及<|>RELATION_NOE 特异度<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 辅助<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 导向<|>RELATION_NOE 下<|>RELATION_NOE ^<|>RELATION_NOE 125<|>RELATION_NOE Ⅰ<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 难<|>RELATION_NOE 治<|>RELATION_NOE 陛<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_S CT<|>RELATION_NOE 导向<|>RELATION_NOE 下<|>RELATION_NOE ^<|>RELATION_NOE 125<|>RELATION_NOE Ⅰ<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 问<|>RELATION_NOE 治疗<|>RELATION_NOE 难治性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
轻度<|>RELATION_NOE 气胸<|>RELATION_NOE 7例<|>RELATION_NOE 未<|>RELATION_NOE 行<|>RELATION_NOE 任何<|>RELATION_NOE 处理<|>RELATION_NOE 而<|>RELATION_NOE 自愈<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE 大多数<|>RELATION_NOE 患者<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 轻微<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 耐受<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 大<|>RELATION_NOE 咳血<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 等<|>RELATION_NOE 严重<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
铁调节<|>RELATION_NOE 蛋白质<|>RELATION_NOE -2<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 铁<|>RELATION_B 代谢<|>RELATION_I 调节<|>RELATION_I 作用<|>RELATION_E 的<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE
培养<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 脂质体<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 含<|>RELATION_NOE 脂质体<|>RELATION_NOE 20<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 对照<|>RELATION_NOE 寡<|>RELATION_NOE 核苷酸组<|>RELATION_NOE 和<|>RELATION_NOE 反义寡核苷<|>RELATION_NOE 酸组<|>RELATION_NOE 3组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 设<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 平行<|>RELATION_NOE 样.<|>RELATION_NOE
利用<|>RELATION_NOE 逆转录<|>RELATION_NOE -PCR<|>RELATION_NOE 、<|>RELATION_NOE Western<|>RELATION_NOE 印迹<|>RELATION_NOE 检测<|>RELATION_S 转铁蛋白<|>RELATION_NOE 、<|>RELATION_NOE 转铁蛋白<|>RELATION_NOE 受体<|>RELATION_NOE 、<|>RELATION_NOE 铁蛋白<|>RELATION_NOE 等<|>RELATION_NOE 铁代谢<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
转染<|>RELATION_NOE 48<|>RELATION_NOE h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 转铁蛋白<|>RELATION_NOE mRNA<|>RELATION_NOE 在<|>RELATION_NOE 3组<|>RELATION_NOE 之间<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 2.<|>RELATION_NOE 18<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 78<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
反义寡核苷<|>RELATION_NOE 酸组<|>RELATION_NOE 转铁蛋白<|>RELATION_NOE 受体<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 脂质体组<|>RELATION_NOE 和<|>RELATION_NOE 对照<|>RELATION_NOE 寡<|>RELATION_NOE 核苷<|>RELATION_NOE 酸组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
IRP2<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 蛋白量<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 来<|>RELATION_NOE 影响<|>RELATION_S 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 转铁蛋白<|>RELATION_NOE 受体<|>RELATION_NOE 和<|>RELATION_NOE 铁蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 调节<|>RELATION_NOE 铁代<|>RELATION_NOE 谢.<|>RELATION_NOE
回顾<|>RELATION_B 分析<|>RELATION_E 100<|>RELATION_NOE 例<|>RELATION_NOE 终末期<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 肺移植<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 受者<|>RELATION_NOE 原发<|>RELATION_NOE 疾病<|>RELATION_NOE 包括<|>RELATION_NOE 特发性<|>RELATION_NOE 肺间<|>RELATION_NOE 质<|>RELATION_NOE 纤维化<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 职业性<|>RELATION_NOE 尘肺<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 先天性<|>RELATION_NOE 房<|>RELATION_NOE 室间隔缺损<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 艾森曼格<|>RELATION_NOE 综合征<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 肺结核<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 特发性<|>RELATION_NOE 肺动脉高压<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 肺<|>RELATION_NOE 淋巴管<|>RELATION_NOE 平滑肌瘤病<|>RELATION_NOE 和<|>RELATION_NOE 原发性<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
100<|>RELATION_NOE 例<|>RELATION_NOE 肺移植<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 单肺<|>RELATION_NOE 移植<|>RELATION_NOE 72<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 双<|>RELATION_NOE 肺移植<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 61<|>RELATION_NOE 例<|>RELATION_NOE 在<|>RELATION_NOE 体外循环<|>RELATION_NOE 支持<|>RELATION_NOE 下<|>RELATION_NOE 完成<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 常规<|>RELATION_NOE 体外循环<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 体<|>RELATION_NOE 外膜<|>RELATION_NOE 肺氧<|>RELATION_NOE 合<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 早期<|>RELATION_NOE (<|>RELATION_NOE 30d<|>RELATION_NOE 内<|>RELATION_NOE )<|>RELATION_NOE 死亡<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 死亡原因<|>RELATION_NOE 包括<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 原发性<|>RELATION_NOE 移植物<|>RELATION_NOE 功能<|>RELATION_NOE 丧失<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 急性<|>RELATION_NOE 排斥<|>RELATION_NOE 反应<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺梗塞<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 主要<|>RELATION_NOE 并发症<|>RELATION_NOE 包括<|>RELATION_NOE 肺部<|>RELATION_NOE 严重<|>RELATION_NOE 感染<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 原发性<|>RELATION_NOE 移植物<|>RELATION_NOE 功能<|>RELATION_NOE 丧失<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 急性<|>RELATION_NOE 排斥<|>RELATION_NOE 反应<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 吻合口<|>RELATION_NOE 狭窄<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 吻合口瘘<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 活动性<|>RELATION_NOE 渗血3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺动脉栓塞<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 肺动脉<|>RELATION_NOE 狭窄<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 下肢<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 远期<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 中<|>RELATION_NOE 出现<|>RELATION_NOE 闭塞性<|>RELATION_NOE 细支气管炎<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 及<|>RELATION_NOE 单肺<|>RELATION_NOE 移植<|>RELATION_NOE 后<|>RELATION_NOE 自体<|>RELATION_NOE 肺并<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
肺移植<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_S 多种<|>RELATION_NOE 终末期<|>RELATION_NOE 肺病<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 二线<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 作用<|>RELATION_S 的<|>RELATION_NOE 研究<|>RELATION_NOE
对<|>RELATION_NOE 2005年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 12月<|>RELATION_NOE 住<|>RELATION_NOE 我院<|>RELATION_NOE 的<|>RELATION_NOE 139<|>RELATION_NOE 例<|>RELATION_NOE 既<|>RELATION_NOE 往<|>RELATION_NOE 至少<|>RELATION_NOE 接受<|>RELATION_NOE 过<|>RELATION_NOE 1次<|>RELATION_NOE 含<|>RELATION_NOE 铂化<|>RELATION_NOE 疗且<|>RELATION_NOE 最近<|>RELATION_NOE 1次<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进展<|>RELATION_NOE 或<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 行<|>RELATION_NOE EGFR<|>RELATION_NOE 基因检测<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 、<|>RELATION_NOE 非吸烟者<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 突变率<|>RELATION_NOE 高于<|>RELATION_S 对应组<|>RELATION_NOE ;<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 指导<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 指标<|>RELATION_E 。<|>RELATION_NOE
紫杉醇<|>RELATION_NOE 分<|>RELATION_NOE 次<|>RELATION_NOE 给<|>RELATION_NOE 药法<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 过敏反应<|>RELATION_NOE 的<|>RELATION_NOE 观察<|>RELATION_NOE
选取<|>RELATION_NOE 2006年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 128<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 入院<|>RELATION_NOE 时间<|>RELATION_NOE 分<|>RELATION_NOE 观察组<|>RELATION_NOE (<|>RELATION_NOE 82<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 采用<|>RELATION_NOE 分次<|>RELATION_NOE 给<|>RELATION_NOE 药法<|>RELATION_NOE ,<|>RELATION_NOE 先<|>RELATION_NOE 将<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 30mg<|>RELATION_NOE 加入<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 250ml<|>RELATION_NOE 中<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 开始<|>RELATION_NOE 15min<|>RELATION_NOE 严格<|>RELATION_NOE 控制<|>RELATION_NOE 滴速<|>RELATION_NOE ,<|>RELATION_NOE 15<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 滴<|>RELATION_NOE /<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 无不良<|>RELATION_NOE 反应<|>RELATION_NOE 调<|>RELATION_NOE 至<|>RELATION_NOE 60滴/<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 1h<|>RELATION_NOE 滴<|>RELATION_NOE 完<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 将<|>RELATION_NOE 余量<|>RELATION_NOE 加入<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 500ml<|>RELATION_NOE 中<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 3h<|>RELATION_NOE 滴<|>RELATION_NOE 完<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 将<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 全部<|>RELATION_NOE 加入<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 500ml<|>RELATION_NOE 中<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 3h<|>RELATION_NOE 滴<|>RELATION_NOE 完<|>RELATION_NOE 。<|>RELATION_NOE
PBMCs<|>RELATION_NOE 结核<|>RELATION_NOE 分枝杆菌<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE 反应性<|>RELATION_NOE MIG<|>RELATION_NOE 和<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE 对<|>RELATION_NOE 活动期<|>RELATION_NOE 肺结核<|>RELATION_NOE 的<|>RELATION_NOE 鉴别<|>RELATION_B 诊断<|>RELATION_I 意义<|>RELATION_E
研究<|>RELATION_NOE 活动期<|>RELATION_NOE 肺结核<|>RELATION_NOE 和<|>RELATION_NOE 常见<|>RELATION_NOE 肺部<|>RELATION_NOE 鉴别诊断<|>RELATION_S 疾病<|>RELATION_NOE 肺炎<|>RELATION_NOE 及<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 单个<|>RELATION_NOE 核细胞<|>RELATION_NOE (<|>RELATION_NOE PBMCs<|>RELATION_NOE )<|>RELATION_NOE 经<|>RELATION_NOE 结核<|>RELATION_NOE 分枝杆菌<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原肽<|>RELATION_NOE 刺激<|>RELATION_NOE 后<|>RELATION_NOE 干扰素<|>RELATION_NOE -<|>RELATION_NOE γ<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 单<|>RELATION_NOE 核<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE Monokine<|>RELATION_NOE induced<|>RELATION_NOE by<|>RELATION_NOE interferon<|>RELATION_NOE gamma<|>RELATION_NOE ,<|>RELATION_NOE MIG<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 干扰素<|>RELATION_NOE -<|>RELATION_NOE γ<|>RELATION_NOE (<|>RELATION_NOE IFN-1<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 诊断<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
90<|>RELATION_NOE 例<|>RELATION_NOE 初治<|>RELATION_NOE 活动期<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 细菌性<|>RELATION_NOE 肺炎<|>RELATION_NOE 和<|>RELATION_NOE 原发性<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 分离<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE PBMCs<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 结核<|>RELATION_NOE 分枝杆菌<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原肽<|>RELATION_NOE 刺激<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Flowcytomix<|>RELATION_NOE 流式<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 细胞培养<|>RELATION_NOE 液上<|>RELATION_NOE 清上<|>RELATION_NOE 中<|>RELATION_NOE MIG<|>RELATION_NOE 和<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 接受者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE ROCcurve<|>RELATION_NOE )<|>RELATION_NOE 评价<|>RELATION_S 结核<|>RELATION_NOE 分枝杆菌<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE 反应性<|>RELATION_NOE MIG<|>RELATION_NOE 和<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
PBMCs<|>RELATION_NOE 经<|>RELATION_NOE 结核<|>RELATION_NOE 分枝杆菌<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原肽<|>RELATION_NOE 刺激<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 培养<|>RELATION_NOE 液上<|>RELATION_NOE 清中<|>RELATION_NOE MIG<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 初治<|>RELATION_NOE 活动期<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE 与<|>RELATION_NOE 其他<|>RELATION_NOE 肺病<|>RELATION_NOE 对照组<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE 3023.0pg<|>RELATION_NOE /<|>RELATION_NOE mlvs112.5pg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.0001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 168<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.0001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 单独<|>RELATION_NOE 应用<|>RELATION_NOE MIG<|>RELATION_NOE 诊断<|>RELATION_NOE 肺结核<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 94.4%<|>RELATION_NOE ,<|>RELATION_NOE 单独<|>RELATION_NOE 应用<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE 诊断<|>RELATION_NOE 肺结核<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 96.8%<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 并联<|>RELATION_NOE 应用<|>RELATION_NOE 诊断<|>RELATION_NOE 肺结核<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 97.8%<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 87.1%<|>RELATION_NOE 。<|>RELATION_NOE
结核<|>RELATION_NOE 分枝杆菌<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原肽<|>RELATION_NOE 刺激<|>RELATION_S 外<|>RELATION_NOE 周血<|>RELATION_NOE 单个<|>RELATION_NOE 核细胞<|>RELATION_NOE 产生<|>RELATION_NOE 的<|>RELATION_NOE MIG<|>RELATION_NOE 和<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE 能够<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE 鉴别<|>RELATION_NOE 初治<|>RELATION_NOE 活动期<|>RELATION_NOE 肺结核<|>RELATION_NOE 及<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 细菌性<|>RELATION_NOE 肺炎<|>RELATION_NOE 和<|>RELATION_NOE 原发性<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 成为<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
鸦<|>RELATION_NOE 胆子<|>RELATION_NOE 油乳<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 鸦<|>RELATION_NOE 胆子<|>RELATION_NOE 油乳<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 机械<|>RELATION_NOE 抽样法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 45.8%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 为<|>RELATION_NOE 41.7%<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 85<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 71<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
鸦<|>RELATION_NOE 胆子<|>RELATION_NOE 油乳<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 改善<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 减轻<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE 鸦<|>RELATION_NOE 胆子<|>RELATION_NOE 油乳<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 改善<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 减轻<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE 鸦<|>RELATION_NOE 胆子<|>RELATION_NOE 油乳<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 改善<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 减轻<|>RELATION_S 化疗<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛周<|>RELATION_NOE 疗法<|>RELATION_NOE 治疗<|>RELATION_S 老年人<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 单药<|>RELATION_NOE 每周<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 老年人<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE 、<|>RELATION_NOE LCSS<|>RELATION_NOE 评分<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 92.4<|>RELATION_NOE ±<|>RELATION_NOE 16.9<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 93.4<|>RELATION_NOE ±<|>RELATION_NOE 17.5<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 82.4<|>RELATION_NOE ±<|>RELATION_NOE 15.0<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 81.3<|>RELATION_NOE ±<|>RELATION_NOE 16.0<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.2<|>RELATION_NOE 150<|>RELATION_NOE 、<|>RELATION_NOE 2.2<|>RELATION_NOE 45<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 该院<|>RELATION_NOE 2005年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 10月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 恶性<|>RELATION_NOE 神经鞘瘤<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 免疫<|>RELATION_NOE 特征<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 进行<|>RELATION_NOE 回顺性<|>RELATION_B 分析<|>RELATION_E 。<|>RELATION_NOE
随访期<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 全<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 死亡<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关性<|>RELATION_NOE 死亡<|>RELATION_NOE :<|>RELATION_NOE 2例<|>RELATION_NOE 发生<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 发生<|>RELATION_NOE 肺<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 发生<|>RELATION_NOE 颌下<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
组<|>RELATION_NOE 纵学<|>RELATION_NOE 形态<|>RELATION_NOE 是<|>RELATION_NOE 恶性<|>RELATION_NOE 神经鞘瘤<|>RELATION_NOE 诊断<|>RELATION_B 重要<|>RELATION_I 依据<|>RELATION_E ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 有助于<|>RELATION_NOE 辅助<|>RELATION_NOE 和<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 。<|>RELATION_NOE
参麦<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE
观察<|>RELATION_NOE 参麦<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE TP<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
参麦<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_S 单纯<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 减轻<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 顺利<|>RELATION_NOE 进行<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 低<|>RELATION_NOE 分割<|>RELATION_NOE 与<|>RELATION_NOE 常规<|>RELATION_NOE 放疗<|>RELATION_NOE 同步<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 肺鳞状细胞癌<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 有<|>RELATION_NOE 锁骨<|>RELATION_NOE 上<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 均<|>RELATION_NOE 给予<|>RELATION_NOE 6MV-X<|>RELATION_NOE 及<|>RELATION_NOE 6－<|>RELATION_NOE 15MeV<|>RELATION_NOE 的<|>RELATION_NOE 电子线<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 剂量<|>RELATION_NOE 65<|>RELATION_NOE －<|>RELATION_NOE 70Gy<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 122<|>RELATION_NOE 例<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血糖<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_S
探讨<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血糖<|>RELATION_NOE 代谢<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
各<|>RELATION_NOE 周期<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 血糖<|>RELATION_NOE 较<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_B 升高<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 血糖<|>RELATION_NOE 平均<|>RELATION_NOE 水平<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 6周期<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 是<|>RELATION_NOE 3.0<|>RELATION_NOE 39<|>RELATION_NOE 、<|>RELATION_NOE 3.7<|>RELATION_NOE 66<|>RELATION_NOE 、<|>RELATION_NOE 3.9<|>RELATION_NOE 39<|>RELATION_NOE 、<|>RELATION_NOE 4.3<|>RELATION_NOE 42<|>RELATION_NOE 、<|>RELATION_NOE 3.8<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 2.8<|>RELATION_NOE 88<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 血糖值<|>RELATION_NOE 随<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE 有<|>RELATION_NOE 逐渐<|>RELATION_NOE 升高<|>RELATION_NOE 趋势<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 手术史<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤分期<|>RELATION_NOE 和<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 种类<|>RELATION_NOE 等<|>RELATION_NOE 对<|>RELATION_NOE 血糖<|>RELATION_NOE 影响<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
探讨<|>RELATION_S 年龄<|>RELATION_NOE ≥<|>RELATION_NOE 65<|>RELATION_NOE 岁<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 含铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 提示<|>RELATION_NOE ECOG<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 数目<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE 数<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 因素<|>RELATION_E 。<|>RELATION_NOE
bcl-2<|>RELATION_NOE 反义寡核苷酸<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE NCI-H69<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE NCI-H69<|>RELATION_NOE 细胞培养<|>RELATION_NOE 传代<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 共<|>RELATION_NOE 分<|>RELATION_NOE 4<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 反义寡核苷<|>RELATION_NOE 酸组<|>RELATION_NOE 、<|>RELATION_NOE 正义寡核苷<|>RELATION_NOE 酸组<|>RELATION_NOE 、<|>RELATION_NOE 无义寡核苷酸组<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 脂质体<|>RELATION_NOE 将<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 寡核苷<|>RELATION_NOE 酸导人<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE WesternBlot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S bcl-2<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 将<|>RELATION_NOE NCI-H69<|>RELATION_NOE 细胞培养<|>RELATION_NOE 传代<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 共<|>RELATION_NOE 分<|>RELATION_NOE 4<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 反义寡核苷<|>RELATION_NOE 酸组<|>RELATION_NOE 、<|>RELATION_NOE 正义寡核苷<|>RELATION_NOE 酸组<|>RELATION_NOE 、<|>RELATION_NOE 无义寡核苷酸组<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 脂质体<|>RELATION_NOE 将<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 寡核苷<|>RELATION_NOE 酸导人<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE WesternBlot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE bcl-2<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡率<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 反义寡核苷<|>RELATION_NOE 酸组<|>RELATION_NOE 的<|>RELATION_NOE bcl-2<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_B 受到<|>RELATION_I 抑制<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 正义<|>RELATION_NOE 寡核苷酸组<|>RELATION_NOE 和<|>RELATION_NOE 无义寡核苷<|>RELATION_NOE 酸组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE
艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE hiCD127<|>RELATION_NOE ^<|>RELATION_NOE low<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
60<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 化疗<|>RELATION_NOE 加艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液组<|>RELATION_NOE (<|>RELATION_NOE 观察组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE (<|>RELATION_NOE FCM<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 于<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 检测<|>RELATION_S 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE hiCD127<|>RELATION_NOE ^<|>RELATION_NOE lowTreg<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE 、<|>RELATION_NOE IL-10<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 同期<|>RELATION_NOE 选取<|>RELATION_NOE 20<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 为<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
中晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血中<|>RELATION_NOE Treg<|>RELATION_NOE 细胞<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 配合<|>RELATION_NOE 化疗<|>RELATION_NOE 可以<|>RELATION_NOE 降低<|>RELATION_S NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE Treg<|>RELATION_NOE 细胞<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 机体<|>RELATION_NOE 免疫<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
厄罗替尼<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE
疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE +<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE +<|>RELATION_NOE 稳定<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 84.2%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE 3－<|>RELATION_NOE 36<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE PFS7.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ;<|>RELATION_NOE
辐射<|>RELATION_NOE 对<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 分子<|>RELATION_NOE 机制<|>RELATION_NOE
用<|>RELATION_NOE Transwell<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S 2<|>RELATION_NOE 和<|>RELATION_NOE 4Gy1<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 反转录<|>RELATION_NOE PCR<|>RELATION_NOE 和<|>RELATION_NOE Westernblot<|>RELATION_NOE 实验<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE Transwell<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验<|>RELATION_NOE 检测2<|>RELATION_NOE 和<|>RELATION_NOE 4Gy1<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 反转录<|>RELATION_NOE PCR<|>RELATION_NOE 和<|>RELATION_NOE Westernblot<|>RELATION_NOE 实验<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE MMP-2<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 及<|>RELATION_NOE 磷酸化<|>RELATION_NOE STAT3<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
热释<|>RELATION_NOE 光剂<|>RELATION_NOE 量计<|>RELATION_NOE 测量<|>RELATION_S ^<|>RELATION_NOE 125I<|>RELATION_NOE 粒子源<|>RELATION_NOE 植<|>RELATION_NOE 人中<|>RELATION_NOE 职业<|>RELATION_NOE 人员<|>RELATION_NOE 剂量<|>RELATION_NOE 方法<|>RELATION_NOE 研究<|>RELATION_NOE
将<|>RELATION_NOE TLD<|>RELATION_NOE 片<|>RELATION_NOE 分别<|>RELATION_NOE 贴<|>RELATION_NOE 在<|>RELATION_NOE 粒子源<|>RELATION_NOE 植入<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 职业<|>RELATION_NOE 人员<|>RELATION_NOE 铅衣<|>RELATION_NOE 内外<|>RELATION_NOE 甲状腺<|>RELATION_NOE 等<|>RELATION_NOE 13<|>RELATION_NOE 个<|>RELATION_NOE 部位<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_NOE 平均<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_S 器官<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 和<|>RELATION_NOE 有效<|>RELATION_NOE 剂量<|>RELATION_NOE 。<|>RELATION_NOE
3例<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 粒子<|>RELATION_NOE 源植<|>RELATION_NOE 入术<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 职业<|>RELATION_NOE 人员<|>RELATION_NOE 铅衣<|>RELATION_NOE 外<|>RELATION_NOE 器官<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 0.02<|>RELATION_NOE －3<|>RELATION_NOE .<|>RELATION_NOE 80<|>RELATION_NOE μ<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE 剂量<|>RELATION_NOE 0.06<|>RELATION_NOE －1.81<|>RELATION_NOE μ<|>RELATION_NOE Sv<|>RELATION_NOE ;<|>RELATION_NOE
3例<|>RELATION_NOE 脑癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 职业<|>RELATION_NOE 人员<|>RELATION_NOE 铅衣<|>RELATION_NOE 外<|>RELATION_NOE 器官<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 0.23<|>RELATION_NOE －1<|>RELATION_NOE 1.31<|>RELATION_NOE μ<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE 剂量<|>RELATION_NOE 0.88<|>RELATION_NOE —<|>RELATION_NOE 4.07<|>RELATION_NOE μ<|>RELATION_NOE Sv<|>RELATION_NOE ;<|>RELATION_NOE
3例<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 职业<|>RELATION_NOE 人员<|>RELATION_NOE 铅衣<|>RELATION_NOE 外<|>RELATION_NOE 器官<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 0.03<|>RELATION_NOE －1<|>RELATION_NOE 4.78<|>RELATION_NOE μ<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE 剂量<|>RELATION_NOE 0.35<|>RELATION_NOE －<|>RELATION_NOE 7.59<|>RELATION_NOE μ<|>RELATION_NOE Sv<|>RELATION_NOE ;<|>RELATION_NOE
2例<|>RELATION_NOE 纵隔癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 职业<|>RELATION_NOE 人员<|>RELATION_NOE 铅衣<|>RELATION_NOE 外<|>RELATION_NOE 器官<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 为<|>RELATION_NOE 0.06<|>RELATION_NOE —<|>RELATION_NOE 74.91<|>RELATION_NOE μ<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE 剂量<|>RELATION_NOE 0.83-17.96<|>RELATION_NOE μ<|>RELATION_NOE Sv<|>RELATION_NOE ;<|>RELATION_NOE
1例<|>RELATION_NOE 卵巢<|>RELATION_NOE 癌中<|>RELATION_NOE ,<|>RELATION_NOE 职业<|>RELATION_NOE 人员<|>RELATION_NOE 铅衣<|>RELATION_NOE 外<|>RELATION_NOE 器官<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 0.09<|>RELATION_NOE －1<|>RELATION_NOE 4.29<|>RELATION_NOE μ<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE 剂量<|>RELATION_NOE 2.40-4.50<|>RELATION_NOE μ<|>RELATION_NOE Sv<|>RELATION_NOE ;<|>RELATION_NOE
探讨<|>RELATION_S 前列腺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 特性<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 以及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
2例术<|>RELATION_NOE 后<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 均<|>RELATION_NOE 诊断<|>RELATION_B 为<|>RELATION_E 前列腺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 。<|>RELATION_NOE
术<|>RELATION_NOE 前<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 直肠<|>RELATION_NOE 前列腺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 确诊<|>RELATION_B 为<|>RELATION_E 前列腺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE ,<|>RELATION_NOE 切<|>RELATION_NOE 片<|>RELATION_NOE 可见<|>RELATION_NOE 肿瘤<|>RELATION_NOE 呈<|>RELATION_NOE 弥漫性<|>RELATION_NOE 巢状<|>RELATION_NOE 结构<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 胞质<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 核染色<|>RELATION_NOE 深<|>RELATION_NOE ,<|>RELATION_NOE 核仁<|>RELATION_NOE 不<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 可见<|>RELATION_NOE 燕麦<|>RELATION_NOE 形<|>RELATION_NOE 小<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 伴<|>RELATION_NOE 凝固性<|>RELATION_NOE 坏死<|>RELATION_NOE 。<|>RELATION_NOE
例<|>RELATION_NOE 1行<|>RELATION_NOE 前列腺<|>RELATION_NOE 姑息切除术<|>RELATION_NOE 并行<|>RELATION_NOE EP<|>RELATION_NOE (<|>RELATION_NOE VP-16<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 后<|>RELATION_NOE 因<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 全身<|>RELATION_NOE 转移<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
例<|>RELATION_NOE 2行<|>RELATION_NOE 前列腺<|>RELATION_NOE 姑息切除术<|>RELATION_NOE 并行<|>RELATION_NOE 口服<|>RELATION_NOE 比<|>RELATION_NOE 卡鲁胺<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 后<|>RELATION_NOE 因<|>RELATION_NOE 颅内<|>RELATION_NOE 病灶<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 肝转移<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
前列腺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 具有<|>RELATION_S 浸润性<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 特性<|>RELATION_NOE ,<|>RELATION_NOE 恶性<|>RELATION_NOE 程度<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血流<|>RELATION_NOE 灌注<|>RELATION_NOE 和<|>RELATION_NOE 乏氧<|>RELATION_NOE 改善<|>RELATION_B 作用<|>RELATION_E 的<|>RELATION_NOE 观察<|>RELATION_NOE
通过<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 和<|>RELATION_NOE 乏氧<|>RELATION_NOE 显像<|>RELATION_NOE 技术<|>RELATION_NOE 评价<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 使用<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE (<|>RELATION_NOE 恩度<|>RELATION_NOE )<|>RELATION_NOE 后癌<|>RELATION_NOE 组织<|>RELATION_NOE 血流<|>RELATION_NOE 灌注<|>RELATION_NOE 和<|>RELATION_NOE 乏氧<|>RELATION_NOE 状态<|>RELATION_NOE 的<|>RELATION_NOE 动态<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 恩度<|>RELATION_NOE (<|>RELATION_NOE 7.5mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ×<|>RELATION_NOE 10d<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 天<|>RELATION_NOE 同时<|>RELATION_NOE 行<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 和<|>RELATION_NOE 乏氧<|>RELATION_NOE 显像<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 了解<|>RELATION_NOE 恩度<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 血流<|>RELATION_NOE 灌注<|>RELATION_NOE 和<|>RELATION_NOE 乏氧<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 动态<|>RELATION_NOE 变化<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 得出<|>RELATION_NOE 恩度<|>RELATION_NOE 在<|>RELATION_NOE 体内<|>RELATION_NOE 改善<|>RELATION_NOE 癌组织<|>RELATION_NOE 血流<|>RELATION_NOE 灌注<|>RELATION_NOE 和<|>RELATION_NOE 乏氧<|>RELATION_NOE 的<|>RELATION_NOE 时间<|>RELATION_NOE 窗<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 恩度<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 毛细血管<|>RELATION_NOE 表面<|>RELATION_NOE 通透性<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE PS<|>RELATION_NOE 值<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 乏<|>RELATION_NOE 氧值<|>RELATION_NOE (<|>RELATION_NOE T<|>RELATION_NOE /<|>RELATION_NOE N<|>RELATION_NOE 值<|>RELATION_NOE )<|>RELATION_NOE 呈现<|>RELATION_NOE 先<|>RELATION_NOE 下降<|>RELATION_NOE 后<|>RELATION_NOE 升高<|>RELATION_NOE 的<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 第5<|>RELATION_NOE 天<|>RELATION_NOE 左右<|>RELATION_NOE 呈现<|>RELATION_NOE 最低点<|>RELATION_NOE ;<|>RELATION_NOE
恩度<|>RELATION_NOE 改善<|>RELATION_S 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 血流<|>RELATION_NOE 灌注<|>RELATION_NOE 和<|>RELATION_NOE 乏氧<|>RELATION_NOE 的<|>RELATION_NOE 时间<|>RELATION_NOE 窗<|>RELATION_NOE 大约<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 第7<|>RELATION_NOE 天<|>RELATION_NOE 左右<|>RELATION_NOE 。<|>RELATION_NOE
促<|>RELATION_NOE 肾上腺皮质<|>RELATION_NOE 激素<|>RELATION_NOE 依赖性<|>RELATION_NOE 库欣综合征<|>RELATION_NOE 患者<|>RELATION_NOE 岩下窦<|>RELATION_NOE 静脉<|>RELATION_NOE 采<|>RELATION_NOE 血<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_I 探讨<|>RELATION_E
研究<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 岩下窦<|>RELATION_NOE 静脉<|>RELATION_NOE 采<|>RELATION_NOE 血<|>RELATION_NOE (<|>RELATION_NOE IPSS<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 疑难<|>RELATION_NOE 库欣综合征<|>RELATION_NOE (<|>RELATION_NOE CS<|>RELATION_NOE )<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
16<|>RELATION_NOE 例<|>RELATION_NOE 疑难<|>RELATION_NOE CS<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 双侧岩<|>RELATION_NOE 下窦<|>RELATION_NOE 和<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 采<|>RELATION_NOE 血<|>RELATION_NOE ,<|>RELATION_NOE 测定<|>RELATION_S 岩<|>RELATION_NOE 下<|>RELATION_NOE 窦<|>RELATION_NOE 与<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 血促<|>RELATION_NOE 肾上腺皮质<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE ACTH<|>RELATION_NOE )<|>RELATION_NOE 浓度<|>RELATION_NOE 比<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE IPSS<|>RELATION_NOE 对<|>RELATION_NOE 库欣病<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 。<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 疑难<|>RELATION_NOE CS<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 双侧岩<|>RELATION_NOE 下窦<|>RELATION_NOE 和<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 采<|>RELATION_NOE 血<|>RELATION_NOE ,<|>RELATION_NOE 测定<|>RELATION_NOE 岩<|>RELATION_NOE 下<|>RELATION_NOE 窦<|>RELATION_NOE 与<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 血促<|>RELATION_NOE 肾上腺皮质<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE ACTH<|>RELATION_NOE )<|>RELATION_NOE 浓度<|>RELATION_NOE 比<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_S IPSS<|>RELATION_NOE 对<|>RELATION_NOE 库欣病<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 。<|>RELATION_NOE
13<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 岩<|>RELATION_NOE 下<|>RELATION_NOE 窦<|>RELATION_NOE 与<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 血<|>RELATION_NOE ACTH<|>RELATION_NOE 的<|>RELATION_NOE 比值<|>RELATION_NOE ><|>RELATION_NOE 2.0<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 蝶窦<|>RELATION_NOE 垂体<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 垂体<|>RELATION_NOE ACTH<|>RELATION_NOE 腺瘤<|>RELATION_NOE ;<|>RELATION_NOE
3例岩<|>RELATION_NOE 下<|>RELATION_NOE 窦<|>RELATION_NOE 与<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 血<|>RELATION_NOE ACTH<|>RELATION_NOE 的<|>RELATION_NOE 比值<|>RELATION_NOE <<|>RELATION_NOE 2.0<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 2例<|>RELATION_NOE 为<|>RELATION_NOE 右肺<|>RELATION_NOE 类癌<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 垂体<|>RELATION_NOE ACTH<|>RELATION_NOE 腺瘤<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
40<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 观察组<|>RELATION_NOE )<|>RELATION_NOE 采用<|>RELATION_S 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE ;<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 临床<|>RELATION_NOE 获益率<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE 改善<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 不<|>RELATION_NOE 增加<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
探讨<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21—1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 分析<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 分别<|>RELATION_NOE 测定<|>RELATION_S 20<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE 初诊<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 分别<|>RELATION_NOE 作<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_S 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 在<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 和<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 和<|>RELATION_NOE 鳞癌<|>RELATION_NOE 以及<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 中<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
三<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 晚期<|>RELATION_NOE 均<|>RELATION_NOE 升高<|>RELATION_S ,<|>RELATION_NOE 其中<|>RELATION_NOE CEA<|>RELATION_NOE 在<|>RELATION_NOE 腺癌<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21—1<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE SCLC<|>RELATION_NOE 中<|>RELATION_NOE 尤为<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 显著<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 作为<|>RELATION_NOE 判定<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 围术期<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_B 分析<|>RELATION_E
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 围术期<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 可<|>RELATION_NOE 促进<|>RELATION_S 患者<|>RELATION_NOE 肺<|>RELATION_NOE 功能恢复<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 还<|>RELATION_NOE 可<|>RELATION_NOE 缩短<|>RELATION_NOE 住院时间<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
尼妥<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
评价<|>RELATION_S 尼妥<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 毒副反应<|>RELATION_NOE 为<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 和<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 仅<|>RELATION_NOE 有<|>RELATION_NOE 1例<|>RELATION_NOE 患者<|>RELATION_NOE 出<|>RELATION_NOE 了<|>RELATION_NOE I<|>RELATION_NOE 度<|>RELATION_NOE 座<|>RELATION_NOE 疮样<|>RELATION_NOE 皮疹<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE hnRNPA2<|>RELATION_NOE /<|>RELATION_NOE B1<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE
冷冻<|>RELATION_NOE 消融<|>RELATION_NOE 挽救<|>RELATION_NOE 治疗<|>RELATION_S 放<|>RELATION_NOE 化疗<|>RELATION_NOE 失败<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 初步<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_S 冷冻<|>RELATION_NOE 消融<|>RELATION_NOE (<|>RELATION_NOE CA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 放化疗<|>RELATION_NOE 失败<|>RELATION_NOE 后<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_NOE 挽救性<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 有效性<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
Akt2<|>RELATION_NOE 特异性<|>RELATION_NOE siRNA<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 化疗<|>RELATION_NOE 敏感性<|>RELATION_NOE 及<|>RELATION_NOE 耐药性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 癌基因<|>RELATION_NOE 蛋白质<|>RELATION_NOE v-akt<|>RELATION_NOE (<|>RELATION_NOE Akt2<|>RELATION_NOE )<|>RELATION_NOE 特异性<|>RELATION_NOE siRNA<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE NCI-H446<|>RELATION_NOE 细胞<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及<|>RELATION_NOE 对<|>RELATION_NOE 耐药<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 调控<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
构建<|>RELATION_NOE 针对<|>RELATION_NOE Akt2<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE NCI-H446<|>RELATION_NOE ,<|>RELATION_NOE 反<|>RELATION_NOE 转录<|>RELATION_NOE -PCR<|>RELATION_NOE 检测<|>RELATION_S Akt2-mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学法<|>RELATION_NOE 构建<|>RELATION_NOE 针对<|>RELATION_NOE Akt2<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE NCI-H446<|>RELATION_NOE ,<|>RELATION_NOE 反<|>RELATION_NOE 转录<|>RELATION_NOE -PCR<|>RELATION_NOE 检测<|>RELATION_NOE Akt2-mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学法<|>RELATION_NOE 检测<|>RELATION_S 肺耐药<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE LRP<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE P<|>RELATION_NOE 糖<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE P-gP<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 顺铂<|>RELATION_NOE 分别<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 未<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 质粒组<|>RELATION_NOE 及<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTr<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 以<|>RELATION_NOE 顺铂<|>RELATION_NOE 分别<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 未<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 质粒组<|>RELATION_NOE 及<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTr<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 。<|>RELATION_NOE
转染<|>RELATION_NOE Akt2-siRNA<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE NCI-H446<|>RELATION_NOE 细胞<|>RELATION_NOE Akt2-mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE LRP<|>RELATION_NOE 及<|>RELATION_NOE P-gP<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 未<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Akt2<|>RELATION_NOE 特异性<|>RELATION_NOE siRNA<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_NOE 下调<|>RELATION_NOE Akt2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S NCI-H446<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE ;<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 在<|>RELATION_NOE 纵隔<|>RELATION_NOE 气管<|>RELATION_NOE 周围<|>RELATION_NOE 病变<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
探讨<|>RELATION_NOE 支气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 针吸活<|>RELATION_NOE 检术<|>RELATION_NOE (<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 纵隔<|>RELATION_NOE 气管<|>RELATION_NOE 周围<|>RELATION_NOE 病变<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_B 总结<|>RELATION_E 2009年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 7月<|>RELATION_NOE ,<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 的<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 或<|>RELATION_NOE 纵隔<|>RELATION_NOE 肿物<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 在<|>RELATION_NOE 纵隔<|>RELATION_NOE 病<|>RELATION_NOE 变良<|>RELATION_NOE 、<|>RELATION_NOE 恶性<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 和<|>RELATION_NOE 准确性<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 90.9%<|>RELATION_NOE 、<|>RELATION_NOE 100%<|>RELATION_NOE 和<|>RELATION_NOE 97.1%<|>RELATION_NOE 。<|>RELATION_NOE
对于<|>RELATION_NOE 纵隔<|>RELATION_NOE 气管<|>RELATION_NOE 周围<|>RELATION_NOE 病变<|>RELATION_NOE ,<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_B 种<|>RELATION_I 安全<|>RELATION_I 、<|>RELATION_I 有效<|>RELATION_I 的<|>RELATION_I 诊断<|>RELATION_I 方法<|>RELATION_E 。<|>RELATION_NOE
cN0-pN2<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 行<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 手术<|>RELATION_NOE 初步<|>RELATION_B 体会<|>RELATION_E
探讨<|>RELATION_NOE 术前<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE N0<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE N2<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_S 。<|>RELATION_NOE
2006年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 施行<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 216<|>RELATION_NOE 例<|>RELATION_NOE 中术<|>RELATION_NOE 前<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE NO<|>RELATION_NOE 患者<|>RELATION_NOE 206<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 男<|>RELATION_NOE 103<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 103<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
按<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 是否<|>RELATION_NOE 转移<|>RELATION_NOE 分为<|>RELATION_NOE pN0<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE pN2<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 存在<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 病例<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 中转<|>RELATION_NOE 开胸<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 及<|>RELATION_NOE 并发症<|>RELATION_NOE 等<|>RELATION_NOE 围手术期<|>RELATION_NOE 数据<|>RELATION_NOE 。<|>RELATION_NOE
无<|>RELATION_NOE 严重<|>RELATION_NOE 围手术期<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 至<|>RELATION_NOE 呼吸功能<|>RELATION_NOE 衰竭<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
术前<|>RELATION_NOE N0<|>RELATION_NOE 分期术<|>RELATION_NOE 后<|>RELATION_NOE 病理<|>RELATION_NOE N2<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 手术<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_B 可行<|>RELATION_I 的<|>RELATION_E 。<|>RELATION_NOE
总结<|>RELATION_S 食管<|>RELATION_NOE 神经<|>RELATION_NOE 内分泌癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
食管<|>RELATION_NOE 神经<|>RELATION_NOE 内分泌癌<|>RELATION_NOE 少见.<|>RELATION_NOE
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S MTX<|>RELATION_NOE 对<|>RELATION_NOE 映体<|>RELATION_NOE 耐药<|>RELATION_NOE A549<|>RELATION_NOE 细胞株<|>RELATION_NOE 及<|>RELATION_NOE 白血病<|>RELATION_NOE 患者<|>RELATION_NOE 骨髓细胞<|>RELATION_NOE 中<|>RELATION_NOE FPGSmRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE
建立<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE FPGSmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE
研究<|>RELATION_S MTX<|>RELATION_NOE 对<|>RELATION_NOE 映体<|>RELATION_NOE [<|>RELATION_NOE L-<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE -MTX<|>RELATION_NOE 和<|>RELATION_NOE D-<|>RELATION_NOE (<|>RELATION_NOE -<|>RELATION_NOE )<|>RELATION_NOE -MTX<|>RELATION_NOE ]<|>RELATION_NOE 耐药<|>RELATION_NOE 细胞株<|>RELATION_NOE 中<|>RELATION_NOE FPGS<|>RELATION_NOE 的<|>RELATION_NOE 基因表达<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用于<|>RELATION_NOE 观察<|>RELATION_NOE 白血病<|>RELATION_NOE 患者<|>RELATION_NOE MTX<|>RELATION_NOE 治疗<|>RELATION_NOE 耐药<|>RELATION_NOE 前后<|>RELATION_NOE FPGSmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 用<|>RELATION_NOE SYBRGreenI<|>RELATION_NOE 为<|>RELATION_NOE 荧光染料<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE β<|>RELATION_NOE -actin<|>RELATION_NOE 作<|>RELATION_NOE 参照<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 检测<|>RELATION_NOE FPGSmRNA<|>RELATION_NOE 的<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
MTX<|>RELATION_NOE 诱导<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 细胞株<|>RELATION_NOE 及<|>RELATION_NOE 白血病<|>RELATION_NOE 患者<|>RELATION_NOE 骨髓细胞<|>RELATION_NOE 中<|>RELATION_NOE FPGSmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 发生<|>RELATION_B 了<|>RELATION_I 变化<|>RELATION_E ,<|>RELATION_NOE MTX2<|>RELATION_NOE 种<|>RELATION_NOE 对<|>RELATION_NOE 映体<|>RELATION_NOE 形式<|>RELATION_NOE 在<|>RELATION_NOE 细胞<|>RELATION_NOE 耐药<|>RELATION_NOE 机制<|>RELATION_NOE 中<|>RELATION_NOE 可能<|>RELATION_NOE 发挥<|>RELATION_NOE 了<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 不同<|>RELATION_NOE 途径<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 封堵<|>RELATION_S 气管<|>RELATION_NOE 瘘<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_S 经<|>RELATION_NOE 气管<|>RELATION_NOE 或<|>RELATION_NOE 食管<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 封<|>RELATION_NOE 堵<|>RELATION_NOE 气管<|>RELATION_NOE 瘘<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
13<|>RELATION_NOE 例<|>RELATION_NOE 气管<|>RELATION_NOE 瘘患者<|>RELATION_NOE ,<|>RELATION_NOE 男<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 女4<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 55<|>RELATION_NOE －<|>RELATION_NOE 83<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 60.3<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 食管<|>RELATION_NOE 癌性<|>RELATION_NOE 狭窄<|>RELATION_NOE 伴<|>RELATION_NOE 气管<|>RELATION_NOE 瘘8<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 食管癌<|>RELATION_NOE 术后<|>RELATION_NOE 胃吻<|>RELATION_NOE 合口<|>RELATION_NOE 伴<|>RELATION_NOE 气管<|>RELATION_NOE 瘘3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 食管癌<|>RELATION_NOE 术后<|>RELATION_NOE 胸腔<|>RELATION_NOE 胃<|>RELATION_NOE 气管<|>RELATION_NOE 隆突瘘<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 左主<|>RELATION_NOE 支气管<|>RELATION_NOE 残端<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘1<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE 原发<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 性质<|>RELATION_NOE 、<|>RELATION_NOE 狭窄<|>RELATION_NOE 范围<|>RELATION_NOE 、<|>RELATION_NOE 瘘口<|>RELATION_NOE 部位<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 数字<|>RELATION_NOE 减影<|>RELATION_NOE 血管<|>RELATION_NOE 造影<|>RELATION_NOE (<|>RELATION_NOE DSA<|>RELATION_NOE )<|>RELATION_NOE 监视<|>RELATION_NOE 下<|>RELATION_NOE 经<|>RELATION_NOE 食管<|>RELATION_NOE 或<|>RELATION_NOE 气管<|>RELATION_NOE 途径<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 个体化<|>RELATION_NOE 设计<|>RELATION_NOE 覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 封堵<|>RELATION_NOE 瘘口<|>RELATION_NOE 。<|>RELATION_NOE
10<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 食管<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 10<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 管状<|>RELATION_NOE 覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 8<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 下端<|>RELATION_NOE 大<|>RELATION_NOE 喇叭<|>RELATION_NOE 口覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 2<|>RELATION_NOE 枚<|>RELATION_NOE ;<|>RELATION_NOE
3例<|>RELATION_NOE 经<|>RELATION_NOE 气管<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 4<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 管状<|>RELATION_NOE 覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 2<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 倒<|>RELATION_NOE “<|>RELATION_NOE Y<|>RELATION_NOE ”<|>RELATION_NOE 型<|>RELATION_NOE 覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 1<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE “<|>RELATION_NOE 子弹头<|>RELATION_NOE ”<|>RELATION_NOE 残端瘘<|>RELATION_NOE 支架<|>RELATION_NOE 1<|>RELATION_NOE 枚<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 气管<|>RELATION_NOE 或<|>RELATION_NOE 食管<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 个体化<|>RELATION_NOE 覆膜<|>RELATION_NOE 支架<|>RELATION_NOE 治疗<|>RELATION_S 气管<|>RELATION_NOE 瘘<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 迅速<|>RELATION_NOE 封堵<|>RELATION_NOE 瘘口<|>RELATION_NOE 和<|>RELATION_NOE 解除<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 简单<|>RELATION_NOE 、<|>RELATION_NOE 安全<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 优势<|>RELATION_S
收集<|>RELATION_NOE 2008年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 11月<|>RELATION_NOE 行<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 患者<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 同期<|>RELATION_NOE 97<|>RELATION_NOE 例行<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 术前<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 等<|>RELATION_NOE 常规<|>RELATION_NOE 检查<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE NSCLC<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 数目<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 胸腔<|>RELATION_NOE 闭式<|>RELATION_NOE 引流<|>RELATION_NOE 天数<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 将<|>RELATION_NOE 数据<|>RELATION_NOE 输入<|>RELATION_NOE SPSS17.0<|>RELATION_NOE 统计<|>RELATION_NOE 软件<|>RELATION_NOE 包<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 均数<|>RELATION_NOE ±<|>RELATION_NOE 标准<|>RELATION_NOE 差<|>RELATION_NOE (<|>RELATION_NOE x<|>RELATION_NOE ±<|>RELATION_NOE S<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_NOE 方法<|>RELATION_NOE 采用<|>RELATION_NOE 两<|>RELATION_NOE 样<|>RELATION_NOE 本均数<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ≤<|>RELATION_NOE 0.05<|>RELATION_NOE 为<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
VATS<|>RELATION_NOE 在<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE NSCLC<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 能<|>RELATION_NOE 达到<|>RELATION_NOE 相似<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_B 减少<|>RELATION_E 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 手术<|>RELATION_NOE 创伤<|>RELATION_NOE 降<|>RELATION_NOE 至<|>RELATION_NOE 最低<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
内科<|>RELATION_NOE 电子<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 诊断<|>RELATION_S 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
我<|>RELATION_NOE 科<|>RELATION_NOE 2008年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 5月<|>RELATION_NOE 期间<|>RELATION_NOE 203<|>RELATION_NOE 例<|>RELATION_NOE 经过<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 细胞<|>RELATION_NOE 病理<|>RELATION_NOE 和<|>RELATION_NOE 胸膜<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE 仍<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_S 胸腔镜检查<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 病例数<|>RELATION_NOE 为<|>RELATION_NOE 172<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 84.7<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 肿瘤<|>RELATION_NOE 82<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 40.3<|>RELATION_NOE 9%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 75<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 36.9<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 0.9<|>RELATION_NOE 9%<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 0.4<|>RELATION_NOE 9%<|>RELATION_NOE ,<|>RELATION_NOE 肾癌<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 0.4<|>RELATION_NOE 9%<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 0.9<|>RELATION_NOE 9%<|>RELATION_NOE ,<|>RELATION_NOE 非何杰<|>RELATION_NOE 金氏<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 1<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 0.4<|>RELATION_NOE 9%<|>RELATION_NOE ,<|>RELATION_NOE 胸膜<|>RELATION_NOE 间皮瘤<|>RELATION_NOE 为<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 9.8<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 结核<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 34.4<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 慢性<|>RELATION_NOE 非<|>RELATION_NOE 特异性<|>RELATION_NOE 炎伴<|>RELATION_NOE 或<|>RELATION_NOE 不<|>RELATION_NOE 伴<|>RELATION_NOE 间皮<|>RELATION_NOE 细胞增生<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 10.3<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 本组<|>RELATION_NOE 病例<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 严重<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 对于<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_B 种<|>RELATION_I 安全<|>RELATION_I 、<|>RELATION_I 简便<|>RELATION_I 、<|>RELATION_I 诊断率<|>RELATION_I 阳性<|>RELATION_I 高<|>RELATION_I 的<|>RELATION_I 方法<|>RELATION_E ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 48<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 与<|>RELATION_NOE 普通<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE DDP<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 96<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 被<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 采用<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 普通<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE －3<|>RELATION_NOE 天<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 按<|>RELATION_NOE RECIST<|>RELATION_NOE 标准<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 患者<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 、<|>RELATION_NOE 皮疹<|>RELATION_NOE 、<|>RELATION_NOE 肌肉<|>RELATION_NOE 痛<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
全身<|>RELATION_NOE 伽玛刀<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
观察<|>RELATION_S 全身<|>RELATION_NOE 伽玛刀<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 远期<|>RELATION_NOE 疗效<|>RELATION_NOE 及其<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE
42<|>RELATION_NOE 例<|>RELATION_NOE 病理<|>RELATION_NOE 明确<|>RELATION_NOE 的<|>RELATION_NOE Ⅰ<|>RELATION_NOE -<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE OUR-QGD<|>RELATION_NOE 型<|>RELATION_NOE 体部<|>RELATION_NOE 伽玛刀<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 为<|>RELATION_NOE 50%<|>RELATION_NOE －<|>RELATION_NOE 75%<|>RELATION_NOE 等<|>RELATION_NOE 剂量<|>RELATION_NOE 曲线<|>RELATION_NOE 4－<|>RELATION_NOE 8Gy<|>RELATION_NOE /<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 1次/<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 每周<|>RELATION_NOE 5<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 4－10<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 照射<|>RELATION_NOE 剂量<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 50Gy<|>RELATION_NOE 。<|>RELATION_NOE
全身<|>RELATION_NOE 伽玛刀<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 肿瘤区<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_NOE 剂量<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 保护<|>RELATION_NOE 肿瘤<|>RELATION_NOE 周围<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 增加<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 局部<|>RELATION_NOE 控制率<|>RELATION_NOE 、<|>RELATION_NOE
甲泼尼龙<|>RELATION_NOE 辅助<|>RELATION_NOE 盐酸<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 甲泼尼龙<|>RELATION_NOE 辅助<|>RELATION_NOE 阿片<|>RELATION_NOE 类<|>RELATION_NOE 药物<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疼痛<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 。<|>RELATION_NOE
选择<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 重度<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 第一<|>RELATION_NOE 组<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 盐酸<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE (<|>RELATION_NOE 美菲康<|>RELATION_NOE )<|>RELATION_NOE 单药<|>RELATION_NOE 治疗<|>RELATION_NOE ;<|>RELATION_NOE
第二<|>RELATION_NOE 组<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 甲泼尼龙<|>RELATION_NOE 辅助<|>RELATION_NOE 盐酸<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE (<|>RELATION_NOE 美菲康<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 均<|>RELATION_NOE 达到<|>RELATION_NOE 完全<|>RELATION_NOE 或<|>RELATION_NOE 明显<|>RELATION_NOE 缓解<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 单用<|>RELATION_NOE 盐酸<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE 获得<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 30.7%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 缓解<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 61.5%<|>RELATION_NOE ;<|>RELATION_NOE
甲泼尼龙<|>RELATION_NOE 辅助<|>RELATION_NOE 盐酸<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE 治疗<|>RELATION_NOE 达到<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 40.7<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 缓解<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 59.2<|>RELATION_NOE 6%<|>RELATION_NOE ;<|>RELATION_NOE
治疗<|>RELATION_NOE 后<|>RELATION_NOE 2周<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 与<|>RELATION_NOE 治疗<|>RELATION_NOE 前进<|>RELATION_NOE 行<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 精神<|>RELATION_NOE 状态<|>RELATION_NOE 、<|>RELATION_NOE 睡眠<|>RELATION_NOE 、<|>RELATION_NOE 食欲<|>RELATION_NOE 等<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE ,<|>RELATION_NOE 特别<|>RELATION_NOE 是<|>RELATION_NOE 睡眠<|>RELATION_NOE 和<|>RELATION_NOE 精神<|>RELATION_NOE 状态<|>RELATION_NOE 改善<|>RELATION_NOE 最为<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE 了<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 榄香烯<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 彗星<|>RELATION_NOE 分析法<|>RELATION_NOE 探讨<|>RELATION_S 损伤<|>RELATION_NOE 修复<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 榄香烯<|>RELATION_NOE 联合<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 照射组<|>RELATION_NOE 与<|>RELATION_NOE 单独<|>RELATION_NOE 照射组<|>RELATION_NOE 和<|>RELATION_NOE 单独<|>RELATION_NOE 药物<|>RELATION_NOE 组<|>RELATION_NOE 0.2<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 24h<|>RELATION_NOE 的<|>RELATION_NOE 彗星<|>RELATION_NOE 尾力矩<|>RELATION_NOE 相比<|>RELATION_NOE 有所<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 7.16<|>RELATION_NOE ±<|>RELATION_NOE 2.61<|>RELATION_NOE 与<|>RELATION_NOE 0.95<|>RELATION_NOE ±<|>RELATION_NOE 0.65<|>RELATION_NOE 和<|>RELATION_NOE 1.81<|>RELATION_NOE ±<|>RELATION_NOE 1.23<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 23<|>RELATION_NOE 1.24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 3.65<|>RELATION_NOE ±<|>RELATION_NOE 2.06<|>RELATION_NOE 与<|>RELATION_NOE 0.11<|>RELATION_NOE ±<|>RELATION_NOE 0.07<|>RELATION_NOE 和<|>RELATION_NOE 1.58<|>RELATION_NOE ±<|>RELATION_NOE 1.40<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 90.22<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 2.09<|>RELATION_NOE ±<|>RELATION_NOE 0.83<|>RELATION_NOE 与<|>RELATION_NOE 0.1<|>RELATION_NOE ±<|>RELATION_NOE 0.05<|>RELATION_NOE 和<|>RELATION_NOE 0.45<|>RELATION_NOE ±<|>RELATION_NOE 0.25<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 23<|>RELATION_NOE 8.44<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 1.45<|>RELATION_NOE ±<|>RELATION_NOE 1.37<|>RELATION_NOE 与<|>RELATION_NOE 0.11<|>RELATION_NOE ±<|>RELATION_NOE 0.08<|>RELATION_NOE 和<|>RELATION_NOE 0.60<|>RELATION_NOE ±<|>RELATION_NOE 0.40<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 38.94<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 表明<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 榄香烯<|>RELATION_NOE 与<|>RELATION_NOE 放射线<|>RELATION_NOE 联合<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 增加<|>RELATION_NOE 和<|>RELATION_NOE 修复<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
β<|>RELATION_NOE -<|>RELATION_NOE 榄香烯<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 可能<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE DNA<|>RELATION_NOE 放射<|>RELATION_NOE 损伤<|>RELATION_NOE 及<|>RELATION_NOE 修复<|>RELATION_NOE 作用<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
顺铂<|>RELATION_NOE 和<|>RELATION_NOE 洛铂<|>RELATION_NOE 与<|>RELATION_NOE 放射<|>RELATION_NOE 联合<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
了解<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 洛铂<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_NOE 增敏<|>RELATION_NOE 作用<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
70<|>RELATION_NOE 只<|>RELATION_NOE C57BL<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 近<|>RELATION_NOE 交系<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 小鼠<|>RELATION_NOE 随机<|>RELATION_NOE 分组<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 10mg<|>RELATION_NOE 药物<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 体重<|>RELATION_NOE 经尾<|>RELATION_NOE 静脉<|>RELATION_NOE 分别<|>RELATION_NOE 注射<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE 洛铂<|>RELATION_NOE ,<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 在<|>RELATION_NOE 0.5<|>RELATION_NOE 、<|>RELATION_NOE 2.0<|>RELATION_NOE 、<|>RELATION_NOE 4.0<|>RELATION_NOE 、<|>RELATION_NOE 24.0<|>RELATION_NOE 、<|>RELATION_NOE 48.0<|>RELATION_NOE 、<|>RELATION_NOE 72.0<|>RELATION_NOE 、<|>RELATION_NOE 96.0h<|>RELATION_NOE 分别<|>RELATION_NOE 将<|>RELATION_NOE 小鼠<|>RELATION_NOE 处死<|>RELATION_NOE 获取<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE ICP-MS<|>RELATION_NOE 方法<|>RELATION_NOE 测定<|>RELATION_S 标本铂<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
80<|>RELATION_NOE 只<|>RELATION_NOE 荷瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 药物<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 照射<|>RELATION_NOE 、<|>RELATION_NOE 药物<|>RELATION_NOE 联合<|>RELATION_NOE 照射组<|>RELATION_NOE 共<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 注射<|>RELATION_NOE 药物<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 24h<|>RELATION_NOE 或<|>RELATION_NOE 72h<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 局部<|>RELATION_NOE 进行<|>RELATION_NOE 照射<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 各组<|>RELATION_NOE 间<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 。<|>RELATION_NOE
顺铂<|>RELATION_NOE 、<|>RELATION_NOE 洛铂<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 浓度<|>RELATION_NOE 均<|>RELATION_NOE 在<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 迅速<|>RELATION_NOE 达到<|>RELATION_NOE 4.78<|>RELATION_NOE 、<|>RELATION_NOE 2.79<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.82<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.005<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 4h<|>RELATION_NOE 后<|>RELATION_NOE 分别<|>RELATION_NOE 降<|>RELATION_NOE 至<|>RELATION_NOE 3.39<|>RELATION_NOE 、<|>RELATION_NOE 0.99<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 9.<|>RELATION_NOE 10<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 96h<|>RELATION_NOE 时<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.41<|>RELATION_NOE 、<|>RELATION_NOE 0.23<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.70<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.006<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
PET-CT<|>RELATION_NOE 定位<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 医生<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 靶体<|>RELATION_NOE 积<|>RELATION_NOE 定义<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
不同<|>RELATION_NOE 放疗科<|>RELATION_NOE 医生<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE PET-CT<|>RELATION_NOE 定位<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 定义<|>RELATION_NOE 靶区<|>RELATION_NOE 存在<|>RELATION_B 差异<|>RELATION_E ,<|>RELATION_NOE GTV<|>RELATION_NOE 、<|>RELATION_NOE CTV<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 值<|>RELATION_NOE 与<|>RELATION_NOE 最<|>RELATION_NOE 小<|>RELATION_NOE 值比<|>RELATION_NOE 的<|>RELATION_NOE 平均值<|>RELATION_NOE 均<|>RELATION_NOE 在<|>RELATION_NOE 1.7<|>RELATION_NOE 以下<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 主要<|>RELATION_NOE 原因<|>RELATION_NOE 为<|>RELATION_NOE 位于<|>RELATION_NOE 肺门<|>RELATION_NOE 或<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 区域<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 经颈<|>RELATION_NOE 电视<|>RELATION_NOE 纵隔镜<|>RELATION_NOE 下<|>RELATION_NOE 纵隔<|>RELATION_NOE 内<|>RELATION_NOE 血管<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 、<|>RELATION_NOE 神经<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 解剖<|>RELATION_B 特点<|>RELATION_E 以及<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
肺动脉<|>RELATION_NOE 窗<|>RELATION_NOE 间隙<|>RELATION_NOE 和<|>RELATION_NOE 隆嵴<|>RELATION_NOE 下<|>RELATION_NOE 间隙<|>RELATION_NOE 的<|>RELATION_NOE 镜<|>RELATION_NOE 下<|>RELATION_NOE 解剖学<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 镜<|>RELATION_NOE 下<|>RELATION_NOE 不同<|>RELATION_NOE 间隙<|>RELATION_NOE 内<|>RELATION_NOE 血管<|>RELATION_NOE 神经<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 解剖学<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE :<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 转移<|>RELATION_NOE 癌8<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 结节病<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结结核<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 恶性淋巴瘤<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 前<|>RELATION_NOE 纵隔<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
经颈<|>RELATION_NOE 电视<|>RELATION_NOE 纵隔镜<|>RELATION_NOE 下行<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 活检<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 清晰<|>RELATION_NOE 显露<|>RELATION_NOE 和<|>RELATION_NOE 打开<|>RELATION_NOE 气管<|>RELATION_NOE 前<|>RELATION_NOE 筋膜<|>RELATION_NOE 是<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 关键<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 气管<|>RELATION_NOE 为<|>RELATION_NOE 中心<|>RELATION_NOE 辨清<|>RELATION_NOE 纵隔<|>RELATION_NOE 内<|>RELATION_NOE 各<|>RELATION_NOE 间隙<|>RELATION_NOE 有利于<|>RELATION_NOE 顺利<|>RELATION_NOE 活检<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 前<|>RELATION_NOE 间隙<|>RELATION_NOE 和<|>RELATION_NOE 隆嵴<|>RELATION_NOE 下<|>RELATION_NOE 间隙<|>RELATION_NOE 淋巴结<|>RELATION_NOE 活检<|>RELATION_NOE 病理<|>RELATION_NOE 确诊率<|>RELATION_NOE 较<|>RELATION_B 高<|>RELATION_E 。<|>RELATION_NOE
3种<|>RELATION_NOE 静脉<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 途径<|>RELATION_NOE 预防<|>RELATION_S 化疗<|>RELATION_NOE 静脉炎<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 评价<|>RELATION_NOE
探讨<|>RELATION_NOE 经<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 穿刺<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 置管<|>RELATION_NOE (<|>RELATION_NOE HCC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 传统<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 置管<|>RELATION_NOE (<|>RELATION_NOE 股静脉<|>RELATION_NOE 置管<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 四肢<|>RELATION_NOE 静脉<|>RELATION_NOE 留置<|>RELATION_NOE 针3<|>RELATION_NOE 种<|>RELATION_NOE 不同<|>RELATION_NOE 静脉<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 途径<|>RELATION_NOE 在<|>RELATION_NOE 预防<|>RELATION_NOE 化疗<|>RELATION_NOE 静脉炎<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_B 效果<|>RELATION_E 。<|>RELATION_NOE
A<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE 发生<|>RELATION_NOE 静脉炎<|>RELATION_NOE 的<|>RELATION_NOE 例数<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE ,<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 静脉炎<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 6.5<|>RELATION_NOE 8%<|>RELATION_NOE 、<|>RELATION_NOE 12.8<|>RELATION_NOE 2%<|>RELATION_NOE 、<|>RELATION_NOE 25.7<|>RELATION_NOE 1%<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 静脉炎<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E C<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 静脉炎<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 无<|>RELATION_NOE 显著<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 抗<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 人<|>RELATION_NOE 鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 临床<|>RELATION_NOE 试验<|>RELATION_NOE
评价<|>RELATION_NOE 重组<|>RELATION_NOE 抗<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 人<|>RELATION_NOE 鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE (<|>RELATION_NOE CMAB009<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 药代动力学<|>RELATION_B 特点<|>RELATION_I 和<|>RELATION_I 安全性<|>RELATION_E ,<|>RELATION_NOE 初步<|>RELATION_NOE 观察<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
2例<|>RELATION_NOE (<|>RELATION_NOE 13.3%<|>RELATION_NOE )<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 患者<|>RELATION_NOE 获得<|>RELATION_NOE PR<|>RELATION_NOE ,<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 24<|>RELATION_NOE 和<|>RELATION_NOE 16<|>RELATION_NOE 周<|>RELATION_NOE 。<|>RELATION_NOE
CMAB009<|>RELATION_NOE 的<|>RELATION_NOE 耐受性<|>RELATION_NOE 良好<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 1－2<|>RELATION_NOE 级<|>RELATION_NOE ,<|>RELATION_NOE 最<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 为<|>RELATION_NOE 皮疹<|>RELATION_NOE 和<|>RELATION_NOE 甲沟炎<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_B 观察<|>RELATION_I 到<|>RELATION_E 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
超前<|>RELATION_NOE 镇痛<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 剖<|>RELATION_NOE 胸术<|>RELATION_NOE 后<|>RELATION_NOE 疼痛<|>RELATION_NOE 控制<|>RELATION_NOE 满意度<|>RELATION_NOE 及<|>RELATION_NOE 慢性<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
对照组<|>RELATION_NOE 实施<|>RELATION_S 传统<|>RELATION_NOE 镇痛<|>RELATION_NOE 模式<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 对照组<|>RELATION_NOE 实施<|>RELATION_NOE 传统<|>RELATION_NOE 镇痛<|>RELATION_NOE 模式<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 实施<|>RELATION_S 超前<|>RELATION_NOE 镇痛<|>RELATION_NOE 模式<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 电语<|>RELATION_NOE 回访<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_S 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 了解<|>RELATION_NOE 患者<|>RELATION_NOE 慢性<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 电语<|>RELATION_NOE 回访<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 了解<|>RELATION_S 患者<|>RELATION_NOE 慢性<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 术后<|>RELATION_NOE 慢性<|>RELATION_NOE 疼痛<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 13.6%<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE 33.3%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 4.79<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
超前<|>RELATION_NOE 镇痛<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_S 肺癌<|>RELATION_NOE 剖<|>RELATION_NOE 胸术<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 控制<|>RELATION_NOE 满意度<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 慢性<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE 超前<|>RELATION_NOE 镇痛<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_NOE 肺癌<|>RELATION_NOE 剖<|>RELATION_NOE 胸术<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 控制<|>RELATION_NOE 满意度<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_S 慢性<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
呼吸<|>RELATION_NOE 助力器<|>RELATION_NOE 训练<|>RELATION_NOE 联合<|>RELATION_NOE 雾化<|>RELATION_NOE 吸入<|>RELATION_NOE 治疗<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 肺功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 呼吸<|>RELATION_NOE 助力器<|>RELATION_NOE 训练<|>RELATION_NOE 联合<|>RELATION_NOE 特步他林<|>RELATION_NOE 及<|>RELATION_NOE 盐酸<|>RELATION_NOE 氨溴索<|>RELATION_NOE 雾化<|>RELATION_NOE 吸入<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 肺功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 围手术期间<|>RELATION_NOE 给予<|>RELATION_S 呼吸<|>RELATION_NOE 助力器<|>RELATION_NOE 训练<|>RELATION_NOE 及<|>RELATION_NOE 特步他林<|>RELATION_NOE 和<|>RELATION_NOE 盐酸<|>RELATION_NOE 氨溴索<|>RELATION_NOE 雾化<|>RELATION_NOE 吸入<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 围手术期间<|>RELATION_NOE 仅<|>RELATION_NOE 治疗组<|>RELATION_NOE 围手术期间<|>RELATION_NOE 给予<|>RELATION_NOE 呼吸<|>RELATION_NOE 助力器<|>RELATION_NOE 训练<|>RELATION_NOE 及<|>RELATION_NOE 特步他林<|>RELATION_NOE 和<|>RELATION_NOE 盐酸<|>RELATION_NOE 氨溴索<|>RELATION_NOE 雾化<|>RELATION_NOE 吸入<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 围手术期间<|>RELATION_NOE 仅<|>RELATION_NOE 给予<|>RELATION_S 特步他林<|>RELATION_NOE 和<|>RELATION_NOE 盐酸<|>RELATION_NOE 氨溴索<|>RELATION_NOE 雾化<|>RELATION_NOE 吸人<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
于<|>RELATION_NOE 围手术期间<|>RELATION_NOE 联合<|>RELATION_NOE 采用<|>RELATION_NOE 呼吸<|>RELATION_NOE 助力器<|>RELATION_NOE 训练<|>RELATION_NOE 及<|>RELATION_NOE 雾化<|>RELATION_NOE (<|>RELATION_NOE 特步他林<|>RELATION_NOE 和<|>RELATION_NOE 盐酸<|>RELATION_NOE 氨溴索<|>RELATION_NOE )<|>RELATION_NOE 吸入<|>RELATION_NOE 治疗<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_B 改善<|>RELATION_E 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 肺功能<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 呼吸系统<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 促进<|>RELATION_NOE 患者<|>RELATION_NOE 早日<|>RELATION_NOE 康复<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE 于<|>RELATION_NOE 围手术期间<|>RELATION_NOE 联合<|>RELATION_NOE 采用<|>RELATION_NOE 呼吸<|>RELATION_NOE 助力器<|>RELATION_NOE 训练<|>RELATION_NOE 及<|>RELATION_NOE 雾化<|>RELATION_NOE (<|>RELATION_NOE 特步他林<|>RELATION_NOE 和<|>RELATION_NOE 盐酸<|>RELATION_NOE 氨溴索<|>RELATION_NOE )<|>RELATION_NOE 吸入<|>RELATION_NOE 治疗<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 后<|>RELATION_NOE 肺<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_S 呼吸系统<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 促进<|>RELATION_NOE 患者<|>RELATION_NOE 早日<|>RELATION_NOE 康复<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
微小<|>RELATION_NOE N2<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 与<|>RELATION_NOE 同期<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 对照<|>RELATION_B 研究<|>RELATION_E
研究<|>RELATION_NOE 分析<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE I<|>RELATION_NOE 期<|>RELATION_NOE 接受<|>RELATION_S 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 意外<|>RELATION_NOE 发现<|>RELATION_NOE 微小<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE N2<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 近<|>RELATION_NOE 、<|>RELATION_NOE 远期<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
VATS<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_S 微小<|>RELATION_NOE N2<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 经过<|>RELATION_NOE 术前<|>RELATION_NOE 严格<|>RELATION_NOE 的<|>RELATION_NOE 评估<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 中<|>RELATION_NOE 出现<|>RELATION_NOE 意料<|>RELATION_NOE 之外<|>RELATION_NOE 的<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 系统<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 后<|>RELATION_NOE 没有<|>RELATION_NOE 必要<|>RELATION_NOE 中转<|>RELATION_NOE 开胸<|>RELATION_NOE 完成<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
双锥面<|>RELATION_NOE 螺旋臼<|>RELATION_NOE 固定<|>RELATION_NOE 治疗<|>RELATION_S 髋关节<|>RELATION_NOE 中心性<|>RELATION_NOE 脱位<|>RELATION_NOE 的<|>RELATION_NOE 中长期<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_S 使用<|>RELATION_NOE 双锥面<|>RELATION_NOE 螺旋臼<|>RELATION_NOE 假体<|>RELATION_NOE 固定<|>RELATION_NOE 髋关节<|>RELATION_NOE 中心性<|>RELATION_NOE 脱位<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 长期<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
19<|>RELATION_NOE 98年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 2006年<|>RELATION_NOE 9月<|>RELATION_NOE 北京大学<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 关节<|>RELATION_NOE 病<|>RELATION_NOE 诊疗<|>RELATION_NOE 研究<|>RELATION_NOE 中心<|>RELATION_NOE 对<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 髋关节<|>RELATION_NOE 中心性<|>RELATION_NOE 脱位<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 39<|>RELATION_NOE 侧<|>RELATION_NOE 髋关节<|>RELATION_NOE 行<|>RELATION_NOE 人工<|>RELATION_NOE 全<|>RELATION_NOE 髋关节<|>RELATION_NOE 置换术<|>RELATION_NOE 或<|>RELATION_NOE 翻修术<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
引起<|>RELATION_NOE 髋关节<|>RELATION_NOE 中心性<|>RELATION_NOE 脱位<|>RELATION_NOE 的<|>RELATION_NOE 病因<|>RELATION_S 包括<|>RELATION_NOE :<|>RELATION_NOE 类<|>RELATION_NOE 风湿<|>RELATION_NOE 关节炎<|>RELATION_NOE 3例<|>RELATION_NOE 6髋<|>RELATION_NOE ;<|>RELATION_NOE
股骨头坏死<|>RELATION_NOE 继<|>RELATION_NOE 发髋<|>RELATION_NOE 关节炎<|>RELATION_NOE 7例<|>RELATION_NOE 12<|>RELATION_NOE 髋<|>RELATION_NOE ,<|>RELATION_NOE 人工<|>RELATION_NOE 股骨头<|>RELATION_NOE 置换术<|>RELATION_NOE 后<|>RELATION_NOE 髋臼<|>RELATION_NOE 磨损<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 11<|>RELATION_NOE 髋<|>RELATION_NOE 、<|>RELATION_NOE 髋臼<|>RELATION_NOE 假体<|>RELATION_NOE 松动<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 10<|>RELATION_NOE 髋<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 病例<|>RELATION_NOE 均<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 、<|>RELATION_NOE 1年<|>RELATION_NOE 时<|>RELATION_NOE 随访<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 3髋<|>RELATION_NOE 患者<|>RELATION_NOE 分别<|>RELATION_NOE 因<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 急性<|>RELATION_NOE 心肌梗死<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
1例<|>RELATION_NOE 股骨头坏死<|>RELATION_NOE 行双髋<|>RELATION_NOE 同时<|>RELATION_NOE 置换<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 右髋<|>RELATION_NOE 出现<|>RELATION_NOE 感染<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 关节<|>RELATION_NOE 取出<|>RELATION_NOE 骨<|>RELATION_NOE 水泥<|>RELATION_NOE 旷置术<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 因<|>RELATION_NOE 内科<|>RELATION_NOE 疾病<|>RELATION_NOE 不<|>RELATION_NOE 稳定<|>RELATION_NOE 未<|>RELATION_NOE 再<|>RELATION_NOE 行<|>RELATION_NOE 翻修术<|>RELATION_NOE 。<|>RELATION_NOE
1例类<|>RELATION_NOE 风湿<|>RELATION_NOE 关节炎<|>RELATION_NOE 患者<|>RELATION_NOE 双<|>RELATION_NOE 髋关节<|>RELATION_NOE 分期<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 7<|>RELATION_NOE 年<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时<|>RELATION_NOE 左侧<|>RELATION_NOE 髋臼<|>RELATION_NOE 假体<|>RELATION_NOE 有<|>RELATION_NOE 内侧<|>RELATION_NOE 轻度<|>RELATION_NOE 移位<|>RELATION_NOE ,<|>RELATION_NOE 边缘<|>RELATION_NOE 有<|>RELATION_NOE 透亮线<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 患者<|>RELATION_NOE 日常<|>RELATION_NOE 功能<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 疼痛<|>RELATION_NOE 。<|>RELATION_NOE
煤焦<|>RELATION_NOE 沥青<|>RELATION_NOE 烟提取物<|>RELATION_NOE 致<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 恶性<|>RELATION_NOE 转化<|>RELATION_NOE 细胞<|>RELATION_NOE 端粒<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_S
通过<|>RELATION_NOE 检测<|>RELATION_S 端粒<|>RELATION_NOE 保卫<|>RELATION_NOE 蛋白<|>RELATION_NOE 复合体<|>RELATION_NOE 中<|>RELATION_NOE 端粒<|>RELATION_NOE 保卫<|>RELATION_NOE 蛋白1<|>RELATION_NOE (<|>RELATION_NOE POT1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 端粒<|>RELATION_NOE 重复<|>RELATION_NOE 序列<|>RELATION_NOE 结合<|>RELATION_NOE 因子1<|>RELATION_NOE (<|>RELATION_NOE TRF1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE TRF2<|>RELATION_NOE 在<|>RELATION_NOE 煤焦<|>RELATION_NOE 沥青<|>RELATION_NOE 烟致<|>RELATION_NOE 永生化<|>RELATION_NOE 人<|>RELATION_NOE 支气管<|>RELATION_NOE 上皮细胞<|>RELATION_NOE (<|>RELATION_NOE BEAS<|>RELATION_NOE －<|>RELATION_NOE 2B<|>RELATION_NOE )<|>RELATION_NOE 癌变<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 煤焦<|>RELATION_NOE 沥青<|>RELATION_NOE 烟致<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 中<|>RELATION_NOE 温<|>RELATION_NOE 煤焦<|>RELATION_NOE 沥青<|>RELATION_NOE 烟提取物<|>RELATION_NOE 作为<|>RELATION_NOE 诱导剂<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE BEAS<|>RELATION_NOE －<|>RELATION_NOE 2B<|>RELATION_NOE 的<|>RELATION_NOE 恶性<|>RELATION_NOE 转化<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 反<|>RELATION_NOE 转录<|>RELATION_NOE -<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应法<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S POTI<|>RELATION_NOE 、<|>RELATION_NOE TRF1<|>RELATION_NOE 和<|>RELATION_NOE TRF2<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ;<|>RELATION_NOE
蛋白<|>RELATION_NOE :<|>RELATION_NOE POT1<|>RELATION_NOE :<|>RELATION_NOE 0.55<|>RELATION_NOE ±<|>RELATION_NOE 0.07<|>RELATION_NOE ,<|>RELATION_NOE TRF1<|>RELATION_NOE :<|>RELATION_NOE 0.27<|>RELATION_NOE ±<|>RELATION_NOE 0.07<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 二甲亚砜<|>RELATION_NOE 溶剂<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE mRNA<|>RELATION_NOE :<|>RELATION_NOE POT1<|>RELATION_NOE :<|>RELATION_NOE 0.89<|>RELATION_NOE ±<|>RELATION_NOE 0.12<|>RELATION_NOE ,<|>RELATION_NOE TRF1<|>RELATION_NOE :<|>RELATION_NOE 0.90<|>RELATION_NOE ±<|>RELATION_NOE 0.08<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 煤焦<|>RELATION_NOE 沥青<|>RELATION_NOE 烟致<|>RELATION_NOE 支气管<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 恶性<|>RELATION_NOE 演化<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE POT1<|>RELATION_NOE 、<|>RELATION_NOE TRF1<|>RELATION_NOE 和<|>RELATION_NOE TRF2<|>RELATION_NOE 基因<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 发生<|>RELATION_S 变化<|>RELATION_NOE 。<|>RELATION_NOE
四维<|>RELATION_NOE CT<|>RELATION_NOE 技术<|>RELATION_NOE 确定<|>RELATION_S 肺内<|>RELATION_NOE 孤立<|>RELATION_NOE 性病<|>RELATION_NOE 灶靶<|>RELATION_NOE 体积<|>RELATION_NOE 应用<|>RELATION_NOE
红外线<|>RELATION_NOE 跟踪<|>RELATION_NOE 摆位<|>RELATION_NOE 系统<|>RELATION_NOE 与<|>RELATION_NOE 电子<|>RELATION_NOE 射野<|>RELATION_NOE 影像<|>RELATION_NOE 装置<|>RELATION_NOE 对<|>RELATION_NOE 摆位<|>RELATION_B 误差<|>RELATION_I 测量<|>RELATION_I 结果<|>RELATION_I 的<|>RELATION_I 比较<|>RELATION_I 研究<|>RELATION_E
比较<|>RELATION_NOE 红外线<|>RELATION_NOE 跟踪<|>RELATION_NOE 摆位<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE IM-BPS<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 电子<|>RELATION_NOE 射野<|>RELATION_NOE 影像<|>RELATION_NOE 装置<|>RELATION_NOE (<|>RELATION_NOE EPID<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 食管癌<|>RELATION_B 和<|>RELATION_I 肺癌<|>RELATION_I 患者<|>RELATION_I 摆位<|>RELATION_I 误差<|>RELATION_I 测量<|>RELATION_I 结果<|>RELATION_I 的<|>RELATION_I 优劣<|>RELATION_E 。<|>RELATION_NOE
IM-BPS<|>RELATION_NOE 对<|>RELATION_NOE 食管癌<|>RELATION_NOE 及<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 摆位<|>RELATION_NOE 误差<|>RELATION_NOE 的<|>RELATION_NOE 测量<|>RELATION_NOE 结果<|>RELATION_NOE 大部分<|>RELATION_NOE 优于<|>RELATION_S EPID<|>RELATION_NOE ,<|>RELATION_NOE 虽然<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 都<|>RELATION_NOE 能<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 摆位<|>RELATION_NOE 进行<|>RELATION_NOE 较为<|>RELATION_NOE 准确<|>RELATION_NOE 测量<|>RELATION_NOE 和<|>RELATION_NOE 质量<|>RELATION_NOE 控制<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 因<|>RELATION_NOE IM-BPS<|>RELATION_NOE 应用<|>RELATION_NOE 直观<|>RELATION_NOE 、<|>RELATION_NOE 简便<|>RELATION_NOE 、<|>RELATION_NOE 耗时<|>RELATION_NOE 短<|>RELATION_NOE 、<|>RELATION_NOE 可<|>RELATION_NOE 实时<|>RELATION_NOE 监测<|>RELATION_NOE 校正<|>RELATION_NOE 而<|>RELATION_NOE 更<|>RELATION_NOE 易于<|>RELATION_NOE 临床<|>RELATION_NOE 使用<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 皮植<|>RELATION_NOE 入<|>RELATION_NOE ^<|>RELATION_NOE 125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 周围型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 探讨<|>RELATION_NOE
探讨<|>RELATION_S cT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 植入<|>RELATION_NOE ^<|>RELATION_NOE 125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 周围型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 可行性<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
PET-CT<|>RELATION_NOE 下<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_S Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_S 在<|>RELATION_NOE PET-CT<|>RELATION_NOE 指导<|>RELATION_NOE 下行<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE 3DCRT<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_S 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 有<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 放<|>RELATION_NOE 疗<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 、<|>RELATION_NOE SUV<|>RELATION_NOE 值<|>RELATION_NOE 、<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 7.46<|>RELATION_NOE 、<|>RELATION_NOE 7.52<|>RELATION_NOE 、<|>RELATION_NOE 8.37<|>RELATION_NOE 、<|>RELATION_NOE 4.97<|>RELATION_NOE 、<|>RELATION_NOE 5.82<|>RELATION_NOE 、<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.006<|>RELATION_NOE 、<|>RELATION_NOE 0.006<|>RELATION_NOE 、<|>RELATION_NOE 0.004<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 26<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_NOE 模型<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_S 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 有<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 放<|>RELATION_NOE 疗<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^2<|>RELATION_NOE =<|>RELATION_NOE 6.20<|>RELATION_NOE 、<|>RELATION_NOE 9.69<|>RELATION_NOE 、<|>RELATION_NOE 6.39<|>RELATION_NOE 、<|>RELATION_NOE 10.09<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 13<|>RELATION_NOE 、<|>RELATION_NOE 0.002<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 11<|>RELATION_NOE 、<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
PET-CT<|>RELATION_NOE 定位<|>RELATION_NOE 下行<|>RELATION_NOE 3DCRT<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 优于<|>RELATION_S 以往<|>RELATION_NOE 报道<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 放<|>RELATION_NOE 疗<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_B 分析<|>RELATION_E 中山大学<|>RELATION_NOE 肿瘤<|>RELATION_NOE 防治<|>RELATION_NOE 中心<|>RELATION_NOE 1990年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 8月<|>RELATION_NOE 诊治<|>RELATION_NOE 的<|>RELATION_NOE 6例<|>RELATION_NOE 原发性<|>RELATION_NOE 喉<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 和<|>RELATION_NOE 纤维<|>RELATION_NOE 喉镜<|>RELATION_NOE 活检<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE
本组<|>RELATION_NOE 6例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 1例<|>RELATION_NOE 放弃<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE 声门<|>RELATION_NOE 上<|>RELATION_NOE 半<|>RELATION_NOE 喉切除术<|>RELATION_NOE 和<|>RELATION_NOE 辅助放化疗<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE 诱导<|>RELATION_NOE 化疗<|>RELATION_NOE +<|>RELATION_NOE 放疗<|>RELATION_NOE +<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 2例行<|>RELATION_NOE 诱导<|>RELATION_NOE 化疗<|>RELATION_NOE +<|>RELATION_NOE 同步<|>RELATION_NOE 放化<|>RELATION_NOE 疗+<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 。<|>RELATION_NOE
化疗<|>RELATION_NOE 药物<|>RELATION_NOE 包括<|>RELATION_S 博来霉素<|>RELATION_NOE 、<|>RELATION_NOE 氟尿嘧啶<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 、<|>RELATION_NOE 紫杉醇<|>RELATION_NOE ,<|>RELATION_NOE 化疗3<|>RELATION_NOE －6<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 安全性<|>RELATION_NOE 的<|>RELATION_NOE meta<|>RELATION_NOE 分析<|>RELATION_NOE
评价<|>RELATION_S 紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE (<|>RELATION_NOE LEP<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
白细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板减少<|>RELATION_NOE 、<|>RELATION_NOE 贫血<|>RELATION_NOE 以及<|>RELATION_NOE 脱发<|>RELATION_NOE 发生率<|>RELATION_NOE 2组<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 皮疹<|>RELATION_NOE 、<|>RELATION_NOE 肌肉<|>RELATION_NOE 痛<|>RELATION_NOE 、<|>RELATION_NOE 周围神经炎<|>RELATION_NOE 和<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 发生率<|>RELATION_NOE LEP<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_S PTX<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE OR<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.48<|>RELATION_NOE (<|>RELATION_NOE 0.33<|>RELATION_NOE －0.69<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 0.17<|>RELATION_NOE (<|>RELATION_NOE 0.08<|>RELATION_NOE －0.40<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 0.23<|>RELATION_NOE (<|>RELATION_NOE 、<|>RELATION_NOE 0.15<|>RELATION_NOE －0.35<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 0.41<|>RELATION_NOE (<|>RELATION_NOE 0.21<|>RELATION_NOE －0.81<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 0.18<|>RELATION_NOE (<|>RELATION_NOE 0.06<|>RELATION_NOE －0.50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 血栓<|>RELATION_NOE 前<|>RELATION_NOE 状态<|>RELATION_NOE (<|>RELATION_NOE ITS<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 低<|>RELATION_NOE 分子<|>RELATION_NOE 质量<|>RELATION_NOE 肝素<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
－Ⅳ期<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 进行<|>RELATION_NOE 常规<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 进行<|>RELATION_NOE 常规<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 低<|>RELATION_NOE 分子量<|>RELATION_NOE 肝素<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 20<|>RELATION_NOE 位<|>RELATION_NOE 体检<|>RELATION_NOE 正常者<|>RELATION_NOE 作为<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
治疗<|>RELATION_NOE 前<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE DD<|>RELATION_NOE 、<|>RELATION_NOE FIB<|>RELATION_NOE 、<|>RELATION_NOE vWF<|>RELATION_NOE 、<|>RELATION_NOE GMP-140<|>RELATION_NOE 、<|>RELATION_NOE TpP<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 1.44<|>RELATION_NOE ±<|>RELATION_NOE 0.10<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 3.81<|>RELATION_NOE ±<|>RELATION_NOE 0.88<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 27<|>RELATION_NOE 2.42<|>RELATION_NOE ±<|>RELATION_NOE 3.74<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 95.16<|>RELATION_NOE ±<|>RELATION_NOE 6.51<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.59<|>RELATION_NOE ±<|>RELATION_NOE 0.61<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 健康<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 0.45<|>RELATION_NOE ±<|>RELATION_NOE 0.12<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.63<|>RELATION_NOE ±<|>RELATION_NOE 0.63<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 91.73<|>RELATION_NOE ±<|>RELATION_NOE 8.38<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 19.75<|>RELATION_NOE ±<|>RELATION_NOE 8.53<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 3.464-0.85<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -10.617<|>RELATION_NOE 、<|>RELATION_NOE 3.4<|>RELATION_NOE 75<|>RELATION_NOE 、<|>RELATION_NOE 24.<|>RELATION_NOE 10<|>RELATION_NOE 0<|>RELATION_NOE 、<|>RELATION_NOE -12.161<|>RELATION_NOE 、<|>RELATION_NOE -5.240<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 存在<|>RELATION_NOE PTS<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 尤为<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 低<|>RELATION_NOE 分子<|>RELATION_NOE 质量<|>RELATION_NOE 肝素<|>RELATION_NOE 可<|>RELATION_NOE 降低<|>RELATION_S 血栓<|>RELATION_NOE 形成<|>RELATION_NOE 风险<|>RELATION_NOE 。<|>RELATION_NOE
ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 意义<|>RELATION_E
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 59<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ERCC1<|>RELATION_NOE 和<|>RELATION_NOE RRM1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
总结<|>RELATION_S 神经系统<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE PNS<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 利于<|>RELATION_NOE 原发性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
10<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 确诊<|>RELATION_NOE 肺癌<|>RELATION_NOE 5例<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 胸腺瘤<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 直肠癌<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
Ki-67<|>RELATION_NOE 与<|>RELATION_NOE p53<|>RELATION_NOE 在<|>RELATION_NOE 肺硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
分析<|>RELATION_NOE Ki-67<|>RELATION_NOE 与<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE (<|>RELATION_NOE PSH<|>RELATION_NOE )<|>RELATION_NOE 表面<|>RELATION_NOE 被<|>RELATION_NOE 覆<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 间质<|>RELATION_NOE 多边<|>RELATION_NOE 形细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 以及<|>RELATION_NOE Ki-67<|>RELATION_NOE 、<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 与<|>RELATION_NOE PSH<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
PSH<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 间质<|>RELATION_NOE 多边<|>RELATION_NOE 形细胞<|>RELATION_NOE 和<|>RELATION_NOE 表面<|>RELATION_NOE 被<|>RELATION_NOE 覆<|>RELATION_NOE 细胞<|>RELATION_NOE 具有<|>RELATION_NOE 形态<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 表型<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 间质<|>RELATION_NOE 多边<|>RELATION_NOE 形细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 指数<|>RELATION_NOE 和<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 被<|>RELATION_NOE 覆<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE PSH<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 可能<|>RELATION_NOE 主要<|>RELATION_NOE 决定<|>RELATION_NOE 于<|>RELATION_NOE 间质<|>RELATION_NOE 多边<|>RELATION_NOE 形细胞<|>RELATION_NOE 。<|>RELATION_NOE
Galectin-3<|>RELATION_NOE 在<|>RELATION_NOE CD133<|>RELATION_NOE +<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 增高<|>RELATION_NOE 诱导<|>RELATION_S CD8<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE
流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 分选<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE fqRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Westernblot<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE 分选<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE fqRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S CD133<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE Galectin-3<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE
流式细胞术<|>RELATION_NOE 结果<|>RELATION_NOE 表明<|>RELATION_NOE 磁珠分<|>RELATION_NOE 选出<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE CD133<|>RELATION_NOE +<|>RELATION_NOE 细胞数<|>RELATION_NOE 为<|>RELATION_NOE 90%<|>RELATION_NOE 。<|>RELATION_NOE
PCR<|>RELATION_NOE 和<|>RELATION_NOE Westernblot<|>RELATION_NOE 结果<|>RELATION_NOE 发现<|>RELATION_NOE Galectin-3<|>RELATION_NOE 在<|>RELATION_NOE CD133<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE CD133<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 1.24<|>RELATION_NOE 倍<|>RELATION_NOE 和<|>RELATION_NOE 1.5<|>RELATION_NOE 倍<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
凋亡<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE CD133<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 上清<|>RELATION_NOE 诱导<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 27.1<|>RELATION_NOE ±<|>RELATION_NOE 2.6<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 这种<|>RELATION_NOE 诱导<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 能力<|>RELATION_NOE 可<|>RELATION_NOE 被<|>RELATION_NOE 乳糖<|>RELATION_NOE 以及<|>RELATION_NOE 抗<|>RELATION_NOE Galectin-3<|>RELATION_NOE 的<|>RELATION_NOE 抗体<|>RELATION_NOE 中和<|>RELATION_S 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 时序性<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_S 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE (<|>RELATION_NOE 恩度<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 的<|>RELATION_NOE 不<|>RELATION_NOE 同时<|>RELATION_NOE 序<|>RELATION_NOE 对<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
60<|>RELATION_NOE 只<|>RELATION_NOE 荷<|>RELATION_NOE A549<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE 移植<|>RELATION_NOE 瘤裸鼠<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 分为<|>RELATION_NOE D1<|>RELATION_NOE 、<|>RELATION_NOE D3<|>RELATION_NOE 、<|>RELATION_NOE D5<|>RELATION_NOE 、<|>RELATION_NOE D7<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 恩度<|>RELATION_NOE 治疗<|>RELATION_NOE 并<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE 恩度<|>RELATION_NOE 治疗<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 7天<|>RELATION_NOE 进行<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_S 各组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 瘤体<|>RELATION_NOE 积<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 抑瘤率<|>RELATION_NOE 。<|>RELATION_NOE
阿司匹林<|>RELATION_NOE 抑制<|>RELATION_NOE 核因子<|>RELATION_NOE -<|>RELATION_NOE κ<|>RELATION_NOE B<|>RELATION_NOE 增强<|>RELATION_S 索拉非尼<|>RELATION_NOE 对<|>RELATION_NOE 肝癌<|>RELATION_NOE 的<|>RELATION_NOE 促<|>RELATION_NOE 凋亡<|>RELATION_NOE 作用<|>RELATION_NOE
采用<|>RELATION_NOE 人<|>RELATION_NOE 肝癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 原<|>RELATION_NOE 位<|>RELATION_NOE 模型<|>RELATION_NOE LCI-D20<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE Sorafenib<|>RELATION_NOE 单用组<|>RELATION_NOE (<|>RELATION_NOE 30mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 灌胃<|>RELATION_NOE ,<|>RELATION_NOE 1d1<|>RELATION_NOE 次<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Sorafenib<|>RELATION_NOE +<|>RELATION_NOE Aspirin<|>RELATION_NOE 合用组<|>RELATION_NOE 、<|>RELATION_NOE Aspirin<|>RELATION_NOE 单用组<|>RELATION_NOE (<|>RELATION_NOE 30mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 灌胃<|>RELATION_NOE ,<|>RELATION_NOE 1d1<|>RELATION_NOE 次<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 4周<|>RELATION_NOE 后<|>RELATION_NOE 观察<|>RELATION_NOE 荷瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 生存期<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 、<|>RELATION_NOE 肺转移<|>RELATION_NOE ,<|>RELATION_NOE 定量<|>RELATION_NOE 比较<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 指数<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 各<|>RELATION_NOE 组荷<|>RELATION_NOE 瘤鼠<|>RELATION_NOE 生存期<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE 核因子<|>RELATION_NOE -<|>RELATION_NOE κ<|>RELATION_NOE B<|>RELATION_NOE (<|>RELATION_NOE NF-<|>RELATION_NOE κ<|>RELATION_NOE B<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE IKB<|>RELATION_NOE α<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE Sorafenib<|>RELATION_NOE 治疗组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE Sorafenib<|>RELATION_NOE +<|>RELATION_NOE Aspirin<|>RELATION_NOE 合用<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 抑制<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 延长<|>RELATION_NOE 荷<|>RELATION_NOE 瘤鼠<|>RELATION_NOE 生存期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 促进<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 与<|>RELATION_NOE Sorafenib<|>RELATION_NOE 治疗组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE Sorafenib<|>RELATION_NOE +<|>RELATION_NOE Aspirin<|>RELATION_NOE 合用<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 抑制<|>RELATION_S 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 延长<|>RELATION_NOE 荷<|>RELATION_NOE 瘤鼠<|>RELATION_NOE 生存期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 促进<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
KB<|>RELATION_NOE 活化<|>RELATION_NOE ,<|>RELATION_NOE 进一步<|>RELATION_NOE 增强<|>RELATION_S Sorafenib<|>RELATION_NOE 对<|>RELATION_NOE 肝癌<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 促进<|>RELATION_NOE 作用<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 肝癌<|>RELATION_NOE 生长<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 延长<|>RELATION_NOE 荷<|>RELATION_NOE 瘤鼠<|>RELATION_NOE 生存期<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE FGF-2<|>RELATION_NOE 和<|>RELATION_NOE hTERT<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 成纤维细胞<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE FGF-2<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 人<|>RELATION_NOE 端粒<|>RELATION_NOE 酶<|>RELATION_NOE 逆转录酶<|>RELATION_NOE (<|>RELATION_NOE hTERT<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 初步<|>RELATION_NOE 评价<|>RELATION_NOE 两者<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 及其<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 两者<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 分析<|>RELATION_S 90<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 肺癌<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE FGF-2<|>RELATION_NOE 和<|>RELATION_NOE hTERT<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE
NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE FGF-2<|>RELATION_NOE 和<|>RELATION_NOE hTERT<|>RELATION_NOE 阳性率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 66.7%<|>RELATION_NOE 和<|>RELATION_NOE 75.6%<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 非<|>RELATION_NOE 肺癌<|>RELATION_NOE 肺组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE FGF-2<|>RELATION_NOE 和<|>RELATION_NOE hTERT<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
FGF-2<|>RELATION_NOE 与<|>RELATION_NOE hTERT<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE NSCLC<|>RELATION_NOE 预后<|>RELATION_NOE 等<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 参考<|>RELATION_I 指标<|>RELATION_E 。<|>RELATION_NOE
组<|>RELATION_NOE 蛋白<|>RELATION_NOE 去<|>RELATION_NOE 乙酰化<|>RELATION_NOE 酶<|>RELATION_NOE 6<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S HDAC6<|>RELATION_NOE 在<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HDAC6<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_B 相关性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HDAC6<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 起<|>RELATION_NOE 一定<|>RELATION_B 的<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE
对<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 出现<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 问题<|>RELATION_NOE 及<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 副作用<|>RELATION_NOE 等<|>RELATION_NOE 进行<|>RELATION_NOE 有<|>RELATION_NOE 针对性<|>RELATION_B 的<|>RELATION_I 护理<|>RELATION_E 。<|>RELATION_NOE
恰当<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 能够<|>RELATION_NOE 减轻<|>RELATION_S 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病痛<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE 恰当<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 能够<|>RELATION_NOE 减轻<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病痛<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE
探讨<|>RELATION_S CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 近<|>RELATION_NOE 距离<|>RELATION_NOE 内<|>RELATION_NOE 照射<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 切除术<|>RELATION_NOE 后<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
辛伐<|>RELATION_NOE 他<|>RELATION_NOE 汀<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺泡<|>RELATION_NOE Ⅱ<|>RELATION_NOE 型<|>RELATION_NOE 细胞<|>RELATION_NOE 缺氧<|>RELATION_NOE 复氧<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 逆转<|>RELATION_S
探讨<|>RELATION_NOE 辛伐<|>RELATION_NOE 他<|>RELATION_NOE 汀<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 对<|>RELATION_NOE 肺泡<|>RELATION_NOE Ⅱ<|>RELATION_NOE 型<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE AT<|>RELATION_NOE Ⅱ<|>RELATION_NOE )<|>RELATION_NOE 缺氧<|>RELATION_NOE 复氧<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 保护<|>RELATION_B 作用<|>RELATION_E 及其<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 人<|>RELATION_NOE AT<|>RELATION_NOE Ⅱ<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞株<|>RELATION_NOE 为<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 化学性<|>RELATION_NOE 缺氧<|>RELATION_NOE 模拟剂<|>RELATION_NOE CoCl2<|>RELATION_NOE 建立<|>RELATION_S 体外<|>RELATION_NOE 缺氧<|>RELATION_NOE 复氧<|>RELATION_NOE 损伤<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 剂量<|>RELATION_NOE 辛伐<|>RELATION_NOE 他<|>RELATION_NOE 汀<|>RELATION_NOE 可<|>RELATION_NOE 逆转<|>RELATION_S AT<|>RELATION_NOE Ⅱ<|>RELATION_NOE 细胞<|>RELATION_NOE 缺氧<|>RELATION_NOE 复氧<|>RELATION_NOE 损伤<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 保护<|>RELATION_NOE 机制<|>RELATION_NOE 与<|>RELATION_NOE 抑制<|>RELATION_NOE 甲羟戊酸<|>RELATION_NOE 代谢<|>RELATION_NOE 通路<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE
总结<|>RELATION_NOE 采用<|>RELATION_NOE 单<|>RELATION_NOE 孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE single<|>RELATION_NOE port<|>RELATION_NOE VATS<|>RELATION_NOE ,<|>RELATION_NOE SPVATs<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 经验<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S 价值<|>RELATION_NOE 。<|>RELATION_NOE
行肺<|>RELATION_NOE 大疱<|>RELATION_NOE 切除<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 脓性<|>RELATION_NOE 纤维板<|>RELATION_NOE 剥<|>RELATION_NOE 脱<|>RELATION_NOE 胸腔<|>RELATION_NOE 冲洗<|>RELATION_NOE 引流术<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 壁层<|>RELATION_NOE 胸膜<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺楔形<|>RELATION_NOE 切除术<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 手术时间<|>RELATION_NOE (<|>RELATION_NOE 22.0<|>RELATION_NOE ±<|>RELATION_NOE 9.5<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 出血<|>RELATION_NOE (<|>RELATION_NOE 14.5<|>RELATION_NOE ±<|>RELATION_NOE 8.8<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 插管<|>RELATION_NOE (<|>RELATION_NOE 3.1<|>RELATION_NOE 土0.6<|>RELATION_NOE )<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 住院<|>RELATION_NOE (<|>RELATION_NOE 6.8<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE )<|>RELATION_NOE 天<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 部分<|>RELATION_NOE 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_S 满意<|>RELATION_NOE ,<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 创伤<|>RELATION_NOE 更<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 针吸活<|>RELATION_NOE 检术<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
EBUS-TBNA<|>RELATION_NOE 作为<|>RELATION_NOE 肺门<|>RELATION_NOE 及<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 活检<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新<|>RELATION_NOE 手段<|>RELATION_NOE ,<|>RELATION_NOE 创伤<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 准确性<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 安全<|>RELATION_I 、<|>RELATION_I 可行<|>RELATION_E 。<|>RELATION_NOE
支气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 针吸活<|>RELATION_NOE 检术<|>RELATION_NOE 诊断<|>RELATION_S 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE
探讨<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 在<|>RELATION_NOE 诊断<|>RELATION_NOE 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
其中<|>RELATION_NOE 影像学<|>RELATION_NOE 可疑<|>RELATION_NOE 或<|>RELATION_NOE 已<|>RELATION_NOE 明确<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 纵隔<|>RELATION_NOE 或<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 208<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
不<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 肺内<|>RELATION_NOE 占位<|>RELATION_NOE 的<|>RELATION_NOE 纵隔<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 或<|>RELATION_NOE 纵隔<|>RELATION_NOE 占<|>RELATION_NOE 位<|>RELATION_NOE 94<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
本组<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 诊断<|>RELATION_NOE 纵隔<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 肺门良<|>RELATION_NOE 、<|>RELATION_NOE 恶性病<|>RELATION_NOE 变<|>RELATION_NOE 总<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 95.6%<|>RELATION_NOE (<|>RELATION_NOE 238<|>RELATION_NOE /<|>RELATION_NOE 249<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 94<|>RELATION_NOE /<|>RELATION_NOE 94<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 238<|>RELATION_NOE /<|>RELATION_NOE 238<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 89.5%<|>RELATION_NOE (<|>RELATION_NOE 94<|>RELATION_NOE /<|>RELATION_NOE 105<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 96.8%<|>RELATION_NOE (<|>RELATION_NOE 332<|>RELATION_NOE /<|>RELATION_NOE 343<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
208<|>RELATION_NOE 例<|>RELATION_NOE 明确<|>RELATION_NOE 或<|>RELATION_NOE 可疑<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 151<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 诊断<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 为<|>RELATION_NOE 结核<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 为<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 结节病<|>RELATION_NOE ;<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 对<|>RELATION_NOE 本组<|>RELATION_NOE 188<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 96.8%<|>RELATION_NOE (<|>RELATION_NOE 151<|>RELATION_NOE /<|>RELATION_NOE 156<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 10<|>RELATION_NOE 0.0%<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 97.3%<|>RELATION_NOE (<|>RELATION_NOE 183<|>RELATION_NOE /<|>RELATION_NOE 188<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 100.0%<|>RELATION_NOE (<|>RELATION_NOE 151<|>RELATION_NOE /<|>RELATION_NOE 151<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 预测<|>RELATION_NOE 值<|>RELATION_NOE 86.5%<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE /<|>RELATION_NOE 37<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
94<|>RELATION_NOE 例<|>RELATION_NOE 纵隔<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 或<|>RELATION_NOE 纵隔<|>RELATION_NOE 占<|>RELATION_NOE 位<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE ,<|>RELATION_NOE 73<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 淋巴结<|>RELATION_NOE 反应性<|>RELATION_NOE 增生<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 有<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 进一步<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 为<|>RELATION_NOE 假<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 诊断<|>RELATION_NOE 本组<|>RELATION_NOE 纵隔<|>RELATION_NOE 病<|>RELATION_NOE 变良<|>RELATION_NOE 、<|>RELATION_NOE 恶性<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 88.0%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 73<|>RELATION_NOE /<|>RELATION_NOE 73<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 95.9%<|>RELATION_NOE (<|>RELATION_NOE 70<|>RELATION_NOE /<|>RELATION_NOE 73<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 准确性<|>RELATION_NOE 97.9%<|>RELATION_NOE (<|>RELATION_NOE 92<|>RELATION_NOE /<|>RELATION_NOE 94<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TBNA<|>RELATION_NOE 术<|>RELATION_NOE 对于<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 可靠<|>RELATION_S ,<|>RELATION_NOE 诊断<|>RELATION_NOE 邻近<|>RELATION_NOE 大气道<|>RELATION_NOE 的<|>RELATION_NOE 肺门<|>RELATION_NOE 或<|>RELATION_NOE 纵隔<|>RELATION_NOE 占位<|>RELATION_NOE 等<|>RELATION_NOE 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 。<|>RELATION_NOE TBNA<|>RELATION_NOE 术<|>RELATION_NOE 对于<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 可靠<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 邻近<|>RELATION_NOE 大气道<|>RELATION_NOE 的<|>RELATION_NOE 肺门<|>RELATION_NOE 或<|>RELATION_NOE 纵隔<|>RELATION_NOE 占位<|>RELATION_NOE 等<|>RELATION_NOE 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 安全<|>RELATION_B 、<|>RELATION_I 有效<|>RELATION_E 。<|>RELATION_NOE
早期<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 荧光<|>RELATION_NOE 电子<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 及其<|>RELATION_NOE 价值<|>RELATION_B 探讨<|>RELATION_E
观察<|>RELATION_NOE 、<|>RELATION_NOE 分析<|>RELATION_NOE 自发性<|>RELATION_NOE 荧光<|>RELATION_NOE 电子<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE AFB<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S 。<|>RELATION_NOE
选取<|>RELATION_NOE 采用<|>RELATION_NOE Olympus<|>RELATION_NOE BF-F260<|>RELATION_NOE 型<|>RELATION_NOE 荧光<|>RELATION_NOE 电子<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 96<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞状<|>RELATION_NOE 上皮<|>RELATION_NOE 异型<|>RELATION_NOE 化生<|>RELATION_NOE 7例<|>RELATION_NOE 。<|>RELATION_NOE
人造血管<|>RELATION_NOE 肺动脉<|>RELATION_NOE 重建<|>RELATION_NOE 术<|>RELATION_NOE 治疗<|>RELATION_S 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE
探讨<|>RELATION_NOE 人造血管<|>RELATION_NOE 在<|>RELATION_NOE 肺动脉<|>RELATION_NOE 重建<|>RELATION_NOE 术<|>RELATION_NOE 对<|>RELATION_NOE 中心型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_S 。<|>RELATION_NOE
用<|>RELATION_NOE 人造血管<|>RELATION_NOE 肺动脉<|>RELATION_NOE 成形术<|>RELATION_NOE 或<|>RELATION_NOE 同时<|>RELATION_NOE 行<|>RELATION_NOE 支气管<|>RELATION_NOE 成形术<|>RELATION_NOE 治疗<|>RELATION_NOE 中心型<|>RELATION_NOE 肺癌<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 鳞癌<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 9例<|>RELATION_NOE ;<|>RELATION_NOE
本组<|>RELATION_NOE 无<|>RELATION_NOE 手术<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 1例<|>RELATION_NOE 发生<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜瘘<|>RELATION_NOE ,<|>RELATION_NOE 余<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 无<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 1年<|>RELATION_NOE 及<|>RELATION_NOE 3年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 69%<|>RELATION_NOE 和<|>RELATION_NOE 36%<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 定期<|>RELATION_NOE 彩超<|>RELATION_NOE 检查<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_B 发现<|>RELATION_E 重建<|>RELATION_NOE 血管<|>RELATION_NOE 内<|>RELATION_NOE 有<|>RELATION_NOE 血栓形成<|>RELATION_NOE 及<|>RELATION_NOE 血流<|>RELATION_NOE 受阻<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
人造血管<|>RELATION_NOE 肺动脉<|>RELATION_NOE 重建<|>RELATION_NOE 术<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 最<|>RELATION_B 大<|>RELATION_I 限度<|>RELATION_I 地<|>RELATION_I 切除<|>RELATION_E 了<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 限度<|>RELATION_NOE 地<|>RELATION_NOE 保留<|>RELATION_NOE 了<|>RELATION_NOE 肺功能<|>RELATION_NOE ,<|>RELATION_NOE 重建<|>RELATION_NOE 肺动脉<|>RELATION_NOE 能<|>RELATION_NOE 长期<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 维持<|>RELATION_NOE 肺循环<|>RELATION_NOE 功能<|>RELATION_NOE 。<|>RELATION_NOE
研究<|>RELATION_NOE Notch-1<|>RELATION_NOE 抗体<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_B 的<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE SP<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_S 43<|>RELATION_NOE 例<|>RELATION_NOE SCLC<|>RELATION_NOE 及<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 癌组织<|>RELATION_NOE Notch-1<|>RELATION_NOE 抗体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE Notch-1<|>RELATION_NOE 抗体<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 与<|>RELATION_NOE SCLC<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
Notch-1<|>RELATION_NOE 抗体<|>RELATION_NOE 在<|>RELATION_NOE SCLC<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE 分别<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 5.42<|>RELATION_NOE 和<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ,<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 4.88<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
Cox<|>RELATION_NOE 比例<|>RELATION_NOE 风险<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE Notch-1<|>RELATION_NOE 抗体<|>RELATION_NOE 阳性<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 死亡<|>RELATION_NOE 风险<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE 气道<|>RELATION_NOE 支架<|>RELATION_NOE 植入术<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE 睡眠<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 肿瘤<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE 气道<|>RELATION_NOE 支架<|>RELATION_NOE 植入术<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE 睡眠<|>RELATION_NOE 状况<|>RELATION_NOE 明显<|>RELATION_B 差于<|>RELATION_E 正常<|>RELATION_NOE 人群<|>RELATION_NOE ,<|>RELATION_NOE 多数<|>RELATION_NOE 患者<|>RELATION_NOE 存在<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 地<|>RELATION_NOE 睡眠障碍<|>RELATION_NOE ,<|>RELATION_NOE VSQI<|>RELATION_NOE ><|>RELATION_NOE 8分者<|>RELATION_NOE 占<|>RELATION_NOE 45.1<|>RELATION_NOE 1%<|>RELATION_NOE ;<|>RELATION_NOE
经<|>RELATION_NOE 气道<|>RELATION_NOE 支架<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 得到<|>RELATION_NOE 改善<|>RELATION_NOE ,<|>RELATION_NOE PSQI<|>RELATION_NOE ><|>RELATION_NOE 8分者<|>RELATION_NOE 占<|>RELATION_NOE 17.3<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 在<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 入睡<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 睡眠<|>RELATION_NOE 效率<|>RELATION_NOE 等<|>RELATION_NOE 方面<|>RELATION_NOE 改善<|>RELATION_B 明显<|>RELATION_E 。<|>RELATION_NOE
气道<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 支架<|>RELATION_NOE 可以<|>RELATION_NOE 明显<|>RELATION_B 地<|>RELATION_I 改善<|>RELATION_E 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 的<|>RELATION_NOE 恶性<|>RELATION_NOE 中央<|>RELATION_NOE 气道<|>RELATION_NOE 狭窄<|>RELATION_NOE 患者<|>RELATION_NOE 睡眠<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 也<|>RELATION_NOE 提高<|>RELATION_NOE 了<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
痰细胞<|>RELATION_NOE 学液<|>RELATION_NOE 基薄层<|>RELATION_NOE 检测<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE Meta<|>RELATION_B 分析<|>RELATION_E
应用<|>RELATION_NOE Meta<|>RELATION_NOE 分析法<|>RELATION_NOE 综合<|>RELATION_B 评价<|>RELATION_E 痰细胞<|>RELATION_NOE 学液<|>RELATION_NOE 基薄层<|>RELATION_NOE 检测<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
检索<|>RELATION_NOE PubMed<|>RELATION_NOE 、<|>RELATION_NOE Cochrane<|>RELATION_NOE 、<|>RELATION_NOE ISIWebofKnowledge<|>RELATION_NOE 等<|>RELATION_NOE 数据库<|>RELATION_NOE ,<|>RELATION_NOE 检索<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 1990年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 2月<|>RELATION_NOE 发表<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 文献<|>RELATION_NOE ,<|>RELATION_NOE 收集<|>RELATION_NOE 关于<|>RELATION_NOE 痰细胞<|>RELATION_NOE 学液<|>RELATION_NOE 基薄层<|>RELATION_NOE 检测<|>RELATION_NOE 技术<|>RELATION_NOE 诊断<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 研究<|>RELATION_NOE 文献<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_S 信息<|>RELATION_NOE 统计<|>RELATION_NOE 、<|>RELATION_NOE 科学性<|>RELATION_NOE 评估<|>RELATION_NOE 及<|>RELATION_NOE 质量<|>RELATION_NOE 分级<|>RELATION_NOE ;<|>RELATION_NOE
通过<|>RELATION_NOE 汇总<|>RELATION_NOE 敏感度<|>RELATION_NOE 、<|>RELATION_NOE 特异度<|>RELATION_NOE 、<|>RELATION_NOE 汇总<|>RELATION_NOE 似然<|>RELATION_NOE 比<|>RELATION_NOE 及<|>RELATION_NOE 汇总<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE SROC<|>RELATION_NOE 曲线<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 统计<|>RELATION_NOE 指标<|>RELATION_NOE 综合<|>RELATION_B 评价<|>RELATION_E 痰细胞<|>RELATION_NOE 学液<|>RELATION_NOE 基薄层<|>RELATION_NOE 检测<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
共<|>RELATION_NOE 纳入<|>RELATION_NOE 8<|>RELATION_NOE 篇<|>RELATION_NOE 文献<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 英文<|>RELATION_NOE 2篇<|>RELATION_NOE ,<|>RELATION_NOE 中文<|>RELATION_NOE 6篇<|>RELATION_NOE ,<|>RELATION_NOE 样本量<|>RELATION_NOE 为<|>RELATION_NOE 25<|>RELATION_NOE 84<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 经<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 确诊<|>RELATION_NOE 或<|>RELATION_NOE 明确<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 共<|>RELATION_NOE 17<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 865<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 肺部<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
汇总<|>RELATION_NOE 相关<|>RELATION_NOE 研究<|>RELATION_NOE 结果<|>RELATION_NOE 表明<|>RELATION_NOE :<|>RELATION_NOE 痰细胞<|>RELATION_NOE 学液<|>RELATION_NOE 基薄层<|>RELATION_NOE 检测<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 特异度<|>RELATION_NOE 达到<|>RELATION_NOE 0.99<|>RELATION_NOE －1.00<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 灵敏度<|>RELATION_NOE 仅<|>RELATION_NOE 为<|>RELATION_NOE 0.44<|>RELATION_NOE ,<|>RELATION_NOE 尚<|>RELATION_NOE 不<|>RELATION_B 适用<|>RELATION_I 于<|>RELATION_E 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 筛查<|>RELATION_NOE 。<|>RELATION_NOE
良性<|>RELATION_NOE 病变<|>RELATION_NOE 中<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 标准<|>RELATION_NOE 摄取值<|>RELATION_NOE (<|>RELATION_NOE SUVmax<|>RELATION_NOE )<|>RELATION_NOE ><|>RELATION_NOE 2.5者<|>RELATION_NOE 占<|>RELATION_NOE 24.3%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 包括<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 增大<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 肺内<|>RELATION_NOE 结节<|>RELATION_NOE (<|>RELATION_NOE ><|>RELATION_NOE 10mm<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺部炎症<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 陈旧性<|>RELATION_NOE 肺结核<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜<|>RELATION_NOE 增生<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 显像<|>RELATION_NOE 诊断<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 灵敏性<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 和<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 92.3%<|>RELATION_NOE 、<|>RELATION_NOE 25.0%<|>RELATION_NOE 、<|>RELATION_NOE 80.8%<|>RELATION_NOE 、<|>RELATION_NOE 85.7%<|>RELATION_NOE 和<|>RELATION_NOE 40.0%<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 针吸活<|>RELATION_NOE 检术<|>RELATION_NOE 在<|>RELATION_NOE 纵隔疾病<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
2009年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 对<|>RELATION_NOE 326<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 发现<|>RELATION_NOE 有<|>RELATION_NOE 纵隔<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 完成<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 操作<|>RELATION_NOE ,<|>RELATION_NOE 直接<|>RELATION_NOE 涂片<|>RELATION_NOE 送检<|>RELATION_NOE 。<|>RELATION_NOE
326<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 192<|>RELATION_NOE 例<|>RELATION_NOE 常规<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 检查<|>RELATION_NOE 无<|>RELATION_NOE 黏膜<|>RELATION_NOE 及<|>RELATION_NOE 管腔<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE 局部<|>RELATION_NOE 黏膜<|>RELATION_NOE 增<|>RELATION_NOE 厚<|>RELATION_NOE 肿胀<|>RELATION_NOE 或<|>RELATION_NOE 有<|>RELATION_NOE 小结节样<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 管腔<|>RELATION_NOE 呈<|>RELATION_NOE 轻度<|>RELATION_NOE 外压型<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE 气管<|>RELATION_NOE 局部<|>RELATION_NOE 软骨<|>RELATION_NOE 环<|>RELATION_NOE 消失<|>RELATION_NOE 。<|>RELATION_NOE
326<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 穿刺<|>RELATION_NOE 486<|>RELATION_NOE 个<|>RELATION_NOE 位点<|>RELATION_NOE ,<|>RELATION_NOE 获得<|>RELATION_NOE 阳性<|>RELATION_NOE 诊断<|>RELATION_NOE 304<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 93.2<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 304<|>RELATION_NOE /<|>RELATION_NOE 326<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 260<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 79.7<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 260<|>RELATION_NOE /<|>RELATION_NOE 326<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 81<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 78<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 肺大<|>RELATION_NOE 细胞<|>RELATION_NOE 未分化癌<|>RELATION_NOE 8例<|>RELATION_NOE 、<|>RELATION_NOE 肺小<|>RELATION_NOE 细胞<|>RELATION_NOE 未分化癌<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 7例<|>RELATION_NOE 、<|>RELATION_NOE 难以<|>RELATION_NOE 分类<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
良性<|>RELATION_NOE 病变<|>RELATION_NOE 44<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 结节病<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 结核<|>RELATION_NOE 病<|>RELATION_NOE 7例<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 淋巴结炎<|>RELATION_NOE 5例<|>RELATION_NOE 。<|>RELATION_NOE
486<|>RELATION_NOE 个<|>RELATION_NOE 位点<|>RELATION_NOE 共<|>RELATION_NOE 穿刺<|>RELATION_NOE 57<|>RELATION_NOE 6针<|>RELATION_NOE ,<|>RELATION_NOE 48<|>RELATION_NOE 2针<|>RELATION_NOE (<|>RELATION_NOE 83.6%<|>RELATION_NOE ,<|>RELATION_NOE 482<|>RELATION_NOE /<|>RELATION_NOE 576<|>RELATION_NOE )<|>RELATION_NOE 经<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE (<|>RELATION_NOE transbronehialneedleaspiration<|>RELATION_NOE ,<|>RELATION_NOE TBNA<|>RELATION_NOE )<|>RELATION_NOE 涂片<|>RELATION_NOE 获得<|>RELATION_NOE 阳性<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 421<|>RELATION_NOE 针<|>RELATION_NOE (<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 13<|>RELATION_NOE 7针<|>RELATION_NOE 、<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 12<|>RELATION_NOE 4针<|>RELATION_NOE 、<|>RELATION_NOE 肺大<|>RELATION_NOE 细胞<|>RELATION_NOE 未分化癌<|>RELATION_NOE 19<|>RELATION_NOE 针<|>RELATION_NOE 、<|>RELATION_NOE 肺小<|>RELATION_NOE 细胞<|>RELATION_NOE 未分化癌<|>RELATION_NOE 117<|>RELATION_NOE 针<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 11<|>RELATION_NOE 针<|>RELATION_NOE 、<|>RELATION_NOE 难以<|>RELATION_NOE 分类<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 13<|>RELATION_NOE 针<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 61<|>RELATION_NOE 针<|>RELATION_NOE (<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 结节病<|>RELATION_NOE 43<|>RELATION_NOE 针<|>RELATION_NOE 、<|>RELATION_NOE 结核病<|>RELATION_NOE 11<|>RELATION_NOE 针<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 淋巴结炎<|>RELATION_NOE 7针<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
29<|>RELATION_NOE 针涂片<|>RELATION_NOE 可见<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE 纤毛<|>RELATION_NOE 柱状<|>RELATION_NOE 上皮细胞<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 穿透<|>RELATION_NOE 气管<|>RELATION_NOE 壁<|>RELATION_NOE ,<|>RELATION_NOE 穿刺<|>RELATION_NOE 失败<|>RELATION_NOE ;<|>RELATION_NOE
未<|>RELATION_NOE 出现<|>RELATION_NOE 纵隔气肿<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 感染<|>RELATION_NOE 等<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 创伤<|>RELATION_NOE 性小<|>RELATION_NOE 、<|>RELATION_NOE 安全性<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 诊断<|>RELATION_NOE 纵隔<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_B 方法<|>RELATION_E 。<|>RELATION_NOE
人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 原代<|>RELATION_NOE 培养<|>RELATION_NOE 及<|>RELATION_NOE 个体化<|>RELATION_NOE 药敏<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_S 人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 原代<|>RELATION_NOE 培养<|>RELATION_NOE 及<|>RELATION_NOE 个体化<|>RELATION_NOE 药敏<|>RELATION_NOE 实验<|>RELATION_B 研究<|>RELATION_E
探讨<|>RELATION_NOE MTr<|>RELATION_NOE 法<|>RELATION_NOE 在<|>RELATION_NOE 原<|>RELATION_NOE 代<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 药物<|>RELATION_NOE 敏感性<|>RELATION_NOE 试验<|>RELATION_NOE 研究<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E 及<|>RELATION_NOE NSCLC<|>RELATION_NOE 对<|>RELATION_NOE 5种<|>RELATION_NOE (<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 、<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 、<|>RELATION_NOE 长春新碱<|>RELATION_NOE 、<|>RELATION_NOE 吉西他滨<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 西他赛<|>RELATION_NOE )<|>RELATION_NOE 临床<|>RELATION_NOE 常用<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
希望<|>RELATION_NOE 能<|>RELATION_NOE 通过<|>RELATION_NOE 本<|>RELATION_NOE 课题<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 个体<|>RELATION_NOE 化化<|>RELATION_NOE 疗<|>RELATION_NOE 敏感<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE 提供<|>RELATION_NOE 参考<|>RELATION_NOE 。<|>RELATION_NOE
30<|>RELATION_NOE 例<|>RELATION_NOE 病例<|>RELATION_NOE 均<|>RELATION_NOE 取白<|>RELATION_NOE 手术<|>RELATION_NOE 新鲜<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 采取<|>RELATION_NOE 体外<|>RELATION_NOE 原代<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 药敏<|>RELATION_NOE 试验<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 5种<|>RELATION_NOE (<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 、<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 、<|>RELATION_NOE 长春新碱<|>RELATION_NOE 、<|>RELATION_NOE 吉西他滨<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE )<|>RELATION_NOE 临床<|>RELATION_NOE 常用<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE ,<|>RELATION_NOE 选取<|>RELATION_NOE 临床<|>RELATION_NOE 最佳<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
本<|>RELATION_NOE 课题<|>RELATION_NOE 之<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 原代<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 可<|>RELATION_NOE 获得<|>RELATION_NOE 药敏<|>RELATION_NOE 实验<|>RELATION_NOE 所<|>RELATION_NOE 需<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
MTT<|>RELATION_NOE 法<|>RELATION_NOE 在<|>RELATION_NOE 原代<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 药物<|>RELATION_NOE 敏感性<|>RELATION_NOE 试验<|>RELATION_NOE 研究<|>RELATION_NOE 中<|>RELATION_NOE 具有<|>RELATION_S 灵敏度<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 重复性<|>RELATION_NOE 好<|>RELATION_NOE 、<|>RELATION_NOE 操作<|>RELATION_NOE 简便<|>RELATION_NOE 、<|>RELATION_NOE 经济<|>RELATION_NOE 、<|>RELATION_NOE 快速<|>RELATION_NOE 、<|>RELATION_NOE 易<|>RELATION_NOE 自动化<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 放射性<|>RELATION_NOE 污染<|>RELATION_NOE 等<|>RELATION_NOE 优点<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 联合<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
化疗<|>RELATION_NOE 方案<|>RELATION_NOE :<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他赛<|>RELATION_NOE 60mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 30mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2第<|>RELATION_NOE 1－3<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 3－<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 血液学<|>RELATION_NOE 及<|>RELATION_NOE 非血液<|>RELATION_NOE 学<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 主要<|>RELATION_B 有<|>RELATION_E 中性<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板减少<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 乏力<|>RELATION_NOE 、<|>RELATION_NOE 心律失常<|>RELATION_NOE 、<|>RELATION_NOE 过敏<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 级<|>RELATION_NOE 以上<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 试验组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ;<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 和<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 15.8%<|>RELATION_NOE 和<|>RELATION_NOE 10.0%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 联合<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 有所<|>RELATION_NOE 提高<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 易于<|>RELATION_NOE 接受<|>RELATION_NOE 。<|>RELATION_NOE
复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 实体瘤<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 荟萃<|>RELATION_NOE 分析<|>RELATION_NOE
共<|>RELATION_NOE 纳入<|>RELATION_NOE 符合<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE 33<|>RELATION_NOE 项<|>RELATION_NOE 涉及<|>RELATION_NOE 28<|>RELATION_NOE 97<|>RELATION_NOE 例<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 大肠癌<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 胃癌<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 亚组<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 荟萃<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 结果<|>RELATION_NOE 异质性<|>RELATION_NOE 检验<|>RELATION_NOE 结果<|>RELATION_NOE 良好<|>RELATION_NOE ,<|>RELATION_NOE 可用<|>RELATION_NOE 固定<|>RELATION_NOE 效应<|>RELATION_NOE 模型<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 大肠癌<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 与<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE [<|>RELATION_NOE OR<|>RELATION_NOE 值<|>RELATION_NOE 及<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 、<|>RELATION_NOE Z<|>RELATION_NOE 值<|>RELATION_NOE 和<|>RELATION_NOE JP<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.48<|>RELATION_NOE (<|>RELATION_NOE 1.59<|>RELATION_NOE —<|>RELATION_NOE 3.90<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Z<|>RELATION_NOE =<|>RELATION_NOE 3.94<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.0001<|>RELATION_NOE ;<|>RELATION_NOE
应用<|>RELATION_NOE BiPAP<|>RELATION_NOE 呼吸机<|>RELATION_NOE 长期<|>RELATION_B 进行<|>RELATION_E 有<|>RELATION_NOE 创<|>RELATION_NOE 通气<|>RELATION_NOE 的<|>RELATION_NOE 尝试<|>RELATION_NOE
报告<|>RELATION_NOE 2例<|>RELATION_NOE BiPAP<|>RELATION_NOE 无<|>RELATION_NOE 创<|>RELATION_NOE 呼吸机<|>RELATION_NOE 经<|>RELATION_NOE 平台<|>RELATION_NOE 呼气阀<|>RELATION_NOE 与<|>RELATION_NOE 气管<|>RELATION_NOE 切开<|>RELATION_NOE 导管<|>RELATION_NOE 相<|>RELATION_NOE 连接<|>RELATION_NOE 进行<|>RELATION_NOE 机械通气<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 应用<|>RELATION_NOE BiPAP<|>RELATION_NOE 呼吸机<|>RELATION_NOE 进行<|>RELATION_NOE 有<|>RELATION_NOE 创<|>RELATION_NOE 通气<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
回顾性研究<|>RELATION_NOE 2例<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 患者<|>RELATION_NOE 用<|>RELATION_NOE 无<|>RELATION_NOE 创<|>RELATION_NOE 呼吸机<|>RELATION_NOE 经<|>RELATION_NOE 平台<|>RELATION_NOE 呼气<|>RELATION_NOE 阀<|>RELATION_NOE 连接<|>RELATION_NOE 气管<|>RELATION_NOE 切开<|>RELATION_NOE 导管<|>RELATION_NOE 进行<|>RELATION_NOE 机械通气<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 复习<|>RELATION_NOE 相关<|>RELATION_NOE 文献<|>RELATION_NOE 。<|>RELATION_NOE
运动神经元<|>RELATION_NOE 病<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 气管<|>RELATION_NOE 切开<|>RELATION_NOE 导管<|>RELATION_NOE 使用<|>RELATION_NOE BiPAP<|>RELATION_NOE 无<|>RELATION_NOE 创<|>RELATION_NOE 呼吸机<|>RELATION_NOE 获得<|>RELATION_NOE 成功<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 失败<|>RELATION_NOE 。<|>RELATION_NOE
miR-21<|>RELATION_NOE 调控<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 研究<|>RELATION_NOE
研究<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE miR-21<|>RELATION_NOE 对<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 调控<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE 检测<|>RELATION_S miR-21<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 抑制<|>RELATION_S miR-21<|>RELATION_NOE 和<|>RELATION_NOE 程序性<|>RELATION_NOE 细胞死亡<|>RELATION_NOE 因子<|>RELATION_NOE 4<|>RELATION_NOE (<|>RELATION_NOE PDCD4<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 台<|>RELATION_NOE 盼<|>RELATION_NOE 蓝染色<|>RELATION_NOE 和<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE 采用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 抑制<|>RELATION_NOE miR-21<|>RELATION_NOE 和<|>RELATION_NOE 程序性<|>RELATION_NOE 细胞死亡<|>RELATION_NOE 因子4<|>RELATION_NOE (<|>RELATION_NOE PDCD4<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 台<|>RELATION_NOE 盼<|>RELATION_NOE 蓝染色<|>RELATION_NOE 和<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE miR-21<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 2.24<|>RELATION_NOE 倍<|>RELATION_NOE 和<|>RELATION_NOE 3.06<|>RELATION_NOE 倍<|>RELATION_NOE 。<|>RELATION_NOE
荧光素<|>RELATION_NOE 酶<|>RELATION_NOE 活性<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 共同<|>RELATION_NOE 转入<|>RELATION_NOE Wt3'UTR<|>RELATION_NOE 和<|>RELATION_NOE miR-21<|>RELATION_NOE 会<|>RELATION_NOE 显著<|>RELATION_B 抑制<|>RELATION_E A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 荧光素<|>RELATION_NOE 酶<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
抑制<|>RELATION_NOE miR-21<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 可以<|>RELATION_NOE 显著<|>RELATION_B 抑制<|>RELATION_E A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 使<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 由<|>RELATION_NOE 2.6%<|>RELATION_NOE 上升<|>RELATION_NOE 到<|>RELATION_NOE 10.9%<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 抑制<|>RELATION_NOE PDCD4<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可以<|>RELATION_NOE 在<|>RELATION_NOE 很<|>RELATION_NOE 大<|>RELATION_NOE 程度<|>RELATION_NOE 上<|>RELATION_NOE 消除<|>RELATION_NOE miR-21<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 障碍<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE 抑癌<|>RELATION_NOE 基因<|>RELATION_NOE PDCD4<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE miR-21<|>RELATION_NOE 介导<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 、<|>RELATION_NOE 抵抗<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 途径<|>RELATION_I 之一<|>RELATION_E 。<|>RELATION_NOE
中国<|>RELATION_NOE 人群<|>RELATION_NOE 细胞<|>RELATION_NOE 色素<|>RELATION_NOE P4501A1<|>RELATION_NOE 基因<|>RELATION_NOE MSP<|>RELATION_NOE Ⅰ位点<|>RELATION_NOE 联合<|>RELATION_NOE GSTM<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE 荟萃<|>RELATION_B 分析<|>RELATION_E
结果<|>RELATION_NOE :<|>RELATION_NOE 共<|>RELATION_NOE 纳入<|>RELATION_NOE 12<|>RELATION_NOE 篇<|>RELATION_NOE 文献<|>RELATION_NOE ,<|>RELATION_NOE 涉及<|>RELATION_NOE 13<|>RELATION_NOE 个<|>RELATION_NOE 人群<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE CYP1A1<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE w<|>RELATION_NOE /<|>RELATION_NOE w<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE GSTM<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 参照<|>RELATION_NOE ,<|>RELATION_NOE CYP1A1<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE w<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE GSTM<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CYP1A1<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE m<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE GSTM<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CYP1A1<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE wlw<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE GSTM<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE -<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CYP1A1<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE w<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE GSTM<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE -<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CYP1A1<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE m<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE GSTM<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE -<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_NOE 合并值<|>RELATION_NOE OR<|>RELATION_NOE 及<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 1.22<|>RELATION_NOE ,<|>RELATION_NOE 0.95<|>RELATION_NOE －1.57<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 1.24<|>RELATION_NOE ,<|>RELATION_NOE 0.88<|>RELATION_NOE －1.76<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 1.51<|>RELATION_NOE ,<|>RELATION_NOE 1.07<|>RELATION_NOE －2<|>RELATION_NOE .<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 1.82<|>RELATION_NOE ,<|>RELATION_NOE 1.30<|>RELATION_NOE －<|>RELATION_NOE 2.54<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 2.06<|>RELATION_NOE ,<|>RELATION_NOE 1.56<|>RELATION_NOE －2.72<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CYP1A1<|>RELATION_NOE 基因<|>RELATION_NOE 突变型<|>RELATION_NOE (<|>RELATION_NOE 杂合子<|>RELATION_NOE 和<|>RELATION_NOE 纯合子<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE GSTM<|>RELATION_NOE 基因缺失型<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 增加<|>RELATION_E 个体<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 风险<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 筛检<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 要<|>RELATION_NOE 重视<|>RELATION_NOE 对<|>RELATION_NOE 基因型<|>RELATION_NOE 的<|>RELATION_NOE 筛查<|>RELATION_NOE ,<|>RELATION_NOE 做<|>RELATION_NOE 好<|>RELATION_NOE 一级<|>RELATION_NOE 预防<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 体外<|>RELATION_NOE 药敏<|>RELATION_NOE 试验<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
收集<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 12月<|>RELATION_NOE 本院<|>RELATION_NOE 呼吸<|>RELATION_NOE 内科<|>RELATION_NOE 住院<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 试验组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
海南<|>RELATION_NOE 橡胶<|>RELATION_NOE 生产<|>RELATION_NOE 和<|>RELATION_NOE 初级<|>RELATION_NOE 加工<|>RELATION_NOE 工人<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病率<|>RELATION_B 调查<|>RELATION_E
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 海南省<|>RELATION_NOE 9<|>RELATION_NOE 个<|>RELATION_NOE 农场<|>RELATION_NOE 2005年<|>RELATION_NOE 1月<|>RELATION_NOE 113<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 10月<|>RELATION_NOE 3i<|>RELATION_NOE 日<|>RELATION_NOE 橡胶<|>RELATION_NOE 工人<|>RELATION_NOE 发生<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 调查<|>RELATION_NOE 。<|>RELATION_NOE
尼古丁<|>RELATION_NOE 乙酰胆碱受体<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 焦炉工<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 关联性<|>RELATION_S
[<|>RELATION_NOE 摘要<|>RELATION_NOE ]<|>RELATION_NOE 目的<|>RELATION_NOE 探讨<|>RELATION_NOE 尼古丁<|>RELATION_NOE 乙酰胆碱受体<|>RELATION_NOE 的<|>RELATION_NOE CHRNA3-CHRNB4<|>RELATION_NOE 一<|>RELATION_NOE CHRNA5<|>RELATION_NOE 基因簇<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 焦炉<|>RELATION_NOE TDNA<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 联系<|>RELATION_S 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 选择<|>RELATION_NOE 中国<|>RELATION_NOE 北方<|>RELATION_NOE 某<|>RELATION_NOE 焦化厂<|>RELATION_NOE 的<|>RELATION_NOE 309<|>RELATION_NOE 名<|>RELATION_NOE 工人<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE 苯并<|>RELATION_NOE (<|>RELATION_NOE a<|>RELATION_NOE )<|>RELATION_NOE 芘<|>RELATION_NOE 二<|>RELATION_NOE 氢二醇<|>RELATION_NOE 环氧化物<|>RELATION_NOE (<|>RELATION_NOE BPDE<|>RELATION_NOE )<|>RELATION_NOE 一<|>RELATION_NOE 自<|>RELATION_NOE 蛋白<|>RELATION_NOE 加合物<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE 分为<|>RELATION_NOE 高<|>RELATION_NOE 暴露组<|>RELATION_NOE (<|>RELATION_NOE 154<|>RELATION_NOE 人<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 低<|>RELATION_NOE 暴露组<|>RELATION_NOE (<|>RELATION_NOE 155<|>RELATION_NOE 人<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE 健康<|>RELATION_NOE 体检<|>RELATION_NOE 调查表<|>RELATION_NOE 收集<|>RELATION_NOE 个人<|>RELATION_NOE 健康<|>RELATION_NOE 信息<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 碱性<|>RELATION_NOE 单细胞<|>RELATION_NOE 凝胶<|>RELATION_NOE 电泳<|>RELATION_NOE 技术<|>RELATION_NOE 评价<|>RELATION_S 淋巴细胞<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE ,<|>RELATION_NOE 基质<|>RELATION_NOE 辅助<|>RELATION_NOE 激光解<|>RELATION_NOE 吸<|>RELATION_NOE 电离<|>RELATION_NOE 飞行<|>RELATION_NOE 时间<|>RELATION_NOE 质谱<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE Phasev2.1.1<|>RELATION_NOE 软件<|>RELATION_NOE 计算单<|>RELATION_NOE 体型<|>RELATION_NOE 对<|>RELATION_NOE 。<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 选择<|>RELATION_NOE 中国<|>RELATION_NOE 北方<|>RELATION_NOE 某<|>RELATION_NOE 焦化厂<|>RELATION_NOE 的<|>RELATION_NOE 309<|>RELATION_NOE 名<|>RELATION_NOE 工人<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE 苯并<|>RELATION_NOE (<|>RELATION_NOE a<|>RELATION_NOE )<|>RELATION_NOE 芘<|>RELATION_NOE 二<|>RELATION_NOE 氢二醇<|>RELATION_NOE 环氧化物<|>RELATION_NOE (<|>RELATION_NOE BPDE<|>RELATION_NOE )<|>RELATION_NOE 一<|>RELATION_NOE 自<|>RELATION_NOE 蛋白<|>RELATION_NOE 加合物<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE 分为<|>RELATION_NOE 高<|>RELATION_NOE 暴露组<|>RELATION_NOE (<|>RELATION_NOE 154<|>RELATION_NOE 人<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 低<|>RELATION_NOE 暴露组<|>RELATION_NOE (<|>RELATION_NOE 155<|>RELATION_NOE 人<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE 健康<|>RELATION_NOE 体检<|>RELATION_NOE 调查表<|>RELATION_NOE 收集<|>RELATION_NOE 个人<|>RELATION_NOE 健康<|>RELATION_NOE 信息<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 碱性<|>RELATION_NOE 单细胞<|>RELATION_NOE 凝胶<|>RELATION_NOE 电泳<|>RELATION_NOE 技术<|>RELATION_NOE 评价<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE ,<|>RELATION_NOE 基质<|>RELATION_NOE 辅助<|>RELATION_NOE 激光解<|>RELATION_NOE 吸<|>RELATION_NOE 电离<|>RELATION_NOE 飞行<|>RELATION_NOE 时间<|>RELATION_NOE 质谱<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 基因<|>RELATION_NOE 多态性<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE Phasev2.1.1<|>RELATION_NOE 软件<|>RELATION_NOE 计算单<|>RELATION_NOE 体型<|>RELATION_NOE 对<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 高<|>RELATION_NOE 暴露组<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE CHRNA3-CHRNB4-CHRNA5<|>RELATION_NOE 基因簇<|>RELATION_NOE 的<|>RELATION_NOE rs667282CC<|>RELATION_NOE 基因型<|>RELATION_NOE 携带者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 的<|>RELATION_NOE OTM<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE 1.64<|>RELATION_NOE ±<|>RELATION_NOE 0.17<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E CT<|>RELATION_NOE 和<|>RELATION_NOE CT<|>RELATION_NOE +<|>RELATION_NOE TT<|>RELATION_NOE 基因型<|>RELATION_NOE 携带者<|>RELATION_NOE (<|>RELATION_NOE 0.95<|>RELATION_NOE ±<|>RELATION_NOE 0.13<|>RELATION_NOE 和<|>RELATION_NOE 1.09<|>RELATION_NOE ±<|>RELATION_NOE 0.11<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
rsl2910984GG<|>RELATION_NOE 基因型<|>RELATION_NOE 携带者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 的<|>RELATION_NOE OTM<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE 1.60<|>RELATION_NOE ±<|>RELATION_NOE 0.17<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E AG<|>RELATION_NOE 和<|>RELATION_NOE AG<|>RELATION_NOE +<|>RELATION_NOE AA<|>RELATION_NOE 基因型<|>RELATION_NOE 携带者<|>RELATION_NOE (<|>RELATION_NOE 0.92<|>RELATION_NOE ±<|>RELATION_NOE 0.13<|>RELATION_NOE 和<|>RELATION_NOE 1.07<|>RELATION_NOE ±<|>RELATION_NOE 0.10<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE O<|>RELATION_NOE .<|>RELATION_NOE
在<|>RELATION_NOE 低<|>RELATION_NOE 暴露组<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 没有<|>RELATION_B 发现<|>RELATION_E 该<|>RELATION_NOE 基因簇<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关联<|>RELATION_NOE 。<|>RELATION_NOE
结论<|>RELATION_NOE :<|>RELATION_NOE CHRNA3<|>RELATION_NOE 一<|>RELATION_NOE CHRNB4<|>RELATION_NOE 一<|>RELATION_NOE CHRNA5<|>RELATION_NOE 基因簇<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 焦炉工<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 程度<|>RELATION_NOE 有<|>RELATION_B 关联<|>RELATION_E 。<|>RELATION_NOE
多<|>RELATION_NOE 层<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
通过<|>RELATION_NOE 多<|>RELATION_NOE 层<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 放疗<|>RELATION_NOE 中血流<|>RELATION_NOE 灌注<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 实用性<|>RELATION_S 。<|>RELATION_NOE
小细胞肺癌<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE MTT<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 12.9<|>RELATION_NOE 和<|>RELATION_NOE 6.5S<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.<|>RELATION_NOE 54<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 2004年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 2008年<|>RELATION_NOE 6月经<|>RELATION_NOE 病理<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 证实<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 进行<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 及<|>RELATION_NOE 以上<|>RELATION_NOE 周期<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 85<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_S 基于<|>RELATION_NOE CT<|>RELATION_NOE 定位<|>RELATION_NOE 的<|>RELATION_NOE 累及<|>RELATION_NOE 野放疗<|>RELATION_NOE ,<|>RELATION_NOE 6－<|>RELATION_NOE 10MVX<|>RELATION_NOE 射线<|>RELATION_NOE ,<|>RELATION_NOE 剂量<|>RELATION_NOE 为<|>RELATION_NOE 46<|>RELATION_NOE —<|>RELATION_NOE 66Gy<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 剂量<|>RELATION_NOE 50Gy<|>RELATION_NOE ,<|>RELATION_NOE 1次/<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 5<|>RELATION_NOE 次<|>RELATION_NOE /<|>RELATION_NOE 周<|>RELATION_NOE ,<|>RELATION_NOE 5<|>RELATION_NOE —<|>RELATION_NOE 7周<|>RELATION_NOE 。<|>RELATION_NOE
59<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 有<|>RELATION_NOE 治疗失败<|>RELATION_NOE 原因<|>RELATION_NOE 记录<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 9例<|>RELATION_NOE 占<|>RELATION_NOE 15.2%<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE +<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 占<|>RELATION_NOE 35.6%<|>RELATION_NOE ,<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE 占<|>RELATION_NOE 49.2%<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 适形<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_S 中<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 接受<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE 3D-CRT<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE ≥<|>RELATION_NOE 2级<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE (<|>RELATION_NOE ARE<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 因素<|>RELATION_E 。<|>RELATION_NOE
非<|>RELATION_NOE 同步<|>RELATION_NOE 化疗组<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_S ,<|>RELATION_NOE 食管%<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.1<|>RELATION_NOE 70<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE ≥<|>RELATION_NOE 2<|>RELATION_NOE 级<|>RELATION_NOE ARE<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 惟一<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 食管<|>RELATION_NOE V55<|>RELATION_NOE 的<|>RELATION_NOE ROC<|>RELATION_NOE 曲线下面积<|>RELATION_NOE 为<|>RELATION_NOE 0.8<|>RELATION_NOE 70<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 0.7<|>RELATION_NOE 82<|>RELATION_NOE －0.9<|>RELATION_NOE 57<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 界值<|>RELATION_NOE 为<|>RELATION_NOE 16.0<|>RELATION_NOE 。<|>RELATION_NOE
同步<|>RELATION_NOE 化疗组<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 食管<|>RELATION_NOE 匕<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.1<|>RELATION_NOE 25<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 同步<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 39.7<|>RELATION_NOE 40<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE ≥<|>RELATION_NOE 2<|>RELATION_NOE 级<|>RELATION_NOE ARE<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 食管<|>RELATION_NOE V35<|>RELATION_NOE 的<|>RELATION_NOE ROC<|>RELATION_NOE 曲线下面积<|>RELATION_NOE 为<|>RELATION_NOE 0.7<|>RELATION_NOE 82<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 0.6<|>RELATION_NOE 36<|>RELATION_NOE －0.9<|>RELATION_NOE 27<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 界值<|>RELATION_NOE 为<|>RELATION_NOE 23.75<|>RELATION_NOE 。<|>RELATION_NOE
榄香<|>RELATION_NOE 烯乳<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 机制<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
榄香<|>RELATION_NOE 烯乳<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_S 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 与<|>RELATION_NOE 下调<|>RELATION_NOE DNA-PKes<|>RELATION_NOE 表达<|>RELATION_NOE 抑制<|>RELATION_NOE DNA<|>RELATION_NOE 双链<|>RELATION_NOE 损伤<|>RELATION_NOE 修复<|>RELATION_NOE 和<|>RELATION_NOE 上调<|>RELATION_NOE p53<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_NOE Bel-2<|>RELATION_NOE 表达<|>RELATION_NOE 促进<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
自噬<|>RELATION_NOE 蛋白<|>RELATION_NOE Beclin1<|>RELATION_NOE 和<|>RELATION_NOE 凝血<|>RELATION_NOE 指标<|>RELATION_NOE 监测<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 进展<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
采用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 和<|>RELATION_NOE 全<|>RELATION_NOE 自动<|>RELATION_NOE 血<|>RELATION_NOE 凝仪<|>RELATION_NOE 以及<|>RELATION_NOE 全自动<|>RELATION_NOE 血细胞<|>RELATION_NOE 分析仪<|>RELATION_NOE 对<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE (<|>RELATION_NOE 正常<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_NOE 定量<|>RELATION_NOE Beclin1<|>RELATION_NOE 和<|>RELATION_NOE D-<|>RELATION_NOE 二聚体<|>RELATION_NOE 、<|>RELATION_NOE 血浆<|>RELATION_NOE Fib<|>RELATION_NOE 水平<|>RELATION_NOE 和<|>RELATION_NOE PLT<|>RELATION_NOE 检测<|>RELATION_S 。<|>RELATION_NOE
与<|>RELATION_NOE 正常<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 随着<|>RELATION_NOE 病理<|>RELATION_NOE 恶性<|>RELATION_NOE 度<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE PLT<|>RELATION_NOE 明显<|>RELATION_B 增高<|>RELATION_E ,<|>RELATION_NOE 同时<|>RELATION_NOE 血浆<|>RELATION_NOE Fib<|>RELATION_NOE 水平<|>RELATION_NOE 亦<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
外<|>RELATION_NOE 周血<|>RELATION_NOE PLT<|>RELATION_NOE 、<|>RELATION_NOE 血浆<|>RELATION_NOE Fib<|>RELATION_NOE 和<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 含量<|>RELATION_NOE 及<|>RELATION_NOE 自噬<|>RELATION_NOE 蛋白<|>RELATION_NOE Beclin1<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 恶性度<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_B 相关性<|>RELATION_E ,<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 参数<|>RELATION_NOE 检测<|>RELATION_NOE 综合<|>RELATION_NOE 分析<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 评估<|>RELATION_NOE 及<|>RELATION_NOE 判断<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
华蟾素<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE Meta<|>RELATION_B 分析<|>RELATION_E
评价<|>RELATION_S 华蟾素<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 中国<|>RELATION_NOE 生物<|>RELATION_NOE 医学<|>RELATION_NOE 文献<|>RELATION_NOE 数据库<|>RELATION_NOE 、<|>RELATION_NOE 中国<|>RELATION_NOE 全文<|>RELATION_NOE 期刊<|>RELATION_NOE 数据库<|>RELATION_NOE 、<|>RELATION_NOE 维普<|>RELATION_NOE 期刊<|>RELATION_NOE 数据库<|>RELATION_NOE 、<|>RELATION_NOE 万方<|>RELATION_NOE 数据库<|>RELATION_NOE 中<|>RELATION_NOE 搜索<|>RELATION_NOE 2000-2011<|>RELATION_NOE 年<|>RELATION_NOE 有关<|>RELATION_NOE 华蟾素<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 方案<|>RELATION_NOE (<|>RELATION_NOE 华蟾素<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE (<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_S NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 对照<|>RELATION_NOE 试验<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 符合<|>RELATION_NOE 纳入<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 文献<|>RELATION_NOE 用<|>RELATION_NOE RevMan5.0<|>RELATION_NOE 软件<|>RELATION_NOE 进行<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE p53<|>RELATION_NOE 腺病毒<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 研究<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE p53<|>RELATION_NOE 腺病毒<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 致<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 完全<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 联合组<|>RELATION_NOE (<|>RELATION_NOE 顺铂<|>RELATION_NOE +<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE p53<|>RELATION_NOE 腺病毒<|>RELATION_NOE 组<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 单药组<|>RELATION_NOE (<|>RELATION_NOE 顺铂组<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
2组<|>RELATION_NOE 分别<|>RELATION_NOE 经<|>RELATION_NOE 胸腔<|>RELATION_NOE 置管<|>RELATION_NOE 向<|>RELATION_NOE 胸腔<|>RELATION_NOE 灌注<|>RELATION_S 重组<|>RELATION_NOE 人<|>RELATION_NOE p53<|>RELATION_NOE 腺病毒<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE ,<|>RELATION_NOE 每周<|>RELATION_NOE 注药<|>RELATION_NOE 1次<|>RELATION_NOE ,<|>RELATION_NOE 4<|>RELATION_NOE 次<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 疗程<|>RELATION_NOE 。<|>RELATION_NOE
联合组<|>RELATION_NOE 发热<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 54.5%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 22<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 单药组<|>RELATION_NOE 为<|>RELATION_NOE 10.2%<|>RELATION_NOE (<|>RELATION_NOE 3/25<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 组间<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 发热<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 自限性<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 上<|>RELATION_NOE 呼吸道感染<|>RELATION_NOE 症状<|>RELATION_NOE 和<|>RELATION_NOE 局部<|>RELATION_NOE 体征<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE p53<|>RELATION_NOE 腺病毒<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 疗效<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 地<|>RELATION_NOE 控制<|>RELATION_NOE 胸腔积液<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 改善<|>RELATION_E 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 胸部<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
探讨<|>RELATION_NOE 检测<|>RELATION_S 胸部<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验法<|>RELATION_NOE 检测<|>RELATION_S 45<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 食管癌<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 志愿者<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 12.50%<|>RELATION_NOE (<|>RELATION_NOE 4/32<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌组<|>RELATION_NOE 为<|>RELATION_NOE 60.00%<|>RELATION_NOE (<|>RELATION_NOE 27N5<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 食管<|>RELATION_NOE 癌组<|>RELATION_NOE 为<|>RELATION_NOE 53.3<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 食管癌<|>RELATION_NOE 组<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 在<|>RELATION_NOE 淋巴结<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 不同<|>RELATION_NOE TNM<|>RELATION_NOE 分<|>RELATION_NOE 期间<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 食管癌<|>RELATION_NOE 组<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 、<|>RELATION_NOE
VEGF<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 有<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
血清<|>RELATION_NOE VEGF<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 、<|>RELATION_NOE 恶性<|>RELATION_NOE 行为<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E 。<|>RELATION_NOE
恩度动<|>RELATION_NOE 静脉<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 配合<|>RELATION_NOE 介入<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE
选择<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 经过<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE Ⅲ<|>RELATION_NOE －<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 介入<|>RELATION_NOE 时<|>RELATION_NOE 给予<|>RELATION_S 动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 恩度<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 于<|>RELATION_NOE 术后<|>RELATION_NOE 继续<|>RELATION_NOE 完成<|>RELATION_NOE 恩度<|>RELATION_NOE 的<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 疗程<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
临床<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 主要<|>RELATION_B 有<|>RELATION_E 心功能<|>RELATION_NOE 异常<|>RELATION_NOE 、<|>RELATION_NOE 过敏性反应<|>RELATION_NOE 、<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 、<|>RELATION_NOE 胸闷<|>RELATION_NOE 、<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 、<|>RELATION_NOE 肝功能<|>RELATION_NOE 异常<|>RELATION_NOE 与<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
恩度动<|>RELATION_NOE 静脉<|>RELATION_NOE 联合<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 配合<|>RELATION_NOE 介入<|>RELATION_NOE 治疗<|>RELATION_NOE 具有<|>RELATION_S 临床<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE ,<|>RELATION_NOE 加强<|>RELATION_NOE 护理<|>RELATION_NOE 观察<|>RELATION_NOE 和<|>RELATION_NOE 及时<|>RELATION_NOE 干预<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 是<|>RELATION_NOE 保证<|>RELATION_NOE 治疗<|>RELATION_NOE 安全<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 措施<|>RELATION_NOE 。<|>RELATION_NOE
吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
观察<|>RELATION_S 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 毒副作用<|>RELATION_NOE 。<|>RELATION_NOE
毒副作用<|>RELATION_NOE 主要<|>RELATION_B 是<|>RELATION_E 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 及<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 。<|>RELATION_NOE
吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 毒副作用<|>RELATION_NOE 可以<|>RELATION_B 耐受<|>RELATION_E 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE EBV<|>RELATION_NOE 感染<|>RELATION_NOE 、<|>RELATION_NOE LMP1<|>RELATION_NOE 和<|>RELATION_NOE Bcl-2<|>RELATION_NOE 表达<|>RELATION_NOE 状况<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
采用<|>RELATION_NOE 原位杂交法<|>RELATION_NOE (<|>RELATION_NOE in<|>RELATION_NOE situ<|>RELATION_NOE hybridization<|>RELATION_NOE ,<|>RELATION_NOE ISH<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE EBV<|>RELATION_NOE 编码<|>RELATION_NOE 的<|>RELATION_NOE 小<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE EBER1<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE (<|>RELATION_NOE immunohistochemistry<|>RELATION_NOE ,<|>RELATION_NOE IHC<|>RELATION_NOE )<|>RELATION_NOE
EBV<|>RELATION_NOE 阳性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组中<|>RELATION_NOE Bcl-2<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E EBV<|>RELATION_NOE 阴性<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE AA<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5801<|>RELATION_NOE 4.23<|>RELATION_NOE ±<|>RELATION_NOE 69<|>RELATION_NOE 18.45<|>RELATION_NOE 和<|>RELATION_NOE 38<|>RELATION_NOE 15<|>RELATION_NOE 6.22<|>RELATION_NOE ±<|>RELATION_NOE 409<|>RELATION_NOE 6.79<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE IA<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 11.00<|>RELATION_NOE ±<|>RELATION_NOE 1.48<|>RELATION_NOE 和<|>RELATION_NOE 8.03<|>RELATION_NOE ±<|>RELATION_NOE 0.78<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
EBV<|>RELATION_NOE 感染<|>RELATION_NOE 使<|>RELATION_NOE Bcl-2<|>RELATION_NOE 表达<|>RELATION_NOE 增加<|>RELATION_S ,<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
取<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 远离<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE ,<|>RELATION_NOE 分<|>RELATION_NOE 肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 不<|>RELATION_NOE 吸<|>RELATION_NOE 烟组<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 吸烟组<|>RELATION_NOE (<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE COPD<|>RELATION_NOE 稳定<|>RELATION_NOE 期组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 3组<|>RELATION_NOE 肺腺泡<|>RELATION_NOE 动脉<|>RELATION_NOE 病理<|>RELATION_NOE 结构<|>RELATION_NOE 改变<|>RELATION_NOE 、<|>RELATION_NOE 炎性<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 肌型<|>RELATION_NOE 动脉<|>RELATION_NOE (<|>RELATION_NOE NMA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 部分<|>RELATION_NOE 肌型<|>RELATION_NOE 动脉<|>RELATION_NOE (<|>RELATION_NOE PMA<|>RELATION_NOE )<|>RELATION_NOE 外膜<|>RELATION_NOE ,<|>RELATION_NOE 肌型<|>RELATION_NOE 动脉<|>RELATION_NOE (<|>RELATION_NOE MA<|>RELATION_NOE )<|>RELATION_NOE 内<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 外膜<|>RELATION_NOE 的<|>RELATION_NOE 浸润<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 、<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 、<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE 在<|>RELATION_NOE 3组<|>RELATION_NOE 各型<|>RELATION_NOE 肺腺泡<|>RELATION_NOE 动脉<|>RELATION_NOE 浸润<|>RELATION_NOE 程度<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE CD45<|>RELATION_NOE +<|>RELATION_NOE 白细胞<|>RELATION_NOE 、<|>RELATION_NOE CD3<|>RELATION_NOE +<|>RELATION_NOE 总<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 、<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 在<|>RELATION_NOE MA<|>RELATION_NOE 的<|>RELATION_NOE 浸润<|>RELATION_NOE 程度<|>RELATION_NOE 与<|>RELATION_NOE MA<|>RELATION_NOE 管壁<|>RELATION_NOE 厚度<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 第1<|>RELATION_NOE 秒<|>RELATION_NOE 用力<|>RELATION_NOE 呼气<|>RELATION_NOE 容积<|>RELATION_NOE 占<|>RELATION_NOE 预计<|>RELATION_NOE 值<|>RELATION_NOE 百分比<|>RELATION_NOE 呈<|>RELATION_NOE 负<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE CD3<|>RELATION_NOE +<|>RELATION_NOE 总<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 、<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 浸润<|>RELATION_NOE 程度<|>RELATION_NOE 与<|>RELATION_NOE BODE<|>RELATION_NOE 指数<|>RELATION_NOE 呈<|>RELATION_NOE
肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 吸烟者<|>RELATION_NOE 和<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 已<|>RELATION_NOE 出现<|>RELATION_S 以<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 浸润<|>RELATION_NOE 为<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 同<|>RELATION_NOE 性质<|>RELATION_NOE 炎症<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 炎症<|>RELATION_NOE 累及<|>RELATION_NOE 各型<|>RELATION_NOE 肺腺泡<|>RELATION_NOE 动脉<|>RELATION_NOE ,<|>RELATION_NOE 肺动脉<|>RELATION_NOE 炎症<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE COPD<|>RELATION_NOE 临床<|>RELATION_NOE 病程<|>RELATION_NOE 发展<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 因素<|>RELATION_NOE 之一<|>RELATION_NOE 。<|>RELATION_NOE
99Tcm-survivinmRNA<|>RELATION_NOE 反义<|>RELATION_NOE 肽核酸制备<|>RELATION_NOE 及<|>RELATION_NOE 荷瘤<|>RELATION_NOE 裸鼠<|>RELATION_NOE 基因<|>RELATION_NOE 显像<|>RELATION_NOE 研究<|>RELATION_S
制备<|>RELATION_NOE 99Tcm<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE survivinmRNA<|>RELATION_NOE 反义<|>RELATION_NOE 肽核酸<|>RELATION_NOE (<|>RELATION_NOE PNA<|>RELATION_NOE )<|>RELATION_NOE 探针<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 荷瘤<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 基因<|>RELATION_NOE 显像<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S 。<|>RELATION_NOE
99Tcm<|>RELATION_NOE 一<|>RELATION_NOE survivinmRNA<|>RELATION_NOE 反义<|>RELATION_NOE PNA<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 内<|>RELATION_NOE 特异性<|>RELATION_NOE 浓<|>RELATION_NOE 聚<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 时间<|>RELATION_NOE 延长<|>RELATION_NOE ,<|>RELATION_NOE 浓聚<|>RELATION_NOE 程度<|>RELATION_NOE 逐渐<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 2和<|>RELATION_NOE 4hT<|>RELATION_NOE /<|>RELATION_NOE NT<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.70<|>RELATION_NOE ±<|>RELATION_NOE 0.28<|>RELATION_NOE ,<|>RELATION_NOE 3.44<|>RELATION_NOE ±<|>RELATION_NOE 0.35<|>RELATION_NOE 和<|>RELATION_NOE 4.21<|>RELATION_NOE ±<|>RELATION_NOE 0.63<|>RELATION_NOE 。<|>RELATION_NOE
99TcmsurvivinmRNA<|>RELATION_NOE 反义<|>RELATION_NOE PNA<|>RELATION_NOE 即刻<|>RELATION_NOE 标记率<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 稳定性<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 需<|>RELATION_NOE 纯化<|>RELATION_NOE 即可<|>RELATION_NOE 用于<|>RELATION_NOE 显像<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 特异性<|>RELATION_NOE 浓<|>RELATION_NOE 聚<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_B 潜在<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
内科<|>RELATION_NOE 电子<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 早期<|>RELATION_B 诊断<|>RELATION_E 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE
新乡<|>RELATION_NOE 市中心<|>RELATION_NOE 医院<|>RELATION_NOE 于<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 2月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE 采用<|>RELATION_NOE 日本<|>RELATION_NOE OlympusLTF240<|>RELATION_NOE 型<|>RELATION_NOE 电子<|>RELATION_NOE 内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 对<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 行<|>RELATION_B 内科<|>RELATION_I 胸腔镜检查<|>RELATION_E 。<|>RELATION_NOE
术后<|>RELATION_NOE 行<|>RELATION_NOE 胸片<|>RELATION_NOE 了解<|>RELATION_NOE 置管<|>RELATION_NOE 位置<|>RELATION_NOE 及<|>RELATION_NOE 胸腔<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 密切<|>RELATION_B 观察<|>RELATION_E 神志<|>RELATION_NOE 及<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 呼吸<|>RELATION_NOE 、<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 心律<|>RELATION_NOE 及<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 胸腔镜检查<|>RELATION_NOE 及<|>RELATION_NOE 活检<|>RELATION_NOE 病理<|>RELATION_NOE 明确<|>RELATION_B 诊断<|>RELATION_E :<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 70%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 结核性<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 30%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胸水<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 高于<|>RELATION_S 正常<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 应<|>RELATION_NOE 全面<|>RELATION_NOE 仔细<|>RELATION_NOE 寻找<|>RELATION_NOE 恶性<|>RELATION_NOE 根据<|>RELATION_NOE 。<|>RELATION_NOE
结核性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 做<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 时<|>RELATION_NOE 均<|>RELATION_NOE 可<|>RELATION_B 找到<|>RELATION_E 结核<|>RELATION_NOE 结节病<|>RELATION_NOE 灶<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 结核<|>RELATION_NOE 变态反应<|>RELATION_NOE 可<|>RELATION_NOE 引起<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 不<|>RELATION_NOE 太<|>RELATION_NOE 支持<|>RELATION_NOE 。<|>RELATION_NOE
内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 作为<|>RELATION_NOE 一<|>RELATION_NOE 项<|>RELATION_NOE 呼吸<|>RELATION_NOE 内科<|>RELATION_NOE 医生<|>RELATION_NOE 可<|>RELATION_NOE 操作<|>RELATION_NOE 的<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 微创<|>RELATION_NOE 诊疗<|>RELATION_NOE 技术<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 具有<|>RELATION_B 重要<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 应用<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
埃罗替尼<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_NOE 埃罗替尼<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
35<|>RELATION_NOE 例<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 失败<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 服用<|>RELATION_NOE 埃罗替尼<|>RELATION_NOE 150mg<|>RELATION_NOE /<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 每日<|>RELATION_NOE 1<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 直至<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进展<|>RELATION_NOE 或<|>RELATION_NOE 出现<|>RELATION_NOE 不可<|>RELATION_NOE 耐受<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
埃罗替尼<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 有<|>RELATION_B 明显<|>RELATION_I 的<|>RELATION_I 抗<|>RELATION_I 肿瘤<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 有效<|>RELATION_NOE 且<|>RELATION_NOE 具有<|>RELATION_NOE 良好<|>RELATION_NOE 耐性<|>RELATION_NOE 的<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 药物<|>RELATION_NOE 。<|>RELATION_NOE
艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 复发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
评价<|>RELATION_S 艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 复发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
70<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 复发<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 对照<|>RELATION_NOE 双盲法<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
乙酰<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 预防<|>RELATION_S 肺癌<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 乙酰<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_NOE 乙酰<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 对<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 有<|>RELATION_B 一定<|>RELATION_I 的<|>RELATION_I 预防<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 不<|>RELATION_NOE 影响<|>RELATION_NOE 放疗<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 机制<|>RELATION_NOE
以<|>RELATION_NOE 噻<|>RELATION_NOE 唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 观察<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE Annexin-V<|>RELATION_NOE /<|>RELATION_NOE PI<|>RELATION_NOE 双染法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 一<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PcR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 检查点<|>RELATION_NOE 蛋白<|>RELATION_NOE 调节<|>RELATION_NOE 因子1<|>RELATION_NOE (<|>RELATION_NOE MDCl<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
顺铂<|>RELATION_NOE 、<|>RELATION_NOE 唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_S 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE ,<|>RELATION_NOE 诱导<|>RELATION_NOE 其<|>RELATION_NOE 凋亡<|>RELATION_NOE ;<|>RELATION_NOE
35<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 除了<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 不明<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 9例<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 。<|>RELATION_NOE
肾癌<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 下咽癌<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 软腭<|>RELATION_NOE 腺样囊性癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 以<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转移<|>RELATION_NOE 癌为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE 从<|>RELATION_NOE 诊断<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 到<|>RELATION_NOE 发现<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转移癌<|>RELATION_NOE ,<|>RELATION_NOE 时间<|>RELATION_NOE 间隔<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 168<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中位<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 有<|>RELATION_NOE 6例<|>RELATION_NOE 时间<|>RELATION_NOE 间隔<|>RELATION_NOE ><|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 经病<|>RELATION_NOE 理学<|>RELATION_NOE 证实<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 细针<|>RELATION_NOE 吸取<|>RELATION_NOE 细胞学<|>RELATION_NOE 诊断<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 标本<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 手段<|>RELATION_NOE 结合<|>RELATION_NOE 使用<|>RELATION_NOE 诊断<|>RELATION_NOE 4例<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 合并颈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 接受<|>RELATION_NOE 甲状腺<|>RELATION_NOE 切除<|>RELATION_NOE 合并<|>RELATION_NOE 颈清<|>RELATION_NOE 扫组<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 与<|>RELATION_NOE 接受<|>RELATION_NOE 单纯<|>RELATION_NOE 甲状腺<|>RELATION_NOE 切除组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
甲状腺<|>RELATION_NOE 转移<|>RELATION_NOE 癌<|>RELATION_NOE 是<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_B 表现<|>RELATION_E ,<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE 。<|>RELATION_NOE
KRAS<|>RELATION_NOE 和<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 突变<|>RELATION_NOE 基因<|>RELATION_NOE 与<|>RELATION_NOE 原发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
研究<|>RELATION_NOE KRAS<|>RELATION_NOE 和<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 原发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_B 状态<|>RELATION_E 以及<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗效果<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 150<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 受累<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_S KRAS<|>RELATION_NOE 和<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 基因<|>RELATION_NOE 序列分析<|>RELATION_NOE 。<|>RELATION_NOE
150<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶经<|>RELATION_NOE DNA<|>RELATION_NOE 序列分析<|>RELATION_NOE 发现<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 后<|>RELATION_NOE 给予<|>RELATION_S 吉非替尼<|>RELATION_NOE 进行<|>RELATION_NOE 术前<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
150<|>RELATION_NOE 对<|>RELATION_NOE (<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 原发灶<|>RELATION_NOE 和<|>RELATION_NOE 受累<|>RELATION_NOE 淋巴结<|>RELATION_NOE )<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 和<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 中<|>RELATION_NOE 检测<|>RELATION_NOE 到<|>RELATION_NOE KRAS<|>RELATION_NOE 突变<|>RELATION_NOE 基因<|>RELATION_NOE ,<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 和<|>RELATION_NOE 44<|>RELATION_NOE 例<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 中<|>RELATION_NOE 检测<|>RELATION_B 到<|>RELATION_E EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 基因<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 中<|>RELATION_NOE KRAS<|>RELATION_NOE 和<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 不<|>RELATION_B 一致<|>RELATION_E ,<|>RELATION_NOE 这<|>RELATION_NOE 对于<|>RELATION_NOE 应用<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE NSCLC<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
肺上沟癌<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 误诊<|>RELATION_NOE 原因<|>RELATION_NOE 分析<|>RELATION_S
26<|>RELATION_NOE 例<|>RELATION_NOE 中肩<|>RELATION_NOE 背部<|>RELATION_NOE 疼痛<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 上肢<|>RELATION_NOE 疼痛<|>RELATION_NOE 、<|>RELATION_NOE 麻木<|>RELATION_NOE 或<|>RELATION_NOE 乏力<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 早期<|>RELATION_NOE 出现<|>RELATION_NOE 呼吸道<|>RELATION_NOE 症状<|>RELATION_NOE (<|>RELATION_NOE 如<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咳痰<|>RELATION_NOE )<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE Homer<|>RELATION_NOE 征<|>RELATION_NOE 阳性<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 声音<|>RELATION_NOE 嘶哑<|>RELATION_NOE l<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
26<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 曾<|>RELATION_NOE 误诊<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肩周炎<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 颈椎病<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 肺结核<|>RELATION_NOE 3例<|>RELATION_NOE 。<|>RELATION_NOE
26<|>RELATION_NOE 例<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 均<|>RELATION_NOE 显示<|>RELATION_NOE 一侧<|>RELATION_NOE 肺上<|>RELATION_NOE 叶尖<|>RELATION_NOE 段<|>RELATION_NOE 软<|>RELATION_NOE 组织<|>RELATION_NOE 密度<|>RELATION_NOE 增<|>RELATION_NOE 高影<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3例<|>RELATION_NOE 患者<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 胸片<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 异常<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 患者<|>RELATION_NOE 因<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 胸片<|>RELATION_NOE 提示<|>RELATION_NOE 肺尖部<|>RELATION_NOE 病变<|>RELATION_NOE 而<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE “<|>RELATION_NOE 肺结核<|>RELATION_NOE ”<|>RELATION_NOE 。<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 第19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 28<|>RELATION_NOE 2例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 癌组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 片段<|>RELATION_NOE 进行<|>RELATION_B 扩增<|>RELATION_I 并<|>RELATION_I 测<|>RELATION_I 序<|>RELATION_E ,<|>RELATION_NOE 分析<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
28<|>RELATION_NOE 2例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 42.6%<|>RELATION_NOE )<|>RELATION_NOE 存在<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 第19<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 61<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 第21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 66<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 7例<|>RELATION_NOE 第19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 同时<|>RELATION_NOE 存在<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
女性<|>RELATION_NOE EGFR<|>RELATION_NOE 突变率<|>RELATION_NOE (<|>RELATION_NOE 55.2%<|>RELATION_NOE ,<|>RELATION_NOE 53<|>RELATION_NOE /<|>RELATION_NOE 96<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_S 男性<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 36.0%<|>RELATION_NOE ,<|>RELATION_NOE 67<|>RELATION_NOE /<|>RELATION_NOE 186<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 51<|>RELATION_NOE －<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 突变率<|>RELATION_NOE (<|>RELATION_NOE 51.3%<|>RELATION_NOE ,<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 76<|>RELATION_NOE )<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 在<|>RELATION_NOE 女性<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 51<|>RELATION_NOE －<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 非吸烟者<|>RELATION_NOE 及<|>RELATION_NOE 腺癌<|>RELATION_NOE 、<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 、<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 中<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 存在<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_NOE 患者<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 筛选<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 和<|>RELATION_NOE 扩增<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 相关性<|>RELATION_B 研究<|>RELATION_E
应用<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE -DNA<|>RELATION_NOE 测序<|>RELATION_NOE 和<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE (<|>RELATION_NOE FISH<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 和<|>RELATION_NOE 扩增<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE DNA<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 454<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 突变率<|>RELATION_NOE 48.2%<|>RELATION_NOE (<|>RELATION_NOE 219<|>RELATION_NOE /<|>RELATION_NOE 454<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
腺癌<|>RELATION_NOE 各<|>RELATION_NOE 亚型<|>RELATION_NOE 之间<|>RELATION_NOE 突变率<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE FISH<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 134<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 基因扩增<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 22.4%<|>RELATION_NOE (<|>RELATION_NOE 30<|>RELATION_NOE /<|>RELATION_NOE 134<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 亚型<|>RELATION_NOE 分型<|>RELATION_NOE 中<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因扩增<|>RELATION_NOE 与<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 之间<|>RELATION_NOE 具有<|>RELATION_B 显著<|>RELATION_I 相关性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0005<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 两者<|>RELATION_NOE 一致性<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE (<|>RELATION_NOE κ<|>RELATION_NOE =<|>RELATION_NOE 0.2<|>RELATION_NOE 75<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 非吸烟者<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 突变率<|>RELATION_B 高<|>RELATION_E ,<|>RELATION_NOE 且<|>RELATION_NOE 腺癌<|>RELATION_NOE 各<|>RELATION_NOE 亚型<|>RELATION_NOE 之间<|>RELATION_NOE 突变率<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_NOE 差异<|>RELATION_NOE ;<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因扩增<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 亚型<|>RELATION_NOE 分型<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关<|>RELATION_E 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
采用<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 扩增<|>RELATION_NOE DNA<|>RELATION_NOE 直接<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S 192<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第18<|>RELATION_NOE －21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 指标<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
192<|>RELATION_NOE 例非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 64<|>RELATION_NOE 例<|>RELATION_NOE 存在<|>RELATION_NOE EGFR<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 结合域<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 33.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 第19<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 缺失<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 60.9%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 64<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 第21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 替代<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 39.1%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 64<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 第18<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 未<|>RELATION_NOE 发现<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
PCR<|>RELATION_NOE 扩增<|>RELATION_NOE DNA<|>RELATION_NOE 直接<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S NSCLC<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 技术<|>RELATION_NOE 稳定<|>RELATION_NOE 、<|>RELATION_NOE 可靠<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 开展<|>RELATION_NOE NSCLC<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
双环<|>RELATION_NOE 探针<|>RELATION_NOE 特异引物<|>RELATION_NOE 荧光<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应法<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE
采用<|>RELATION_NOE BPSP-qPCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S NSCLC<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第18<|>RELATION_NOE －21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 、<|>RELATION_NOE 不同<|>RELATION_NOE
资料<|>RELATION_NOE 完整<|>RELATION_NOE 的<|>RELATION_NOE 184<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 吸烟者<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 有<|>RELATION_NOE 更<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 19-del<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE L858R<|>RELATION_NOE 突变率<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 39.7%<|>RELATION_NOE (<|>RELATION_NOE 31<|>RELATION_NOE /<|>RELATION_NOE 78<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 41.0%<|>RELATION_NOE (<|>RELATION_NOE 43<|>RELATION_NOE /<|>RELATION_NOE 105<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 37.8%<|>RELATION_NOE (<|>RELATION_NOE 51<|>RELATION_NOE /<|>RELATION_NOE 135<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
男性<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 吸烟者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 样本<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 19-del<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE L858R<|>RELATION_NOE 阳性<|>RELATION_NOE 突变率<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 29.6%<|>RELATION_NOE (<|>RELATION_NOE 8/<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 42.9%<|>RELATION_NOE (<|>RELATION_NOE 9/21<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 40.7%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 非<|>RELATION_NOE 腺癌<|>RELATION_NOE 转移<|>RELATION_NOE 灶为0<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 敏感<|>RELATION_NOE 突变<|>RELATION_NOE 多<|>RELATION_B 见于<|>RELATION_E 女性<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE ,<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 样本<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 少量<|>RELATION_NOE 样本<|>RELATION_NOE 能够<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 指导<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
应用<|>RELATION_NOE 即时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 14<|>RELATION_NOE 44<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第19<|>RELATION_NOE 号<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
14<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 成功<|>RELATION_NOE 分型<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 401<|>RELATION_NOE 例<|>RELATION_NOE 存在<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 突变<|>RELATION_NOE 检出率<|>RELATION_NOE 为<|>RELATION_NOE 27.8%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 193<|>RELATION_NOE 例<|>RELATION_NOE 第19<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 发生<|>RELATION_NOE 缺<|>RELATION_NOE 失<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 208<|>RELATION_NOE 例<|>RELATION_NOE 第21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 发生<|>RELATION_NOE 替代<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 更<|>RELATION_B 常<|>RELATION_I 见于<|>RELATION_E 腺癌<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 或<|>RELATION_NOE 女性<|>RELATION_NOE 患者<|>RELATION_NOE [<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 33.5%<|>RELATION_NOE (<|>RELATION_NOE 367<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE 94<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE 37.6%<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE 1/8<|>RELATION_NOE 53<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 43.2%<|>RELATION_NOE (<|>RELATION_NOE 225<|>RELATION_NOE /<|>RELATION_NOE 521<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 及伴<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 分化<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE 突变率<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 普通<|>RELATION_NOE 腺癌<|>RELATION_NOE [<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 61.3%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 48.0%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 32.4%<|>RELATION_NOE (<|>RELATION_NOE 336<|>RELATION_NOE /<|>RELATION_NOE 10<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 突变率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 。<|>RELATION_NOE
即时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 技术<|>RELATION_NOE 可<|>RELATION_NOE 快速<|>RELATION_B 、<|>RELATION_I 敏感<|>RELATION_I 、<|>RELATION_I 准确<|>RELATION_I 地<|>RELATION_I 检测<|>RELATION_E E<|>RELATION_NOE GFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
探讨<|>RELATION_NOE 中国<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 优化<|>RELATION_NOE 寡<|>RELATION_NOE 核苷<|>RELATION_NOE 酸探针<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 309<|>RELATION_NOE 例<|>RELATION_NOE 甲醛<|>RELATION_NOE 固定<|>RELATION_NOE 、<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第18<|>RELATION_NOE －21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
受<|>RELATION_NOE 检<|>RELATION_NOE 309<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 样本<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第18<|>RELATION_NOE 、<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 总<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 34%<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE /<|>RELATION_NOE 309<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 大<|>RELATION_NOE 细胞<|>RELATION_NOE 未分化癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检出率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 22.2%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 72<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 3/14<|>RELATION_NOE 。<|>RELATION_NOE
检<|>RELATION_NOE 出<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 类型<|>RELATION_NOE 包括<|>RELATION_NOE 第18<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 点突变<|>RELATION_NOE (<|>RELATION_NOE 5.7%<|>RELATION_NOE ,<|>RELATION_NOE 6/<|>RELATION_NOE 105<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 第19<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 缺失<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 39.0%<|>RELATION_NOE ,<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 105<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 第21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 点突变<|>RELATION_NOE (<|>RELATION_NOE 55.2%<|>RELATION_NOE ,<|>RELATION_NOE 58<|>RELATION_NOE /<|>RELATION_NOE 105<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 第18<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 整体<|>RELATION_NOE 突变率<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 所<|>RELATION_NOE 占<|>RELATION_NOE 突变<|>RELATION_NOE 比例<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 中国<|>RELATION_NOE 人群<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 多<|>RELATION_B 见于<|>RELATION_E 女性<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE ≤<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 吸烟史<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
优化<|>RELATION_NOE 寡<|>RELATION_NOE 核苷<|>RELATION_NOE 酸探针<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 敏感<|>RELATION_NOE 、<|>RELATION_NOE 便捷<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_B 用于<|>RELATION_E EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 直接<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 分析<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 采用<|>RELATION_NOE 直接<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S 的<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 、<|>RELATION_NOE 突变<|>RELATION_NOE 分布<|>RELATION_NOE 特征<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 样本<|>RELATION_NOE 均<|>RELATION_NOE 通过<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 、<|>RELATION_NOE 切片<|>RELATION_NOE 后<|>RELATION_NOE 确定<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 显微切割<|>RELATION_NOE 富集<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 采用<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE -<|>RELATION_NOE 直接<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 编码区<|>RELATION_NOE 第18<|>RELATION_NOE 至<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第18<|>RELATION_NOE 至<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.0%<|>RELATION_NOE (<|>RELATION_NOE 4/<|>RELATION_NOE 193<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 48.7%<|>RELATION_NOE (<|>RELATION_NOE 94<|>RELATION_NOE /<|>RELATION_NOE 193<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 6.7%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 193<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 42.5%<|>RELATION_NOE (<|>RELATION_NOE 82<|>RELATION_NOE /<|>RELATION_NOE 193<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 总<|>RELATION_NOE 突变率<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 无<|>RELATION_B 显著<|>RELATION_I 相关性<|>RELATION_E ,<|>RELATION_NOE 但<|>RELATION_NOE 在<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 女性<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE (<|>RELATION_NOE 53.5%<|>RELATION_NOE ,<|>RELATION_NOE 107<|>RELATION_NOE /<|>RELATION_NOE 200<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_S 男性<|>RELATION_NOE 患者<|>RELATION_NOE 突变率<|>RELATION_NOE (<|>RELATION_NOE 33.7%<|>RELATION_NOE ,<|>RELATION_NOE 82<|>RELATION_NOE /<|>RELATION_NOE 243<|>RELATION_NOE ;<|>RELATION_NOE
直接<|>RELATION_NOE 测序法<|>RELATION_NOE 是<|>RELATION_NOE 检测<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_B 方法<|>RELATION_E ,<|>RELATION_NOE 特别<|>RELATION_NOE 对<|>RELATION_NOE 未知<|>RELATION_NOE 突变<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 检出<|>RELATION_NOE 具有<|>RELATION_NOE 优势<|>RELATION_NOE ;<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检出率<|>RELATION_NOE 与<|>RELATION_NOE 样本<|>RELATION_NOE 类型<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 活检<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 细胞学<|>RELATION_NOE 样本<|>RELATION_NOE 是<|>RELATION_NOE 检测<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 有用<|>RELATION_NOE 材料<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 可能<|>RELATION_NOE 会<|>RELATION_NOE 漏检<|>RELATION_NOE 部分<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾<|>RELATION_B 分析<|>RELATION_E 32<|>RELATION_NOE 例<|>RELATION_NOE 结节性<|>RELATION_NOE 甲状腺肿<|>RELATION_NOE 伴<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
术前<|>RELATION_NOE 超声诊断<|>RELATION_NOE 符合率<|>RELATION_NOE 为<|>RELATION_NOE 71.8<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE 23<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 均<|>RELATION_NOE 痊愈<|>RELATION_NOE 出<|>RELATION_NOE 院<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 1－<|>RELATION_NOE 7<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 余<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 1例<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
彩色<|>RELATION_NOE 超声检查<|>RELATION_NOE 是<|>RELATION_NOE 诊断<|>RELATION_NOE 结节性<|>RELATION_NOE 甲状腺肿<|>RELATION_NOE 伴<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 手段<|>RELATION_E ,<|>RELATION_NOE 合理<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 范围<|>RELATION_NOE 是<|>RELATION_NOE 患<|>RELATION_NOE 侧腺<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 峡部<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 对<|>RELATION_NOE 侧腺<|>RELATION_NOE 叶次<|>RELATION_NOE 全切<|>RELATION_NOE 除术<|>RELATION_NOE ,<|>RELATION_NOE 一般<|>RELATION_NOE 不<|>RELATION_NOE 作<|>RELATION_NOE 预防<|>RELATION_NOE 性颈<|>RELATION_NOE 清扫<|>RELATION_NOE 术.<|>RELATION_NOE
热休克<|>RELATION_NOE 蛋白<|>RELATION_NOE 70<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 顺铂<|>RELATION_NOE 耐药性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 用<|>RELATION_NOE 替普瑞酮<|>RELATION_NOE 诱导<|>RELATION_S 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE SPCA-1<|>RELATION_NOE 中热<|>RELATION_NOE 休克<|>RELATION_NOE 蛋白<|>RELATION_NOE 70<|>RELATION_NOE (<|>RELATION_NOE HSP70<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 耐药<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 与<|>RELATION_NOE 联系<|>RELATION_NOE 。<|>RELATION_NOE
1×<|>RELATION_NOE 106<|>RELATION_NOE 株<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE SPCA-1<|>RELATION_NOE 细胞<|>RELATION_NOE 完全<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 不同<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE 替普瑞酮<|>RELATION_NOE 处理组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 5×<|>RELATION_NOE 105<|>RELATION_NOE 株<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 加入<|>RELATION_S 磷酸盐<|>RELATION_NOE 缓冲<|>RELATION_NOE 溶液<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE 替<|>RELATION_NOE 普瑞酮<|>RELATION_NOE 各组<|>RELATION_NOE 分别<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 、<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE HSP70mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
替普瑞酮<|>RELATION_NOE 可<|>RELATION_NOE 上调<|>RELATION_S SPCA-l<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE HSP70<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE HSP70<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_NOE SPCA-1<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 耐药<|>RELATION_NOE 性.<|>RELATION_NOE 替普瑞酮<|>RELATION_NOE 可<|>RELATION_NOE 上调<|>RELATION_NOE SPCA-l<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE HSP70<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE HSP70<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_S SPCA-1<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 耐药性<|>RELATION_NOE .<|>RELATION_NOE
水通道<|>RELATION_NOE 蛋白1<|>RELATION_NOE 及<|>RELATION_NOE 水通道<|>RELATION_NOE 蛋白4<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
取<|>RELATION_NOE 癌周<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE (<|>RELATION_NOE 距<|>RELATION_NOE 癌缘<|>RELATION_NOE ><|>RELATION_NOE 3cm<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 无<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE )<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
放射<|>RELATION_NOE 治疗<|>RELATION_NOE 联合<|>RELATION_NOE 拓朴<|>RELATION_NOE 替康<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE
观察<|>RELATION_NOE 全脑<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 加<|>RELATION_NOE 立体<|>RELATION_NOE 定向<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 联合<|>RELATION_NOE 拓朴<|>RELATION_NOE 替康<|>RELATION_NOE 同步<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 脑转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE
治疗组<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 症<|>RELATION_NOE 、<|>RELATION_NOE 血小板减少<|>RELATION_NOE 症<|>RELATION_NOE 发生率<|>RELATION_NOE 均<|>RELATION_NOE 升高<|>RELATION_S ,<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 可<|>RELATION_NOE 控制<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 治疗<|>RELATION_NOE 相关<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
Sanger<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_B 分析<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE
收集<|>RELATION_NOE 63<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE (<|>RELATION_NOE 石蜡<|>RELATION_NOE 切片<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 提取<|>RELATION_NOE 组织<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE EGFR<|>RELATION_NOE 外显子<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 四<|>RELATION_NOE 位<|>RELATION_NOE 点<|>RELATION_NOE 的<|>RELATION_NOE 分子<|>RELATION_NOE 扩增<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE 进行<|>RELATION_S 外显子<|>RELATION_NOE 扩增<|>RELATION_NOE ,<|>RELATION_NOE 扩增<|>RELATION_NOE 产物<|>RELATION_NOE 先后<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 测试<|>RELATION_NOE 显示<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 33.3%<|>RELATION_NOE (<|>RELATION_NOE 21<|>RELATION_NOE /<|>RELATION_NOE 63<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 状态<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 联合化疗<|>RELATION_NOE 不同<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 时<|>RELATION_NOE 序<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
60<|>RELATION_NOE 只<|>RELATION_NOE 荷<|>RELATION_NOE A549<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE 移植<|>RELATION_NOE 瘤裸鼠<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 分为<|>RELATION_NOE D1<|>RELATION_NOE 、<|>RELATION_NOE D3<|>RELATION_NOE 、<|>RELATION_NOE 195<|>RELATION_NOE 、<|>RELATION_NOE D7<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 恩度<|>RELATION_NOE 治疗<|>RELATION_NOE 并<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE 恩度<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 7天<|>RELATION_NOE 进行<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_S 各组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 情况<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 指数<|>RELATION_NOE 。<|>RELATION_NOE
治疗<|>RELATION_NOE 后<|>RELATION_NOE 第<|>RELATION_NOE 40<|>RELATION_NOE 天<|>RELATION_NOE 各<|>RELATION_NOE 治疗组<|>RELATION_NOE 移植<|>RELATION_NOE 瘤体<|>RELATION_NOE 积<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 小于<|>RELATION_E 对照组<|>RELATION_NOE 且<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 极<|>RELATION_NOE 显著<|>RELATION_NOE 性垆<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE D3<|>RELATION_NOE 、<|>RELATION_NOE D5<|>RELATION_NOE 、<|>RELATION_NOE D7<|>RELATION_NOE 组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 小于<|>RELATION_NOE D1<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE D1<|>RELATION_NOE 、<|>RELATION_NOE 193<|>RELATION_NOE 、<|>RELATION_NOE D5<|>RELATION_NOE 、<|>RELATION_NOE D7<|>RELATION_NOE 组<|>RELATION_NOE 凋亡<|>RELATION_NOE 指数<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14.28<|>RELATION_NOE ±<|>RELATION_NOE 1.93<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 15.76<|>RELATION_NOE ±<|>RELATION_NOE 1.96<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 15.44<|>RELATION_NOE ±<|>RELATION_NOE 1.91<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 16.55<|>RELATION_NOE ±<|>RELATION_NOE 2.07<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 的<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE
观察<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 影响<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 和<|>RELATION_NOE 物理<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE 观察<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 影响<|>RELATION_S 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 和<|>RELATION_NOE 物理<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
照射野<|>RELATION_NOE 内<|>RELATION_NOE 食管<|>RELATION_NOE 受照<|>RELATION_NOE 长度<|>RELATION_NOE 、<|>RELATION_NOE 照射野<|>RELATION_NOE 内<|>RELATION_NOE 食管<|>RELATION_NOE 受照<|>RELATION_NOE 平均<|>RELATION_NOE 剂量<|>RELATION_NOE 与<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE :<|>RELATION_NOE 20.82<|>RELATION_NOE 、<|>RELATION_NOE 83.08<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Logistic<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 放疗<|>RELATION_NOE 增敏<|>RELATION_NOE 、<|>RELATION_NOE 照射野<|>RELATION_NOE 内<|>RELATION_NOE 食管<|>RELATION_NOE 受照<|>RELATION_NOE 长度<|>RELATION_NOE 、<|>RELATION_NOE 照射野<|>RELATION_NOE 内<|>RELATION_NOE 食管<|>RELATION_NOE 受照<|>RELATION_NOE 平均<|>RELATION_NOE 剂量<|>RELATION_NOE 和<|>RELATION_NOE V50<|>RELATION_NOE 与<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 21<|>RELATION_NOE 、<|>RELATION_NOE 2.8<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 7.307<|>RELATION_NOE 、<|>RELATION_NOE 8.5<|>RELATION_NOE 58<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
放疗<|>RELATION_NOE 增敏<|>RELATION_NOE 、<|>RELATION_NOE 照射野<|>RELATION_NOE 内<|>RELATION_NOE 食管<|>RELATION_NOE 受照<|>RELATION_NOE 长度<|>RELATION_NOE 、<|>RELATION_NOE 照射野<|>RELATION_NOE 内<|>RELATION_NOE 食管<|>RELATION_NOE 受照<|>RELATION_NOE 平均<|>RELATION_NOE 剂量<|>RELATION_NOE 和<|>RELATION_NOE VS0<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 因素<|>RELATION_E ,<|>RELATION_NOE V50<|>RELATION_NOE 对<|>RELATION_NOE 判断<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
紫杉醇<|>RELATION_NOE 卡铂<|>RELATION_NOE 联合<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 注射液<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 分析<|>RELATION_NOE
比较<|>RELATION_S 泰素<|>RELATION_NOE 、<|>RELATION_NOE 卡铂<|>RELATION_NOE (<|>RELATION_NOE TC<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 注射液<|>RELATION_NOE (<|>RELATION_NOE 商品<|>RELATION_NOE 名恩度<|>RELATION_NOE @)<|>RELATION_NOE 与<|>RELATION_NOE TC<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
恩度<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 24<|>RELATION_NOE 周<|>RELATION_NOE 的<|>RELATION_NOE 尤<|>RELATION_NOE 进展<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 78.3%<|>RELATION_NOE 和<|>RELATION_NOE 58.8%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 17<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 风险<|>RELATION_NOE 比<|>RELATION_NOE 为<|>RELATION_NOE 0.35<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE 置信区间<|>RELATION_NOE 0.13<|>RELATION_NOE －0.90<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
恩度<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 7.1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 和<|>RELATION_NOE 6.3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
恩度<|>RELATION_NOE 治疗组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE LCSS<|>RELATION_NOE 患者量表<|>RELATION_NOE )<|>RELATION_NOE 有所<|>RELATION_B 改善<|>RELATION_E ,<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 完成<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 和<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 改善<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 和<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 片段<|>RELATION_NOE 19<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_B 与<|>RELATION_I 临床<|>RELATION_I 价值<|>RELATION_E
探讨<|>RELATION_NOE 血清<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 片段<|>RELATION_NOE 19<|>RELATION_NOE (<|>RELATION_NOE CYFRA21—1<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE 102<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 78<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性病<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 104<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 血清<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S CEA<|>RELATION_NOE 和<|>RELATION_NOE CYFRA21—1<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 25.77<|>RELATION_NOE ±<|>RELATION_NOE 15.34<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 47.1%<|>RELATION_NOE ]<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺良<|>RELATION_NOE 性病<|>RELATION_NOE 组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 4.67<|>RELATION_NOE ±<|>RELATION_NOE 2.21<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 7.7%<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 健康组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 3.98<|>RELATION_NOE ±<|>RELATION_NOE 3.00<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 3.8%<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CYFRA21—1<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 14.08<|>RELATION_NOE ±<|>RELATION_NOE 8.34<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 62.7%<|>RELATION_NOE ]<|>RELATION_NOE 也<|>RELATION_NOE 同样<|>RELATION_NOE 高于<|>RELATION_S 肺良<|>RELATION_NOE 性病<|>RELATION_NOE 组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 3.27<|>RELATION_NOE ±<|>RELATION_NOE 2.87<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 7.7%<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 健康组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.69<|>RELATION_NOE ±<|>RELATION_NOE 2.02<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 3.8%<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 良性<|>RELATION_NOE 病组<|>RELATION_NOE 和<|>RELATION_NOE 健康组<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 积极<|>RELATION_NOE 处理<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 能否<|>RELATION_NOE 使<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 同步脑<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 受益<|>RELATION_S ,<|>RELATION_NOE 以<|>RELATION_NOE 寻找<|>RELATION_NOE 合理<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
尤其<|>RELATION_NOE 是<|>RELATION_NOE 单发脑<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 处理<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 的<|>RELATION_NOE 同时<|>RELATION_NOE ,<|>RELATION_NOE 积极<|>RELATION_NOE 处理<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 可<|>RELATION_NOE 延长<|>RELATION_S 患者<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
β<|>RELATION_NOE -<|>RELATION_NOE 榄香烯<|>RELATION_NOE 联合<|>RELATION_NOE 热化疗<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE A549<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
高浓度<|>RELATION_NOE 榄香烯<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 主要<|>RELATION_NOE 通过<|>RELATION_B 抑制<|>RELATION_I Stat3<|>RELATION_I 和<|>RELATION_I pStat3<|>RELATION_I 蛋白<|>RELATION_I 的<|>RELATION_I 表达<|>RELATION_I 及<|>RELATION_I 使<|>RELATION_I Survivin<|>RELATION_I 蛋白<|>RELATION_I 降低<|>RELATION_E ,<|>RELATION_NOE 抑制<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE ;<|>RELATION_NOE
研究<|>RELATION_S 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 功能<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
分别<|>RELATION_NOE 测定<|>RELATION_NOE 初次<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 中青年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 及<|>RELATION_NOE 健康<|>RELATION_NOE 老年人<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE (<|>RELATION_NOE CD3<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE 、<|>RELATION_NOE CD8<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE /<|>RELATION_NOE CD8<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 自然<|>RELATION_NOE 杀伤<|>RELATION_NOE (<|>RELATION_NOE NK<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 值<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 比较<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 化疗<|>RELATION_NOE 结束<|>RELATION_NOE 、<|>RELATION_NOE 第3<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 开始<|>RELATION_NOE 前<|>RELATION_NOE 的<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 及<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 数值<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE CD3<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE 、<|>RELATION_NOE CD8<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE /<|>RELATION_NOE CD8<|>RELATION_NOE 及<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 58.9<|>RELATION_NOE ±<|>RELATION_NOE 15.8<|>RELATION_NOE 、<|>RELATION_NOE 32.3<|>RELATION_NOE ±<|>RELATION_NOE 12.7<|>RELATION_NOE 、<|>RELATION_NOE 22.0<|>RELATION_NOE ±<|>RELATION_NOE 9.8<|>RELATION_NOE 、<|>RELATION_NOE 1.3<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 、<|>RELATION_NOE 21.6<|>RELATION_NOE ±<|>RELATION_NOE 7.7<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 中青年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 65.9<|>RELATION_NOE ±<|>RELATION_NOE 7.2<|>RELATION_NOE 、<|>RELATION_NOE 38.5<|>RELATION_NOE ±<|>RELATION_NOE 7.6<|>RELATION_NOE 、<|>RELATION_NOE 23.1<|>RELATION_NOE ±<|>RELATION_NOE 9.2<|>RELATION_NOE 、<|>RELATION_NOE 1.5<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 、<|>RELATION_NOE 16.8<|>RELATION_NOE ±<|>RELATION_NOE 6.2<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE CD3<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE 细胞<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 增加<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.<|>RELATION_NOE 109<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 59<|>RELATION_NOE 、<|>RELATION_NOE 2.2<|>RELATION_NOE 73<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CD8<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE /<|>RELATION_NOE CD8<|>RELATION_NOE 变化<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 0.406<|>RELATION_NOE 、<|>RELATION_NOE 0.7<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 51.6<|>RELATION_NOE ±<|>RELATION_NOE 10.3<|>RELATION_NOE 、<|>RELATION_NOE 31.7<|>RELATION_NOE ±<|>RELATION_NOE 11.7<|>RELATION_NOE 、<|>RELATION_NOE 21.6<|>RELATION_NOE ±<|>RELATION_NOE 6.5<|>RELATION_NOE 、<|>RELATION_NOE 1.3<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 、<|>RELATION_NOE 26.0<|>RELATION_NOE ±<|>RELATION_NOE 12.7<|>RELATION_NOE ,<|>RELATION_NOE CD3<|>RELATION_NOE 明显<|>RELATION_NOE 减低<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.0<|>RELATION_NOE 67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CD4<|>RELATION_NOE 、<|>RELATION_NOE CD8<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE /<|>RELATION_NOE CD8<|>RELATION_NOE 及<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 86<|>RELATION_NOE 、<|>RELATION_NOE 0.18<|>RELATION_NOE 0<|>RELATION_NOE 、<|>RELATION_NOE 0.2<|>RELATION_NOE 89<|>RELATION_NOE 、<|>RELATION_NOE 1.5<|>RELATION_NOE 70<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_S 小细胞肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 术后<|>RELATION_NOE 恼<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 术<|>RELATION_NOE 后脑<|>RELATION_NOE 预防<|>RELATION_NOE 照射<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
小细胞肺癌<|>RELATION_NOE 胸内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_NOE 对<|>RELATION_NOE 确定<|>RELATION_NOE 放疗<|>RELATION_NOE 范围<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
通过<|>RELATION_NOE 分析<|>RELATION_S 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE small<|>RELATION_NOE cell<|>RELATION_NOE lungcancer<|>RELATION_NOE ,<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 胸内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 方式<|>RELATION_NOE 和<|>RELATION_NOE 规律<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE SCLC<|>RELATION_NOE 放疗<|>RELATION_NOE 靶区<|>RELATION_NOE 的<|>RELATION_NOE 合理<|>RELATION_NOE 范围<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 本院<|>RELATION_NOE 150<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 根治性<|>RELATION_NOE 切除<|>RELATION_NOE 及<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 的<|>RELATION_NOE 局限期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 胸内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 进行<|>RELATION_NOE 分组<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 胸内<|>RELATION_NOE 各组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 方式<|>RELATION_NOE 和<|>RELATION_NOE 规律<|>RELATION_NOE 。<|>RELATION_NOE
150<|>RELATION_NOE 例<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 清扫<|>RELATION_NOE 胸内<|>RELATION_NOE 631<|>RELATION_NOE 个<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 23<|>RELATION_NOE 72<|>RELATION_NOE 个<|>RELATION_NOE 淋巴结<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 188<|>RELATION_NOE 个<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 29.8%<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 413<|>RELATION_NOE 个<|>RELATION_NOE 淋巴结<|>RELATION_NOE (<|>RELATION_NOE 17.4%<|>RELATION_NOE )<|>RELATION_NOE 存在<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 88<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 58.7%<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 存在<|>RELATION_NOE 胸内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
胸内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 是<|>RELATION_NOE 11<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 中央型<|>RELATION_NOE 、<|>RELATION_NOE T<|>RELATION_NOE 分期晚<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 15.32<|>RELATION_NOE 、<|>RELATION_NOE 39.72<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE 、<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
右肺<|>RELATION_NOE 上<|>RELATION_NOE 叶<|>RELATION_NOE 和<|>RELATION_NOE 中下叶<|>RELATION_NOE 肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 高危<|>RELATION_NOE 转移<|>RELATION_NOE 区域<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 11<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 左<|>RELATION_NOE 肺上叶<|>RELATION_NOE 和<|>RELATION_NOE 下叶<|>RELATION_NOE 肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 高危<|>RELATION_NOE 转移<|>RELATION_NOE 区域<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 、<|>RELATION_NOE 9<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 11<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 72<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 无<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 跳跃性<|>RELATION_NOE 转移<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 肺上<|>RELATION_NOE 叶癌<|>RELATION_NOE 主要<|>RELATION_NOE 向上<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE ,<|>RELATION_NOE 肺中<|>RELATION_NOE 下<|>RELATION_NOE 叶癌<|>RELATION_NOE 可<|>RELATION_NOE 向<|>RELATION_NOE 上<|>RELATION_NOE 、<|>RELATION_NOE 下<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
SCLC<|>RELATION_NOE 胸内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 遵循<|>RELATION_NOE 由<|>RELATION_NOE 肺内经<|>RELATION_NOE 肺门<|>RELATION_NOE 向<|>RELATION_NOE 纵隔<|>RELATION_NOE 依次<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 规律<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 存在<|>RELATION_NOE 部分<|>RELATION_NOE 跳跃性<|>RELATION_NOE 转移<|>RELATION_NOE ;<|>RELATION_NOE
对<|>RELATION_NOE 不同<|>RELATION_NOE 肺叶<|>RELATION_NOE 肺癌<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 高危<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 区域<|>RELATION_NOE 给予<|>RELATION_NOE 预防<|>RELATION_NOE 照射<|>RELATION_NOE 有<|>RELATION_NOE 可能<|>RELATION_NOE 提高<|>RELATION_S SCLC<|>RELATION_NOE 的<|>RELATION_NOE 放疗<|>RELATION_NOE 增益<|>RELATION_NOE 比<|>RELATION_NOE 。<|>RELATION_NOE
Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 同期<|>RELATION_NOE 胸部<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 前瞻性<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE (<|>RELATION_NOE 二<|>RELATION_NOE )<|>RELATION_NOE ——<|>RELATION_NOE 不同<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 状态<|>RELATION_NOE 对<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
评价<|>RELATION_NOE 化疗<|>RELATION_NOE 同期<|>RELATION_NOE 胸部<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 不同<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 状态<|>RELATION_NOE 对<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
单纯骨<|>RELATION_NOE 及<|>RELATION_NOE 肺转移<|>RELATION_NOE 与<|>RELATION_NOE 多<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 58%<|>RELATION_NOE 、<|>RELATION_NOE 25%<|>RELATION_NOE 、<|>RELATION_NOE 16%<|>RELATION_NOE 和<|>RELATION_NOE 14<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 与<|>RELATION_NOE 29%<|>RELATION_NOE 、<|>RELATION_NOE 12%<|>RELATION_NOE 、<|>RELATION_NOE 0%<|>RELATION_NOE 和<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 10.42<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 49%<|>RELATION_NOE 、<|>RELATION_NOE 21%<|>RELATION_NOE 、<|>RELATION_NOE 21%<|>RELATION_NOE 和<|>RELATION_NOE 11<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 与<|>RELATION_NOE 29%<|>RELATION_NOE 、<|>RELATION_NOE 12%<|>RELATION_NOE 、<|>RELATION_NOE 0%<|>RELATION_NOE 和<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 6.39<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 11<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 单纯脑<|>RELATION_NOE 转移<|>RELATION_NOE 与<|>RELATION_NOE 多<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 49%<|>RELATION_NOE 、<|>RELATION_NOE 8%<|>RELATION_NOE 、<|>RELATION_NOE 0%<|>RELATION_NOE 和<|>RELATION_NOE 12<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 与<|>RELATION_NOE 29%<|>RELATION_NOE 、<|>RELATION_NOE 12%<|>RELATION_NOE 、<|>RELATION_NOE 0%<|>RELATION_NOE 和<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 0.71<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.401<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
相同<|>RELATION_NOE 转移<|>RELATION_NOE 状态<|>RELATION_NOE 和<|>RELATION_NOE 4－5<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 化疗<|>RELATION_NOE 强度<|>RELATION_NOE 的<|>RELATION_NOE 单<|>RELATION_NOE 器官<|>RELATION_NOE 以及<|>RELATION_NOE 多<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 放疗<|>RELATION_NOE ≥<|>RELATION_NOE 63Gy<|>RELATION_NOE 及<|>RELATION_NOE <<|>RELATION_NOE 63Gy<|>RELATION_NOE 的<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 71%<|>RELATION_NOE 、<|>RELATION_NOE 25%<|>RELATION_NOE 、<|>RELATION_NOE 25%<|>RELATION_NOE 和<|>RELATION_NOE 16.8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 及<|>RELATION_NOE 33%<|>RELATION_NOE 、<|>RELATION_NOE 17%<|>RELATION_NOE 、<|>RELATION_NOE 0%<|>RELATION_NOE 和<|>RELATION_NOE 10.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 4.73<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE 54%<|>RELATION_NOE 、<|>RELATION_NOE 21%<|>RELATION_NOE 、<|>RELATION_NOE 0%<|>RELATION_NOE 和<|>RELATION_NOE 14.3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 及<|>RELATION_NOE 29%<|>RELATION_NOE 、<|>RELATION_NOE 10%<|>RELATION_NOE 、<|>RELATION_NOE 0%<|>RELATION_NOE 和<|>RELATION_NOE 7.6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 8.16<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE :<|>RELATION_NOE 0.004<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 同期<|>RELATION_NOE 胸部<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 前瞻性<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_S (<|>RELATION_NOE 一<|>RELATION_NOE )<|>RELATION_NOE ——<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE
分析<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 胃肠道<|>RELATION_NOE 、<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 和<|>RELATION_NOE 食管炎<|>RELATION_NOE 。<|>RELATION_NOE
2+<|>RELATION_NOE 3级<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 和<|>RELATION_NOE 食管炎<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 9.5%<|>RELATION_NOE 和<|>RELATION_NOE 13.4%<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 在<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
甲状腺癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 的<|>RELATION_NOE 术前<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 提供<|>RELATION_B 重要<|>RELATION_I 信息<|>RELATION_E 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE
探讨<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I<|>RELATION_NOE 粒子<|>RELATION_NOE 近<|>RELATION_B 距离<|>RELATION_I 治疗<|>RELATION_E 肺癌<|>RELATION_NOE 溶骨<|>RELATION_NOE 性骨<|>RELATION_NOE 转移<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 镇痛<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE CT<|>RELATION_NOE 、<|>RELATION_NOE MRI<|>RELATION_NOE 、<|>RELATION_NOE PET-CT<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 伴溶<|>RELATION_NOE 骨<|>RELATION_NOE 性骨<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 20<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE ;<|>RELATION_NOE
处方<|>RELATION_NOE 剂量<|>RELATION_NOE (<|>RELATION_NOE priscribed<|>RELATION_NOE dose<|>RELATION_NOE ,<|>RELATION_NOE PD<|>RELATION_NOE )<|>RELATION_NOE 110Gy<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 靶区<|>RELATION_NOE 接受<|>RELATION_NOE 的<|>RELATION_NOE 照射<|>RELATION_NOE 剂量<|>RELATION_NOE (<|>RELATION_NOE 159<|>RELATION_NOE ±<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE D90<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE 6.5<|>RELATION_NOE ±<|>RELATION_NOE 14<|>RELATION_NOE )<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下行<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 植入<|>RELATION_NOE 放射性<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I<|>RELATION_NOE 粒子<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 复查<|>RELATION_NOE CT<|>RELATION_NOE 判定<|>RELATION_NOE 瘤体<|>RELATION_NOE 直径<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 疼痛<|>RELATION_NOE 缓解<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 6－<|>RELATION_NOE 29<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
15<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 20<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 顺利<|>RELATION_NOE 植入<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 并发症<|>RELATION_NOE 及<|>RELATION_NOE 放射性<|>RELATION_NOE 损伤<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE CR<|>RELATION_NOE 占<|>RELATION_NOE 35%<|>RELATION_NOE (<|>RELATION_NOE 7<|>RELATION_NOE /<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE PR<|>RELATION_NOE 占<|>RELATION_NOE 65%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 100%<|>RELATION_NOE ;<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 125<|>RELATION_NOE ↑<|>RELATION_NOE I<|>RELATION_NOE 粒子<|>RELATION_NOE 近<|>RELATION_NOE 距离<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 溶骨<|>RELATION_NOE 性骨<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 有效<|>RELATION_NOE 微创<|>RELATION_NOE 的<|>RELATION_NOE
应用<|>RELATION_NOE 比较<|>RELATION_S 基因组杂交<|>RELATION_NOE 检测<|>RELATION_NOE 肺癌<|>RELATION_NOE 染色体异常<|>RELATION_NOE
17<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 均<|>RELATION_NOE 检<|>RELATION_B 出<|>RELATION_E 染色体畸变<|>RELATION_NOE (<|>RELATION_NOE 扩增<|>RELATION_NOE 和<|>RELATION_NOE /<|>RELATION_NOE 或<|>RELATION_NOE 缺失<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 每个<|>RELATION_NOE 病例<|>RELATION_NOE 涉及<|>RELATION_NOE 多<|>RELATION_NOE 条<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 染色体<|>RELATION_NOE 扩增<|>RELATION_NOE 和<|>RELATION_NOE 缺失<|>RELATION_NOE 平均<|>RELATION_NOE 发生率<|>RELATION_NOE (<|>RELATION_NOE 7处/例<|>RELATION_NOE 和<|>RELATION_NOE 4.8<|>RELATION_NOE 处/例<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE 8.4<|>RELATION_NOE 处/例<|>RELATION_NOE 和<|>RELATION_NOE 9.6<|>RELATION_NOE 处/例<|>RELATION_NOE )<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE NSCLC<|>RELATION_NOE 与<|>RELATION_NOE SCLC<|>RELATION_NOE 的<|>RELATION_NOE 染色体<|>RELATION_NOE 扩增<|>RELATION_NOE 和<|>RELATION_NOE 缺失<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 部位<|>RELATION_NOE 及其<|>RELATION_NOE 频率<|>RELATION_NOE 有所不同<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE 染色体<|>RELATION_NOE 3q24—28<|>RELATION_NOE 和<|>RELATION_NOE 11q13<|>RELATION_NOE 的<|>RELATION_NOE 扩增<|>RELATION_NOE 的<|>RELATION_NOE 频率<|>RELATION_NOE (<|>RELATION_NOE 58.3%<|>RELATION_NOE 和<|>RELATION_NOE 58.3%<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E SCLC<|>RELATION_NOE (<|>RELATION_NOE 0%<|>RELATION_NOE 和<|>RELATION_NOE 0%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 和<|>RELATION_NOE SCLC<|>RELATION_NOE 在<|>RELATION_NOE 发生<|>RELATION_NOE 和<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 都<|>RELATION_NOE 涉及<|>RELATION_NOE 多<|>RELATION_NOE 部位<|>RELATION_NOE 染色体<|>RELATION_NOE (<|>RELATION_NOE 多<|>RELATION_NOE 基因<|>RELATION_NOE )<|>RELATION_NOE 异常<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE 与<|>RELATION_NOE SCLC<|>RELATION_NOE 染色体<|>RELATION_NOE 扩增<|>RELATION_NOE 和<|>RELATION_NOE 缺失<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 部位<|>RELATION_NOE 及其<|>RELATION_NOE 频率<|>RELATION_NOE 有所不同<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 导致<|>RELATION_S 两者<|>RELATION_NOE 不同<|>RELATION_NOE 生物学<|>RELATION_NOE 特性<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 。<|>RELATION_NOE
40%<|>RELATION_NOE －8<|>RELATION_NOE 5%<|>RELATION_NOE 剂量<|>RELATION_NOE 曲线<|>RELATION_NOE 完全<|>RELATION_NOE 包裹<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 靶区<|>RELATION_NOE (<|>RELATION_NOE GTV<|>RELATION_NOE )<|>RELATION_NOE 勾画<|>RELATION_NOE ,<|>RELATION_NOE 计划<|>RELATION_NOE 靶区<|>RELATION_NOE (<|>RELATION_NOE PTV<|>RELATION_NOE )<|>RELATION_NOE 紧贴<|>RELATION_NOE 肿瘤<|>RELATION_NOE 外缘<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_NOE 进行<|>RELATION_NOE 外放<|>RELATION_NOE (<|>RELATION_NOE PTV<|>RELATION_NOE =<|>RELATION_NOE GTV<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE PTV<|>RELATION_NOE 边缘<|>RELATION_NOE 处方<|>RELATION_NOE 剂量<|>RELATION_NOE 1200-2500cGy<|>RELATION_NOE ,<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 加用<|>RELATION_NOE 保护<|>RELATION_NOE 胃黏膜<|>RELATION_NOE 药物<|>RELATION_NOE 、<|>RELATION_NOE 脱水剂<|>RELATION_NOE 、<|>RELATION_NOE 激素<|>RELATION_NOE 等<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 支持<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 放射性<|>RELATION_NOE 脑水肿<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE
46<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 3－<|>RELATION_NOE 28<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 12<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 随访期<|>RELATION_NOE 内<|>RELATION_NOE 出现<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 出现<|>RELATION_NOE 放射性<|>RELATION_NOE 脑水肿<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 瘤体<|>RELATION_NOE 稳定<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE ,<|>RELATION_NOE 随访期<|>RELATION_NOE 内<|>RELATION_NOE 疗效<|>RELATION_NOE :<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE CR<|>RELATION_NOE )<|>RELATION_NOE 率<|>RELATION_NOE 60.8<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE 28<|>RELATION_NOE /<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 率<|>RELATION_NOE 32.6<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE 15<|>RELATION_NOE /<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE (<|>RELATION_NOE CR<|>RELATION_NOE +<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 率<|>RELATION_NOE 3.4<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 稳定<|>RELATION_NOE (<|>RELATION_NOE SD<|>RELATION_NOE )<|>RELATION_NOE 率<|>RELATION_NOE 13.04%<|>RELATION_NOE (<|>RELATION_NOE 6/46<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 神经<|>RELATION_NOE 功能<|>RELATION_NOE 症状<|>RELATION_NOE 改善<|>RELATION_NOE 率<|>RELATION_NOE 93.4<|>RELATION_NOE 8%<|>RELATION_NOE (<|>RELATION_NOE 43<|>RELATION_NOE /<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 全<|>RELATION_NOE 组<|>RELATION_NOE 病例<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 43.5%<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE /<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 2年<|>RELATION_NOE 生存率<|>RELATION_NOE 13.0%<|>RELATION_NOE (<|>RELATION_NOE 6/46<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
香菇多糖<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE
观察<|>RELATION_S 香菇多糖<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 采用<|>RELATION_S 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 导管<|>RELATION_NOE 建立<|>RELATION_NOE 闭式<|>RELATION_NOE 引流<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 基本<|>RELATION_NOE 引流<|>RELATION_NOE 干净<|>RELATION_NOE 后<|>RELATION_NOE 注入<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 6mg<|>RELATION_NOE 加<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 溶液<|>RELATION_NOE 20ml<|>RELATION_NOE 。<|>RELATION_NOE
香菇多糖<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 疗效<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 轻且<|>RELATION_NOE 发生率<|>RELATION_NOE 低<|>RELATION_S ,<|>RELATION_NOE 易<|>RELATION_NOE 被<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 黏膜<|>RELATION_NOE 细胞学<|>RELATION_NOE 膜式<|>RELATION_NOE 超薄<|>RELATION_NOE 液基<|>RELATION_NOE 细胞学<|>RELATION_NOE 制片<|>RELATION_NOE 技术<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 涂片<|>RELATION_NOE 方法<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
支气管<|>RELATION_NOE 黏膜<|>RELATION_NOE 细胞学<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 354<|>RELATION_NOE 例<|>RELATION_NOE 支气管<|>RELATION_NOE 黏膜<|>RELATION_NOE 细胞<|>RELATION_NOE 同时<|>RELATION_NOE 采用<|>RELATION_S TCT<|>RELATION_NOE 技术<|>RELATION_NOE 制片<|>RELATION_NOE 和<|>RELATION_NOE 传统<|>RELATION_NOE 涂片<|>RELATION_NOE 方法<|>RELATION_NOE 制片<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 116<|>RELATION_NOE 例<|>RELATION_NOE 活检<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE
有<|>RELATION_NOE 活<|>RELATION_NOE 检<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 对照<|>RELATION_NOE 的<|>RELATION_NOE 116<|>RELATION_NOE 例<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE TCT<|>RELATION_NOE 技术<|>RELATION_NOE 制片<|>RELATION_NOE 结果<|>RELATION_NOE 与<|>RELATION_NOE 活检<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 完全<|>RELATION_NOE 符合<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 84.4<|>RELATION_NOE 8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE TCT<|>RELATION_NOE 技术<|>RELATION_NOE 制片<|>RELATION_NOE 诊断<|>RELATION_NOE 可<|>RELATION_NOE 疑癌<|>RELATION_NOE 的<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 活检<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 95.6<|>RELATION_NOE 8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 准确率<|>RELATION_NOE 提高<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 未能<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 因<|>RELATION_NOE 取材<|>RELATION_NOE 组织<|>RELATION_NOE 太<|>RELATION_NOE 少<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 。<|>RELATION_NOE
TGT<|>RELATION_NOE 技术<|>RELATION_NOE 制片<|>RELATION_NOE 方法<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 涂片<|>RELATION_NOE 相<|>RELATION_NOE 对比<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 黏膜<|>RELATION_NOE 异常<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 检出率<|>RELATION_NOE 提高<|>RELATION_S 。<|>RELATION_NOE
活检<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确率<|>RELATION_B 提高<|>RELATION_E 。<|>RELATION_NOE
在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE TCT<|>RELATION_NOE 技术<|>RELATION_NOE 制片<|>RELATION_NOE 检测<|>RELATION_NOE 与<|>RELATION_NOE 活检<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 检查<|>RELATION_NOE 结合<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_S 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确率<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 趋化因子<|>RELATION_NOE 及其<|>RELATION_NOE 受体<|>RELATION_NOE CXCR4<|>RELATION_NOE 和<|>RELATION_NOE 缺氧<|>RELATION_NOE 诱导<|>RELATION_NOE 因子<|>RELATION_NOE -1<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 食管<|>RELATION_NOE 鳞状<|>RELATION_NOE 上皮癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 食管<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 56<|>RELATION_NOE 例<|>RELATION_NOE 食管<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 黏膜组织<|>RELATION_NOE 中<|>RELATION_NOE CXCR4<|>RELATION_NOE 和<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
食管<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE CXCR4<|>RELATION_NOE 、<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 62.<|>RELATION_NOE 50%<|>RELATION_NOE (<|>RELATION_NOE 35<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 57.1<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 正常<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 10.00%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 0<|>RELATION_NOE (<|>RELATION_NOE 0<|>RELATION_NOE /<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 16.2<|>RELATION_NOE 59<|>RELATION_NOE 、<|>RELATION_NOE 19.7<|>RELATION_NOE 40<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CXCR4<|>RELATION_NOE 和<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE 在<|>RELATION_NOE 食管<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 浸润<|>RELATION_NOE 深度<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE CXCR4<|>RELATION_NOE :<|>RELATION_NOE χ<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 4.7<|>RELATION_NOE 36<|>RELATION_NOE 、<|>RELATION_NOE 7.6<|>RELATION_NOE 65<|>RELATION_NOE 与<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE :<|>RELATION_NOE χ<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 7.207<|>RELATION_NOE 、<|>RELATION_NOE 6.3<|>RELATION_NOE 89<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 癌组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 无关<|>RELATION_NOE ;<|>RELATION_NOE
靶向<|>RELATION_NOE 同<|>RELATION_NOE 源盒<|>RELATION_NOE A10<|>RELATION_NOE 特异性<|>RELATION_NOE 干扰性<|>RELATION_NOE 小<|>RELATION_NOE RNA<|>RELATION_NOE 序列<|>RELATION_NOE 的<|>RELATION_NOE 筛选<|>RELATION_B 及<|>RELATION_I 功能<|>RELATION_I 鉴定<|>RELATION_E
筛选<|>RELATION_S 有效<|>RELATION_NOE 干扰<|>RELATION_NOE 同<|>RELATION_NOE 源盒<|>RELATION_NOE (<|>RELATION_NOE HOX<|>RELATION_NOE )<|>RELATION_NOE A10<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 干扰性<|>RELATION_NOE 小<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 序列<|>RELATION_NOE 并<|>RELATION_NOE 鉴定<|>RELATION_NOE 其<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 靶向<|>RELATION_NOE HOXA10<|>RELATION_NOE 防治<|>RELATION_NOE 肿瘤<|>RELATION_NOE 提供<|>RELATION_NOE 实验<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
筛选<|>RELATION_NOE 出<|>RELATION_NOE 抑制<|>RELATION_NOE HOXA10<|>RELATION_NOE 效果<|>RELATION_NOE 最佳<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE 序列<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑盐<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_S 该<|>RELATION_NOE siRNA<|>RELATION_NOE 干扰<|>RELATION_NOE HOXA10<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
泡膜<|>RELATION_NOE 蛋白1<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 预后<|>RELATION_I 价值<|>RELATION_E
收集<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 蜡块<|>RELATION_NOE 78<|>RELATION_NOE 例<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 随访<|>RELATION_NOE ,<|>RELATION_NOE 订制<|>RELATION_NOE 兔抗人<|>RELATION_NOE VMP1<|>RELATION_NOE 抗体<|>RELATION_NOE 并<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检测<|>RELATION_S VMP1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 指标<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 生存率<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
VMP1<|>RELATION_NOE 只<|>RELATION_NOE 表达<|>RELATION_NOE 于<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 且<|>RELATION_NOE 定位<|>RELATION_NOE 于<|>RELATION_NOE 胞质<|>RELATION_NOE ,<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 35.9%<|>RELATION_NOE (<|>RELATION_NOE 28<|>RELATION_NOE /<|>RELATION_NOE 78<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE VMP1<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 关系<|>RELATION_B 密切<|>RELATION_E ,<|>RELATION_NOE 分期<|>RELATION_NOE 越<|>RELATION_NOE 晚<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 越<|>RELATION_NOE 高(χ^2<|>RELATION_NOE =<|>RELATION_NOE 6.8<|>RELATION_NOE 29<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 号<|>RELATION_NOE 陛别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 大体<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 等<|>RELATION_NOE 均<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE VMP1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 具有<|>RELATION_B 较<|>RELATION_I 好<|>RELATION_I 的<|>RELATION_I 预后<|>RELATION_I 价值<|>RELATION_E ,<|>RELATION_NOE VMP1<|>RELATION_NOE 阳性<|>RELATION_NOE 提示<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 。<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE VMP1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE VMP1<|>RELATION_NOE 阳性<|>RELATION_NOE 提示<|>RELATION_S 预后<|>RELATION_NOE 不良<|>RELATION_NOE 。<|>RELATION_NOE
双源<|>RELATION_NOE 容积<|>RELATION_NOE 灌注<|>RELATION_NOE CT<|>RELATION_NOE 对<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 近期<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 评价<|>RELATION_S
双源<|>RELATION_NOE VPCT<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 评价<|>RELATION_E 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 肺癌<|>RELATION_NOE 血管<|>RELATION_NOE 灌注<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 判断<|>RELATION_NOE 疗效<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 剂量<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 应用<|>RELATION_B 于<|>RELATION_E 高危<|>RELATION_NOE 人群<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 筛查<|>RELATION_NOE 的<|>RELATION_NOE 荟萃<|>RELATION_NOE 分析<|>RELATION_NOE
LDCT<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 具有<|>RELATION_B 较<|>RELATION_I 高<|>RELATION_I 的<|>RELATION_I 检出率<|>RELATION_E 。<|>RELATION_NOE
调查<|>RELATION_NOE 非呼吸科<|>RELATION_NOE 医师<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 治疗<|>RELATION_I 情况<|>RELATION_E ,<|>RELATION_NOE 以<|>RELATION_NOE 促进<|>RELATION_NOE 其<|>RELATION_NOE 规范<|>RELATION_NOE 诊治<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 调查<|>RELATION_NOE 2009年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 在<|>RELATION_NOE 复旦<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 中山<|>RELATION_NOE 医院<|>RELATION_NOE 非<|>RELATION_NOE 呼吸科<|>RELATION_NOE (<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 胸外科<|>RELATION_NOE )<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 收集<|>RELATION_NOE 其<|>RELATION_NOE 出入院<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 一般<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 检查<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 非呼吸科<|>RELATION_NOE 接诊<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 240<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE COPD<|>RELATION_NOE 诊断者<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 2.1%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
非呼吸科<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE COPD<|>RELATION_B 漏诊<|>RELATION_I 情况<|>RELATION_I 严重<|>RELATION_E ,<|>RELATION_NOE 治疗<|>RELATION_NOE 不<|>RELATION_NOE 充分<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 规范<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 嗜酸细胞<|>RELATION_NOE 浸润<|>RELATION_NOE 及<|>RELATION_NOE 白细胞介素<|>RELATION_NOE 5<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
采用<|>RELATION_NOE 组织<|>RELATION_NOE 化学变<|>RELATION_NOE 色酸<|>RELATION_NOE 2R<|>RELATION_NOE 特殊<|>RELATION_NOE 染色法<|>RELATION_NOE 标记<|>RELATION_S 45<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌及<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 嗜酸细胞<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 嗜酸细胞<|>RELATION_NOE 浸润<|>RELATION_NOE 情况<|>RELATION_NOE ;<|>RELATION_NOE
45<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 91.1%<|>RELATION_NOE )<|>RELATION_NOE IL-5<|>RELATION_NOE 强<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 8.9%<|>RELATION_NOE )<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 癌细胞<|>RELATION_NOE 胞质<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_NOE 阴性<|>RELATION_NOE 或<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 与<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE IL-5<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 嗜酸细胞<|>RELATION_NOE 浸润<|>RELATION_NOE 的<|>RELATION_NOE 数量<|>RELATION_NOE 与<|>RELATION_NOE 癌细胞<|>RELATION_NOE 中<|>RELATION_NOE IL-5<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关性<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 26<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
部分<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 内<|>RELATION_NOE 存在<|>RELATION_S 嗜酸细胞<|>RELATION_NOE 高<|>RELATION_NOE 浸润<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE NSGLC<|>RELATION_NOE 更为<|>RELATION_NOE 多见.<|>RELATION_NOE
肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE 普遍<|>RELATION_NOE 存在<|>RELATION_NOE IL-5<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE IL-5<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 嗜酸细胞<|>RELATION_NOE 的<|>RELATION_NOE 浸润量<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关性<|>RELATION_E .<|>RELATION_NOE
人类<|>RELATION_NOE 皮层<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE 基因<|>RELATION_NOE siRNA<|>RELATION_NOE 干预<|>RELATION_S 结肠<|>RELATION_NOE 癌细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
构建<|>RELATION_S 针对<|>RELATION_NOE Cortactin<|>RELATION_NOE 的<|>RELATION_NOE 编码<|>RELATION_NOE 基因<|>RELATION_NOE EMS1<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE 转染<|>RELATION_NOE 结肠<|>RELATION_NOE 癌细胞<|>RELATION_NOE HCT8<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 3组<|>RELATION_NOE :<|>RELATION_NOE EMS1-siRNA<|>RELATION_NOE 转染组<|>RELATION_NOE 、<|>RELATION_NOE 空<|>RELATION_NOE 载体组<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 未<|>RELATION_NOE 转染组<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 尾静脉<|>RELATION_NOE 分别<|>RELATION_NOE 注射<|>RELATION_NOE 上述<|>RELATION_NOE 3<|>RELATION_NOE 种<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 6<|>RELATION_NOE 周<|>RELATION_NOE 后<|>RELATION_NOE 处死<|>RELATION_NOE 并<|>RELATION_NOE 观察<|>RELATION_S 这<|>RELATION_NOE 3组<|>RELATION_NOE 动物<|>RELATION_NOE 的<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 形成<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
Cortactin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 减少<|>RELATION_NOE 可以<|>RELATION_NOE 降低<|>RELATION_S 结肠<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE .<|>RELATION_NOE
苦<|>RELATION_NOE 碟子<|>RELATION_NOE 注射液<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 与<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 苦<|>RELATION_NOE 碟子<|>RELATION_NOE 注射液<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 与<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTr<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 、<|>RELATION_NOE 激光<|>RELATION_NOE 共<|>RELATION_NOE 聚焦<|>RELATION_NOE 显微镜<|>RELATION_NOE (<|>RELATION_NOE LSM<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE (<|>RELATION_NOE FCM<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE Westernblot<|>RELATION_NOE 技术<|>RELATION_NOE 观察<|>RELATION_S 12.5－<|>RELATION_NOE 400.0s<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 苦碟子<|>RELATION_NOE 注射液<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 、<|>RELATION_NOE 细胞周期<|>RELATION_NOE 及<|>RELATION_NOE p53<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 浓度<|>RELATION_NOE KDI<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 50g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE 100g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE 200g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 及<|>RELATION_NOE 400g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 组<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12.78<|>RELATION_NOE ±<|>RELATION_NOE 0.29<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 13.46<|>RELATION_NOE ±<|>RELATION_NOE 0.64<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 20.52<|>RELATION_NOE ±<|>RELATION_NOE 0.73<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 13.64<|>RELATION_NOE ±<|>RELATION_NOE 0.21<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 0.89<|>RELATION_NOE ±<|>RELATION_NOE 0.11<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE G0<|>RELATION_NOE /<|>RELATION_NOE G1<|>RELATION_NOE 期细胞<|>RELATION_NOE 百分比<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 75.15<|>RELATION_NOE ±<|>RELATION_NOE 1.00<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 77.52<|>RELATION_NOE ±<|>RELATION_NOE 1.09<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 79.70<|>RELATION_NOE ±<|>RELATION_NOE 1.48<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 74.55<|>RELATION_NOE ±<|>RELATION_NOE 0.91<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 66.28<|>RELATION_NOE ±<|>RELATION_NOE 1.91<|>RELATION_NOE )%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ASd9<|>RELATION_NOE 细胞<|>RELATION_NOE p53<|>RELATION_NOE 表达量<|>RELATION_NOE 较<|>RELATION_NOE 正常<|>RELATION_NOE 对照组<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血浆<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE ,<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 对<|>RELATION_NOE 各型<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
探讨<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE (<|>RELATION_NOE ProGRP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE (<|>RELATION_NOE CYFRA21—1<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 各型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
检测<|>RELATION_S 85<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 对照<|>RELATION_NOE 人群<|>RELATION_NOE 、<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 143<|>RELATION_NOE 例<|>RELATION_NOE 各型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE ProGRP<|>RELATION_NOE ,<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 三<|>RELATION_NOE 个<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE ProGRP<|>RELATION_NOE 的<|>RELATION_NOE 跟踪<|>RELATION_NOE 监测<|>RELATION_NOE 。<|>RELATION_NOE
非恶性<|>RELATION_NOE 疾病<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 先天性<|>RELATION_NOE 疾病<|>RELATION_NOE 、<|>RELATION_NOE 感染性疾病<|>RELATION_NOE 及<|>RELATION_NOE 原发性<|>RELATION_NOE 气胸<|>RELATION_NOE 常见<|>RELATION_S 。<|>RELATION_NOE
结论<|>RELATION_NOE :<|>RELATION_NOE 飞行<|>RELATION_NOE 人员<|>RELATION_NOE 罹患<|>RELATION_NOE 胸外科<|>RELATION_NOE 疾病<|>RELATION_NOE 相对<|>RELATION_NOE 较<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 年度<|>RELATION_NOE 大体检<|>RELATION_NOE 特别<|>RELATION_NOE 是<|>RELATION_NOE 胸部<|>RELATION_NOE X<|>RELATION_NOE 线片<|>RELATION_NOE 检查<|>RELATION_NOE 对<|>RELATION_NOE 疾病<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_B 重要<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
还原型<|>RELATION_NOE 谷胱甘肽<|>RELATION_NOE 预处理<|>RELATION_NOE 对<|>RELATION_NOE 单肺通气<|>RELATION_NOE 患者<|>RELATION_NOE 围手术期<|>RELATION_NOE 炎性<|>RELATION_NOE 因子<|>RELATION_NOE 和<|>RELATION_NOE 自由基<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
GSH<|>RELATION_NOE 组<|>RELATION_NOE 于<|>RELATION_NOE 麻醉<|>RELATION_NOE 诱导<|>RELATION_NOE 后<|>RELATION_NOE 单肺通气<|>RELATION_NOE 前<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE GSH30mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE 等量<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 。<|>RELATION_NOE
于<|>RELATION_NOE 麻醉<|>RELATION_NOE 诱导<|>RELATION_NOE 前<|>RELATION_NOE (<|>RELATION_NOE T0<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 单肺通气<|>RELATION_NOE 30min<|>RELATION_NOE (<|>RELATION_NOE T1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 单肺通气<|>RELATION_NOE 60min<|>RELATION_NOE (<|>RELATION_NOE T2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 恢复<|>RELATION_NOE 双<|>RELATION_NOE 肺通气<|>RELATION_NOE 60min<|>RELATION_NOE (<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 2h<|>RELATION_NOE (<|>RELATION_NOE T4<|>RELATION_NOE )<|>RELATION_NOE 采集<|>RELATION_NOE 桡动脉<|>RELATION_NOE 血<|>RELATION_NOE ,<|>RELATION_NOE 测定<|>RELATION_S 血浆<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE TNF<|>RELATION_NOE )<|>RELATION_NOE -<|>RELATION_NOE α<|>RELATION_NOE 、<|>RELATION_NOE 白细胞介素<|>RELATION_NOE (<|>RELATION_NOE IL<|>RELATION_NOE )<|>RELATION_NOE -8<|>RELATION_NOE 、<|>RELATION_NOE 丙二醛<|>RELATION_NOE (<|>RELATION_NOE MDA<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 和<|>RELATION_NOE 超<|>RELATION_NOE 氧化物<|>RELATION_NOE 歧化<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE SOD<|>RELATION_NOE )<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE
探讨<|>RELATION_NOE 研究<|>RELATION_NOE 临床<|>RELATION_NOE 护理<|>RELATION_NOE 工作<|>RELATION_NOE 在<|>RELATION_NOE 培美<|>RELATION_NOE 曲赛<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_B 与<|>RELATION_I 效果<|>RELATION_E 。<|>RELATION_NOE
选择<|>RELATION_NOE 本院<|>RELATION_NOE 心胸<|>RELATION_NOE 外科<|>RELATION_NOE 2009年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 使用<|>RELATION_NOE 培美<|>RELATION_NOE 曲赛<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 8例<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 进行<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 次<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 与<|>RELATION_NOE 效果<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_S 以<|>RELATION_NOE 胸壁<|>RELATION_NOE 肿物<|>RELATION_NOE 合并<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE 的<|>RELATION_NOE 多发性<|>RELATION_NOE 骨髓瘤<|>RELATION_NOE (<|>RELATION_NOE MM<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肺部<|>RELATION_NOE 浸润<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 体征<|>RELATION_NOE 、<|>RELATION_NOE 各项<|>RELATION_NOE 理化<|>RELATION_NOE 和<|>RELATION_NOE 影像学<|>RELATION_NOE 检查<|>RELATION_NOE 及<|>RELATION_NOE 胸壁<|>RELATION_NOE 肿物<|>RELATION_NOE 细针<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 的<|>RELATION_NOE 病理学<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 明确<|>RELATION_B 诊断<|>RELATION_I 为<|>RELATION_E MM<|>RELATION_NOE (<|>RELATION_NOE IgG<|>RELATION_NOE 型<|>RELATION_NOE ,<|>RELATION_NOE ISS<|>RELATION_NOE 分期<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胸壁<|>RELATION_NOE 肿物<|>RELATION_NOE 合并<|>RELATION_NOE 大量<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 表现<|>RELATION_NOE 的<|>RELATION_NOE MM<|>RELATION_NOE 非常<|>RELATION_NOE 少见<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 极<|>RELATION_NOE 易<|>RELATION_NOE 被<|>RELATION_NOE 误诊<|>RELATION_NOE ,<|>RELATION_NOE 全面<|>RELATION_NOE 观察<|>RELATION_NOE 病情<|>RELATION_NOE 及<|>RELATION_NOE 各项<|>RELATION_NOE 检查<|>RELATION_NOE 结果<|>RELATION_NOE 对<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 有<|>RELATION_B 重要<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
考虑<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 除外<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 全身麻醉<|>RELATION_NOE 下<|>RELATION_NOE 行左<|>RELATION_NOE 上<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术加<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 报告<|>RELATION_NOE :<|>RELATION_NOE 左上肺<|>RELATION_NOE BAC<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
采用<|>RELATION_NOE 非随机<|>RELATION_NOE 同期<|>RELATION_NOE 对照<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 接受<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合化疗<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 试验组<|>RELATION_NOE ,<|>RELATION_NOE 单纯<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗者<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE .<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_S 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE RR<|>RELATION_NOE 、<|>RELATION_NOE CBR<|>RELATION_NOE 及<|>RELATION_NOE 中位<|>RELATION_NOE TTP<|>RELATION_NOE ,<|>RELATION_NOE 安全性<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 前景<|>RELATION_NOE
水通道<|>RELATION_NOE 蛋白1<|>RELATION_NOE 在<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 意义<|>RELATION_E
培养<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学法<|>RELATION_NOE 、<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE 及<|>RELATION_NOE Westernblot<|>RELATION_NOE 等<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 水通道<|>RELATION_NOE 蛋白1<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 存在<|>RELATION_S 水通道<|>RELATION_NOE 蛋白1<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 已<|>RELATION_NOE 知<|>RELATION_NOE 水通道<|>RELATION_NOE 蛋白1<|>RELATION_NOE 的<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE 深入<|>RELATION_NOE 探讨<|>RELATION_NOE 水通道<|>RELATION_NOE 蛋白1<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 及<|>RELATION_NOE 迁移<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 为<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 提供<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 机理<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_S 尘肺<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE
应用<|>RELATION_NOE 重复<|>RELATION_NOE 定位<|>RELATION_NOE 缩野<|>RELATION_NOE 3D-CRT<|>RELATION_NOE 治疗<|>RELATION_NOE 尘肺<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 无<|>RELATION_NOE 尘肺<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 相同<|>RELATION_S ,<|>RELATION_NOE 不良<|>RELATION_NOE 作用<|>RELATION_NOE 可<|>RELATION_NOE 接受<|>RELATION_NOE 。<|>RELATION_NOE
人格<|>RELATION_NOE 特征<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 围手术期<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_NOE 健康<|>RELATION_NOE 状况<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 人格<|>RELATION_NOE 特征<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 围手术期<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_NOE 健康<|>RELATION_NOE 状况<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
以<|>RELATION_NOE 97<|>RELATION_NOE 名<|>RELATION_NOE 中南<|>RELATION_NOE 大学<|>RELATION_NOE 湘雅二<|>RELATION_NOE 医院<|>RELATION_NOE 普胸<|>RELATION_NOE 外科<|>RELATION_NOE 肺癌<|>RELATION_NOE 围手术期<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 自制<|>RELATION_NOE 的<|>RELATION_NOE 一般<|>RELATION_NOE 资料<|>RELATION_NOE 问卷<|>RELATION_NOE 、<|>RELATION_NOE 艾森克人格<|>RELATION_NOE 问卷<|>RELATION_NOE 成人版<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE 、<|>RELATION_NOE 焦虑<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE 、<|>RELATION_NOE 症状<|>RELATION_NOE 自评量表<|>RELATION_NOE 对<|>RELATION_NOE 他们<|>RELATION_NOE 的<|>RELATION_NOE 一般<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 人格<|>RELATION_NOE 特征<|>RELATION_NOE 以及<|>RELATION_NOE 心理<|>RELATION_NOE 状况<|>RELATION_NOE 进行<|>RELATION_NOE 调查<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 围手术期<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_NOE 状态<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 人格<|>RELATION_NOE 方面<|>RELATION_NOE 喜欢<|>RELATION_NOE 独处<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_NOE 关心<|>RELATION_NOE 他人<|>RELATION_NOE ,<|>RELATION_NOE 心理<|>RELATION_NOE 状态<|>RELATION_NOE 与<|>RELATION_NOE 人格<|>RELATION_NOE 特征<|>RELATION_NOE 之间<|>RELATION_NOE 存在<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 人格<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 内外<|>RELATION_NOE 向<|>RELATION_NOE 维度<|>RELATION_NOE 和<|>RELATION_NOE 神经质<|>RELATION_NOE 维度<|>RELATION_NOE 可以<|>RELATION_NOE 预测<|>RELATION_S 负性<|>RELATION_NOE 心理<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE .<|>RELATION_NOE
慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE 介导<|>RELATION_S 人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE Akt2<|>RELATION_NOE 基因<|>RELATION_NOE 靶向<|>RELATION_NOE 抑制<|>RELATION_NOE
通过<|>RELATION_NOE 构建<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE shRNA<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 靶向<|>RELATION_B 抑制<|>RELATION_E Akt2<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 获得<|>RELATION_NOE 稳定<|>RELATION_NOE 干扰<|>RELATION_NOE Akt2<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 克隆<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 进一步<|>RELATION_NOE 探讨<|>RELATION_NOE Akt2<|>RELATION_NOE 的<|>RELATION_NOE 功能<|>RELATION_NOE 奠定<|>RELATION_NOE 基础<|>RELATION_NOE 。<|>RELATION_NOE
设计<|>RELATION_NOE 并<|>RELATION_NOE 合成<|>RELATION_NOE 针对<|>RELATION_NOE Akt2<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 双链寡<|>RELATION_NOE 核苷酸序列<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 退火<|>RELATION_NOE 、<|>RELATION_NOE 酶切<|>RELATION_NOE 、<|>RELATION_NOE 连接<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 干扰<|>RELATION_NOE 序列插入<|>RELATION_NOE pGCsil-GFP<|>RELATION_NOE 质粒<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 感受<|>RELATION_NOE 态细胞<|>RELATION_NOE 转化<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 克隆<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 鉴定所<|>RELATION_NOE 插入<|>RELATION_NOE 的<|>RELATION_NOE 片段<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 转染<|>RELATION_NOE 及<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 包装<|>RELATION_NOE ,<|>RELATION_NOE 收集<|>RELATION_NOE 浓缩<|>RELATION_NOE 病毒<|>RELATION_NOE 进行<|>RELATION_NOE 滴度<|>RELATION_NOE 测定<|>RELATION_NOE ,<|>RELATION_NOE 感染<|>RELATION_NOE 至<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 无<|>RELATION_NOE 菌流式<|>RELATION_NOE 细胞<|>RELATION_NOE 分选<|>RELATION_NOE GFP<|>RELATION_NOE 强<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 应用<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 及<|>RELATION_NOE Western-blot<|>RELATION_NOE 验证<|>RELATION_S 干扰<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE shAkt2<|>RELATION_NOE 感染<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 分选<|>RELATION_NOE 90.1%<|>RELATION_NOE GFP<|>RELATION_NOE 为<|>RELATION_NOE 强<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞群<|>RELATION_NOE 。<|>RELATION_NOE
本<|>RELATION_NOE 研究所<|>RELATION_NOE 构建<|>RELATION_NOE 的<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE shAkt2<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE 稳定<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_S 靶<|>RELATION_NOE 基因<|>RELATION_NOE Akt2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 深入<|>RELATION_NOE 研究<|>RELATION_NOE Akt2<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 奠定<|>RELATION_NOE 了<|>RELATION_NOE 基础<|>RELATION_NOE 。<|>RELATION_NOE
粒细胞<|>RELATION_NOE 集落<|>RELATION_NOE 刺激<|>RELATION_NOE 因子<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 意义<|>RELATION_NOE
观察癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 粒细胞<|>RELATION_NOE 浸润<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE (<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 癌组织<|>RELATION_NOE 中<|>RELATION_NOE G-CSF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE G-CSF<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 进行<|>RELATION_S 统计学<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 全部<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE G-CSF<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 大细胞癌<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 54<|>RELATION_NOE ,<|>RELATION_NOE 75.9%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 9例<|>RELATION_NOE (<|>RELATION_NOE 9/30<|>RELATION_NOE ,<|>RELATION_NOE 30.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 5/30<|>RELATION_NOE ,<|>RELATION_NOE 16.7%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
表达<|>RELATION_NOE 阳<|>RELATION_NOE 性者<|>RELATION_NOE 发生<|>RELATION_NOE 坏死<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 相对危险度<|>RELATION_NOE 分别<|>RELATION_B 是<|>RELATION_E 阴<|>RELATION_NOE 性者<|>RELATION_NOE 的<|>RELATION_NOE 5.57<|>RELATION_NOE 、<|>RELATION_NOE 6.28<|>RELATION_NOE 和<|>RELATION_NOE 5.24<|>RELATION_NOE 倍<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
易<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 复发<|>RELATION_NOE ;<|>RELATION_NOE
探讨<|>RELATION_NOE 肿瘤<|>RELATION_NOE 跨<|>RELATION_NOE 肺裂<|>RELATION_NOE 侵犯<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 生存率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及<|>RELATION_NOE 合适<|>RELATION_NOE 的<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 是否<|>RELATION_NOE 跨<|>RELATION_NOE 肺裂<|>RELATION_NOE 侵犯<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 统计<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 和<|>RELATION_NOE Cox<|>RELATION_NOE 比例<|>RELATION_NOE 风险<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 进行<|>RELATION_B 分析<|>RELATION_E 。<|>RELATION_NOE
高频<|>RELATION_NOE 彩色<|>RELATION_NOE 多普勒<|>RELATION_NOE 超声<|>RELATION_NOE 在<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中高<|>RELATION_NOE 迁移<|>RELATION_NOE 蛋白<|>RELATION_NOE A2<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE C<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
提取<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌组<|>RELATION_NOE 与<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 的<|>RELATION_NOE 总<|>RELATION_NOE RNA<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 反<|>RELATION_NOE 转录<|>RELATION_NOE 为<|>RELATION_NOE cDNA<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链式<|>RELATION_NOE 反应<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S HMGA2<|>RELATION_NOE 和<|>RELATION_NOE VEGF-C<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE HMGA2<|>RELATION_NOE 和<|>RELATION_NOE VEGF-C<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 提示<|>RELATION_NOE HMGA2<|>RELATION_NOE 和<|>RELATION_NOE VEGF-C<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 存在<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE HMGA2<|>RELATION_NOE 和<|>RELATION_NOE VEGF-C<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_B 相关性<|>RELATION_E 。<|>RELATION_NOE
HMGA2<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 有助于<|>RELATION_S 评价<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 提供<|>RELATION_NOE 新<|>RELATION_NOE 思路<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE Ⅰ<|>RELATION_NOE -<|>RELATION_NOE Ⅱ<|>RELATION_NOE 级<|>RELATION_NOE 外周<|>RELATION_NOE 神经炎<|>RELATION_NOE 、<|>RELATION_NOE 乏力<|>RELATION_NOE 、<|>RELATION_NOE 便秘<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE 或<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE Ⅲ<|>RELATION_NOE -<|>RELATION_NOE Ⅳ级<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
成纤维细胞<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 相互作用<|>RELATION_NOE 对<|>RELATION_NOE 膜型<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -1<|>RELATION_NOE 及<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -2<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
取<|>RELATION_NOE 其<|>RELATION_NOE 上<|>RELATION_NOE 清<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 细胞培养<|>RELATION_NOE 液中<|>RELATION_NOE 活性<|>RELATION_NOE MMP-2<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE 。<|>RELATION_NOE
H460<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 胚肺<|>RELATION_NOE 成纤维细胞<|>RELATION_NOE 单独<|>RELATION_NOE 培养<|>RELATION_NOE 时<|>RELATION_NOE MMP-2<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 分泌<|>RELATION_NOE ,<|>RELATION_NOE 混合<|>RELATION_NOE 培养<|>RELATION_NOE MMP2<|>RELATION_NOE 分泌<|>RELATION_NOE 增强<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胚肺<|>RELATION_NOE 成纤维细胞<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 相互作用<|>RELATION_NOE 能<|>RELATION_NOE 通过<|>RELATION_B 上调<|>RELATION_I MT1-MMP<|>RELATION_I 、<|>RELATION_I MMP-2<|>RELATION_I 的<|>RELATION_I 表达<|>RELATION_E 从而<|>RELATION_NOE 促进<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 可能<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 侵袭<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 一个<|>RELATION_NOE 重要<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
参芪<|>RELATION_NOE 十一<|>RELATION_NOE 味<|>RELATION_NOE 胶囊<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_B 治疗<|>RELATION_I 作用<|>RELATION_E
观察<|>RELATION_NOE 参芪<|>RELATION_NOE 十一<|>RELATION_NOE 味<|>RELATION_NOE 胶囊<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_B 治疗<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 将<|>RELATION_NOE 58<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 采用<|>RELATION_NOE 吉西<|>RELATION_NOE +<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE GP<|>RELATION_NOE )<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE :<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE (<|>RELATION_NOE 健泽<|>RELATION_NOE )<|>RELATION_NOE 1000<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 30<|>RELATION_NOE min<|>RELATION_NOE 内<|>RELATION_NOE 注<|>RELATION_NOE 完<|>RELATION_NOE ;<|>RELATION_NOE
A<|>RELATION_NOE 组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血<|>RELATION_NOE 色素<|>RELATION_NOE 下降<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 好转<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ<|>RELATION_NOE 2值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.6<|>RELATION_NOE 78<|>RELATION_NOE 、<|>RELATION_NOE 4.5<|>RELATION_NOE 49<|>RELATION_NOE 、<|>RELATION_NOE 4.6<|>RELATION_NOE 87<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
X<|>RELATION_NOE 线<|>RELATION_NOE 胸片<|>RELATION_NOE 对<|>RELATION_NOE 高危<|>RELATION_NOE 人群<|>RELATION_NOE 肺癌<|>RELATION_NOE 筛查<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE 系统<|>RELATION_B 评价<|>RELATION_E
异质性<|>RELATION_NOE 检验<|>RELATION_NOE 提示<|>RELATION_S 无阈值<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 存在<|>RELATION_NOE 其他<|>RELATION_NOE 原因<|>RELATION_NOE 导致<|>RELATION_NOE 的<|>RELATION_NOE 异质性<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 效应<|>RELATION_NOE 模型<|>RELATION_NOE 进行<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE 得出<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 胸片<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 筛查<|>RELATION_NOE 中<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE 汇总<|>RELATION_NOE 阳性<|>RELATION_NOE 似然<|>RELATION_NOE 比<|>RELATION_NOE 为<|>RELATION_NOE 9.13<|>RELATION_NOE ,<|>RELATION_NOE 汇总<|>RELATION_NOE 阴性<|>RELATION_NOE 似然<|>RELATION_NOE 比<|>RELATION_NOE 为<|>RELATION_NOE 0.72<|>RELATION_NOE ,<|>RELATION_NOE 汇总<|>RELATION_NOE 灵敏度<|>RELATION_NOE 为<|>RELATION_NOE 0.2<|>RELATION_NOE 50<|>RELATION_NOE (<|>RELATION_NOE 0.2<|>RELATION_NOE 19<|>RELATION_NOE －0.2<|>RELATION_NOE 82<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 汇总<|>RELATION_NOE 特异度<|>RELATION_NOE 为<|>RELATION_NOE 0.9<|>RELATION_NOE 32<|>RELATION_NOE (<|>RELATION_NOE 0.9<|>RELATION_NOE 30<|>RELATION_NOE －0.9<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE SROC<|>RELATION_NOE 曲线下面积<|>RELATION_NOE 为<|>RELATION_NOE 0.85<|>RELATION_NOE 36<|>RELATION_NOE 。<|>RELATION_NOE
pGSK-3<|>RELATION_NOE β<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 关系<|>RELATION_B 分析<|>RELATION_E
阳性<|>RELATION_NOE 表达<|>RELATION_NOE pGSK-3<|>RELATION_NOE β<|>RELATION_NOE 的<|>RELATION_NOE 部分<|>RELATION_NOE 患者<|>RELATION_NOE 平均<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 明显<|>RELATION_NOE 缩短<|>RELATION_NOE (<|>RELATION_NOE 45.000vs63.77<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.005<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 其它<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_NOE 影响<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE 进行<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 预后<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE pGSK-3<|>RELATION_NOE β<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 为<|>RELATION_NOE 独立<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_S (<|>RELATION_NOE 风险<|>RELATION_NOE 比<|>RELATION_NOE 2.0<|>RELATION_NOE 12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Notch1<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE Notch1mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.99<|>RELATION_NOE ±<|>RELATION_NOE 1.40<|>RELATION_NOE 和<|>RELATION_NOE 1.50<|>RELATION_NOE ±<|>RELATION_NOE 1.03<|>RELATION_NOE ,<|>RELATION_NOE 组间<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 组织<|>RELATION_NOE 间<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 老年人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
18<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE cT<|>RELATION_NOE 定位<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 穿刺<|>RELATION_NOE 将<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 到<|>RELATION_NOE 肺癌<|>RELATION_NOE 病灶<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 影像学<|>RELATION_NOE 检查<|>RELATION_NOE 评价<|>RELATION_S 疗效<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
并发症<|>RELATION_NOE :<|>RELATION_NOE 气胸<|>RELATION_NOE 3冽<|>RELATION_NOE ,<|>RELATION_NOE 少量<|>RELATION_NOE 咯血<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 内<|>RELATION_NOE 明显<|>RELATION_NOE 出血<|>RELATION_NOE ,<|>RELATION_NOE 粒子<|>RELATION_NOE 脱<|>RELATION_NOE 入<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 1冽<|>RELATION_NOE 。<|>RELATION_NOE
LCT<|>RELATION_NOE 制片<|>RELATION_NOE 技术<|>RELATION_NOE 能够<|>RELATION_NOE 保证<|>RELATION_NOE 临床<|>RELATION_NOE 取<|>RELATION_NOE 到<|>RELATION_NOE 的<|>RELATION_NOE 样本<|>RELATION_NOE 得到<|>RELATION_NOE 及时<|>RELATION_NOE 充分<|>RELATION_NOE 的<|>RELATION_NOE 固定<|>RELATION_NOE ,<|>RELATION_NOE 涂片<|>RELATION_NOE 中<|>RELATION_NOE 细胞<|>RELATION_NOE 更<|>RELATION_NOE 集中<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 形态<|>RELATION_NOE 更<|>RELATION_NOE 清晰<|>RELATION_NOE ,<|>RELATION_NOE 去除<|>RELATION_NOE 血液<|>RELATION_NOE 、<|>RELATION_NOE 黏液<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 有助于<|>RELATION_S 获得<|>RELATION_NOE 组织<|>RELATION_NOE 条<|>RELATION_NOE 进行<|>RELATION_NOE 石蜡<|>RELATION_NOE 切片<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 病理<|>RELATION_NOE 医生<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效率<|>RELATION_NOE 。<|>RELATION_NOE LCT<|>RELATION_NOE 制片<|>RELATION_NOE 技术<|>RELATION_NOE 能够<|>RELATION_NOE 保证<|>RELATION_NOE 临床<|>RELATION_NOE 取<|>RELATION_NOE 到<|>RELATION_NOE 的<|>RELATION_NOE 样本<|>RELATION_NOE 得到<|>RELATION_NOE 及时<|>RELATION_NOE 充分<|>RELATION_NOE 的<|>RELATION_NOE 固定<|>RELATION_NOE ,<|>RELATION_NOE 涂片<|>RELATION_NOE 中<|>RELATION_NOE 细胞<|>RELATION_NOE 更<|>RELATION_NOE 集中<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 形态<|>RELATION_NOE 更<|>RELATION_NOE 清晰<|>RELATION_NOE ,<|>RELATION_NOE 去除<|>RELATION_NOE 血液<|>RELATION_NOE 、<|>RELATION_NOE 黏液<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 有助于<|>RELATION_NOE 获得<|>RELATION_NOE 组织<|>RELATION_NOE 条<|>RELATION_NOE 进行<|>RELATION_NOE 石蜡<|>RELATION_NOE 切片<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 病理<|>RELATION_NOE 医生<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效率<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m<|>RELATION_NOE 标记<|>RELATION_NOE RGD<|>RELATION_NOE 环肽<|>RELATION_NOE 在<|>RELATION_NOE 荷<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 显像<|>RELATION_B 研究<|>RELATION_E
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 以<|>RELATION_NOE HYNIC<|>RELATION_NOE 为<|>RELATION_NOE 双<|>RELATION_NOE 功能<|>RELATION_NOE 螯合剂<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 三<|>RELATION_NOE 羟<|>RELATION_NOE 甲基<|>RELATION_NOE 甘氨酸<|>RELATION_NOE (<|>RELATION_NOE tricine<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 乙二胺二乙酸<|>RELATION_NOE 为<|>RELATION_NOE 协同<|>RELATION_NOE 配体<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 二<|>RELATION_NOE 步法<|>RELATION_NOE 制备<|>RELATION_S ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m<|>RELATION_NOE 标记<|>RELATION_NOE HYNIC-c<|>RELATION_NOE (<|>RELATION_NOE RGDfK<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 结合<|>RELATION_NOE 实验<|>RELATION_NOE ,<|>RELATION_NOE 测定<|>RELATION_NOE 标记物<|>RELATION_NOE 生物学<|>RELATION_NOE 活性<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 将<|>RELATION_NOE 荷<|>RELATION_NOE A549<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 模型<|>RELATION_NOE 小鼠<|>RELATION_NOE 分为<|>RELATION_NOE 7组<|>RELATION_NOE [<|>RELATION_NOE 第7<|>RELATION_NOE 组<|>RELATION_NOE 作为<|>RELATION_NOE 竞争性<|>RELATION_NOE 抑制组<|>RELATION_NOE ,<|>RELATION_NOE 注射<|>RELATION_NOE 显像剂<|>RELATION_NOE 前<|>RELATION_NOE 0.5h<|>RELATION_NOE 先<|>RELATION_NOE 注射<|>RELATION_NOE HYNIC-c<|>RELATION_NOE (<|>RELATION_NOE CRDGfk<|>RELATION_NOE )<|>RELATION_NOE 100<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 5<|>RELATION_NOE 只<|>RELATION_NOE ,<|>RELATION_NOE 经尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 7.4MBq<|>RELATION_NOE 的<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-HYNIC-c<|>RELATION_NOE (<|>RELATION_NOE RGDfK<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 于<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 0.5<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE ,<|>RELATION_NOE 4<|>RELATION_NOE ,<|>RELATION_NOE 8<|>RELATION_NOE ,<|>RELATION_NOE 12h<|>RELATION_NOE 处死<|>RELATION_NOE ,<|>RELATION_NOE 计算荷<|>RELATION_NOE A549<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 小鼠<|>RELATION_NOE 模型<|>RELATION_NOE 各<|>RELATION_NOE 脏器%<|>RELATION_NOE ID<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 采用<|>RELATION_NOE ROI<|>RELATION_NOE 技术<|>RELATION_NOE 研究<|>RELATION_S ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-HYNIC-c<|>RELATION_NOE (<|>RELATION_NOE RGDfK<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 小鼠<|>RELATION_NOE 体内<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 分布<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 点<|>RELATION_NOE 的<|>RELATION_NOE T<|>RELATION_NOE /<|>RELATION_NOE NT<|>RELATION_NOE 比值<|>RELATION_NOE (<|>RELATION_NOE NT<|>RELATION_NOE 选取<|>RELATION_NOE 肌肉<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 取6<|>RELATION_NOE 只<|>RELATION_NOE 荷瘤<|>RELATION_NOE 裸鼠<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3<|>RELATION_NOE 只<|>RELATION_NOE 为<|>RELATION_NOE 竞争性<|>RELATION_NOE 抑制组<|>RELATION_NOE ,<|>RELATION_NOE 经尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 7.4MBq<|>RELATION_NOE 的<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-HYNIC-c<|>RELATION_NOE (<|>RELATION_NOE RGDfK<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 于<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 0.5<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE ,<|>RELATION_NOE 4<|>RELATION_NOE ,<|>RELATION_NOE 8<|>RELATION_NOE ,<|>RELATION_NOE 12h<|>RELATION_NOE 进行<|>RELATION_NOE 静态<|>RELATION_NOE 1显像<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-HYNIC-c<|>RELATION_NOE (<|>RELATION_NOE RGDfK<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE A549<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 特异性<|>RELATION_NOE 结合率<|>RELATION_NOE 最高<|>RELATION_S 为<|>RELATION_NOE 36.14%<|>RELATION_NOE ,<|>RELATION_NOE 体内<|>RELATION_NOE 分布<|>RELATION_NOE 实验<|>RELATION_NOE 显示<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-HYNIC-c<|>RELATION_NOE (<|>RELATION_NOE RGDfK<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肾<|>RELATION_NOE 的<|>RELATION_NOE 摄取率<|>RELATION_NOE 始终<|>RELATION_NOE 高于<|>RELATION_NOE 20%<|>RELATION_NOE ID<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 0.5h<|>RELATION_NOE 肿瘤%<|>RELATION_NOE ID<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE 为<|>RELATION_NOE 10.52<|>RELATION_NOE ±<|>RELATION_NOE 1.48<|>RELATION_NOE ,<|>RELATION_NOE 8h<|>RELATION_NOE 为<|>RELATION_NOE 17.26<|>RELATION_NOE ±<|>RELATION_NOE 2.81<|>RELATION_NOE ,<|>RELATION_NOE 12h<|>RELATION_NOE 为<|>RELATION_NOE 8.93<|>RELATION_NOE ±<|>RELATION_NOE 0.90<|>RELATION_NOE ,<|>RELATION_NOE 竞争性<|>RELATION_NOE 抑制组<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 0.5h<|>RELATION_NOE 为<|>RELATION_NOE 2.29<|>RELATION_NOE ±<|>RELATION_NOE 0.85<|>RELATION_NOE 。<|>RELATION_NOE
循证<|>RELATION_NOE 护理<|>RELATION_NOE 在<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 化疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
回顾性<|>RELATION_B 分析<|>RELATION_E 15<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 期间<|>RELATION_NOE 合并<|>RELATION_NOE 带状疱疹<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 和<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
早<|>RELATION_NOE 发现<|>RELATION_NOE 、<|>RELATION_NOE 早<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 早<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 及时<|>RELATION_NOE 提供<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 饮食<|>RELATION_NOE 护理<|>RELATION_NOE 及<|>RELATION_NOE 局部<|>RELATION_NOE 创面<|>RELATION_NOE 的<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 减轻<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 痛苦<|>RELATION_NOE 和<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_S 局限期<|>RELATION_NOE 原发性<|>RELATION_NOE 食管<|>RELATION_NOE 小细胞癌<|>RELATION_NOE (<|>RELATION_NOE PESC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 及其<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
PESC<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 和<|>RELATION_NOE 内窥镜<|>RELATION_NOE 下<|>RELATION_NOE 表现<|>RELATION_NOE 与<|>RELATION_NOE 食管<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 相似<|>RELATION_S 。<|>RELATION_NOE
26<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 行<|>RELATION_NOE 胃镜<|>RELATION_NOE 活组织检查<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 小细胞癌<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_NOE 肺<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 的<|>RELATION_NOE 流行病学<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 临床<|>RELATION_NOE 医师<|>RELATION_NOE 对<|>RELATION_NOE 肺<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊治<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
报道<|>RELATION_NOE 宁波<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 呼吸科<|>RELATION_NOE 1例<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 支气管<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 病例<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 国内<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE 肺<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 病例<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 女性<|>RELATION_NOE ,<|>RELATION_NOE 57<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 因<|>RELATION_NOE “<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咯<|>RELATION_NOE 痰2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 发热<|>RELATION_NOE 3周<|>RELATION_NOE ”<|>RELATION_NOE 于<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 8月<|>RELATION_NOE 24日<|>RELATION_NOE 入院<|>RELATION_NOE ,<|>RELATION_NOE 当地<|>RELATION_NOE 医院<|>RELATION_NOE 考虑<|>RELATION_NOE “<|>RELATION_NOE 肺炎<|>RELATION_NOE ”<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 抗菌<|>RELATION_NOE 药物治疗<|>RELATION_NOE ,<|>RELATION_NOE 疗效<|>RELATION_NOE 欠佳<|>RELATION_NOE 转入<|>RELATION_NOE 我院<|>RELATION_NOE 。<|>RELATION_NOE
入院<|>RELATION_NOE 后<|>RELATION_NOE 行<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 发现<|>RELATION_NOE 左下叶<|>RELATION_NOE 开口<|>RELATION_NOE 处<|>RELATION_NOE 肿物<|>RELATION_NOE ,<|>RELATION_NOE 后<|>RELATION_NOE 转入<|>RELATION_NOE 胸外科手术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 支气管<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 。<|>RELATION_NOE
54<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 包括<|>RELATION_NOE 男性<|>RELATION_NOE 44<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 51.7<|>RELATION_NOE ±<|>RELATION_NOE 11.6<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 内<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 44<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺内<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 存在<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 症状<|>RELATION_NOE 无<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咯痰<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE 、<|>RELATION_NOE 气促<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE 。<|>RELATION_NOE
23<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 仅<|>RELATION_NOE 有<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 26.1%<|>RELATION_NOE )<|>RELATION_NOE 得到<|>RELATION_NOE 正确<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
硬质<|>RELATION_NOE 支气管镜<|>RELATION_NOE 镜<|>RELATION_NOE 下<|>RELATION_NOE 切除<|>RELATION_NOE 为<|>RELATION_NOE 支气管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 首选<|>RELATION_B 的<|>RELATION_I 治疗<|>RELATION_I 方式<|>RELATION_E ,<|>RELATION_NOE 肺内<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 或<|>RELATION_NOE 支气管<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 已<|>RELATION_NOE 发生<|>RELATION_NOE 肺<|>RELATION_NOE 实质<|>RELATION_NOE 的<|>RELATION_NOE 不可逆<|>RELATION_NOE 损害<|>RELATION_NOE 应<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 。<|>RELATION_NOE
了解<|>RELATION_S 间质性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 12<|>RELATION_NOE 例<|>RELATION_NOE 北京<|>RELATION_NOE 协和<|>RELATION_NOE 医院<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 诊断<|>RELATION_NOE 间质性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
12<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE ±<|>RELATION_NOE 8<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 男女<|>RELATION_NOE 比例<|>RELATION_NOE 11<|>RELATION_NOE :<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE ±<|>RELATION_NOE 5<|>RELATION_NOE )<|>RELATION_NOE 包·年<|>RELATION_NOE ,<|>RELATION_NOE 8例<|>RELATION_NOE 为<|>RELATION_NOE 特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 以<|>RELATION_NOE 腺癌<|>RELATION_NOE (<|>RELATION_NOE 4/12<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 鳞癌<|>RELATION_NOE (<|>RELATION_NOE 5/12<|>RELATION_NOE )<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 还<|>RELATION_NOE 包括<|>RELATION_NOE 复合癌<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE 1/12<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 占<|>RELATION_NOE 同期<|>RELATION_NOE 全部<|>RELATION_NOE 特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 15%<|>RELATION_NOE (<|>RELATION_NOE 8/54<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 住院<|>RELATION_NOE 病死率<|>RELATION_NOE (<|>RELATION_NOE 38%<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_S 单纯<|>RELATION_NOE 特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 15%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 多<|>RELATION_B 周期<|>RELATION_I 治疗<|>RELATION_E 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE
观察<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE TP<|>RELATION_NOE 或<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 与<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE TP<|>RELATION_NOE 或<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 能<|>RELATION_NOE 显著<|>RELATION_NOE 提高<|>RELATION_S 远期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 长<|>RELATION_NOE 周期<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE rITrP<|>RELATION_NOE 和<|>RELATION_NOE OS<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 短<|>RELATION_NOE 周期者<|>RELATION_NOE 延长<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 长<|>RELATION_NOE 周期<|>RELATION_NOE 治疗<|>RELATION_NOE 并<|>RELATION_NOE 不<|>RELATION_NOE 增加<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 及<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 研究<|>RELATION_S
采用<|>RELATION_NOE 描述性<|>RELATION_NOE 相关性<|>RELATION_NOE 研究设计<|>RELATION_NOE ,<|>RELATION_NOE 方便<|>RELATION_NOE 抽样<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Piper<|>RELATION_NOE 疲乏<|>RELATION_NOE 修正量表<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE 、<|>RELATION_NOE 匹兹堡<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 指数<|>RELATION_NOE 量表<|>RELATION_NOE 对<|>RELATION_NOE 广州市<|>RELATION_NOE 2家<|>RELATION_NOE 三级<|>RELATION_NOE 甲等<|>RELATION_NOE 医院<|>RELATION_NOE 的<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 水平<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 水平<|>RELATION_NOE 、<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 进行<|>RELATION_NOE 调查<|>RELATION_NOE 。<|>RELATION_NOE
83%<|>RELATION_NOE 患者<|>RELATION_NOE 存在<|>RELATION_NOE 抑郁<|>RELATION_NOE 情绪<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 抑郁<|>RELATION_NOE 程度<|>RELATION_NOE 越<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE CRF<|>RELATION_NOE 水平<|>RELATION_NOE 越<|>RELATION_B 高<|>RELATION_E 。<|>RELATION_NOE
患者<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE PSQI<|>RELATION_NOE 评分<|>RELATION_NOE 总分<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 11.00<|>RELATION_NOE ±<|>RELATION_NOE 3.85<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 影响<|>RELATION_NOE 其<|>RELATION_NOE CRF<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE CRF<|>RELATION_NOE 总分<|>RELATION_NOE 与<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 得分<|>RELATION_NOE 呈<|>RELATION_B 正<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.2<|>RELATION_NOE 34<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 普遍<|>RELATION_B 存在<|>RELATION_E 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE ,<|>RELATION_NOE 医护<|>RELATION_NOE 人员<|>RELATION_NOE 应<|>RELATION_NOE 关注<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 情绪<|>RELATION_NOE 和<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 尽可能<|>RELATION_NOE 创造<|>RELATION_NOE 条件<|>RELATION_NOE 减轻<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疲乏<|>RELATION_NOE 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 联合<|>RELATION_NOE 贞芪<|>RELATION_NOE 扶<|>RELATION_NOE 正<|>RELATION_NOE 胶囊<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 人中<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 联合<|>RELATION_NOE 贞芪<|>RELATION_NOE 扶<|>RELATION_NOE 正<|>RELATION_NOE 胶囊<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 人中<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
跨膜<|>RELATION_NOE 丝氨酸<|>RELATION_NOE 蛋白<|>RELATION_NOE 酶4<|>RELATION_NOE 诱导<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 肝细胞癌<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 研究<|>RELATION_S
探讨<|>RELATION_NOE 跨膜<|>RELATION_NOE 丝氨酸<|>RELATION_NOE 蛋白<|>RELATION_NOE 酶<|>RELATION_NOE 4<|>RELATION_NOE (<|>RELATION_NOE transmembrane<|>RELATION_NOE protease<|>RELATION_NOE serine<|>RELATION_NOE 4<|>RELATION_NOE ,<|>RELATION_NOE TMPRSS4<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 残余<|>RELATION_NOE 肝细胞癌<|>RELATION_NOE 转移<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_B 及<|>RELATION_I 机制<|>RELATION_E 。<|>RELATION_NOE
HE<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_S 放疗<|>RELATION_NOE 后<|>RELATION_NOE 肝癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 形态<|>RELATION_NOE .<|>RELATION_NOE
对照组<|>RELATION_NOE 肝癌<|>RELATION_NOE 切除<|>RELATION_NOE 再<|>RELATION_NOE 种植<|>RELATION_NOE 后<|>RELATION_NOE 42<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 及<|>RELATION_NOE 肺转移率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 2.2<|>RELATION_NOE 5士<|>RELATION_NOE 0.52<|>RELATION_NOE )<|>RELATION_NOE cm3<|>RELATION_NOE 和<|>RELATION_NOE 66.7%<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 放疗后<|>RELATION_NOE 2d<|>RELATION_NOE 和<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 30<|>RELATION_NOE d<|>RELATION_NOE 残癌<|>RELATION_NOE 切除<|>RELATION_NOE 再<|>RELATION_NOE 种植组<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 1.61<|>RELATION_NOE ±<|>RELATION_NOE 0.51<|>RELATION_NOE )<|>RELATION_NOE cm3<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 2.60<|>RELATION_NOE ±<|>RELATION_NOE 0.61<|>RELATION_NOE )<|>RELATION_NOE cm3<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺转移率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 12.5%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
对照组<|>RELATION_NOE 及<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 2d<|>RELATION_NOE 残癌<|>RELATION_NOE 切除<|>RELATION_NOE 再<|>RELATION_NOE 种植<|>RELATION_NOE 组<|>RELATION_NOE 无<|>RELATION_NOE 肝内<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE ,<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 30<|>RELATION_NOE d<|>RELATION_NOE 残癌<|>RELATION_NOE 切除<|>RELATION_NOE 再<|>RELATION_NOE 种植<|>RELATION_NOE 组<|>RELATION_NOE 肝内<|>RELATION_NOE 转移<|>RELATION_NOE 灶数<|>RELATION_NOE 为<|>RELATION_NOE 18<|>RELATION_NOE ±<|>RELATION_NOE 8.05<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
了解<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 家属<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 家属<|>RELATION_NOE 焦虑<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 焦虑<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE (<|>RELATION_NOE SAS<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 自行<|>RELATION_NOE 设计<|>RELATION_NOE 的<|>RELATION_NOE 一般<|>RELATION_NOE 情况<|>RELATION_NOE 调查表<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 北京<|>RELATION_NOE 某<|>RELATION_NOE 三级<|>RELATION_NOE 甲等<|>RELATION_NOE 医院<|>RELATION_NOE 96<|>RELATION_NOE 例晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 家属<|>RELATION_NOE 进行<|>RELATION_NOE 问卷调查<|>RELATION_NOE 。<|>RELATION_NOE
晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 家属<|>RELATION_NOE 较<|>RELATION_NOE 常人<|>RELATION_NOE 普遍<|>RELATION_NOE 存在<|>RELATION_NOE 焦虑<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 家属<|>RELATION_NOE 的<|>RELATION_NOE 居住地<|>RELATION_NOE 、<|>RELATION_NOE 经济<|>RELATION_NOE 状况<|>RELATION_NOE 和<|>RELATION_NOE 确诊<|>RELATION_NOE 后<|>RELATION_NOE 多次<|>RELATION_NOE 住院<|>RELATION_NOE 是<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 家属<|>RELATION_NOE 焦虑<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 因素<|>RELATION_E 。<|>RELATION_NOE
乳腺球<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 细针<|>RELATION_NOE 穿刺<|>RELATION_NOE 吸取<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
对<|>RELATION_NOE 91<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 行术<|>RELATION_NOE 前<|>RELATION_NOE 细针<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 吸取<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 制备<|>RELATION_NOE 涂片<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE (<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S MAM<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE
同时<|>RELATION_NOE 另<|>RELATION_NOE 收集<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 乳腺癌<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 增生性<|>RELATION_NOE 淋巴结炎<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 三者<|>RELATION_NOE 间术<|>RELATION_NOE 前<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE MAM<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 区别<|>RELATION_NOE .<|>RELATION_NOE
MAM<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 雌激素受体<|>RELATION_NOE (<|>RELATION_NOE ER<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 孕激素<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 、<|>RELATION_NOE 细胞学<|>RELATION_NOE 分级<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 是否<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE HER-2<|>RELATION_NOE 状态<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 观察<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE MAM<|>RELATION_NOE 在<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_B 阳性<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 增生性<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结炎<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 阴性<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
MAM<|>RELATION_NOE 可<|>RELATION_NOE 表达<|>RELATION_NOE 于<|>RELATION_NOE 原发性<|>RELATION_NOE 和<|>RELATION_NOE 转移性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE ,<|>RELATION_NOE 细针<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 结合<|>RELATION_NOE MAM<|>RELATION_NOE 的<|>RELATION_NOE 测定<|>RELATION_NOE 对<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 鉴别<|>RELATION_NOE 具有<|>RELATION_B 一定<|>RELATION_I 辅助<|>RELATION_I 判断<|>RELATION_I 价值<|>RELATION_E .<|>RELATION_NOE
MAM<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE ER<|>RELATION_NOE 、<|>RELATION_NOE PR<|>RELATION_NOE 状态<|>RELATION_NOE 、<|>RELATION_NOE 细胞学<|>RELATION_NOE 分级<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 有利于<|>RELATION_NOE 了解<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 指标<|>RELATION_NOE 及<|>RELATION_NOE 判断<|>RELATION_NOE 预后<|>RELATION_NOE .<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 在<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 肺<|>RELATION_NOE 转移<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 复发<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 人群<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE (<|>RELATION_NOE sVEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 肺<|>RELATION_NOE 转移<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 复发<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 人群<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE (<|>RELATION_NOE sVEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 血清<|>RELATION_NOE 甲状腺<|>RELATION_NOE 球<|>RELATION_NOE 蛋白<|>RELATION_NOE 浓度<|>RELATION_NOE 。<|>RELATION_NOE
肺转移组<|>RELATION_NOE sVEGF<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 局部<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 未<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 复发组<|>RELATION_NOE sVEGF<|>RELATION_NOE 肺转移<|>RELATION_NOE 组<|>RELATION_NOE sVEGF<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 未<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 复发组<|>RELATION_NOE sVEGF<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 未<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 甲状腺<|>RELATION_NOE 球<|>RELATION_NOE 蛋白<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE sVEGF<|>RELATION_NOE 表达<|>RELATION_NOE 成<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
VEGF<|>RELATION_NOE 在<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 评估<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_B 项<|>RELATION_I 重要<|>RELATION_I 指标<|>RELATION_E 。<|>RELATION_NOE
沙利度胺<|>RELATION_NOE 联合<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
试验组<|>RELATION_NOE 手术<|>RELATION_NOE 切口<|>RELATION_NOE 长度<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 镇痛<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 5.8<|>RELATION_NOE ±<|>RELATION_NOE 1.5<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 6.5<|>RELATION_NOE ±<|>RELATION_NOE 26.4<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.8<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE )<|>RELATION_NOE 枚<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE 7.5<|>RELATION_NOE ±<|>RELATION_NOE 79.5<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 3.2<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 2.0<|>RELATION_NOE ±<|>RELATION_NOE 0.4<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 9.5<|>RELATION_NOE ±<|>RELATION_NOE 2.6<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 28.7<|>RELATION_NOE ±<|>RELATION_NOE 3.1<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 2.3<|>RELATION_NOE ±<|>RELATION_NOE 28.6<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 8.2<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE )<|>RELATION_NOE 枚<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 49<|>RELATION_NOE 5.3<|>RELATION_NOE ±<|>RELATION_NOE 97.6<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 5.7<|>RELATION_NOE ±<|>RELATION_NOE 1.0<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 3.6<|>RELATION_NOE ±<|>RELATION_NOE 0.8<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 16.3<|>RELATION_NOE ±<|>RELATION_NOE 2.7<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 。<|>RELATION_NOE
试验组<|>RELATION_NOE 手术<|>RELATION_NOE 切口<|>RELATION_NOE 长度<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 镇痛<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE 或<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 术中<|>RELATION_NOE 具有<|>RELATION_B 安全<|>RELATION_I 、<|>RELATION_I 有效<|>RELATION_I 、<|>RELATION_I 创伤<|>RELATION_I 小<|>RELATION_I 的<|>RELATION_I 特点<|>RELATION_E ,<|>RELATION_NOE 并且<|>RELATION_NOE 可以<|>RELATION_NOE 在<|>RELATION_NOE 与<|>RELATION_NOE 常规<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 相仿<|>RELATION_NOE 的<|>RELATION_NOE 手术时间<|>RELATION_NOE 内<|>RELATION_NOE 获得<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 中<|>RELATION_NOE 广泛<|>RELATION_NOE 使用<|>RELATION_NOE 并<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
扶正<|>RELATION_NOE 消瘤<|>RELATION_NOE 汤<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE
将<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 与<|>RELATION_NOE 治疗组<|>RELATION_NOE 均<|>RELATION_NOE 采用<|>RELATION_NOE PD<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 联合<|>RELATION_B 服用<|>RELATION_E 扶正<|>RELATION_NOE 消瘤<|>RELATION_NOE 汤<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 及<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 。<|>RELATION_NOE
扶正<|>RELATION_NOE 消瘤<|>RELATION_NOE 汤<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_S 中<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 。<|>RELATION_NOE
伊立<|>RELATION_NOE 替康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 伊立<|>RELATION_NOE 替康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
伊立<|>RELATION_NOE 替康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 有效<|>RELATION_B 方法<|>RELATION_I 之一<|>RELATION_E 。<|>RELATION_NOE
痰<|>RELATION_NOE 热清<|>RELATION_NOE 注射液<|>RELATION_NOE 防治<|>RELATION_S 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 痰<|>RELATION_NOE 热清<|>RELATION_NOE 注射液<|>RELATION_NOE 对<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 防治<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
将<|>RELATION_NOE 诊断<|>RELATION_NOE 明确<|>RELATION_NOE 的<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 在<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 同时<|>RELATION_NOE 应用<|>RELATION_NOE 痰<|>RELATION_NOE 热清<|>RELATION_NOE 注射液<|>RELATION_NOE ;<|>RELATION_NOE
治疗组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 11.4%<|>RELATION_NOE 和<|>RELATION_NOE 33.3%<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
治疗组<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_NOE 时间<|>RELATION_NOE 相对<|>RELATION_NOE 延迟<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
痰<|>RELATION_NOE 热清<|>RELATION_NOE 注射液<|>RELATION_NOE 能<|>RELATION_NOE 降低<|>RELATION_S 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 延迟<|>RELATION_NOE 发生<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
细胞<|>RELATION_NOE 块<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 检测<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_E
收集<|>RELATION_NOE 滨州市<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 2009年<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 167<|>RELATION_NOE 例<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 103<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 64<|>RELATION_NOE 例<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 进行<|>RELATION_NOE 离心<|>RELATION_NOE ,<|>RELATION_NOE 制作<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE 切片<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 。<|>RELATION_NOE
HE<|>RELATION_NOE 染色<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 和<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 诊断<|>RELATION_NOE 困难<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 20.4%<|>RELATION_NOE 和<|>RELATION_NOE 20.3%<|>RELATION_NOE 。<|>RELATION_NOE
1<|>RELATION_NOE 、<|>RELATION_NOE CK5<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE WT-1<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 81.3%<|>RELATION_NOE 、<|>RELATION_NOE 83.5%<|>RELATION_NOE 、<|>RELATION_NOE 87.9%<|>RELATION_NOE 、<|>RELATION_NOE 91.2%<|>RELATION_NOE 、<|>RELATION_NOE 86.8%<|>RELATION_NOE 、<|>RELATION_NOE 36.3%<|>RELATION_NOE 、<|>RELATION_NOE 0<|>RELATION_NOE 、<|>RELATION_NOE 0<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 23.4%<|>RELATION_NOE 、<|>RELATION_NOE O<|>RELATION_NOE 、<|>RELATION_NOE 1.5%<|>RELATION_NOE 、<|>RELATION_NOE 3.1%<|>RELATION_NOE 、<|>RELATION_NOE 0<|>RELATION_NOE 、<|>RELATION_NOE 87.5%<|>RELATION_NOE 、<|>RELATION_NOE 81.3%<|>RELATION_NOE 、<|>RELATION_NOE 84.4%<|>RELATION_NOE 。<|>RELATION_NOE
细胞<|>RELATION_NOE 块<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 是<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_B 方法<|>RELATION_E ,<|>RELATION_NOE 结合<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 及<|>RELATION_NOE 多种<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 抗体<|>RELATION_NOE 联合<|>RELATION_NOE 使用<|>RELATION_NOE 可以<|>RELATION_NOE 显著<|>RELATION_NOE 提高<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 。<|>RELATION_NOE
回<|>RELATION_NOE 生<|>RELATION_NOE 口服液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE
评价<|>RELATION_NOE 回<|>RELATION_NOE 生<|>RELATION_NOE 口服液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 药物<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 给予<|>RELATION_S 回<|>RELATION_NOE 生<|>RELATION_NOE 口服液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 药物治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 观察组<|>RELATION_NOE 给予<|>RELATION_NOE 回生<|>RELATION_NOE 口服液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 药物治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 给予<|>RELATION_S 化疗<|>RELATION_NOE 药物治疗<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 患者<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 最<|>RELATION_NOE 长<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 最<|>RELATION_NOE 短<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 均<|>RELATION_B 长<|>RELATION_I 于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 半<|>RELATION_NOE 年<|>RELATION_NOE 、<|>RELATION_NOE 1年<|>RELATION_NOE 生存<|>RELATION_NOE 例数<|>RELATION_NOE 均<|>RELATION_NOE 多于<|>RELATION_NOE
适形<|>RELATION_NOE 放疗<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_I 探究<|>RELATION_E
3DCRT<|>RELATION_NOE 组<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 和<|>RELATION_NOE 血液<|>RELATION_NOE 反应率<|>RELATION_NOE 为<|>RELATION_NOE 21%<|>RELATION_NOE 、<|>RELATION_NOE 30%<|>RELATION_NOE 和<|>RELATION_NOE 71%<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 略<|>RELATION_NOE 低于<|>RELATION_S 常规组<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 癌蛋白18<|>RELATION_NOE (<|>RELATION_NOE stathmin<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对抗<|>RELATION_NOE 微管<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
Stathmin<|>RELATION_NOE 只<|>RELATION_B 表达<|>RELATION_I 于<|>RELATION_E 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 且<|>RELATION_NOE 定位<|>RELATION_NOE 于<|>RELATION_NOE 胞浆<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 51.3%<|>RELATION_NOE (<|>RELATION_NOE 40<|>RELATION_NOE /<|>RELATION_NOE 78<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 、<|>RELATION_NOE 中央型<|>RELATION_NOE 、<|>RELATION_NOE 累及<|>RELATION_NOE 胸膜<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 分组<|>RELATION_NOE 中<|>RELATION_NOE 差异<|>RELATION_NOE 不<|>RELATION_NOE 明显<|>RELATION_NOE 。<|>RELATION_NOE
分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE stathmin<|>RELATION_NOE 表达<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检测<|>RELATION_NOE NSCLC<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE stathmin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 估计<|>RELATION_NOE 有<|>RELATION_B 一定<|>RELATION_I 的<|>RELATION_I 价值<|>RELATION_E ,<|>RELATION_NOE 其中<|>RELATION_NOE stathmin<|>RELATION_NOE 阴<|>RELATION_NOE 性者<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 对抗<|>RELATION_NOE 微管<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE 意义<|>RELATION_NOE 不<|>RELATION_NOE 大<|>RELATION_NOE 。<|>RELATION_NOE
分化<|>RELATION_NOE 程度<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE stathmin<|>RELATION_NOE 阴性<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 培养<|>RELATION_S 具有<|>RELATION_NOE 肺转移<|>RELATION_NOE 潜能<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE MHCC97L<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 不同<|>RELATION_NOE 剂量<|>RELATION_NOE 组合<|>RELATION_NOE 的<|>RELATION_NOE 阿司匹林<|>RELATION_NOE 和<|>RELATION_NOE IFN-<|>RELATION_NOE α<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 荷瘤<|>RELATION_NOE 裸鼠<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE ,<|>RELATION_NOE 计算肺<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE 及<|>RELATION_NOE 肺转移率<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE IFN-<|>RELATION_NOE α<|>RELATION_NOE [<|>RELATION_NOE 1.5<|>RELATION_NOE ×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 7/<|>RELATION_NOE (<|>RELATION_NOE kg<|>RELATION_NOE ·<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 治疗组<|>RELATION_NOE 、<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE IFN-<|>RELATION_NOE α<|>RELATION_NOE +<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 阿司匹林<|>RELATION_NOE 治疗组<|>RELATION_NOE 、<|>RELATION_NOE 小<|>RELATION_NOE 剂量<|>RELATION_NOE IFN-<|>RELATION_NOE α<|>RELATION_NOE [<|>RELATION_NOE 7.5<|>RELATION_NOE ×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 6/<|>RELATION_NOE (<|>RELATION_NOE kg<|>RELATION_NOE ·<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE +<|>RELATION_NOE 小<|>RELATION_NOE 剂量<|>RELATION_NOE 阿司匹林<|>RELATION_NOE [<|>RELATION_NOE 15mg<|>RELATION_NOE /<|>RELATION_NOE (<|>RELATION_NOE kg<|>RELATION_NOE ·<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 治疗组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 0.69<|>RELATION_NOE ±<|>RELATION_NOE 0.40<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE ^<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.55<|>RELATION_NOE ±<|>RELATION_NOE 0.31<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE ^<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.40<|>RELATION_NOE ±<|>RELATION_NOE 0.43<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE ^<|>RELATION_NOE 3<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺转移率<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
结论<|>RELATION_NOE :<|>RELATION_NOE 小<|>RELATION_NOE 剂量<|>RELATION_NOE 阿司匹林<|>RELATION_NOE 可<|>RELATION_NOE 协同<|>RELATION_NOE IFN-<|>RELATION_NOE α<|>RELATION_NOE 抑制<|>RELATION_S HCC<|>RELATION_NOE 生长<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE
三<|>RELATION_NOE 种<|>RELATION_NOE 不同<|>RELATION_NOE 组织<|>RELATION_NOE 来源<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE CXCR4mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 研究<|>RELATION_S
选取<|>RELATION_NOE 不同<|>RELATION_NOE 组织<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE 95C<|>RELATION_NOE 和<|>RELATION_NOE H1299<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 反转录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE Westernblot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S CXCR4mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 组织<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE 95C<|>RELATION_NOE 和<|>RELATION_NOE H1299<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 表达<|>RELATION_NOE CXCR4<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 相对<|>RELATION_NOE 表达量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.9<|>RELATION_NOE 53<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 30<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 0.22S<|>RELATION_NOE ±<|>RELATION_NOE 0.00<|>RELATION_NOE 9.<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 依次<|>RELATION_NOE 减低<|>RELATION_NOE ;<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 19<|>RELATION_NOE 78年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 12月<|>RELATION_NOE 接受<|>RELATION_NOE 免疫<|>RELATION_NOE 抑制<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肾移植<|>RELATION_NOE 受者<|>RELATION_NOE 中<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
恶性肿瘤<|>RELATION_NOE 于<|>RELATION_NOE 移植术<|>RELATION_NOE 后<|>RELATION_NOE 8－<|>RELATION_NOE 1<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 中位<|>RELATION_NOE 时间<|>RELATION_NOE 57<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 得到<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 泌尿<|>RELATION_NOE 系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 各<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 硬<|>RELATION_NOE 脑膜<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 低<|>RELATION_NOE 分化癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 有<|>RELATION_NOE 1例<|>RELATION_NOE 转移性<|>RELATION_NOE 肝癌<|>RELATION_NOE 患者<|>RELATION_NOE 人院<|>RELATION_NOE 后<|>RELATION_NOE 3d<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 不明<|>RELATION_NOE 。<|>RELATION_NOE
11<|>RELATION_NOE 例<|>RELATION_NOE 未<|>RELATION_NOE 手术者<|>RELATION_NOE 于<|>RELATION_NOE 诊断<|>RELATION_NOE 后<|>RELATION_NOE 3d<|>RELATION_NOE 一<|>RELATION_NOE 36<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 中位<|>RELATION_NOE 时间<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌脑<|>RELATION_NOE 转移<|>RELATION_NOE 危险因素<|>RELATION_NOE 研究<|>RELATION_S
鳞状细胞癌<|>RELATION_NOE 及<|>RELATION_NOE 腺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE 均数<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.8em<|>RELATION_NOE 和<|>RELATION_NOE 3.9em<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大<|>RELATION_NOE 、<|>RELATION_NOE 乳酸脱氢酶<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 站<|>RELATION_NOE 及<|>RELATION_NOE 多<|>RELATION_NOE 个<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 可<|>RELATION_B 作为<|>RELATION_E 脑转移<|>RELATION_NOE 相关<|>RELATION_NOE 危险因素<|>RELATION_NOE 进行<|>RELATION_NOE 预防<|>RELATION_NOE 性脑<|>RELATION_NOE 照射<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 6月<|>RELATION_NOE 140<|>RELATION_NOE 例<|>RELATION_NOE 胸外科<|>RELATION_NOE I<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性研究<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 辅助<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE 采用<|>RELATION_NOE 不<|>RELATION_NOE 撑<|>RELATION_NOE 开<|>RELATION_NOE 肋骨<|>RELATION_NOE ,<|>RELATION_NOE 完全<|>RELATION_NOE 在<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 完成<|>RELATION_NOE 单向式<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 左<|>RELATION_NOE 肺上叶<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 下叶<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 单向式<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 对于<|>RELATION_NOE 可<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE Ⅰ/Ⅱ期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 可行<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE ,<|>RELATION_NOE 此术式<|>RELATION_NOE 能<|>RELATION_NOE 减少<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE ,<|>RELATION_NOE 缩短<|>RELATION_S 术后<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 平均<|>RELATION_NOE 住院时间<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 不<|>RELATION_NOE 增加<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 完成<|>RELATION_NOE 纵隔<|>RELATION_NOE 及<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 清扫<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
细胞<|>RELATION_NOE 块<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 胸腔<|>RELATION_NOE 转移<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E
探讨<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 胸腔<|>RELATION_NOE 转移<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
利用<|>RELATION_NOE 细胞块<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 形态学<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 68<|>RELATION_NOE 例<|>RELATION_NOE 经常<|>RELATION_NOE 规细胞学<|>RELATION_NOE 涂片<|>RELATION_NOE 未<|>RELATION_NOE 明确<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 性质<|>RELATION_NOE 但<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 疑<|>RELATION_NOE 为<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 胸腔<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 标本<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 形态学<|>RELATION_NOE 并<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 考虑<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 胸腔<|>RELATION_NOE 转移<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 间皮<|>RELATION_NOE 细胞<|>RELATION_NOE 反应性<|>RELATION_NOE 增生<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 未<|>RELATION_NOE 确诊<|>RELATION_NOE 病例<|>RELATION_NOE 经<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 确诊<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 胸腔<|>RELATION_NOE 转移<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 间皮<|>RELATION_NOE 细胞<|>RELATION_NOE 反应性<|>RELATION_NOE 增生<|>RELATION_NOE 4例<|>RELATION_NOE ;<|>RELATION_NOE
分析<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 资料<|>RELATION_NOE 显示<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE (<|>RELATION_NOE CK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 钙黏附<|>RELATION_NOE 蛋白.<|>RELATION_NOE
E<|>RELATION_NOE (<|>RELATION_NOE E-cad<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 诊断<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 胸腔<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 95.8%<|>RELATION_NOE (<|>RELATION_NOE 23<|>RELATION_NOE /<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 0.0%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 91.7%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE E-cad<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE TTF-1<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 诊断<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 胸腔<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 特异度<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 95.5%<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE 144<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 0.0%<|>RELATION_NOE (<|>RELATION_NOE 44<|>RELATION_NOE 144<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 0.0%<|>RELATION_NOE (<|>RELATION_NOE 44<|>RELATION_NOE /<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
而<|>RELATION_NOE 钙网膜蛋白<|>RELATION_NOE (<|>RELATION_NOE CR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 波形蛋白<|>RELATION_NOE 对<|>RELATION_NOE 诊断<|>RELATION_NOE 间皮<|>RELATION_NOE 细胞<|>RELATION_NOE 反应性<|>RELATION_NOE 增生<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 相当<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 86.4%<|>RELATION_NOE (<|>RELATION_NOE 38<|>RELATION_NOE /<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 100.0%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CEA<|>RELATION_NOE 、<|>RELATION_NOE E-cad<|>RELATION_NOE 、<|>RELATION_NOE TTF-1<|>RELATION_NOE 联合<|>RELATION_NOE CR<|>RELATION_NOE 或许<|>RELATION_NOE 对<|>RELATION_NOE 确定<|>RELATION_NOE 细胞<|>RELATION_NOE 来源<|>RELATION_NOE 及<|>RELATION_NOE 鉴别<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 和<|>RELATION_NOE 增生性<|>RELATION_NOE 间皮<|>RELATION_NOE 细胞<|>RELATION_NOE 价值<|>RELATION_B 较<|>RELATION_I 大<|>RELATION_E ;<|>RELATION_NOE
细胞块<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 形态学<|>RELATION_NOE 结合<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 提高<|>RELATION_E 疑难<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 检出率<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 漏诊<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 生物钟<|>RELATION_NOE 基因<|>RELATION_NOE Per2<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色法<|>RELATION_NOE 检测<|>RELATION_S 60<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE Per2<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Per2<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 71.7%<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_S 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 95.0%<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 4.6<|>RELATION_NOE 83<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 58.3%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE Per2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 与<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE TMN<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE ∥<|>RELATION_NOE =<|>RELATION_NOE 4.4<|>RELATION_NOE 13<|>RELATION_NOE ,<|>RELATION_NOE 6.1<|>RELATION_NOE 79<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE Per2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 与<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE TMN<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE ∥<|>RELATION_NOE =<|>RELATION_NOE 4.4<|>RELATION_NOE 13<|>RELATION_NOE ,<|>RELATION_NOE 6.1<|>RELATION_NOE 79<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 6.5<|>RELATION_NOE 24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 血清<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 片段<|>RELATION_NOE 21<|>RELATION_NOE —<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE cyfra21<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 测定<|>RELATION_S 50<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小<|>RELATION_NOE 细胞<|>RELATION_NOE 肺<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE cyfra21<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
cyfra21<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 判定<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_S 不同<|>RELATION_NOE 病理分型<|>RELATION_NOE 、<|>RELATION_NOE 不同<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 促<|>RELATION_NOE 血管<|>RELATION_NOE 生成素<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE Ang-2<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 进<|>RELATION_NOE -<|>RELATION_NOE 步<|>RELATION_NOE 探讨<|>RELATION_NOE 该病<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE 机理<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 提供<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE Ang-2<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_S 正常<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 与<|>RELATION_NOE 鳞癌<|>RELATION_NOE 比较<|>RELATION_NOE Sig<|>RELATION_NOE 值<|>RELATION_NOE 为<|>RELATION_NOE 0.0<|>RELATION_NOE 49<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ;<|>RELATION_NOE
析<|>RELATION_NOE 血清<|>RELATION_NOE Ang-2<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 预测<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 判断<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Ang-2<|>RELATION_NOE 与<|>RELATION_NOE 其他<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 诊断<|>RELATION_NOE 阳性率<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 呼<|>RELATION_NOE 出气<|>RELATION_NOE 冷凝液<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
研究<|>RELATION_S 呼<|>RELATION_NOE 出气<|>RELATION_NOE 冷凝液<|>RELATION_NOE (<|>RELATION_NOE EBC<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE EBC<|>RELATION_NOE 中<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE EBC<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 同期<|>RELATION_NOE 20<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 的<|>RELATION_NOE EBC<|>RELATION_NOE 标本<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
提取<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE β<|>RELATION_NOE -actin<|>RELATION_NOE 基因<|>RELATION_NOE 片段<|>RELATION_NOE 扩增<|>RELATION_NOE 阳性<|>RELATION_NOE 的<|>RELATION_NOE EBC<|>RELATION_NOE 标本<|>RELATION_NOE 和<|>RELATION_NOE 已<|>RELATION_NOE 提取<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE DNA<|>RELATION_NOE 进行<|>RELATION_S p16<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3号<|>RELATION_NOE 外显子<|>RELATION_NOE PCR<|>RELATION_NOE 扩增<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE ①<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE EBC<|>RELATION_NOE 中<|>RELATION_NOE β<|>RELATION_NOE -actin<|>RELATION_NOE 基因<|>RELATION_NOE 片段<|>RELATION_NOE 扩增<|>RELATION_NOE 阳性<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 9例<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 34.6%<|>RELATION_NOE ;<|>RELATION_NOE
EBC<|>RELATION_NOE 中检<|>RELATION_NOE 出<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 发现<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
②<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 检测<|>RELATION_NOE 到<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 50.0%<|>RELATION_NOE ;<|>RELATION_NOE
癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 检测<|>RELATION_NOE 到<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
③<|>RELATION_NOE 9例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EBC<|>RELATION_NOE 中<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 外显子<|>RELATION_NOE 为<|>RELATION_NOE 1号<|>RELATION_NOE 外显子<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 2号<|>RELATION_NOE 外显子<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 3号<|>RELATION_NOE 外显子<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
15<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 外湿子<|>RELATION_NOE 为<|>RELATION_NOE 1号<|>RELATION_NOE 外显子<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 2号<|>RELATION_NOE 外显子<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 3号<|>RELATION_NOE 外显子<|>RELATION_NOE 3例<|>RELATION_NOE 。<|>RELATION_NOE
④<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EBC<|>RELATION_NOE 中<|>RELATION_NOE G<|>RELATION_NOE －<|>RELATION_NOE actin<|>RELATION_NOE 基因扩增<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ期<|>RELATION_NOE 和<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 患者<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 25.0%<|>RELATION_NOE (<|>RELATION_NOE 3/12<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 28.6%<|>RELATION_NOE (<|>RELATION_NOE 2/7<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 57.1%<|>RELATION_NOE (<|>RELATION_NOE 4/7<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 42.9<|>RELATION_NOE 0.4<|>RELATION_NOE (<|>RELATION_NOE 6/14<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 25.0%<|>RELATION_NOE (<|>RELATION_NOE 3/12<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
⑤<|>RELATION_NOE 同一<|>RELATION_NOE 患者<|>RELATION_NOE EBC<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 外显子<|>RELATION_NOE 种类<|>RELATION_NOE 、<|>RELATION_NOE 突变<|>RELATION_NOE 方式<|>RELATION_NOE 、<|>RELATION_NOE 突变<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 密码子<|>RELATION_NOE 均<|>RELATION_NOE 相同<|>RELATION_S 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE EBC<|>RELATION_NOE 和<|>RELATION_NOE 癌组织<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_NOE 检测<|>RELATION_B 到<|>RELATION_E p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 有<|>RELATION_NOE 高度<|>RELATION_NOE 的<|>RELATION_NOE 一致性<|>RELATION_NOE 。<|>RELATION_NOE
EBC<|>RELATION_NOE 中<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 简便<|>RELATION_NOE 、<|>RELATION_NOE 快速<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
STAT3<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
利用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 免疫法<|>RELATION_NOE 检测<|>RELATION_S 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE 人<|>RELATION_NOE 胚胎<|>RELATION_NOE 成纤维细胞<|>RELATION_NOE MRC-5<|>RELATION_NOE 培养<|>RELATION_NOE 3d<|>RELATION_NOE 的<|>RELATION_NOE 培养液<|>RELATION_NOE 中<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE 人<|>RELATION_NOE 胚胎<|>RELATION_NOE 成纤维细胞<|>RELATION_NOE MRC-5<|>RELATION_NOE 中<|>RELATION_NOE STAT3mRNA<|>RELATION_NOE 、<|>RELATION_NOE CEAmRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
STAT3mRNA<|>RELATION_NOE 、<|>RELATION_NOE CEAmRNA<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE 6.96<|>RELATION_NOE ±<|>RELATION_NOE 3.37<|>RELATION_NOE ,<|>RELATION_NOE 5.68<|>RELATION_NOE ±<|>RELATION_NOE 2.70<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E MRC-5<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE 1.01<|>RELATION_NOE ±<|>RELATION_NOE 0.19<|>RELATION_NOE ,<|>RELATION_NOE 1.02<|>RELATION_NOE ±<|>RELATION_NOE 0.21<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE STAT3<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.5<|>RELATION_NOE 21<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 47<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胸腔<|>RELATION_NOE 循环<|>RELATION_NOE 热灌<|>RELATION_NOE 注化<|>RELATION_NOE 疗<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE
观察<|>RELATION_NOE 胸腔<|>RELATION_NOE 循环<|>RELATION_NOE 热灌<|>RELATION_NOE 注化<|>RELATION_NOE 疗<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_S 体腔<|>RELATION_NOE 热灌<|>RELATION_NOE 注化<|>RELATION_NOE 疗仪<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 顺铂<|>RELATION_NOE 注入<|>RELATION_NOE 胸腔<|>RELATION_NOE ,<|>RELATION_NOE 加热<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 循环<|>RELATION_NOE 热灌<|>RELATION_NOE 注化<|>RELATION_NOE 疗<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对比<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 性质<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
胸腔<|>RELATION_NOE 循环<|>RELATION_NOE 热灌<|>RELATION_NOE 注化<|>RELATION_NOE 疗<|>RELATION_NOE 治疗<|>RELATION_S 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 有效率<|>RELATION_NOE 高<|>RELATION_NOE 且<|>RELATION_NOE 安全性<|>RELATION_NOE 良好<|>RELATION_NOE 。<|>RELATION_NOE
CYP1A1<|>RELATION_NOE 和<|>RELATION_NOE GSTM1<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE BPDE-DNA<|>RELATION_NOE 加合物<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 及其<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
用<|>RELATION_NOE 病例<|>RELATION_NOE 一<|>RELATION_NOE 对照<|>RELATION_NOE 方法<|>RELATION_NOE 收集<|>RELATION_NOE 200<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 流行病学<|>RELATION_NOE 调查<|>RELATION_NOE 资料<|>RELATION_NOE 及<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 样本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 限制性<|>RELATION_NOE 片段<|>RELATION_NOE 长度<|>RELATION_NOE 多态性<|>RELATION_NOE -PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 血<|>RELATION_NOE 中<|>RELATION_NOE CYP1A1<|>RELATION_NOE 、<|>RELATION_NOE GSTM1<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 竞争性<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 用<|>RELATION_NOE 病例<|>RELATION_NOE 一<|>RELATION_NOE 对照<|>RELATION_NOE 方法<|>RELATION_NOE 收集<|>RELATION_NOE 200<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 流行病学<|>RELATION_NOE 调查<|>RELATION_NOE 资料<|>RELATION_NOE 及<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 样本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 限制性<|>RELATION_NOE 片段<|>RELATION_NOE 长度<|>RELATION_NOE 多态性<|>RELATION_NOE -PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE CYP1A1<|>RELATION_NOE 、<|>RELATION_NOE GSTM1<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 竞争性<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 检测<|>RELATION_S BPDE-DNA<|>RELATION_NOE 加合物<|>RELATION_NOE 浓度<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE BPDE-DNA<|>RELATION_NOE 加合物<|>RELATION_NOE 浓度<|>RELATION_NOE 高于<|>RELATION_S 对照<|>RELATION_NOE 人群<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 肺癌<|>RELATION_NOE 吸烟者<|>RELATION_NOE 加合物<|>RELATION_NOE 浓度<|>RELATION_NOE 明显<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE BPDE-DNA<|>RELATION_NOE 加合物<|>RELATION_NOE 浓度<|>RELATION_NOE 高于<|>RELATION_NOE 对照<|>RELATION_NOE 人群<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 肺癌<|>RELATION_NOE 吸烟者<|>RELATION_NOE 加合物<|>RELATION_NOE 浓度<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺癌<|>RELATION_NOE 不<|>RELATION_NOE 吸烟者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.02<|>RELATION_NOE 52<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CYP1A1<|>RELATION_NOE 变异型<|>RELATION_NOE 吸烟者<|>RELATION_NOE 形成<|>RELATION_NOE 高<|>RELATION_NOE 水平<|>RELATION_NOE DNA<|>RELATION_NOE 加合物<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E CYP1A1<|>RELATION_NOE 野生型<|>RELATION_NOE 不<|>RELATION_NOE 吸<|>RELATION_NOE 烟者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.04<|>RELATION_NOE 59<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CYP1A1<|>RELATION_NOE 变异型<|>RELATION_NOE 吸烟者<|>RELATION_NOE 、<|>RELATION_NOE GSTM1<|>RELATION_NOE 缺<|>RELATION_NOE 失型<|>RELATION_NOE 吸烟者<|>RELATION_NOE 更<|>RELATION_NOE 容易<|>RELATION_B 形成<|>RELATION_E 高<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE DNA<|>RELATION_NOE 加合物<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 可能<|>RELATION_NOE 有<|>RELATION_NOE 重要<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
综合<|>RELATION_NOE 保温<|>RELATION_NOE 措施<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
选择<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 拟行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 综合<|>RELATION_NOE 保温组<|>RELATION_NOE (<|>RELATION_NOE 观察组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 常规<|>RELATION_NOE 保温组<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 各<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 多<|>RELATION_NOE 功能<|>RELATION_NOE 监护仪<|>RELATION_NOE 体温<|>RELATION_NOE 监测<|>RELATION_NOE 模块<|>RELATION_NOE 持续<|>RELATION_NOE 测量<|>RELATION_NOE 直肠<|>RELATION_NOE 温度<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 入室<|>RELATION_NOE 时<|>RELATION_NOE 、<|>RELATION_NOE 皮肤<|>RELATION_NOE 消毒<|>RELATION_NOE 后<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 1h<|>RELATION_NOE 、<|>RELATION_NOE 胸腔<|>RELATION_NOE 冲洗<|>RELATION_NOE 后<|>RELATION_NOE 和<|>RELATION_NOE 术毕<|>RELATION_NOE 体温<|>RELATION_NOE 。<|>RELATION_NOE
XRCC1<|>RELATION_NOE 基因<|>RELATION_NOE 多<|>RELATION_NOE 态<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE DNA<|>RELATION_NOE 修复<|>RELATION_NOE 基因<|>RELATION_NOE XRCC1<|>RELATION_NOE 多<|>RELATION_NOE 态<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 病例<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 选择<|>RELATION_NOE 209<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 病例组<|>RELATION_NOE ,<|>RELATION_NOE 256<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 检查者<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE -<|>RELATION_NOE 限制性<|>RELATION_NOE 片段<|>RELATION_NOE 长度<|>RELATION_NOE 多态性<|>RELATION_NOE (<|>RELATION_NOE PCR-RFLP<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S XRCC1<|>RELATION_NOE 基因<|>RELATION_NOE 194<|>RELATION_NOE 、<|>RELATION_NOE 280<|>RELATION_NOE 和<|>RELATION_NOE 39<|>RELATION_NOE 9位点<|>RELATION_NOE 的<|>RELATION_NOE 多态性<|>RELATION_NOE 。<|>RELATION_NOE
尘肺<|>RELATION_NOE 诊断<|>RELATION_NOE 由<|>RELATION_NOE 职业病<|>RELATION_NOE 诊断<|>RELATION_NOE 小组<|>RELATION_NOE 确定<|>RELATION_NOE .<|>RELATION_NOE
诊断<|>RELATION_NOE 尘肺<|>RELATION_NOE 316<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 人年<|>RELATION_NOE 发病率<|>RELATION_NOE 为<|>RELATION_NOE 0.2<|>RELATION_NOE 4%<|>RELATION_NOE .<|>RELATION_NOE
尘肺<|>RELATION_NOE 患者<|>RELATION_NOE 年<|>RELATION_NOE 平均<|>RELATION_NOE 累积<|>RELATION_NOE 接尘量<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE 3.7<|>RELATION_NOE ±<|>RELATION_NOE 91.6<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m3<|>RELATION_NOE ,<|>RELATION_NOE 远<|>RELATION_B 高于<|>RELATION_E 非尘肺<|>RELATION_NOE 接尘<|>RELATION_NOE 工人<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE 2.1<|>RELATION_NOE ±<|>RELATION_NOE 64.8<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m3<|>RELATION_NOE .<|>RELATION_NOE 除<|>RELATION_NOE 累积<|>RELATION_NOE 接尘量<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_NOE 尘肺<|>RELATION_NOE 发病<|>RELATION_NOE 风险<|>RELATION_NOE 因素<|>RELATION_NOE 包括<|>RELATION_NOE 肺结核<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE =<|>RELATION_NOE 5.9<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE =<|>RELATION_NOE 1.7<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
累积<|>RELATION_NOE 接尘量<|>RELATION_NOE 与<|>RELATION_NOE 尘肺<|>RELATION_NOE 发病<|>RELATION_NOE 之间<|>RELATION_NOE 存在<|>RELATION_B 明显<|>RELATION_I 的<|>RELATION_I 剂量<|>RELATION_I -<|>RELATION_I 反应<|>RELATION_I 关系<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 结核<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE
X<|>RELATION_NOE 射线<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE Pokemon<|>RELATION_NOE 表达<|>RELATION_NOE 影响<|>RELATION_S
研究<|>RELATION_NOE 不同<|>RELATION_NOE 剂量<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 及<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 点<|>RELATION_NOE 对<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞系<|>RELATION_NOE Pokemon<|>RELATION_NOE 基因<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
用<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 8Gy<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 照射<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞系<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 荧光<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 技术<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 印记法<|>RELATION_NOE 检测<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE 的<|>RELATION_NOE PokemonmRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 未<|>RELATION_NOE 照射组<|>RELATION_NOE 为<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
照射组<|>RELATION_NOE 细胞<|>RELATION_NOE 接种<|>RELATION_NOE 后<|>RELATION_NOE 第<|>RELATION_NOE 3-5<|>RELATION_NOE 天<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 能力<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.34-18.19<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000-0.040<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
一定<|>RELATION_NOE 剂量<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 在<|>RELATION_NOE 特定<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE 可<|>RELATION_NOE 诱导<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE PokemonmRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 辐射<|>RELATION_NOE 抗性<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
不同<|>RELATION_NOE 算法<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 均匀<|>RELATION_NOE 组织<|>RELATION_NOE 模体<|>RELATION_NOE 中<|>RELATION_NOE 光子<|>RELATION_NOE 剂量<|>RELATION_NOE 计算<|>RELATION_NOE 精确度<|>RELATION_NOE 比较<|>RELATION_S
比较<|>RELATION_S 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE TPS<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 光子<|>RELATION_NOE 束<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE 筒串<|>RELATION_NOE 卷积<|>RELATION_NOE 算法<|>RELATION_NOE (<|>RELATION_NOE CCC<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 笔形<|>RELATION_NOE 束<|>RELATION_NOE 卷积<|>RELATION_NOE 算法<|>RELATION_NOE (<|>RELATION_NOE PBC<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非均匀<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 计算<|>RELATION_NOE 精确度<|>RELATION_NOE 。<|>RELATION_NOE
另<|>RELATION_NOE 一个<|>RELATION_NOE 在<|>RELATION_NOE 光子束<|>RELATION_NOE 前后<|>RELATION_NOE 对<|>RELATION_NOE 穿野<|>RELATION_NOE 入<|>RELATION_NOE 射<|>RELATION_NOE ,<|>RELATION_NOE 模体<|>RELATION_NOE 中心<|>RELATION_NOE 有<|>RELATION_NOE 一个<|>RELATION_NOE 肿瘤<|>RELATION_NOE 等<|>RELATION_NOE 效<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 算法<|>RELATION_NOE 计算<|>RELATION_NOE 光子<|>RELATION_NOE 束<|>RELATION_NOE 穿过<|>RELATION_NOE 肺等效<|>RELATION_NOE 组织<|>RELATION_NOE 到达<|>RELATION_NOE 肿瘤<|>RELATION_NOE 等<|>RELATION_NOE 效<|>RELATION_NOE 组织<|>RELATION_NOE 时<|>RELATION_NOE 肺和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 等<|>RELATION_NOE 效<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 单前野<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 光子<|>RELATION_NOE 束<|>RELATION_NOE 从<|>RELATION_NOE 高<|>RELATION_NOE 密度<|>RELATION_NOE 组织<|>RELATION_NOE 入射<|>RELATION_NOE 到<|>RELATION_NOE 低<|>RELATION_NOE 密度<|>RELATION_NOE 的<|>RELATION_NOE 肺等效<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE MC<|>RELATION_NOE 算法<|>RELATION_NOE 比较<|>RELATION_NOE PBC<|>RELATION_NOE 算法<|>RELATION_NOE 高估<|>RELATION_B 了<|>RELATION_E 肺等效<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.90<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE :<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CCC<|>RELATION_NOE 算法<|>RELATION_NOE 与<|>RELATION_NOE 之<|>RELATION_NOE 接近<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.25<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 87<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
前后<|>RELATION_NOE 对<|>RELATION_NOE 穿野<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE CCC<|>RELATION_NOE 算法<|>RELATION_NOE 和<|>RELATION_NOE MC<|>RELATION_NOE 算法<|>RELATION_NOE 计算<|>RELATION_NOE 出<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 等<|>RELATION_NOE 效<|>RELATION_NOE 组织<|>RELATION_NOE 边界<|>RELATION_NOE 剂量<|>RELATION_NOE 都<|>RELATION_NOE 要<|>RELATION_NOE 低于<|>RELATION_S PBC<|>RELATION_NOE 算法<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.43<|>RELATION_NOE 、<|>RELATION_NOE 3.18<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 38<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 11<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 能量<|>RELATION_NOE 越<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 肺密度<|>RELATION_NOE 越<|>RELATION_NOE 小时<|>RELATION_NOE ,<|>RELATION_NOE 这种<|>RELATION_NOE 差别<|>RELATION_NOE 越<|>RELATION_NOE 大<|>RELATION_NOE 。<|>RELATION_NOE
计算<|>RELATION_NOE 低<|>RELATION_NOE 密度<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 或<|>RELATION_NOE 其<|>RELATION_NOE 后方<|>RELATION_NOE 肿瘤<|>RELATION_NOE 剂量<|>RELATION_NOE 时<|>RELATION_NOE 最<|>RELATION_B 好<|>RELATION_I 采用<|>RELATION_E CCC<|>RELATION_NOE 算法<|>RELATION_NOE (<|>RELATION_NOE 如<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 以及<|>RELATION_NOE 胀气<|>RELATION_NOE 的<|>RELATION_NOE 直肠<|>RELATION_NOE 和<|>RELATION_NOE 胃后方<|>RELATION_NOE 肿瘤<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
32<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 颅内<|>RELATION_NOE 进展<|>RELATION_NOE ,<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 颅外<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 脑脊<|>RELATION_NOE 髓膜<|>RELATION_NOE 广泛<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 其他<|>RELATION_NOE 原因<|>RELATION_NOE (<|>RELATION_NOE 2例<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 死因<|>RELATION_NOE 不明<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛加<|>RELATION_NOE 顺铂<|>RELATION_NOE 诱导<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 观察<|>RELATION_E
ICCRT<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE CCRT<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 80%<|>RELATION_NOE 和<|>RELATION_NOE 70%<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 1.26<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.2<|>RELATION_NOE 61<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 总<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 85%<|>RELATION_NOE 和<|>RELATION_NOE 65%<|>RELATION_NOE 、<|>RELATION_NOE 50%<|>RELATION_NOE 和<|>RELATION_NOE 40%<|>RELATION_NOE 、<|>RELATION_NOE 44%<|>RELATION_NOE 和<|>RELATION_NOE 33%<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 3.90<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 48<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 白细胞减少<|>RELATION_NOE (<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 3.48<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.06<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 0.12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血红<|>RELATION_NOE 蛋白<|>RELATION_NOE 减低<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 2.<|>RELATION_NOE 34<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 0.37<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.5<|>RELATION_NOE 41<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
扶<|>RELATION_NOE 正<|>RELATION_NOE 升<|>RELATION_NOE 白汤<|>RELATION_NOE 预防<|>RELATION_S 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 中<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 扶<|>RELATION_NOE 正<|>RELATION_NOE 升<|>RELATION_NOE 白汤<|>RELATION_NOE 对<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 中<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 症<|>RELATION_NOE 发生率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_NOE 循证<|>RELATION_NOE 护理<|>RELATION_NOE 预防<|>RELATION_S 肺部<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 评价<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 选取<|>RELATION_NOE 我院<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 1-6<|>RELATION_NOE 月<|>RELATION_NOE 所<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 各<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 临床<|>RELATION_B 给予<|>RELATION_E 常规<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE ;<|>RELATION_NOE
观察组<|>RELATION_NOE 给予<|>RELATION_S 循证<|>RELATION_NOE 思维<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 2组<|>RELATION_NOE 患者<|>RELATION_NOE 肺部<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
循证<|>RELATION_NOE 思维<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 能够<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 程度<|>RELATION_NOE 地<|>RELATION_NOE 满足<|>RELATION_S 患者<|>RELATION_NOE 以及<|>RELATION_NOE 家属<|>RELATION_NOE 对<|>RELATION_NOE 医疗<|>RELATION_NOE 保健<|>RELATION_NOE 的<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 肺部<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 帮助<|>RELATION_NOE 患者<|>RELATION_NOE 早日<|>RELATION_NOE 恢复<|>RELATION_NOE 健康<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 与<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE 循证<|>RELATION_NOE 思维<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 能够<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 程度<|>RELATION_NOE 地<|>RELATION_NOE 满足<|>RELATION_NOE 患者<|>RELATION_NOE 以及<|>RELATION_NOE 家属<|>RELATION_NOE 对<|>RELATION_NOE 医疗<|>RELATION_NOE 保健<|>RELATION_NOE 的<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_S 肺部<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 帮助<|>RELATION_NOE 患者<|>RELATION_NOE 早日<|>RELATION_NOE 恢复<|>RELATION_NOE 健康<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 与<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
估计<|>RELATION_S 2008年<|>RELATION_NOE 中国<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 、<|>RELATION_NOE 死亡<|>RELATION_NOE 和<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 预测<|>RELATION_NOE 今后<|>RELATION_NOE 20<|>RELATION_NOE 年<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 数<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 数<|>RELATION_NOE 。<|>RELATION_NOE 估计<|>RELATION_NOE 2008年<|>RELATION_NOE 中国<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 、<|>RELATION_NOE 死亡<|>RELATION_NOE 和<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 预测<|>RELATION_S 今后<|>RELATION_NOE 20<|>RELATION_NOE 年<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病数<|>RELATION_NOE 和<|>RELATION_NOE 死亡数<|>RELATION_NOE 。<|>RELATION_NOE
估计<|>RELATION_NOE 2008年<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 、<|>RELATION_NOE 死亡<|>RELATION_NOE 和<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 预测<|>RELATION_S 20<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 15<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 25<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 30<|>RELATION_NOE 年<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病数<|>RELATION_NOE 和<|>RELATION_NOE 死亡数<|>RELATION_NOE 。<|>RELATION_NOE
2008年<|>RELATION_NOE 中国<|>RELATION_NOE 15<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 成年人<|>RELATION_NOE 肺癌<|>RELATION_NOE 5年<|>RELATION_NOE 患病<|>RELATION_NOE 数<|>RELATION_NOE 约<|>RELATION_NOE 为<|>RELATION_NOE 48.8万<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 所有<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 患病<|>RELATION_NOE 数<|>RELATION_NOE 的<|>RELATION_NOE 10.6%<|>RELATION_NOE ,<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 患病率<|>RELATION_NOE 为<|>RELATION_NOE 45.6<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 居<|>RELATION_NOE 全部<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 第4<|>RELATION_NOE 位<|>RELATION_NOE (<|>RELATION_NOE 低于<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 结直肠癌<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 是<|>RELATION_NOE 我国<|>RELATION_NOE 人群<|>RELATION_NOE 首<|>RELATION_NOE 位<|>RELATION_NOE 癌症<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 发病<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 情况<|>RELATION_NOE 在<|>RELATION_NOE 未来<|>RELATION_NOE 20<|>RELATION_NOE 年<|>RELATION_NOE 将<|>RELATION_NOE 越来越<|>RELATION_NOE 严重<|>RELATION_NOE ,<|>RELATION_NOE 重点<|>RELATION_B 防控<|>RELATION_I 人群<|>RELATION_I 为<|>RELATION_E 45<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 中老年人<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 男性<|>RELATION_NOE 人群<|>RELATION_NOE 。<|>RELATION_NOE
半<|>RELATION_NOE 乳凝素<|>RELATION_NOE -9<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SABC<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 64<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 腺癌<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 癌组织<|>RELATION_NOE 及<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 半<|>RELATION_NOE 乳凝素<|>RELATION_NOE -9<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
半<|>RELATION_NOE 乳凝素<|>RELATION_NOE -9<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 程度<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 种类<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 无<|>RELATION_B 显著<|>RELATION_I 相关<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 13<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 半<|>RELATION_NOE 乳凝素<|>RELATION_NOE -9<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 程度<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 种类<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 无<|>RELATION_NOE 显著<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 13<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
半<|>RELATION_NOE 乳凝素<|>RELATION_NOE -9<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞<|>RELATION_NOE 癌癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 同<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 具有<|>RELATION_B 显著<|>RELATION_I 统计学<|>RELATION_I 相关性<|>RELATION_E ,<|>RELATION_NOE 因此<|>RELATION_NOE 有<|>RELATION_NOE 可能<|>RELATION_NOE 作为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 评判<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 标志物<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 为<|>RELATION_NOE 基因治疗<|>RELATION_NOE 提供<|>RELATION_NOE 潜在<|>RELATION_NOE 靶点<|>RELATION_NOE 。<|>RELATION_NOE
术前<|>RELATION_NOE 进行<|>RELATION_NOE 必要<|>RELATION_NOE 的<|>RELATION_NOE 影像学<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 了解<|>RELATION_NOE 肺门区<|>RELATION_NOE 肺癌<|>RELATION_NOE 对<|>RELATION_NOE 肺动脉<|>RELATION_NOE 、<|>RELATION_NOE 肺静脉<|>RELATION_NOE 大<|>RELATION_NOE 分支<|>RELATION_NOE 、<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 和<|>RELATION_NOE 左右<|>RELATION_NOE 心房<|>RELATION_NOE 的<|>RELATION_NOE 侵犯<|>RELATION_NOE ,<|>RELATION_NOE 评判<|>RELATION_S 手术<|>RELATION_NOE 的<|>RELATION_NOE 可能性<|>RELATION_NOE 及<|>RELATION_NOE 难<|>RELATION_NOE 易<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 手术<|>RELATION_NOE 成功率<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 剖胸<|>RELATION_NOE 探查率<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE Raptopoulos<|>RELATION_NOE 的<|>RELATION_NOE 五分制<|>RELATION_NOE 评分法<|>RELATION_NOE 对<|>RELATION_NOE 相关<|>RELATION_NOE 血管<|>RELATION_NOE 进行<|>RELATION_B 评分<|>RELATION_E ,<|>RELATION_NOE 0<|>RELATION_NOE －2<|>RELATION_NOE 分<|>RELATION_NOE 的<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 9例行<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 评分<|>RELATION_NOE 从<|>RELATION_NOE 3－<|>RELATION_NOE 4<|>RELATION_NOE 分<|>RELATION_NOE 降<|>RELATION_NOE 为<|>RELATION_NOE 2分<|>RELATION_NOE ,<|>RELATION_NOE 共计<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 标准<|>RELATION_NOE 肺叶切<|>RELATION_NOE ,<|>RELATION_NOE 8例<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 肺切除<|>RELATION_NOE 合并<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 或<|>RELATION_NOE 左<|>RELATION_NOE 心房<|>RELATION_NOE 部分<|>RELATION_NOE 切除<|>RELATION_NOE 重建术<|>RELATION_NOE ;<|>RELATION_NOE
评分<|>RELATION_NOE 为<|>RELATION_NOE 3－4<|>RELATION_NOE 分<|>RELATION_NOE 的<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 判断<|>RELATION_NOE 为<|>RELATION_NOE 完全<|>RELATION_NOE 失去<|>RELATION_NOE 手术<|>RELATION_NOE 机会<|>RELATION_NOE 未<|>RELATION_NOE 行<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 发现<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 无法<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 分别<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 肺切除<|>RELATION_NOE 合并<|>RELATION_NOE 左<|>RELATION_NOE 心房<|>RELATION_NOE 、<|>RELATION_NOE 右<|>RELATION_NOE 心房<|>RELATION_NOE 、<|>RELATION_NOE 左右<|>RELATION_NOE 心耳<|>RELATION_NOE 、<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 或<|>RELATION_NOE 右<|>RELATION_NOE 肺动脉<|>RELATION_NOE 部分<|>RELATION_NOE 切除<|>RELATION_NOE 重建<|>RELATION_NOE 术.<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 我院<|>RELATION_NOE 2005年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 连续<|>RELATION_NOE 收治<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 102<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 鳞癌<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 神经<|>RELATION_NOE 内分泌癌<|>RELATION_NOE 3例<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 纤维蛋白原<|>RELATION_NOE (<|>RELATION_NOE FIB<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 数值<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 良性肿<|>RELATION_NOE 瘤组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 血浆<|>RELATION_NOE 凝血酶原<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PT<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 活化<|>RELATION_NOE 部分<|>RELATION_NOE 凝血<|>RELATION_NOE 活<|>RELATION_NOE 酶<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE APTT<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 国际<|>RELATION_NOE 标准化<|>RELATION_NOE 比值<|>RELATION_NOE (<|>RELATION_NOE INR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血小板<|>RELATION_NOE (<|>RELATION_NOE PLT<|>RELATION_NOE )<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
淋巴结<|>RELATION_NOE 及<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE FIB<|>RELATION_NOE 及<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 无<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 中<|>RELATION_NOE 胃肠道<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 占<|>RELATION_NOE 50.8%<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 占<|>RELATION_NOE 24.6%<|>RELATION_NOE ;<|>RELATION_NOE
80.3%<|>RELATION_NOE 肝转移<|>RELATION_NOE 患者<|>RELATION_NOE 同时<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 肝外<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 胃肠道<|>RELATION_NOE 肿瘤<|>RELATION_NOE 中<|>RELATION_NOE 29%<|>RELATION_NOE 患者<|>RELATION_NOE 仅<|>RELATION_NOE 有<|>RELATION_NOE 肝转移<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 肺癌<|>RELATION_NOE 则<|>RELATION_NOE 全部<|>RELATION_NOE 同时<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 肝外<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
肝转<|>RELATION_NOE 移癌<|>RELATION_NOE 多<|>RELATION_B 来源于<|>RELATION_E 消化道<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 常<|>RELATION_NOE 为<|>RELATION_NOE 多发病灶<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 多<|>RELATION_NOE 同时<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 其他<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
温下方<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 药物<|>RELATION_NOE 转运<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 温下方<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE DDP<|>RELATION_NOE )<|>RELATION_NOE 合用<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 多药<|>RELATION_NOE 耐药<|>RELATION_NOE 裸鼠<|>RELATION_NOE 模型<|>RELATION_NOE 皮下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E 及其<|>RELATION_NOE 相关<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_S 耐药<|>RELATION_NOE 特性<|>RELATION_NOE 稳定<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 裸小鼠<|>RELATION_NOE 动物模型<|>RELATION_NOE 。<|>RELATION_NOE
RT-PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 多<|>RELATION_NOE 药<|>RELATION_NOE 耐药<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE mdr1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 药耐<|>RELATION_NOE 药<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE mrp<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
温下方<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 药合<|>RELATION_NOE 用<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 多药<|>RELATION_NOE 耐药<|>RELATION_NOE 裸鼠皮<|>RELATION_NOE 下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 具有<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 降低<|>RELATION_NOE 药物<|>RELATION_NOE 转运<|>RELATION_NOE 蛋白<|>RELATION_NOE mdr1<|>RELATION_NOE 和<|>RELATION_NOE mrp<|>RELATION_NOE 基因<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 增强<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
胸部<|>RELATION_NOE CT<|>RELATION_NOE 以<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肿块<|>RELATION_NOE 常见<|>RELATION_NOE ,<|>RELATION_NOE 肿块<|>RELATION_NOE 平均<|>RELATION_NOE 直径<|>RELATION_NOE (<|>RELATION_NOE 4.7<|>RELATION_NOE ±<|>RELATION_NOE 1.7<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 有<|>RELATION_NOE 毛刺征<|>RELATION_NOE 及<|>RELATION_NOE 分叶征<|>RELATION_NOE ,<|>RELATION_NOE 也<|>RELATION_NOE 可<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 厚壁<|>RELATION_NOE 空洞<|>RELATION_NOE 、<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 及<|>RELATION_NOE 肺不张<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
HE<|>RELATION_NOE 染色<|>RELATION_NOE 结合<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染色<|>RELATION_NOE 可见<|>RELATION_S 上皮<|>RELATION_NOE 性癌<|>RELATION_NOE 成分<|>RELATION_NOE 及<|>RELATION_NOE 肉瘤<|>RELATION_NOE 样<|>RELATION_NOE 成分<|>RELATION_NOE 并存<|>RELATION_NOE 。<|>RELATION_NOE
6例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE Ⅰ<|>RELATION_NOE b<|>RELATION_NOE 期<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE a<|>RELATION_NOE 期<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 行根治性<|>RELATION_NOE 手术<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE Ⅰ<|>RELATION_NOE b<|>RELATION_NOE 期<|>RELATION_NOE 患者<|>RELATION_NOE 长期<|>RELATION_NOE 存活<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE Ⅲ<|>RELATION_NOE a<|>RELATION_NOE 期<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 后<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
Ⅳ期<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 予<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 存活<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 2例<|>RELATION_NOE 确诊<|>RELATION_NOE 后<|>RELATION_NOE 即<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
肺肉瘤<|>RELATION_NOE 样癌<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 极<|>RELATION_NOE 少<|>RELATION_NOE 见<|>RELATION_NOE 的<|>RELATION_NOE 高度<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 影像学<|>RELATION_NOE 无<|>RELATION_B 特异性<|>RELATION_E ,<|>RELATION_NOE 主要<|>RELATION_NOE 依靠<|>RELATION_NOE 病理<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染色<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 容易<|>RELATION_NOE 出现<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
shRNA<|>RELATION_NOE 沉默<|>RELATION_NOE EZH2<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
利用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S EZH2<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE shRNA<|>RELATION_NOE 沉默<|>RELATION_NOE EZH2<|>RELATION_NOE 表达<|>RELATION_NOE 后<|>RELATION_NOE 分析<|>RELATION_NOE NCI-A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
shRNA<|>RELATION_NOE 阻断<|>RELATION_NOE EZH2<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EZH2<|>RELATION_NOE 基因沉默<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 抑制<|>RELATION_E 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 深入<|>RELATION_NOE 研究<|>RELATION_NOE EZH2<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 作用<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 研究<|>RELATION_NOE 基础<|>RELATION_NOE 。<|>RELATION_NOE
从<|>RELATION_NOE 临床<|>RELATION_NOE 医师<|>RELATION_NOE 角度<|>RELATION_NOE 对<|>RELATION_NOE 病理<|>RELATION_NOE 报告<|>RELATION_NOE 分为<|>RELATION_NOE 明确<|>RELATION_B 诊断<|>RELATION_I 、<|>RELATION_I 提示性<|>RELATION_I 诊断<|>RELATION_I 和<|>RELATION_I 非<|>RELATION_I 特异性<|>RELATION_I 诊断<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 依<|>RELATION_NOE 此<|>RELATION_NOE 分类<|>RELATION_NOE 对<|>RELATION_NOE 经皮<|>RELATION_NOE 肺活检<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
105<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 110<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 111<|>RELATION_NOE 例<|>RELATION_NOE 次<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 病理<|>RELATION_NOE 明确<|>RELATION_NOE 诊断率<|>RELATION_NOE 、<|>RELATION_NOE 提示性<|>RELATION_NOE 诊断率<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 特异性<|>RELATION_NOE 诊断率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 66.6<|>RELATION_NOE 7%<|>RELATION_NOE 、<|>RELATION_NOE 10.0%<|>RELATION_NOE 和<|>RELATION_NOE 23.3%<|>RELATION_NOE 。<|>RELATION_NOE
11<|>RELATION_NOE 例<|>RELATION_NOE 肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 与<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 病理<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 8例<|>RELATION_NOE 一致<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 不<|>RELATION_NOE 一致<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 皮肺<|>RELATION_NOE 活检<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 对<|>RELATION_NOE 肺部<|>RELATION_NOE 占位<|>RELATION_NOE 病变<|>RELATION_NOE 有<|>RELATION_B 明确<|>RELATION_I 诊断<|>RELATION_I 或<|>RELATION_I 提示性<|>RELATION_I 诊断<|>RELATION_I 恶性肿瘤<|>RELATION_I 和<|>RELATION_I 良性<|>RELATION_I 疾病<|>RELATION_I 的<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 非<|>RELATION_NOE 特异性<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 除外<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 高压氧<|>RELATION_NOE 环境<|>RELATION_NOE 下<|>RELATION_NOE 槲皮素<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞株<|>RELATION_NOE 耐药<|>RELATION_NOE 的<|>RELATION_NOE 逆转<|>RELATION_NOE 及其<|>RELATION_NOE 对<|>RELATION_NOE P-gp<|>RELATION_NOE 和<|>RELATION_NOE survivin<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
槲皮素<|>RELATION_NOE 在<|>RELATION_NOE 高压氧<|>RELATION_NOE 环境<|>RELATION_NOE 下<|>RELATION_NOE 使<|>RELATION_NOE DDP<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 半<|>RELATION_NOE 抑制<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IC50<|>RELATION_NOE )<|>RELATION_NOE 从<|>RELATION_NOE (<|>RELATION_NOE 31.34<|>RELATION_NOE ±<|>RELATION_NOE 2.99<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 下降<|>RELATION_NOE 至<|>RELATION_NOE (<|>RELATION_NOE 7.56<|>RELATION_NOE ±<|>RELATION_NOE 0.87<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 逆转<|>RELATION_NOE 倍数<|>RELATION_NOE 为<|>RELATION_NOE 4.15<|>RELATION_NOE ;<|>RELATION_NOE
纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 代替<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 与<|>RELATION_NOE 内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 对<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
将<|>RELATION_NOE 我<|>RELATION_NOE 科<|>RELATION_NOE 采用<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 代替<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 对<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE 与<|>RELATION_NOE 采用<|>RELATION_NOE 内科<|>RELATION_NOE 胸腔镜检查<|>RELATION_NOE 的<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 检查<|>RELATION_NOE 结果<|>RELATION_NOE 做出<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_S 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 代替<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 与<|>RELATION_NOE 内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 的<|>RELATION_NOE 优缺点<|>RELATION_NOE 及<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 我<|>RELATION_NOE 科<|>RELATION_NOE 于<|>RELATION_NOE 1995年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 1997年<|>RELATION_NOE 12月<|>RELATION_NOE 采用<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 代替<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 对<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 代替<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 确诊<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 58.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 转移<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜<|>RELATION_NOE 间皮瘤<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 结核性<|>RELATION_NOE 胸膜炎<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
内科<|>RELATION_NOE 胸腔镜检查<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 确诊<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 94.3%<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 73.6%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 53<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 并<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 49.1%<|>RELATION_NOE ,<|>RELATION_NOE 26<|>RELATION_NOE /<|>RELATION_NOE 53<|>RELATION_NOE ,<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 3例<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
淋巴瘤<|>RELATION_NOE 胸腔<|>RELATION_NOE 侵犯<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 1.9%<|>RELATION_NOE (<|>RELATION_NOE 1/53<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胸腔<|>RELATION_NOE 转移<|>RELATION_NOE 瘤1<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 1.9%<|>RELATION_NOE (<|>RELATION_NOE 1/53<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 结核性<|>RELATION_NOE 胸膜炎<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 17%<|>RELATION_NOE (<|>RELATION_NOE 9/53<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
探讨<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE (<|>RELATION_NOE pro-GRP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 鳞状<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 癌抗原<|>RELATION_NOE (<|>RELATION_NOE SCC-Ag<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 以及<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E 。<|>RELATION_NOE
应用<|>RELATION_NOE ELISA<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 50<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 、<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 92<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 5<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 健康组<|>RELATION_NOE 和<|>RELATION_NOE 良性<|>RELATION_NOE 肺部疾病组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
化疗<|>RELATION_NOE 后<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 5<|>RELATION_NOE 种<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 化疗<|>RELATION_NOE 前<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE pro-GRP<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 、<|>RELATION_NOE SCC-Ag<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 以及<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_B 很<|>RELATION_I 重要<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
康艾<|>RELATION_NOE 注射液<|>RELATION_NOE 在<|>RELATION_NOE Ⅲ<|>RELATION_NOE A<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
观察<|>RELATION_NOE 康艾<|>RELATION_NOE 注射液<|>RELATION_NOE 对<|>RELATION_NOE Ⅲ<|>RELATION_NOE A<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 术后<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE KPS<|>RELATION_NOE 评分<|>RELATION_NOE 变化<|>RELATION_NOE 以及<|>RELATION_NOE 化疗毒性<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_B 研究<|>RELATION_E
KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 可能<|>RELATION_NOE 导致<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE EGFR-TKIs<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 耐药<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 120<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 标本<|>RELATION_NOE 和<|>RELATION_NOE 97<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 70<|>RELATION_NOE 例外<|>RELATION_NOE 周血<|>RELATION_NOE 标本<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 相<|>RELATION_NOE 匹配<|>RELATION_NOE 。<|>RELATION_NOE
比较<|>RELATION_S 外<|>RELATION_NOE 周血<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 突变<|>RELATION_NOE 一致性<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE 比较<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 突变<|>RELATION_NOE 一致性<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 一致性<|>RELATION_B 较<|>RELATION_I 高<|>RELATION_E ,<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 检测<|>RELATION_NOE
分<|>RELATION_NOE 叶征<|>RELATION_NOE 和<|>RELATION_NOE 伪足征<|>RELATION_NOE 对<|>RELATION_NOE 煤工尘肺<|>RELATION_NOE 合并<|>RELATION_NOE 肿块<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
23<|>RELATION_NOE 例<|>RELATION_NOE CWP<|>RELATION_NOE 合并<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 23<|>RELATION_NOE 个<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 病灶<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 由<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 明确<|>RELATION_NOE ;<|>RELATION_NOE
对<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE -C<|>RELATION_NOE (<|>RELATION_NOE VEGF-C<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE -D<|>RELATION_NOE (<|>RELATION_NOE VEGF-D<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 进行<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE VEGF-D<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 淋巴管生成<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 早期<|>RELATION_NOE 转移<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 肺组织<|>RELATION_NOE 标本<|>RELATION_NOE 52<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 半定量<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应法<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE VEGF-DmRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 3)<|>RELATION_NOE VEGF-C<|>RELATION_NOE /<|>RELATION_NOE VEGF-D<|>RELATION_NOE 在<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 阳<|>RELATION_NOE 性组<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 较<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 值<|>RELATION_NOE 为<|>RELATION_NOE 高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
沉默<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 及<|>RELATION_NOE 促<|>RELATION_NOE 血管<|>RELATION_NOE 生成素<|>RELATION_NOE -2<|>RELATION_NOE 基因<|>RELATION_NOE 抑制<|>RELATION_S 裸鼠<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE
研究<|>RELATION_NOE 沉默<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 促<|>RELATION_NOE 血管<|>RELATION_NOE 生成素<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE Ang-2<|>RELATION_NOE )<|>RELATION_NOE 基因表达<|>RELATION_NOE 对<|>RELATION_NOE 裸鼠<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤生物学<|>RELATION_NOE 特性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
制备<|>RELATION_NOE 裸鼠<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞移植<|>RELATION_NOE 瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 后<|>RELATION_NOE (<|>RELATION_NOE RNAi<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生物学<|>RELATION_NOE 特性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
重组<|>RELATION_NOE 腺病毒<|>RELATION_NOE 接种<|>RELATION_NOE 裸鼠<|>RELATION_NOE 30d<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE Ad-VEGFshRNA<|>RELATION_NOE 、<|>RELATION_NOE Ad-Ang-2shRNA<|>RELATION_NOE 干扰组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 及<|>RELATION_NOE 重量<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 减小<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE Ad-VEGFshRNA<|>RELATION_NOE 及<|>RELATION_NOE Ad-Ang-2shRNA<|>RELATION_NOE 联合<|>RELATION_NOE 干扰组<|>RELATION_NOE 与<|>RELATION_NOE Ad-VEGFshRNA<|>RELATION_NOE 、<|>RELATION_NOE Ad-Ang-2shRNA<|>RELATION_NOE 干扰组<|>RELATION_NOE 比较<|>RELATION_NOE 能够<|>RELATION_NOE 更<|>RELATION_NOE 有效<|>RELATION_NOE 地<|>RELATION_NOE 抑制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
对<|>RELATION_NOE 其中<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S TS<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE .<|>RELATION_NOE
根据<|>RELATION_NOE 美国<|>RELATION_NOE 国立<|>RELATION_NOE 癌症<|>RELATION_NOE 研究所<|>RELATION_NOE 常见<|>RELATION_NOE 毒性<|>RELATION_NOE 分级<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 3－4<|>RELATION_NOE 级<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 包括<|>RELATION_NOE 白细胞减少<|>RELATION_NOE (<|>RELATION_NOE 5/51<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE 51<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE 2/51<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
吲哚美辛<|>RELATION_NOE 联合<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞株<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植<|>RELATION_NOE 瘤微<|>RELATION_NOE 淋巴管生成<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 化疗<|>RELATION_NOE 增敏<|>RELATION_NOE 作用<|>RELATION_NOE
研究<|>RELATION_NOE 非甾体<|>RELATION_NOE 抗炎<|>RELATION_NOE 药物<|>RELATION_NOE 吲哚美辛<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞株<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植<|>RELATION_NOE 瘤微<|>RELATION_NOE 淋巴管生成<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及<|>RELATION_NOE 化疗<|>RELATION_NOE 增敏<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 接种<|>RELATION_B 于<|>RELATION_E 裸鼠<|>RELATION_NOE 背部<|>RELATION_NOE 皮下<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 裸鼠<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 4组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 吲哚美辛<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 奥沙利<|>RELATION_NOE 铂组<|>RELATION_NOE 、<|>RELATION_NOE 吲哚美辛<|>RELATION_NOE 和<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 给予<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 药物<|>RELATION_NOE .<|>RELATION_NOE
观察<|>RELATION_NOE 裸鼠<|>RELATION_NOE 生长<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 7<|>RELATION_NOE 天<|>RELATION_NOE 测量<|>RELATION_NOE 1次<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积.<|>RELATION_NOE
42<|>RELATION_NOE d<|>RELATION_NOE 后<|>RELATION_NOE 处死<|>RELATION_NOE 裸鼠<|>RELATION_NOE ,<|>RELATION_NOE 切取<|>RELATION_NOE 移植<|>RELATION_NOE 瘤组织<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色法<|>RELATION_NOE 检测<|>RELATION_S 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE C<|>RELATION_NOE (<|>RELATION_NOE VEGF-C<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 连环素<|>RELATION_NOE 及<|>RELATION_NOE 生存素<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 测定<|>RELATION_NOE 微<|>RELATION_NOE 淋巴管<|>RELATION_NOE 密度<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 吲哚美辛<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 奥沙利<|>RELATION_NOE 铂组<|>RELATION_NOE 和<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 移植<|>RELATION_NOE 瘤体<|>RELATION_NOE 积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE 22<|>RELATION_NOE ±<|>RELATION_NOE 327<|>RELATION_NOE )<|>RELATION_NOE mm3<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 962<|>RELATION_NOE ±<|>RELATION_NOE 221<|>RELATION_NOE )<|>RELATION_NOE mm3<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 611<|>RELATION_NOE ±<|>RELATION_NOE 161<|>RELATION_NOE )<|>RELATION_NOE mm3<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE 64<|>RELATION_NOE ±<|>RELATION_NOE 318<|>RELATION_NOE )<|>RELATION_NOE mm3<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 23.33<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 吲哚美辛<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE 生存素<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 连环素<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及微<|>RELATION_NOE 淋巴管<|>RELATION_NOE 密度<|>RELATION_NOE 积分<|>RELATION_NOE 吸<|>RELATION_NOE 光度值<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
奥沙利<|>RELATION_NOE 铂组<|>RELATION_NOE VEGF-C<|>RELATION_NOE 蛋白<|>RELATION_NOE 含量<|>RELATION_NOE (<|>RELATION_NOE 208<|>RELATION_NOE 25<|>RELATION_NOE ±<|>RELATION_NOE 2067<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE 16075<|>RELATION_NOE ±<|>RELATION_NOE 875<|>RELATION_NOE ,<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 97.24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 连环素<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE 微<|>RELATION_NOE 淋巴管<|>RELATION_NOE 密度<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE 396<|>RELATION_NOE ±<|>RELATION_NOE 16<|>RELATION_NOE 93<|>RELATION_NOE ,<|>RELATION_NOE 96<|>RELATION_NOE 66<|>RELATION_NOE ±<|>RELATION_NOE 978<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE
吲哚美辛<|>RELATION_NOE 与<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 抗微<|>RELATION_NOE 淋巴管生成<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 协同<|>RELATION_NOE 抑制<|>RELATION_NOE 了<|>RELATION_NOE VEGF-C<|>RELATION_NOE /<|>RELATION_NOE VEGF<|>RELATION_NOE 受体<|>RELATION_NOE 3<|>RELATION_NOE 和<|>RELATION_NOE Wnt<|>RELATION_NOE 信号<|>RELATION_NOE 途径<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE 可溶性<|>RELATION_NOE 程序性<|>RELATION_NOE 死亡<|>RELATION_NOE 配体<|>RELATION_NOE -1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
检测<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 可溶性<|>RELATION_NOE 程序性<|>RELATION_NOE 死亡<|>RELATION_NOE 配体<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE sPD-L1<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 生物学<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 初诊<|>RELATION_NOE 且<|>RELATION_NOE 经<|>RELATION_NOE 组织<|>RELATION_NOE 或<|>RELATION_NOE 细胞<|>RELATION_NOE 病理学<|>RELATION_NOE 确诊<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 方法<|>RELATION_NOE 和<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 方法<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 上述<|>RELATION_NOE 人员<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE sPD-L1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE sPD-L1<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 程度<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 5.6<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血中<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 也<|>RELATION_NOE 呈<|>RELATION_NOE 异常<|>RELATION_B 改变<|>RELATION_E ,<|>RELATION_NOE 其中<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 数量<|>RELATION_NOE 显著<|>RELATION_NOE 减少<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CD4<|>RELATION_NOE /<|>RELATION_NOE CD8<|>RELATION_NOE 比值<|>RELATION_NOE 显著<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 进一步<|>RELATION_NOE 行<|>RELATION_NOE 双<|>RELATION_NOE 标<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 中<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE PD-1<|>RELATION_NOE +<|>RELATION_NOE 及<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE PD-1<|>RELATION_NOE +<|>RELATION_NOE 百分率<|>RELATION_NOE 均<|>RELATION_NOE 增高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE sPD-L1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 异常<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 疗效<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 有助于<|>RELATION_NOE 判断<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 成为<|>RELATION_NOE 重要<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 靶点<|>RELATION_NOE 或<|>RELATION_NOE 分子<|>RELATION_NOE 标记<|>RELATION_NOE 物.<|>RELATION_NOE
以<|>RELATION_NOE 手术<|>RELATION_NOE 为主<|>RELATION_NOE 的<|>RELATION_NOE 综合治疗<|>RELATION_NOE 对<|>RELATION_NOE 食管<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
化疗<|>RELATION_NOE 采用<|>RELATION_S EP<|>RELATION_NOE 、<|>RELATION_NOE FP<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 即<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷加<|>RELATION_NOE 顺铂<|>RELATION_NOE 注射液<|>RELATION_NOE 、<|>RELATION_NOE 氟尿嘧啶<|>RELATION_NOE 加<|>RELATION_NOE 顺铂<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE +<|>RELATION_NOE 放<|>RELATION_NOE
观察<|>RELATION_NOE 舒适<|>RELATION_NOE 护理<|>RELATION_NOE 模式<|>RELATION_NOE 对<|>RELATION_NOE 合并<|>RELATION_NOE 慢性<|>RELATION_NOE 呼吸系统<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 期间<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
选择<|>RELATION_NOE 近期<|>RELATION_NOE 接受<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 合并<|>RELATION_NOE 慢性<|>RELATION_NOE 呼吸系统<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 采用<|>RELATION_S 常规<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 舒适<|>RELATION_NOE 护理<|>RELATION_NOE 应用<|>RELATION_NOE 于<|>RELATION_NOE 合并<|>RELATION_NOE 有<|>RELATION_NOE 慢性<|>RELATION_NOE 呼吸系统<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 得到<|>RELATION_NOE 生理<|>RELATION_NOE 、<|>RELATION_NOE 心理<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 满足感<|>RELATION_NOE 和<|>RELATION_NOE 安全感<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
GSTMl<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 中国<|>RELATION_NOE 汉族<|>RELATION_NOE 人群<|>RELATION_NOE 肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE Meta<|>RELATION_B 分析<|>RELATION_E
探索<|>RELATION_NOE 谷胱甘肽<|>RELATION_NOE 硫转移酶<|>RELATION_NOE M1<|>RELATION_NOE (<|>RELATION_NOE GSTMl<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 中国<|>RELATION_NOE 汉族<|>RELATION_NOE 人群<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
检索<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 8月<|>RELATION_NOE 之前<|>RELATION_NOE GSTMl<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 相关性<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 文献<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 纳入<|>RELATION_NOE 、<|>RELATION_NOE 排除<|>RELATION_NOE 标准<|>RELATION_NOE 选择<|>RELATION_NOE 符合<|>RELATION_NOE 要求<|>RELATION_NOE 的<|>RELATION_NOE 文献<|>RELATION_NOE ,<|>RELATION_NOE 整理<|>RELATION_NOE GSTMl<|>RELATION_NOE 功能型<|>RELATION_NOE 基因型<|>RELATION_NOE 、<|>RELATION_NOE 缺失型<|>RELATION_NOE 基因型<|>RELATION_NOE 频数<|>RELATION_NOE 或<|>RELATION_NOE 频率<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Mantel-Haenszel<|>RELATION_NOE 固定<|>RELATION_NOE 效应<|>RELATION_NOE 模型<|>RELATION_NOE 分析<|>RELATION_NOE 合并<|>RELATION_NOE OR<|>RELATION_NOE 值<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 漏斗图<|>RELATION_NOE 和<|>RELATION_NOE Egger<|>RELATION_NOE 线性<|>RELATION_NOE 回归分析<|>RELATION_NOE 评估<|>RELATION_S 文献<|>RELATION_NOE 的<|>RELATION_NOE 发表<|>RELATION_NOE 偏<|>RELATION_NOE 倚<|>RELATION_NOE 。<|>RELATION_NOE
GSTMl<|>RELATION_NOE 基因<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 易感<|>RELATION_NOE 基因<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE GSTMl<|>RELATION_NOE 缺失型<|>RELATION_NOE 基因型<|>RELATION_NOE 是<|>RELATION_NOE 中国<|>RELATION_NOE 汉族<|>RELATION_NOE 人群<|>RELATION_NOE 发生<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_B 因子<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 计算<|>RELATION_S 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE 0s<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE Cox<|>RELATION_NOE 回归分析<|>RELATION_NOE OS<|>RELATION_NOE 和<|>RELATION_NOE PFS<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 和<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 增加<|>RELATION_E ,<|>RELATION_NOE 但<|>RELATION_NOE 大多<|>RELATION_NOE 可以<|>RELATION_NOE 耐受<|>RELATION_NOE 。<|>RELATION_NOE
干扰素γ<|>RELATION_NOE 和<|>RELATION_NOE γ射线<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 联合<|>RELATION_B 作用<|>RELATION_E 的<|>RELATION_NOE 体外<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 干扰素γ<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S ,<|>RELATION_NOE 探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE 途径<|>RELATION_NOE 。<|>RELATION_NOE
单独<|>RELATION_NOE γ射线<|>RELATION_NOE 辐照<|>RELATION_NOE 细胞<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 干扰素γ<|>RELATION_NOE 处理<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 细胞存活率<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE 印迹法<|>RELATION_NOE 分析<|>RELATION_NOE 细胞<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 测定<|>RELATION_NOE 细胞周期<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE 单独<|>RELATION_NOE γ射线<|>RELATION_NOE 辐照<|>RELATION_NOE 细胞<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 干扰素γ<|>RELATION_NOE 处理<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞存活率<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE 印迹法<|>RELATION_NOE 分析<|>RELATION_S 细胞<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 测定<|>RELATION_NOE 细胞周期<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
此外<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 单独<|>RELATION_NOE γ射线<|>RELATION_NOE 辐照组<|>RELATION_NOE 和<|>RELATION_NOE 单独<|>RELATION_NOE 干扰素γ<|>RELATION_NOE 给<|>RELATION_NOE 药组<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 有所<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 干扰素γ<|>RELATION_NOE 和<|>RELATION_NOE γ射线<|>RELATION_NOE 联合<|>RELATION_NOE 作用<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
同时<|>RELATION_NOE 与<|>RELATION_NOE 单独<|>RELATION_NOE γ射线<|>RELATION_NOE 治疗<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_NOE 还<|>RELATION_NOE 能够<|>RELATION_NOE 显著<|>RELATION_B 影响<|>RELATION_E 细胞周期<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE S<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 增加<|>RELATION_NOE (<|>RELATION_NOE 12.9%<|>RELATION_NOE 比<|>RELATION_NOE 20.9%<|>RELATION_NOE ,<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 5<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 引起<|>RELATION_NOE G2<|>RELATION_NOE /<|>RELATION_NOE M<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 阻滞<|>RELATION_NOE (<|>RELATION_NOE 28.8%<|>RELATION_NOE 比<|>RELATION_NOE 38.9%<|>RELATION_NOE ,<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 5<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
干扰素γ<|>RELATION_NOE 和<|>RELATION_NOE γ射线<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_S 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_NOE 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 可能<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值.<|>RELATION_NOE
评价<|>RELATION_NOE 磁性<|>RELATION_NOE 脂质体<|>RELATION_NOE 作为<|>RELATION_NOE 基因<|>RELATION_NOE 载体<|>RELATION_NOE 在<|>RELATION_NOE 外加<|>RELATION_NOE 磁场<|>RELATION_NOE 的<|>RELATION_NOE 介导<|>RELATION_NOE 下<|>RELATION_NOE 发夹<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE shRNA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 体内外<|>RELATION_NOE 人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E 和<|>RELATION_NOE 评价<|>RELATION_NOE 外加<|>RELATION_NOE 磁场<|>RELATION_NOE 对于<|>RELATION_NOE 体外<|>RELATION_NOE 磁<|>RELATION_NOE 转染<|>RELATION_NOE 效率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
构建<|>RELATION_S 表达<|>RELATION_NOE 绿色<|>RELATION_NOE 荧光<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE GFP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 胰岛素<|>RELATION_NOE 样<|>RELATION_NOE 生长因子<|>RELATION_NOE -1<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE IGF-1R<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE shRNA<|>RELATION_NOE 的<|>RELATION_NOE 质粒<|>RELATION_NOE pGFPshIGF-1R<|>RELATION_NOE ,<|>RELATION_NOE 由<|>RELATION_NOE 磁性<|>RELATION_NOE 氧化铁<|>RELATION_NOE 纳米<|>RELATION_NOE 颗粒<|>RELATION_NOE CombiMAG<|>RELATION_NOE 和<|>RELATION_NOE 脂质体<|>RELATION_NOE lipofectamine2000<|>RELATION_NOE 组成<|>RELATION_NOE 磁性<|>RELATION_NOE 脂质体<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE pGFPshIGF-1R<|>RELATION_NOE 转染<|>RELATION_NOE 进<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 此<|>RELATION_NOE 过程<|>RELATION_NOE 被<|>RELATION_NOE 称为<|>RELATION_NOE 磁<|>RELATION_NOE 转染<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 外加<|>RELATION_NOE 不同<|>RELATION_NOE 强度<|>RELATION_NOE 和<|>RELATION_NOE 不同<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 磁场<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 磁场<|>RELATION_NOE 对磁<|>RELATION_NOE 转染<|>RELATION_NOE 效率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
将<|>RELATION_NOE 质粒<|>RELATION_NOE pGFPshIGF-1R<|>RELATION_NOE 分别<|>RELATION_NOE 通过<|>RELATION_NOE 磁<|>RELATION_NOE 转染<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 传递<|>RELATION_NOE 到<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Western<|>RELATION_NOE 印迹<|>RELATION_NOE 评价<|>RELATION_S 两<|>RELATION_NOE 种<|>RELATION_NOE 转染<|>RELATION_NOE 方法<|>RELATION_NOE 下<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE IGF-1R<|>RELATION_NOE 蛋白<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 情况<|>RELATION_NOE ;<|>RELATION_NOE
外加<|>RELATION_NOE 磁场<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 和<|>RELATION_NOE 磁场<|>RELATION_NOE 强度<|>RELATION_NOE 可<|>RELATION_NOE 影响<|>RELATION_S 磁<|>RELATION_NOE 转染<|>RELATION_NOE 效率<|>RELATION_NOE .<|>RELATION_NOE
体外<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 和<|>RELATION_NOE 磁<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE shRNA<|>RELATION_NOE 都<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_S 了<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE IGF-1R<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 干扰率<|>RELATION_NOE 分别<|>RELATION_NOE 达<|>RELATION_NOE 56.1%<|>RELATION_NOE ±<|>RELATION_NOE 6.0%<|>RELATION_NOE 和<|>RELATION_NOE 85.1<|>RELATION_NOE ±<|>RELATION_NOE 3.0%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
体内<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 和<|>RELATION_NOE 磁<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE shRNA<|>RELATION_NOE 都<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_S 了<|>RELATION_NOE 荷瘤<|>RELATION_NOE 鼠皮<|>RELATION_NOE 下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 体内<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染组<|>RELATION_NOE 和<|>RELATION_NOE 磁<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植<|>RELATION_NOE 瘤瘤<|>RELATION_NOE 重<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 0.46<|>RELATION_NOE ±<|>RELATION_NOE 0.12<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.27<|>RELATION_NOE ±<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.16<|>RELATION_NOE ±<|>RELATION_NOE 0.04<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染组<|>RELATION_NOE 和<|>RELATION_NOE 磁<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 抑瘤率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 41.3%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 65.2%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 磁性<|>RELATION_NOE 脂质体<|>RELATION_NOE 作为<|>RELATION_NOE 基因<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE 磁<|>RELATION_NOE 转染<|>RELATION_NOE 可能<|>RELATION_NOE 会<|>RELATION_NOE 成为<|>RELATION_NOE 靶向<|>RELATION_NOE 肺癌<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 的<|>RELATION_I 转染<|>RELATION_I 方法<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 转染<|>RELATION_NOE 效率<|>RELATION_NOE 受到<|>RELATION_NOE 外部<|>RELATION_NOE 磁场<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE RAR<|>RELATION_NOE β<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 甲基化<|>RELATION_NOE 与<|>RELATION_NOE P53<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
应用<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE 以及<|>RELATION_NOE PCR<|>RELATION_NOE 产物<|>RELATION_NOE 直接<|>RELATION_NOE 测序法<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_S 198<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE RAR<|>RELATION_NOE β<|>RELATION_NOE 启动子<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 甲基化<|>RELATION_NOE 以及<|>RELATION_NOE P53<|>RELATION_NOE 基因<|>RELATION_NOE 第5<|>RELATION_NOE －9<|>RELATION_NOE 外显子<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE RAR<|>RELATION_NOE β<|>RELATION_NOE 甲基化<|>RELATION_NOE 与<|>RELATION_NOE P53G<|>RELATION_NOE :<|>RELATION_NOE C<|>RELATION_NOE ><|>RELATION_NOE T<|>RELATION_NOE :<|>RELATION_NOE A<|>RELATION_NOE 型<|>RELATION_NOE 突变<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
CXCR4<|>RELATION_NOE 基因沉默<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 黑素瘤<|>RELATION_NOE 的<|>RELATION_NOE 抑瘤<|>RELATION_B 效应<|>RELATION_E 及<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 影响<|>RELATION_NOE
设计<|>RELATION_NOE 合成<|>RELATION_NOE CXCR4<|>RELATION_NOE 特异性<|>RELATION_NOE shRNA<|>RELATION_NOE 插入<|>RELATION_NOE pSilencer<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE 人<|>RELATION_NOE 高<|>RELATION_NOE 转移<|>RELATION_NOE 性黑素瘤<|>RELATION_NOE 细胞株<|>RELATION_NOE MV3<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 小鼠尾<|>RELATION_NOE 静脉<|>RELATION_NOE 瘤细胞<|>RELATION_NOE 注射<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_S 黑素瘤<|>RELATION_NOE 转移<|>RELATION_NOE 模制<|>RELATION_NOE .<|>RELATION_NOE
规察<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE CXCR4<|>RELATION_NOE 基因沉默<|>RELATION_NOE 对<|>RELATION_NOE 黑素瘤<|>RELATION_NOE 细胞肝<|>RELATION_NOE 、<|>RELATION_NOE 脑<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 等<|>RELATION_NOE 实质性<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
黑素瘢<|>RELATION_NOE 定向肺<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE F<|>RELATION_NOE 降<|>RELATION_NOE :<|>RELATION_NOE B<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE A<|>RELATION_NOE 纰肺<|>RELATION_NOE 转移<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 90.0%<|>RELATION_NOE 、<|>RELATION_NOE 87.5%<|>RELATION_NOE 和<|>RELATION_NOE 20.0%<|>RELATION_NOE ;<|>RELATION_NOE
了解<|>RELATION_S 胸外科<|>RELATION_NOE 肿瘤<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 心理<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 、<|>RELATION_NOE 基础<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE 、<|>RELATION_NOE 最<|>RELATION_NOE 需<|>RELATION_NOE 护理<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 提供<|>RELATION_NOE 有<|>RELATION_NOE 针对性<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 自行<|>RELATION_NOE 设计<|>RELATION_NOE 的<|>RELATION_NOE 问卷<|>RELATION_NOE 对<|>RELATION_NOE 随机<|>RELATION_NOE 抽取<|>RELATION_NOE 的<|>RELATION_NOE 150<|>RELATION_NOE 名<|>RELATION_NOE 胸外科<|>RELATION_NOE 肿瘤<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 问卷调查<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE SPSS13.0<|>RELATION_NOE 软件<|>RELATION_NOE 对<|>RELATION_NOE 调查<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 胸外科<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 护理<|>RELATION_NOE 需求<|>RELATION_NOE 呈现<|>RELATION_S 多样化<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 护士<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 关怀<|>RELATION_NOE 需求<|>RELATION_NOE 高<|>RELATION_NOE 占<|>RELATION_NOE 92.6%<|>RELATION_NOE 、<|>RELATION_NOE 技术<|>RELATION_NOE 操作<|>RELATION_NOE 需求<|>RELATION_NOE 占<|>RELATION_NOE 96.6%<|>RELATION_NOE 、<|>RELATION_NOE 但<|>RELATION_NOE 解除<|>RELATION_NOE 疼痛<|>RELATION_NOE 成<|>RELATION_NOE 了<|>RELATION_NOE 患者<|>RELATION_NOE 最<|>RELATION_NOE 迫切<|>RELATION_NOE 的<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 需求<|>RELATION_NOE 最高<|>RELATION_NOE 占<|>RELATION_NOE 100%<|>RELATION_NOE 、<|>RELATION_NOE 对<|>RELATION_NOE 护士<|>RELATION_NOE 责任心<|>RELATION_NOE 需求<|>RELATION_NOE 占<|>RELATION_NOE 94.6%<|>RELATION_NOE 、<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 对<|>RELATION_NOE 出院<|>RELATION_NOE 指导<|>RELATION_NOE 需求<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 91.2%<|>RELATION_NOE ,<|>RELATION_NOE 此外<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 相关<|>RELATION_NOE 知识<|>RELATION_NOE 需求<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 占<|>RELATION_NOE 88.5%<|>RELATION_NOE 、<|>RELATION_NOE 病房<|>RELATION_NOE 环境<|>RELATION_NOE 的<|>RELATION_NOE 需求<|>RELATION_NOE 也<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 占<|>RELATION_NOE 87.8%<|>RELATION_NOE ,<|>RELATION_NOE 基础<|>RELATION_NOE 护理<|>RELATION_NOE 中<|>RELATION_NOE 除<|>RELATION_NOE 基本<|>RELATION_NOE 生活<|>RELATION_NOE 护理<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 病情<|>RELATION_NOE 需要<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 家属<|>RELATION_NOE 希望<|>RELATION_NOE 护士<|>RELATION_NOE 能<|>RELATION_NOE 指导<|>RELATION_NOE 或<|>RELATION_NOE 协助<|>RELATION_NOE 翻身<|>RELATION_NOE 及<|>RELATION_NOE 有效<|>RELATION_NOE 咳嗽<|>RELATION_NOE 的<|>RELATION_NOE 需求<|>RELATION_NOE 最高<|>RELATION_NOE 占<|>RELATION_NOE 93.2%<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 与<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_B 研究<|>RELATION_E
疲乏<|>RELATION_NOE 总分<|>RELATION_NOE (<|>RELATION_NOE 5.18<|>RELATION_NOE ±<|>RELATION_NOE 1.61<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 行为<|>RELATION_NOE 疲乏<|>RELATION_NOE (<|>RELATION_NOE 5.66<|>RELATION_NOE ±<|>RELATION_NOE 2.22<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 情感<|>RELATION_NOE 疲乏<|>RELATION_NOE (<|>RELATION_NOE 5.36<|>RELATION_NOE ±<|>RELATION_NOE 2.26<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 躯体<|>RELATION_NOE 疲乏<|>RELATION_NOE (<|>RELATION_NOE 5.69<|>RELATION_NOE ±<|>RELATION_NOE 1.97<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 认知<|>RELATION_NOE 疲乏<|>RELATION_NOE (<|>RELATION_NOE 4.11<|>RELATION_NOE ±<|>RELATION_NOE 1.81<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ;<|>RELATION_NOE
癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 因素<|>RELATION_E ,<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 应<|>RELATION_NOE 提供<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 缓解<|>RELATION_NOE 患者<|>RELATION_NOE 疲乏<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 癌症<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 尿道<|>RELATION_NOE 2微米<|>RELATION_NOE 激光<|>RELATION_NOE 膀胱<|>RELATION_NOE 部分<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_S 膀胱<|>RELATION_NOE 黏膜<|>RELATION_NOE 下<|>RELATION_NOE 占<|>RELATION_NOE 位<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE
探讨<|>RELATION_S 经<|>RELATION_NOE 尿道<|>RELATION_NOE 2μ<|>RELATION_NOE m<|>RELATION_NOE 激光<|>RELATION_NOE 膀胱<|>RELATION_NOE 部分<|>RELATION_NOE 切除术<|>RELATION_NOE 应用<|>RELATION_NOE 于<|>RELATION_NOE 膀胱<|>RELATION_NOE 黏膜<|>RELATION_NOE 下<|>RELATION_NOE 占<|>RELATION_NOE 位<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
2009年<|>RELATION_NOE 8月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE ,<|>RELATION_NOE 选取<|>RELATION_NOE 解放军<|>RELATION_NOE 总医院<|>RELATION_NOE 门诊<|>RELATION_NOE 初诊<|>RELATION_NOE 为<|>RELATION_NOE 膀胱<|>RELATION_NOE 黏膜<|>RELATION_NOE 下<|>RELATION_NOE 占<|>RELATION_NOE 位<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 但<|>RELATION_NOE 病理<|>RELATION_NOE
应用<|>RELATION_NOE 经<|>RELATION_NOE 尿道<|>RELATION_NOE 2μ<|>RELATION_NOE m<|>RELATION_NOE 激光<|>RELATION_NOE 膀胱<|>RELATION_NOE 部分<|>RELATION_NOE 切除术<|>RELATION_NOE 切除<|>RELATION_S 肿物<|>RELATION_NOE 。<|>RELATION_NOE
术<|>RELATION_NOE 中<|>RELATION_NOE 用<|>RELATION_NOE 2<|>RELATION_NOE μ<|>RELATION_NOE m<|>RELATION_NOE 激光<|>RELATION_NOE 沿<|>RELATION_NOE 肿瘤<|>RELATION_NOE 周围<|>RELATION_NOE 全<|>RELATION_NOE 层<|>RELATION_NOE 切开<|>RELATION_NOE 膀胱壁<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肌层<|>RELATION_NOE 与<|>RELATION_NOE 外层<|>RELATION_NOE 结缔组织<|>RELATION_NOE 之间<|>RELATION_NOE 剥离<|>RELATION_NOE 整<|>RELATION_NOE 块<|>RELATION_NOE 膀胱壁<|>RELATION_NOE ,<|>RELATION_NOE 完整<|>RELATION_NOE 切除<|>RELATION_NOE 肿块<|>RELATION_NOE 及其<|>RELATION_NOE 基底部<|>RELATION_NOE 膀胱<|>RELATION_NOE 全<|>RELATION_NOE 肌层<|>RELATION_NOE 标本<|>RELATION_NOE 送<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 。<|>RELATION_NOE
术中<|>RELATION_NOE 出血量<|>RELATION_NOE 极<|>RELATION_NOE 少<|>RELATION_NOE 或<|>RELATION_NOE 几乎<|>RELATION_NOE 不<|>RELATION_NOE 出血<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 闭孔神经<|>RELATION_NOE 反射<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 无<|>RELATION_NOE 继发<|>RELATION_NOE 出血<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
全部<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 获得<|>RELATION_NOE 明确<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE :<|>RELATION_NOE 平滑肌瘤<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 嗜铬细胞瘤<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 子宫内膜<|>RELATION_NOE 异位症<|>RELATION_NOE l<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 膀胱<|>RELATION_NOE 转移<|>RELATION_NOE 瘤2<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 尿道<|>RELATION_NOE 2恤<|>RELATION_NOE m<|>RELATION_NOE 激光<|>RELATION_NOE 膀胱<|>RELATION_NOE 部分<|>RELATION_NOE 切除术<|>RELATION_NOE 应用<|>RELATION_B 于<|>RELATION_E 膀胱<|>RELATION_NOE 黏膜<|>RELATION_NOE 下<|>RELATION_NOE 占<|>RELATION_NOE 位<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 方法<|>RELATION_NOE 有效<|>RELATION_NOE 、<|>RELATION_NOE 安全<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 可以<|>RELATION_NOE 在<|>RELATION_NOE 避免<|>RELATION_NOE 更<|>RELATION_NOE 大<|>RELATION_NOE 痛苦<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 获得<|>RELATION_NOE 明确<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 部分<|>RELATION_NOE 肿瘤<|>RELATION_NOE 达到<|>RELATION_NOE 微创<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 目的<|>RELATION_NOE 。<|>RELATION_NOE
术中<|>RELATION_NOE 肺内<|>RELATION_NOE 肿物<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 诊断<|>RELATION_S 肺内单<|>RELATION_NOE 发<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE
11<|>RELATION_NOE 例术<|>RELATION_NOE 中<|>RELATION_NOE 穿刺<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 良性<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 4例术<|>RELATION_NOE 后<|>RELATION_NOE 石蜡<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 假<|>RELATION_NOE 阴性率<|>RELATION_NOE 为<|>RELATION_NOE 9.3%<|>RELATION_NOE 。<|>RELATION_NOE
术中<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_B 并发症<|>RELATION_E 为<|>RELATION_NOE 穿刺<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 损伤<|>RELATION_NOE 肿瘤<|>RELATION_NOE 周围<|>RELATION_NOE 血管<|>RELATION_NOE ,<|>RELATION_NOE 造成<|>RELATION_NOE 穿刺点<|>RELATION_NOE 出血<|>RELATION_NOE ,<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 4.0%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 1985年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 肺硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 和<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 经过<|>RELATION_NOE .<|>RELATION_NOE
手术<|>RELATION_NOE 并发症<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 平均<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 34.7<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE 。<|>RELATION_NOE
硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 是<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 术中<|>RELATION_NOE 诊断<|>RELATION_NOE 困难<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 是<|>RELATION_NOE 惟一<|>RELATION_NOE 治疗<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 入<|>RELATION_NOE 路<|>RELATION_NOE 首选<|>RELATION_NOE 胸腔镜.<|>RELATION_NOE
PPAR<|>RELATION_NOE γ<|>RELATION_NOE 激动剂<|>RELATION_NOE 抗<|>RELATION_NOE 呼吸道<|>RELATION_NOE 合胞<|>RELATION_NOE 病毒<|>RELATION_NOE 感染<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 体外研究<|>RELATION_S
探讨<|>RELATION_S 过氧化物<|>RELATION_NOE 酶体<|>RELATION_NOE 增殖物<|>RELATION_NOE 活化<|>RELATION_NOE 受体<|>RELATION_NOE γ<|>RELATION_NOE (<|>RELATION_NOE PPAR<|>RELATION_NOE γ<|>RELATION_NOE )<|>RELATION_NOE 激动剂<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 抗<|>RELATION_NOE 呼吸道<|>RELATION_NOE 合胞<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE RSv<|>RELATION_NOE )<|>RELATION_NOE 感染<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 细胞存活率<|>RELATION_NOE 和<|>RELATION_NOE 病毒<|>RELATION_NOE 抑制率<|>RELATION_NOE 为<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 细胞<|>RELATION_NOE 病变<|>RELATION_NOE 效应<|>RELATION_NOE (<|>RELATION_NOE CPE<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 不同<|>RELATION_NOE 浓度<|>RELATION_NOE PPAR<|>RELATION_NOE γ<|>RELATION_NOE 激动剂<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE (<|>RELATION_NOE A549<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE CPE<|>RELATION_NOE 及<|>RELATION_NOE RSV<|>RELATION_NOE 感染<|>RELATION_NOE 后<|>RELATION_NOE CPE<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE
采用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S PPAR<|>RELATION_NOE γ<|>RELATION_NOE 激动剂<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 毒性<|>RELATION_NOE 作用<|>RELATION_NOE 和<|>RELATION_NOE RSV<|>RELATION_NOE 感染<|>RELATION_NOE 后<|>RELATION_NOE 细胞存活率<|>RELATION_NOE 和<|>RELATION_NOE 病毒<|>RELATION_NOE 抑制率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
PPAR<|>RELATION_NOE γ<|>RELATION_NOE 激动剂<|>RELATION_NOE 既<|>RELATION_NOE 可<|>RELATION_NOE 减轻<|>RELATION_S RSV<|>RELATION_NOE 感染<|>RELATION_NOE 后<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE CPE<|>RELATION_NOE ,<|>RELATION_NOE 又<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_NOE 细胞存活率<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 体外<|>RELATION_NOE 抗<|>RELATION_NOE RSV<|>RELATION_NOE 感染<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE
单<|>RELATION_NOE 光子<|>RELATION_NOE 发射型<|>RELATION_NOE 计算机<|>RELATION_NOE 断层<|>RELATION_NOE 肺灌<|>RELATION_NOE 注<|>RELATION_NOE 扫描<|>RELATION_NOE 联合<|>RELATION_NOE 肺功能<|>RELATION_NOE 检查<|>RELATION_NOE 筛选<|>RELATION_S 发生<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 高危<|>RELATION_NOE 人群<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
前瞻性<|>RELATION_NOE 入组<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 根治性<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 或<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 观察<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE NCICTC3.0<|>RELATION_NOE 标准<|>RELATION_NOE 对<|>RELATION_NOE RP<|>RELATION_NOE 进行<|>RELATION_B 分级<|>RELATION_E 。<|>RELATION_NOE
RP<|>RELATION_NOE 组<|>RELATION_NOE 肺通气<|>RELATION_NOE 功能<|>RELATION_NOE 参数<|>RELATION_NOE 有<|>RELATION_NOE 下降<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 没有<|>RELATION_NOE 达到<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 的<|>RELATION_NOE 程度<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 范围<|>RELATION_NOE 0.1<|>RELATION_NOE 11<|>RELATION_NOE —<|>RELATION_NOE 0.8<|>RELATION_NOE 54<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 然而<|>RELATION_NOE 当<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 用力肺活量<|>RELATION_NOE (<|>RELATION_NOE FVC<|>RELATION_NOE )<|>RELATION_NOE ≤<|>RELATION_NOE 2.4L<|>RELATION_NOE 或<|>RELATION_NOE 第1<|>RELATION_NOE 秒<|>RELATION_NOE 用力<|>RELATION_NOE 呼气<|>RELATION_NOE 容积<|>RELATION_NOE (<|>RELATION_NOE FEV1.0<|>RELATION_NOE )<|>RELATION_NOE ≤<|>RELATION_NOE 1.8L<|>RELATION_NOE 或<|>RELATION_NOE 平均<|>RELATION_NOE 用力<|>RELATION_NOE 呼气<|>RELATION_NOE 流量<|>RELATION_NOE (<|>RELATION_NOE FEF25<|>RELATION_NOE %<|>RELATION_NOE -75<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE ≤<|>RELATION_NOE 2.0L<|>RELATION_NOE /<|>RELATION_NOE s<|>RELATION_NOE 时<|>RELATION_NOE 发生<|>RELATION_NOE RP<|>RELATION_NOE 的<|>RELATION_NOE 概率<|>RELATION_NOE 显著<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 17<|>RELATION_NOE ,<|>RELATION_NOE 0.0<|>RELATION_NOE 26<|>RELATION_NOE ,<|>RELATION_NOE 0.0<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 凝血<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 分析<|>RELATION_E
血浆<|>RELATION_NOE Fib<|>RELATION_NOE 含量<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 明显<|>RELATION_B 升高<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 分子<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 循证医学<|>RELATION_NOE 研究<|>RELATION_S
p53<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 在<|>RELATION_NOE Ⅰ<|>RELATION_NOE －Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 出现<|>RELATION_NOE 提示<|>RELATION_S 预后<|>RELATION_NOE 不良<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 对<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 意义<|>RELATION_NOE 更<|>RELATION_NOE 强<|>RELATION_NOE ;<|>RELATION_NOE
对于<|>RELATION_NOE 各期<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 到<|>RELATION_NOE K-ras<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE ;<|>RELATION_NOE
Survivin<|>RELATION_NOE 在<|>RELATION_NOE Ⅰ<|>RELATION_NOE －<|>RELATION_NOE Ⅲ<|>RELATION_NOE A<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_S 患者<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 对<|>RELATION_NOE 鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 意义<|>RELATION_NOE 更<|>RELATION_NOE 大<|>RELATION_NOE 。<|>RELATION_NOE
基于<|>RELATION_NOE 三维<|>RELATION_NOE CT<|>RELATION_NOE 影像<|>RELATION_NOE 的<|>RELATION_NOE 计算机<|>RELATION_NOE 辅助<|>RELATION_NOE 肺结节<|>RELATION_NOE 检测<|>RELATION_NOE 原型<|>RELATION_NOE 系统<|>RELATION_NOE 具有<|>RELATION_S 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 用于<|>RELATION_NOE 辅助<|>RELATION_NOE 医师<|>RELATION_NOE 进行<|>RELATION_NOE CT<|>RELATION_NOE 图像<|>RELATION_NOE 中<|>RELATION_NOE 肺癌<|>RELATION_NOE 等<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE 基于<|>RELATION_NOE 三维<|>RELATION_NOE CT<|>RELATION_NOE 影像<|>RELATION_NOE 的<|>RELATION_NOE 计算机<|>RELATION_NOE 辅助<|>RELATION_NOE 肺结节<|>RELATION_NOE 检测<|>RELATION_NOE 原型<|>RELATION_NOE 系统<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 用于<|>RELATION_NOE 辅助<|>RELATION_S 医师<|>RELATION_NOE 进行<|>RELATION_NOE CT<|>RELATION_NOE 图像<|>RELATION_NOE 中<|>RELATION_NOE 肺癌<|>RELATION_NOE 等<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_S 无<|>RELATION_NOE 症状<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 诊断<|>RELATION_NOE 策略<|>RELATION_NOE 以<|>RELATION_NOE 利于<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 近<|>RELATION_NOE 6年<|>RELATION_NOE 在<|>RELATION_NOE 内蒙古<|>RELATION_NOE 医学院<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 发现<|>RELATION_NOE 的<|>RELATION_NOE 17<|>RELATION_NOE 4例<|>RELATION_NOE 可疑<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 无<|>RELATION_NOE 症状<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 91<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 良性<|>RELATION_NOE 肺病<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE 于<|>RELATION_NOE 右<|>RELATION_NOE 肺上叶<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_B 表现<|>RELATION_E 以<|>RELATION_NOE 肿块影<|>RELATION_NOE 和<|>RELATION_NOE 结<|>RELATION_NOE 节影<|>RELATION_NOE 为主<|>RELATION_NOE 及<|>RELATION_NOE 支气管镜<|>RELATION_NOE 下<|>RELATION_NOE 以<|>RELATION_NOE 增生<|>RELATION_NOE 型<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 、<|>RELATION_NOE 支气管镜<|>RELATION_NOE 、<|>RELATION_NOE 经皮<|>RELATION_NOE 肺穿刺<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 活检<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 正确率<|>RELATION_NOE 分别<|>RELATION_NOE 是<|>RELATION_NOE :<|>RELATION_NOE 80.4%<|>RELATION_NOE (<|>RELATION_NOE 40<|>RELATION_NOE /<|>RELATION_NOE 51<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 32.8%<|>RELATION_NOE (<|>RELATION_NOE 40<|>RELATION_NOE /<|>RELATION_NOE 122<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 24.2%<|>RELATION_NOE (<|>RELATION_NOE 8/<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 15<|>RELATION_NOE /<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Logistic<|>RELATION_NOE 逐步<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE 肺癌<|>RELATION_NOE 与<|>RELATION_NOE 病灶<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 影像<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 支气管镜<|>RELATION_NOE 下<|>RELATION_NOE 改变<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE R2<|>RELATION_NOE =<|>RELATION_NOE 0.5<|>RELATION_NOE 34<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
坚持<|>RELATION_NOE 追踪<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 可疑<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 无<|>RELATION_NOE 症状<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 病变<|>RELATION_NOE 部位<|>RELATION_NOE 不同<|>RELATION_NOE ,<|>RELATION_NOE 及时<|>RELATION_NOE 选用<|>RELATION_NOE 针对性<|>RELATION_NOE 的<|>RELATION_NOE 检查<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 有助于<|>RELATION_S 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 。<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 选取<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 宣威<|>RELATION_NOE 地区<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 病例组<|>RELATION_NOE ,<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 宣威<|>RELATION_NOE 地区<|>RELATION_NOE 女性<|>RELATION_NOE 肺良性<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 剂量<|>RELATION_NOE 米非司酮<|>RELATION_NOE 诱导<|>RELATION_NOE Nrf2<|>RELATION_NOE 基因表达<|>RELATION_NOE 对<|>RELATION_NOE 百草枯<|>RELATION_NOE 致<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
Ad-RUNrf2<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 给予<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE -10<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE -9<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE -8<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE -7mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 的<|>RELATION_NOE RU486<|>RELATION_NOE 诱导<|>RELATION_NOE 表达<|>RELATION_NOE 6h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 加入<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE -3mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 的<|>RELATION_NOE PQ<|>RELATION_NOE 培养<|>RELATION_NOE 48h<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链式<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE real<|>RELATION_NOE .<|>RELATION_NOE
Real-timePCR<|>RELATION_NOE 、<|>RELATION_NOE ELISA<|>RELATION_NOE 检测<|>RELATION_S 不同<|>RELATION_NOE 浓度<|>RELATION_NOE Nrf2<|>RELATION_NOE 对<|>RELATION_NOE PO<|>RELATION_NOE 致<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 损伤<|>RELATION_NOE 炎症<|>RELATION_NOE 因子<|>RELATION_NOE 白细胞介素<|>RELATION_NOE (<|>RELATION_NOE IL<|>RELATION_NOE )<|>RELATION_NOE -6<|>RELATION_NOE 、<|>RELATION_NOE IL-10<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE TNF<|>RELATION_NOE )<|>RELATION_NOE -<|>RELATION_NOE α<|>RELATION_NOE ,<|>RELATION_NOE 凋亡<|>RELATION_NOE 因子<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 天冬氨酸<|>RELATION_NOE 蛋白<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE Caspase<|>RELATION_NOE )<|>RELATION_NOE -3<|>RELATION_NOE 、<|>RELATION_NOE Caspase-9<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 色素<|>RELATION_NOE c<|>RELATION_NOE (<|>RELATION_NOE CytC<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 相对<|>RELATION_NOE 表达量<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 含量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 化学<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S 氧化因子<|>RELATION_NOE 过氧化氢酶<|>RELATION_NOE (<|>RELATION_NOE CAT<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 丙二醛<|>RELATION_NOE (<|>RELATION_NOE MDA<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
RU486<|>RELATION_NOE 诱导<|>RELATION_NOE Nrf2<|>RELATION_NOE 基因表达<|>RELATION_NOE 能<|>RELATION_NOE 促进<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 氧化<|>RELATION_NOE 一<|>RELATION_NOE 抗<|>RELATION_NOE 氧化<|>RELATION_NOE 系统<|>RELATION_NOE 平衡<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 抑制<|>RELATION_NOE 炎症<|>RELATION_NOE 因子<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 因子<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE PO<|>RELATION_NOE 致<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 损伤<|>RELATION_NOE 有<|>RELATION_NOE 保护<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 卵巢<|>RELATION_NOE 恶性<|>RELATION_NOE 生殖细胞<|>RELATION_NOE 肿瘤<|>RELATION_NOE (<|>RELATION_NOE MOGCT<|>RELATION_NOE )<|>RELATION_NOE 合并肺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 出现<|>RELATION_NOE 肺转移<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
首发<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 以<|>RELATION_NOE 腹部<|>RELATION_NOE 疼痛<|>RELATION_NOE 和<|>RELATION_NOE 不规则<|>RELATION_NOE 阴道<|>RELATION_NOE 流血<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 8<|>RELATION_NOE 、<|>RELATION_NOE 4例.<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 诊断<|>RELATION_NOE :<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 单纯性<|>RELATION_NOE 卵巢<|>RELATION_NOE 非<|>RELATION_NOE 妊娠性<|>RELATION_NOE 绒毛膜癌<|>RELATION_NOE (<|>RELATION_NOE 绒癌<|>RELATION_NOE ;<|>RELATION_NOE
NGOC<|>RELATION_NOE )<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 含有<|>RELATION_NOE 绒癌<|>RELATION_NOE 成分<|>RELATION_NOE 的<|>RELATION_NOE 卵巢<|>RELATION_NOE 混合性<|>RELATION_NOE 生殖细胞<|>RELATION_NOE 肿瘤<|>RELATION_NOE 3例<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 卵巢<|>RELATION_NOE 成熟性<|>RELATION_NOE 畸胎瘤<|>RELATION_NOE 合并<|>RELATION_NOE 绒癌<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 卵<|>RELATION_NOE 黄瘤<|>RELATION_NOE 为<|>RELATION_NOE 主伴<|>RELATION_NOE 绒癌<|>RELATION_NOE 及<|>RELATION_NOE 胚胎<|>RELATION_NOE 癌<|>RELATION_NOE 成分<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 绒<|>RELATION_NOE 癌伴<|>RELATION_NOE 无性细胞瘤<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_NOE 含<|>RELATION_NOE 绒癌<|>RELATION_NOE 成分<|>RELATION_NOE 的<|>RELATION_NOE 卵巢<|>RELATION_NOE 恶性<|>RELATION_NOE 生殖细胞<|>RELATION_NOE 肿瘤<|>RELATION_NOE 3例<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 内<|>RELATION_NOE 胚窦<|>RELATION_NOE 瘤2<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 未<|>RELATION_NOE 成熟性<|>RELATION_NOE 畸胎瘤<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 出现<|>RELATION_NOE 肺转移<|>RELATION_NOE 时间<|>RELATION_NOE :<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE NGOC<|>RELATION_NOE 或<|>RELATION_NOE 含绒癌<|>RELATION_NOE 成分<|>RELATION_NOE 的<|>RELATION_NOE 混合性<|>RELATION_NOE 生殖细胞<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 在<|>RELATION_NOE 初始<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 即<|>RELATION_NOE 出现<|>RELATION_NOE 肺转移<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 后<|>RELATION_NOE 出现<|>RELATION_NOE 肺转移<|>RELATION_NOE ;<|>RELATION_NOE
3例<|>RELATION_NOE 不<|>RELATION_NOE 含<|>RELATION_NOE 绒癌<|>RELATION_NOE 成分<|>RELATION_NOE 的<|>RELATION_NOE 卵巢<|>RELATION_NOE 恶性<|>RELATION_NOE 生殖细胞<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 后<|>RELATION_NOE 在<|>RELATION_NOE 疾病<|>RELATION_NOE 晚期<|>RELATION_NOE 出现<|>RELATION_NOE 肺转移<|>RELATION_NOE .<|>RELATION_NOE
(<|>RELATION_NOE 5<|>RELATION_NOE )<|>RELATION_NOE 预后<|>RELATION_NOE :<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE NGOC<|>RELATION_NOE 或<|>RELATION_NOE 含绒癌<|>RELATION_NOE 成分<|>RELATION_NOE 的<|>RELATION_NOE 混合性<|>RELATION_NOE 生殖细胞<|>RELATION_NOE 肿瘤<|>RELATION_NOE ;<|>RELATION_NOE
3例<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 病情<|>RELATION_NOE 进展<|>RELATION_NOE 死亡<|>RELATION_NOE (<|>RELATION_NOE 1例<|>RELATION_NOE NGOC<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 内<|>RELATION_NOE 胚窦瘤<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 未<|>RELATION_NOE 成熟性<|>RELATION_NOE 畸胎瘤<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进展<|>RELATION_NOE (<|>RELATION_NOE 1例<|>RELATION_NOE NGOC<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 内<|>RELATION_NOE 胚窦瘤<|>RELATION_NOE )<|>RELATION_NOE 放弃<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 失访<|>RELATION_NOE 。<|>RELATION_NOE
全身麻醉<|>RELATION_NOE 下<|>RELATION_NOE 气管<|>RELATION_NOE 支架<|>RELATION_NOE 置入<|>RELATION_NOE 治疗<|>RELATION_S 恶性气道<|>RELATION_NOE 狭窄<|>RELATION_NOE
18<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 引起<|>RELATION_NOE 的<|>RELATION_NOE 气管<|>RELATION_NOE 、<|>RELATION_NOE 主<|>RELATION_NOE 支气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 气管<|>RELATION_NOE 腺癌<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 9例<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 癌7<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 纵隔<|>RELATION_NOE 内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 64<|>RELATION_NOE 排<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 及<|>RELATION_NOE 气道<|>RELATION_NOE 重组<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 右<|>RELATION_NOE 支气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 合并<|>RELATION_NOE 左<|>RELATION_NOE 或<|>RELATION_NOE 右<|>RELATION_NOE 支气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 、<|>RELATION_NOE 左右<|>RELATION_NOE 支气管<|>RELATION_NOE 均<|>RELATION_NOE 狭窄<|>RELATION_NOE 5例<|>RELATION_NOE ;<|>RELATION_NOE
患者<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 全身麻醉<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE DSA<|>RELATION_NOE 监视<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 气管<|>RELATION_NOE 插管<|>RELATION_NOE 连接<|>RELATION_NOE 管<|>RELATION_NOE 的<|>RELATION_NOE 吸<|>RELATION_NOE 痰孔<|>RELATION_NOE 进入<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 气管<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 术<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 全程<|>RELATION_NOE 监测<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 心电图<|>RELATION_NOE 、<|>RELATION_NOE 经<|>RELATION_NOE 皮血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE (<|>RELATION_NOE SaO2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 观察<|>RELATION_NOE 患者<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 缓解<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 麻醉<|>RELATION_NOE 及<|>RELATION_NOE 手术<|>RELATION_NOE 相关<|>RELATION_NOE 重要<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 全<|>RELATION_NOE 麻<|>RELATION_NOE 效果<|>RELATION_NOE (<|>RELATION_NOE 舒适度<|>RELATION_NOE 评分<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 气管<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 操作<|>RELATION_NOE 顺利度<|>RELATION_NOE 综合<|>RELATION_NOE 评价<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 麻醉<|>RELATION_NOE 过程<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 呼吸<|>RELATION_NOE 、<|>RELATION_NOE SaO2<|>RELATION_NOE 以及<|>RELATION_NOE 手术<|>RELATION_NOE 前后<|>RELATION_NOE 动脉<|>RELATION_NOE 血气<|>RELATION_NOE 监测<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 成功<|>RELATION_NOE 置入<|>RELATION_NOE 支架<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 缓解<|>RELATION_E ,<|>RELATION_NOE 7例<|>RELATION_NOE 出现<|>RELATION_NOE 轻度痰<|>RELATION_NOE 中<|>RELATION_NOE 带<|>RELATION_NOE 血<|>RELATION_NOE 、<|>RELATION_NOE 1例<|>RELATION_NOE 痰液<|>RELATION_NOE 涌出<|>RELATION_NOE 堵住<|>RELATION_NOE 支架<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 好转<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 均<|>RELATION_NOE 顺利<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 出现<|>RELATION_NOE 其他<|>RELATION_NOE 麻醉<|>RELATION_NOE 及<|>RELATION_NOE 手术<|>RELATION_NOE 相关<|>RELATION_NOE 严重<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
呼吸频率<|>RELATION_NOE 及<|>RELATION_NOE 心率<|>RELATION_NOE 在<|>RELATION_NOE 麻醉<|>RELATION_NOE 苏<|>RELATION_NOE 醒<|>RELATION_NOE 后<|>RELATION_NOE [<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 18.6<|>RELATION_NOE ±<|>RELATION_NOE 1.4<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 73.2<|>RELATION_NOE ±<|>RELATION_NOE 7.6<|>RELATION_NOE )<|>RELATION_NOE 次/<|>RELATION_NOE min<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 麻醉<|>RELATION_NOE 前<|>RELATION_NOE [<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 37.1<|>RELATION_NOE ±<|>RELATION_NOE 2.8<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE 6.5<|>RELATION_NOE ±<|>RELATION_NOE 14.2<|>RELATION_NOE )<|>RELATION_NOE 次/<|>RELATION_NOE min<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 17.81<|>RELATION_NOE 、<|>RELATION_NOE 3.80<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE SaO2<|>RELATION_NOE 在<|>RELATION_NOE 术中<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 91.2<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 高于<|>RELATION_NOE 术前<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 76.3<|>RELATION_NOE ±<|>RELATION_NOE 8.6<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.06<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血压<|>RELATION_NOE 在<|>RELATION_NOE 麻醉<|>RELATION_NOE 苏<|>RELATION_NOE 醒<|>RELATION_NOE 后<|>RELATION_NOE 较<|>RELATION_NOE 麻醉<|>RELATION_NOE 前<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 变化<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
恶性<|>RELATION_NOE 气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 在<|>RELATION_NOE 充分<|>RELATION_NOE 评估<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 全身麻醉<|>RELATION_NOE 下<|>RELATION_NOE 进行<|>RELATION_NOE 气管<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 入术<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_B 可行<|>RELATION_E 的<|>RELATION_NOE 。<|>RELATION_NOE
超声<|>RELATION_NOE 造影<|>RELATION_NOE 对<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 鉴别<|>RELATION_B 诊断<|>RELATION_I 价值<|>RELATION_E
探讨<|>RELATION_NOE 超声<|>RELATION_NOE 造影<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
选取<|>RELATION_NOE 周围型<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE 59<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 肺脓肿<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 结核<|>RELATION_NOE 球<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 血管<|>RELATION_NOE 瘤1<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
超声<|>RELATION_NOE 造影<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 对<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 内<|>RELATION_NOE 有<|>RELATION_NOE 血<|>RELATION_NOE 供<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 坏死<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 鉴别<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_NOE
回顾性<|>RELATION_NOE 总结<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE 肺硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 和<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 组织<|>RELATION_NOE 芯片<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 49<|>RELATION_NOE 例<|>RELATION_NOE 硬化性<|>RELATION_NOE 血管<|>RELATION_NOE 瘤中广谱<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE (<|>RELATION_NOE CKpan<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞膜<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE EMA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 波形蛋白<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE (<|>RELATION_NOE TTF<|>RELATION_NOE )<|>RELATION_NOE -1<|>RELATION_NOE 、<|>RELATION_NOE napsinA<|>RELATION_NOE 、<|>RELATION_NOE 突触素<|>RELATION_NOE 、<|>RELATION_NOE 嗜<|>RELATION_NOE 铬粒素<|>RELATION_NOE A<|>RELATION_NOE (<|>RELATION_NOE CgA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CD56<|>RELATION_NOE 、<|>RELATION_NOE E-cadherin<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE -catenin<|>RELATION_NOE 、<|>RELATION_NOE CD117<|>RELATION_NOE 、<|>RELATION_NOE CD68<|>RELATION_NOE 及<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE TGF<|>RELATION_NOE )<|>RELATION_NOE -<|>RELATION_NOE β1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表面<|>RELATION_NOE 立方<|>RELATION_NOE 细胞<|>RELATION_NOE 表达<|>RELATION_B CKpan<|>RELATION_I 、<|>RELATION_I EMA<|>RELATION_I 、<|>RELATION_I TTF-1<|>RELATION_I 、<|>RELATION_I napsinA<|>RELATION_E ;<|>RELATION_NOE
E-cadherin<|>RELATION_NOE 、<|>RELATION_NOE B-catenin<|>RELATION_NOE 在<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE 硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 的<|>RELATION_NOE 表面<|>RELATION_NOE 立方<|>RELATION_NOE 细胞<|>RELATION_NOE 均<|>RELATION_NOE 呈强<|>RELATION_B 阳性<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE E-cadherin<|>RELATION_NOE 呈<|>RELATION_NOE 胞膜<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE β<|>RELATION_NOE -catenin<|>RELATION_NOE 呈<|>RELATION_NOE 胞膜<|>RELATION_NOE 及<|>RELATION_NOE 胞质<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
波形蛋白<|>RELATION_NOE 在<|>RELATION_NOE 所有<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE 硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 的<|>RELATION_NOE 多<|>RELATION_NOE 角形<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 见<|>RELATION_NOE 强阳性<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 其中<|>RELATION_NOE 立方<|>RELATION_NOE 细胞<|>RELATION_NOE 仅<|>RELATION_NOE 见<|>RELATION_NOE 少量<|>RELATION_NOE 细胞<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
肺硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 起源于<|>RELATION_S 原始<|>RELATION_NOE 呼吸上皮<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 角形<|>RELATION_NOE 间质细胞<|>RELATION_NOE 可能<|>RELATION_NOE 来源于<|>RELATION_NOE 立方<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 转化<|>RELATION_NOE 。<|>RELATION_NOE 肺硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 起源<|>RELATION_NOE 于<|>RELATION_NOE 原始<|>RELATION_NOE 呼吸上皮<|>RELATION_NOE ,<|>RELATION_NOE 多角形<|>RELATION_NOE 间质细胞<|>RELATION_NOE 可能<|>RELATION_NOE 来源于<|>RELATION_S 立方<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 转化<|>RELATION_NOE 。<|>RELATION_NOE
TGF-<|>RELATION_NOE β1<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_B 着<|>RELATION_I 重要<|>RELATION_I 的<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
重组<|>RELATION_NOE CKB<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE 构建<|>RELATION_NOE 及其<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE NCI-H520<|>RELATION_NOE 细胞系<|>RELATION_NOE 的<|>RELATION_NOE 建立<|>RELATION_S
构建<|>RELATION_NOE pEGFP-N1<|>RELATION_NOE －<|>RELATION_NOE CKB<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE 并<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 稳定<|>RELATION_B 转染<|>RELATION_I 到<|>RELATION_E 肺鳞<|>RELATION_NOE 癌细胞<|>RELATION_NOE NCI-H520<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE NCI-H520<|>RELATION_NOE 细胞系<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 后续<|>RELATION_NOE 研究<|>RELATION_NOE 奠定<|>RELATION_NOE 基础<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE 转染<|>RELATION_NOE 株<|>RELATION_NOE 中<|>RELATION_NOE CKB<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 证实<|>RELATION_NOE CKB<|>RELATION_NOE 基因<|>RELATION_NOE 已<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 到<|>RELATION_NOE NCI-H520<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 并<|>RELATION_NOE 得到<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
96<|>RELATION_NOE 例<|>RELATION_NOE 出现<|>RELATION_NOE 电解质<|>RELATION_NOE 紊乱者<|>RELATION_NOE 有<|>RELATION_NOE 6例<|>RELATION_NOE 出现<|>RELATION_NOE 上<|>RELATION_NOE 消化道<|>RELATION_NOE 出血<|>RELATION_NOE ;<|>RELATION_NOE
156<|>RELATION_NOE 例<|>RELATION_NOE 出现<|>RELATION_NOE 低氧血症<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 有<|>RELATION_NOE 8例<|>RELATION_NOE 上<|>RELATION_NOE 消化道<|>RELATION_NOE 出血<|>RELATION_NOE ;<|>RELATION_NOE
术后<|>RELATION_NOE 出现<|>RELATION_NOE 低血压<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 3例<|>RELATION_NOE 出现<|>RELATION_NOE 上<|>RELATION_NOE 消化道<|>RELATION_NOE 出血<|>RELATION_NOE ;<|>RELATION_NOE
老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 上<|>RELATION_NOE 消化道<|>RELATION_NOE 出血<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 2.8%<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 并<|>RELATION_NOE 不<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 主要<|>RELATION_B 的<|>RELATION_I 危险因素<|>RELATION_E 是<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 低氧血症<|>RELATION_NOE 、<|>RELATION_NOE 电解质<|>RELATION_NOE 紊乱<|>RELATION_NOE 及<|>RELATION_NOE 低血压<|>RELATION_NOE 。<|>RELATION_NOE
护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 应<|>RELATION_NOE 对<|>RELATION_NOE 方式<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
护理<|>RELATION_NOE 干预<|>RELATION_NOE 有助于<|>RELATION_S 提高<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 积极<|>RELATION_NOE 应对<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 其<|>RELATION_NOE 消极<|>RELATION_NOE 应对<|>RELATION_NOE 方式<|>RELATION_NOE 。<|>RELATION_NOE
c-Jun<|>RELATION_NOE 氨基末<|>RELATION_NOE 端激酶<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 在<|>RELATION_NOE 高氧<|>RELATION_NOE 诱导<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
培养<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 1×<|>RELATION_NOE 105<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 密度<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 6孔板<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE ml<|>RELATION_NOE /<|>RELATION_NOE 孔<|>RELATION_NOE )<|>RELATION_NOE 或<|>RELATION_NOE 10<|>RELATION_NOE cm<|>RELATION_NOE 培养<|>RELATION_NOE 皿<|>RELATION_NOE (<|>RELATION_NOE 5ml<|>RELATION_NOE /<|>RELATION_NOE 皿<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 4组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 空气<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 空气<|>RELATION_NOE +<|>RELATION_NOE JNK<|>RELATION_NOE 抑制<|>RELATION_NOE 剂组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE +<|>RELATION_NOE S<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 高氧组<|>RELATION_NOE (<|>RELATION_NOE O2<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 高氧<|>RELATION_NOE +<|>RELATION_NOE JNK<|>RELATION_NOE 抑制<|>RELATION_NOE 剂组<|>RELATION_NOE (<|>RELATION_NOE O2<|>RELATION_NOE +<|>RELATION_NOE S<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
C<|>RELATION_NOE +<|>RELATION_NOE S<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE O2<|>RELATION_NOE +<|>RELATION_NOE S<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 加入<|>RELATION_NOE 终浓度<|>RELATION_NOE 为<|>RELATION_NOE 5μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 的<|>RELATION_NOE JNK<|>RELATION_NOE 抑制剂<|>RELATION_NOE SP600125<|>RELATION_NOE .<|>RELATION_NOE 将<|>RELATION_NOE 细胞<|>RELATION_NOE 分别<|>RELATION_NOE 放<|>RELATION_NOE 入<|>RELATION_NOE 空气<|>RELATION_NOE 或<|>RELATION_NOE 95%<|>RELATION_NOE O2<|>RELATION_NOE 中<|>RELATION_NOE 进行<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE 培养<|>RELATION_NOE 24h<|>RELATION_NOE 时<|>RELATION_NOE 测定<|>RELATION_S 细胞存活率<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 裂解液<|>RELATION_NOE 中<|>RELATION_NOE Fas-L<|>RELATION_NOE 和<|>RELATION_NOE 裂解<|>RELATION_NOE caspase-3<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
右美托咪啶<|>RELATION_NOE 辅助<|>RELATION_NOE 麻醉<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 病人<|>RELATION_NOE 麻醉<|>RELATION_NOE 后<|>RELATION_NOE 寒战<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_S
评价<|>RELATION_S 右美托咪啶<|>RELATION_NOE 辅助<|>RELATION_NOE 麻醉<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 病人<|>RELATION_NOE 麻醉<|>RELATION_NOE 后<|>RELATION_NOE 寒战<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE
择期<|>RELATION_NOE 全麻<|>RELATION_NOE 复合<|>RELATION_NOE 硬膜外麻醉<|>RELATION_NOE 下<|>RELATION_NOE 开<|>RELATION_NOE 胸行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 病人<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 性别<|>RELATION_NOE 不<|>RELATION_NOE 限<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 50<|>RELATION_NOE －<|>RELATION_NOE 75<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 身高<|>RELATION_NOE 158<|>RELATION_NOE －1<|>RELATION_NOE 80<|>RELATION_NOE cm<|>RELATION_NOE ,<|>RELATION_NOE 体重<|>RELATION_NOE 48<|>RELATION_NOE －<|>RELATION_NOE 79<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE ASA<|>RELATION_NOE 分级<|>RELATION_NOE Ⅰ<|>RELATION_NOE 或<|>RELATION_NOE Ⅱ<|>RELATION_NOE 级<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 分层法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 病人<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 2组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 右美托咪啶组<|>RELATION_NOE (<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
静脉<|>RELATION_NOE 注射<|>RELATION_NOE 咪达唑仑<|>RELATION_NOE 、<|>RELATION_NOE 芬太尼<|>RELATION_NOE 、<|>RELATION_NOE 异丙酚<|>RELATION_NOE 和<|>RELATION_NOE 罗库<|>RELATION_NOE 溴铵<|>RELATION_NOE 进行<|>RELATION_B 麻醉<|>RELATION_I 诱导<|>RELATION_E ,<|>RELATION_NOE 气管<|>RELATION_NOE 插<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE 机械通气<|>RELATION_NOE .<|>RELATION_NOE
麻醉<|>RELATION_NOE 维持<|>RELATION_NOE :<|>RELATION_NOE 吸入<|>RELATION_NOE 七<|>RELATION_NOE 氟醚<|>RELATION_NOE ,<|>RELATION_NOE 间断<|>RELATION_NOE 硬膜外注射<|>RELATION_NOE 罗哌卡因<|>RELATION_NOE ,<|>RELATION_NOE 维持<|>RELATION_NOE BIS<|>RELATION_NOE 值<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 55.D<|>RELATION_NOE 组<|>RELATION_NOE 气管<|>RELATION_NOE 插<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE 右美托咪啶<|>RELATION_NOE 0.5<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ·<|>RELATION_NOE kg-1<|>RELATION_NOE ·<|>RELATION_NOE h-1<|>RELATION_NOE 至<|>RELATION_NOE 手术<|>RELATION_NOE 结束<|>RELATION_NOE 前<|>RELATION_NOE 1h<|>RELATION_NOE ,<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE 给予<|>RELATION_NOE 等<|>RELATION_NOE 容量<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE .<|>RELATION_NOE
右美托咪啶<|>RELATION_NOE 辅助<|>RELATION_NOE 麻醉<|>RELATION_NOE 可<|>RELATION_NOE 降低<|>RELATION_S 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 病人<|>RELATION_NOE 麻醉<|>RELATION_NOE 后<|>RELATION_NOE 寒战<|>RELATION_NOE 的<|>RELATION_NOE 发生机率<|>RELATION_NOE .<|>RELATION_NOE
探讨<|>RELATION_S 肺黏膜<|>RELATION_NOE 相关<|>RELATION_NOE 淋巴组织<|>RELATION_NOE (<|>RELATION_NOE MALT<|>RELATION_NOE )<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 影像学<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE :<|>RELATION_NOE 咳嗽<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 51.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 发热<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 20.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胸闷<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 17.2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胸痛<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 17.2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乏力<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 13.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 体重<|>RELATION_NOE 下降<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 13.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 症状<|>RELATION_NOE 患者<|>RELATION_NOE 9例<|>RELATION_NOE (<|>RELATION_NOE 31.O<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 13.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 活检<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 17.2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 外周<|>RELATION_NOE 淋巴结<|>RELATION_NOE 活检<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 6.9%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
治疗<|>RELATION_NOE 方法<|>RELATION_NOE 包括<|>RELATION_S 单纯<|>RELATION_NOE 手术<|>RELATION_NOE 、<|>RELATION_NOE 联合化疗<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 以及<|>RELATION_NOE 中药<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
肺<|>RELATION_NOE MALT<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 和<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 不<|>RELATION_B 典型<|>RELATION_E ,<|>RELATION_NOE 易于<|>RELATION_NOE 误诊<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 主要<|>RELATION_NOE 依靠<|>RELATION_NOE 病理<|>RELATION_NOE 活检<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 中热<|>RELATION_NOE 休克<|>RELATION_NOE 蛋白<|>RELATION_NOE 70-2<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE mRNA<|>RELATION_NOE 转录<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
以<|>RELATION_NOE 郑州市<|>RELATION_NOE 某<|>RELATION_NOE 医院<|>RELATION_NOE 2008年<|>RELATION_NOE 2-8<|>RELATION_NOE 月经<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE PCR-<|>RELATION_NOE 限制性<|>RELATION_NOE 片段<|>RELATION_NOE 长度<|>RELATION_NOE 多态性<|>RELATION_NOE (<|>RELATION_NOE PCR-RFLP<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_NOE 其<|>RELATION_NOE HSP70-21267A<|>RELATION_NOE /<|>RELATION_NOE G<|>RELATION_NOE 位点<|>RELATION_NOE 多态性<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S HSP70-2mRNA<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Westernhlt<|>RELATION_NOE ,<|>RELATION_NOE tting<|>RELATION_NOE 测定<|>RELATION_NOE HSP70<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE 以<|>RELATION_NOE 郑州市<|>RELATION_NOE 某<|>RELATION_NOE 医院<|>RELATION_NOE 2008年<|>RELATION_NOE 2-8<|>RELATION_NOE 月经<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE PCR-<|>RELATION_NOE 限制性<|>RELATION_NOE 片段<|>RELATION_NOE 长度<|>RELATION_NOE 多态性<|>RELATION_NOE (<|>RELATION_NOE PCR-RFLP<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_NOE 其<|>RELATION_NOE HSP70-21267A<|>RELATION_NOE /<|>RELATION_NOE G<|>RELATION_NOE 位点<|>RELATION_NOE 多态性<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE HSP70-2mRNA<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Westernhlt<|>RELATION_NOE ,<|>RELATION_NOE tting<|>RELATION_NOE 测定<|>RELATION_S HSP70<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
福建<|>RELATION_NOE 汉族<|>RELATION_NOE 胰岛素<|>RELATION_NOE 样<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE 关联<|>RELATION_B 研究<|>RELATION_E
采用<|>RELATION_NOE 病例<|>RELATION_NOE 一<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE 限制性<|>RELATION_NOE 片段<|>RELATION_NOE 长度<|>RELATION_NOE 多态性<|>RELATION_NOE 和<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S 福建籍<|>RELATION_NOE 汉族<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 258<|>RELATION_NOE 名<|>RELATION_NOE 和<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 260<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE IGF-1R<|>RELATION_NOE +<|>RELATION_NOE 10<|>RELATION_NOE 13<|>RELATION_NOE 和<|>RELATION_NOE IGF-2R<|>RELATION_NOE +<|>RELATION_NOE 16<|>RELATION_NOE 19<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE 位点<|>RELATION_NOE 的<|>RELATION_NOE 等位基因<|>RELATION_NOE 分布<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 不同<|>RELATION_NOE 基因型<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 发病<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 采用<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_S 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 理论<|>RELATION_NOE 依据<|>RELATION_NOE 和<|>RELATION_NOE 实践<|>RELATION_NOE 规范<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
术前<|>RELATION_NOE 诊断<|>RELATION_NOE 包括<|>RELATION_S 肺良性<|>RELATION_NOE 结节<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺转移瘤<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 肺内<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 性质<|>RELATION_NOE 不明<|>RELATION_NOE ,<|>RELATION_NOE 误诊率<|>RELATION_NOE 56.3%<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE 全部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 均<|>RELATION_NOE 可见<|>RELATION_S 炭末<|>RELATION_NOE 沉着<|>RELATION_NOE ,<|>RELATION_NOE 8例<|>RELATION_NOE
总结<|>RELATION_S 完全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下行<|>RELATION_NOE 单向式<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 围手术期<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 经验<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_B 分析<|>RELATION_E 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 282<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 单向式<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 上述<|>RELATION_NOE 282<|>RELATION_NOE 例行<|>RELATION_NOE 该<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 加强<|>RELATION_NOE 术前<|>RELATION_NOE 宣教<|>RELATION_NOE ,<|>RELATION_NOE 指导<|>RELATION_NOE 有效<|>RELATION_NOE 咳嗽<|>RELATION_NOE 和<|>RELATION_NOE 深<|>RELATION_NOE 呼吸锻炼<|>RELATION_NOE ,<|>RELATION_NOE 做<|>RELATION_NOE 好<|>RELATION_NOE 呼吸道<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 加强<|>RELATION_NOE 生命体征<|>RELATION_NOE 及<|>RELATION_NOE 引流<|>RELATION_NOE 管<|>RELATION_NOE 观察<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 具有<|>RELATION_S 创伤<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 痛苦<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE 等<|>RELATION_NOE 优点<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 正确<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 加强<|>RELATION_NOE 围手术期<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 严密<|>RELATION_NOE 观察<|>RELATION_NOE 病情<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 减少<|>RELATION_NOE 护理<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 促进<|>RELATION_NOE 术后<|>RELATION_NOE 恢复<|>RELATION_NOE 。<|>RELATION_NOE
Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 原发性<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 52<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 石蜡<|>RELATION_NOE 标本<|>RELATION_NOE 及<|>RELATION_NOE 7例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 对<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 无<|>RELATION_B 统计学<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE (<|>RELATION_NOE 57.8<|>RELATION_NOE 9%<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 36.3<|>RELATION_NOE 7%<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE ≥<|>RELATION_NOE 400<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 53.5<|>RELATION_NOE 7%<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE <<|>RELATION_NOE 400<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 33.3<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 无关<|>RELATION_S ,<|>RELATION_NOE 与<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 无关<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E 。<|>RELATION_NOE
近<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 来<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 诱因<|>RELATION_NOE 出现<|>RELATION_NOE 反复<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咳痰<|>RELATION_NOE ,<|>RELATION_NOE 痰液<|>RELATION_NOE 黄白色<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 泡沫<|>RELATION_NOE ,<|>RELATION_NOE 痰量<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE ,<|>RELATION_NOE 每日<|>RELATION_NOE 约<|>RELATION_NOE 100ml<|>RELATION_NOE ,<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 活动<|>RELATION_NOE 后<|>RELATION_NOE 气促<|>RELATION_NOE 、<|>RELATION_NOE 胸闷<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 发热<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE 、<|>RELATION_NOE 胸痛<|>RELATION_NOE 、<|>RELATION_NOE 盗汗<|>RELATION_NOE 、<|>RELATION_NOE 双<|>RELATION_NOE 下肢<|>RELATION_NOE 水肿<|>RELATION_NOE 、<|>RELATION_NOE 夜间<|>RELATION_NOE 呼吸困难<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 寒战<|>RELATION_NOE 、<|>RELATION_NOE 关节<|>RELATION_NOE 酸痛<|>RELATION_NOE 。<|>RELATION_NOE
否认<|>RELATION_NOE 慢性<|>RELATION_NOE 疾病<|>RELATION_NOE 史<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 宠物<|>RELATION_NOE 饲养史<|>RELATION_NOE 。<|>RELATION_NOE
基于<|>RELATION_NOE KVCBCT<|>RELATION_NOE 形变<|>RELATION_NOE 配<|>RELATION_NOE 准<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 自<|>RELATION_NOE 适应<|>RELATION_NOE 计划<|>RELATION_NOE 与<|>RELATION_NOE 静态<|>RELATION_NOE 3DCRT<|>RELATION_NOE 计划<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_B 研究<|>RELATION_E
三维<|>RELATION_NOE 放疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE 心肌<|>RELATION_NOE 酶谱<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 心脏体<|>RELATION_NOE 积<|>RELATION_NOE 剂量<|>RELATION_NOE 相关性<|>RELATION_B 分析<|>RELATION_E
探讨<|>RELATION_NOE 胸部肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE 心肌<|>RELATION_NOE 酶谱<|>RELATION_NOE 改变<|>RELATION_NOE 与<|>RELATION_NOE 心脏体<|>RELATION_NOE 积<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
心脏体<|>RELATION_NOE 积剂量<|>RELATION_NOE 与<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 前后<|>RELATION_NOE 心肌<|>RELATION_NOE 酶<|>RELATION_NOE 水平<|>RELATION_NOE 变化<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_S 心脏<|>RELATION_NOE DVH<|>RELATION_NOE 参数<|>RELATION_NOE 有助于<|>RELATION_NOE 评价<|>RELATION_NOE 放疗<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 心肌<|>RELATION_NOE 损伤<|>RELATION_NOE 。<|>RELATION_NOE
射波刀<|>RELATION_NOE 治疗<|>RELATION_S 48<|>RELATION_NOE 例<|>RELATION_NOE 肺转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 分析<|>RELATION_NOE
不良<|>RELATION_NOE 反应<|>RELATION_NOE 为<|>RELATION_NOE 1级<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 损伤<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3级<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 皮下组织<|>RELATION_NOE 纤维化<|>RELATION_NOE 改变<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 局部<|>RELATION_NOE 皮肤<|>RELATION_NOE 色素沉着<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE ^<|>RELATION_NOE 125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
^<|>RELATION_NOE 125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 显示<|>RELATION_S 了<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
参<|>RELATION_NOE 一<|>RELATION_NOE 胶囊<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 观察<|>RELATION_E
应用<|>RELATION_NOE 参<|>RELATION_NOE 一<|>RELATION_NOE 胶囊<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S Ⅲ<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
63<|>RELATION_NOE 例<|>RELATION_NOE Ⅲ<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 简单<|>RELATION_NOE 随机化<|>RELATION_NOE 方法<|>RELATION_NOE 分为<|>RELATION_NOE 2组<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE ,<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 放疗<|>RELATION_NOE +<|>RELATION_NOE 参<|>RELATION_NOE 一<|>RELATION_NOE 胶囊<|>RELATION_NOE 处理<|>RELATION_NOE ;<|>RELATION_NOE
治疗组<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 为<|>RELATION_NOE 57.1<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 32.14%<|>RELATION_NOE ,<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 3.91<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 为<|>RELATION_NOE 14.2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_NOE 长于<|>RELATION_NOE
治疗组<|>RELATION_NOE 中<|>RELATION_NOE 各种<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE 除<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE 外<|>RELATION_NOE )<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
厄洛替尼<|>RELATION_NOE 和<|>RELATION_NOE 塞来昔布<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射<|>RELATION_NOE 增敏<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 细胞凋亡<|>RELATION_NOE 和<|>RELATION_NOE 细胞周期<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE
丹皮酚<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射<|>RELATION_NOE 增敏<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
分为<|>RELATION_NOE 细胞<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 加<|>RELATION_NOE 药组<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 照射组<|>RELATION_NOE 和<|>RELATION_NOE 药物<|>RELATION_NOE 联合<|>RELATION_NOE 照射组<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 丹皮酚<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE TUNEL<|>RELATION_NOE 染色<|>RELATION_NOE 与<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 观察<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE Survivin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
丹皮酚<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 有<|>RELATION_B 放射<|>RELATION_I 增敏<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 下调<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE Survivin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 支气管<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 病理<|>RELATION_NOE 比较<|>RELATION_B 分析<|>RELATION_E
研究<|>RELATION_S 经<|>RELATION_NOE 支气管<|>RELATION_NOE 针吸活检<|>RELATION_NOE (<|>RELATION_NOE TBNA<|>RELATION_NOE )<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 病理学<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 结果<|>RELATION_NOE 比较<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_NOE TBNA<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 分期<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE TBNA<|>RELATION_NOE 方法<|>RELATION_NOE 21G<|>RELATION_NOE 针取材<|>RELATION_NOE 共<|>RELATION_NOE 374<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
TBNA<|>RELATION_NOE 标本<|>RELATION_NOE 细胞<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_S 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 假阳<|>RELATION_NOE 性率<|>RELATION_NOE 、<|>RELATION_NOE 假阴<|>RELATION_NOE 性率<|>RELATION_NOE 和<|>RELATION_NOE 准确性<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 95.7%<|>RELATION_NOE (<|>RELATION_NOE 266<|>RELATION_NOE /<|>RELATION_NOE 278<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 96<|>RELATION_NOE /<|>RELATION_NOE 96<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 0<|>RELATION_NOE (<|>RELATION_NOE 0/96<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 4.3%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 278<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 96.8%<|>RELATION_NOE (<|>RELATION_NOE 362<|>RELATION_NOE /<|>RELATION_NOE 374<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
62.8%<|>RELATION_NOE (<|>RELATION_NOE 167<|>RELATION_NOE /<|>RELATION_NOE 266<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE 分型<|>RELATION_NOE 准确<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 95.7%<|>RELATION_NOE (<|>RELATION_NOE 88<|>RELATION_NOE /<|>RELATION_NOE 92<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 73.5%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 34<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 和<|>RELATION_NOE 67.9%<|>RELATION_NOE (<|>RELATION_NOE 53<|>RELATION_NOE /<|>RELATION_NOE 78<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE 。<|>RELATION_NOE
细胞<|>RELATION_NOE 病理学<|>RELATION_NOE 对<|>RELATION_NOE 肺肿物<|>RELATION_NOE TBNA<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE TBNA<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 两者<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 0.21<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 隆突<|>RELATION_NOE 下<|>RELATION_NOE 淋巴结<|>RELATION_NOE TBNA<|>RELATION_NOE 与<|>RELATION_NOE 其他<|>RELATION_NOE 淋巴结<|>RELATION_NOE TBNA<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE
TBNA<|>RELATION_NOE 标本<|>RELATION_NOE 细胞<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 结果<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 临床<|>RELATION_NOE 确诊<|>RELATION_NOE 肺癌<|>RELATION_NOE 及其<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 可靠<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
细针<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 在<|>RELATION_NOE 确诊<|>RELATION_NOE 肺部<|>RELATION_NOE 肿块<|>RELATION_NOE 性质<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
彩超<|>RELATION_NOE 或<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 肺占位<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 定位<|>RELATION_NOE 精确<|>RELATION_NOE ,<|>RELATION_NOE 穿刺<|>RELATION_NOE 成功率<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 是<|>RELATION_NOE 诊断<|>RELATION_NOE 肺部<|>RELATION_NOE 肿块<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_B 方法<|>RELATION_E 。<|>RELATION_NOE
莱菔<|>RELATION_NOE 硫烷<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE NCI-H446<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 以及<|>RELATION_NOE MMP-9<|>RELATION_NOE 活性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
H446<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抑制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 11.1<|>RELATION_NOE ±<|>RELATION_NOE 2.26<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 25.2<|>RELATION_NOE ±<|>RELATION_NOE 3.24<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 44.6<|>RELATION_NOE ±<|>RELATION_NOE 4.2<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 溶剂<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 10.6<|>RELATION_NOE 85<|>RELATION_NOE ,<|>RELATION_NOE 8.4<|>RELATION_NOE 17<|>RELATION_NOE ,<|>RELATION_NOE 5.2<|>RELATION_NOE 64<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
25<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE LSFN<|>RELATION_NOE 作用<|>RELATION_NOE NCI-H446<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE NCI-H446<|>RELATION_NOE 细胞<|>RELATION_NOE 穿<|>RELATION_NOE 膜数<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 48.6<|>RELATION_NOE ±<|>RELATION_NOE 1.84<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 35.4<|>RELATION_NOE ±<|>RELATION_NOE 2.22<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 27.8<|>RELATION_NOE ±<|>RELATION_NOE 1.36<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 溶剂<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 68.4<|>RELATION_NOE ±<|>RELATION_NOE 2.21<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 6.3<|>RELATION_NOE 41<|>RELATION_NOE ,<|>RELATION_NOE 5.5<|>RELATION_NOE 62<|>RELATION_NOE ,<|>RELATION_NOE 4.9<|>RELATION_NOE 25<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
SFN<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE NCI-H446<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 、<|>RELATION_NOE 侵袭力<|>RELATION_NOE 及<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 具有<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
探讨<|>RELATION_S 非<|>RELATION_NOE 典型<|>RELATION_NOE 心力衰竭<|>RELATION_NOE 的<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 体征<|>RELATION_NOE 及<|>RELATION_NOE 常见<|>RELATION_NOE 误诊<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 总结<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 经验<|>RELATION_NOE ,<|>RELATION_NOE 提出<|>RELATION_NOE 防范<|>RELATION_NOE 对策<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 误诊<|>RELATION_NOE 误治<|>RELATION_NOE 。<|>RELATION_NOE
误诊<|>RELATION_NOE 为<|>RELATION_NOE 慢性<|>RELATION_NOE 支气管炎<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 及<|>RELATION_NOE 支气管<|>RELATION_NOE 哮喘<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜炎<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 慢性<|>RELATION_NOE 胃炎<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 高血压<|>RELATION_NOE 脑动脉硬化<|>RELATION_NOE 症1<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 低血<|>RELATION_NOE 容量性<|>RELATION_NOE 休克<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺转移<|>RELATION_NOE 瘤1<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 慢性<|>RELATION_NOE 肾炎<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
58<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 3.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 27.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 41.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 36.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 为<|>RELATION_NOE 72.4%<|>RELATION_NOE 。<|>RELATION_NOE
中医<|>RELATION_NOE 辨证<|>RELATION_NOE 施<|>RELATION_NOE 治<|>RELATION_NOE 联合<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
不良<|>RELATION_NOE 反应<|>RELATION_NOE 方面<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE Ⅱ<|>RELATION_NOE -<|>RELATION_NOE Ⅲ<|>RELATION_NOE 度<|>RELATION_NOE 皮疹<|>RELATION_NOE 发生率<|>RELATION_NOE 及<|>RELATION_NOE 腹泻<|>RELATION_NOE 发生率<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.49<|>RELATION_NOE 、<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
探讨<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE (<|>RELATION_NOE video-assisted<|>RELATION_NOE minithoraeotomy<|>RELATION_NOE ,<|>RELATION_NOE VAMT<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S 。<|>RELATION_NOE
手术<|>RELATION_NOE 切口<|>RELATION_NOE 包括<|>RELATION_NOE 腋中线<|>RELATION_NOE 第<|>RELATION_NOE 6-8<|>RELATION_NOE 肋<|>RELATION_NOE 间<|>RELATION_NOE 一个<|>RELATION_NOE 1.5cm<|>RELATION_NOE 长<|>RELATION_NOE 的<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 光源<|>RELATION_NOE 切口<|>RELATION_NOE ,<|>RELATION_NOE 插入<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 电视<|>RELATION_NOE 显示器<|>RELATION_NOE 观察<|>RELATION_S 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 粘连<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 与否<|>RELATION_NOE 以及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 广泛<|>RELATION_NOE 转移<|>RELATION_NOE ;<|>RELATION_NOE
根据<|>RELATION_NOE 病变<|>RELATION_NOE 情况<|>RELATION_NOE 在<|>RELATION_NOE 腋前<|>RELATION_NOE 到<|>RELATION_NOE 腋中线<|>RELATION_NOE 第4<|>RELATION_NOE 或<|>RELATION_NOE 第5<|>RELATION_NOE 肋<|>RELATION_NOE 间作<|>RELATION_NOE 一个<|>RELATION_NOE 5－<|>RELATION_NOE 7cm<|>RELATION_NOE 的<|>RELATION_NOE 胸壁<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 拉钩<|>RELATION_NOE 牵<|>RELATION_NOE 开<|>RELATION_NOE 胸壁<|>RELATION_NOE 组织<|>RELATION_NOE 或者<|>RELATION_NOE 放置<|>RELATION_NOE 一<|>RELATION_NOE 小<|>RELATION_NOE 撑开器<|>RELATION_NOE ,<|>RELATION_NOE 屏视<|>RELATION_NOE 与<|>RELATION_NOE 直视<|>RELATION_NOE 相<|>RELATION_NOE 结合<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 微创<|>RELATION_NOE 操作<|>RELATION_NOE 器械<|>RELATION_NOE 或<|>RELATION_NOE 微创<|>RELATION_NOE 器械<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 手术<|>RELATION_NOE 器械<|>RELATION_NOE 结合<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 处理<|>RELATION_NOE 血管<|>RELATION_NOE 和<|>RELATION_NOE 支气管<|>RELATION_NOE ,<|>RELATION_NOE 完成<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 。<|>RELATION_NOE
游离<|>RELATION_NOE 肺叶<|>RELATION_NOE 的<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 肺叶<|>RELATION_NOE 淋巴结<|>RELATION_NOE 随<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺叶<|>RELATION_NOE 一并<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 后<|>RELATION_NOE 清扫<|>RELATION_NOE 肺门<|>RELATION_NOE 和<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 。<|>RELATION_NOE
VAMT<|>RELATION_NOE 组<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 完成<|>RELATION_NOE 顺利<|>RELATION_NOE ,<|>RELATION_NOE 手术时间<|>RELATION_NOE 较<|>RELATION_NOE 常规<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 长<|>RELATION_NOE 约<|>RELATION_NOE 30min<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 术中<|>RELATION_NOE 出血<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 输血<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE ,<|>RELATION_NOE 住院时间<|>RELATION_NOE 缩短<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE 。<|>RELATION_NOE
VAMT<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE VATS<|>RELATION_NOE 技术<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 技术<|>RELATION_NOE 相<|>RELATION_NOE 结合<|>RELATION_NOE ,<|>RELATION_NOE 既<|>RELATION_NOE 发挥<|>RELATION_NOE 了<|>RELATION_NOE 微创<|>RELATION_NOE 外科<|>RELATION_NOE 的<|>RELATION_NOE 优越性<|>RELATION_NOE ,<|>RELATION_NOE 又<|>RELATION_NOE 达到<|>RELATION_NOE 了<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 可靠<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 清扫<|>RELATION_NOE 淋巴结<|>RELATION_NOE 符合<|>RELATION_S 肿瘤<|>RELATION_NOE 手术<|>RELATION_NOE 原则<|>RELATION_NOE 。<|>RELATION_NOE
无创通气<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
对照组<|>RELATION_NOE 2例<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 无<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 。<|>RELATION_NOE
无创通气<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 安全<|>RELATION_B 有效<|>RELATION_E 。<|>RELATION_NOE
基于<|>RELATION_NOE 人工<|>RELATION_NOE 神经<|>RELATION_NOE 网络<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE 诊断<|>RELATION_NOE 模型<|>RELATION_NOE 的<|>RELATION_NOE 建立<|>RELATION_S 及<|>RELATION_NOE 应用<|>RELATION_NOE
使用<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 刷片<|>RELATION_NOE 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE 定量<|>RELATION_NOE 参数<|>RELATION_NOE 建立<|>RELATION_S 基于<|>RELATION_NOE 人工<|>RELATION_NOE 神经<|>RELATION_NOE 网络<|>RELATION_NOE (<|>RELATION_NOE ANN<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 验证<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
取<|>RELATION_NOE 系统<|>RELATION_NOE 误差<|>RELATION_NOE 阈值<|>RELATION_NOE 为<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE -8<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 法<|>RELATION_NOE 选取<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 8例肺<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 对<|>RELATION_NOE 获得<|>RELATION_NOE 的<|>RELATION_NOE 22<|>RELATION_NOE 项<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE ANN<|>RELATION_NOE 建模<|>RELATION_NOE 及<|>RELATION_NOE 模型<|>RELATION_NOE 训练<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 盲法<|>RELATION_NOE 测试<|>RELATION_NOE 验证<|>RELATION_S 模型<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE 。<|>RELATION_NOE
ANN<|>RELATION_NOE 模型<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 94.7%<|>RELATION_NOE (<|>RELATION_NOE 72<|>RELATION_NOE /<|>RELATION_NOE 76<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 96.9%<|>RELATION_NOE (<|>RELATION_NOE 31<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
使用<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 刷片<|>RELATION_NOE 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE 定量<|>RELATION_NOE 参数<|>RELATION_NOE 成功<|>RELATION_NOE 建立<|>RELATION_NOE 了<|>RELATION_NOE 基于<|>RELATION_NOE ANN<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 具有<|>RELATION_B 一定<|>RELATION_I 的<|>RELATION_I 应用<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
活性氧<|>RELATION_NOE 在<|>RELATION_NOE 荆花<|>RELATION_NOE 牡荆素<|>RELATION_NOE 诱导<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
H2DCFH-DA<|>RELATION_NOE 探针<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 分析<|>RELATION_B 表明<|>RELATION_E ,<|>RELATION_NOE 完全<|>RELATION_NOE 培养基<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 溶媒<|>RELATION_NOE (<|>RELATION_NOE 0.1%<|>RELATION_NOE DMSO<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 对<|>RELATION_NOE A459<|>RELATION_NOE 细胞<|>RELATION_NOE 作用<|>RELATION_NOE 0h<|>RELATION_NOE ;<|>RELATION_NOE
N-<|>RELATION_NOE 乙酰<|>RELATION_NOE -L<|>RELATION_NOE -<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE (<|>RELATION_NOE NAC<|>RELATION_NOE ,<|>RELATION_NOE 10mmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE +<|>RELATION_NOE CAS<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 作用<|>RELATION_NOE 6h<|>RELATION_NOE 的<|>RELATION_NOE ROS<|>RELATION_NOE 生成<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 8.47<|>RELATION_NOE 、<|>RELATION_NOE 15.26<|>RELATION_NOE 、<|>RELATION_NOE 66.2<|>RELATION_NOE 、<|>RELATION_NOE 74.1<|>RELATION_NOE 、<|>RELATION_NOE 82.2<|>RELATION_NOE 、<|>RELATION_NOE 67.3<|>RELATION_NOE ,<|>RELATION_NOE 随着<|>RELATION_NOE CAS<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 延长<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE ROS<|>RELATION_NOE 水平<|>RELATION_NOE 增加<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经<|>RELATION_NOE 皮氩<|>RELATION_NOE 氦刀<|>RELATION_NOE 适形<|>RELATION_NOE 冷冻<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
非细胞<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 172<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 全部<|>RELATION_NOE 行<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 氩氦<|>RELATION_NOE 刀<|>RELATION_NOE 适形<|>RELATION_NOE 冷冻消融术<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 局部<|>RELATION_NOE 病灶<|>RELATION_NOE 变化<|>RELATION_NOE 、<|>RELATION_NOE 卡氏<|>RELATION_NOE (<|>RELATION_NOE KPS<|>RELATION_NOE )<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 下降<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 生存率<|>RELATION_NOE 进行<|>RELATION_S 动态<|>RELATION_NOE 观察<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 56<|>RELATION_NOE 例痰<|>RELATION_NOE 中<|>RELATION_NOE 带<|>RELATION_NOE 血丝<|>RELATION_NOE ,<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE 出现<|>RELATION_NOE 气胸<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3例行<|>RELATION_NOE 胸腔<|>RELATION_NOE 闭式<|>RELATION_NOE 引流<|>RELATION_NOE ,<|>RELATION_NOE 气体<|>RELATION_NOE 完全<|>RELATION_NOE 吸收<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 出现<|>RELATION_NOE 迟发型<|>RELATION_NOE 气胸<|>RELATION_NOE 并行闭式<|>RELATION_NOE 引流<|>RELATION_NOE ,<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 5d<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 监测<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 适形<|>RELATION_NOE 冷冻<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 疗效<|>RELATION_NOE 肯定<|>RELATION_NOE 、<|>RELATION_NOE 安全<|>RELATION_NOE 可靠<|>RELATION_NOE 、<|>RELATION_NOE 具有<|>RELATION_NOE 推广<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE 微创<|>RELATION_NOE
外<|>RELATION_NOE 周血<|>RELATION_NOE miR-183<|>RELATION_NOE 作为<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 转移<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
探索<|>RELATION_S 外<|>RELATION_NOE 周血<|>RELATION_NOE miR<|>RELATION_NOE －<|>RELATION_NOE 183<|>RELATION_NOE 作为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 转移<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 可能性<|>RELATION_NOE 。<|>RELATION_NOE
化疗<|>RELATION_NOE 联合<|>RELATION_NOE 经<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 氩等<|>RELATION_NOE 离子体<|>RELATION_NOE 凝固<|>RELATION_NOE 治疗<|>RELATION_S 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_S 给予<|>RELATION_NOE 含铂<|>RELATION_NOE 方案<|>RELATION_NOE 全身<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 经<|>RELATION_NOE 支气管镜<|>RELATION_NOE 氩等<|>RELATION_NOE 离子体<|>RELATION_NOE 凝固<|>RELATION_NOE 技术<|>RELATION_NOE 治疗<|>RELATION_NOE 中央型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 支气管镜<|>RELATION_NOE 对<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 中央型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 1－3<|>RELATION_NOE 次<|>RELATION_NOE 氩等<|>RELATION_NOE 离子体<|>RELATION_NOE 凝固<|>RELATION_NOE 联合<|>RELATION_NOE 2－<|>RELATION_NOE 8<|>RELATION_NOE 次<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 从<|>RELATION_NOE 支气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 再<|>RELATION_NOE 通<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 气促<|>RELATION_NOE 好转<|>RELATION_NOE 、<|>RELATION_NOE 体力<|>RELATION_NOE 状况<|>RELATION_NOE 变化<|>RELATION_NOE 等<|>RELATION_NOE 方面<|>RELATION_NOE 进行<|>RELATION_NOE 评价<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE HTB-56<|>RELATION_NOE 及其<|>RELATION_NOE 耐<|>RELATION_NOE DDP<|>RELATION_NOE 细胞株<|>RELATION_NOE HTB-56<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE MTT<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S 不同<|>RELATION_NOE 浓度<|>RELATION_NOE LBP<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 腺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 株<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE OD<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE optical<|>RELATION_NOE density<|>RELATION_NOE ,<|>RELATION_NOE 光密度<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 药物<|>RELATION_NOE 剂量<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 生长<|>RELATION_NOE 抑制<|>RELATION_NOE 效应<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
随着<|>RELATION_NOE 小<|>RELATION_NOE 剂量<|>RELATION_NOE LBP<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 延长<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_B 的<|>RELATION_I 生长<|>RELATION_I 抑制<|>RELATION_I 呈现<|>RELATION_E 浓度<|>RELATION_NOE 与<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 依赖<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 支气管镜<|>RELATION_NOE 肺活检<|>RELATION_NOE 对<|>RELATION_NOE 弥漫性<|>RELATION_NOE 肺间<|>RELATION_NOE 质性<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 及<|>RELATION_NOE 文献<|>RELATION_NOE 复习<|>RELATION_NOE
探讨<|>RELATION_NOE 经<|>RELATION_NOE 支气管镜<|>RELATION_NOE 肺活检<|>RELATION_NOE (<|>RELATION_NOE TBLB<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 弥漫性<|>RELATION_NOE 肺间<|>RELATION_NOE 质性<|>RELATION_NOE 疾病<|>RELATION_NOE (<|>RELATION_NOE DILD<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 71<|>RELATION_NOE 例<|>RELATION_NOE DILD<|>RELATION_NOE 中<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 确诊率<|>RELATION_NOE 达<|>RELATION_NOE 31.0%<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 疾病<|>RELATION_NOE 种类<|>RELATION_NOE 主要<|>RELATION_NOE 有<|>RELATION_NOE 肺结核<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 31.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 普通型<|>RELATION_NOE 间质性<|>RELATION_NOE 肺炎<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 22.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 18.2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 9.1%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺真菌病<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 4.5%<|>RELATION_NOE )<|>RELATION_NOE 结节病<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 4.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺泡<|>RELATION_NOE 微石症<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 4.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 隐原性<|>RELATION_NOE 机化性<|>RELATION_NOE 肺炎<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 4.5%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
临床<|>RELATION_NOE 诊断<|>RELATION_NOE 病例<|>RELATION_NOE 共<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 诊断率<|>RELATION_NOE 达<|>RELATION_NOE 43.7%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 48.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 结缔组织<|>RELATION_NOE 病<|>RELATION_NOE 相关<|>RELATION_NOE 肺疾病<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 弥漫<|>RELATION_NOE 性泛<|>RELATION_NOE 细支气管炎<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 6.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 癌性<|>RELATION_NOE 淋巴管炎<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 6.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 3.2%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
TBLB<|>RELATION_NOE 对<|>RELATION_NOE DILD<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 简便<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 特别<|>RELATION_NOE 是<|>RELATION_NOE 在<|>RELATION_NOE 除外<|>RELATION_NOE 结节病<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 和<|>RELATION_NOE 某些<|>RELATION_NOE 特殊<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 感染<|>RELATION_NOE (<|>RELATION_NOE 结核<|>RELATION_NOE )<|>RELATION_NOE 有<|>RELATION_NOE 重要<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
肺间<|>RELATION_NOE 质性<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 特别<|>RELATION_NOE 是<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 需要<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 必要<|>RELATION_NOE 时<|>RELATION_NOE 可行<|>RELATION_NOE 胸腔镜<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 肺活检<|>RELATION_NOE 或<|>RELATION_NOE 开<|>RELATION_NOE 胸肺<|>RELATION_NOE 活检<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 提高<|>RELATION_S 对<|>RELATION_NOE DILD<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 断层<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 射频<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_S 肺肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
治疗<|>RELATION_NOE 后<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 肿瘤<|>RELATION_NOE 密度<|>RELATION_NOE 降低<|>RELATION_S ,<|>RELATION_NOE 治疗<|>RELATION_NOE 区域<|>RELATION_NOE 治疗<|>RELATION_NOE 无<|>RELATION_NOE 强化<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 代谢<|>RELATION_NOE 监测<|>RELATION_NOE 显示<|>RELATION_NOE 肿瘤<|>RELATION_NOE 代谢<|>RELATION_NOE 消失<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 灭活率<|>RELATION_NOE 为<|>RELATION_NOE 93.5%<|>RELATION_NOE ,<|>RELATION_NOE 远期<|>RELATION_NOE 生存率<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE 。<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 肿瘤<|>RELATION_NOE 密度<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 区域<|>RELATION_NOE 治疗<|>RELATION_NOE 无<|>RELATION_NOE 强化<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 代谢<|>RELATION_NOE 监测<|>RELATION_NOE 显示<|>RELATION_S 肿瘤<|>RELATION_NOE 代谢<|>RELATION_NOE 消失<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 灭活率<|>RELATION_NOE 为<|>RELATION_NOE 93.5%<|>RELATION_NOE ,<|>RELATION_NOE 远期<|>RELATION_NOE 生存率<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE 。<|>RELATION_NOE
RFA<|>RELATION_NOE 治疗<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 创伤<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 效果<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 安全<|>RELATION_NOE 可靠<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 提供<|>RELATION_S 了<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
靶向<|>RELATION_NOE 活化<|>RELATION_NOE T<|>RELATION_NOE 细胞核<|>RELATION_NOE 因子<|>RELATION_NOE 1基因<|>RELATION_NOE 的<|>RELATION_NOE shRNA<|>RELATION_NOE 质粒<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE 构建<|>RELATION_S
筛选<|>RELATION_NOE 与<|>RELATION_NOE 人类<|>RELATION_NOE 其他<|>RELATION_NOE 基因<|>RELATION_NOE 同<|>RELATION_NOE 源性<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 针对<|>RELATION_NOE 目的<|>RELATION_NOE :<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE 。<|>RELATION_NOE
构建<|>RELATION_NOE 的<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 靶向<|>RELATION_NOE NFAT1<|>RELATION_NOE 基因<|>RELATION_NOE shRNA<|>RELATION_NOE 质粒<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE 有助于<|>RELATION_S 肺癌<|>RELATION_NOE 靶向<|>RELATION_NOE 基因治疗<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
为<|>RELATION_NOE 筛选<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 干扰<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 对<|>RELATION_NOE 荷瘤<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 靶<|>RELATION_NOE 向<|>RELATION_NOE RNAi<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE 鉴定<|>RELATION_NOE 了<|>RELATION_NOE 基础<|>RELATION_NOE 。<|>RELATION_NOE
GP<|>RELATION_NOE 方案<|>RELATION_NOE 与<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨单<|>RELATION_NOE 药<|>RELATION_NOE 治疗<|>RELATION_S 老年人<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 治疗<|>RELATION_NOE 3周<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 至少<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 按<|>RELATION_NOE 实体瘤<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 标准<|>RELATION_NOE (<|>RELATION_NOE RECIST<|>RELATION_NOE )<|>RELATION_NOE 评价<|>RELATION_S 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 生存<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE
分析<|>RELATION_S 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液和<|>RELATION_NOE 艾迪<|>RELATION_NOE 注射液<|>RELATION_NOE 改善<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 随机<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液和<|>RELATION_NOE 艾迪<|>RELATION_NOE 注射液<|>RELATION_NOE 在<|>RELATION_NOE 改善<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
60<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 信封法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 2<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 苦<|>RELATION_NOE 参组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 采用<|>RELATION_S 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液加<|>RELATION_NOE 基础<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 艾迪组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 信封法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 2组<|>RELATION_NOE ,<|>RELATION_NOE 苦参组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 采用<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液加<|>RELATION_NOE 基础<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 艾迪组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 采用<|>RELATION_S 艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液加<|>RELATION_NOE 基础<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
艾迪组<|>RELATION_NOE 在<|>RELATION_NOE 改善<|>RELATION_NOE 神疲<|>RELATION_NOE 乏力<|>RELATION_NOE 、<|>RELATION_NOE 气<|>RELATION_NOE 短<|>RELATION_NOE 懒言<|>RELATION_NOE 、<|>RELATION_NOE 烦渴<|>RELATION_NOE 欲<|>RELATION_NOE 饮<|>RELATION_NOE 、<|>RELATION_NOE 腰<|>RELATION_NOE 膝酸软<|>RELATION_NOE 等<|>RELATION_NOE 气虚<|>RELATION_NOE 症状<|>RELATION_NOE 上<|>RELATION_NOE 优于<|>RELATION_S 苦<|>RELATION_NOE 参组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 艾迪组<|>RELATION_NOE 在<|>RELATION_NOE 改善<|>RELATION_NOE 神疲<|>RELATION_NOE 乏力<|>RELATION_NOE 、<|>RELATION_NOE 气<|>RELATION_NOE 短<|>RELATION_NOE 懒言<|>RELATION_NOE 、<|>RELATION_NOE 烦渴<|>RELATION_NOE 欲<|>RELATION_NOE 饮<|>RELATION_NOE 、<|>RELATION_NOE 腰<|>RELATION_NOE 膝酸软<|>RELATION_NOE 等<|>RELATION_NOE 气虚<|>RELATION_NOE 症状<|>RELATION_NOE 上<|>RELATION_NOE 优于<|>RELATION_NOE 苦参组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 苦参组<|>RELATION_NOE 在<|>RELATION_NOE 改善<|>RELATION_NOE 大便<|>RELATION_NOE 干结<|>RELATION_NOE 、<|>RELATION_NOE 五心烦热<|>RELATION_NOE 、<|>RELATION_NOE 午后<|>RELATION_NOE 颧红<|>RELATION_NOE 等<|>RELATION_NOE 阴虚<|>RELATION_NOE 内<|>RELATION_NOE 热<|>RELATION_NOE 症状<|>RELATION_NOE 上<|>RELATION_NOE 优于<|>RELATION_S 艾迪组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液和<|>RELATION_NOE 艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 均<|>RELATION_NOE 具有<|>RELATION_S 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 疗效<|>RELATION_NOE 相当<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 辅助<|>RELATION_NOE 胸外科手术<|>RELATION_NOE 与<|>RELATION_NOE 常规<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_B 效果<|>RELATION_I 比较<|>RELATION_E
比较<|>RELATION_S 电视<|>RELATION_NOE 辅助<|>RELATION_NOE 胸外科手术<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 常规<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 中国<|>RELATION_NOE 医学<|>RELATION_NOE 科学院<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科<|>RELATION_NOE VATS<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 73<|>RELATION_NOE 7例非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 连续<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 同期<|>RELATION_NOE 常规<|>RELATION_NOE 开<|>RELATION_NOE 胸行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 或<|>RELATION_NOE 楔形<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 630<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 手术<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
VATS<|>RELATION_NOE 组<|>RELATION_NOE 506<|>RELATION_NOE 例<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 2.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 0.2%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对于<|>RELATION_NOE 须<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 或<|>RELATION_NOE 肺楔形<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE VATS<|>RELATION_NOE 近期<|>RELATION_NOE 效果<|>RELATION_NOE 与<|>RELATION_NOE 常规<|>RELATION_NOE 开<|>RELATION_NOE 胸术<|>RELATION_NOE 相当<|>RELATION_S 。<|>RELATION_NOE
尼妥<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 联合<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 和<|>RELATION_NOE 卡铂<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 毒副反应<|>RELATION_NOE
治疗<|>RELATION_NOE 前后<|>RELATION_NOE 每周<|>RELATION_NOE 检测<|>RELATION_S 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFR21-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
小<|>RELATION_NOE 分子<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 和<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞二<|>RELATION_NOE 钠互<|>RELATION_NOE 为<|>RELATION_NOE 二三<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
比较<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_S 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE EGFR-TKIs<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞互为<|>RELATION_NOE 二<|>RELATION_NOE 、<|>RELATION_NOE 三<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 是否<|>RELATION_NOE 存在<|>RELATION_NOE 优先<|>RELATION_NOE 顺序<|>RELATION_NOE 。<|>RELATION_NOE
A<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE PFS<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 8.05<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE C15.90-10.20<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 4.20<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI3.33-5.06<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE PFS<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.69<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CU5.00-7.59<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 7.12<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE C15.51-8.38<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.007<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 女性<|>RELATION_NOE 患者<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE PFS<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.56<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE C14.02-7.10<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 6.85<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI4.98-7.58<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.2<|>RELATION_NOE 79<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
A<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 三<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE PFS<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 6.88<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI5.07-8.69<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 7.60<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI5.59-9.12<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.8<|>RELATION_NOE 99<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 三<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE PFS<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.95<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE C12.83-7.05<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 8.49<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE C16.27-10.76<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 患者<|>RELATION_NOE 与<|>RELATION_NOE 女性<|>RELATION_NOE 患者<|>RELATION_NOE 三<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE PFS<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.96<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE C14.02-7.91<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 8.38<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI5.68-11.07<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE :<|>RELATION_NOE 0.1<|>RELATION_NOE 76<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
A<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE MST<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 23.60<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE C119.23-28.00<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 15.58<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI11.85-19.32<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.021<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE MST<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 11.99<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI8.55-15.49<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 23.18<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI19.33-27.02<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 患者<|>RELATION_NOE 与<|>RELATION_NOE 女性<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE MST<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 17.40<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI13.19-21.61<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 22.74<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI18.29-27.19<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 11<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
一线<|>RELATION_NOE 治疗失败<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE EGFR-TKIs<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 失败<|>RELATION_NOE 后<|>RELATION_NOE 选择<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE 三<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE 较<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞二线<|>RELATION_NOE 治疗<|>RELATION_NOE 失败<|>RELATION_NOE 后<|>RELATION_NOE 选择<|>RELATION_NOE EGFR-TKIs<|>RELATION_NOE 治疗<|>RELATION_NOE 更<|>RELATION_B 能<|>RELATION_I 延长<|>RELATION_I 患者<|>RELATION_I 的<|>RELATION_I PFS<|>RELATION_I 和<|>RELATION_I MST<|>RELATION_E ,<|>RELATION_NOE 且<|>RELATION_NOE 更为<|>RELATION_NOE 合理<|>RELATION_NOE 。<|>RELATION_NOE
吸烟<|>RELATION_NOE 为<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 危险因素<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体<|>RELATION_NOE 和<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 2003年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 10月<|>RELATION_NOE 在<|>RELATION_NOE 天津<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 接受<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 65<|>RELATION_NOE 例<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE CXCR4<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE x2<|>RELATION_NOE 检验<|>RELATION_NOE 、<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 探讨<|>RELATION_NOE 二者<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE SCLC<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
CXCR4<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 主要<|>RELATION_NOE 与<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_B 显著<|>RELATION_I 的<|>RELATION_I 相关性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 脑转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 68<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 85<|>RELATION_NOE )<|>RELATION_NOE 无<|>RELATION_NOE 显著<|>RELATION_NOE 相关性<|>RELATION_NOE ;<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 联合<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌脑<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
收集<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 肉瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE P-TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 和<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
气管<|>RELATION_NOE 袖式<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 治疗<|>RELATION_S 中央型<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE
探讨<|>RELATION_S 气管<|>RELATION_NOE 袖式<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 治疗<|>RELATION_NOE 支气管<|>RELATION_NOE 肺<|>RELATION_NOE 癌术<|>RELATION_NOE 后<|>RELATION_NOE 并发症<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 全<|>RELATION_NOE 组<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 病死率<|>RELATION_NOE 为<|>RELATION_NOE 6.3%<|>RELATION_NOE ,<|>RELATION_NOE 无术<|>RELATION_NOE 中<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE ;<|>RELATION_NOE
淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 状况<|>RELATION_NOE 为<|>RELATION_NOE 独立<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 影响<|>RELATION_B 因子<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.006<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
只要<|>RELATION_NOE 严格<|>RELATION_NOE 掌握<|>RELATION_NOE 手术<|>RELATION_NOE 指征<|>RELATION_NOE 、<|>RELATION_NOE 加强<|>RELATION_NOE 麻醉<|>RELATION_NOE 和<|>RELATION_NOE 围手术期<|>RELATION_NOE 管理<|>RELATION_NOE 、<|>RELATION_NOE 在<|>RELATION_NOE 有<|>RELATION_NOE 经验<|>RELATION_NOE 的<|>RELATION_NOE 外科<|>RELATION_NOE 医师<|>RELATION_NOE 操作<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 袖式<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 治疗<|>RELATION_S 中央型<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 术式<|>RELATION_NOE 之一<|>RELATION_NOE 。<|>RELATION_NOE
外源性<|>RELATION_NOE CXCL16<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_B 促进<|>RELATION_E A549<|>RELATION_NOE 、<|>RELATION_NOE 95D<|>RELATION_NOE 和<|>RELATION_NOE H292<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 增殖<|>RELATION_NOE 活力<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE CXCL16<|>RELATION_NOE 中和抗体<|>RELATION_NOE 可以<|>RELATION_NOE 有效<|>RELATION_NOE 阻断<|>RELATION_NOE CXCL16<|>RELATION_NOE 蛋白<|>RELATION_NOE 对<|>RELATION_NOE 3种<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 的<|>RELATION_NOE 刺激<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE 外源性<|>RELATION_NOE CXCL16<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_NOE 促进<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE 95D<|>RELATION_NOE 和<|>RELATION_NOE H292<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 增殖<|>RELATION_NOE 活力<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE CXCL16<|>RELATION_NOE 中和抗体<|>RELATION_NOE 可以<|>RELATION_NOE 有效<|>RELATION_B 阻断<|>RELATION_E CXCL16<|>RELATION_NOE 蛋白<|>RELATION_NOE 对<|>RELATION_NOE 3种<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 的<|>RELATION_NOE 刺激<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 结直肠癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
矢车菊素<|>RELATION_NOE -3<|>RELATION_NOE -<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 苷<|>RELATION_NOE 在<|>RELATION_NOE 体<|>RELATION_NOE 内外<|>RELATION_NOE 抑制<|>RELATION_NOE 肺癌<|>RELATION_NOE 生长<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
探讨<|>RELATION_NOE 矢车菊素<|>RELATION_NOE -3<|>RELATION_NOE -<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 苷<|>RELATION_NOE (<|>RELATION_NOE C3G<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 体<|>RELATION_NOE 内外<|>RELATION_NOE 肺癌<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 下<|>RELATION_NOE 观察<|>RELATION_S 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE 变化<|>RELATION_NOE ;<|>RELATION_NOE
Westernblotting<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE X<|>RELATION_NOE 连锁<|>RELATION_NOE 凋亡<|>RELATION_NOE 抑制蛋白<|>RELATION_NOE (<|>RELATION_NOE XIAP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Smac<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
建立<|>RELATION_NOE 起<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 皮下<|>RELATION_NOE 移植<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE C3G<|>RELATION_NOE 对<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 皮下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ;<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Ki-67<|>RELATION_NOE 、<|>RELATION_NOE XIAP<|>RELATION_NOE 和<|>RELATION_NOE Smac<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE C3G<|>RELATION_NOE 可<|>RELATION_NOE 呈<|>RELATION_B 浓度<|>RELATION_I 依赖性<|>RELATION_I 抑制<|>RELATION_E 体外<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 明显<|>RELATION_NOE 诱导细胞凋亡<|>RELATION_NOE ;<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE C3G<|>RELATION_NOE 可<|>RELATION_NOE 呈<|>RELATION_NOE 浓度<|>RELATION_NOE 依赖性<|>RELATION_NOE 抑制<|>RELATION_NOE 体外<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 明显<|>RELATION_B 诱导<|>RELATION_E 细胞凋亡<|>RELATION_NOE ;<|>RELATION_NOE
肝细胞核<|>RELATION_NOE 因子<|>RELATION_NOE 3<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 人类<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 意义<|>RELATION_E
探讨<|>RELATION_NOE 肝细胞核<|>RELATION_NOE 因<|>RELATION_NOE 子3<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE HNF-3<|>RELATION_NOE β<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 情况<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
分别<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 和<|>RELATION_NOE RT-PCR<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 50<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE HNF-3<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
初步<|>RELATION_NOE 认定<|>RELATION_NOE HNF-3<|>RELATION_NOE β<|>RELATION_NOE 对<|>RELATION_NOE 人类<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 形成<|>RELATION_NOE 起<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
洛铂<|>RELATION_NOE 诱导<|>RELATION_S 肺腺癌<|>RELATION_NOE HTB-56<|>RELATION_NOE 表达<|>RELATION_NOE ERCC1<|>RELATION_NOE 及其<|>RELATION_NOE 意义<|>RELATION_NOE 初<|>RELATION_NOE 探<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 肺活检<|>RELATION_NOE 在<|>RELATION_NOE 弥漫性<|>RELATION_NOE 实质性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_E
选择<|>RELATION_NOE 2000年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2008年<|>RELATION_NOE 12月<|>RELATION_NOE 北京<|>RELATION_NOE 协和<|>RELATION_NOE 医院<|>RELATION_NOE 行<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 肺活检<|>RELATION_NOE 、<|>RELATION_NOE 胸部<|>RELATION_NOE cT<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 双<|>RELATION_NOE 肺<|>RELATION_NOE 弥漫<|>RELATION_NOE 病变<|>RELATION_NOE 且<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 完整<|>RELATION_NOE 的<|>RELATION_NOE 弥漫性<|>RELATION_NOE 实质性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 248<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
248<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 经皮<|>RELATION_NOE 肺活检<|>RELATION_NOE 获得<|>RELATION_NOE 病理<|>RELATION_NOE 形态学<|>RELATION_NOE 诊断<|>RELATION_NOE 130<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 52.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_NOE 疾病<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 肺部<|>RELATION_NOE 感染性疾病<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 35.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 25.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 闭塞型<|>RELATION_NOE 细支气管炎<|>RELATION_NOE 伴机化性<|>RELATION_NOE 肺炎<|>RELATION_NOE /<|>RELATION_NOE 机化性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE BOOP<|>RELATION_NOE /<|>RELATION_NOE OP<|>RELATION_NOE )<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 22.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血管炎<|>RELATION_NOE 8例<|>RELATION_NOE (<|>RELATION_NOE 6.2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 病变<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 4.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 结节病<|>RELATION_NOE 3例<|>RELATION_NOE (<|>RELATION_NOE 2.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 弥漫性<|>RELATION_NOE 肺泡<|>RELATION_NOE 损伤<|>RELATION_NOE 和<|>RELATION_NOE 肺淀粉<|>RELATION_NOE 样变<|>RELATION_NOE 各<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 1.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 肺泡<|>RELATION_NOE 蛋白<|>RELATION_NOE 沉积症<|>RELATION_NOE (<|>RELATION_NOE PAP<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 0.7%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 皮肺<|>RELATION_NOE 活检<|>RELATION_NOE 未<|>RELATION_NOE 确定<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 118<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 37<|>RELATION_NOE 例<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 开胸<|>RELATION_NOE 或<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺活检<|>RELATION_NOE ,<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE 确定<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 非特异性<|>RELATION_NOE 间质性肺炎<|>RELATION_NOE (<|>RELATION_NOE NSIP<|>RELATION_NOE )<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 寻常型<|>RELATION_NOE 间质性肺炎<|>RELATION_NOE (<|>RELATION_NOE UIP<|>RELATION_NOE )<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 感染<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 间质性肺炎<|>RELATION_NOE (<|>RELATION_NOE LIP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺血管炎<|>RELATION_NOE 和<|>RELATION_NOE 过敏性肺炎<|>RELATION_NOE (<|>RELATION_NOE HP<|>RELATION_NOE )<|>RELATION_NOE 各<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 结节病<|>RELATION_NOE 、<|>RELATION_NOE ABPA<|>RELATION_NOE 、<|>RELATION_NOE 肺透明<|>RELATION_NOE 样<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 病<|>RELATION_NOE 、<|>RELATION_NOE 肺尘埃<|>RELATION_NOE 沉积症<|>RELATION_NOE 、<|>RELATION_NOE Castleman<|>RELATION_NOE 病<|>RELATION_NOE 及<|>RELATION_NOE 淋巴<|>RELATION_NOE 增殖性<|>RELATION_NOE 疾病<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
约<|>RELATION_NOE 半数<|>RELATION_NOE 弥漫性<|>RELATION_NOE 实质性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 肺活检<|>RELATION_NOE 能够<|>RELATION_NOE 获得<|>RELATION_B 特定<|>RELATION_I 的<|>RELATION_I 病理<|>RELATION_I 形态学<|>RELATION_I 诊断<|>RELATION_E ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 双<|>RELATION_NOE 肺<|>RELATION_NOE 弥漫<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 感染<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病例<|>RELATION_NOE 确<|>RELATION_NOE 诊阳<|>RELATION_NOE 性率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 对于<|>RELATION_NOE 特发性<|>RELATION_NOE 间质性<|>RELATION_NOE 肺炎<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 有限<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 结合<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 实际<|>RELATION_NOE 情况<|>RELATION_NOE 选择<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE 约<|>RELATION_NOE 半数<|>RELATION_NOE 弥漫性<|>RELATION_NOE 实质性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 肺活检<|>RELATION_NOE 能够<|>RELATION_NOE 获得<|>RELATION_NOE 特定<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 形态学<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 双<|>RELATION_NOE 肺<|>RELATION_NOE 弥漫<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 感染<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病例<|>RELATION_NOE 确<|>RELATION_NOE 诊阳<|>RELATION_NOE 性率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 对于<|>RELATION_NOE 特发性<|>RELATION_NOE 间质性<|>RELATION_NOE 肺炎<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_I 有限<|>RELATION_E ,<|>RELATION_NOE 应<|>RELATION_NOE 结合<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 实际<|>RELATION_NOE 情况<|>RELATION_NOE 选择<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 有效<|>RELATION_NOE 检测<|>RELATION_NOE 出<|>RELATION_NOE 区域<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_S 靶区<|>RELATION_NOE 遗漏<|>RELATION_NOE 的<|>RELATION_NOE 可能<|>RELATION_NOE ;<|>RELATION_NOE
经过<|>RELATION_NOE 后台<|>RELATION_NOE 处理<|>RELATION_NOE 得到<|>RELATION_NOE 呼吸<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE 相<|>RELATION_NOE 匹配<|>RELATION_NOE 的<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 呼吸<|>RELATION_NOE 周期<|>RELATION_NOE 内<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 时相的<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 融合<|>RELATION_NOE 图像<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 门控<|>RELATION_NOE 显像<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 时相<|>RELATION_NOE 不<|>RELATION_NOE 同时<|>RELATION_NOE 相间<|>RELATION_NOE SUV<|>RELATION_NOE 以<|>RELATION_NOE 时相1<|>RELATION_NOE 即<|>RELATION_NOE 吸气<|>RELATION_NOE 末<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 时相4<|>RELATION_NOE (<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 吸气<|>RELATION_NOE 初<|>RELATION_NOE )<|>RELATION_NOE 最低<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 锥形束<|>RELATION_NOE CT<|>RELATION_NOE 图像<|>RELATION_NOE 引导<|>RELATION_NOE 技术<|>RELATION_NOE 分析<|>RELATION_S 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 摆位<|>RELATION_NOE 误差<|>RELATION_NOE 及其<|>RELATION_NOE 对<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 影响<|>RELATION_NOE
546<|>RELATION_NOE 例<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 放疗<|>RELATION_B 意义<|>RELATION_I 分析<|>RELATION_E
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 546<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 初诊<|>RELATION_NOE 时<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 器官<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 数目<|>RELATION_NOE 等<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 肿瘤分期<|>RELATION_NOE 对<|>RELATION_NOE 远处<|>RELATION_NOE 转移率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
546<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 骨<|>RELATION_NOE 、<|>RELATION_NOE 脑<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 、<|>RELATION_NOE 肝<|>RELATION_NOE 、<|>RELATION_NOE 。<|>RELATION_NOE
肾上腺<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 淋巴结<|>RELATION_NOE 、<|>RELATION_NOE 皮下<|>RELATION_NOE 、<|>RELATION_NOE 其他<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 294<|>RELATION_NOE 、<|>RELATION_NOE 167<|>RELATION_NOE 、<|>RELATION_NOE 137<|>RELATION_NOE 、<|>RELATION_NOE 79<|>RELATION_NOE 、<|>RELATION_NOE 66<|>RELATION_NOE 、<|>RELATION_NOE 37<|>RELATION_NOE 、<|>RELATION_NOE 35<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
单器官<|>RELATION_NOE 转移<|>RELATION_NOE 37<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 骨<|>RELATION_NOE 、<|>RELATION_NOE 脑<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 、<|>RELATION_NOE 肝<|>RELATION_NOE 、<|>RELATION_NOE 肾上腺<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 淋巴结<|>RELATION_NOE 、<|>RELATION_NOE 皮下<|>RELATION_NOE 、<|>RELATION_NOE 其他<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 分别<|>RELATION_NOE 占<|>RELATION_NOE 37.7%<|>RELATION_NOE 、<|>RELATION_NOE 19.8%<|>RELATION_NOE 、<|>RELATION_NOE 16.9%<|>RELATION_NOE 、<|>RELATION_NOE 7.4%<|>RELATION_NOE 、<|>RELATION_NOE 7.4%<|>RELATION_NOE 、<|>RELATION_NOE 4.5%<|>RELATION_NOE 、<|>RELATION_NOE 5.5%<|>RELATION_NOE 、<|>RELATION_NOE 0.8%<|>RELATION_NOE 。<|>RELATION_NOE
Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 初诊<|>RELATION_NOE 时<|>RELATION_NOE 远处<|>RELATION_NOE 转移率<|>RELATION_NOE 由<|>RELATION_B 高<|>RELATION_I 到<|>RELATION_I 低<|>RELATION_I 依次<|>RELATION_I 为<|>RELATION_E 骨<|>RELATION_NOE 、<|>RELATION_NOE 脑<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 、<|>RELATION_NOE 肝<|>RELATION_NOE 、<|>RELATION_NOE 肾上腺<|>RELATION_NOE 和<|>RELATION_NOE 其他<|>RELATION_NOE 器官<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 单<|>RELATION_NOE 器官<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE ;<|>RELATION_NOE
探讨<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE (<|>RELATION_NOE RILT<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 和<|>RELATION_NOE 剂量学<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S ,<|>RELATION_NOE 以<|>RELATION_NOE 寻找<|>RELATION_NOE RILT<|>RELATION_NOE 的<|>RELATION_NOE 可能<|>RELATION_NOE 风险<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
152<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 立体<|>RELATION_NOE 定向<|>RELATION_NOE 放疗<|>RELATION_NOE 预后<|>RELATION_B 分析<|>RELATION_E
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 到<|>RELATION_NOE 脑转移<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 卡氏<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 切除<|>RELATION_NOE 、<|>RELATION_NOE GPA<|>RELATION_NOE 分级<|>RELATION_NOE 、<|>RELATION_NOE RPA<|>RELATION_NOE 分级<|>RELATION_NOE 、<|>RELATION_NOE 颅外<|>RELATION_NOE 病变<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_S 生存<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE x<|>RELATION_NOE 。<|>RELATION_NOE
变形<|>RELATION_NOE 配准<|>RELATION_NOE 与<|>RELATION_NOE 经验<|>RELATION_NOE 计算<|>RELATION_NOE 剂量<|>RELATION_NOE 累加法<|>RELATION_NOE 用于<|>RELATION_S 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 累加<|>RELATION_NOE 剂量<|>RELATION_NOE 计算<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
应用<|>RELATION_NOE 变形<|>RELATION_NOE 配<|>RELATION_NOE 准<|>RELATION_NOE 功能<|>RELATION_NOE 评价<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 中<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 危及器官<|>RELATION_NOE 的<|>RELATION_NOE 累加<|>RELATION_NOE 剂量<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 经验<|>RELATION_NOE 计算<|>RELATION_NOE 剂量<|>RELATION_NOE 累加法<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
变形<|>RELATION_NOE 配<|>RELATION_NOE 准法<|>RELATION_NOE 可以<|>RELATION_NOE 准确<|>RELATION_B 评价<|>RELATION_E 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 多次<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 中<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 危及器官<|>RELATION_NOE 的<|>RELATION_NOE 累加<|>RELATION_NOE 剂量<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 靶区<|>RELATION_NOE 变化<|>RELATION_NOE 不<|>RELATION_NOE 大<|>RELATION_NOE 并且<|>RELATION_NOE 采用<|>RELATION_NOE 相同<|>RELATION_NOE 的<|>RELATION_NOE 计划<|>RELATION_NOE 方式<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 经验<|>RELATION_NOE 计算<|>RELATION_NOE 剂量<|>RELATION_NOE 累加法<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 粗略<|>RELATION_B 评价<|>RELATION_E 肺和<|>RELATION_NOE 心脏<|>RELATION_NOE 等<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 危及器官<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 。<|>RELATION_NOE
异常<|>RELATION_NOE 高氡<|>RELATION_NOE 温泉<|>RELATION_NOE 周围<|>RELATION_NOE 居民<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE 肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 和<|>RELATION_NOE miRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
探讨<|>RELATION_NOE 四川省<|>RELATION_NOE 若尔盖县<|>RELATION_NOE 降扎乡<|>RELATION_NOE 异常<|>RELATION_NOE 高氡<|>RELATION_NOE 温泉<|>RELATION_NOE 对<|>RELATION_NOE 周围<|>RELATION_NOE 居民<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE 肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 和<|>RELATION_NOE miRNA<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
获取<|>RELATION_NOE 高氡<|>RELATION_NOE 温泉<|>RELATION_NOE 及<|>RELATION_NOE 对照<|>RELATION_NOE 地区<|>RELATION_NOE 居民<|>RELATION_NOE 外周<|>RELATION_NOE 血样<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 实时<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_NOE 肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE p53<|>RELATION_NOE 、<|>RELATION_NOE k-ras<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE 相关<|>RELATION_NOE miRNA<|>RELATION_NOE (<|>RELATION_NOE 1et-7a<|>RELATION_NOE 、<|>RELATION_NOE miR-34a<|>RELATION_NOE /<|>RELATION_NOE b<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S 靶<|>RELATION_NOE 蛋白<|>RELATION_NOE p53<|>RELATION_NOE 和<|>RELATION_NOE k-ra8<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 检测<|>RELATION_NOE p53<|>RELATION_NOE 和<|>RELATION_NOE k-ras<|>RELATION_NOE 基因<|>RELATION_NOE 以及<|>RELATION_NOE miRNA<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 椎测<|>RELATION_S 高氡<|>RELATION_NOE 温泉<|>RELATION_NOE 周围<|>RELATION_NOE 居民<|>RELATION_NOE 受到<|>RELATION_NOE 了<|>RELATION_NOE 辐射损伤<|>RELATION_NOE 。<|>RELATION_NOE
动态<|>RELATION_NOE 增强<|>RELATION_NOE MRI<|>RELATION_NOE 、<|>RELATION_NOE 扩散<|>RELATION_NOE 加权<|>RELATION_NOE 成像<|>RELATION_NOE 及<|>RELATION_NOE 光学<|>RELATION_NOE 成像<|>RELATION_NOE 联合<|>RELATION_B 监测<|>RELATION_E 抗<|>RELATION_NOE 血管<|>RELATION_NOE 生成<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 动物实验<|>RELATION_NOE 研究<|>RELATION_NOE
利用<|>RELATION_NOE 多模态成像<|>RELATION_NOE 技术<|>RELATION_NOE 即<|>RELATION_NOE 小<|>RELATION_NOE 动物<|>RELATION_NOE 活体<|>RELATION_NOE 光学<|>RELATION_NOE 成像<|>RELATION_NOE 、<|>RELATION_NOE 动态<|>RELATION_NOE 增强<|>RELATION_NOE MRI<|>RELATION_NOE (<|>RELATION_NOE DCE-MRI<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE DWI<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_S 裸鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 皮下<|>RELATION_NOE 移植<|>RELATION_NOE 瘤经<|>RELATION_NOE 抗<|>RELATION_NOE 血管<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 解剖<|>RELATION_NOE 形态<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 功能<|>RELATION_NOE 及<|>RELATION_NOE 细胞<|>RELATION_NOE 分子<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
治疗<|>RELATION_NOE 7d<|>RELATION_NOE 后<|>RELATION_NOE 利用<|>RELATION_NOE 小<|>RELATION_NOE 动物<|>RELATION_NOE 光学<|>RELATION_NOE 活体<|>RELATION_NOE 成像<|>RELATION_NOE 系统<|>RELATION_NOE 、<|>RELATION_NOE DCE-MRI<|>RELATION_NOE 、<|>RELATION_NOE DWI<|>RELATION_NOE 评价<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 、<|>RELATION_NOE 荧光<|>RELATION_NOE 信号<|>RELATION_NOE 强度值<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 功能<|>RELATION_NOE 参数<|>RELATION_NOE [<|>RELATION_NOE 对比<|>RELATION_NOE 剂<|>RELATION_NOE 容积<|>RELATION_NOE 转移<|>RELATION_NOE 常量<|>RELATION_NOE (<|>RELATION_NOE Ktrans<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 速度<|>RELATION_NOE 常量<|>RELATION_NOE (<|>RELATION_NOE Kep<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 外细胞外间隙<|>RELATION_NOE 容积<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE Ve<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 对比剂<|>RELATION_NOE 浓度<|>RELATION_NOE 下峰<|>RELATION_NOE 面积<|>RELATION_NOE (<|>RELATION_NOE iAUC<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 以及<|>RELATION_NOE ADC<|>RELATION_NOE 值<|>RELATION_NOE ;<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 接种<|>RELATION_NOE 第7<|>RELATION_NOE 天<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 皮<|>RELATION_NOE 下<|>RELATION_NOE 均<|>RELATION_NOE 出现<|>RELATION_NOE 荧光团<|>RELATION_NOE ,<|>RELATION_NOE 随着<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 延长<|>RELATION_NOE 荧光团<|>RELATION_NOE 范围<|>RELATION_NOE 逐渐<|>RELATION_NOE 增大<|>RELATION_NOE ,<|>RELATION_NOE 强度<|>RELATION_NOE 也<|>RELATION_NOE 逐渐<|>RELATION_NOE 增加<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检查<|>RELATION_NOE 结果<|>RELATION_NOE 示<|>RELATION_NOE :<|>RELATION_NOE 治疗组<|>RELATION_NOE MVD<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 11.9<|>RELATION_NOE ±<|>RELATION_NOE 4.8<|>RELATION_NOE )<|>RELATION_NOE 条/高倍<|>RELATION_NOE 视野<|>RELATION_NOE ]<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 19.2<|>RELATION_NOE ±<|>RELATION_NOE 4.3<|>RELATION_NOE )<|>RELATION_NOE 条/高倍<|>RELATION_NOE 视野<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.7<|>RELATION_NOE 74<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE VEGF<|>RELATION_NOE 表达<|>RELATION_NOE 较<|>RELATION_NOE
利用<|>RELATION_NOE 多模态成像<|>RELATION_NOE 技术<|>RELATION_NOE 能够<|>RELATION_NOE 提供<|>RELATION_S 肿瘤<|>RELATION_NOE 抗<|>RELATION_NOE 血管<|>RELATION_NOE 生成<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 解剖<|>RELATION_NOE 形态<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 功能<|>RELATION_NOE 及<|>RELATION_NOE 细胞<|>RELATION_NOE 分子<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 动态<|>RELATION_NOE 信息<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_NOE 及时<|>RELATION_NOE 评估<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE CT<|>RELATION_NOE 动态<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 定量<|>RELATION_NOE 参数<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_B 特点<|>RELATION_E 及<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE
研究<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE MS<|>RELATION_NOE CT<|>RELATION_NOE 动态<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 定量<|>RELATION_NOE 参数<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_B 特点<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 评价<|>RELATION_NOE 标准<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 找<|>RELATION_NOE 出<|>RELATION_NOE 能<|>RELATION_NOE 及时<|>RELATION_NOE 、<|>RELATION_NOE 客观<|>RELATION_NOE 评价<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗效果<|>RELATION_NOE 的<|>RELATION_NOE 参数<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 动态<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 灌<|>RELATION_NOE 注值<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 一致<|>RELATION_S ;<|>RELATION_NOE
用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE sP<|>RELATION_NOE 法检<|>RELATION_NOE On<|>RELATION_NOE ,<|>RELATION_NOE 0<|>RELATION_NOE 144<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 肺良<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 和<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE HAb18G<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 图像<|>RELATION_NOE 分析<|>RELATION_NOE 软件<|>RELATION_NOE 对<|>RELATION_NOE HAb18G<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 单位<|>RELATION_NOE (<|>RELATION_NOE PU<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_B 定量<|>RELATION_I 测试<|>RELATION_E 。<|>RELATION_NOE
HAb18G<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 主要<|>RELATION_NOE 定位<|>RELATION_B 于<|>RELATION_E 肺癌<|>RELATION_NOE 细胞膜<|>RELATION_NOE 或<|>RELATION_NOE 胞质<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 肺良性<|>RELATION_NOE 病变<|>RELATION_NOE 及<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 几乎<|>RELATION_NOE 不<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
HAb18G<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE PU<|>RELATION_NOE 值<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 非<|>RELATION_NOE 肺癌<|>RELATION_NOE 肺组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
HAb18G<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE TNMI<|>RELATION_NOE 期<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE －<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 中<|>RELATION_NOE 依次<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌伴<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 原发灶<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 原发灶<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
蛋白<|>RELATION_NOE Pu<|>RELATION_NOE 值<|>RELATION_NOE 在<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE ><|>RELATION_NOE 5cm<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 大于<|>RELATION_S 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 5em<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE :<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 患者<|>RELATION_NOE 高于<|>RELATION_NOE 女性<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 大体<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 原发灶<|>RELATION_NOE 和<|>RELATION_NOE 相应<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE 均<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 表明<|>RELATION_NOE HAb18G<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.007<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
HAb18G<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E .<|>RELATION_NOE
不同<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 分级<|>RELATION_NOE 评分<|>RELATION_NOE 系统<|>RELATION_NOE 在<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 预后<|>RELATION_NOE 评估<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
新<|>RELATION_NOE 分类<|>RELATION_NOE 分级<|>RELATION_NOE 评分<|>RELATION_NOE 系统<|>RELATION_NOE 与<|>RELATION_NOE WHO<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 系统<|>RELATION_NOE 存在<|>RELATION_B 相关性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE WHO<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_NOE 与<|>RELATION_NOE 总<|>RELATION_NOE 生存期<|>RELATION_NOE 存在<|>RELATION_NOE 负<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 级别<|>RELATION_NOE 或<|>RELATION_NOE 评分<|>RELATION_NOE 越<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 生存期<|>RELATION_NOE 越<|>RELATION_NOE 短<|>RELATION_NOE 。<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 分级<|>RELATION_NOE 评分<|>RELATION_NOE 系统<|>RELATION_NOE 与<|>RELATION_NOE WHO<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 系统<|>RELATION_NOE 存在<|>RELATION_NOE 相关性<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE WHO<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_NOE 与<|>RELATION_NOE 总<|>RELATION_NOE 生存期<|>RELATION_NOE 存在<|>RELATION_B 负<|>RELATION_I 相关性<|>RELATION_E ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 级别<|>RELATION_NOE 或<|>RELATION_NOE 评分<|>RELATION_NOE 越<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 生存期<|>RELATION_NOE 越<|>RELATION_NOE 短<|>RELATION_NOE 。<|>RELATION_NOE
另外<|>RELATION_NOE 与<|>RELATION_NOE WHO<|>RELATION_NOE 分级<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.8<|>RELATION_NOE 55<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 分级<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 73<|>RELATION_NOE )<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 评分<|>RELATION_NOE 系统<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE 具有<|>RELATION_B 明确<|>RELATION_I 的<|>RELATION_I 正<|>RELATION_I 相关性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 11<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 评分<|>RELATION_NOE 越<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 几<|>RELATION_NOE 率<|>RELATION_NOE 越<|>RELATION_NOE 大<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 方差分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE WHO<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE :<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 脉管<|>RELATION_NOE 侵犯<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.021<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_S 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 肺转移瘤<|>RELATION_NOE
探讨<|>RELATION_S 肺转移<|>RELATION_NOE 瘤<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 适应证<|>RELATION_NOE 和<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
无<|>RELATION_NOE 住院<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸功<|>RELATION_NOE 能<|>RELATION_NOE 不<|>RELATION_NOE 全<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 漏气<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 积极<|>RELATION_NOE 治疗<|>RELATION_NOE 予以<|>RELATION_NOE 治愈<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中骨桥<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE OPN<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 测定<|>RELATION_S 102<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE OPN<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 选取<|>RELATION_NOE 同期<|>RELATION_NOE 本院<|>RELATION_NOE 门诊<|>RELATION_NOE 健康<|>RELATION_NOE 体检<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 正常人<|>RELATION_NOE 血清<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE OPN<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE OPN<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 良性<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ;<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 131<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 不同<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 化疗组<|>RELATION_NOE 86<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 第三<|>RELATION_NOE 代<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 加<|>RELATION_NOE 铂类<|>RELATION_NOE 方案<|>RELATION_NOE 化疗2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 以上<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 化疗组<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE 因<|>RELATION_NOE 患者<|>RELATION_NOE 意愿<|>RELATION_NOE 未<|>RELATION_NOE 行<|>RELATION_NOE 任何<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
鳞癌<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 60<|>RELATION_NOE 、<|>RELATION_NOE 54<|>RELATION_NOE 、<|>RELATION_NOE 34<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 手术<|>RELATION_NOE 预后<|>RELATION_NOE 相对<|>RELATION_B 较<|>RELATION_I 好<|>RELATION_E ;<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 在<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 定性<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
探讨<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 在<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 定性<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 在<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 患者<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 行<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 明确<|>RELATION_NOE 是否<|>RELATION_NOE 有<|>RELATION_NOE 气胸<|>RELATION_NOE 、<|>RELATION_NOE 出血<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
螺旋<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 对<|>RELATION_NOE 明确<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 性质<|>RELATION_NOE 具有<|>RELATION_B 较<|>RELATION_I 高<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 实用<|>RELATION_I 价值<|>RELATION_E ,<|>RELATION_NOE 是<|>RELATION_NOE 对于<|>RELATION_NOE 依靠<|>RELATION_NOE 临床<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 检查<|>RELATION_NOE 及<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 等<|>RELATION_NOE 检查<|>RELATION_NOE 未能<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 协助<|>RELATION_NOE 诊断<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
恩度<|>RELATION_NOE 联合<|>RELATION_NOE TP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
P53<|>RELATION_NOE 和<|>RELATION_NOE Wip1<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_S 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_NOE 指标<|>RELATION_NOE 和<|>RELATION_NOE 基因治疗<|>RELATION_NOE 的<|>RELATION_NOE 可能<|>RELATION_NOE 靶点<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 前列腺素<|>RELATION_NOE E<|>RELATION_NOE 合成酶<|>RELATION_NOE 和<|>RELATION_NOE 环<|>RELATION_NOE 氧化酶<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 生物学<|>RELATION_NOE 意义<|>RELATION_NOE
采用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE mPGES-1<|>RELATION_NOE 、<|>RELATION_NOE COX-2mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE S-P<|>RELATION_NOE 法<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE mPGES-1<|>RELATION_NOE 和<|>RELATION_NOE COX-2mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
mPGES-1<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 为<|>RELATION_NOE 66.7%<|>RELATION_NOE (<|>RELATION_NOE 40<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 相应<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 10.0%<|>RELATION_NOE (<|>RELATION_NOE 6<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 20.38<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
COX-2<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 为<|>RELATION_NOE 73.3%<|>RELATION_NOE (<|>RELATION_NOE 44<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 在<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 13.3%<|>RELATION_NOE (<|>RELATION_NOE 8/<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 21.99<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE mPGES-1<|>RELATION_NOE 和<|>RELATION_NOE COX-2<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 等<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE mPGES-1<|>RELATION_NOE 和<|>RELATION_NOE COX-2<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 等<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
mPGES-1<|>RELATION_NOE 和<|>RELATION_NOE COX-2<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 着<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 开发<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 提供<|>RELATION_B 一定<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 依据<|>RELATION_E 。<|>RELATION_NOE
老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞体<|>RELATION_NOE 外<|>RELATION_NOE 化疗<|>RELATION_NOE 药敏<|>RELATION_NOE 试验<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
选取<|>RELATION_NOE 52<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 体外<|>RELATION_NOE 药敏<|>RELATION_NOE 试验<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 13<|>RELATION_NOE 种<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE CDDP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 卡铂<|>RELATION_NOE (<|>RELATION_NOE CBP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE (<|>RELATION_NOE LOHP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 紫杉醇<|>RELATION_NOE (<|>RELATION_NOE PTX<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE (<|>RELATION_NOE CTX<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 异环磷酰胺<|>RELATION_NOE (<|>RELATION_NOE ICTX<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 吡喃阿<|>RELATION_NOE 霉素<|>RELATION_NOE (<|>RELATION_NOE THP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE (<|>RELATION_NOE VP<|>RELATION_NOE .<|>RELATION_NOE
老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 可以<|>RELATION_B 应用<|>RELATION_E 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 代替<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 进行<|>RELATION_NOE 体外<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 敏感<|>RELATION_NOE 试验<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
探讨<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE (<|>RELATION_NOE video-assisted<|>RELATION_NOE mini<|>RELATION_NOE thoracotomy<|>RELATION_NOE ,<|>RELATION_NOE VAMT<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S 。<|>RELATION_NOE
手术<|>RELATION_NOE 切口<|>RELATION_NOE 包括<|>RELATION_NOE 腋中线<|>RELATION_NOE 第<|>RELATION_NOE 6-8<|>RELATION_NOE 肋问<|>RELATION_NOE 一个<|>RELATION_NOE 1.5cm<|>RELATION_NOE 长<|>RELATION_NOE 的<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 光源<|>RELATION_NOE 切口<|>RELATION_NOE ,<|>RELATION_NOE 插入<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 电视<|>RELATION_NOE 显示器<|>RELATION_NOE 观察<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 粘连<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 与否<|>RELATION_NOE 以及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 广泛<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 病变<|>RELATION_NOE 情况<|>RELATION_NOE 在<|>RELATION_NOE 腋前<|>RELATION_NOE 到<|>RELATION_NOE 腋中线<|>RELATION_NOE 第4<|>RELATION_NOE 或<|>RELATION_NOE 第5<|>RELATION_NOE 肋<|>RELATION_NOE 间作<|>RELATION_NOE 一个<|>RELATION_NOE 5-7cm<|>RELATION_NOE 的<|>RELATION_NOE 胸壁<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 拉钩<|>RELATION_NOE 牵<|>RELATION_NOE 开<|>RELATION_NOE 胸壁<|>RELATION_NOE 组织<|>RELATION_NOE 或者<|>RELATION_NOE 放置<|>RELATION_NOE 一<|>RELATION_NOE 小<|>RELATION_NOE 撑开器<|>RELATION_NOE ,<|>RELATION_NOE 屏视<|>RELATION_NOE 与<|>RELATION_NOE 直视<|>RELATION_NOE 相<|>RELATION_NOE 结合<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 微创<|>RELATION_NOE 操作<|>RELATION_NOE 器械<|>RELATION_NOE 或<|>RELATION_NOE 微创<|>RELATION_NOE 器械<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 手术<|>RELATION_NOE 器械<|>RELATION_NOE 结合<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 处理<|>RELATION_S 血管<|>RELATION_NOE 和<|>RELATION_NOE 支气管<|>RELATION_NOE ,<|>RELATION_NOE 完成<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 。<|>RELATION_NOE
游离<|>RELATION_NOE 肺叶<|>RELATION_NOE 的<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 将<|>RELATION_NOE 肺叶<|>RELATION_NOE 淋巴结<|>RELATION_NOE 随<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺叶<|>RELATION_NOE 一并<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 后<|>RELATION_NOE 清扫<|>RELATION_NOE 肺门<|>RELATION_NOE 和<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 。<|>RELATION_NOE
VAMT<|>RELATION_NOE 组<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 完成<|>RELATION_NOE 顺利<|>RELATION_NOE ,<|>RELATION_NOE 手术时间<|>RELATION_NOE 较<|>RELATION_NOE 常规<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 长<|>RELATION_NOE 大约<|>RELATION_NOE 30min<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 术中<|>RELATION_NOE 出血<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 输血<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE ,<|>RELATION_NOE 住院时间<|>RELATION_NOE 缩短<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE 。<|>RELATION_NOE
VAMT<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE VATS<|>RELATION_NOE 技术<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 技术<|>RELATION_NOE 相<|>RELATION_NOE 结合<|>RELATION_NOE ,<|>RELATION_NOE 既<|>RELATION_NOE 发挥<|>RELATION_NOE 了<|>RELATION_NOE 微创<|>RELATION_NOE 外科<|>RELATION_NOE 的<|>RELATION_NOE 优越性<|>RELATION_NOE ,<|>RELATION_NOE 又<|>RELATION_NOE 达到<|>RELATION_NOE 了<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 可靠<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 清扫<|>RELATION_NOE 淋巴结<|>RELATION_NOE 符合<|>RELATION_NOE 肿瘤<|>RELATION_NOE 手术<|>RELATION_NOE 原则<|>RELATION_NOE 。<|>RELATION_NOE
淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE CT<|>RELATION_NOE 影像<|>RELATION_NOE 表现<|>RELATION_B 为<|>RELATION_E 癌性<|>RELATION_NOE 淋巴管炎<|>RELATION_NOE ,<|>RELATION_NOE 肺门<|>RELATION_NOE 及<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE VEGF-C<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 无<|>RELATION_NOE 转移组<|>RELATION_NOE (<|>RELATION_NOE 90%<|>RELATION_NOE VS31.8<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 存在<|>RELATION_S VEGF-C<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 后者<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 淋巴管生成<|>RELATION_NOE 促进<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
61<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 气管<|>RELATION_NOE 袖状<|>RELATION_NOE 切除<|>RELATION_NOE 端<|>RELATION_NOE -<|>RELATION_NOE 端<|>RELATION_NOE 吻合<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 隆嵴<|>RELATION_NOE 切除<|>RELATION_NOE 重建<|>RELATION_NOE 术6<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 半隆嵴<|>RELATION_NOE 切除<|>RELATION_NOE 重建<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 颈段<|>RELATION_NOE 气管肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 垂直<|>RELATION_NOE 半<|>RELATION_NOE 喉切<|>RELATION_NOE 除<|>RELATION_NOE +<|>RELATION_NOE 胸锁<|>RELATION_NOE 乳突<|>RELATION_NOE 肌瓣<|>RELATION_NOE 喉室<|>RELATION_NOE 气管<|>RELATION_NOE 缺<|>RELATION_NOE 损<|>RELATION_NOE 重建<|>RELATION_NOE 术2<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 气管肿瘤<|>RELATION_NOE 局部<|>RELATION_NOE 切除<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 切除<|>RELATION_NOE 造口术<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 颈段<|>RELATION_NOE 气管<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 甲状腺<|>RELATION_NOE 部分<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 食管<|>RELATION_NOE 肌层<|>RELATION_NOE 切除<|>RELATION_NOE 术1<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 颈段<|>RELATION_NOE 气管<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 全<|>RELATION_NOE 喉切<|>RELATION_NOE 除<|>RELATION_NOE +<|>RELATION_NOE 单纯<|>RELATION_NOE 气管<|>RELATION_NOE 切除<|>RELATION_NOE 造口术<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 隆突搔<|>RELATION_NOE 刮术<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
61<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 出现<|>RELATION_NOE 并发症<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 发生<|>RELATION_NOE 气管<|>RELATION_NOE 纵隔<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘2<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 因<|>RELATION_NOE 喉返神经<|>RELATION_NOE 损伤<|>RELATION_NOE 出现<|>RELATION_NOE 声音<|>RELATION_NOE 嘶哑<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 感染<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
原发性<|>RELATION_NOE 气管肿瘤<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 不<|>RELATION_B 典型<|>RELATION_E ,<|>RELATION_NOE 易<|>RELATION_NOE 误诊<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 预后<|>RELATION_NOE 不<|>RELATION_NOE 佳<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE KPS<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 前血红<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 方法<|>RELATION_NOE 和<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 是<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 总<|>RELATION_NOE 生存<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 专项<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 影响<|>RELATION_I 因素<|>RELATION_E ,<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗组<|>RELATION_NOE 的<|>RELATION_NOE 总<|>RELATION_NOE 生存率<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 专项<|>RELATION_NOE 生存率<|>RELATION_NOE 较<|>RELATION_NOE 常规<|>RELATION_NOE 放疗组<|>RELATION_NOE 显著<|>RELATION_NOE 提高<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.7<|>RELATION_NOE 62<|>RELATION_NOE 和<|>RELATION_NOE 0.6<|>RELATION_NOE 80<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
四<|>RELATION_NOE 种<|>RELATION_NOE 显像剂<|>RELATION_NOE 在<|>RELATION_NOE NCI-H358<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 模型<|>RELATION_NOE 中<|>RELATION_NOE 显像<|>RELATION_NOE 效果<|>RELATION_NOE 和<|>RELATION_NOE 生物<|>RELATION_NOE 分布<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_S
比较<|>RELATION_NOE ^<|>RELATION_NOE 18F-<|>RELATION_NOE 脱氧葡萄糖<|>RELATION_NOE (<|>RELATION_NOE ^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-<|>RELATION_NOE 甲<|>RELATION_NOE 氧荩<|>RELATION_NOE 异丁基<|>RELATION_NOE 异腈<|>RELATION_NOE (<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-MIBI<|>RELATION_NOE )<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-<|>RELATION_NOE 氮<|>RELATION_NOE -<|>RELATION_NOE 二<|>RELATION_NOE (<|>RELATION_NOE N-2<|>RELATION_NOE 基<|>RELATION_NOE N-2<|>RELATION_NOE 氧基二<|>RELATION_NOE 硫代<|>RELATION_NOE 氧基甲酸盐<|>RELATION_NOE )<|>RELATION_NOE [<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-N<|>RELATION_NOE (<|>RELATION_NOE NOET<|>RELATION_NOE )<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-RGD-4CK<|>RELATION_NOE 娃像剂<|>RELATION_NOE 任<|>RELATION_NOE NCI-H358<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 摄取<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 4种<|>RELATION_NOE 硅像剂<|>RELATION_NOE 对<|>RELATION_NOE 低<|>RELATION_NOE 代谢<|>RELATION_NOE 肺胆瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
建立<|>RELATION_NOE 人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE NCIH358<|>RELATION_NOE 细胞<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 模型<|>RELATION_NOE 20<|>RELATION_NOE 只<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 4<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 经尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE ^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 、<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-MIBI<|>RELATION_NOE 、<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-N<|>RELATION_NOE (<|>RELATION_NOE NOErr<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 和<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-RGD-4CK<|>RELATION_NOE 移像剂<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 显像<|>RELATION_NOE 和<|>RELATION_NOE 生物<|>RELATION_NOE 分布<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
SPECT<|>RELATION_NOE 全身<|>RELATION_NOE 平面<|>RELATION_NOE 显像<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE ^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 组<|>RELATION_NOE 倚瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 胸部<|>RELATION_NOE 放射性核素<|>RELATION_NOE 明妙<|>RELATION_NOE 浓<|>RELATION_NOE 聚<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 部分<|>RELATION_NOE 重叠<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 敛<|>RELATION_NOE 肿瘤<|>RELATION_NOE 轮廓<|>RELATION_NOE 显示<|>RELATION_NOE 不<|>RELATION_NOE 清晰<|>RELATION_NOE ;<|>RELATION_NOE
^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-N<|>RELATION_NOE (<|>RELATION_NOE NOET<|>RELATION_NOE )<|>RELATION_NOE 2组<|>RELATION_NOE 和<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-RGD-4CK<|>RELATION_NOE 组<|>RELATION_NOE 荷瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 右<|>RELATION_NOE 前肢<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 硅影<|>RELATION_NOE 均<|>RELATION_NOE 清晰<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-N<|>RELATION_NOE (<|>RELATION_NOE NOET<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-RGD-4CK<|>RELATION_NOE 组<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 模型<|>RELATION_NOE 显像<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 勺<|>RELATION_NOE 肌肉<|>RELATION_NOE 放射性<|>RELATION_NOE 比值<|>RELATION_NOE (<|>RELATION_NOE T<|>RELATION_NOE /<|>RELATION_NOE NT<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.85<|>RELATION_NOE ±<|>RELATION_NOE 0.07<|>RELATION_NOE 、<|>RELATION_NOE 0.99<|>RELATION_NOE ±<|>RELATION_NOE 0.16<|>RELATION_NOE 、<|>RELATION_NOE 2.78<|>RELATION_NOE ±<|>RELATION_NOE 2.26<|>RELATION_NOE 和<|>RELATION_NOE 3.40<|>RELATION_NOE ±<|>RELATION_NOE 0.27<|>RELATION_NOE ,<|>RELATION_NOE 生物<|>RELATION_NOE 分布<|>RELATION_NOE 的<|>RELATION_NOE T<|>RELATION_NOE /<|>RELATION_NOE NT<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.32<|>RELATION_NOE ±<|>RELATION_NOE 0.14<|>RELATION_NOE 、<|>RELATION_NOE 0.44<|>RELATION_NOE ±<|>RELATION_NOE 0.08<|>RELATION_NOE 、<|>RELATION_NOE 2.59<|>RELATION_NOE ±<|>RELATION_NOE 0.53<|>RELATION_NOE 和<|>RELATION_NOE 3.43<|>RELATION_NOE ±<|>RELATION_NOE 0.36<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-RGD-4CK<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE rf<|>RELATION_NOE /<|>RELATION_NOE NT<|>RELATION_NOE 值<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 其他<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-RGD-4CK<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE NCI-H358<|>RELATION_NOE 细胞移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 湿<|>RELATION_NOE 像<|>RELATION_NOE 效果<|>RELATION_NOE 好<|>RELATION_B 于<|>RELATION_E ^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 诊断<|>RELATION_NOE 低<|>RELATION_NOE 代谢<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-RGD-4CK<|>RELATION_NOE 妊像町<|>RELATION_NOE 能<|>RELATION_NOE 比<|>RELATION_NOE
H1N1<|>RELATION_NOE 亚型<|>RELATION_NOE 流感病毒<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 复制<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 初步<|>RELATION_B 研究<|>RELATION_E
探讨<|>RELATION_NOE 不同<|>RELATION_NOE 宿主<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE H1N1<|>RELATION_NOE 亚型<|>RELATION_NOE 流感病毒<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 复制<|>RELATION_B 情况<|>RELATION_E 。<|>RELATION_NOE
用<|>RELATION_NOE 分离<|>RELATION_NOE 自<|>RELATION_NOE 人<|>RELATION_NOE 、<|>RELATION_NOE 禽<|>RELATION_NOE 、<|>RELATION_NOE 猪三<|>RELATION_NOE 种<|>RELATION_NOE 宿主<|>RELATION_NOE 的<|>RELATION_NOE 7株<|>RELATION_NOE H1N1<|>RELATION_NOE 甲型<|>RELATION_NOE 流感病毒<|>RELATION_NOE 分别<|>RELATION_NOE 接种<|>RELATION_S A549<|>RELATION_NOE 和<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 病毒<|>RELATION_NOE 感染<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 不同<|>RELATION_NOE 时段<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_NOE ;<|>RELATION_NOE
三<|>RELATION_NOE 种<|>RELATION_NOE 宿主<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE H1N1<|>RELATION_NOE 亚型<|>RELATION_NOE 流感病毒<|>RELATION_NOE 感染<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE CPE<|>RELATION_NOE 十分<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 36h<|>RELATION_NOE 病毒滴度<|>RELATION_NOE 达到<|>RELATION_NOE 最高<|>RELATION_NOE 值<|>RELATION_NOE ;<|>RELATION_NOE
而<|>RELATION_NOE 感染<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 从<|>RELATION_NOE 24h-120h<|>RELATION_NOE CPE<|>RELATION_NOE 都<|>RELATION_NOE 不<|>RELATION_NOE 是<|>RELATION_NOE 很<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 所有<|>RELATION_NOE 病毒<|>RELATION_NOE 的<|>RELATION_NOE 病毒滴度<|>RELATION_NOE 都<|>RELATION_NOE 很<|>RELATION_NOE 低.<|>RELATION_NOE
而<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 均<|>RELATION_NOE 含有<|>RELATION_NOE SA<|>RELATION_NOE a-2<|>RELATION_NOE ,<|>RELATION_NOE 3Gal<|>RELATION_NOE 及<|>RELATION_NOE SA<|>RELATION_NOE a-2<|>RELATION_NOE ,<|>RELATION_NOE 6Gal<|>RELATION_NOE 受体<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 糖<|>RELATION_NOE 受体<|>RELATION_NOE 含量<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 宿主<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE H1N1<|>RELATION_NOE 亚型<|>RELATION_NOE 流感病毒<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 都<|>RELATION_NOE 易感<|>RELATION_S 并<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 增殖<|>RELATION_NOE 复制<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 对<|>RELATION_NOE 具有<|>RELATION_NOE 相似<|>RELATION_NOE 受体<|>RELATION_NOE 特性<|>RELATION_NOE 、<|>RELATION_NOE 上皮<|>RELATION_NOE 组织<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 不<|>RELATION_NOE 不同<|>RELATION_NOE 宿主<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE H1N1<|>RELATION_NOE 亚型<|>RELATION_NOE 流感病毒<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 都<|>RELATION_NOE 易感<|>RELATION_NOE 并<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 增殖<|>RELATION_NOE 复制<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 对<|>RELATION_NOE 具有<|>RELATION_NOE 相似<|>RELATION_NOE 受体<|>RELATION_NOE 特性<|>RELATION_NOE 、<|>RELATION_NOE 上皮<|>RELATION_NOE 组织<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 不易感<|>RELATION_S ,<|>RELATION_NOE 提示<|>RELATION_NOE 支持<|>RELATION_NOE 流感病毒<|>RELATION_NOE 有效<|>RELATION_NOE 感染<|>RELATION_NOE 、<|>RELATION_NOE 复制<|>RELATION_NOE 存在<|>RELATION_NOE 宿主<|>RELATION_NOE 内<|>RELATION_NOE 的<|>RELATION_NOE 调节<|>RELATION_NOE 机制<|>RELATION_NOE .<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE p53<|>RELATION_NOE 腺病毒<|>RELATION_NOE 治疗<|>RELATION_S 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE
探讨<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE p53<|>RELATION_NOE 腺病毒<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 并发<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 疗效<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 近期<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 71.7%<|>RELATION_NOE (<|>RELATION_NOE 33<|>RELATION_NOE /<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 局部<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 胸痛<|>RELATION_NOE 和<|>RELATION_NOE 咳嗽<|>RELATION_NOE 加重<|>RELATION_NOE 明显<|>RELATION_NOE 小于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 4.3%<|>RELATION_NOE 比<|>RELATION_NOE 20.O<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 4.3%<|>RELATION_NOE 比<|>RELATION_NOE 22.O<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE p53<|>RELATION_NOE 腺病毒<|>RELATION_NOE 治疗<|>RELATION_S 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 比<|>RELATION_NOE A<|>RELATION_NOE 群链<|>RELATION_NOE 球菌<|>RELATION_NOE 低.<|>RELATION_NOE
对<|>RELATION_NOE 分离<|>RELATION_NOE 于<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 尘肺<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 下<|>RELATION_NOE 呼吸道感染<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 108<|>RELATION_NOE 株<|>RELATION_NOE IRPA<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE Kerby-Bauer<|>RELATION_NOE 法<|>RELATION_NOE 进行<|>RELATION_S 耐药性<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
煤工尘肺<|>RELATION_NOE 肺癌<|>RELATION_NOE 并发<|>RELATION_NOE 下<|>RELATION_NOE 呼吸道感染<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 痰液<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 分离<|>RELATION_NOE 出<|>RELATION_NOE 106<|>RELATION_NOE 株<|>RELATION_NOE 铜绿<|>RELATION_NOE 假<|>RELATION_NOE 单胞菌<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE ,<|>RELATION_NOE IRPA<|>RELATION_NOE 32<|>RELATION_NOE 株<|>RELATION_NOE ,<|>RELATION_NOE 检出率<|>RELATION_NOE 为<|>RELATION_NOE 30.2%<|>RELATION_NOE .<|>RELATION_NOE
共同<|>RELATION_NOE 急性<|>RELATION_NOE 淋巴<|>RELATION_NOE 母细胞性<|>RELATION_NOE 白血病<|>RELATION_NOE 抗原<|>RELATION_NOE 及<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE -1<|>RELATION_NOE 在<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
评价<|>RELATION_NOE 共同<|>RELATION_NOE 急性<|>RELATION_NOE 淋巴<|>RELATION_NOE 母细胞性<|>RELATION_NOE 白血病<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE CD10<|>RELATION_NOE 、<|>RELATION_NOE CD13<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE TTF-1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_B 及<|>RELATION_I 敏感性<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 以上<|>RELATION_NOE 标记物<|>RELATION_NOE 在<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 97<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 腺癌<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 进行<|>RELATION_S CD10<|>RELATION_NOE 、<|>RELATION_NOE CD13<|>RELATION_NOE 及<|>RELATION_NOE TTF-1<|>RELATION_NOE 检测<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 及<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE ,<|>RELATION_NOE CD10<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 53.5%<|>RELATION_NOE 、<|>RELATION_NOE 20.4%<|>RELATION_NOE 、<|>RELATION_NOE 25.0%<|>RELATION_NOE 、<|>RELATION_NOE 0<|>RELATION_NOE ;<|>RELATION_NOE
CD10<|>RELATION_NOE 、<|>RELATION_NOE CD13<|>RELATION_NOE 和<|>RELATION_NOE TTF-1<|>RELATION_NOE 在<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_B 一定<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
本文<|>RELATION_NOE 回顾性<|>RELATION_NOE 总结<|>RELATION_NOE 中国<|>RELATION_NOE 医学<|>RELATION_NOE 科学院<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 89<|>RELATION_NOE 例<|>RELATION_NOE 肺硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE (<|>RELATION_NOE PSH<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 经验<|>RELATION_NOE 。<|>RELATION_NOE
dsRNA<|>RELATION_NOE 激活<|>RELATION_NOE PTEN<|>RELATION_NOE 基因<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生物<|>RELATION_NOE 活性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 双链<|>RELATION_NOE RNA<|>RELATION_NOE 分子<|>RELATION_NOE (<|>RELATION_NOE dsRNA<|>RELATION_NOE )<|>RELATION_NOE 促进<|>RELATION_S 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE PTEN<|>RELATION_NOE 基因表达<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生物<|>RELATION_NOE 活性<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE 针对<|>RELATION_NOE PTEN<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 区域<|>RELATION_NOE 非<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 序列<|>RELATION_NOE 的<|>RELATION_NOE dsRNA<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 转染<|>RELATION_NOE 入<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE H292<|>RELATION_NOE ,<|>RELATION_NOE 绘制<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 转染<|>RELATION_NOE 后<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 变化<|>RELATION_NOE 通过<|>RELATION_NOE Transwell<|>RELATION_NOE 小<|>RELATION_NOE 室法<|>RELATION_NOE 检测<|>RELATION_S 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 通过<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 利用<|>RELATION_NOE 针对<|>RELATION_NOE PTEN<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 区域<|>RELATION_NOE 非<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 序列<|>RELATION_NOE 的<|>RELATION_NOE dsRNA<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 转染<|>RELATION_NOE 入<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE H292<|>RELATION_NOE ,<|>RELATION_NOE 绘制<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 转染<|>RELATION_NOE 后<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 变化<|>RELATION_NOE 通过<|>RELATION_NOE Transwell<|>RELATION_NOE 小<|>RELATION_NOE 室法<|>RELATION_NOE 检测<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 通过<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 细胞周期<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 对照组<|>RELATION_NOE 比<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE 细胞<|>RELATION_NOE 停留<|>RELATION_NOE 于<|>RELATION_NOE G1<|>RELATION_NOE 期<|>RELATION_NOE 。<|>RELATION_NOE
总结<|>RELATION_S 肺类癌<|>RELATION_NOE 的<|>RELATION_NOE 外科<|>RELATION_NOE 治疗<|>RELATION_NOE 经验<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2000年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 10月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 肺类癌<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 对<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 进行<|>RELATION_NOE 单及<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 预后<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
1例<|>RELATION_NOE 左下<|>RELATION_NOE 肺切除者<|>RELATION_NOE 术后<|>RELATION_NOE 2周<|>RELATION_NOE 发生<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘急<|>RELATION_NOE 诊行<|>RELATION_NOE 支气管<|>RELATION_NOE 残端<|>RELATION_NOE 修补<|>RELATION_NOE 加<|>RELATION_NOE 网膜<|>RELATION_NOE 填塞术<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 2周<|>RELATION_NOE 痊愈<|>RELATION_NOE 出<|>RELATION_NOE 院<|>RELATION_NOE ;<|>RELATION_NOE
1例<|>RELATION_NOE 右上<|>RELATION_NOE 叶<|>RELATION_NOE 支气管<|>RELATION_NOE 袖状<|>RELATION_NOE 切除者<|>RELATION_NOE 术后<|>RELATION_NOE 0.5<|>RELATION_NOE 年<|>RELATION_NOE 吻合口<|>RELATION_NOE 瘢痕<|>RELATION_NOE 增生<|>RELATION_NOE 致<|>RELATION_NOE 右余<|>RELATION_NOE 肺不张<|>RELATION_NOE 行右<|>RELATION_NOE 余<|>RELATION_NOE 肺切除术<|>RELATION_NOE 。<|>RELATION_NOE
42<|>RELATION_NOE 例<|>RELATION_NOE 典型<|>RELATION_NOE 类癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 8.3%<|>RELATION_NOE )<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE N1<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 97.8%<|>RELATION_NOE ,<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 94.7%<|>RELATION_NOE ;<|>RELATION_NOE
20<|>RELATION_NOE 例<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 类癌<|>RELATION_NOE 中<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 37.5%<|>RELATION_NOE )<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE N1<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE N2<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 84.4%<|>RELATION_NOE 、<|>RELATION_NOE 58.8%<|>RELATION_NOE 。<|>RELATION_NOE
典型<|>RELATION_NOE 类癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 类癌<|>RELATION_NOE 患者<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.00<|>RELATION_NOE 47<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 典型<|>RELATION_NOE 类癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 类癌<|>RELATION_NOE 患者<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.00<|>RELATION_NOE 47<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.00<|>RELATION_NOE 48<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_S 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 因素<|>RELATION_NOE 是<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 23<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
原发性<|>RELATION_NOE 肺类癌<|>RELATION_NOE 预后<|>RELATION_NOE 好<|>RELATION_B 于<|>RELATION_E 其他<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_NOE 主要<|>RELATION_NOE 依靠<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 根治性<|>RELATION_NOE 手术<|>RELATION_NOE 是<|>RELATION_NOE 主要<|>RELATION_NOE 治疗<|>RELATION_NOE 手段<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 中央型<|>RELATION_NOE 肺类癌<|>RELATION_NOE 应<|>RELATION_NOE 首选<|>RELATION_NOE 袖状切<|>RELATION_NOE 除术<|>RELATION_NOE 。<|>RELATION_NOE
影响<|>RELATION_NOE 其<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 因素<|>RELATION_NOE 是<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 23<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 针吸活<|>RELATION_NOE 检术<|>RELATION_NOE 在<|>RELATION_NOE 肺内<|>RELATION_NOE 病变<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2009年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 9月<|>RELATION_NOE ,<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE 常规<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 等<|>RELATION_NOE 检查<|>RELATION_NOE 未能<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 影像学<|>RELATION_NOE 可疑<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 明确<|>RELATION_NOE 肺内<|>RELATION_NOE 邻近<|>RELATION_NOE 大气道<|>RELATION_NOE 病变<|>RELATION_NOE 诊断<|>RELATION_NOE 接受<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 。<|>RELATION_NOE
33<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 检查<|>RELATION_NOE 后<|>RELATION_NOE 明确<|>RELATION_NOE 肺部<|>RELATION_NOE 恶性病<|>RELATION_NOE 变<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ;<|>RELATION_NOE
4例<|>RELATION_NOE 患者<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 细胞<|>RELATION_NOE 及<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 检查<|>RELATION_NOE 无<|>RELATION_NOE 明确<|>RELATION_NOE 恶性<|>RELATION_NOE 证据<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3例经<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 或<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 鳞癌<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 经<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 肺内炎<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 。<|>RELATION_NOE
本组<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 在<|>RELATION_NOE 大气道<|>RELATION_NOE 旁<|>RELATION_NOE 肺<|>RELATION_NOE 实质<|>RELATION_NOE 内<|>RELATION_NOE 占<|>RELATION_NOE 位<|>RELATION_NOE 中<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 和<|>RELATION_NOE 准确性<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 90.2%<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 0.0%<|>RELATION_NOE 和<|>RELATION_NOE 90.9%<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 预测<|>RELATION_NOE 价值<|>RELATION_NOE 和<|>RELATION_NOE 阴性<|>RELATION_NOE 预测<|>RELATION_NOE 价值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE 和<|>RELATION_NOE 25%<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 肺单纯性<|>RELATION_NOE 磨玻璃<|>RELATION_NOE 样病灶<|>RELATION_NOE
收集<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺单纯性<|>RELATION_NOE 磨玻璃<|>RELATION_NOE 样病灶<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
单发性<|>RELATION_NOE 病灶<|>RELATION_NOE 患者<|>RELATION_NOE 37<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 楔形<|>RELATION_NOE 切除<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺段<|>RELATION_NOE 切除<|>RELATION_NOE 9例<|>RELATION_NOE ;<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 非<|>RELATION_NOE 典型<|>RELATION_NOE 腺瘤<|>RELATION_NOE 样<|>RELATION_NOE 增生<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 直径<|>RELATION_NOE (<|>RELATION_NOE 15<|>RELATION_NOE ±<|>RELATION_NOE 5<|>RELATION_NOE )<|>RELATION_NOE mm<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 典型<|>RELATION_NOE 腺瘤<|>RELATION_NOE 样<|>RELATION_NOE 增生<|>RELATION_NOE 病灶<|>RELATION_NOE 直径<|>RELATION_NOE (<|>RELATION_NOE 8±4<|>RELATION_NOE )<|>RELATION_NOE mm<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE -6<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 生存<|>RELATION_NOE ,<|>RELATION_NOE 接受<|>RELATION_NOE 根治<|>RELATION_NOE 性切除<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_S 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
单纯性<|>RELATION_NOE 磨玻璃样<|>RELATION_NOE 病灶<|>RELATION_NOE 中<|>RELATION_NOE 多数<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞<|>RELATION_NOE 癌病灶<|>RELATION_NOE 直径<|>RELATION_NOE 大于<|>RELATION_S 非<|>RELATION_NOE 典型<|>RELATION_NOE 腺瘤<|>RELATION_NOE 样<|>RELATION_NOE 增生<|>RELATION_NOE 病灶<|>RELATION_NOE 。<|>RELATION_NOE
开展<|>RELATION_NOE 优质<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 对<|>RELATION_NOE 护士长<|>RELATION_NOE 管理<|>RELATION_NOE 效能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
比较<|>RELATION_S 开展<|>RELATION_NOE 优质<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 前后<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 不良<|>RELATION_NOE 事件<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 患者<|>RELATION_NOE 满意度<|>RELATION_NOE 等<|>RELATION_NOE 护理<|>RELATION_NOE 管理<|>RELATION_NOE 指标<|>RELATION_NOE 变化<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 了解<|>RELATION_NOE 优质<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 对<|>RELATION_NOE 护士长<|>RELATION_NOE 管理<|>RELATION_NOE 效能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
开展<|>RELATION_NOE 优质<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 中<|>RELATION_NOE 特<|>RELATION_NOE 一级<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 静脉<|>RELATION_NOE 治疗<|>RELATION_NOE 管理<|>RELATION_NOE 、<|>RELATION_NOE 基础<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 病室<|>RELATION_NOE 管理<|>RELATION_NOE 、<|>RELATION_NOE 安全<|>RELATION_NOE 管理<|>RELATION_NOE 得分<|>RELATION_NOE 分别<|>RELATION_NOE 由<|>RELATION_NOE (<|>RELATION_NOE 93.08<|>RELATION_NOE ±<|>RELATION_NOE 1.03<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 94.48<|>RELATION_NOE ±<|>RELATION_NOE 0.82<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 95.46<|>RELATION_NOE ±<|>RELATION_NOE 0.50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 95.30<|>RELATION_NOE ±<|>RELATION_NOE 0.68<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 95.70<|>RELATION_NOE ±<|>RELATION_NOE 0.63<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 上升<|>RELATION_NOE 至<|>RELATION_NOE (<|>RELATION_NOE 95.88<|>RELATION_NOE ±<|>RELATION_NOE 0.88<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 96.48<|>RELATION_NOE ±<|>RELATION_NOE 0.76<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 97.29<|>RELATION_NOE ±<|>RELATION_NOE 0.59<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 97.09<|>RELATION_NOE ±<|>RELATION_NOE 0.59<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 97.42<|>RELATION_NOE ±<|>RELATION_NOE 0.57<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE -12.928<|>RELATION_NOE ,<|>RELATION_NOE -8.697<|>RELATION_NOE ,<|>RELATION_NOE -19.018<|>RELATION_NOE ,<|>RELATION_NOE -14.898<|>RELATION_NOE ,<|>RELATION_NOE -15.910<|>RELATION_NOE ;<|>RELATION_NOE
建立<|>RELATION_NOE 以<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 中心<|>RELATION_NOE 提供<|>RELATION_NOE 优质<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 工作<|>RELATION_NOE 模式<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 提高<|>RELATION_E 护理<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 患者<|>RELATION_NOE 满意度<|>RELATION_NOE ,<|>RELATION_NOE 打造<|>RELATION_NOE 活力<|>RELATION_NOE 团队<|>RELATION_NOE ,<|>RELATION_NOE 促进<|>RELATION_NOE 护士长<|>RELATION_NOE 管理<|>RELATION_NOE 效能<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 1996年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 81<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 肺<|>RELATION_NOE 隐球菌病<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 及<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE
术后<|>RELATION_NOE 抗<|>RELATION_NOE 真菌<|>RELATION_NOE 治疗<|>RELATION_NOE 63<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 77.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE :<|>RELATION_NOE 氟康唑<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 伊曲康唑<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 两性<|>RELATION_NOE 霉素<|>RELATION_NOE B6<|>RELATION_NOE 例次<|>RELATION_NOE ,<|>RELATION_NOE 氟胞嘧啶<|>RELATION_NOE 4例次<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 42.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 出现<|>RELATION_NOE 药物治疗<|>RELATION_NOE 并发症<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 复发<|>RELATION_NOE 。<|>RELATION_NOE
肺<|>RELATION_NOE 隐球菌病<|>RELATION_NOE 无<|>RELATION_NOE 特征性<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 酷似<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 能够<|>RELATION_NOE 有效<|>RELATION_B 诊治<|>RELATION_E 肺<|>RELATION_NOE 隐球菌病<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 应<|>RELATION_NOE 联合<|>RELATION_NOE 抗真菌<|>RELATION_NOE 药物治疗<|>RELATION_NOE 。<|>RELATION_NOE
特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 患者<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 和<|>RELATION_NOE 细胞外基质<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
研究<|>RELATION_NOE 特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE (<|>RELATION_NOE IPF<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肺组织<|>RELATION_NOE 窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 和<|>RELATION_NOE 细胞外基质<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
6例<|>RELATION_NOE IPF<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺组织<|>RELATION_NOE 标本<|>RELATION_NOE 来自<|>RELATION_NOE 2005年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2008年<|>RELATION_NOE 12月<|>RELATION_NOE 南京<|>RELATION_NOE 大学<|>RELATION_NOE 医学院<|>RELATION_NOE 附属<|>RELATION_NOE 鼓楼<|>RELATION_NOE 医院<|>RELATION_NOE 呼吸科<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 开<|>RELATION_NOE 胸肺<|>RELATION_NOE 活检<|>RELATION_NOE 组织<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 符合<|>RELATION_S 普通型<|>RELATION_NOE 间质性<|>RELATION_NOE 肺炎<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 、<|>RELATION_NOE Westernblot<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 肺组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 肺鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 突变<|>RELATION_NOE 及<|>RELATION_NOE EGFR<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2004年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 6月<|>RELATION_NOE 北京大学<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 胸部肿瘤<|>RELATION_NOE 内科<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 79<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 或<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 接受<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其中<|>RELATION_NOE 67<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 组织<|>RELATION_NOE 或<|>RELATION_NOE 血浆<|>RELATION_NOE EGFR19<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE EGFR<|>RELATION_NOE .<|>RELATION_NOE
Cox<|>RELATION_NOE 回归<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 67<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存期<|>RELATION_NOE 、<|>RELATION_NOE 总<|>RELATION_NOE 生存期<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
建立<|>RELATION_NOE 云南省<|>RELATION_NOE 宣威<|>RELATION_NOE 地区<|>RELATION_NOE 女性<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞系<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 该<|>RELATION_NOE 地区<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 机制<|>RELATION_NOE 提供<|>RELATION_NOE 体外<|>RELATION_NOE 实验<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
新<|>RELATION_NOE 建立<|>RELATION_NOE 的<|>RELATION_NOE XLA-07<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 稳定<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 连续<|>RELATION_NOE 长期<|>RELATION_NOE 传代<|>RELATION_NOE ,<|>RELATION_NOE 形态<|>RELATION_NOE 呈<|>RELATION_NOE 梭形<|>RELATION_NOE 与<|>RELATION_NOE 多边形<|>RELATION_NOE ,<|>RELATION_NOE 异型性<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 电镜<|>RELATION_NOE 下<|>RELATION_NOE 可见<|>RELATION_NOE 微腺腔<|>RELATION_NOE 与<|>RELATION_NOE 排列<|>RELATION_NOE 紊乱<|>RELATION_NOE 的<|>RELATION_NOE 微丝<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE 染色<|>RELATION_NOE 显示<|>RELATION_NOE 细胞角蛋白7<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 广谱<|>RELATION_NOE 角蛋白<|>RELATION_NOE 和<|>RELATION_NOE 上皮细胞膜<|>RELATION_NOE 抗原<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE CD59<|>RELATION_NOE 与<|>RELATION_NOE CD13<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE 呈<|>RELATION_NOE “<|>RELATION_NOE S<|>RELATION_NOE ”<|>RELATION_NOE 形<|>RELATION_NOE ,<|>RELATION_NOE 群体<|>RELATION_NOE 倍增<|>RELATION_NOE 时间<|>RELATION_NOE 约<|>RELATION_NOE 46.7h<|>RELATION_NOE ,<|>RELATION_NOE 细胞分裂<|>RELATION_NOE 指数<|>RELATION_NOE 为<|>RELATION_NOE 1.5%<|>RELATION_NOE ,<|>RELATION_NOE 软<|>RELATION_NOE 琼脂<|>RELATION_NOE 克隆<|>RELATION_NOE 形成率<|>RELATION_NOE 为<|>RELATION_NOE 8.3%<|>RELATION_NOE ,<|>RELATION_NOE 细胞周期<|>RELATION_NOE G0<|>RELATION_NOE /<|>RELATION_NOE G1<|>RELATION_NOE 期<|>RELATION_NOE 占<|>RELATION_NOE 76.9%<|>RELATION_NOE ,<|>RELATION_NOE G2<|>RELATION_NOE /<|>RELATION_NOE M<|>RELATION_NOE 期<|>RELATION_NOE 占<|>RELATION_NOE 8.0%<|>RELATION_NOE ,<|>RELATION_NOE S<|>RELATION_NOE 期<|>RELATION_NOE 占<|>RELATION_NOE 15.1%<|>RELATION_NOE ,<|>RELATION_NOE 染色体<|>RELATION_NOE 主干系<|>RELATION_NOE 为<|>RELATION_NOE 亚<|>RELATION_NOE 三倍体<|>RELATION_NOE 核型<|>RELATION_NOE ,<|>RELATION_NOE 众数<|>RELATION_NOE 为<|>RELATION_NOE 66<|>RELATION_NOE 条<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 数<|>RELATION_NOE 64<|>RELATION_NOE 条<|>RELATION_NOE ,<|>RELATION_NOE 符合<|>RELATION_NOE 恶性腺<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 特征<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE α<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 耐<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
收集<|>RELATION_NOE 本院<|>RELATION_NOE 185<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 提取<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 荧光<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 扩增<|>RELATION_S EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第18<|>RELATION_NOE 、<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE
185<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 33.5%<|>RELATION_NOE )<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 5例<|>RELATION_NOE 、<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
共<|>RELATION_NOE 见<|>RELATION_NOE 突变<|>RELATION_NOE 类型<|>RELATION_NOE 16<|>RELATION_NOE 种<|>RELATION_NOE ,<|>RELATION_NOE 热点<|>RELATION_NOE 突变<|>RELATION_NOE 类型<|>RELATION_NOE 为<|>RELATION_NOE 19<|>RELATION_NOE 外显子<|>RELATION_NOE DelL747<|>RELATION_NOE →<|>RELATION_NOE P752<|>RELATION_NOE (<|>RELATION_NOE P753S<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 8.1%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE DelE746<|>RELATION_NOE →<|>RELATION_NOE A750<|>RELATION_NOE (<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 45.1%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE L858R<|>RELATION_NOE (<|>RELATION_NOE 构成<|>RELATION_NOE 比<|>RELATION_NOE 22.6%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
华南<|>RELATION_NOE 地区<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 以<|>RELATION_B 19<|>RELATION_I 、<|>RELATION_I 21<|>RELATION_I 外显子<|>RELATION_I 突变<|>RELATION_I 为主<|>RELATION_E 。<|>RELATION_NOE
突变率<|>RELATION_NOE 以<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 腺癌者<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 。<|>RELATION_NOE
螺旋<|>RELATION_NOE CT<|>RELATION_NOE 在<|>RELATION_NOE 孤立性<|>RELATION_NOE 肺结节<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E
在<|>RELATION_NOE 孤正性<|>RELATION_NOE 肺结节<|>RELATION_NOE 定期<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 螺旋<|>RELATION_NOE cT<|>RELATION_NOE 测量<|>RELATION_NOE 结节<|>RELATION_NOE 直径<|>RELATION_NOE 预测<|>RELATION_S 结节<|>RELATION_NOE 的<|>RELATION_NOE 倍增<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 对比<|>RELATION_NOE 观察<|>RELATION_NOE 病灶<|>RELATION_NOE 前后<|>RELATION_NOE 形态<|>RELATION_NOE 以<|>RELATION_NOE 评价<|>RELATION_NOE 结节<|>RELATION_NOE 生长<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 孤立性<|>RELATION_NOE 肺结节<|>RELATION_NOE 尤其<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 判断<|>RELATION_NOE 有<|>RELATION_NOE 重要<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
异氟醚<|>RELATION_NOE 和<|>RELATION_NOE 七<|>RELATION_NOE 氟醚<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 及<|>RELATION_NOE 细胞分裂<|>RELATION_NOE 周期<|>RELATION_NOE 蛋白<|>RELATION_NOE 42<|>RELATION_NOE 、<|>RELATION_NOE 成束<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 培养<|>RELATION_NOE 板<|>RELATION_NOE ,<|>RELATION_NOE 培养<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 3组<|>RELATION_NOE (<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 6例<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 2.3%<|>RELATION_NOE 异氟<|>RELATION_NOE 醚组<|>RELATION_NOE (<|>RELATION_NOE Iso<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 3.4%<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE (<|>RELATION_NOE Sev<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
于<|>RELATION_NOE 24h<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Transwell<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 处理<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 6h<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 迁移<|>RELATION_NOE 细胞<|>RELATION_NOE 数目<|>RELATION_NOE ,<|>RELATION_NOE 蛋白<|>RELATION_NOE 印迹法<|>RELATION_NOE 于<|>RELATION_NOE 24h<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Transwell<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 处理<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 6h<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 迁移<|>RELATION_NOE 细胞<|>RELATION_NOE 数目<|>RELATION_NOE ,<|>RELATION_NOE 蛋白<|>RELATION_NOE 印迹法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 处理<|>RELATION_NOE 4h<|>RELATION_NOE 的<|>RELATION_NOE Cdc42<|>RELATION_NOE 和<|>RELATION_NOE Fascin<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
构成<|>RELATION_NOE 比<|>RELATION_NOE 位于<|>RELATION_NOE 前<|>RELATION_NOE 10<|>RELATION_NOE 位<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 依次<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 头颈部癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 、<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 、<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 、<|>RELATION_NOE 肾癌<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 占<|>RELATION_NOE 27.2<|>RELATION_NOE 6%<|>RELATION_NOE (<|>RELATION_NOE 319<|>RELATION_NOE /<|>RELATION_NOE 1170<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 占<|>RELATION_NOE 47.18<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 495<|>RELATION_NOE /<|>RELATION_NOE 1170<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 性别<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 疾病谱<|>RELATION_NOE 不同<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 发病率<|>RELATION_NOE 位于<|>RELATION_NOE 前<|>RELATION_NOE 4<|>RELATION_NOE 位<|>RELATION_NOE 的<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE ;<|>RELATION_NOE
女性<|>RELATION_NOE 发病率<|>RELATION_NOE 位于<|>RELATION_NOE 前<|>RELATION_NOE 4<|>RELATION_NOE 位<|>RELATION_NOE 的<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 平庄<|>RELATION_NOE 矿区<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 是<|>RELATION_NOE 防治<|>RELATION_B 的<|>RELATION_I 重点<|>RELATION_E ;<|>RELATION_NOE
乙酰胆碱<|>RELATION_NOE 联合<|>RELATION_NOE 长春新碱<|>RELATION_NOE 对<|>RELATION_NOE 人类<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 生长<|>RELATION_NOE 及<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 及<|>RELATION_NOE Westernblot<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S 乙酰胆碱<|>RELATION_NOE 联合<|>RELATION_NOE VCR<|>RELATION_NOE 对<|>RELATION_NOE bcl-2<|>RELATION_NOE 及<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
乙酰胆碱<|>RELATION_NOE 单独<|>RELATION_NOE 及<|>RELATION_NOE 联合<|>RELATION_NOE VCR<|>RELATION_NOE 均<|>RELATION_B 能<|>RELATION_I 抑制<|>RELATION_E A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 乙酰胆碱<|>RELATION_NOE 与<|>RELATION_NOE VCR<|>RELATION_NOE 协同<|>RELATION_NOE 或<|>RELATION_NOE 相加<|>RELATION_NOE 作用<|>RELATION_NOE 影响<|>RELATION_NOE 了<|>RELATION_NOE bel-2<|>RELATION_NOE 及<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
中国<|>RELATION_NOE 2008年<|>RELATION_NOE 肝癌<|>RELATION_NOE 发病<|>RELATION_NOE 、<|>RELATION_NOE 死亡<|>RELATION_NOE 和<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 估计<|>RELATION_B 与<|>RELATION_I 预测<|>RELATION_E
估计<|>RELATION_S 中国<|>RELATION_NOE 2008年<|>RELATION_NOE 肝癌<|>RELATION_NOE 发病<|>RELATION_NOE 、<|>RELATION_NOE 死亡<|>RELATION_NOE 和<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 预测<|>RELATION_NOE 未来<|>RELATION_NOE 20<|>RELATION_NOE 年<|>RELATION_NOE 发病数<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 数<|>RELATION_NOE 。<|>RELATION_NOE
估计<|>RELATION_NOE 中国<|>RELATION_NOE 2008年<|>RELATION_NOE 肝癌<|>RELATION_NOE 发病<|>RELATION_NOE 、<|>RELATION_NOE 死亡<|>RELATION_NOE 和<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 预测<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 15<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 25<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 30<|>RELATION_NOE 年<|>RELATION_NOE 肝癌<|>RELATION_NOE 的<|>RELATION_NOE 发病数<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 数<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 2008年<|>RELATION_NOE 中国<|>RELATION_NOE 肝癌<|>RELATION_NOE 新<|>RELATION_NOE 发病<|>RELATION_NOE 例数<|>RELATION_NOE 约<|>RELATION_NOE 为<|>RELATION_NOE 40.2万<|>RELATION_NOE (<|>RELATION_NOE 占<|>RELATION_NOE 所有<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 例数<|>RELATION_NOE 的<|>RELATION_NOE 14.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 数<|>RELATION_NOE 约<|>RELATION_NOE 为<|>RELATION_NOE 37.2万<|>RELATION_NOE (<|>RELATION_NOE 占<|>RELATION_NOE 所有<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡<|>RELATION_NOE 例数<|>RELATION_NOE 的<|>RELATION_NOE 19.0%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 任何<|>RELATION_NOE 年龄段<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 肝癌<|>RELATION_NOE 的<|>RELATION_NOE 发病率<|>RELATION_NOE 和<|>RELATION_NOE 死亡率<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 女性<|>RELATION_NOE 。<|>RELATION_NOE
肝癌<|>RELATION_NOE 是<|>RELATION_NOE 中国<|>RELATION_NOE 主要<|>RELATION_NOE 癌症<|>RELATION_NOE 之一<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 死亡率<|>RELATION_NOE 仅次于<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 发病<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 情况<|>RELATION_NOE 在<|>RELATION_NOE 未来<|>RELATION_NOE 20<|>RELATION_NOE 年<|>RELATION_NOE 将<|>RELATION_NOE 越来越<|>RELATION_NOE 严峻<|>RELATION_NOE ,<|>RELATION_NOE 40<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 男性<|>RELATION_NOE 是<|>RELATION_NOE 肝癌<|>RELATION_NOE 重点<|>RELATION_NOE 防控<|>RELATION_NOE 人群<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE 癌症<|>RELATION_NOE 登记<|>RELATION_NOE 报告<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 描述<|>RELATION_B 和<|>RELATION_I 探讨<|>RELATION_E 2003<|>RELATION_NOE —<|>RELATION_NOE 2007年<|>RELATION_NOE 中国<|>RELATION_NOE 肝癌<|>RELATION_NOE 发病<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 的<|>RELATION_NOE 特征<|>RELATION_NOE 与<|>RELATION_NOE 趋势<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 中国<|>RELATION_NOE 32<|>RELATION_NOE 个<|>RELATION_NOE 癌症<|>RELATION_NOE 登记处<|>RELATION_NOE 2003<|>RELATION_NOE —<|>RELATION_NOE 2007年<|>RELATION_NOE 肝癌<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 登记<|>RELATION_NOE 年报<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_B 与<|>RELATION_I 分析<|>RELATION_E 肝癌<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE (<|>RELATION_NOE 死亡<|>RELATION_NOE )<|>RELATION_NOE 率<|>RELATION_NOE 、<|>RELATION_NOE 中国<|>RELATION_NOE 人口<|>RELATION_NOE 标化率<|>RELATION_NOE 及<|>RELATION_NOE 世界<|>RELATION_NOE 人口<|>RELATION_NOE 标化率<|>RELATION_NOE ;<|>RELATION_NOE 采用<|>RELATION_NOE 中国<|>RELATION_NOE 32<|>RELATION_NOE 个<|>RELATION_NOE 癌症<|>RELATION_NOE 登记处<|>RELATION_NOE 2003<|>RELATION_NOE —<|>RELATION_NOE 2007年<|>RELATION_NOE 肝癌<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 登记<|>RELATION_NOE 年报<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_B 与<|>RELATION_I 分析<|>RELATION_E 肝癌<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE (<|>RELATION_NOE 死亡<|>RELATION_NOE )<|>RELATION_NOE 率<|>RELATION_NOE 、<|>RELATION_NOE 中国<|>RELATION_NOE 人口<|>RELATION_NOE 标化率<|>RELATION_NOE 及<|>RELATION_NOE 世界<|>RELATION_NOE 人口<|>RELATION_NOE 标化率<|>RELATION_NOE ;<|>RELATION_NOE
2003<|>RELATION_NOE —<|>RELATION_NOE 2007年<|>RELATION_NOE 中国<|>RELATION_NOE 32<|>RELATION_NOE 个<|>RELATION_NOE 癌症<|>RELATION_NOE 登记处<|>RELATION_NOE 观察<|>RELATION_NOE 总数<|>RELATION_NOE 为<|>RELATION_NOE 2554<|>RELATION_NOE 30<|>RELATION_NOE 909<|>RELATION_NOE 人<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 城市<|>RELATION_NOE 197<|>RELATION_NOE 65<|>RELATION_NOE 14<|>RELATION_NOE 28<|>RELATION_NOE 人<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 农村<|>RELATION_NOE 57<|>RELATION_NOE 77<|>RELATION_NOE 94<|>RELATION_NOE 81<|>RELATION_NOE 人<|>RELATION_NOE 年<|>RELATION_NOE 。<|>RELATION_NOE
共<|>RELATION_NOE 登记<|>RELATION_NOE 报告<|>RELATION_NOE 肝癌<|>RELATION_NOE 发病<|>RELATION_NOE 68<|>RELATION_NOE 146<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 全部<|>RELATION_NOE 癌症<|>RELATION_NOE 发病<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 10.03%<|>RELATION_NOE (<|>RELATION_NOE 居<|>RELATION_NOE 第2<|>RELATION_NOE 位<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
登记<|>RELATION_NOE 报告<|>RELATION_NOE 肝癌<|>RELATION_NOE 死亡<|>RELATION_NOE 639<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 全部<|>RELATION_NOE 癌症<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 14.5<|>RELATION_NOE 6%<|>RELATION_NOE (<|>RELATION_NOE 居<|>RELATION_NOE 第2<|>RELATION_NOE 位<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肝癌<|>RELATION_NOE 发病率<|>RELATION_NOE 和<|>RELATION_NOE 死亡率<|>RELATION_NOE 性别<|>RELATION_NOE 比<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.89<|>RELATION_NOE :<|>RELATION_NOE 1<|>RELATION_NOE 和<|>RELATION_NOE 2.72<|>RELATION_NOE :<|>RELATION_NOE 1<|>RELATION_NOE 。<|>RELATION_NOE
城市<|>RELATION_NOE 和<|>RELATION_NOE 农村<|>RELATION_NOE 地区<|>RELATION_NOE 肝癌<|>RELATION_NOE 发病率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 23.91<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE 和<|>RELATION_NOE 36.15<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 死亡率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 22.39<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE 和<|>RELATION_NOE 34.05<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE 。<|>RELATION_NOE
肝癌<|>RELATION_NOE 发病<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 地区<|>RELATION_NOE 差异<|>RELATION_NOE :<|>RELATION_NOE 城市<|>RELATION_NOE 发病率<|>RELATION_NOE 10.15<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE 至<|>RELATION_NOE 33.85<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 农村<|>RELATION_NOE 为<|>RELATION_NOE 11.83<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE 至<|>RELATION_NOE 78.59<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 同期<|>RELATION_NOE 全球<|>RELATION_NOE 184<|>RELATION_NOE 个<|>RELATION_NOE 国家<|>RELATION_NOE 或<|>RELATION_NOE 地区<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 中国<|>RELATION_NOE 肝癌<|>RELATION_NOE 发病率<|>RELATION_NOE 水平<|>RELATION_NOE 男性<|>RELATION_NOE 居<|>RELATION_NOE 第5<|>RELATION_NOE 位<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 居<|>RELATION_NOE 第6<|>RELATION_NOE 位<|>RELATION_NOE ;<|>RELATION_NOE
自<|>RELATION_NOE 荧光<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_E
探讨<|>RELATION_NOE 自<|>RELATION_NOE 荧光<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE (<|>RELATION_NOE AFB<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S 。<|>RELATION_NOE
对<|>RELATION_NOE 198<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 怀疑<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_S AFB<|>RELATION_NOE 联合<|>RELATION_NOE 白光<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE (<|>RELATION_NOE WLB<|>RELATION_NOE )<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE
行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 增生<|>RELATION_NOE 定义<|>RELATION_NOE 为<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 正常<|>RELATION_NOE 黏膜<|>RELATION_NOE 、<|>RELATION_NOE 增生<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 炎症<|>RELATION_NOE 定义<|>RELATION_NOE 为<|>RELATION_NOE 阴性<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_S AFB<|>RELATION_NOE 与<|>RELATION_NOE WLB<|>RELATION_NOE 镜<|>RELATION_NOE 下<|>RELATION_NOE 异常<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 结果<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 。<|>RELATION_NOE
着丝粒<|>RELATION_NOE 蛋白<|>RELATION_NOE A<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S CENP-A<|>RELATION_NOE 在<|>RELATION_NOE 66<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 了<|>RELATION_NOE 66<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 电话<|>RELATION_NOE 和<|>RELATION_NOE 信件<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 的<|>RELATION_NOE 方式<|>RELATION_NOE ,<|>RELATION_NOE 了解<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
CENP-A<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 低于<|>RELATION_S 分化<|>RELATION_NOE 程度<|>RELATION_NOE 低<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE CENP-A<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 高于<|>RELATION_NOE 非吸烟<|>RELATION_NOE 患者<|>RELATION_NOE ;<|>RELATION_NOE CENP-A<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 低于<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 低<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE CENP-A<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 高于<|>RELATION_S 非<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE ;<|>RELATION_NOE
52<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 心<|>RELATION_NOE 肺并发症<|>RELATION_NOE 相关<|>RELATION_B 因素<|>RELATION_I 分析<|>RELATION_E
观察<|>RELATION_NOE 指标<|>RELATION_NOE 包括<|>RELATION_S 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 、<|>RELATION_NOE 严重<|>RELATION_NOE 心律失常<|>RELATION_NOE 、<|>RELATION_NOE 低<|>RELATION_NOE 血<|>RELATION_NOE 容量<|>RELATION_NOE 性循环<|>RELATION_NOE 障碍<|>RELATION_NOE 及<|>RELATION_NOE 急性<|>RELATION_NOE 呼吸窘迫<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE ARDS<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 常见<|>RELATION_NOE 心<|>RELATION_NOE 肺并发症<|>RELATION_NOE 。<|>RELATION_NOE
围手术期<|>RELATION_NOE 无<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 出现<|>RELATION_NOE 严重<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 严重<|>RELATION_NOE 心律失常<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 如<|>RELATION_NOE 阵发性<|>RELATION_NOE 室上性<|>RELATION_NOE 心动过速<|>RELATION_NOE 或<|>RELATION_NOE 频发性<|>RELATION_NOE 室<|>RELATION_NOE 性期<|>RELATION_NOE 前<|>RELATION_NOE 收缩<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_NOE 包括<|>RELATION_NOE 窦性<|>RELATION_NOE 心动过速<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 低血<|>RELATION_NOE 容量<|>RELATION_NOE 性循环<|>RELATION_NOE 障碍<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE ARDS1<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
黏液<|>RELATION_NOE 样隆突性<|>RELATION_NOE 皮<|>RELATION_NOE 纤维肉瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理学<|>RELATION_NOE 观察<|>RELATION_S
回顾性<|>RELATION_B 复习<|>RELATION_E 16<|>RELATION_NOE 例<|>RELATION_NOE 黏液<|>RELATION_NOE 样<|>RELATION_NOE DFSP<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 形态<|>RELATION_NOE 和<|>RELATION_NOE 免疫学<|>RELATION_NOE 表型<|>RELATION_NOE 。<|>RELATION_NOE
镜<|>RELATION_NOE 下<|>RELATION_NOE 观察<|>RELATION_NOE :<|>RELATION_NOE 肿瘤<|>RELATION_NOE 境界<|>RELATION_NOE 不<|>RELATION_NOE 清<|>RELATION_NOE ,<|>RELATION_NOE 呈<|>RELATION_NOE 浸润性<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 7例<|>RELATION_NOE 完全<|>RELATION_NOE 呈<|>RELATION_NOE 黏液样<|>RELATION_NOE ,<|>RELATION_NOE 由<|>RELATION_NOE 短梭形<|>RELATION_NOE 和<|>RELATION_NOE 星状<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 大量<|>RELATION_NOE 的<|>RELATION_NOE 黏液<|>RELATION_NOE 样<|>RELATION_NOE 基质<|>RELATION_NOE 和<|>RELATION_NOE 纤细<|>RELATION_NOE 的<|>RELATION_NOE 血管<|>RELATION_NOE 网<|>RELATION_NOE 组成<|>RELATION_NOE ,<|>RELATION_NOE 核分裂<|>RELATION_NOE 象<|>RELATION_NOE 范围<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE /<|>RELATION_NOE HPF<|>RELATION_NOE ;<|>RELATION_NOE
另<|>RELATION_NOE 9例除<|>RELATION_NOE 黏液<|>RELATION_NOE 样<|>RELATION_NOE 区域<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 5例可见经<|>RELATION_NOE 典型<|>RELATION_NOE DFSP<|>RELATION_NOE 区域<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 1例<|>RELATION_NOE 含有<|>RELATION_NOE 灶性<|>RELATION_NOE 的<|>RELATION_NOE 巨细胞<|>RELATION_NOE 纤维<|>RELATION_NOE 母细胞<|>RELATION_NOE 瘤样<|>RELATION_NOE 区域<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 4例<|>RELATION_NOE 则<|>RELATION_NOE 呈<|>RELATION_NOE 纤维肉瘤<|>RELATION_NOE 样<|>RELATION_NOE 变<|>RELATION_NOE 。<|>RELATION_NOE
随<|>RELATION_NOE 访<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 复发<|>RELATION_NOE 性病<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 1例<|>RELATION_NOE 发生<|>RELATION_NOE 肺转移<|>RELATION_NOE 和<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 。<|>RELATION_NOE
黏液<|>RELATION_NOE 样<|>RELATION_NOE DFSP<|>RELATION_NOE 是<|>RELATION_NOE DFSP<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 少见<|>RELATION_NOE 亚型<|>RELATION_NOE ,<|>RELATION_NOE 当<|>RELATION_NOE 肿瘤<|>RELATION_NOE 完全<|>RELATION_NOE 呈<|>RELATION_NOE 黏液<|>RELATION_NOE 样时<|>RELATION_NOE 容易<|>RELATION_NOE 被<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 其他<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 黏液<|>RELATION_NOE 样<|>RELATION_NOE 软组织肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 诊断<|>RELATION_NOE 时<|>RELATION_NOE 应<|>RELATION_NOE 注意<|>RELATION_NOE 加以<|>RELATION_NOE 鉴别<|>RELATION_NOE 。<|>RELATION_NOE
舒适<|>RELATION_NOE 护理<|>RELATION_NOE 模式<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 应用<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_B 评价<|>RELATION_E
随机<|>RELATION_NOE 抽取<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 1月<|>RELATION_NOE 我院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_S 常规<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 进行<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 随机<|>RELATION_NOE 抽取<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 1月<|>RELATION_NOE 我院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 进行<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_S 舒适<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 进行<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 经过<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE 比较<|>RELATION_NOE 2组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 满意度<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE
奥曲肽<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE 5-<|>RELATION_NOE 氟尿嘧啶<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 抑制<|>RELATION_NOE 的<|>RELATION_NOE 增效<|>RELATION_B 作用<|>RELATION_E
探讨<|>RELATION_NOE 生长抑素<|>RELATION_NOE 类似<|>RELATION_NOE 物<|>RELATION_NOE 奥曲肽<|>RELATION_NOE 能否<|>RELATION_NOE 增强<|>RELATION_S 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 奥曲肽<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE 5-<|>RELATION_NOE 氟尿嘧啶<|>RELATION_NOE (<|>RELATION_NOE 5-Fu<|>RELATION_NOE )<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑盐<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 奥曲肽<|>RELATION_NOE 单独<|>RELATION_NOE 以及<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE 5-Fu<|>RELATION_NOE 联合<|>RELATION_NOE 作用<|>RELATION_NOE 后<|>RELATION_NOE 48h<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞株<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 每个<|>RELATION_NOE 药物<|>RELATION_NOE 浓度<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 复孔<|>RELATION_NOE ,<|>RELATION_NOE 实验<|>RELATION_NOE 重复<|>RELATION_NOE 3<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE MTr<|>RELATION_NOE 法<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 奥曲肽<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 起<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 浓度<|>RELATION_NOE 1.3<|>RELATION_NOE —<|>RELATION_NOE 166.7mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 范围<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 抑制率<|>RELATION_NOE 呈<|>RELATION_NOE 剂量<|>RELATION_NOE 依赖性<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 体外<|>RELATION_NOE 实验<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 奥曲肽<|>RELATION_NOE 能够<|>RELATION_NOE 抑制<|>RELATION_S A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE 5.Fu<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE
奥曲肽<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE 5-Fu<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
气管<|>RELATION_NOE 镜<|>RELATION_NOE 对<|>RELATION_NOE 肺腺样囊性癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
气管<|>RELATION_NOE 镜<|>RELATION_NOE 检查<|>RELATION_NOE 发现<|>RELATION_S 肿瘤<|>RELATION_NOE 多<|>RELATION_NOE 呈<|>RELATION_NOE 息肉<|>RELATION_NOE 样类<|>RELATION_NOE 圆形<|>RELATION_NOE 肿物<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 表面<|>RELATION_NOE 有<|>RELATION_NOE 2-3<|>RELATION_NOE 个<|>RELATION_NOE 小分叶<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 发生<|>RELATION_NOE 于<|>RELATION_NOE 总<|>RELATION_NOE 气管<|>RELATION_NOE 及<|>RELATION_NOE 主<|>RELATION_NOE 支气管<|>RELATION_NOE 等<|>RELATION_NOE 大气道<|>RELATION_NOE ,<|>RELATION_NOE 沿<|>RELATION_NOE 黏膜<|>RELATION_NOE 下<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 一般<|>RELATION_NOE 表面<|>RELATION_NOE 黏膜<|>RELATION_NOE 光整<|>RELATION_NOE 。<|>RELATION_NOE
气管<|>RELATION_NOE 镜<|>RELATION_NOE 下<|>RELATION_NOE 可以<|>RELATION_NOE 更<|>RELATION_NOE 直观<|>RELATION_NOE 、<|>RELATION_NOE 清晰<|>RELATION_NOE 的<|>RELATION_NOE 观察<|>RELATION_NOE 该病<|>RELATION_NOE 的<|>RELATION_NOE 几<|>RELATION_NOE 项<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 诊断<|>RELATION_S 肺腺样囊性癌<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 23<|>RELATION_NOE 6.70<|>RELATION_NOE 、<|>RELATION_NOE 26<|>RELATION_NOE 0.13<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 6.27<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 间<|>RELATION_NOE FoxA2<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.86<|>RELATION_NOE 、<|>RELATION_NOE 1.69<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 低<|>RELATION_NOE 分化组<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 及<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 相应<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 分化<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE Ⅰ<|>RELATION_NOE -<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 及<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 蛋白<|>RELATION_NOE 比较<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4-31<|>RELATION_NOE 、<|>RELATION_NOE 3.92<|>RELATION_NOE 、<|>RELATION_NOE 3.41<|>RELATION_NOE ;<|>RELATION_NOE
FoxA2<|>RELATION_NOE 可能<|>RELATION_NOE 对<|>RELATION_NOE 人类<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 形成<|>RELATION_NOE 起<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 参与<|>RELATION_NOE 了<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 过程<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_S 。<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 联合<|>RELATION_NOE nm23<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 诊治<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
研究<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE nm23<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 相互<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 诊治<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 呈<|>RELATION_B 正<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 7.25<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE 。<|>RELATION_NOE
VEGF<|>RELATION_NOE 和<|>RELATION_NOE tam23<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 检测<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE nm23<|>RELATION_NOE 可能<|>RELATION_NOE 有助于<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 诊治<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 评估<|>RELATION_NOE 有<|>RELATION_NOE 积极<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE tam23<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE nm23<|>RELATION_NOE 可能<|>RELATION_NOE 有助于<|>RELATION_S 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 诊治<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 评估<|>RELATION_NOE 有<|>RELATION_NOE 积极<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE RGC32<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_S 36<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 及<|>RELATION_NOE 相应<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE RGC32<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
应用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 抑制<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE RGC32<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_NOE 应用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 抑制<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE RGC32<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_S 抑制<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 抑制率<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 应用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 抑制<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE RGC32<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_NOE 抑制<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 抑制率<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 。<|>RELATION_NOE 应用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 抑制<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE RGC32<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_NOE 抑制<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 抑制率<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 。<|>RELATION_NOE
RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 能够<|>RELATION_NOE 显著<|>RELATION_B 抑制<|>RELATION_E A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE RGC32<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
RGC32<|>RELATION_NOE 基因表达<|>RELATION_NOE 降低<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡率<|>RELATION_NOE 由<|>RELATION_NOE (<|>RELATION_NOE 2.47<|>RELATION_NOE ±<|>RELATION_NOE 0.17<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 提高<|>RELATION_NOE 至<|>RELATION_NOE (<|>RELATION_NOE 4.65<|>RELATION_NOE ±<|>RELATION_NOE 0.26<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -202.868<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 生长<|>RELATION_NOE 抑制率<|>RELATION_NOE 由<|>RELATION_NOE 2.9%<|>RELATION_NOE 提高<|>RELATION_NOE 至<|>RELATION_NOE 45.4%<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -37.915<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 活力<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE 。<|>RELATION_NOE
RGC32<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_NOE 上调<|>RELATION_NOE ,<|>RELATION_NOE RGC32<|>RELATION_NOE 基因表达<|>RELATION_NOE 降低<|>RELATION_NOE 能够<|>RELATION_NOE 促进<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 并<|>RELATION_NOE 抑制<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 。<|>RELATION_NOE
1989<|>RELATION_NOE －<|>RELATION_NOE 2008<|>RELATION_NOE 年<|>RELATION_NOE 中国<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡<|>RELATION_NOE 趋势<|>RELATION_NOE 分析<|>RELATION_S
根据<|>RELATION_NOE 中国<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 中心<|>RELATION_NOE 1989-2008<|>RELATION_NOE 年<|>RELATION_NOE 登记<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 地区<|>RELATION_NOE 划分<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_S 1989-2008<|>RELATION_NOE 年<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE Joinpoint<|>RELATION_NOE 软件<|>RELATION_NOE 估计<|>RELATION_S 死亡率<|>RELATION_NOE 的<|>RELATION_NOE 年度<|>RELATION_NOE 变化<|>RELATION_NOE 百分比<|>RELATION_NOE (<|>RELATION_NOE APC<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡率<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 美国<|>RELATION_NOE 死亡率<|>RELATION_NOE 趋势<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
中国<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 1989年<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 15<|>RELATION_NOE 6.93<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 2008年<|>RELATION_NOE 上升<|>RELATION_NOE 至<|>RELATION_NOE 18<|>RELATION_NOE 4.67<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ;<|>RELATION_NOE
1989年<|>RELATION_NOE 女性<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 12<|>RELATION_NOE 5.70<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_S 同时期<|>RELATION_NOE 男性<|>RELATION_NOE 死亡率<|>RELATION_NOE ,<|>RELATION_NOE 2008年<|>RELATION_NOE 女性<|>RELATION_NOE 死亡率<|>RELATION_NOE 上升<|>RELATION_NOE 至<|>RELATION_NOE 14<|>RELATION_NOE 0.48<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ;<|>RELATION_NOE
我国<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡率<|>RELATION_NOE 男性<|>RELATION_NOE 高于<|>RELATION_S 女性<|>RELATION_NOE 、<|>RELATION_NOE 农村<|>RELATION_NOE
在<|>RELATION_NOE 城市<|>RELATION_NOE 地区<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 居<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡谱<|>RELATION_NOE 第1<|>RELATION_NOE 位<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE 农村<|>RELATION_NOE 地区<|>RELATION_NOE 胃癌<|>RELATION_NOE 居<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡谱<|>RELATION_NOE 之<|>RELATION_NOE 首<|>RELATION_NOE 。<|>RELATION_NOE
我国<|>RELATION_NOE 男性<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡率<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 同一<|>RELATION_NOE 时期<|>RELATION_NOE 美国<|>RELATION_NOE 死亡率<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 女性<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡率<|>RELATION_NOE 下降<|>RELATION_NOE 趋势<|>RELATION_NOE 也<|>RELATION_NOE 不如<|>RELATION_NOE 美国<|>RELATION_NOE 明显<|>RELATION_NOE 。<|>RELATION_NOE
1989<|>RELATION_NOE －<|>RELATION_NOE 2008年<|>RELATION_NOE 中国<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 趋势<|>RELATION_NOE 分析<|>RELATION_S
城市<|>RELATION_NOE 发病率<|>RELATION_NOE 从<|>RELATION_NOE 20<|>RELATION_NOE 9.33<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 1989年<|>RELATION_NOE )<|>RELATION_NOE 上升<|>RELATION_NOE 到<|>RELATION_NOE 30<|>RELATION_NOE 7.04<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 2008年<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 农村<|>RELATION_NOE 发病率<|>RELATION_NOE 从<|>RELATION_NOE 17<|>RELATION_NOE 6.10<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 1989年<|>RELATION_NOE )<|>RELATION_NOE 上升<|>RELATION_NOE 到<|>RELATION_NOE 26<|>RELATION_NOE 9.57<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 2008年<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
中国<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 世界<|>RELATION_NOE 人口<|>RELATION_NOE 标化<|>RELATION_NOE 发病率<|>RELATION_NOE 保持<|>RELATION_NOE 稳定<|>RELATION_NOE ,<|>RELATION_NOE 城市<|>RELATION_NOE 地区<|>RELATION_NOE 每年<|>RELATION_NOE 平均<|>RELATION_NOE 上升<|>RELATION_NOE 0.5%<|>RELATION_NOE ,<|>RELATION_NOE 农村<|>RELATION_NOE 地区<|>RELATION_NOE 变化<|>RELATION_NOE 不<|>RELATION_NOE 明显<|>RELATION_NOE 。<|>RELATION_NOE
1989-2008<|>RELATION_NOE 年<|>RELATION_NOE 中国<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 排<|>RELATION_NOE 位居<|>RELATION_NOE 前<|>RELATION_NOE 10<|>RELATION_NOE 位<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病率<|>RELATION_NOE 持续<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 。<|>RELATION_NOE
胃癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 和<|>RELATION_NOE 食管癌<|>RELATION_NOE 发病率<|>RELATION_NOE 缓慢<|>RELATION_B 上升<|>RELATION_E ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE
曲古<|>RELATION_NOE 抑菌素<|>RELATION_NOE A<|>RELATION_NOE 和<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
以<|>RELATION_NOE TSA<|>RELATION_NOE 和<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 单独<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 锥虫蓝<|>RELATION_NOE 拒染法<|>RELATION_NOE 观察<|>RELATION_S 药物<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Hoechst33258<|>RELATION_NOE 染色法<|>RELATION_NOE 以<|>RELATION_NOE TSA<|>RELATION_NOE 和<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 单独<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 锥虫蓝<|>RELATION_NOE 拒染法<|>RELATION_NOE 观察<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Hoechst33258<|>RELATION_NOE 染色法<|>RELATION_NOE 观察<|>RELATION_S 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE 以<|>RELATION_NOE TSA<|>RELATION_NOE 和<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 单独<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 锥虫蓝<|>RELATION_NOE 拒染法<|>RELATION_NOE 观察<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Hoechst33258<|>RELATION_NOE 染色法<|>RELATION_NOE 观察<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 和<|>RELATION_NOE 细胞周期<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Westernblot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 中<|>RELATION_NOE 多<|>RELATION_NOE 聚<|>RELATION_NOE 二<|>RELATION_NOE 磷酸<|>RELATION_NOE 腺苷<|>RELATION_NOE 核糖<|>RELATION_NOE 多<|>RELATION_NOE 聚<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE PARP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE casapase-3<|>RELATION_NOE 、<|>RELATION_NOE 乙酰化<|>RELATION_NOE 微管蛋白<|>RELATION_NOE 和<|>RELATION_NOE survivin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 用<|>RELATION_NOE TSA<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 均<|>RELATION_B 可<|>RELATION_I 诱导<|>RELATION_E A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 17.6<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 39.2<|>RELATION_NOE ±<|>RELATION_NOE 3.7<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE TSA<|>RELATION_NOE 和<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 可<|>RELATION_NOE 使<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡率<|>RELATION_NOE 增至<|>RELATION_NOE (<|>RELATION_NOE 64.2<|>RELATION_NOE ±<|>RELATION_NOE 4.2<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 1.2<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TSA<|>RELATION_NOE 和<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 能<|>RELATION_NOE 抑制<|>RELATION_S A549<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 诱导细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_NOE 具有<|>RELATION_NOE 协同<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 先天性膈疝<|>RELATION_NOE 9例<|>RELATION_NOE (<|>RELATION_NOE 18.4%<|>RELATION_NOE ,<|>RELATION_NOE 9/49<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 超声<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 见<|>RELATION_NOE 腹腔<|>RELATION_NOE 脏器<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 7例<|>RELATION_NOE 引产<|>RELATION_NOE (<|>RELATION_NOE 1例<|>RELATION_NOE 合并<|>RELATION_NOE 18-<|>RELATION_NOE 三体<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 出生<|>RELATION_NOE 后<|>RELATION_NOE 新生儿<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 活产<|>RELATION_NOE ,<|>RELATION_NOE 产后<|>RELATION_NOE 手术<|>RELATION_NOE 存活<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 10.2%<|>RELATION_NOE ,<|>RELATION_NOE 5/49<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 超声<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 无<|>RELATION_NOE 回声区<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 4例<|>RELATION_NOE 引产<|>RELATION_NOE (<|>RELATION_NOE 分别<|>RELATION_NOE 合并<|>RELATION_NOE 有<|>RELATION_NOE 21-<|>RELATION_NOE 三体<|>RELATION_NOE 、<|>RELATION_NOE 胎儿<|>RELATION_NOE 水肿<|>RELATION_NOE 、<|>RELATION_NOE Turner<|>RELATION_NOE 综合征<|>RELATION_NOE 、<|>RELATION_NOE 大量<|>RELATION_NOE 腹腔<|>RELATION_NOE 积液<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 于<|>RELATION_NOE 孕<|>RELATION_NOE 34<|>RELATION_NOE 周<|>RELATION_NOE 时<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 消失<|>RELATION_NOE 。<|>RELATION_NOE
超声检查<|>RELATION_NOE 是<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 胎儿<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 可靠<|>RELATION_B 方法<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 从<|>RELATION_NOE 超声<|>RELATION_NOE 观察<|>RELATION_NOE 角度<|>RELATION_NOE 预测<|>RELATION_NOE 肺内<|>RELATION_NOE 病变<|>RELATION_NOE 胎儿<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 预后<|>RELATION_NOE 与<|>RELATION_NOE 转归<|>RELATION_NOE ;<|>RELATION_NOE
胎儿<|>RELATION_NOE 纵隔<|>RELATION_NOE 和<|>RELATION_NOE 心脏<|>RELATION_NOE 移位<|>RELATION_NOE 、<|>RELATION_NOE 胎儿水肿<|>RELATION_NOE 或<|>RELATION_NOE 合并<|>RELATION_NOE 染色体异常<|>RELATION_NOE 是<|>RELATION_NOE 终止<|>RELATION_NOE 妊娠<|>RELATION_NOE 的<|>RELATION_NOE 指征<|>RELATION_S 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_B 因素<|>RELATION_I 分析<|>RELATION_E
对<|>RELATION_NOE 86<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 行<|>RELATION_NOE 12<|>RELATION_NOE 导联<|>RELATION_NOE 心电图<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 心包<|>RELATION_NOE 内<|>RELATION_NOE 肺切除<|>RELATION_NOE 和<|>RELATION_NOE 常规<|>RELATION_NOE 肺切除<|>RELATION_NOE 、<|>RELATION_NOE 术式<|>RELATION_NOE (<|>RELATION_NOE 全肺<|>RELATION_NOE 和<|>RELATION_NOE 肺叶<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 术前<|>RELATION_NOE 心电图<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 对<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
术后<|>RELATION_NOE 发生<|>RELATION_NOE 心律失常<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 50.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 窦性<|>RELATION_NOE 心动过速<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 房性<|>RELATION_NOE 早搏<|>RELATION_NOE 和<|>RELATION_NOE 交界性<|>RELATION_NOE 早搏<|>RELATION_NOE 5例<|>RELATION_NOE 、<|>RELATION_NOE 房颤<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 占<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 72.1%<|>RELATION_NOE 、<|>RELATION_NOE 11.6%<|>RELATION_NOE 、<|>RELATION_NOE 16.3%<|>RELATION_NOE 。<|>RELATION_NOE
全肺<|>RELATION_NOE 和<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 心律失常<|>RELATION_NOE 发生率<|>RELATION_NOE 比较<|>RELATION_B 无<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 心电图<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 异常<|>RELATION_NOE 术后<|>RELATION_NOE 全肺<|>RELATION_NOE 和<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 心律失常<|>RELATION_NOE 发生率<|>RELATION_NOE 比较<|>RELATION_NOE 无<|>RELATION_NOE 差异<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术前<|>RELATION_NOE 心电图<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 异常<|>RELATION_NOE 术后<|>RELATION_NOE 心律失常<|>RELATION_NOE 发生率<|>RELATION_NOE 与<|>RELATION_NOE 术前<|>RELATION_NOE 心电图<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 比较<|>RELATION_B 无<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
心包<|>RELATION_NOE 内<|>RELATION_NOE 肺切除<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE ≥<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE 肺癌<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 心律失常<|>RELATION_NOE 发生率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_NOE 发生<|>RELATION_NOE 房<|>RELATION_NOE 颤<|>RELATION_NOE 。<|>RELATION_NOE
猪源<|>RELATION_NOE 人工骨<|>RELATION_NOE 进行<|>RELATION_S 胸壁<|>RELATION_NOE 缺损<|>RELATION_NOE 修复<|>RELATION_NOE 重建<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 2008年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 9月<|>RELATION_NOE 我院<|>RELATION_NOE 胸外科<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 胸壁<|>RELATION_NOE 缺损<|>RELATION_NOE 患者<|>RELATION_NOE 用<|>RELATION_NOE 猪源<|>RELATION_NOE 生物材料<|>RELATION_NOE 骨<|>RELATION_NOE 进行<|>RELATION_B 重建<|>RELATION_E 。<|>RELATION_NOE
其中<|>RELATION_NOE 男<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE 45.8<|>RELATION_NOE 岁<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE －<|>RELATION_NOE 72<|>RELATION_NOE 岁<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 胸壁<|>RELATION_NOE 肿瘤<|>RELATION_NOE 或<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 侵犯<|>RELATION_NOE 胸壁<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 后<|>RELATION_NOE 造成<|>RELATION_NOE 胸壁<|>RELATION_NOE 缺损<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 猪源<|>RELATION_NOE 生物材料<|>RELATION_NOE 骨<|>RELATION_NOE 进行<|>RELATION_NOE 肋骨<|>RELATION_NOE 重建<|>RELATION_NOE ,<|>RELATION_NOE 外<|>RELATION_NOE 被<|>RELATION_NOE 自身<|>RELATION_NOE 软<|>RELATION_NOE 组织<|>RELATION_NOE ;<|>RELATION_NOE
4例<|>RELATION_NOE 为<|>RELATION_NOE 纵隔<|>RELATION_NOE 或<|>RELATION_NOE 胸骨肿瘤<|>RELATION_NOE 切除<|>RELATION_NOE 后<|>RELATION_NOE 造成<|>RELATION_NOE 胸骨<|>RELATION_NOE 或<|>RELATION_NOE 胸骨<|>RELATION_NOE 合并<|>RELATION_NOE 前<|>RELATION_NOE 胸壁<|>RELATION_NOE 缺损<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 猪源<|>RELATION_NOE 生物材料<|>RELATION_NOE 骨<|>RELATION_NOE 替代<|>RELATION_S 胸骨<|>RELATION_NOE 与<|>RELATION_NOE 两侧<|>RELATION_NOE 前肋<|>RELATION_NOE 及<|>RELATION_NOE 锁骨<|>RELATION_NOE 固定<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 猪源<|>RELATION_NOE 生物材料<|>RELATION_NOE 骨<|>RELATION_NOE 进行<|>RELATION_S 胸壁<|>RELATION_NOE 缺损<|>RELATION_NOE 修复<|>RELATION_NOE 重建<|>RELATION_NOE 疗效<|>RELATION_NOE 满意<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 见<|>RELATION_NOE 连接部<|>RELATION_NOE 有<|>RELATION_NOE 骨痂<|>RELATION_NOE 形成<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 经氩<|>RELATION_NOE 氦刀<|>RELATION_NOE 冷冻<|>RELATION_NOE 联合<|>RELATION_NOE BACE<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 影像学<|>RELATION_NOE 动态<|>RELATION_NOE 观察<|>RELATION_NOE 及<|>RELATION_NOE KPS<|>RELATION_NOE 评分<|>RELATION_NOE 变化<|>RELATION_NOE 的<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_S 联合<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
健康<|>RELATION_NOE 体检<|>RELATION_NOE 人群<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 检<|>RELATION_B 出<|>RELATION_I 特点<|>RELATION_E
前<|>RELATION_NOE 5<|>RELATION_NOE 位<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 0.03<|>RELATION_NOE 6%<|>RELATION_NOE (<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 0.01<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肾癌<|>RELATION_NOE 0.01<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 0.01<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 胃癌<|>RELATION_NOE 0.0<|>RELATION_NOE 11%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
超声<|>RELATION_NOE 对<|>RELATION_NOE 肝<|>RELATION_NOE 、<|>RELATION_NOE 肾<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 等<|>RELATION_NOE 实质性<|>RELATION_NOE 脏器<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 优于<|>RELATION_S 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE (<|>RELATION_NOE TM<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
半<|>RELATION_NOE 肝血流<|>RELATION_NOE 完全<|>RELATION_NOE 阻断<|>RELATION_NOE 预防<|>RELATION_S 肝癌<|>RELATION_NOE 切除<|>RELATION_NOE 术中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 播散<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE
半<|>RELATION_NOE 肝血流<|>RELATION_NOE 完全<|>RELATION_NOE 阻断法<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 降低<|>RELATION_E 肝癌<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 早期<|>RELATION_NOE 肺转移<|>RELATION_NOE 发生率<|>RELATION_NOE 并<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 近期<|>RELATION_NOE 无<|>RELATION_NOE 瘤生存率<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 预防<|>RELATION_NOE 术中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 播<|>RELATION_NOE 散<|>RELATION_NOE 并<|>RELATION_NOE 改善<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 有<|>RELATION_NOE 积极<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
计算机<|>RELATION_NOE 辅助<|>RELATION_NOE 检测<|>RELATION_NOE 系统<|>RELATION_NOE 在<|>RELATION_NOE 低<|>RELATION_NOE 剂量<|>RELATION_NOE 肺癌<|>RELATION_NOE 筛查<|>RELATION_NOE 结节<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E
其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 胃肠道<|>RELATION_NOE 肿瘤<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 恶心<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 和<|>RELATION_NOE 白血病<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 原因<|>RELATION_NOE 不明<|>RELATION_NOE 3例<|>RELATION_NOE ;<|>RELATION_NOE
脑膜癌病<|>RELATION_NOE 是<|>RELATION_NOE 肿瘤<|>RELATION_NOE 颅内<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 特殊<|>RELATION_NOE 形式<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 以<|>RELATION_NOE 头痛<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 脑脊液<|>RELATION_NOE 的<|>RELATION_NOE 常规<|>RELATION_NOE 、<|>RELATION_NOE 生化<|>RELATION_NOE 、<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 有助于<|>RELATION_S 早期<|>RELATION_NOE 确诊<|>RELATION_NOE 。<|>RELATION_NOE
主成分分析<|>RELATION_NOE 用于<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 自体<|>RELATION_NOE 荧光<|>RELATION_NOE 光谱<|>RELATION_NOE 特征<|>RELATION_NOE 参数<|>RELATION_NOE 的<|>RELATION_NOE 提取<|>RELATION_NOE
对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 及<|>RELATION_NOE 正常者<|>RELATION_NOE 血清<|>RELATION_NOE 自体<|>RELATION_NOE 荧光<|>RELATION_NOE 光谱<|>RELATION_NOE 进行<|>RELATION_S 特征<|>RELATION_NOE 提取<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 主成分分析<|>RELATION_NOE -y<|>RELATION_NOE ~<|>RELATION_NOE x<|>RELATION_NOE 提取<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 信息<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 了<|>RELATION_NOE 应用<|>RELATION_NOE 全<|>RELATION_NOE 光谱<|>RELATION_NOE 识别<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 效率<|>RELATION_NOE 。<|>RELATION_NOE
STAT3<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 初<|>RELATION_NOE 探<|>RELATION_NOE
通过<|>RELATION_NOE 检测<|>RELATION_NOE 信号<|>RELATION_NOE 转导<|>RELATION_NOE 及<|>RELATION_NOE 转录<|>RELATION_NOE 活化<|>RELATION_NOE 因子3<|>RELATION_NOE (<|>RELATION_NOE STAT3<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_S STAT3<|>RELATION_NOE 作为<|>RELATION_NOE 潜在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE RealtimePCR<|>RELATION_NOE 检测<|>RELATION_S STAT3mRNA<|>RELATION_NOE 、<|>RELATION_NOE ELISA<|>RELATION_NOE 方法<|>RELATION_NOE 用<|>RELATION_NOE RealtimePCR<|>RELATION_NOE 检测<|>RELATION_NOE STAT3mRNA<|>RELATION_NOE 、<|>RELATION_NOE ELISA<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S STAT3<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 正常人<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
灶性<|>RELATION_NOE 机化性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发病率<|>RELATION_NOE 低<|>RELATION_S ,<|>RELATION_NOE 可<|>RELATION_NOE 有<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咯痰<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE 、<|>RELATION_NOE 胸痛<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE 等<|>RELATION_NOE 多种<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 影像学<|>RELATION_NOE 上<|>RELATION_NOE 缺乏<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 孤立<|>RELATION_NOE 的<|>RELATION_NOE 局限<|>RELATION_NOE 性病<|>RELATION_NOE 灶<|>RELATION_NOE 。<|>RELATION_NOE
灶性<|>RELATION_NOE 机化性<|>RELATION_NOE 肺炎<|>RELATION_NOE 实际<|>RELATION_NOE 是<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 病理<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 它<|>RELATION_NOE 多<|>RELATION_NOE 由<|>RELATION_NOE 肺内<|>RELATION_NOE 感染性疾病<|>RELATION_NOE 等<|>RELATION_NOE 多种<|>RELATION_NOE 因素<|>RELATION_NOE 导致<|>RELATION_NOE 肺部<|>RELATION_NOE 改变<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 共同<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 表现<|>RELATION_NOE 常<|>RELATION_NOE 需<|>RELATION_NOE 与<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 鉴别<|>RELATION_NOE ,<|>RELATION_NOE 有时<|>RELATION_NOE 也<|>RELATION_NOE 可<|>RELATION_NOE 出现<|>RELATION_NOE 类似<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 的<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 需要<|>RELATION_NOE 临床<|>RELATION_NOE 综合<|>RELATION_NOE 分析<|>RELATION_NOE 做出<|>RELATION_NOE 判断<|>RELATION_NOE 。<|>RELATION_NOE
联合<|>RELATION_NOE 检测<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 、<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
探讨<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 、<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA15-3<|>RELATION_NOE 、<|>RELATION_NOE cYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 伴<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE 测定<|>RELATION_S 27<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 及其<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA15-3<|>RELATION_NOE 、<|>RELATION_NOE cYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
联合<|>RELATION_NOE 检测<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 及其<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 鉴别良<|>RELATION_NOE 、<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 有<|>RELATION_B 一定<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉<|>RELATION_NOE 醇加<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_NOE 艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉<|>RELATION_NOE 醇加<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
76<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 数字<|>RELATION_NOE 分组法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 研究组<|>RELATION_NOE 为<|>RELATION_NOE 艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 50ml<|>RELATION_NOE 加入<|>RELATION_NOE 0.9%<|>RELATION_NOE NaCl<|>RELATION_NOE 溶液<|>RELATION_NOE 或<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 500ml<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 1次/<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 连<|>RELATION_NOE 用<|>RELATION_NOE 14d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 疗程<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 1h<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 至<|>RELATION_NOE 第3<|>RELATION_NOE 天<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 方面<|>RELATION_NOE ,<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 及<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 研究组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_B 差异<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 食欲<|>RELATION_NOE 减退<|>RELATION_NOE 及<|>RELATION_NOE 肝功能<|>RELATION_NOE 异常<|>RELATION_NOE 方面<|>RELATION_NOE 研究组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
山西省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 2005年<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 死因<|>RELATION_NOE 分析<|>RELATION_S
2005年<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 总<|>RELATION_NOE 的<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 0.8<|>RELATION_NOE 6%<|>RELATION_NOE (<|>RELATION_NOE 1277<|>RELATION_NOE /<|>RELATION_NOE 14<|>RELATION_NOE 68<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 有<|>RELATION_NOE 逐年<|>RELATION_NOE 下降<|>RELATION_NOE 的<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 2005年<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 死亡率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.16%<|>RELATION_NOE 、<|>RELATION_NOE 1.05%<|>RELATION_NOE 、<|>RELATION_NOE 0.99%<|>RELATION_NOE 、<|>RELATION_NOE 0.8<|>RELATION_NOE 5%<|>RELATION_NOE 、<|>RELATION_NOE 0.84%<|>RELATION_NOE 、<|>RELATION_NOE 0.6<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 45.7<|>RELATION_NOE 63<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
住院<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 男性<|>RELATION_NOE 总<|>RELATION_NOE 死亡率<|>RELATION_NOE (<|>RELATION_NOE 1.2<|>RELATION_NOE 6%<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_S 女性<|>RELATION_NOE (<|>RELATION_NOE 0.5<|>RELATION_NOE 3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 21<|>RELATION_NOE 5.3<|>RELATION_NOE 67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肿瘤<|>RELATION_NOE 死<|>RELATION_NOE 因<|>RELATION_NOE 顺位<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_S ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 占<|>RELATION_NOE 癌症<|>RELATION_NOE 死因<|>RELATION_NOE 比例<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 36.4%<|>RELATION_NOE (<|>RELATION_NOE 456<|>RELATION_NOE /<|>RELATION_NOE 12<|>RELATION_NOE 53<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
前<|>RELATION_NOE 10<|>RELATION_NOE 位<|>RELATION_NOE 肿瘤<|>RELATION_NOE 死<|>RELATION_NOE 因<|>RELATION_NOE 顺位<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 表明<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 、<|>RELATION_NOE 干部<|>RELATION_NOE 职员<|>RELATION_NOE 和<|>RELATION_NOE 工人<|>RELATION_NOE 、<|>RELATION_NOE 中学<|>RELATION_NOE 文化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 人群<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 死亡<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 占<|>RELATION_B 大多数<|>RELATION_E 。<|>RELATION_NOE
RNAi<|>RELATION_NOE 下调<|>RELATION_NOE LOX<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 乏氧<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 分子<|>RELATION_NOE 机制<|>RELATION_NOE
应用<|>RELATION_NOE 针对<|>RELATION_NOE 人<|>RELATION_NOE LOX<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 小于扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE LOX<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 转染<|>RELATION_S 常氧<|>RELATION_NOE (<|>RELATION_NOE 19%<|>RELATION_NOE O2<|>RELATION_NOE )<|>RELATION_NOE 95D<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE 将<|>RELATION_NOE 细胞<|>RELATION_NOE 蚩乏氧<|>RELATION_NOE (<|>RELATION_NOE 0.5%<|>RELATION_NOE O2<|>RELATION_NOE )<|>RELATION_NOE 培养<|>RELATION_NOE 箱<|>RELATION_NOE 孵育<|>RELATION_NOE ,<|>RELATION_NOE 乏氧<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE 采用<|>RELATION_NOE 实时<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE LOX<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE Snail<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 技术<|>RELATION_NOE 评价<|>RELATION_NOE Src<|>RELATION_NOE 、<|>RELATION_NOE 磷酸化<|>RELATION_NOE Src<|>RELATION_NOE (<|>RELATION_NOE P-Src<|>RELATION_NOE Y418<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Snail<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Transwell<|>RELATION_NOE 小空<|>RELATION_NOE 评价<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 常氧<|>RELATION_NOE 95D<|>RELATION_NOE 细胞<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 乏氧<|>RELATION_NOE 引起<|>RELATION_NOE 细胞<|>RELATION_NOE LOX<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 分别<|>RELATION_NOE 增加<|>RELATION_NOE 14<|>RELATION_NOE 倍<|>RELATION_NOE 和<|>RELATION_NOE 2.12<|>RELATION_NOE 倍<|>RELATION_NOE 。<|>RELATION_NOE
LOX<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 降低<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 乏氧<|>RELATION_NOE 侵袭<|>RELATION_NOE 与<|>RELATION_NOE 减少<|>RELATION_NOE Src<|>RELATION_NOE 活化<|>RELATION_NOE 和<|>RELATION_NOE Snail<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 为<|>RELATION_NOE LOX<|>RELATION_NOE 成为<|>RELATION_NOE 防治<|>RELATION_NOE 肺癌<|>RELATION_NOE 乏氧<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 潜在<|>RELATION_NOE 靶点<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 实验<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE CpGODN<|>RELATION_NOE 对<|>RELATION_NOE 荷<|>RELATION_NOE 瘤鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 皮下<|>RELATION_NOE 种植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 生成<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 。<|>RELATION_NOE
接种<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 7d<|>RELATION_NOE 开始<|>RELATION_NOE 瘤内<|>RELATION_NOE 注射<|>RELATION_NOE 药物<|>RELATION_NOE 并<|>RELATION_NOE 照射<|>RELATION_NOE 5d<|>RELATION_NOE ,<|>RELATION_NOE 计算抑<|>RELATION_NOE 瘤率<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE -C<|>RELATION_NOE (<|>RELATION_NOE VEGF-C<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE neuropilin-1<|>RELATION_NOE (<|>RELATION_NOE NRP-1<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE RT-PCR<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_NOE 瘤组织<|>RELATION_NOE 中<|>RELATION_NOE VEGF-CmRNA<|>RELATION_NOE 、<|>RELATION_NOE NRP-1mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE -C<|>RELATION_NOE (<|>RELATION_NOE VEGF-C<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE neuropilin-1<|>RELATION_NOE (<|>RELATION_NOE NRP-1<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE RT-PCR<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S 瘤组织<|>RELATION_NOE 中<|>RELATION_NOE VEGF-CmRNA<|>RELATION_NOE 、<|>RELATION_NOE NRP-1mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
Ⅰ<|>RELATION_NOE A<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 冷冻<|>RELATION_NOE 消融<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
观察<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 氩<|>RELATION_NOE 氦刀<|>RELATION_NOE 冷冻<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_S IA<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 及<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 医院<|>RELATION_NOE 伦理<|>RELATION_NOE 委员会<|>RELATION_NOE 批准<|>RELATION_NOE 2008年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 11月<|>RELATION_NOE 接受<|>RELATION_NOE 氩氦<|>RELATION_NOE 刀<|>RELATION_NOE 冷冻<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE IA<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 62.1<|>RELATION_NOE ±<|>RELATION_NOE 7.4<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE (<|>RELATION_NOE BAC<|>RELATION_NOE )<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 术后<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 观察<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_S 原位<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 、<|>RELATION_NOE 生长<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
其余<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 内<|>RELATION_NOE 原位<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 其后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 发现<|>RELATION_NOE 3例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ;<|>RELATION_NOE
21<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 术后<|>RELATION_NOE 2年<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 或<|>RELATION_NOE 转移<|>RELATION_NOE 征象<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 切除<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 222<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 84<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 37.8%<|>RELATION_NOE )<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 与<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 及<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 71.4%<|>RELATION_NOE (<|>RELATION_NOE 60<|>RELATION_NOE /<|>RELATION_NOE 84<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 66.7%<|>RELATION_NOE (<|>RELATION_NOE 92<|>RELATION_NOE /<|>RELATION_NOE 138<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 68.5%<|>RELATION_NOE (<|>RELATION_NOE 152<|>RELATION_NOE /<|>RELATION_NOE 222<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 56.6%<|>RELATION_NOE (<|>RELATION_NOE 60<|>RELATION_NOE /<|>RELATION_NOE 106<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 79.3%<|>RELATION_NOE (<|>RELATION_NOE 92<|>RELATION_NOE /<|>RELATION_NOE 116<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 48.8%<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 84<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 49.3%<|>RELATION_NOE (<|>RELATION_NOE 68<|>RELATION_NOE /<|>RELATION_NOE 138<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 49.1%<|>RELATION_NOE (<|>RELATION_NOE 109<|>RELATION_NOE /<|>RELATION_NOE 222<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 36.9%<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 111<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 61.3%<|>RELATION_NOE (<|>RELATION_NOE 68<|>RELATION_NOE /<|>RELATION_NOE 111<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^2<|>RELATION_NOE =<|>RELATION_NOE 8.96<|>RELATION_NOE 、<|>RELATION_NOE 8.57<|>RELATION_NOE 、<|>RELATION_NOE 17.19<|>RELATION_NOE 、<|>RELATION_NOE 8.43<|>RELATION_NOE 及<|>RELATION_NOE 8.88<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
术前<|>RELATION_NOE 2周<|>RELATION_NOE 内行<|>RELATION_NOE ^<|>RELATION_NOE 18F-FLT<|>RELATION_NOE 和<|>RELATION_NOE ^<|>RELATION_NOE 18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 行<|>RELATION_NOE 病理<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE CyclinD1<|>RELATION_NOE 检测<|>RELATION_S 。<|>RELATION_NOE
FLTPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 区域<|>RELATION_NOE 淋巴结<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 和<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 65%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 98%<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE 1/2<|>RELATION_NOE 96<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 93%<|>RELATION_NOE (<|>RELATION_NOE 330<|>RELATION_NOE /<|>RELATION_NOE 356<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 85%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 则<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 85%<|>RELATION_NOE (<|>RELATION_NOE 51<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 84%<|>RELATION_NOE (<|>RELATION_NOE 249<|>RELATION_NOE /<|>RELATION_NOE 296<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 84%<|>RELATION_NOE (<|>RELATION_NOE 300<|>RELATION_NOE /<|>RELATION_NOE 356<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 52%<|>RELATION_NOE (<|>RELATION_NOE 51<|>RELATION_NOE /<|>RELATION_NOE 98<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 区域<|>RELATION_NOE 淋巴结<|>RELATION_NOE 诊断<|>RELATION_NOE 灵敏度<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 有<|>RELATION_NOE 更<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 和<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 。<|>RELATION_NOE
YC-1<|>RELATION_NOE 改善<|>RELATION_NOE 乏氧<|>RELATION_NOE 增强<|>RELATION_S 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 体外研究<|>RELATION_NOE
用<|>RELATION_NOE 噻<|>RELATION_NOE 唑蓝<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S YC-1<|>RELATION_NOE 对<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 活性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE YC-1<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 作用<|>RELATION_NOE 24h<|>RELATION_NOE 的<|>RELATION_NOE 20%<|>RELATION_NOE 药物<|>RELATION_NOE 抑制<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IC20<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 用<|>RELATION_NOE 噻<|>RELATION_NOE 唑蓝<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S YC-1<|>RELATION_NOE 对<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 活性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE YC-1<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 作用<|>RELATION_NOE 24h<|>RELATION_NOE 的<|>RELATION_NOE 20%<|>RELATION_NOE 药物<|>RELATION_NOE 抑制<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IC20<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
细胞<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 计算<|>RELATION_S 细胞存活<|>RELATION_NOE 分数<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 靶<|>RELATION_NOE 单击<|>RELATION_NOE 模型<|>RELATION_NOE 拟合<|>RELATION_NOE 细胞存活<|>RELATION_NOE 曲线<|>RELATION_NOE 并<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 3－<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 脑转移瘤<|>RELATION_NOE 优选<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 可行性研究<|>RELATION_S
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 同期<|>RELATION_NOE 放化<|>RELATION_NOE 疗<|>RELATION_NOE 后<|>RELATION_NOE 重度<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_B 因素<|>RELATION_E
评价<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方<|>RELATION_NOE 图<|>RELATION_NOE 参数<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE 对<|>RELATION_NOE 非细胞<|>RELATION_NOE 肺癌<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 同期<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 急性<|>RELATION_NOE 重度<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE SARP<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
体部<|>RELATION_NOE 伽<|>RELATION_NOE 马刀<|>RELATION_NOE 治疗<|>RELATION_S 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 累及野<|>RELATION_NOE 和<|>RELATION_NOE 选择性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 照射<|>RELATION_NOE 前瞻性<|>RELATION_B 随机<|>RELATION_I 研究<|>RELATION_E
前瞻性<|>RELATION_NOE 比较<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE LA-NSCLC<|>RELATION_NOE )<|>RELATION_NOE 采用<|>RELATION_S 累及<|>RELATION_NOE 野照射<|>RELATION_NOE (<|>RELATION_NOE IFRT<|>RELATION_NOE )<|>RELATION_NOE 或<|>RELATION_NOE 选择性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 照射<|>RELATION_NOE (<|>RELATION_NOE ENI<|>RELATION_NOE )<|>RELATION_NOE 局部<|>RELATION_NOE 失败<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
99<|>RELATION_NOE 例<|>RELATION_NOE LA-NSCLC<|>RELATION_NOE 经<|>RELATION_NOE 紫杉<|>RELATION_NOE 醇加<|>RELATION_NOE 卡铂化<|>RELATION_NOE 疗2<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 无远处<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE IFRT<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 或<|>RELATION_NOE ENI<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE IFRT<|>RELATION_NOE 组<|>RELATION_NOE 照射<|>RELATION_NOE 原<|>RELATION_NOE 发病灶<|>RELATION_NOE 、<|>RELATION_NOE 同侧<|>RELATION_NOE 肺门<|>RELATION_NOE 和<|>RELATION_NOE 纵隔<|>RELATION_NOE 阳性<|>RELATION_NOE 淋巴结<|>RELATION_NOE ,<|>RELATION_NOE ENI<|>RELATION_NOE 组<|>RELATION_NOE 照射<|>RELATION_NOE 原<|>RELATION_NOE 发病灶<|>RELATION_NOE 、<|>RELATION_NOE 同侧<|>RELATION_NOE 肺门<|>RELATION_NOE 、<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 中<|>RELATION_NOE 上<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴<|>RELATION_NOE 引流区<|>RELATION_NOE 及<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 锁骨<|>RELATION_NOE 上<|>RELATION_NOE 区<|>RELATION_NOE 。<|>RELATION_NOE
含<|>RELATION_NOE 非<|>RELATION_NOE 甲基化<|>RELATION_NOE 二<|>RELATION_NOE 核苷酸<|>RELATION_NOE 的<|>RELATION_NOE 寡脱<|>RELATION_NOE 氧核苷酸<|>RELATION_NOE 7909<|>RELATION_NOE 对<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 诱导<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞周期<|>RELATION_NOE 阻滞<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 与<|>RELATION_NOE ATM<|>RELATION_NOE 激酶<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE
含<|>RELATION_NOE 非<|>RELATION_NOE 甲基化<|>RELATION_NOE 二<|>RELATION_NOE 核苷酸<|>RELATION_NOE 的<|>RELATION_NOE 寡脱<|>RELATION_NOE 氧核苷酸<|>RELATION_NOE 18<|>RELATION_NOE 26<|>RELATION_NOE 对<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_B 联合<|>RELATION_I 作用<|>RELATION_E 及其<|>RELATION_NOE 剂量<|>RELATION_NOE -<|>RELATION_NOE 效应<|>RELATION_NOE 关系<|>RELATION_NOE
将<|>RELATION_NOE 64<|>RELATION_NOE 只<|>RELATION_NOE 荷瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 按<|>RELATION_NOE 完全<|>RELATION_NOE 随机化<|>RELATION_NOE 方法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE x<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE (<|>RELATION_NOE IR<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 低<|>RELATION_NOE 剂量<|>RELATION_NOE CpGODN1826<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 0.15mg<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 中剂量<|>RELATION_NOE CpGODN1826<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 0.30mg<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 高剂量<|>RELATION_NOE CpGODN1826<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 0.45mg<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 低<|>RELATION_NOE 剂量<|>RELATION_NOE CpG0DN826<|>RELATION_NOE +<|>RELATION_NOE IR<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE CpG18260.15mg<|>RELATION_NOE +<|>RELATION_NOE IR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 中剂量<|>RELATION_NOE CpGODN1826<|>RELATION_NOE +<|>RELATION_NOE IR<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE CpG0.30mg<|>RELATION_NOE +<|>RELATION_NOE IR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 高<|>RELATION_NOE 剂量<|>RELATION_NOE CpG0DN1826<|>RELATION_NOE +<|>RELATION_NOE IR<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE CpG0.45mg<|>RELATION_NOE +<|>RELATION_NOE IR<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 8<|>RELATION_NOE 只<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 各组<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE 和<|>RELATION_NOE 各<|>RELATION_NOE 治疗组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 延迟<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TGD<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE DNA<|>RELATION_NOE 断裂<|>RELATION_NOE 的<|>RELATION_NOE 原位<|>RELATION_NOE 末端<|>RELATION_NOE 标记法<|>RELATION_NOE 检测<|>RELATION_S 细胞凋亡<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 各组<|>RELATION_NOE 小鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 都<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 明显<|>RELATION_NOE 减小<|>RELATION_NOE ,<|>RELATION_NOE CpGODN18260.45mg<|>RELATION_NOE +<|>RELATION_NOE IR<|>RELATION_NOE 组<|>RELATION_NOE 移植<|>RELATION_NOE 瘤体<|>RELATION_NOE 积<|>RELATION_NOE 最<|>RELATION_NOE 小<|>RELATION_NOE 。<|>RELATION_NOE
CpGODN1826<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_B 地<|>RELATION_I 抑制<|>RELATION_E 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 促进<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 呈<|>RELATION_NOE 剂量<|>RELATION_NOE -<|>RELATION_NOE 效应<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
电离辐射<|>RELATION_NOE 及<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE TOB1<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
体外<|>RELATION_NOE 培养<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE SPCA-1<|>RELATION_NOE 、<|>RELATION_NOE LTEP-<|>RELATION_NOE α<|>RELATION_NOE -2<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE -<|>RELATION_NOE 次性<|>RELATION_NOE 照射<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量<|>RELATION_NOE 为<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 和<|>RELATION_NOE 10Gy<|>RELATION_NOE ,<|>RELATION_NOE 源<|>RELATION_NOE 靶距<|>RELATION_NOE 为<|>RELATION_NOE 100cm<|>RELATION_NOE ,<|>RELATION_NOE 吸收<|>RELATION_NOE 剂量率<|>RELATION_NOE 为<|>RELATION_NOE 200cGy<|>RELATION_NOE /<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 6GyX<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 18<|>RELATION_NOE 和<|>RELATION_NOE 24h<|>RELATION_NOE 取样<|>RELATION_NOE ;<|>RELATION_NOE
不同<|>RELATION_NOE 时间<|>RELATION_NOE 检测<|>RELATION_NOE 提示<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE x<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 6h<|>RELATION_NOE ,<|>RELATION_NOE TOB1<|>RELATION_NOE 蛋白<|>RELATION_NOE 及<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 即<|>RELATION_NOE 开始<|>RELATION_NOE 上升<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 持续<|>RELATION_NOE 到<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 24h<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 14.23<|>RELATION_NOE －1<|>RELATION_NOE 5.82<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
小<|>RELATION_NOE 剂量<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 树突<|>RELATION_NOE 状<|>RELATION_NOE 细胞<|>RELATION_NOE 抗原<|>RELATION_NOE 递呈<|>RELATION_NOE 及<|>RELATION_NOE 白介素<|>RELATION_NOE -12<|>RELATION_NOE 分泌<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
分离<|>RELATION_NOE 人<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 单个<|>RELATION_NOE 核细胞<|>RELATION_NOE (<|>RELATION_NOE PBMC<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 人<|>RELATION_NOE 粒<|>RELATION_NOE -<|>RELATION_NOE 巨细胞<|>RELATION_NOE 集落<|>RELATION_NOE 刺激<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE GM-CSF<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE IL-4<|>RELATION_NOE 等<|>RELATION_NOE 诱导<|>RELATION_B 分化<|>RELATION_I 成<|>RELATION_E DC<|>RELATION_NOE 。<|>RELATION_NOE
各组<|>RELATION_NOE DC<|>RELATION_NOE 培养<|>RELATION_NOE 至<|>RELATION_NOE 第8<|>RELATION_NOE 天<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE DC<|>RELATION_NOE 致敏<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE CCK-8<|>RELATION_NOE (<|>RELATION_NOE cellcountingkit-8<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 混合<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE mixedlymphocytereaction<|>RELATION_NOE ,<|>RELATION_NOE MLR<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 评估<|>RELATION_NOE 抗原<|>RELATION_NOE 递<|>RELATION_NOE 呈<|>RELATION_NOE 能力<|>RELATION_NOE ;<|>RELATION_NOE
酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S DC<|>RELATION_NOE 细胞培养<|>RELATION_NOE 液中<|>RELATION_NOE IL-12<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
检测<|>RELATION_S 致敏<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 抑制<|>RELATION_NOE A549<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE 减弱<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.89<|>RELATION_NOE 和<|>RELATION_NOE 2.91<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 抑制<|>RELATION_NOE A549<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE 明显<|>RELATION_NOE 增强<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.91<|>RELATION_NOE 和<|>RELATION_NOE 2.82<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
DC<|>RELATION_NOE 在<|>RELATION_NOE 培养<|>RELATION_NOE 早期<|>RELATION_NOE 阶段<|>RELATION_NOE 接受<|>RELATION_NOE 0.5Gy<|>RELATION_NOE 以下<|>RELATION_NOE 的<|>RELATION_NOE x<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE ,<|>RELATION_NOE 会<|>RELATION_NOE 降低<|>RELATION_S 抗原<|>RELATION_NOE 递<|>RELATION_NOE 呈<|>RELATION_NOE 能力<|>RELATION_NOE 及<|>RELATION_NOE 致敏<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 杀伤<|>RELATION_NOE A549<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 培养<|>RELATION_NOE 阶段<|>RELATION_NOE 的<|>RELATION_NOE 后期<|>RELATION_NOE 给予<|>RELATION_NOE 此<|>RELATION_NOE 剂量<|>RELATION_NOE 照射<|>RELATION_NOE 则<|>RELATION_NOE 会<|>RELATION_NOE 增强<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 肺结核<|>RELATION_NOE 误<|>RELATION_NOE 漏诊<|>RELATION_NOE 原因<|>RELATION_NOE 探讨<|>RELATION_S
误诊<|>RELATION_NOE 为<|>RELATION_NOE 间质性<|>RELATION_NOE 肺炎<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 尘肺<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺脓肿<|>RELATION_NOE 3例<|>RELATION_NOE ;<|>RELATION_NOE
伴类<|>RELATION_NOE 风湿性<|>RELATION_NOE 关节炎<|>RELATION_NOE 的<|>RELATION_NOE 1例<|>RELATION_NOE 漏诊<|>RELATION_NOE 肺结核<|>RELATION_NOE ;<|>RELATION_NOE
并<|>RELATION_NOE 发<|>RELATION_NOE 冠心病<|>RELATION_NOE 的<|>RELATION_NOE 2例<|>RELATION_NOE 按<|>RELATION_NOE 肺水肿<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE 漏诊<|>RELATION_NOE 肺结核<|>RELATION_NOE 。<|>RELATION_NOE
唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 骨<|>RELATION_NOE 相关<|>RELATION_NOE 事件<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 临终<|>RELATION_NOE 期<|>RELATION_NOE 并发<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_B 因素<|>RELATION_I 分析<|>RELATION_E
回顾性<|>RELATION_B 分析<|>RELATION_E 310<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 临终<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 是否<|>RELATION_NOE 并发<|>RELATION_NOE 心律失常<|>RELATION_NOE 分为<|>RELATION_NOE 并发<|>RELATION_NOE 心律失常<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 78<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 未<|>RELATION_NOE 并发<|>RELATION_NOE 心律失常<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 232<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 单因素<|>RELATION_NOE 及<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 临终<|>RELATION_NOE 患者<|>RELATION_NOE 并发<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE Logistic<|>RELATION_NOE 逐步<|>RELATION_NOE 回归<|>RELATION_NOE 结果<|>RELATION_NOE 示<|>RELATION_NOE 低氧血症<|>RELATION_NOE 、<|>RELATION_NOE 体力<|>RELATION_NOE 状况<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 和<|>RELATION_NOE 低血红<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE OR<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE 可信<|>RELATION_NOE 区间<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.7<|>RELATION_NOE 93<|>RELATION_NOE (<|>RELATION_NOE 1.400<|>RELATION_NOE －1<|>RELATION_NOE 6.407<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 2.0<|>RELATION_NOE 20<|>RELATION_NOE (<|>RELATION_NOE 1.2<|>RELATION_NOE 76<|>RELATION_NOE －3<|>RELATION_NOE .<|>RELATION_NOE 200<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 1.2<|>RELATION_NOE 73<|>RELATION_NOE (<|>RELATION_NOE 1.1<|>RELATION_NOE 75<|>RELATION_NOE －1.3<|>RELATION_NOE 78<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 1.<|>RELATION_NOE 103<|>RELATION_NOE (<|>RELATION_NOE 1.03<|>RELATION_NOE 1－<|>RELATION_NOE 1.181<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 1.005<|>RELATION_NOE (<|>RELATION_NOE 1.001<|>RELATION_NOE －1.009<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 0.9<|>RELATION_NOE 66<|>RELATION_NOE (<|>RELATION_NOE 0.9<|>RELATION_NOE 39<|>RELATION_NOE －0.9<|>RELATION_NOE 95<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE 或<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 辅助<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下周<|>RELATION_NOE 围型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 与<|>RELATION_NOE 常规<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 对照<|>RELATION_B 研究<|>RELATION_E
通过<|>RELATION_NOE 对<|>RELATION_NOE 电视<|>RELATION_NOE 辅助<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 周围型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_S VATS<|>RELATION_NOE 下周围<|>RELATION_NOE 型<|>RELATION_NOE NSCLC<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE 、<|>RELATION_NOE 有效性<|>RELATION_NOE 及<|>RELATION_NOE 优缺点<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 60<|>RELATION_NOE 例行<|>RELATION_NOE VATS<|>RELATION_NOE 下周围<|>RELATION_NOE 型<|>RELATION_NOE NSCLC<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE 采用<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 周围型<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 开<|>RELATION_NOE 胸组<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 清扫<|>RELATION_NOE 淋巴结<|>RELATION_NOE 总数<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 总量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 及<|>RELATION_NOE 止痛药<|>RELATION_NOE 使用量<|>RELATION_NOE 等<|>RELATION_NOE 进行<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
VATS<|>RELATION_NOE 组<|>RELATION_NOE 手术<|>RELATION_NOE 均<|>RELATION_NOE 成功<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 2例<|>RELATION_NOE 中转<|>RELATION_NOE 开胸<|>RELATION_NOE 。<|>RELATION_NOE
VATS<|>RELATION_NOE 下周围<|>RELATION_NOE 型<|>RELATION_NOE NSCLC<|>RELATION_NOE 根治术<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 可行<|>RELATION_NOE 的<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_S 达到<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 根治<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 具有<|>RELATION_NOE 创伤<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 轻<|>RELATION_NOE 、<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
例<|>RELATION_NOE 软组织<|>RELATION_NOE 原发<|>RELATION_NOE ASPS<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 后<|>RELATION_NOE 局部<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 复发率<|>RELATION_NOE 为<|>RELATION_NOE 8.0%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 再次<|>RELATION_NOE 术后<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 复发<|>RELATION_NOE 。<|>RELATION_NOE
3例骨原发<|>RELATION_NOE ASPS<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 局部<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 其中<|>RELATION_NOE 2例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进展<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE 肺转移<|>RELATION_NOE 。<|>RELATION_NOE
28<|>RELATION_NOE 例<|>RELATION_NOE ASPS<|>RELATION_NOE 患者<|>RELATION_NOE 总体<|>RELATION_NOE 预后<|>RELATION_NOE 情况<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 无瘤<|>RELATION_NOE 生存<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 带瘤<|>RELATION_NOE 生存<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 死亡<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 38.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 46.4%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 28<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 患者<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 50.0%<|>RELATION_NOE (<|>RELATION_NOE 5/10<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 44.4%<|>RELATION_NOE (<|>RELATION_NOE 8/18<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 男女性<|>RELATION_NOE 患者<|>RELATION_NOE 5年<|>RELATION_NOE 生存率<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE 尸=<|>RELATION_NOE 0.2<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
未<|>RELATION_NOE 出现<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 81.8%<|>RELATION_NOE (<|>RELATION_NOE 9/11<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 出现<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE 肺转移<|>RELATION_NOE 、<|>RELATION_NOE 脑转移<|>RELATION_NOE 及<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 仅<|>RELATION_NOE 为<|>RELATION_NOE 23.5%<|>RELATION_NOE (<|>RELATION_NOE 4/17<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 无<|>RELATION_B 显著<|>RELATION_I 相关性<|>RELATION_E ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 部位<|>RELATION_NOE 及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE
SPS<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE 于<|>RELATION_NOE 青年人<|>RELATION_NOE ,<|>RELATION_NOE 臀部<|>RELATION_NOE 及<|>RELATION_NOE 大腿<|>RELATION_NOE 是<|>RELATION_NOE 软组织<|>RELATION_NOE 原发<|>RELATION_NOE ASPS<|>RELATION_NOE 的<|>RELATION_NOE 最<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE 部位<|>RELATION_NOE ,<|>RELATION_NOE 预后<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 是否<|>RELATION_NOE 彻底<|>RELATION_NOE 切除<|>RELATION_NOE 相关<|>RELATION_S 。<|>RELATION_NOE
尽早<|>RELATION_NOE 评估<|>RELATION_NOE 病情<|>RELATION_NOE ,<|>RELATION_NOE 制订<|>RELATION_NOE 合适<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 原发病灶<|>RELATION_NOE 采取<|>RELATION_NOE 广泛<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 降低<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 风险<|>RELATION_NOE 。<|>RELATION_NOE
胸腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 顺铂<|>RELATION_NOE 与<|>RELATION_NOE 胸腺<|>RELATION_NOE 五肽<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 顺铂<|>RELATION_NOE 与<|>RELATION_NOE 胸腺<|>RELATION_NOE 五肽<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
筛选<|>RELATION_NOE Ⅲ<|>RELATION_NOE -<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 中等量<|>RELATION_NOE 以上<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 给予<|>RELATION_S 胸腔<|>RELATION_NOE 注入<|>RELATION_NOE 顺铂<|>RELATION_NOE 80mg<|>RELATION_NOE 、<|>RELATION_NOE 地塞米松<|>RELATION_NOE 10mg<|>RELATION_NOE 。<|>RELATION_NOE
胸腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 顺铂<|>RELATION_NOE 与<|>RELATION_NOE 胸腺<|>RELATION_NOE 五肽<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 控制<|>RELATION_E 肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 手术<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 后<|>RELATION_NOE 无<|>RELATION_NOE 复发<|>RELATION_NOE 患者<|>RELATION_NOE 晚期<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_B 和<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
5<|>RELATION_NOE 年<|>RELATION_NOE 无<|>RELATION_NOE 复发者<|>RELATION_NOE 336<|>RELATION_NOE 例<|>RELATION_NOE 继续<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 收集<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 终点<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 数据收集<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 1月<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 估算<|>RELATION_S 无<|>RELATION_NOE 复发<|>RELATION_NOE 生存率<|>RELATION_NOE ,<|>RELATION_NOE Log-rank<|>RELATION_NOE 法<|>RELATION_NOE 进行<|>RELATION_NOE 生存率<|>RELATION_NOE 显著性<|>RELATION_NOE 检验<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Cox<|>RELATION_NOE 比例<|>RELATION_NOE 风险<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE 进行<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 探讨<|>RELATION_NOE 晚期<|>RELATION_NOE 复发<|>RELATION_NOE 与<|>RELATION_NOE 危险因素<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 估算<|>RELATION_NOE 无<|>RELATION_NOE 复发<|>RELATION_NOE 生存率<|>RELATION_NOE ,<|>RELATION_NOE Log-rank<|>RELATION_NOE 法<|>RELATION_NOE 进行<|>RELATION_S 生存率<|>RELATION_NOE 显著性<|>RELATION_NOE 检验<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Cox<|>RELATION_NOE 比例<|>RELATION_NOE 风险<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE
496<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 5年<|>RELATION_NOE 109<|>RELATION_NOE 例<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 其他<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 带瘤<|>RELATION_NOE 生存<|>RELATION_NOE ,<|>RELATION_NOE 336<|>RELATION_NOE 例<|>RELATION_NOE 无<|>RELATION_NOE 复发<|>RELATION_NOE 。<|>RELATION_NOE
随访期<|>RELATION_NOE 中<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 10.1%<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 晚期<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE (<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 复发<|>RELATION_NOE 6例<|>RELATION_NOE 、<|>RELATION_NOE 同侧<|>RELATION_NOE 肺<|>RELATION_NOE 复发<|>RELATION_NOE 3例<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 播散<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 其他<|>RELATION_NOE 2例<|>RELATION_NOE )<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 38.2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE 多<|>RELATION_NOE 器官<|>RELATION_NOE 转移<|>RELATION_NOE 8例<|>RELATION_NOE 、<|>RELATION_NOE 单器官<|>RELATION_NOE 转移<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 对<|>RELATION_NOE 侧<|>RELATION_NOE 肺脏<|>RELATION_NOE 5例<|>RELATION_NOE 、<|>RELATION_NOE 肝脏<|>RELATION_NOE 3例<|>RELATION_NOE 、<|>RELATION_NOE 中枢神经<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 其他<|>RELATION_NOE 3例<|>RELATION_NOE )<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 61.8%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 发现<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 瘤内<|>RELATION_NOE 淋巴管<|>RELATION_NOE 浸润<|>RELATION_NOE 、<|>RELATION_NOE 瘤内<|>RELATION_NOE 血管<|>RELATION_NOE 浸润<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 受累<|>RELATION_NOE 和<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 无<|>RELATION_NOE 复发<|>RELATION_NOE 生存率<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_S 。<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE 瘤内<|>RELATION_NOE 血管<|>RELATION_NOE 浸润<|>RELATION_NOE 和<|>RELATION_NOE 瘤内<|>RELATION_NOE 淋巴管<|>RELATION_NOE 浸润<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 晚期<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 危险因素<|>RELATION_E 。<|>RELATION_NOE
完全<|>RELATION_NOE 性切<|>RELATION_NOE 除术<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 仍<|>RELATION_NOE 存在<|>RELATION_NOE 晚期<|>RELATION_NOE 复发<|>RELATION_NOE 风险<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 有<|>RELATION_NOE 瘤内<|>RELATION_NOE 血管<|>RELATION_NOE 浸润<|>RELATION_NOE 和<|>RELATION_NOE 淋巴管<|>RELATION_NOE 浸润<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 该类<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 继续<|>RELATION_NOE 随访<|>RELATION_NOE 是<|>RELATION_NOE 有<|>RELATION_NOE 必要<|>RELATION_NOE 和<|>RELATION_NOE 有<|>RELATION_NOE 意义<|>RELATION_NOE 的<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 物1<|>RELATION_NOE 和<|>RELATION_NOE Wnt-1<|>RELATION_NOE 诱导<|>RELATION_NOE 分泌<|>RELATION_NOE 蛋白3<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 80<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 癌组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE TSLC1<|>RELATION_NOE 和<|>RELATION_NOE WISP-3<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
TSLC1<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 30.00%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 80<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 在<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达率<|>RELATION_NOE 71.25<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 57<|>RELATION_NOE /<|>RELATION_NOE 80<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE WISP-3<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 67.50%<|>RELATION_NOE (<|>RELATION_NOE 54<|>RELATION_NOE /<|>RELATION_NOE 80<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 在<|>RELATION_NOE
w-3<|>RELATION_NOE 多<|>RELATION_NOE 不饱和脂肪<|>RELATION_NOE 酸廿烷<|>RELATION_NOE 五烯<|>RELATION_NOE 酸单剂<|>RELATION_NOE 以及<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A-549<|>RELATION_NOE 细胞系<|>RELATION_NOE 增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 廿烷<|>RELATION_NOE 五烯酸<|>RELATION_NOE (<|>RELATION_NOE EPA<|>RELATION_NOE )<|>RELATION_NOE 单剂<|>RELATION_NOE 以及<|>RELATION_NOE 与<|>RELATION_NOE 卡铂<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A-549<|>RELATION_NOE 细胞系<|>RELATION_NOE 增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
分别<|>RELATION_NOE 用<|>RELATION_NOE 100<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 卡铂<|>RELATION_NOE 、<|>RELATION_NOE 80<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE mlEPA<|>RELATION_NOE 以及<|>RELATION_NOE 100<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 卡铂<|>RELATION_NOE 联合<|>RELATION_NOE 80<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE mlEPA<|>RELATION_NOE 孵育<|>RELATION_NOE A-549<|>RELATION_NOE 细胞<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE MTr<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 药物<|>RELATION_NOE 对<|>RELATION_NOE h-549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 抑制率<|>RELATION_NOE ,<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 定量分析<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 。<|>RELATION_NOE
HE<|>RELATION_NOE 染色<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE 药物<|>RELATION_NOE 干<|>RELATION_NOE 预后<|>RELATION_NOE 部分<|>RELATION_NOE A-549<|>RELATION_NOE 细胞<|>RELATION_NOE 出现<|>RELATION_S 凋亡<|>RELATION_NOE 形态学<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
EPA<|>RELATION_NOE 可能<|>RELATION_NOE 具有<|>RELATION_NOE 增强<|>RELATION_S 卡铂<|>RELATION_NOE 抑制<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A-549<|>RELATION_NOE 细胞系<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 促进<|>RELATION_NOE A-549<|>RELATION_NOE 细胞系<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 敲除<|>RELATION_NOE Smac<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 促进<|>RELATION_S 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 及<|>RELATION_NOE 增强<|>RELATION_NOE 顺铂<|>RELATION_NOE 耐药性<|>RELATION_NOE
探讨<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_S 敲除<|>RELATION_NOE Smac<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 及<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE cDDP<|>RELATION_NOE )<|>RELATION_NOE 耐药性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 转染<|>RELATION_NOE 含有<|>RELATION_NOE 以<|>RELATION_NOE 人<|>RELATION_NOE Smac<|>RELATION_NOE 基因为<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE 系统<|>RELATION_NOE ,<|>RELATION_NOE 即<|>RELATION_NOE 含有<|>RELATION_NOE 小分子<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE 序列<|>RELATION_NOE 的<|>RELATION_NOE pGC-FU<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE 95D<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 实施<|>RELATION_NOE Smac<|>RELATION_NOE 基因敲除<|>RELATION_NOE .<|>RELATION_NOE
细胞<|>RELATION_NOE 生长<|>RELATION_NOE 、<|>RELATION_NOE 细胞周期<|>RELATION_NOE 及<|>RELATION_NOE 凋亡<|>RELATION_NOE 采用<|>RELATION_NOE 四甲基偶<|>RELATION_NOE 氮唑盐<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 、<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 及<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 测定<|>RELATION_S .<|>RELATION_NOE
Smac<|>RELATION_NOE 下调<|>RELATION_NOE 表达<|>RELATION_NOE 促进<|>RELATION_S A549<|>RELATION_NOE 和<|>RELATION_NOE 95D<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 及<|>RELATION_NOE 增强<|>RELATION_NOE 顺铂<|>RELATION_NOE 耐药性<|>RELATION_NOE ;<|>RELATION_NOE
Smac<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 抑制<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 并且<|>RELATION_NOE 增强<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
Smac<|>RELATION_NOE 抑制<|>RELATION_S 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 并且<|>RELATION_NOE 增强<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 敏感<|>RELATION_NOE 性.<|>RELATION_NOE
乙酰<|>RELATION_NOE 肝素酶<|>RELATION_NOE mRNA<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
HPA<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 较<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 明显<|>RELATION_NOE 上调<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 以及<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S .<|>RELATION_NOE
运用<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光法<|>RELATION_NOE 检测<|>RELATION_S 温热<|>RELATION_NOE 对于<|>RELATION_NOE 硼化合物<|>RELATION_NOE 细胞微<|>RELATION_NOE 分布<|>RELATION_NOE 影响<|>RELATION_NOE
硼中子<|>RELATION_NOE 俘获<|>RELATION_NOE 疗法<|>RELATION_NOE (<|>RELATION_NOE BNCT<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 有效性<|>RELATION_NOE 主要<|>RELATION_B 取决于<|>RELATION_E 硼<|>RELATION_NOE -10<|>RELATION_NOE 元素<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE 的<|>RELATION_NOE 聚集<|>RELATION_NOE .<|>RELATION_NOE
目前<|>RELATION_NOE 的<|>RELATION_NOE 硼检测<|>RELATION_NOE 手段<|>RELATION_NOE 仅<|>RELATION_NOE 限于<|>RELATION_NOE 分析<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 硼<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_B 能<|>RELATION_I 准确<|>RELATION_I 地<|>RELATION_I 评价<|>RELATION_E 硼化合物<|>RELATION_NOE (<|>RELATION_NOE BPA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 详细<|>RELATION_NOE 分布<|>RELATION_NOE .<|>RELATION_NOE
通过<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光法<|>RELATION_NOE 分析<|>RELATION_S 硼化合物<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 以及<|>RELATION_NOE 温热<|>RELATION_NOE 对<|>RELATION_NOE BPA<|>RELATION_NOE 分布<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE .<|>RELATION_NOE
另外<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 经<|>RELATION_NOE 温热<|>RELATION_NOE 处理<|>RELATION_NOE 1h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 抗<|>RELATION_NOE BPA<|>RELATION_NOE 抗体<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光法<|>RELATION_NOE 进行<|>RELATION_NOE 检测.<|>RELATION_NOE
检测<|>RELATION_NOE 发现<|>RELATION_NOE BPA<|>RELATION_NOE 主要<|>RELATION_B 聚集于<|>RELATION_E 细胞核<|>RELATION_NOE 周围<|>RELATION_NOE ,<|>RELATION_NOE
尽管<|>RELATION_NOE 在<|>RELATION_NOE 26<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE 13<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 浓度<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 强度<|>RELATION_NOE 相近<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 直方<|>RELATION_NOE 图<|>RELATION_NOE 分析<|>RELATION_NOE 发现<|>RELATION_NOE 26<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 时<|>RELATION_NOE 细胞<|>RELATION_NOE 主要<|>RELATION_NOE 向<|>RELATION_NOE 高<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 区域<|>RELATION_NOE 移动<|>RELATION_NOE .<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 利用<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光法<|>RELATION_NOE 对<|>RELATION_NOE BPA<|>RELATION_NOE 在<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 以上<|>RELATION_NOE 结果<|>RELATION_NOE 暗示<|>RELATION_NOE 温热<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞硼<|>RELATION_NOE 摄取<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 可能<|>RELATION_NOE 主要<|>RELATION_NOE 需要<|>RELATION_NOE 通过<|>RELATION_NOE 改善<|>RELATION_NOE 肿瘤<|>RELATION_NOE 循环<|>RELATION_NOE 、<|>RELATION_NOE 增加<|>RELATION_NOE 肿瘤<|>RELATION_NOE 内<|>RELATION_NOE BPA<|>RELATION_NOE 的<|>RELATION_NOE 输送<|>RELATION_NOE 来<|>RELATION_NOE 实现<|>RELATION_NOE .<|>RELATION_NOE
血清<|>RELATION_NOE 血管<|>RELATION_NOE 生成素<|>RELATION_NOE -2<|>RELATION_NOE 定量<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 诊断<|>RELATION_NOE 应用<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
观察<|>RELATION_NOE 血管<|>RELATION_NOE 生成素<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE Ang-2<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 水平<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE Ang-2<|>RELATION_NOE 均值<|>RELATION_NOE 及<|>RELATION_NOE 阳性率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 与<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE ,<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 与<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 及<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 与<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期间<|>RELATION_NOE Ang-2<|>RELATION_NOE 均值<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.1<|>RELATION_NOE 14<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.0<|>RELATION_NOE 25<|>RELATION_NOE ;<|>RELATION_NOE
Ang-2<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 各期<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_B 较<|>RELATION_I 高<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 有<|>RELATION_NOE 参考<|>RELATION_NOE 价值<|>RELATION_NOE ;<|>RELATION_NOE
高温<|>RELATION_NOE 射频<|>RELATION_NOE 消融<|>RELATION_NOE 结合<|>RELATION_NOE 放化疗<|>RELATION_NOE 治疗<|>RELATION_S 肺部肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
RFA<|>RELATION_NOE 结合<|>RELATION_NOE 放化<|>RELATION_NOE 疗组<|>RELATION_NOE 术后<|>RELATION_NOE 7d<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 气胸<|>RELATION_NOE (<|>RELATION_NOE 36.7<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 胸腔<|>RELATION_NOE 穿<|>RELATION_NOE 刺5<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1例痰<|>RELATION_NOE 中<|>RELATION_NOE 带<|>RELATION_NOE 血<|>RELATION_NOE (<|>RELATION_NOE 2.04%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 3例<|>RELATION_NOE (<|>RELATION_NOE 6.1<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE 胸腔<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺炎<|>RELATION_NOE 发热<|>RELATION_NOE 3例<|>RELATION_NOE (<|>RELATION_NOE 6.12%<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
前列腺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 总体<|>RELATION_NOE 分布<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_S
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 的<|>RELATION_NOE 盆腔<|>RELATION_NOE 骨骼<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 比例<|>RELATION_NOE 为<|>RELATION_NOE 28.6%<|>RELATION_NOE (<|>RELATION_NOE 572<|>RELATION_NOE /<|>RELATION_NOE 2000<|>RELATION_NOE 个<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 盆腔<|>RELATION_NOE 骨骼<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 比例<|>RELATION_NOE (<|>RELATION_NOE 19.8%<|>RELATION_NOE ,<|>RELATION_NOE 262<|>RELATION_NOE /<|>RELATION_NOE 13<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE ;<|>RELATION_NOE
χ<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 33.6<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 盆腔<|>RELATION_NOE 骨骼<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 比例<|>RELATION_NOE (<|>RELATION_NOE 21.8%<|>RELATION_NOE ,<|>RELATION_NOE 496<|>RELATION_NOE /<|>RELATION_NOE 22<|>RELATION_NOE 79<|>RELATION_NOE 个<|>RELATION_NOE ;<|>RELATION_NOE
前列腺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 脊椎骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 比例<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 0.5<|>RELATION_NOE 52<|>RELATION_NOE ,<|>RELATION_NOE υ<|>RELATION_NOE =<|>RELATION_NOE 2<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 59<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 颈椎<|>RELATION_NOE 、<|>RELATION_NOE 胸椎<|>RELATION_NOE 、<|>RELATION_NOE 腰椎<|>RELATION_NOE 、<|>RELATION_NOE 骶<|>RELATION_NOE 尾骨<|>RELATION_NOE 、<|>RELATION_NOE 锁骨<|>RELATION_NOE 、<|>RELATION_NOE 肱骨<|>RELATION_NOE 、<|>RELATION_NOE 股骨<|>RELATION_NOE 和<|>RELATION_NOE 四肢<|>RELATION_NOE 骨<|>RELATION_NOE 中远端<|>RELATION_NOE 的<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 分布<|>RELATION_NOE 比例<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 的<|>RELATION_NOE 髂骨<|>RELATION_NOE 、<|>RELATION_NOE 坐骨<|>RELATION_NOE 、<|>RELATION_NOE 耻骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 比例<|>RELATION_NOE 相对<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 的<|>RELATION_NOE 胸骨<|>RELATION_NOE 、<|>RELATION_NOE 颅骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 比例<|>RELATION_NOE 相对<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 肋骨<|>RELATION_NOE 、<|>RELATION_NOE 肩胛骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 比例<|>RELATION_NOE 相对<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
前列腺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 总体<|>RELATION_NOE 分布<|>RELATION_NOE 既<|>RELATION_NOE 有<|>RELATION_NOE 共同<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 又<|>RELATION_NOE 呈现<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 认识<|>RELATION_NOE 这些<|>RELATION_NOE 特点<|>RELATION_NOE 有助于<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 鉴别<|>RELATION_NOE 诊断<|>RELATION_NOE .<|>RELATION_NOE
三<|>RELATION_NOE 氧化二砷<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 治疗<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
探讨<|>RELATION_NOE 三<|>RELATION_NOE 氧化二砷<|>RELATION_NOE (<|>RELATION_NOE As2O3<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_B 肿瘤<|>RELATION_I 作用<|>RELATION_E 及<|>RELATION_NOE 可能<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_NOE C57BL<|>RELATION_NOE /<|>RELATION_NOE 6皮<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 三<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE As2O3<|>RELATION_NOE 治疗组<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE DDP<|>RELATION_NOE )<|>RELATION_NOE 治疗组<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 情况<|>RELATION_NOE 计算抑<|>RELATION_NOE 瘤率<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 内<|>RELATION_NOE 增殖<|>RELATION_NOE 细胞核<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE PCNA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
实验<|>RELATION_NOE 表明<|>RELATION_NOE As2O3<|>RELATION_NOE 组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE ,<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE PCNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_NOE 下降<|>RELATION_NOE 。<|>RELATION_NOE
As2O3<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植瘤<|>RELATION_NOE 有<|>RELATION_B 显著<|>RELATION_I 的<|>RELATION_I 抑制<|>RELATION_I 作用<|>RELATION_E ;<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 和<|>RELATION_NOE ki67<|>RELATION_NOE 表达<|>RELATION_NOE 相关性<|>RELATION_B 分析<|>RELATION_E
检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 外显子<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE EGFR<|>RELATION_NOE 和<|>RELATION_NOE ki67<|>RELATION_NOE 表达<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 联系<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S 80<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 用<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S EGFR<|>RELATION_NOE 和<|>RELATION_NOE ki67<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
80<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 存在<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 5例<|>RELATION_NOE 为<|>RELATION_NOE 第19<|>RELATION_NOE 外显子<|>RELATION_NOE 缺失<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 第21<|>RELATION_NOE 外显子<|>RELATION_NOE 替代<|>RELATION_NOE 突变<|>RELATION_NOE .<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 以<|>RELATION_NOE 女性<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE EGFR<|>RELATION_NOE 和<|>RELATION_NOE ki67<|>RELATION_NOE 表达<|>RELATION_NOE 无关<|>RELATION_S .<|>RELATION_NOE
观察<|>RELATION_NOE 康复<|>RELATION_NOE 治疗<|>RELATION_NOE 联合<|>RELATION_NOE 无<|>RELATION_NOE 创<|>RELATION_NOE 呼吸机<|>RELATION_NOE 治疗<|>RELATION_NOE 对<|>RELATION_NOE 萤石<|>RELATION_NOE 矿工<|>RELATION_NOE 尘肺<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_S 。<|>RELATION_NOE
将<|>RELATION_NOE 72<|>RELATION_NOE 例<|>RELATION_NOE 萤石<|>RELATION_NOE 矿工<|>RELATION_NOE 尘肺<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 予<|>RELATION_NOE 药物治疗<|>RELATION_NOE 及<|>RELATION_NOE 常规<|>RELATION_NOE 康复<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE SP70<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
评价<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 单抗<|>RELATION_NOE NJ001<|>RELATION_NOE 相关<|>RELATION_NOE 靶<|>RELATION_NOE 抗原<|>RELATION_NOE SP70<|>RELATION_NOE 能否<|>RELATION_B 成为<|>RELATION_I 检测<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 新型<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE SPC-A1<|>RELATION_NOE 为<|>RELATION_NOE 抗原<|>RELATION_NOE 免疫<|>RELATION_S 新西兰兔<|>RELATION_NOE ,<|>RELATION_NOE 制备<|>RELATION_NOE 多抗<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 多<|>RELATION_NOE 抗包<|>RELATION_NOE 被<|>RELATION_NOE 微孔板<|>RELATION_NOE ,<|>RELATION_NOE NJ001<|>RELATION_NOE 为<|>RELATION_NOE 一<|>RELATION_NOE 抗<|>RELATION_NOE ,<|>RELATION_NOE 酶<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 羊抗鼠<|>RELATION_NOE 抗体<|>RELATION_NOE 为<|>RELATION_NOE 标记<|>RELATION_NOE 抗体<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 双<|>RELATION_NOE 抗体<|>RELATION_NOE 夹心<|>RELATION_NOE ELISA<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 优化<|>RELATION_NOE 实验<|>RELATION_NOE 条件<|>RELATION_NOE ;<|>RELATION_NOE
同时<|>RELATION_NOE 与<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 角质<|>RELATION_NOE 蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE ;<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE SP70<|>RELATION_NOE 阳性<|>RELATION_NOE 检出率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE SP70<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 潜在<|>RELATION_B 的<|>RELATION_I 用于<|>RELATION_E 诊断<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 。<|>RELATION_NOE
系统化<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 缓解<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_B 评价<|>RELATION_E
对照组<|>RELATION_NOE 实施<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ;<|>RELATION_NOE
应用<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 一般<|>RELATION_NOE 状况<|>RELATION_NOE 调查<|>RELATION_NOE 量表<|>RELATION_NOE 、<|>RELATION_NOE 简易<|>RELATION_NOE 疲乏量表<|>RELATION_NOE 、<|>RELATION_NOE 症状<|>RELATION_NOE 评估<|>RELATION_NOE 量表<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE ,<|>RELATION_NOE 干预<|>RELATION_NOE 1<|>RELATION_NOE 周<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE 2组<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 症状<|>RELATION_NOE 评估<|>RELATION_S 。<|>RELATION_NOE
应用<|>RELATION_NOE 有<|>RELATION_NOE 氧运动<|>RELATION_NOE 、<|>RELATION_NOE 心理<|>RELATION_NOE 疏导<|>RELATION_NOE 、<|>RELATION_NOE 疲乏<|>RELATION_NOE 日记<|>RELATION_NOE 、<|>RELATION_NOE 健康<|>RELATION_NOE 宣教<|>RELATION_NOE 等<|>RELATION_NOE 系统化<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 消除<|>RELATION_I 或<|>RELATION_I 减轻<|>RELATION_E 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 依从性<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 不同<|>RELATION_NOE 转移<|>RELATION_NOE 潜能<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE 埃兹<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE ezrin<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ezrin<|>RELATION_NOE 与<|>RELATION_NOE E-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE CD44V6<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 半定量<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Westernblot<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 不同<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE ezrinmRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 150<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ezrin<|>RELATION_NOE 、<|>RELATION_NOE E-cadherin<|>RELATION_NOE 和<|>RELATION_NOE CD44V6<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE Westernblot<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 新鲜<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 相应<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ezrin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
高<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE ezrinmRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 低<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 。<|>RELATION_NOE
ezrin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 以及<|>RELATION_NOE 病理<|>RELATION_NOE 分级<|>RELATION_NOE 均<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 仅<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 9.0<|>RELATION_NOE 13<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE ezrin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 以及<|>RELATION_NOE 病理<|>RELATION_NOE 分级<|>RELATION_NOE 均<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 仅<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 9.0<|>RELATION_NOE 13<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE ezrin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
ezrin<|>RELATION_NOE 、<|>RELATION_NOE E-eadherin<|>RELATION_NOE 和<|>RELATION_NOE CD44V6<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 发挥<|>RELATION_NOE 着<|>RELATION_NOE 重要<|>RELATION_NOE 的<|>RELATION_NOE 调控<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE ezrin<|>RELATION_NOE 、<|>RELATION_NOE E-eadherin<|>RELATION_NOE 和<|>RELATION_NOE CD44V6<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 判断<|>RELATION_NOE NSCLC<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 生物学<|>RELATION_I 指标<|>RELATION_E 。<|>RELATION_NOE
不同<|>RELATION_NOE 三<|>RELATION_NOE 代<|>RELATION_NOE 新药<|>RELATION_NOE 与<|>RELATION_NOE 铂<|>RELATION_NOE 联合<|>RELATION_NOE 一线<|>RELATION_NOE 双药<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
回顾性<|>RELATION_B 分析<|>RELATION_E 2005年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 8月<|>RELATION_NOE 中国<|>RELATION_NOE 医学<|>RELATION_NOE 科学院<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 11<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 三<|>RELATION_NOE 代<|>RELATION_NOE 新药<|>RELATION_NOE (<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 、<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 、<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 铂类<|>RELATION_NOE (<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE 卡铂<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 一线<|>RELATION_NOE 双药<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE (<|>RELATION_NOE ORR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存期<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 统计学<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_NOE 不同<|>RELATION_NOE 三<|>RELATION_NOE 代<|>RELATION_NOE 新药<|>RELATION_NOE 与<|>RELATION_NOE 铂<|>RELATION_NOE 联合<|>RELATION_NOE 一线<|>RELATION_NOE 双药<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE ORR<|>RELATION_NOE 相似<|>RELATION_S ,<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 卡铂<|>RELATION_NOE 双药<|>RELATION_NOE 方案<|>RELATION_NOE 可<|>RELATION_NOE 延长<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE PFS<|>RELATION_NOE 。<|>RELATION_NOE
环孢素<|>RELATION_NOE A<|>RELATION_NOE 和<|>RELATION_NOE 他<|>RELATION_NOE 克莫司<|>RELATION_NOE 对<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 移植<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
对照组<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_B 给予<|>RELATION_E 任何<|>RELATION_NOE 免疫<|>RELATION_NOE 抑制剂<|>RELATION_NOE ;<|>RELATION_NOE
以<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_S 各组<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
荧光<|>RELATION_NOE 定量<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 抑制基因<|>RELATION_NOE (<|>RELATION_NOE Bcl2<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 促进<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE Bax<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
CsA<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE Tac<|>RELATION_NOE 组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 迁移<|>RELATION_NOE 能力<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE (<|>RELATION_NOE 1.01<|>RELATION_NOE )<|>RELATION_NOE
CsA<|>RELATION_NOE 和<|>RELATION_NOE Tac<|>RELATION_NOE 对<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 移植<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_B 促进<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 会<|>RELATION_NOE 增强<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭力<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 影响<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE
脂联素<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
观察<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 脂联素<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 测定<|>RELATION_S 54<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 24<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 的<|>RELATION_NOE 脂联素<|>RELATION_NOE 浓度<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 及<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 脂联素<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE 1.86<|>RELATION_NOE ±<|>RELATION_NOE 24.38<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE 3.39<|>RELATION_NOE ±<|>RELATION_NOE 51.34<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 脂联素<|>RELATION_NOE 水平<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 血清<|>RELATION_NOE 脂联素<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.19<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 13<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
脂联素<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 降低<|>RELATION_NOE 提示<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 具有<|>RELATION_NOE 更<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 侵袭性<|>RELATION_NOE 和<|>RELATION_NOE 转移性<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 成为<|>RELATION_NOE 反映<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 的<|>RELATION_NOE 一个<|>RELATION_NOE 血清<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 评价<|>RELATION_S P53<|>RELATION_NOE 抗体<|>RELATION_NOE 及<|>RELATION_NOE 核内<|>RELATION_NOE 小<|>RELATION_NOE 核糖体<|>RELATION_NOE 蛋白<|>RELATION_NOE U1-A<|>RELATION_NOE 抗体<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE
评价<|>RELATION_S P53<|>RELATION_NOE 抗体<|>RELATION_NOE 和<|>RELATION_NOE U1AsnRNP<|>RELATION_NOE (<|>RELATION_NOE 核内<|>RELATION_NOE 小<|>RELATION_NOE 核糖体<|>RELATION_NOE 蛋白<|>RELATION_NOE U1-A<|>RELATION_NOE )<|>RELATION_NOE 抗体<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 检测<|>RELATION_S 了<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE P53<|>RELATION_NOE 抗体<|>RELATION_NOE 及<|>RELATION_NOE U1-AsnRNP<|>RELATION_NOE 抗体<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 43<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 血清<|>RELATION_NOE 作<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌组<|>RELATION_NOE 血清<|>RELATION_NOE P53<|>RELATION_NOE 抗体<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 中位数<|>RELATION_NOE (<|>RELATION_NOE 四分位数<|>RELATION_NOE 间距<|>RELATION_NOE )<|>RELATION_NOE E25.38<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE (<|>RELATION_NOE 65.69pg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE 血清<|>RELATION_NOE P53<|>RELATION_NOE 抗体<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 中位数<|>RELATION_NOE (<|>RELATION_NOE 四分位数<|>RELATION_NOE 间距<|>RELATION_NOE )<|>RELATION_NOE [<|>RELATION_NOE 10.45fig<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE (<|>RELATION_NOE 10.44<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 间<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌组<|>RELATION_NOE 血清<|>RELATION_NOE U1-AsnRNP<|>RELATION_NOE 抗体<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 中位数<|>RELATION_NOE (<|>RELATION_NOE 四分位数<|>RELATION_NOE 间距<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 血清<|>RELATION_NOE U1-AsnRNP<|>RELATION_NOE 抗体<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 中位数<|>RELATION_NOE (<|>RELATION_NOE 四分位数<|>RELATION_NOE 间距<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 165.57U<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE (<|>RELATION_NOE 104.51U<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 170.05U<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE (<|>RELATION_NOE 74.12U<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 间<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
P53<|>RELATION_NOE 抗体<|>RELATION_NOE 对<|>RELATION_NOE tP4<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE 血清<|>RELATION_NOE P53<|>RELATION_NOE 抗体<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_B 一定<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E ;<|>RELATION_NOE
U1-AsnRNP<|>RELATION_NOE 抗体<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 欠佳<|>RELATION_NOE 。<|>RELATION_NOE
周期性<|>RELATION_NOE 机械<|>RELATION_NOE 牵拉<|>RELATION_NOE 诱导<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE p38MAPK<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE
探讨<|>RELATION_S p38<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE p38MAPK<|>RELATION_NOE )<|>RELATION_NOE 是否<|>RELATION_NOE 参与<|>RELATION_NOE 周期性<|>RELATION_NOE 机械<|>RELATION_NOE 牵拉<|>RELATION_NOE 刺激<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺泡<|>RELATION_NOE Ⅱ型<|>RELATION_NOE 上皮<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 信号<|>RELATION_NOE 转导<|>RELATION_NOE 过程<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_NOE 离体<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 机械<|>RELATION_NOE 牵拉<|>RELATION_NOE 模型<|>RELATION_NOE :<|>RELATION_NOE 以<|>RELATION_NOE 大小<|>RELATION_NOE 为<|>RELATION_NOE 1000<|>RELATION_NOE μ<|>RELATION_NOE strain<|>RELATION_NOE 的<|>RELATION_NOE 牵拉力<|>RELATION_NOE 刺激<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 刺激<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 刺激<|>RELATION_NOE 后<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 15<|>RELATION_NOE 、<|>RELATION_NOE 30<|>RELATION_NOE 、<|>RELATION_NOE 60min<|>RELATION_NOE 时间点<|>RELATION_NOE 进行<|>RELATION_NOE 观察<|>RELATION_NOE 。<|>RELATION_NOE
分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 患者<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 及<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 在<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
复发<|>RELATION_NOE 后<|>RELATION_NOE 肺转移组<|>RELATION_NOE 患者<|>RELATION_NOE sVEGF<|>RELATION_NOE 、<|>RELATION_NOE sES<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 62<|>RELATION_NOE 3.2<|>RELATION_NOE ±<|>RELATION_NOE 13<|>RELATION_NOE 9.4<|>RELATION_NOE )<|>RELATION_NOE pg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 38.7<|>RELATION_NOE ±<|>RELATION_NOE 9.2<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 局部<|>RELATION_NOE 复发组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE 7.5<|>RELATION_NOE ±<|>RELATION_NOE 60.2<|>RELATION_NOE )<|>RELATION_NOE pg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 31.2<|>RELATION_NOE ±<|>RELATION_NOE 7.6<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.1<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE 2.0<|>RELATION_NOE 92<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺转移组<|>RELATION_NOE 在<|>RELATION_NOE 复发<|>RELATION_NOE 前后<|>RELATION_NOE sVEGF<|>RELATION_NOE 、<|>RELATION_NOE sES<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE 7.6<|>RELATION_NOE ±<|>RELATION_NOE 33.4<|>RELATION_NOE )<|>RELATION_NOE pg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 26.2<|>RELATION_NOE ±<|>RELATION_NOE 6.8<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 397.54-60.2<|>RELATION_NOE )<|>RELATION_NOE pg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 31.2<|>RELATION_NOE ±<|>RELATION_NOE 7.6<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 亦<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 9.<|>RELATION_NOE 609<|>RELATION_NOE ,<|>RELATION_NOE 2.7<|>RELATION_NOE 21<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 甲状腺<|>RELATION_NOE 球<|>RELATION_NOE 蛋白<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE sVEGF<|>RELATION_NOE 及<|>RELATION_NOE sES<|>RELATION_NOE 表达<|>RELATION_NOE 呈<|>RELATION_B 直线<|>RELATION_I 正<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 86<|>RELATION_NOE ,<|>RELATION_NOE 0.3<|>RELATION_NOE 27<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
sVEGF<|>RELATION_NOE 、<|>RELATION_NOE sES<|>RELATION_NOE 在<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 评估<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 项<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 中叶综合征<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE
2002年<|>RELATION_NOE 4月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 3月<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 中叶综合征<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 病因<|>RELATION_NOE 病理<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE :<|>RELATION_NOE 中叶<|>RELATION_NOE 肺癌<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 慢性<|>RELATION_NOE 炎性<|>RELATION_NOE 病变<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 肺囊肿<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 异物<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 结核<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 肺综合征<|>RELATION_NOE 是<|>RELATION_B 合理<|>RELATION_I 可行<|>RELATION_I 的<|>RELATION_E ,<|>RELATION_NOE 且<|>RELATION_NOE 具有<|>RELATION_NOE 损伤<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
miRNAlet7<|>RELATION_NOE 、<|>RELATION_NOE Ras<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
let7<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE (<|>RELATION_NOE 39.7%<|>RELATION_NOE )<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE 75.0%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Ras<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE (<|>RELATION_NOE 66.2%<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_NOE
let7<|>RELATION_NOE 阳性率<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ras<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 与<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE let7<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ras<|>RELATION_NOE 阳性率<|>RELATION_NOE 与<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
let7<|>RELATION_NOE 与<|>RELATION_NOE Ras<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 呈<|>RELATION_B 明显<|>RELATION_I 负<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE -0.627<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_B 分析<|>RELATION_E 56<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 的<|>RELATION_NOE 各项<|>RELATION_NOE 术前<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
本组<|>RELATION_NOE 患者<|>RELATION_NOE 无<|>RELATION_NOE 围术期<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 继发<|>RELATION_NOE 心律失常<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 继发<|>RELATION_NOE 轻度<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE 急性<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 3倒<|>RELATION_NOE ,<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 出血<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 经过<|>RELATION_NOE 积极<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 康复<|>RELATION_NOE 出院<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 创伤<|>RELATION_NOE 比较<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 术前<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 的<|>RELATION_NOE 精心<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 防止<|>RELATION_E 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 痛苦<|>RELATION_NOE ,<|>RELATION_NOE 促进<|>RELATION_NOE 患者<|>RELATION_NOE 顺利<|>RELATION_NOE 康复<|>RELATION_NOE 出院<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 标志<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
评价<|>RELATION_S 肿瘤<|>RELATION_NOE 标志<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 鳞状<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 癌抗原<|>RELATION_NOE (<|>RELATION_NOE SCC-Ag<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片断<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE p16<|>RELATION_NOE 基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
Ag<|>RELATION_NOE 及<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_S 血浆<|>RELATION_NOE 中<|>RELATION_NOE p16<|>RELATION_NOE 甲基化<|>RELATION_NOE 情况<|>RELATION_NOE ;<|>RELATION_NOE
同时<|>RELATION_NOE 运用<|>RELATION_NOE Fisher<|>RELATION_NOE 判<|>RELATION_NOE 别法<|>RELATION_NOE 探讨<|>RELATION_S 该<|>RELATION_NOE 5<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
该<|>RELATION_NOE 5<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 方面<|>RELATION_NOE 有<|>RELATION_B 一定<|>RELATION_I 的<|>RELATION_I 参考<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
64<|>RELATION_NOE 排<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 靶区<|>RELATION_NOE 勾画<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
对<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 检查<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 先后<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE 常规<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 及<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 扫描<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 不同<|>RELATION_NOE 剂量<|>RELATION_NOE 分割<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察组<|>RELATION_NOE 血液<|>RELATION_NOE 系统<|>RELATION_NOE 副<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 4.73<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 发生率<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE p<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
153Sm-EDTMP<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_S 止痛<|>RELATION_NOE 、<|>RELATION_NOE 改善<|>RELATION_NOE 活动<|>RELATION_NOE 能力<|>RELATION_NOE 、<|>RELATION_NOE 提高<|>RELATION_NOE 生治<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
术前<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 亚甲蓝<|>RELATION_NOE 与<|>RELATION_NOE Hookwire<|>RELATION_NOE 联合<|>RELATION_NOE 定位<|>RELATION_NOE 肺小<|>RELATION_NOE 结节<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_I 价值<|>RELATION_E
术后<|>RELATION_NOE 病理<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE (<|>RELATION_NOE BAC<|>RELATION_NOE )<|>RELATION_NOE 33<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 55.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞<|>RELATION_NOE 癌伴<|>RELATION_NOE 腺癌<|>RELATION_NOE (<|>RELATION_NOE BAC<|>RELATION_NOE +<|>RELATION_NOE AC<|>RELATION_NOE )<|>RELATION_NOE 11<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 18.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 增生<|>RELATION_NOE (<|>RELATION_NOE AAH<|>RELATION_NOE )<|>RELATION_NOE 7枚<|>RELATION_NOE (<|>RELATION_NOE 11.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 炎性<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 4<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 6.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 错构瘤<|>RELATION_NOE 3<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 5.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 结核性<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 2<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 3.3%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜术<|>RELATION_NOE 前<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 亚甲蓝<|>RELATION_NOE 与<|>RELATION_NOE Hookwire<|>RELATION_NOE 联合<|>RELATION_NOE 定位<|>RELATION_NOE 准确率<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 楔形<|>RELATION_NOE 切除<|>RELATION_NOE 病灶<|>RELATION_NOE 有<|>RELATION_B 极大<|>RELATION_I 的<|>RELATION_I 帮助<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 具有<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
162<|>RELATION_NOE 例<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 孤立性<|>RELATION_NOE 肺结节<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 延误<|>RELATION_NOE 诊治<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 分析<|>RELATION_E
分析<|>RELATION_S 从<|>RELATION_NOE 发现<|>RELATION_NOE SPN<|>RELATION_NOE 到<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 时间<|>RELATION_NOE 延迟<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 期间<|>RELATION_NOE 各组<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 分布<|>RELATION_NOE 。<|>RELATION_NOE
延误<|>RELATION_NOE 诊治<|>RELATION_NOE 原因<|>RELATION_NOE 按<|>RELATION_NOE 3方面<|>RELATION_NOE 归纳<|>RELATION_NOE :<|>RELATION_NOE 患者<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 患者<|>RELATION_NOE 犹豫<|>RELATION_NOE 、<|>RELATION_NOE 未<|>RELATION_NOE 重视<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 合并症<|>RELATION_NOE 延误<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 医师<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 炎症<|>RELATION_NOE 、<|>RELATION_NOE 结核<|>RELATION_NOE 、<|>RELATION_NOE 陈旧<|>RELATION_NOE 病变<|>RELATION_NOE 、<|>RELATION_NOE 良性肿瘤<|>RELATION_NOE 、<|>RELATION_NOE 转移瘤<|>RELATION_NOE 等<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 医院<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 入院<|>RELATION_NOE 前<|>RELATION_NOE 检查<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
延误<|>RELATION_NOE 时间<|>RELATION_NOE 越<|>RELATION_NOE 长<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 出现<|>RELATION_NOE 增大<|>RELATION_NOE 的<|>RELATION_NOE 可能<|>RELATION_NOE 越<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE ≥<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 及<|>RELATION_NOE 12<|>RELATION_NOE －<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 增大<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 73.3%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 87.5%<|>RELATION_NOE (<|>RELATION_NOE 7/8<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肝细胞癌<|>RELATION_NOE 根治<|>RELATION_NOE 术后<|>RELATION_NOE 早期<|>RELATION_NOE 肺转移<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_S 及<|>RELATION_NOE 预测<|>RELATION_NOE 的<|>RELATION_NOE 数学<|>RELATION_NOE 模型<|>RELATION_NOE
对<|>RELATION_NOE 400<|>RELATION_NOE 例根治<|>RELATION_NOE 性切<|>RELATION_NOE 除术<|>RELATION_NOE 的<|>RELATION_NOE 肝细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 甲胎<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE AFP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 合并<|>RELATION_NOE 乙型<|>RELATION_NOE 肝炎病毒<|>RELATION_NOE (<|>RELATION_NOE HBV<|>RELATION_NOE )<|>RELATION_NOE 感染<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 前<|>RELATION_NOE 肿瘤<|>RELATION_NOE 数目<|>RELATION_NOE 、<|>RELATION_NOE 合并<|>RELATION_NOE 肝硬化<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 包膜<|>RELATION_NOE 、<|>RELATION_NOE 镜下<|>RELATION_NOE 脉管<|>RELATION_NOE 癌栓<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分化<|>RELATION_NOE 分级<|>RELATION_NOE 进行<|>RELATION_NOE 单因素<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 及<|>RELATION_NOE 数学<|>RELATION_NOE 建模<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 1<|>RELATION_NOE 年<|>RELATION_NOE 内<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 判断<|>RELATION_NOE 因素<|>RELATION_NOE 为<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 镜下<|>RELATION_NOE 脉管<|>RELATION_NOE 癌栓<|>RELATION_NOE ,<|>RELATION_NOE 预测<|>RELATION_NOE 概率<|>RELATION_NOE 为<|>RELATION_NOE 1.1<|>RELATION_NOE 4%<|>RELATION_NOE －2<|>RELATION_NOE 7.2<|>RELATION_NOE 3%<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 可溶性<|>RELATION_NOE B7-H4<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
探讨<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 可溶性<|>RELATION_NOE (<|>RELATION_NOE sB7-H4<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
ELISA<|>RELATION_NOE 测定<|>RELATION_S 102<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 90<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 血清<|>RELATION_NOE sB7.H4<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 组<|>RELATION_NOE 血清<|>RELATION_NOE sB7-H4<|>RELATION_NOE 水平<|>RELATION_NOE 高<|>RELATION_NOE 达<|>RELATION_NOE (<|>RELATION_NOE 45.61<|>RELATION_NOE ±<|>RELATION_NOE 5.67<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 良性<|>RELATION_NOE 肺部疾病组<|>RELATION_NOE 和<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 30.14<|>RELATION_NOE ±<|>RELATION_NOE 3.51<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 28.52<|>RELATION_NOE ±<|>RELATION_NOE 4.76<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE 组<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 良性<|>RELATION_NOE 肺部疾病组<|>RELATION_NOE 和<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.59<|>RELATION_NOE 和<|>RELATION_NOE 3.61<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE sB7-H4<|>RELATION_NOE 水平<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 61.73<|>RELATION_NOE ±<|>RELATION_NOE 3.97<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 40.26<|>RELATION_NOE ±<|>RELATION_NOE 5.39<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.73<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ]<|>RELATION_NOE ;<|>RELATION_NOE
探讨<|>RELATION_S 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 棘皮<|>RELATION_NOE 动物<|>RELATION_NOE 微管<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 样4<|>RELATION_NOE 与<|>RELATION_NOE 间变<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE )<|>RELATION_NOE 变异<|>RELATION_NOE 的<|>RELATION_NOE 复杂性<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE TK<|>RELATION_NOE )<|>RELATION_NOE 结构域<|>RELATION_NOE 是否<|>RELATION_NOE 存在<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
3例<|>RELATION_NOE 阳性<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 未<|>RELATION_B 发现<|>RELATION_E ALK<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE TK<|>RELATION_NOE 结构域<|>RELATION_NOE 有<|>RELATION_NOE 耐药<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
E-cadherin<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 联系<|>RELATION_S
探讨<|>RELATION_NOE E-cadherin<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 112<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE E-cadherin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
E-cadherin<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 状况<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 等<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 关系<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 区域<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 状况<|>RELATION_NOE (<|>RELATION_NOE N-status<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 及<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 检测<|>RELATION_NOE E-cadherin<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 判断<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 趋势<|>RELATION_NOE 、<|>RELATION_NOE 及<|>RELATION_NOE 判断<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 有<|>RELATION_B 重要<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
观察<|>RELATION_NOE 临床<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 口服厄洛替尼<|>RELATION_NOE 后<|>RELATION_NOE 出现<|>RELATION_NOE 的<|>RELATION_NOE 药物<|>RELATION_NOE 相关性<|>RELATION_NOE 皮疹<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 诊疗<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_S 皮疹<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE 以及<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 糖类<|>RELATION_NOE 抗原<|>RELATION_NOE CA-125<|>RELATION_NOE 、<|>RELATION_NOE CA-153<|>RELATION_NOE 、<|>RELATION_NOE CA-199<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 价值<|>RELATION_E
选取<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 空腹<|>RELATION_NOE 静脉<|>RELATION_NOE 采<|>RELATION_NOE 血<|>RELATION_NOE 5ml<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 瑞士<|>RELATION_NOE 产全<|>RELATION_NOE 自动<|>RELATION_NOE 化学发<|>RELATION_NOE 光仪<|>RELATION_NOE 测定<|>RELATION_S 血清<|>RELATION_NOE 中<|>RELATION_NOE CA-125<|>RELATION_NOE 、<|>RELATION_NOE CA-153<|>RELATION_NOE 、<|>RELATION_NOE CA-199<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 糖类<|>RELATION_NOE 抗原<|>RELATION_NOE CA<|>RELATION_NOE .<|>RELATION_NOE
联合<|>RELATION_NOE 检测<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 糖类<|>RELATION_NOE 抗原<|>RELATION_NOE CA<|>RELATION_NOE .<|>RELATION_NOE
多<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 预防<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 中<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_B 观察<|>RELATION_E
观察<|>RELATION_S 多<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 预防<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 中<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 接受<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 115<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 58<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 止吐<|>RELATION_NOE 方案<|>RELATION_NOE 为<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 半<|>RELATION_NOE 小时<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 阿扎司琼<|>RELATION_NOE 10mg<|>RELATION_NOE /<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE —<|>RELATION_NOE 5<|>RELATION_NOE 天<|>RELATION_NOE ;<|>RELATION_NOE
静脉<|>RELATION_NOE 注射<|>RELATION_NOE 地塞米松<|>RELATION_NOE 10mg<|>RELATION_NOE /<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE －3<|>RELATION_NOE 天<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 对照<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 加<|>RELATION_NOE 用<|>RELATION_NOE 异丙嗪<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE 次<|>RELATION_NOE 、<|>RELATION_NOE 甲氧氯普胺<|>RELATION_NOE 10mg<|>RELATION_NOE /<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 半<|>RELATION_NOE 小时<|>RELATION_NOE 肌肉<|>RELATION_NOE 注射<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE －<|>RELATION_NOE 5<|>RELATION_NOE 天<|>RELATION_NOE ;<|>RELATION_NOE
观察<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 预防<|>RELATION_NOE 急性<|>RELATION_NOE 、<|>RELATION_NOE 迟发性<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 中<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 特别<|>RELATION_NOE 是<|>RELATION_NOE 对<|>RELATION_NOE 迟发性<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 有<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
周剂量<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 同步<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
观察<|>RELATION_NOE 周剂量<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 同步<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 毒副反应<|>RELATION_NOE 。<|>RELATION_NOE
50<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 全部<|>RELATION_NOE 完成<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE ,<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE 12.0%<|>RELATION_NOE (<|>RELATION_NOE 6/50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE 64.0%<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE /<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 76.0%<|>RELATION_NOE (<|>RELATION_NOE 38<|>RELATION_NOE /<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无效<|>RELATION_NOE 和<|>RELATION_NOE 进展<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 12.0%<|>RELATION_NOE (<|>RELATION_NOE 6/50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 和<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 22%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 64%<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE /<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
托瑞米芬<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE p53<|>RELATION_NOE 缺<|>RELATION_NOE 失型<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE H1299<|>RELATION_NOE 生长<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
本<|>RELATION_NOE 研究<|>RELATION_NOE 设<|>RELATION_NOE 空白<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 单细胞<|>RELATION_NOE 悬液<|>RELATION_NOE 100ul<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 实验组<|>RELATION_NOE (<|>RELATION_NOE 单细胞<|>RELATION_NOE 悬液<|>RELATION_NOE 100ul<|>RELATION_NOE +<|>RELATION_NOE 不同<|>RELATION_NOE 药物<|>RELATION_NOE 及<|>RELATION_NOE 浓度<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 又<|>RELATION_NOE 分为<|>RELATION_NOE 托瑞米芬<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE 该2<|>RELATION_NOE 种<|>RELATION_NOE 药物<|>RELATION_NOE 联合组<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑兰<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S 托瑞米芬<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联用<|>RELATION_NOE 后<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 抑制率<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 细胞周期<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE
托瑞米芬<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联用<|>RELATION_NOE 促进<|>RELATION_S H1299<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 呈现<|>RELATION_NOE 浓度<|>RELATION_NOE 依赖性<|>RELATION_NOE 。<|>RELATION_NOE
托瑞米芬<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联用<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 单用<|>RELATION_NOE 顺铂<|>RELATION_NOE 组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE H1299<|>RELATION_NOE 细胞周期<|>RELATION_NOE 发生<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE G0<|>RELATION_NOE /<|>RELATION_NOE G1<|>RELATION_NOE 期<|>RELATION_NOE 比例<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE S<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 出<|>RELATION_NOE 44.9%<|>RELATION_NOE 的<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 有<|>RELATION_NOE P<|>RELATION_NOE 糖<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 存在<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 单药<|>RELATION_NOE 与<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 单药<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 毒性<|>RELATION_NOE 比较<|>RELATION_NOE
选<|>RELATION_NOE 我<|>RELATION_NOE 院非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 61<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 全部<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 初治<|>RELATION_NOE 且<|>RELATION_NOE 连续<|>RELATION_NOE 使用<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 同样<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 化疗2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 评价<|>RELATION_NOE ,<|>RELATION_NOE 除了<|>RELATION_NOE 病情<|>RELATION_NOE 进展<|>RELATION_NOE 改用<|>RELATION_NOE 其他<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 余<|>RELATION_NOE 均<|>RELATION_NOE 按<|>RELATION_NOE 原<|>RELATION_NOE 方案<|>RELATION_NOE 再<|>RELATION_NOE 巩固<|>RELATION_NOE 化疗2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 完成<|>RELATION_NOE 分组<|>RELATION_NOE 治疗<|>RELATION_NOE 病例<|>RELATION_NOE 共<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 采用<|>RELATION_NOE 化学<|>RELATION_NOE 治疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 分为<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛组<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨组<|>RELATION_NOE (<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
①<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛组<|>RELATION_NOE :<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他赛<|>RELATION_NOE 70mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 溶于<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 注射液<|>RELATION_NOE 250ml<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 1h<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE ,<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 21<|>RELATION_NOE 天<|>RELATION_NOE 为<|>RELATION_NOE 1周期<|>RELATION_NOE ;<|>RELATION_NOE
②<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨组<|>RELATION_NOE :<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 25ng<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 溶于<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 注射液<|>RELATION_NOE 100nd<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 1次<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 时间<|>RELATION_NOE 需<|>RELATION_NOE ><|>RELATION_NOE 10min<|>RELATION_NOE ,<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 注射<|>RELATION_NOE 液冲<|>RELATION_NOE 管<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE ,<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 21<|>RELATION_NOE 天<|>RELATION_NOE 为<|>RELATION_NOE 1周期<|>RELATION_NOE ,<|>RELATION_NOE 观察4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
研究<|>RELATION_B 和<|>RELATION_I 评价<|>RELATION_E 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 毒副反应<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 我院<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病区<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 经病<|>RELATION_NOE 理学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 初治<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 方案<|>RELATION_NOE 如下<|>RELATION_NOE :<|>RELATION_NOE 注射<|>RELATION_NOE 用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞二钠<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE +<|>RELATION_NOE 注射<|>RELATION_NOE 用<|>RELATION_NOE 顺铂<|>RELATION_NOE 72mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 为<|>RELATION_NOE 1周期<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 至少<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 确切<|>RELATION_NOE ,<|>RELATION_NOE 耐受性<|>RELATION_NOE 良好<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 诊断<|>RELATION_NOE 明确<|>RELATION_NOE 的<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
应<|>RELATION_NOE 综合<|>RELATION_NOE 运用<|>RELATION_NOE B<|>RELATION_NOE 超<|>RELATION_NOE 、<|>RELATION_NOE 细针<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 快速<|>RELATION_NOE 冰冻<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 等<|>RELATION_NOE 方法<|>RELATION_NOE 以<|>RELATION_NOE 求<|>RELATION_NOE 提高<|>RELATION_S 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 术后<|>RELATION_NOE 仍<|>RELATION_NOE 需<|>RELATION_NOE 长期<|>RELATION_NOE 随访.<|>RELATION_NOE
血清<|>RELATION_NOE 唾液酸<|>RELATION_NOE 水平<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
评估<|>RELATION_NOE 血清<|>RELATION_NOE 唾液酸<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 疗效<|>RELATION_NOE 监测<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
健康<|>RELATION_NOE 对照组<|>RELATION_NOE 血清<|>RELATION_NOE 唾液酸<|>RELATION_NOE 水平<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 568<|>RELATION_NOE ±<|>RELATION_NOE 62<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌组<|>RELATION_NOE 血清<|>RELATION_NOE 唾液酸<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 639<|>RELATION_NOE ±<|>RELATION_NOE 92<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 813<|>RELATION_NOE ±<|>RELATION_NOE 218<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 的<|>RELATION_NOE 唾液酸<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
根据<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 数值<|>RELATION_NOE ,<|>RELATION_NOE 唾液酸<|>RELATION_NOE 检测<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE Cut-off<|>RELATION_NOE 值<|>RELATION_NOE 为<|>RELATION_NOE 695<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 敏感度<|>RELATION_NOE 为<|>RELATION_NOE 69.00%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 为<|>RELATION_NOE 88.90%<|>RELATION_NOE .<|>RELATION_NOE
100<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞腺癌<|>RELATION_NOE 和<|>RELATION_NOE 未分化癌<|>RELATION_NOE 各<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE .<|>RELATION_NOE
其中<|>RELATION_NOE 腺癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 鳞<|>RELATION_NOE 癌组<|>RELATION_NOE 、<|>RELATION_NOE 鳞腺癌<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 未分化<|>RELATION_NOE 癌组<|>RELATION_NOE 血清<|>RELATION_NOE 唾液酸<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 845<|>RELATION_NOE ±<|>RELATION_NOE 91<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 782<|>RELATION_NOE ±<|>RELATION_NOE 91<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 794<|>RELATION_NOE ±<|>RELATION_NOE 126<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 831<|>RELATION_NOE ±<|>RELATION_NOE 113<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 组织<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 唾液酸<|>RELATION_NOE 含量<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 各<|>RELATION_NOE 组织<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 唾液酸<|>RELATION_NOE 含量<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 唾液酸<|>RELATION_NOE 水平<|>RELATION_NOE 随着<|>RELATION_NOE 肿瘤分级<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 升高<|>RELATION_NOE 而<|>RELATION_NOE 升高<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 中<|>RELATION_NOE 唾液酸<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 筛查<|>RELATION_NOE 、<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 疗效<|>RELATION_NOE 评估<|>RELATION_NOE 及<|>RELATION_NOE 监测<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_B 重要<|>RELATION_I 意义<|>RELATION_E .<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 和<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 骨髓微<|>RELATION_NOE 转移<|>RELATION_NOE
选取<|>RELATION_NOE 2004年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 2007年<|>RELATION_NOE 5月<|>RELATION_NOE 我院<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 160<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 术前<|>RELATION_NOE 未经<|>RELATION_NOE 化疗<|>RELATION_NOE 及<|>RELATION_NOE 放疗<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 抽取<|>RELATION_NOE 肋骨<|>RELATION_NOE 骨髓<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 应用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞<|>RELATION_NOE 技术<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_S 骨髓<|>RELATION_NOE 中<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE 表达率<|>RELATION_NOE 。<|>RELATION_NOE
160<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检测<|>RELATION_NOE 骨髓<|>RELATION_NOE 转移<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 30.0%<|>RELATION_NOE (<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE 骨髓<|>RELATION_NOE 转移<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 34.4%<|>RELATION_NOE (<|>RELATION_NOE 55<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
112<|>RELATION_NOE 例<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检查<|>RELATION_NOE 阴性<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 骨髓<|>RELATION_NOE 中<|>RELATION_NOE 存在<|>RELATION_NOE 微转移<|>RELATION_NOE ;<|>RELATION_NOE
进口<|>RELATION_NOE 与<|>RELATION_NOE 国产<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞二钠<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 成本<|>RELATION_NOE 效果<|>RELATION_NOE 分析<|>RELATION_NOE
对<|>RELATION_NOE 进口<|>RELATION_NOE 与<|>RELATION_NOE 国产<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞二钠<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_NOE 成本<|>RELATION_NOE 效果<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
筛选<|>RELATION_NOE 2009年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 7月<|>RELATION_NOE 我院<|>RELATION_NOE 应用<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞二钠<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 中<|>RELATION_NOE 选用<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞二钠<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 将<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 进口<|>RELATION_NOE 药组<|>RELATION_NOE (<|>RELATION_NOE 应用<|>RELATION_NOE 进口培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞二钠<|>RELATION_NOE ,<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 国产<|>RELATION_NOE 药组<|>RELATION_NOE (<|>RELATION_NOE 应用<|>RELATION_NOE 国产培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞二钠<|>RELATION_NOE ,<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE 药物<|>RELATION_NOE 经济学<|>RELATION_NOE 成本<|>RELATION_NOE -<|>RELATION_NOE 效果<|>RELATION_NOE 分析<|>RELATION_NOE 方法<|>RELATION_NOE 进行<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
微波<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_S 肺部<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
评估<|>RELATION_S 微波<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_NOE 原发性<|>RELATION_NOE 或<|>RELATION_NOE 复发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2005年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 间<|>RELATION_NOE 在<|>RELATION_NOE 唐都<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 69<|>RELATION_NOE 例<|>RELATION_NOE 原发<|>RELATION_NOE 或<|>RELATION_NOE 复发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 及<|>RELATION_NOE 肺转移癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 不同<|>RELATION_NOE 大小<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 内<|>RELATION_NOE 生存率<|>RELATION_NOE 及<|>RELATION_NOE 病死率<|>RELATION_NOE 进行<|>RELATION_B 比较<|>RELATION_E 。<|>RELATION_NOE
①<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE :<|>RELATION_NOE 共计<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 气胸<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 咯血<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 血胸<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 肺炎<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 暂时性<|>RELATION_NOE 胸痛<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 低热<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 皮肤<|>RELATION_NOE 烧伤<|>RELATION_NOE .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺转移<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 和<|>RELATION_NOE 3年<|>RELATION_NOE 的<|>RELATION_NOE 总<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 77.1%<|>RELATION_NOE (<|>RELATION_NOE 37<|>RELATION_NOE /<|>RELATION_NOE 48<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 43.7%<|>RELATION_NOE (<|>RELATION_NOE 21<|>RELATION_NOE /<|>RELATION_NOE 48<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 22.9%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 48<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 52.4%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 28.6%<|>RELATION_NOE (<|>RELATION_NOE 6/21<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 14.3%<|>RELATION_NOE (<|>RELATION_NOE 3/21<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肺部肿瘤<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 延长<|>RELATION_S 癌症<|>RELATION_NOE 患者<|>RELATION_NOE 生存期<|>RELATION_NOE 、<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 率.<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 延长<|>RELATION_NOE 癌症<|>RELATION_NOE 患者<|>RELATION_NOE 生存期<|>RELATION_NOE 、<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E 患者<|>RELATION_NOE 生存率<|>RELATION_NOE .<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 有效<|>RELATION_B 的<|>RELATION_I 方法<|>RELATION_I 之一<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 易于<|>RELATION_NOE 耐受<|>RELATION_NOE 。<|>RELATION_NOE
共有<|>RELATION_NOE 8例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 误诊<|>RELATION_NOE ,<|>RELATION_NOE 误诊率<|>RELATION_NOE 为<|>RELATION_NOE 72.7<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 8/11<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 2例<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肺结核<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_S 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 加用<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE (<|>RELATION_NOE 恩度<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE 选取<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 加<|>RELATION_B 用<|>RELATION_E 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE (<|>RELATION_NOE 恩度<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 可靠<|>RELATION_S ,<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 严重<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 克服<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 耐药性<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 手段<|>RELATION_NOE 。<|>RELATION_NOE
复方<|>RELATION_NOE 阿胶浆<|>RELATION_NOE 治疗<|>RELATION_S 化疗<|>RELATION_NOE 周期<|>RELATION_NOE 血红<|>RELATION_NOE 蛋白<|>RELATION_NOE 降低<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
盐酸埃克替尼<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 盐酸埃克替尼<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 毒副反应<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 有<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因检测<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 19<|>RELATION_NOE 外显子<|>RELATION_NOE 缺失<|>RELATION_NOE 突变<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 错义<|>RELATION_NOE 突变<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 20<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 双<|>RELATION_NOE 突变<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 野生型<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
59<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 45.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 28.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 25.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 为<|>RELATION_NOE 45.8%<|>RELATION_NOE (<|>RELATION_NOE 27<|>RELATION_NOE /<|>RELATION_NOE 59<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 为<|>RELATION_NOE 74.6%<|>RELATION_NOE (<|>RELATION_NOE 44<|>RELATION_NOE /<|>RELATION_NOE 59<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 为<|>RELATION_NOE 73.9%<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE /<|>RELATION_NOE 23<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 为<|>RELATION_NOE 95.7%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 23<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
59<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 61.0%<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 症状<|>RELATION_NOE 缓解<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 缓解<|>RELATION_NOE 的<|>RELATION_NOE 症状<|>RELATION_NOE 为<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 喘憋<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 和<|>RELATION_NOE 声嘶<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
盐酸埃克替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 美国<|>RELATION_NOE 东部<|>RELATION_NOE 肿瘤<|>RELATION_NOE 协作组<|>RELATION_NOE (<|>RELATION_NOE ECOG<|>RELATION_NOE )<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 方式<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 、<|>RELATION_NOE 皮疹<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 针吸活<|>RELATION_NOE 检术<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 经<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 体层<|>RELATION_NOE 摄影<|>RELATION_NOE 检查<|>RELATION_NOE 诊断<|>RELATION_NOE 纵隔<|>RELATION_NOE 阳性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 评估<|>RELATION_S
PET-CT<|>RELATION_NOE 检查<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 并<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 代谢<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 异常<|>RELATION_NOE 浓<|>RELATION_NOE 聚<|>RELATION_NOE ,<|>RELATION_NOE 标准<|>RELATION_NOE 摄取值<|>RELATION_NOE (<|>RELATION_NOE SUV<|>RELATION_NOE )<|>RELATION_NOE ><|>RELATION_NOE 2.5<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE PET-CT<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 纵隔<|>RELATION_NOE 阳性<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 再行<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE ,<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 为<|>RELATION_NOE 95.7%<|>RELATION_NOE ,<|>RELATION_NOE 灵敏度<|>RELATION_NOE 为<|>RELATION_NOE 95.7%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE 。<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 作为<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结病<|>RELATION_NOE 理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 检查<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 创伤性<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 准确性<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE PET-CT<|>RELATION_NOE 检查<|>RELATION_NOE 为<|>RELATION_NOE 纵隔<|>RELATION_NOE 阳性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 评估<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 可行<|>RELATION_NOE 和<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 。<|>RELATION_NOE
促<|>RELATION_NOE 红细胞生成素<|>RELATION_NOE 及其<|>RELATION_NOE 受体<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 31<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EPO<|>RELATION_NOE 和<|>RELATION_NOE EPO-R<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 肺良<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 组织<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE EPO<|>RELATION_NOE 和<|>RELATION_NOE EPO-R<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 各<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE CD34<|>RELATION_NOE 标记<|>RELATION_NOE 血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EPO<|>RELATION_NOE 和<|>RELATION_NOE EPO-R<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 67.7%<|>RELATION_NOE 和<|>RELATION_NOE 96.8%<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 19.4%<|>RELATION_NOE 和<|>RELATION_NOE 35.5%<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺良性<|>RELATION_NOE 病变<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 9.5%<|>RELATION_NOE 和<|>RELATION_NOE 19.O<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EPO<|>RELATION_NOE 和<|>RELATION_NOE EPO-R<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_S 102<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE CD4<|>RELATION_NOE 、<|>RELATION_NOE IL-17<|>RELATION_NOE 、<|>RELATION_NOE Foxp3<|>RELATION_NOE 、<|>RELATION_NOE CD31<|>RELATION_NOE 和<|>RELATION_NOE CD34<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
冠状动脉<|>RELATION_NOE 支架<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_B 分析<|>RELATION_E
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 8例<|>RELATION_NOE 合并<|>RELATION_NOE 严重<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 狭窄<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 完成<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 支架<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE (<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 支架<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 同期<|>RELATION_NOE 未<|>RELATION_NOE 合并<|>RELATION_NOE 心血管疾病<|>RELATION_NOE 、<|>RELATION_NOE 未行<|>RELATION_NOE 抗凝<|>RELATION_NOE 治疗<|>RELATION_NOE 但<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
冠状动脉<|>RELATION_NOE 支架<|>RELATION_NOE 组<|>RELATION_NOE 8例<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 支架<|>RELATION_NOE 20<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 左前<|>RELATION_NOE 降支<|>RELATION_NOE 7<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 左<|>RELATION_NOE 回旋<|>RELATION_NOE 支<|>RELATION_NOE 8<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 右<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 5枚<|>RELATION_NOE ;<|>RELATION_NOE
手术<|>RELATION_NOE 成功率<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 8/8<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 狭窄<|>RELATION_NOE 程度<|>RELATION_NOE 由<|>RELATION_NOE 术前<|>RELATION_NOE 的<|>RELATION_NOE 80%<|>RELATION_NOE -100<|>RELATION_NOE %<|>RELATION_NOE 降<|>RELATION_NOE 至<|>RELATION_NOE 术后<|>RELATION_NOE 的<|>RELATION_NOE 5%<|>RELATION_NOE 以下<|>RELATION_NOE ,<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 支架<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 至<|>RELATION_NOE 肺叶切<|>RELATION_NOE 除术<|>RELATION_NOE 前<|>RELATION_NOE 行<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 造影<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 明显<|>RELATION_NOE 狭窄<|>RELATION_NOE ,<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术前<|>RELATION_NOE NYHA<|>RELATION_NOE 心<|>RELATION_NOE 功能<|>RELATION_NOE 分级<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 1级<|>RELATION_NOE ;<|>RELATION_NOE
左<|>RELATION_NOE 肺上叶<|>RELATION_NOE 肺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 左<|>RELATION_NOE 肺下叶<|>RELATION_NOE 肺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 上<|>RELATION_NOE 叶<|>RELATION_NOE 肺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 中<|>RELATION_NOE 下<|>RELATION_NOE 叶<|>RELATION_NOE 肺癌<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 切<|>RELATION_NOE 121<|>RELATION_NOE 感染<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 二<|>RELATION_NOE 次<|>RELATION_NOE 开胸<|>RELATION_NOE 止血<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
冠状动脉<|>RELATION_NOE 支架组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 支架<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 引流量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE 25<|>RELATION_NOE ±<|>RELATION_NOE 248<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 10.0±<|>RELATION_NOE 2.1<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.5<|>RELATION_NOE ±<|>RELATION_NOE 1.9<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 1200<|>RELATION_NOE ±<|>RELATION_NOE 263<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.0<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 4.5<|>RELATION_NOE ±<|>RELATION_NOE 2.3<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 合理<|>RELATION_NOE 的<|>RELATION_NOE 术前<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 应用<|>RELATION_NOE 抗凝<|>RELATION_NOE 药物<|>RELATION_NOE 、<|>RELATION_NOE 充分<|>RELATION_NOE 做好<|>RELATION_NOE 围手术期<|>RELATION_NOE 准备<|>RELATION_NOE 的<|>RELATION_NOE 前提<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 支架<|>RELATION_NOE 植入术<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 可行<|>RELATION_NOE 的<|>RELATION_NOE 。<|>RELATION_NOE
紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE
探讨<|>RELATION_S 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 永城市<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 于<|>RELATION_NOE 2008年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 3月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 使用<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 进行<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 即<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 135mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2第1<|>RELATION_NOE 天<|>RELATION_NOE 加<|>RELATION_NOE 卡铂<|>RELATION_NOE 300mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 4周<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 治疗<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 以后<|>RELATION_NOE 观察<|>RELATION_NOE 分析<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
不良<|>RELATION_NOE 反应<|>RELATION_NOE 主要<|>RELATION_NOE 以<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 度<|>RELATION_NOE 以上<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降率<|>RELATION_NOE 为<|>RELATION_NOE 35.5%<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 轻微<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 脱发<|>RELATION_NOE 。<|>RELATION_NOE
紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 安全<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 容易<|>RELATION_NOE 忍受<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 能够<|>RELATION_NOE 改善<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 机体<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 延长<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
康艾<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
观察<|>RELATION_S 康艾<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨单<|>RELATION_NOE 药<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 58<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 原发性<|>RELATION_NOE 胰腺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
纳入<|>RELATION_NOE 28<|>RELATION_NOE 篇<|>RELATION_NOE 文献<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 诊断<|>RELATION_NOE 明确<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 加上<|>RELATION_NOE 鼓楼<|>RELATION_NOE 医院<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE 胰腺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
该病<|>RELATION_NOE 以<|>RELATION_NOE 男性<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 年龄<|>RELATION_NOE 62<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 以<|>RELATION_NOE 腹痛<|>RELATION_NOE 、<|>RELATION_NOE 黄疸<|>RELATION_NOE 及<|>RELATION_NOE 消瘦<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 少<|>RELATION_NOE 产生<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤<|>RELATION_NOE 综合征<|>RELATION_NOE ;<|>RELATION_NOE
多<|>RELATION_NOE 见<|>RELATION_NOE 血清<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 升高<|>RELATION_NOE ;<|>RELATION_NOE
胰腺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 发生率<|>RELATION_NOE 低<|>RELATION_NOE 、<|>RELATION_NOE 恶性<|>RELATION_NOE 程度<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 侵袭性<|>RELATION_NOE 强<|>RELATION_NOE 、<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_NOE 的<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 。<|>RELATION_NOE
小檗胺<|>RELATION_NOE 诱导<|>RELATION_S 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 视网膜<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE HXO-RB44<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
体外<|>RELATION_NOE 培养<|>RELATION_NOE RB<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 取<|>RELATION_NOE 对<|>RELATION_NOE 数<|>RELATION_NOE 生长期<|>RELATION_NOE 细胞<|>RELATION_NOE 分为<|>RELATION_NOE BBM<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
4<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 、<|>RELATION_NOE 16mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE BBM<|>RELATION_NOE 作用<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 早期<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE ,<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 、<|>RELATION_NOE 16mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE BBM<|>RELATION_NOE 作用<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 早期<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE ,<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE B<|>RELATION_NOE 细胞<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE /<|>RELATION_NOE 白血病<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE bcl-2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Bax<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S 半胱氨酸<|>RELATION_NOE 蛋白酶<|>RELATION_NOE -3<|>RELATION_NOE (<|>RELATION_NOE Caspase-3<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
BBM<|>RELATION_NOE 以<|>RELATION_NOE 时间<|>RELATION_NOE 剂量<|>RELATION_NOE 依赖<|>RELATION_NOE 方式<|>RELATION_NOE 显著<|>RELATION_B 抑制<|>RELATION_E RB<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增生<|>RELATION_NOE (<|>RELATION_NOE 24h<|>RELATION_NOE :<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 70.5<|>RELATION_NOE 47<|>RELATION_NOE ,<|>RELATION_NOE 48h<|>RELATION_NOE :<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 60<|>RELATION_NOE 3.4<|>RELATION_NOE 38<|>RELATION_NOE ,<|>RELATION_NOE 72h<|>RELATION_NOE :<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 57<|>RELATION_NOE 7.5<|>RELATION_NOE 21<|>RELATION_NOE ;<|>RELATION_NOE
空白<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE BBM<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 坏死率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 1.25<|>RELATION_NOE ±<|>RELATION_NOE 0.45<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 4.10<|>RELATION_NOE ±<|>RELATION_NOE 2.9<|>RELATION_NOE 5)%<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 4.39<|>RELATION_NOE ±<|>RELATION_NOE 0.21<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 10.54<|>RELATION_NOE ±<|>RELATION_NOE 4.38<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 6.5<|>RELATION_NOE 27<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
总结<|>RELATION_NOE 同<|>RELATION_NOE 种<|>RELATION_NOE 异体<|>RELATION_NOE 原位<|>RELATION_NOE 肺移植术<|>RELATION_NOE 后<|>RELATION_NOE 早期<|>RELATION_NOE 监护<|>RELATION_NOE 与<|>RELATION_NOE 治疗<|>RELATION_NOE 经验<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 提高<|>RELATION_S 肺移植<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 成功率<|>RELATION_NOE 。<|>RELATION_NOE
病<|>RELATION_NOE 因为<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 肺<|>RELATION_NOE 淋巴管<|>RELATION_NOE 平滑肌瘤病<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE (<|>RELATION_NOE 支扩<|>RELATION_NOE )<|>RELATION_NOE 2例<|>RELATION_NOE ;<|>RELATION_NOE
行<|>RELATION_NOE 单纯<|>RELATION_NOE 左<|>RELATION_NOE 肺移植<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 移植<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 双侧单<|>RELATION_NOE 肺序贯式<|>RELATION_NOE 肺移植<|>RELATION_NOE 5例<|>RELATION_NOE 。<|>RELATION_NOE
死亡<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 死<|>RELATION_NOE 因为<|>RELATION_NOE 感染<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 循环衰竭<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
肺移植术<|>RELATION_NOE 后<|>RELATION_NOE 早期<|>RELATION_NOE 处理<|>RELATION_NOE 应<|>RELATION_NOE 重视<|>RELATION_NOE 血流动力学<|>RELATION_NOE 监测<|>RELATION_NOE 和<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE 合理<|>RELATION_NOE 应用<|>RELATION_NOE 血管<|>RELATION_NOE 活<|>RELATION_NOE 性药<|>RELATION_NOE 和<|>RELATION_NOE 利尿<|>RELATION_NOE 药物<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 药物<|>RELATION_NOE 和<|>RELATION_NOE 通气<|>RELATION_NOE 调整<|>RELATION_NOE 肺循环<|>RELATION_NOE 阻力<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 肺<|>RELATION_NOE 保护<|>RELATION_NOE 机械通气<|>RELATION_NOE 策略<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 机械通气<|>RELATION_NOE 和<|>RELATION_NOE 带<|>RELATION_NOE 管<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 控制术<|>RELATION_NOE 后<|>RELATION_NOE 肺<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 患病率<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 肺移植<|>RELATION_NOE 患者<|>RELATION_NOE 安全<|>RELATION_NOE 度过<|>RELATION_NOE 围术期<|>RELATION_NOE 至关重要<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 2006年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 6月<|>RELATION_NOE 连续<|>RELATION_NOE 开展<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 复杂<|>RELATION_NOE 的<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 58<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE 结果<|>RELATION_NOE 腺癌<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 类癌<|>RELATION_NOE 各<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 大<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 肉瘤<|>RELATION_NOE 样癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
黄芩苷<|>RELATION_NOE 体外<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
1.22mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 黄芩<|>RELATION_NOE 苷<|>RELATION_NOE 孵育<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 收集<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 逆转<|>RELATION_NOE 录.<|>RELATION_NOE
聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 测定<|>RELATION_S 增殖<|>RELATION_NOE 细胞核<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE PCNA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞周期<|>RELATION_NOE 蛋白1<|>RELATION_NOE (<|>RELATION_NOE CyclinD1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE p21mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ;<|>RELATION_NOE
与<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 1.75<|>RELATION_NOE ±<|>RELATION_NOE 0.05<|>RELATION_NOE ,<|>RELATION_NOE 1.59<|>RELATION_NOE ±<|>RELATION_NOE 0.24<|>RELATION_NOE ,<|>RELATION_NOE 0.59<|>RELATION_NOE ±<|>RELATION_NOE 0.02<|>RELATION_NOE )<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 黄芩<|>RELATION_NOE 苷组<|>RELATION_NOE PCNA<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.34<|>RELATION_NOE ±<|>RELATION_NOE 0.02<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CyclinD1<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.50<|>RELATION_NOE ±<|>RELATION_NOE 0.02<|>RELATION_NOE )<|>RELATION_NOE 冠著<|>RELATION_NOE 下降<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE p21<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 1.39<|>RELATION_NOE ±<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 与<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 长链<|>RELATION_NOE 非编码<|>RELATION_NOE RNA<|>RELATION_NOE 表达<|>RELATION_NOE 谱<|>RELATION_NOE 的<|>RELATION_NOE 筛选<|>RELATION_S
应用<|>RELATION_NOE 高通量<|>RELATION_NOE 长链<|>RELATION_NOE 非编码<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE 1ncRNA<|>RELATION_NOE )<|>RELATION_NOE 芯片<|>RELATION_NOE 检测<|>RELATION_S 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE IncRNA<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 进行<|>RELATION_NOE 初步<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
分别<|>RELATION_NOE 提取<|>RELATION_NOE 6例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE RNA<|>RELATION_NOE ,<|>RELATION_NOE 体外<|>RELATION_NOE 逆转<|>RELATION_NOE 录制<|>RELATION_NOE 备<|>RELATION_NOE 并<|>RELATION_NOE 标记<|>RELATION_NOE 为<|>RELATION_NOE 双链<|>RELATION_NOE cDNA<|>RELATION_NOE (<|>RELATION_NOE ds-cDNA<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 含有<|>RELATION_NOE 22000<|>RELATION_NOE 条<|>RELATION_NOE lncRNA<|>RELATION_NOE 芯片<|>RELATION_NOE 进行<|>RELATION_NOE 杂交<|>RELATION_NOE ,<|>RELATION_NOE 计算机<|>RELATION_NOE 扫描<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 芯片<|>RELATION_NOE 荧光<|>RELATION_NOE 信号<|>RELATION_NOE 图像<|>RELATION_NOE ,<|>RELATION_NOE 筛选<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE lncRNA<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE lncRNA<|>RELATION_NOE 达<|>RELATION_NOE 10<|>RELATION_NOE 25<|>RELATION_NOE 条<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE IncRNA464<|>RELATION_NOE 条<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE IncRNA561<|>RELATION_NOE 条<|>RELATION_NOE (<|>RELATION_NOE 变化<|>RELATION_NOE ><|>RELATION_NOE 2倍且<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE α<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 耐<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 逆转<|>RELATION_B 作用<|>RELATION_E
250<|>RELATION_NOE 、<|>RELATION_NOE 1000U<|>RELATION_NOE /<|>RELATION_NOE mlTNF-<|>RELATION_NOE α<|>RELATION_NOE 可<|>RELATION_NOE 使<|>RELATION_NOE DDP<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 半数<|>RELATION_NOE 抑制<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IC50<|>RELATION_NOE )<|>RELATION_NOE 从<|>RELATION_NOE 7.12mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 分别<|>RELATION_NOE 降<|>RELATION_NOE 至<|>RELATION_NOE 5.02<|>RELATION_NOE 、<|>RELATION_NOE 4.28mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 逆转<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 对<|>RELATION_NOE DDP<|>RELATION_NOE 的<|>RELATION_NOE 耐药<|>RELATION_NOE ,<|>RELATION_NOE 逆转<|>RELATION_NOE 倍数<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.4<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 1.6<|>RELATION_NOE 63<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
表观<|>RELATION_NOE 遗传<|>RELATION_NOE 调控<|>RELATION_NOE 联合<|>RELATION_NOE 内分泌<|>RELATION_NOE 治疗<|>RELATION_NOE 降低<|>RELATION_S 女性<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE NCI-H1975<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE
观察<|>RELATION_S 通过<|>RELATION_NOE 表观<|>RELATION_NOE 遗传<|>RELATION_NOE 调控<|>RELATION_NOE 手段<|>RELATION_NOE 联合<|>RELATION_NOE 内分泌<|>RELATION_NOE 治疗<|>RELATION_NOE 对于<|>RELATION_NOE 女性<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE NCI-H1975<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 组<|>RELATION_NOE 蛋白<|>RELATION_NOE 去<|>RELATION_NOE 乙酰化酶<|>RELATION_NOE (<|>RELATION_NOE HDAC<|>RELATION_NOE )<|>RELATION_NOE 抑制剂<|>RELATION_NOE 曲古<|>RELATION_NOE 抑菌素<|>RELATION_NOE A<|>RELATION_NOE (<|>RELATION_NOE TSA<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE DNA<|>RELATION_NOE 甲基<|>RELATION_NOE 转移酶<|>RELATION_NOE (<|>RELATION_NOE DNMTI<|>RELATION_NOE )<|>RELATION_NOE 抑制剂<|>RELATION_NOE 5-<|>RELATION_NOE 杂氮<|>RELATION_NOE -2<|>RELATION_NOE '<|>RELATION_NOE -<|>RELATION_NOE 脱氧<|>RELATION_NOE 胞嘧啶<|>RELATION_NOE (<|>RELATION_NOE 5-AZA-CdR<|>RELATION_NOE ,<|>RELATION_NOE AZA<|>RELATION_NOE )<|>RELATION_NOE 作用<|>RELATION_B 于<|>RELATION_E 雌激素受体<|>RELATION_NOE d<|>RELATION_NOE (<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 阴性<|>RELATION_NOE 的<|>RELATION_NOE NCI-H1975<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PcR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 及其<|>RELATION_NOE 下游<|>RELATION_NOE 的<|>RELATION_NOE 产物<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 水平<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_S 联合<|>RELATION_NOE 缺氧<|>RELATION_NOE 诱导<|>RELATION_NOE 因子<|>RELATION_NOE -1<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE bcl-xL<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 分为<|>RELATION_NOE 4组<|>RELATION_NOE :<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 用<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 用<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE 用<|>RELATION_NOE bcl-xL<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE 用<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE bcl-xL<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE 联合<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
逆转<|>RELATION_NOE 录<|>RELATION_NOE 一<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S HIF-1<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE bcl-xL<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Western-blot<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 一<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE bcl-xL<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Western-blot<|>RELATION_NOE 检测<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 。<|>RELATION_NOE
甲基丙烯酸<|>RELATION_NOE 甲酯<|>RELATION_NOE 单体<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_B 反应<|>RELATION_E
观察<|>RELATION_S 甲基丙烯酸<|>RELATION_NOE 甲酯<|>RELATION_NOE (<|>RELATION_NOE MMA<|>RELATION_NOE )<|>RELATION_NOE 单体<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
设置<|>RELATION_NOE 实验组<|>RELATION_NOE (<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 单体<|>RELATION_NOE 浓度组<|>RELATION_NOE :<|>RELATION_NOE l<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 40<|>RELATION_NOE 、<|>RELATION_NOE 80<|>RELATION_NOE 、<|>RELATION_NOE 120mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 阴性<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 测定<|>RELATION_S 单体<|>RELATION_NOE 与<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 接触<|>RELATION_NOE 后<|>RELATION_NOE 30min<|>RELATION_NOE 、<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 5d<|>RELATION_NOE 细胞<|>RELATION_NOE 吸<|>RELATION_NOE 光度<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE )<|>RELATION_NOE 值<|>RELATION_NOE 。<|>RELATION_NOE
10<|>RELATION_NOE 、<|>RELATION_NOE 40<|>RELATION_NOE 、<|>RELATION_NOE 80<|>RELATION_NOE 、<|>RELATION_NOE 120mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 组<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 百分比<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 1.78<|>RELATION_NOE ±<|>RELATION_NOE 0.09<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 3.97<|>RELATION_NOE ±<|>RELATION_NOE 0.22<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 4.58<|>RELATION_NOE ±<|>RELATION_NOE 0.36<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 5.27<|>RELATION_NOE ±<|>RELATION_NOE 0.14<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 坏死<|>RELATION_NOE 百分比<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 3.43<|>RELATION_NOE ±<|>RELATION_NOE 0.08<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 6.70<|>RELATION_NOE ±<|>RELATION_NOE 0.21<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.93<|>RELATION_NOE ±<|>RELATION_NOE 0.40<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 9.51<|>RELATION_NOE ±<|>RELATION_NOE 0.64<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 凋亡<|>RELATION_NOE 及<|>RELATION_NOE 坏死<|>RELATION_NOE 百分比<|>RELATION_NOE (<|>RELATION_NOE 1.14<|>RELATION_NOE ±<|>RELATION_NOE 0.08<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.24<|>RELATION_NOE ±<|>RELATION_NOE 0.09<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
MMA<|>RELATION_NOE 单体<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 有<|>RELATION_B 毒性<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
中期<|>RELATION_NOE 因子<|>RELATION_NOE mRNA<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
采用<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 87<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 志愿者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE MKmRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE MKmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与其<|>RELATION_NOE 临床<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 与否<|>RELATION_NOE 和<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE MKmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与其<|>RELATION_NOE 临床<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 与否<|>RELATION_NOE 和<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 学<|>RELATION_NOE 技术<|>RELATION_NOE 筛选<|>RELATION_S I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 蛋白<|>RELATION_NOE
筛选<|>RELATION_B 和<|>RELATION_I 鉴定<|>RELATION_E I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 蛋白<|>RELATION_NOE 。<|>RELATION_NOE
分别<|>RELATION_NOE 收集<|>RELATION_NOE 经<|>RELATION_NOE 手术<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 6例<|>RELATION_NOE I<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 7例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 双向<|>RELATION_NOE 凝胶<|>RELATION_NOE 电泳<|>RELATION_NOE (<|>RELATION_NOE 2-DE<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 基质<|>RELATION_NOE 辅助<|>RELATION_NOE 激光解<|>RELATION_NOE 吸<|>RELATION_NOE 电离<|>RELATION_NOE 飞行<|>RELATION_NOE 时间<|>RELATION_NOE 质谱<|>RELATION_NOE (<|>RELATION_NOE MALDI<|>RELATION_NOE .<|>RELATION_NOE
共<|>RELATION_NOE 挖<|>RELATION_NOE 取<|>RELATION_NOE 51<|>RELATION_NOE 个<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白质<|>RELATION_NOE 点<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE MALDI-TOF-MS<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 成功<|>RELATION_NOE 鉴定<|>RELATION_NOE 出<|>RELATION_NOE 5种<|>RELATION_NOE 蛋白质<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 上调<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE α<|>RELATION_NOE 1-<|>RELATION_NOE 酸性<|>RELATION_NOE 糖<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE c1<|>RELATION_NOE 酯<|>RELATION_NOE 酶抑制<|>RELATION_NOE 物<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 紧张<|>RELATION_NOE 素原<|>RELATION_NOE 、<|>RELATION_NOE 转铁蛋白<|>RELATION_NOE 及<|>RELATION_NOE 转<|>RELATION_NOE 甲状腺素<|>RELATION_NOE 蛋白<|>RELATION_NOE A<|>RELATION_NOE 链<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 学<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE I<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 鉴定<|>RELATION_NOE 出<|>RELATION_NOE 5种<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 开发<|>RELATION_NOE NSCLC<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 标志物<|>RELATION_NOE 提供<|>RELATION_B 了<|>RELATION_I 重要<|>RELATION_I 的<|>RELATION_I 候选<|>RELATION_I 蛋白<|>RELATION_E 。<|>RELATION_NOE
支气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 突变<|>RELATION_NOE
探讨<|>RELATION_S 经<|>RELATION_NOE 气管<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 内镜<|>RELATION_NOE 穿刺<|>RELATION_NOE (<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE )<|>RELATION_NOE 纵膈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 穿刺<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
穿<|>RELATION_NOE 刺针<|>RELATION_NOE 为<|>RELATION_NOE EBUS<|>RELATION_NOE 标准<|>RELATION_NOE 22G<|>RELATION_NOE 针<|>RELATION_NOE ,<|>RELATION_NOE 待<|>RELATION_NOE 涂片<|>RELATION_NOE 快速<|>RELATION_NOE 细胞学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 腺癌<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 同一<|>RELATION_NOE 部位<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 穿刺<|>RELATION_NOE 标本<|>RELATION_NOE 推人<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 中<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 离心<|>RELATION_NOE 后<|>RELATION_NOE 首先<|>RELATION_NOE 提取<|>RELATION_NOE 组织<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 胸外科<|>RELATION_NOE 优化<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 体富<|>RELATION_NOE 集法<|>RELATION_NOE 检测<|>RELATION_S 外显子<|>RELATION_NOE 19<|>RELATION_NOE 及<|>RELATION_NOE 21<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
首先<|>RELATION_NOE 经过<|>RELATION_NOE 特异性<|>RELATION_NOE 消化<|>RELATION_NOE 野生型<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 限制性<|>RELATION_NOE 内切<|>RELATION_NOE 酶<|>RELATION_NOE 切割<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 进行<|>RELATION_S 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 扩增<|>RELATION_NOE 。<|>RELATION_NOE
因<|>RELATION_NOE 绝大部分<|>RELATION_NOE 野生型<|>RELATION_NOE 基因<|>RELATION_NOE 已<|>RELATION_NOE 断裂<|>RELATION_NOE ,<|>RELATION_NOE 无法<|>RELATION_NOE 作为<|>RELATION_NOE PCR<|>RELATION_NOE 反应<|>RELATION_NOE 模板<|>RELATION_NOE ,<|>RELATION_NOE 使得<|>RELATION_NOE 扩增<|>RELATION_NOE 产物<|>RELATION_NOE 中<|>RELATION_NOE 突变型<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 大大<|>RELATION_NOE 增加<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE EBUS<|>RELATION_NOE 穿刺<|>RELATION_NOE 2组<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 7组<|>RELATION_NOE 或<|>RELATION_NOE 10<|>RELATION_NOE 组<|>RELATION_NOE 淋巴结<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 肺腺癌<|>RELATION_NOE ,<|>RELATION_NOE 涂片<|>RELATION_NOE 标本<|>RELATION_NOE 均<|>RELATION_NOE 显示<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 背景<|>RELATION_NOE 中<|>RELATION_NOE 可见多量腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 改良<|>RELATION_NOE 突变<|>RELATION_NOE 体富<|>RELATION_NOE 集法<|>RELATION_NOE 检测<|>RELATION_NOE 示<|>RELATION_NOE 其中<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 存在<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 突变率<|>RELATION_NOE 达到<|>RELATION_NOE 46.2%<|>RELATION_NOE ,<|>RELATION_NOE 7例<|>RELATION_NOE 为<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 为<|>RELATION_NOE 外显子<|>RELATION_NOE 21<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 余<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE
全部<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 4例<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 根治性<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标本<|>RELATION_NOE 再次<|>RELATION_NOE 检测<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 与<|>RELATION_NOE 术前<|>RELATION_NOE 相同<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 纵膈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 来<|>RELATION_NOE 检测<|>RELATION_S EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 是<|>RELATION_NOE 可行<|>RELATION_NOE 的<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 高<|>RELATION_NOE 灵敏度<|>RELATION_NOE 的<|>RELATION_NOE
分析<|>RELATION_S 非<|>RELATION_NOE 血液<|>RELATION_NOE 系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 贫血<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 贫血<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 贫血<|>RELATION_NOE 时<|>RELATION_NOE 红细胞<|>RELATION_NOE 形态<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE 在<|>RELATION_NOE 我院<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 530<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 血液<|>RELATION_NOE 系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_B 回顾性<|>RELATION_I 分析<|>RELATION_E 。<|>RELATION_NOE
非<|>RELATION_NOE 血液<|>RELATION_NOE 系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 贫血<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 达<|>RELATION_NOE 20.9<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 111<|>RELATION_NOE /<|>RELATION_NOE 530<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 贫血<|>RELATION_NOE 发生率<|>RELATION_NOE 最高<|>RELATION_NOE 35.3%<|>RELATION_NOE (<|>RELATION_NOE 65<|>RELATION_NOE /<|>RELATION_NOE 184<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 妇科肿瘤<|>RELATION_NOE 19.4%<|>RELATION_NOE (<|>RELATION_NOE 6/31<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 18.3%<|>RELATION_NOE (<|>RELATION_NOE 34<|>RELATION_NOE /<|>RELATION_NOE 186<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 泌尿<|>RELATION_NOE 生殖<|>RELATION_NOE 系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 6.8%<|>RELATION_NOE (<|>RELATION_NOE 5/74<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 1.8%<|>RELATION_NOE (<|>RELATION_NOE 1/55<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 度<|>RELATION_NOE 贫血<|>RELATION_NOE 发生率<|>RELATION_NOE 15.6<|>RELATION_NOE 6%<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ<|>RELATION_NOE 贫血<|>RELATION_NOE 发生率<|>RELATION_NOE 5.2<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 发生<|>RELATION_NOE 于<|>RELATION_NOE 消化道<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 血液<|>RELATION_NOE 系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 贫血<|>RELATION_NOE 发生率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 呈<|>RELATION_NOE 小细胞性<|>RELATION_NOE ,<|>RELATION_NOE 常<|>RELATION_NOE 不<|>RELATION_NOE 引起<|>RELATION_NOE 医<|>RELATION_NOE 患<|>RELATION_NOE 双方<|>RELATION_NOE 注意<|>RELATION_NOE ,<|>RELATION_NOE 治疗率<|>RELATION_NOE 低<|>RELATION_NOE 。<|>RELATION_NOE
聚乙烯<|>RELATION_NOE 醇颗粒<|>RELATION_NOE 介入<|>RELATION_NOE 栓塞<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 远期<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE
PVA<|>RELATION_NOE 颗粒<|>RELATION_NOE 介入<|>RELATION_NOE 栓塞<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 远期<|>RELATION_NOE 疗效<|>RELATION_NOE 满意<|>RELATION_S ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 较<|>RELATION_NOE 早<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位于<|>RELATION_NOE 中央<|>RELATION_NOE 、<|>RELATION_NOE 联合化疗<|>RELATION_NOE 相对<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 。<|>RELATION_NOE
护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
对照组<|>RELATION_NOE 给予<|>RELATION_S 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 除<|>RELATION_NOE 接受<|>RELATION_NOE 对照组<|>RELATION_NOE 给予<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 除<|>RELATION_NOE 接受<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 进行<|>RELATION_S 系统<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 。<|>RELATION_NOE
系统<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 效果<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE ,<|>RELATION_NOE 社会<|>RELATION_NOE 、<|>RELATION_NOE 心理<|>RELATION_NOE 支持<|>RELATION_NOE ,<|>RELATION_NOE 适当<|>RELATION_NOE 活动<|>RELATION_NOE 锻炼<|>RELATION_NOE ,<|>RELATION_NOE 保证<|>RELATION_NOE 充足<|>RELATION_NOE 的<|>RELATION_NOE 睡眠<|>RELATION_NOE ,<|>RELATION_NOE 饮食<|>RELATION_NOE 调理<|>RELATION_NOE 等<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 缓解<|>RELATION_B 或<|>RELATION_I 消除<|>RELATION_E 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE 系统<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 效果<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE ,<|>RELATION_NOE 社会<|>RELATION_NOE 、<|>RELATION_NOE 心理<|>RELATION_NOE 支持<|>RELATION_NOE ,<|>RELATION_NOE 适当<|>RELATION_NOE 活动<|>RELATION_NOE 锻炼<|>RELATION_NOE ,<|>RELATION_NOE 保证<|>RELATION_NOE 充足<|>RELATION_NOE 的<|>RELATION_NOE 睡眠<|>RELATION_NOE ,<|>RELATION_NOE 饮食<|>RELATION_NOE 调理<|>RELATION_NOE 等<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 缓解<|>RELATION_NOE 或<|>RELATION_NOE 消除<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
熏烟<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺内<|>RELATION_NOE Mucl<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及<|>RELATION_NOE 机制<|>RELATION_NOE
C57<|>RELATION_NOE 雄性<|>RELATION_NOE 小鼠<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 熏<|>RELATION_NOE 烟组<|>RELATION_NOE (<|>RELATION_NOE 8<|>RELATION_NOE 只<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 8<|>RELATION_NOE 只<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 熏烟<|>RELATION_NOE 处理<|>RELATION_NOE 或<|>RELATION_NOE 正常<|>RELATION_NOE 饲养<|>RELATION_NOE 相同<|>RELATION_NOE 时间<|>RELATION_NOE 后<|>RELATION_NOE 处死<|>RELATION_NOE 小鼠<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡灌洗液<|>RELATION_NOE (<|>RELATION_NOE BALF<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_S 细胞计数<|>RELATION_NOE 、<|>RELATION_NOE 染色<|>RELATION_NOE 和<|>RELATION_NOE 分类<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 测定<|>RELATION_NOE BALF<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE ;<|>RELATION_NOE
通过<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 测定法<|>RELATION_NOE 及<|>RELATION_NOE 蛋白质<|>RELATION_NOE 免疫印迹法<|>RELATION_NOE 对<|>RELATION_NOE BALF<|>RELATION_NOE 及<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE Mucl<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 进行<|>RELATION_B 检测<|>RELATION_E 。<|>RELATION_NOE
与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 熏<|>RELATION_NOE 烟组<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 出现<|>RELATION_NOE 明显<|>RELATION_NOE 炎症<|>RELATION_NOE 细胞<|>RELATION_NOE 浸润<|>RELATION_NOE ,<|>RELATION_NOE BALF<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 总数<|>RELATION_NOE 、<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞数<|>RELATION_NOE 、<|>RELATION_NOE 巨噬细胞数<|>RELATION_NOE 均<|>RELATION_NOE 增高<|>RELATION_NOE 。<|>RELATION_NOE
熏烟<|>RELATION_NOE 可以<|>RELATION_NOE 导致<|>RELATION_S 小鼠<|>RELATION_NOE 肺组织<|>RELATION_NOE 炎症<|>RELATION_NOE 反应<|>RELATION_NOE 并<|>RELATION_NOE 伴随<|>RELATION_NOE Mucl<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_NOE 和<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 分泌<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE MUCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 香烟<|>RELATION_NOE 烟雾<|>RELATION_NOE 直接<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 肺<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE 熏烟<|>RELATION_NOE 可以<|>RELATION_NOE 导致<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺组织<|>RELATION_NOE 炎症<|>RELATION_NOE 反应<|>RELATION_NOE 并<|>RELATION_NOE 伴随<|>RELATION_NOE Mucl<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_NOE 和<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 分泌<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE MUCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 香烟<|>RELATION_NOE 烟雾<|>RELATION_NOE 直接<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 肺<|>RELATION_NOE 上皮<|>RELATION_NOE 细<|>RELATION_NOE 胞<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
本例<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 女性<|>RELATION_NOE ,<|>RELATION_NOE 45<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 反复<|>RELATION_NOE 咳嗽<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 示<|>RELATION_NOE 两<|>RELATION_NOE 肺<|>RELATION_NOE 多<|>RELATION_NOE 发结节<|>RELATION_NOE 灶<|>RELATION_NOE 合并<|>RELATION_NOE 肺门<|>RELATION_NOE 及<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺活检<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 原发性<|>RELATION_NOE 肺透明<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE
临床<|>RELATION_NOE 表现<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 咳嗽<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 胸痛<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
确诊<|>RELATION_NOE 多<|>RELATION_NOE 依赖<|>RELATION_NOE 开<|>RELATION_NOE 胸肺<|>RELATION_NOE 组织<|>RELATION_NOE 病理<|>RELATION_NOE 活检<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 有助于<|>RELATION_S 鉴别<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 同济<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 上海市<|>RELATION_NOE 肺科<|>RELATION_NOE 医院<|>RELATION_NOE 2002年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 期间<|>RELATION_NOE 596<|>RELATION_NOE 例<|>RELATION_NOE PTE<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 完整<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 65<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 实验室<|>RELATION_NOE 检查<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
胸闷<|>RELATION_NOE /<|>RELATION_NOE 呼吸困难<|>RELATION_NOE (<|>RELATION_NOE 76.9<|>RELATION_NOE 2%<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 最<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 其次<|>RELATION_NOE 为<|>RELATION_NOE 咳嗽<|>RELATION_NOE (<|>RELATION_NOE 41.5<|>RELATION_NOE 4%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 胸痛<|>RELATION_NOE (<|>RELATION_NOE 29.2<|>RELATION_NOE 3%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
呼吸频率<|>RELATION_NOE 增快<|>RELATION_NOE (<|>RELATION_NOE 69.2<|>RELATION_NOE 3%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE (<|>RELATION_NOE 67.6<|>RELATION_NOE 9%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 心动过速<|>RELATION_NOE (<|>RELATION_NOE 61.5<|>RELATION_NOE 4%<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 最<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 体征<|>RELATION_NOE 。<|>RELATION_NOE
伴<|>RELATION_NOE 下肢<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 形成<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 36.9<|>RELATION_NOE 2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 下肢<|>RELATION_NOE 浮肿<|>RELATION_NOE 、<|>RELATION_NOE 压<|>RELATION_NOE 痛<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 合并<|>RELATION_NOE PTE<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 血小板计数<|>RELATION_NOE 、<|>RELATION_NOE 白介素<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE IL-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE TNF<|>RELATION_NOE )<|>RELATION_NOE 升高者<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 66.15%<|>RELATION_NOE 、<|>RELATION_NOE 63.08%<|>RELATION_NOE 、<|>RELATION_NOE 36.9<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 肺癌<|>RELATION_NOE PTE<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 血小板计数<|>RELATION_NOE 、<|>RELATION_NOE II<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE TNF<|>RELATION_NOE 升高者<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 36.9<|>RELATION_NOE 1%<|>RELATION_NOE 、<|>RELATION_NOE 19.21%<|>RELATION_NOE 、<|>RELATION_NOE 21.6<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 是<|>RELATION_NOE PTE<|>RELATION_NOE 的<|>RELATION_NOE 常见<|>RELATION_NOE 病因<|>RELATION_NOE 之一<|>RELATION_NOE ,<|>RELATION_NOE 常<|>RELATION_NOE 合并<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 形成<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 合并<|>RELATION_NOE PTE<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 无<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 是<|>RELATION_NOE 最<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE b<|>RELATION_NOE －<|>RELATION_NOE IV<|>RELATION_NOE 期<|>RELATION_NOE 最为<|>RELATION_NOE 常见<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE SELDI-TOF-MS<|>RELATION_NOE 技术<|>RELATION_NOE 筛选<|>RELATION_S 肺鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
应用<|>RELATION_NOE 表面<|>RELATION_NOE 增强<|>RELATION_NOE 激光<|>RELATION_NOE 解析<|>RELATION_NOE 电离<|>RELATION_NOE 飞行<|>RELATION_NOE 时间<|>RELATION_NOE 质谱<|>RELATION_NOE (<|>RELATION_NOE sELDI-TOF-MS<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 筛选<|>RELATION_S 出<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡灌洗液<|>RELATION_NOE (<|>RELATION_NOE BALF<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
①<|>RELATION_NOE 肺鳞<|>RELATION_NOE 癌组<|>RELATION_NOE 与<|>RELATION_NOE 肺良<|>RELATION_NOE 性病<|>RELATION_NOE 变组<|>RELATION_NOE :<|>RELATION_NOE 在<|>RELATION_NOE 血清<|>RELATION_NOE 、<|>RELATION_NOE BALF<|>RELATION_NOE 、<|>RELATION_NOE 肺组织<|>RELATION_NOE 匀浆<|>RELATION_NOE 中<|>RELATION_NOE 发现<|>RELATION_NOE 存在<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 9<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白峰<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 选用<|>RELATION_NOE 其中<|>RELATION_NOE 质<|>RELATION_NOE 荷比<|>RELATION_NOE 为<|>RELATION_NOE 512<|>RELATION_NOE 4.24<|>RELATION_NOE 、<|>RELATION_NOE 796<|>RELATION_NOE 7.29<|>RELATION_NOE 联合<|>RELATION_NOE 10<|>RELATION_NOE 84<|>RELATION_NOE 3.45<|>RELATION_NOE 、<|>RELATION_NOE 79<|>RELATION_NOE 14.59<|>RELATION_NOE 联合<|>RELATION_NOE 870<|>RELATION_NOE 9.66<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白<|>RELATION_NOE 波峰<|>RELATION_NOE 建立<|>RELATION_NOE 分类树<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 诊断<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 85%<|>RELATION_NOE 、<|>RELATION_NOE 80%<|>RELATION_NOE 、<|>RELATION_NOE 75%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 65%<|>RELATION_NOE 、<|>RELATION_NOE 80%<|>RELATION_NOE 、<|>RELATION_NOE 90%<|>RELATION_NOE ,<|>RELATION_NOE 正确率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 75%<|>RELATION_NOE 、<|>RELATION_NOE 80%<|>RELATION_NOE 、<|>RELATION_NOE 83%<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 71%<|>RELATION_NOE 、<|>RELATION_NOE 80%<|>RELATION_NOE 、<|>RELATION_NOE 88%<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 81%<|>RELATION_NOE 、<|>RELATION_NOE 80%<|>RELATION_NOE 、<|>RELATION_NOE 78%<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 相<|>RELATION_NOE 对应<|>RELATION_NOE ROC<|>RELATION_NOE 曲线下面积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.7<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 0.9<|>RELATION_NOE 16<|>RELATION_NOE 、<|>RELATION_NOE 0.9<|>RELATION_NOE 30<|>RELATION_NOE 。<|>RELATION_NOE
②<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌组<|>RELATION_NOE 与<|>RELATION_NOE 肺良<|>RELATION_NOE 性病<|>RELATION_NOE 变组<|>RELATION_NOE :<|>RELATION_NOE 在<|>RELATION_NOE 血清<|>RELATION_NOE 、<|>RELATION_NOE BALF<|>RELATION_NOE 、<|>RELATION_NOE 肺组织<|>RELATION_NOE 匀浆<|>RELATION_NOE 中<|>RELATION_NOE 发现<|>RELATION_NOE 存在<|>RELATION_NOE 8<|>RELATION_NOE 、<|>RELATION_NOE 9<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白峰<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 选用<|>RELATION_NOE 其中<|>RELATION_NOE 质<|>RELATION_NOE 荷比<|>RELATION_NOE 为<|>RELATION_NOE 92<|>RELATION_NOE 95.79<|>RELATION_NOE 、<|>RELATION_NOE 792<|>RELATION_NOE 3.01<|>RELATION_NOE 、<|>RELATION_NOE 245<|>RELATION_NOE 2.49<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白<|>RELATION_NOE 波峰<|>RELATION_NOE 建立<|>RELATION_NOE 分类树<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 诊断<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 75%<|>RELATION_NOE 、<|>RELATION_NOE 80%<|>RELATION_NOE 、<|>RELATION_NOE 70%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 65%<|>RELATION_NOE 、<|>RELATION_NOE 90%<|>RELATION_NOE 、<|>RELATION_NOE 85%<|>RELATION_NOE ,<|>RELATION_NOE 正确率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 70%<|>RELATION_NOE 、<|>RELATION_NOE 85%<|>RELATION_NOE 、<|>RELATION_NOE 78%<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 68%<|>RELATION_NOE 、<|>RELATION_NOE 89%<|>RELATION_NOE ,<|>RELATION_NOE 82%<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 72%<|>RELATION_NOE 、<|>RELATION_NOE 82%<|>RELATION_NOE 、<|>RELATION_NOE 71%<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 相<|>RELATION_NOE 对应<|>RELATION_NOE ROC<|>RELATION_NOE 曲线下面积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.8<|>RELATION_NOE 44<|>RELATION_NOE 、<|>RELATION_NOE 0.9<|>RELATION_NOE 33<|>RELATION_NOE 、<|>RELATION_NOE 0.8<|>RELATION_NOE 25<|>RELATION_NOE 。<|>RELATION_NOE
云南省<|>RELATION_NOE 富源<|>RELATION_NOE 地区<|>RELATION_NOE 肺癌<|>RELATION_NOE 危险因素<|>RELATION_NOE 的<|>RELATION_NOE Meta<|>RELATION_B 分析<|>RELATION_E
通过<|>RELATION_NOE Pubmed<|>RELATION_NOE 、<|>RELATION_NOE Webofknowledge<|>RELATION_NOE 、<|>RELATION_NOE Google<|>RELATION_NOE 、<|>RELATION_NOE 中国<|>RELATION_NOE 期刊<|>RELATION_NOE 全文<|>RELATION_NOE 数据库<|>RELATION_NOE 和<|>RELATION_NOE 万方<|>RELATION_NOE 数据<|>RELATION_NOE 资源<|>RELATION_NOE 系统<|>RELATION_NOE 等<|>RELATION_NOE 检索<|>RELATION_NOE 1995年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 公开<|>RELATION_NOE 发表<|>RELATION_NOE 的<|>RELATION_NOE 关于<|>RELATION_NOE 该<|>RELATION_NOE 地区<|>RELATION_NOE 人群<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 危险因素<|>RELATION_NOE 的<|>RELATION_NOE 国内外<|>RELATION_NOE 研究<|>RELATION_NOE 文献<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE RevMan4.2<|>RELATION_NOE 软件<|>RELATION_NOE 进行<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
各<|>RELATION_NOE 因素<|>RELATION_NOE 合并<|>RELATION_NOE 比值比<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 生活<|>RELATION_NOE 用<|>RELATION_NOE 煤<|>RELATION_NOE (<|>RELATION_NOE 4.40<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 居室<|>RELATION_NOE 通风<|>RELATION_NOE 情况<|>RELATION_NOE (<|>RELATION_NOE 2.15<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 炼煤<|>RELATION_NOE 环境<|>RELATION_NOE (<|>RELATION_NOE 2.02<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE (<|>RELATION_NOE 1.72<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 被动吸烟<|>RELATION_NOE (<|>RELATION_NOE 1.70<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 易感<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE 1.65<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 呼吸道疾病<|>RELATION_NOE (<|>RELATION_NOE 1.52<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 饮食习惯<|>RELATION_NOE (<|>RELATION_NOE 饮酒<|>RELATION_NOE 和<|>RELATION_NOE 高脂<|>RELATION_NOE 饮食<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE 1.39<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 蔬果<|>RELATION_NOE 摄<|>RELATION_NOE 人<|>RELATION_NOE 多<|>RELATION_NOE (<|>RELATION_NOE 0.65<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 性别<|>RELATION_NOE 差异<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 研究<|>RELATION_E
分析<|>RELATION_S 男性<|>RELATION_NOE 和<|>RELATION_NOE 女性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE non-small<|>RELATION_NOE cell<|>RELATION_NOE lung<|>RELATION_NOE cancer<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 等<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 。<|>RELATION_NOE
女性<|>RELATION_NOE 确诊<|>RELATION_NOE NSCLC<|>RELATION_NOE 早<|>RELATION_B 于<|>RELATION_E 男性<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 57.9<|>RELATION_NOE ±<|>RELATION_NOE 11.4<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE VN<|>RELATION_NOE (<|>RELATION_NOE 60.9<|>RELATION_NOE ±<|>RELATION_NOE 10.9<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.0<|>RELATION_NOE 13<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 女性<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE 亦<|>RELATION_NOE 低于<|>RELATION_NOE 女性<|>RELATION_NOE 确诊<|>RELATION_NOE NSCLC<|>RELATION_NOE 早<|>RELATION_NOE 于<|>RELATION_NOE 男性<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 57.9<|>RELATION_NOE ±<|>RELATION_NOE 11.4<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE VN<|>RELATION_NOE (<|>RELATION_NOE 60.9<|>RELATION_NOE ±<|>RELATION_NOE 10.9<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.0<|>RELATION_NOE 13<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 女性<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE 亦<|>RELATION_NOE 低于<|>RELATION_S 男性<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 57.9<|>RELATION_NOE ±<|>RELATION_NOE 11.6<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE vs<|>RELATION_NOE (<|>RELATION_NOE 59.<|>RELATION_NOE 8士<|>RELATION_NOE 11.1<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 41<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
男性<|>RELATION_NOE 鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 女性<|>RELATION_NOE (<|>RELATION_NOE 39.6%<|>RELATION_NOE vs7.7<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 男性<|>RELATION_NOE 鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 女性<|>RELATION_NOE (<|>RELATION_NOE 39.6%<|>RELATION_NOE vs7.7<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 女性<|>RELATION_NOE 中<|>RELATION_NOE 腺癌<|>RELATION_NOE 比例<|>RELATION_NOE 高于<|>RELATION_S 男性<|>RELATION_NOE (<|>RELATION_NOE 88.7%<|>RELATION_NOE vs55.2<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
女性<|>RELATION_NOE 发病<|>RELATION_NOE 早<|>RELATION_B 于<|>RELATION_E 男性<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE 低于<|>RELATION_NOE 女性<|>RELATION_NOE 发病<|>RELATION_NOE 早<|>RELATION_NOE 于<|>RELATION_NOE 男性<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE 低于<|>RELATION_S 男性<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
男性<|>RELATION_NOE 中鳞癌<|>RELATION_NOE 比例<|>RELATION_NOE 高于<|>RELATION_S 女性<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE
研究<|>RELATION_S 抑癌<|>RELATION_NOE 基因<|>RELATION_NOE WWOX<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 二<|>RELATION_NOE 步<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 40<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 石蜡<|>RELATION_NOE 标本<|>RELATION_NOE 及<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE WWOX<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
①<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE WWOX<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 高于<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE 85.71oAVS37.50oA<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 中<|>RELATION_NOE WWOX<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE 腺癌<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 34.6<|>RELATION_NOE 2%<|>RELATION_NOE VS42.86<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE o<|>RELATION_NOE .<|>RELATION_NOE
②<|>RELATION_NOE 男性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌组织<|>RELATION_NOE 中<|>RELATION_NOE WWOX<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 低于<|>RELATION_S 女性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 25.00%<|>RELATION_NOE VS56.25<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE ≥<|>RELATION_NOE 400<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 癌组织<|>RELATION_NOE 中<|>RELATION_NOE WWOX<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE
③<|>RELATION_NOE 分化<|>RELATION_NOE 不良<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE WWOX<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE 中等<|>RELATION_NOE 分化<|>RELATION_NOE 和<|>RELATION_NOE 分化<|>RELATION_NOE 良好<|>RELATION_NOE 者<|>RELATION_NOE 相近<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE o<|>RELATION_NOE .<|>RELATION_NOE
④<|>RELATION_NOE I<|>RELATION_NOE +<|>RELATION_NOE II<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌组织<|>RELATION_NOE 中<|>RELATION_NOE WWOX<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE Ⅲ<|>RELATION_NOE +<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 患者<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE WWOX<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE 无<|>RELATION_NOE 转移<|>RELATION_NOE 病例<|>RELATION_NOE 相近<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
WWOX<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 较<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 及<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 以及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 转移<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
组织因子<|>RELATION_NOE 途径<|>RELATION_NOE 抑制物<|>RELATION_NOE -2<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE
研究<|>RELATION_S 组织因子<|>RELATION_NOE 途径<|>RELATION_NOE 抑制物<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE TFPI-2<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 56<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 石蜡<|>RELATION_NOE 标本<|>RELATION_NOE 及<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 肺正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE TFPI-2<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
②<|>RELATION_NOE TFPI-2<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 低于<|>RELATION_S 腺癌<|>RELATION_NOE (<|>RELATION_NOE 9.4%<|>RELATION_NOE VS37.5<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ⅰ<|>RELATION_NOE +<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE TFPI-2<|>RELATION_NOE 表达<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 高于<|>RELATION_NOE Ⅲ<|>RELATION_NOE +<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE 31.3%<|>RELATION_NOE vs8.3<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 对<|>RELATION_NOE TFPL2<|>RELATION_NOE 表达<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE ;<|>RELATION_NOE ②<|>RELATION_NOE TFPI-2<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 低于<|>RELATION_NOE 腺癌<|>RELATION_NOE (<|>RELATION_NOE 9.4%<|>RELATION_NOE VS37.5<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ⅰ<|>RELATION_NOE +<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE TFPI-2<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 高于<|>RELATION_S Ⅲ<|>RELATION_NOE +<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE 31.3%<|>RELATION_NOE vs8.3<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 对<|>RELATION_NOE TFPL2<|>RELATION_NOE 表达<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE ;<|>RELATION_NOE
③<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE ≥<|>RELATION_NOE 400<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE TFPI-2<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 低于<|>RELATION_S 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE <<|>RELATION_NOE 400<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 不<|>RELATION_NOE 吸烟者<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 8.6%<|>RELATION_NOE VS42.9<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
④<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE TFPI-2<|>RELATION_NOE 表达<|>RELATION_NOE 阳性<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE 均<|>RELATION_NOE 小于<|>RELATION_NOE 5cm<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE 大于<|>RELATION_NOE 5cm<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE TFPb2<|>RELATION_NOE 基本<|>RELATION_NOE 不<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
TFPI-2<|>RELATION_NOE 的<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE TFPI-2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 是否<|>RELATION_NOE 小于<|>RELATION_NOE 5cm<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 无关<|>RELATION_NOE 。<|>RELATION_NOE
气道<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 模型<|>RELATION_NOE 在<|>RELATION_NOE 预测<|>RELATION_NOE 肺外<|>RELATION_NOE 周<|>RELATION_NOE 病变<|>RELATION_NOE 恶性<|>RELATION_NOE 概率<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 探索性<|>RELATION_B 应用<|>RELATION_E
②<|>RELATION_NOE 筛选<|>RELATION_S 出<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 气道<|>RELATION_NOE 内<|>RELATION_NOE 超声诊断<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 肺外周<|>RELATION_NOE 病变<|>RELATION_NOE 恶性<|>RELATION_NOE 概率<|>RELATION_NOE 估算<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 评价<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
②<|>RELATION_NOE 经<|>RELATION_NOE 二<|>RELATION_NOE 分类<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 超声<|>RELATION_NOE 特征<|>RELATION_NOE 纳入<|>RELATION_NOE 回归<|>RELATION_NOE 方程<|>RELATION_NOE ,<|>RELATION_NOE 恶性<|>RELATION_NOE 概率<|>RELATION_NOE 预测<|>RELATION_NOE 模型<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 1/[<|>RELATION_NOE l<|>RELATION_NOE +<|>RELATION_NOE e-<|>RELATION_NOE (<|>RELATION_NOE -1272<|>RELATION_NOE +<|>RELATION_NOE 1.2<|>RELATION_NOE 71<|>RELATION_NOE 病灶<|>RELATION_NOE 形状<|>RELATION_NOE +<|>RELATION_NOE 1.4<|>RELATION_NOE 52<|>RELATION_NOE 边界<|>RELATION_NOE +<|>RELATION_NOE 4.6<|>RELATION_NOE 45<|>RELATION_NOE 异质<|>RELATION_NOE 回声<|>RELATION_NOE -1.687<|>RELATION_NOE 支气管<|>RELATION_NOE 充气<|>RELATION_NOE 征+<|>RELATION_NOE 1.8<|>RELATION_NOE 99<|>RELATION_NOE 无<|>RELATION_NOE 回声区<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 其中<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 呈<|>RELATION_NOE 圆形<|>RELATION_NOE 或<|>RELATION_NOE 类<|>RELATION_NOE 圆形<|>RELATION_NOE 、<|>RELATION_NOE 边界<|>RELATION_NOE 清晰<|>RELATION_NOE 、<|>RELATION_NOE 内部<|>RELATION_NOE 回声<|>RELATION_NOE 异质<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 充气征<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 规则<|>RELATION_NOE 无<|>RELATION_NOE 回声区<|>RELATION_NOE 存在者<|>RELATION_NOE 记<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 否则<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE ;<|>RELATION_NOE
中国<|>RELATION_NOE 人群<|>RELATION_NOE 饮茶<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 关系<|>RELATION_NOE 的<|>RELATION_NOE Meta<|>RELATION_B 分析<|>RELATION_E
检索<|>RELATION_NOE 中<|>RELATION_NOE 英文<|>RELATION_NOE 文献<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 在<|>RELATION_NOE 中国<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE 进行<|>RELATION_NOE 的<|>RELATION_NOE 饮茶<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 合并<|>RELATION_NOE OR<|>RELATION_NOE 值<|>RELATION_NOE 及其<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_S 饮茶<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 联系<|>RELATION_NOE 及<|>RELATION_NOE 剂量<|>RELATION_NOE 反应<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
寻找<|>RELATION_S 有效<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 判断<|>RELATION_NOE 肝细胞癌<|>RELATION_NOE (<|>RELATION_NOE HCC<|>RELATION_NOE )<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 标志物<|>RELATION_NOE 。<|>RELATION_NOE
另<|>RELATION_NOE 取<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE HCC<|>RELATION_NOE 、<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE 肝硬化<|>RELATION_NOE 、<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 大肠癌<|>RELATION_NOE 、<|>RELATION_NOE 55<|>RELATION_NOE 例<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 、<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 志愿者<|>RELATION_NOE 血清<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE PS20<|>RELATION_NOE 免疫<|>RELATION_NOE 芯片<|>RELATION_NOE 和<|>RELATION_NOE SEI-DI<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 候选<|>RELATION_NOE 标志物<|>RELATION_NOE 进行<|>RELATION_B 验证<|>RELATION_E 。<|>RELATION_NOE
荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 55<|>RELATION_NOE 例<|>RELATION_NOE HCC<|>RELATION_NOE 患者<|>RELATION_NOE 癌和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肝组织<|>RELATION_NOE 中<|>RELATION_NOE 候选<|>RELATION_NOE 标志物<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 它们<|>RELATION_NOE 与<|>RELATION_NOE HCC<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
检<|>RELATION_NOE 出<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE HCC<|>RELATION_NOE 候选<|>RELATION_NOE 标志物<|>RELATION_NOE 凝血酶<|>RELATION_NOE 轻链<|>RELATION_NOE (<|>RELATION_NOE Thrombinlightchain<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 生长<|>RELATION_NOE 相关性<|>RELATION_NOE 癌基因<|>RELATION_NOE 编码<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE GRO1<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
HCC<|>RELATION_NOE 患者<|>RELATION_NOE 癌组织<|>RELATION_NOE 的<|>RELATION_NOE GRO-1<|>RELATION_NOE 与<|>RELATION_NOE Thrombin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 具有<|>RELATION_B 显著<|>RELATION_I 相关性<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.73<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE GRO-1<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肝外<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 显著<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Thrombin<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 与<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE AFP<|>RELATION_NOE 升高<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Thrombinlightchain<|>RELATION_NOE 和<|>RELATION_NOE GRO-1<|>RELATION_NOE 是<|>RELATION_NOE HCC<|>RELATION_NOE 的<|>RELATION_NOE 潜在<|>RELATION_NOE 血清<|>RELATION_NOE 标志物<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 有<|>RELATION_NOE 希望<|>RELATION_NOE 成为<|>RELATION_NOE HCC<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
总结<|>RELATION_S 肾小细胞性<|>RELATION_NOE 神经<|>RELATION_NOE 内分泌癌<|>RELATION_NOE (<|>RELATION_NOE 简称<|>RELATION_NOE 小细胞癌<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理学<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 1999年<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 间<|>RELATION_NOE 解放军<|>RELATION_NOE 总医院<|>RELATION_NOE 病理科<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 肾<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE HE<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE 进行<|>RELATION_S 病理学<|>RELATION_NOE 观察<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE
12<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 6例<|>RELATION_NOE 为<|>RELATION_NOE 肾原发性<|>RELATION_NOE 小细胞癌<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 2例<|>RELATION_NOE 发生<|>RELATION_NOE 于<|>RELATION_NOE 肾<|>RELATION_NOE 实质<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 发生<|>RELATION_NOE 于<|>RELATION_NOE 肾盂<|>RELATION_NOE ;<|>RELATION_NOE
胸部<|>RELATION_NOE 影像学<|>RELATION_NOE 检查<|>RELATION_NOE 双<|>RELATION_NOE 肺<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 发现<|>RELATION_NOE 占<|>RELATION_NOE 位<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE ,<|>RELATION_NOE 肾<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 单<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE ;<|>RELATION_NOE
大体<|>RELATION_NOE 检查<|>RELATION_NOE 见<|>RELATION_NOE 4例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位于<|>RELATION_NOE 肾盂<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 位于<|>RELATION_NOE 肾<|>RELATION_NOE 实质<|>RELATION_NOE 。<|>RELATION_NOE
其余<|>RELATION_NOE 6例<|>RELATION_NOE 为<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 肾转移<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 4例<|>RELATION_NOE 为<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 治疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 检查<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 以<|>RELATION_NOE 腰痛<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE 就诊<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 发现<|>RELATION_NOE 肺部<|>RELATION_NOE 与<|>RELATION_NOE 肾<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE ;<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 显示<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_NOE CK<|>RELATION_NOE 、<|>RELATION_NOE 突触素<|>RELATION_NOE 、<|>RELATION_NOE CD56<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 转移<|>RELATION_NOE 性病<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 4例<|>RELATION_NOE 原发性<|>RELATION_NOE 病例<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE 1阳性<|>RELATION_NOE 。<|>RELATION_NOE
6例<|>RELATION_NOE 肾原发性<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 2例<|>RELATION_NOE 分别<|>RELATION_NOE 于<|>RELATION_NOE 术后<|>RELATION_NOE 4<|>RELATION_NOE 及<|>RELATION_NOE 9<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 失访<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 存活<|>RELATION_NOE (<|>RELATION_NOE 分别<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 25<|>RELATION_NOE 及<|>RELATION_NOE 138<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肾<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 有<|>RELATION_NOE 原发<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 虽然<|>RELATION_NOE 罕见<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 肾<|>RELATION_NOE 可以<|>RELATION_NOE 原发<|>RELATION_NOE 小细胞癌<|>RELATION_NOE ,<|>RELATION_NOE 肾盂<|>RELATION_NOE 和<|>RELATION_NOE 肾<|>RELATION_NOE 实质<|>RELATION_NOE 均<|>RELATION_NOE 可<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 主要<|>RELATION_NOE 依靠<|>RELATION_NOE 病理学<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE 1<|>RELATION_NOE 在<|>RELATION_NOE 鉴别<|>RELATION_NOE 原发<|>RELATION_NOE 与<|>RELATION_NOE 转移<|>RELATION_NOE 性肿瘤<|>RELATION_NOE 时<|>RELATION_NOE 参考<|>RELATION_B 意义<|>RELATION_I 不<|>RELATION_I 大<|>RELATION_E ,<|>RELATION_NOE 鉴别<|>RELATION_NOE 诊断<|>RELATION_NOE 需要<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 病史<|>RELATION_NOE 、<|>RELATION_NOE 胸部<|>RELATION_NOE 影像学<|>RELATION_NOE 检查<|>RELATION_NOE 和<|>RELATION_NOE 形态学<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 合并<|>RELATION_NOE 尿路<|>RELATION_NOE 上皮癌<|>RELATION_NOE 成分<|>RELATION_NOE 等<|>RELATION_NOE 来<|>RELATION_NOE 综合<|>RELATION_NOE 判定<|>RELATION_NOE 。<|>RELATION_NOE
22<|>RELATION_NOE 例<|>RELATION_NOE 肺<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 症伴<|>RELATION_NOE 发神经<|>RELATION_NOE 内分泌细胞增生<|>RELATION_NOE 及<|>RELATION_NOE 微小瘤<|>RELATION_NOE 形成<|>RELATION_NOE 患者<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE 53<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 男女<|>RELATION_NOE 比例<|>RELATION_NOE 9<|>RELATION_NOE :<|>RELATION_NOE 13<|>RELATION_NOE ,<|>RELATION_NOE 大体<|>RELATION_NOE 检查<|>RELATION_NOE 为<|>RELATION_NOE 典型<|>RELATION_NOE 的<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张症<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 仅<|>RELATION_NOE 1例<|>RELATION_NOE 切面<|>RELATION_NOE 可见<|>RELATION_NOE 灰白<|>RELATION_NOE 色质<|>RELATION_NOE 软结节<|>RELATION_NOE ,<|>RELATION_NOE 直径<|>RELATION_NOE <<|>RELATION_NOE 5mm<|>RELATION_NOE ;<|>RELATION_NOE
镜<|>RELATION_NOE 下<|>RELATION_NOE 观察<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张症<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 此<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 均<|>RELATION_NOE 可见细<|>RELATION_NOE 小气道<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 下<|>RELATION_NOE 神经<|>RELATION_NOE 内分泌细胞增生<|>RELATION_NOE 并<|>RELATION_NOE 形成<|>RELATION_NOE 微小瘤<|>RELATION_NOE (<|>RELATION_NOE 直径<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 5mm<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 伴单<|>RELATION_NOE 发<|>RELATION_NOE 微小瘤<|>RELATION_NOE 形成<|>RELATION_NOE ,<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 伴<|>RELATION_NOE 多<|>RELATION_NOE 发<|>RELATION_NOE 微小瘤<|>RELATION_NOE 形成<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 直径<|>RELATION_NOE 1.6mm<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 发现<|>RELATION_NOE 特殊<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 分别<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 17<|>RELATION_NOE －1<|>RELATION_NOE 17<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 58<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 类癌<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 猝死<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 失访<|>RELATION_NOE 。<|>RELATION_NOE
白细胞介素<|>RELATION_NOE 7<|>RELATION_NOE 及其<|>RELATION_NOE 受体<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 调控<|>RELATION_B 细胞增殖<|>RELATION_I 和<|>RELATION_I 促进<|>RELATION_I 淋巴管<|>RELATION_I 形成<|>RELATION_E
应用<|>RELATION_NOE 体<|>RELATION_NOE 内外<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 白细胞介素<|>RELATION_NOE 7<|>RELATION_NOE 及其<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE IL-7<|>RELATION_NOE /<|>RELATION_NOE IL-7R<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 调控<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 促进<|>RELATION_NOE 淋巴管<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_B 机制<|>RELATION_E 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_S 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 120<|>RELATION_NOE 例<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 依据<|>RELATION_NOE 治疗<|>RELATION_NOE 方式<|>RELATION_NOE 不同<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 传统<|>RELATION_NOE 的<|>RELATION_NOE MVP<|>RELATION_NOE 方案<|>RELATION_NOE :<|>RELATION_NOE 丝裂霉素<|>RELATION_NOE 、<|>RELATION_NOE 长春地辛<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_NOE )<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE (<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE )<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小<|>RELATION_NOE 细胞性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 总<|>RELATION_NOE 缓解率<|>RELATION_NOE 和<|>RELATION_NOE 5年<|>RELATION_NOE 生存率<|>RELATION_NOE 均<|>RELATION_NOE 优于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 60.O<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE 36.7%<|>RELATION_NOE 和<|>RELATION_NOE 43.3%<|>RELATION_NOE 、<|>RELATION_NOE 30.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 10.87<|>RELATION_NOE 、<|>RELATION_NOE 3.81<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 、<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板减少<|>RELATION_NOE 等<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 0.25<|>RELATION_NOE 、<|>RELATION_NOE 1.01<|>RELATION_NOE 、<|>RELATION_NOE 1.04<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 近期<|>RELATION_NOE 、<|>RELATION_NOE 远期<|>RELATION_NOE 疗效<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 安全性<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
健脾<|>RELATION_NOE 补<|>RELATION_NOE 肺汤<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_S 健脾<|>RELATION_NOE 补<|>RELATION_NOE 肺汤<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 毒副反应<|>RELATION_NOE 。<|>RELATION_NOE
60<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 应用<|>RELATION_S 紫杉<|>RELATION_NOE 醇+<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE TP<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 自<|>RELATION_NOE 拟<|>RELATION_NOE 健<|>RELATION_NOE 脾补<|>RELATION_NOE 肺汤<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 单纯<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 应用<|>RELATION_NOE 紫杉醇<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE TP<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 自<|>RELATION_NOE 拟<|>RELATION_NOE 健<|>RELATION_NOE 脾补<|>RELATION_NOE 肺汤<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 单纯<|>RELATION_B 应用<|>RELATION_E TP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 。<|>RELATION_NOE
健脾<|>RELATION_NOE 补<|>RELATION_NOE 肺汤<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 能<|>RELATION_NOE 减轻<|>RELATION_NOE 化疗<|>RELATION_NOE 引起<|>RELATION_NOE 的<|>RELATION_NOE 毒副反应<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 昆明<|>RELATION_NOE 医学院<|>RELATION_NOE 第三<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 2007年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 9月<|>RELATION_NOE 住院<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 合并<|>RELATION_NOE HIV<|>RELATION_NOE 感染<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 数据<|>RELATION_NOE ,<|>RELATION_NOE 总结<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 。<|>RELATION_NOE
所<|>RELATION_NOE 患<|>RELATION_NOE 肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE 男性<|>RELATION_NOE 以<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 17.8<|>RELATION_NOE 6%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 13.3<|>RELATION_NOE 9%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
女性<|>RELATION_NOE 以<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 和<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 18.7<|>RELATION_NOE 5%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 13.3<|>RELATION_NOE 9%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
重视<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 合并<|>RELATION_NOE HIV<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 权衡<|>RELATION_NOE 治疗<|>RELATION_NOE 利弊<|>RELATION_NOE ,<|>RELATION_NOE 尽早<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 防止<|>RELATION_NOE 院内<|>RELATION_NOE 感染<|>RELATION_NOE 。<|>RELATION_NOE
超声<|>RELATION_NOE 引导<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 在<|>RELATION_NOE 近<|>RELATION_NOE 胸壁<|>RELATION_NOE 肺部<|>RELATION_NOE 肿块<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
本组<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 95.6%<|>RELATION_NOE )<|>RELATION_NOE 经<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 获得<|>RELATION_NOE 了<|>RELATION_NOE 明确<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 病种<|>RELATION_NOE 包括<|>RELATION_NOE 肺癌<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 71.1%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 鳞癌<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 大细胞癌<|>RELATION_NOE 4例<|>RELATION_NOE ;<|>RELATION_NOE
江苏省<|>RELATION_NOE 启东市<|>RELATION_NOE 1972<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 11<|>RELATION_NOE 年<|>RELATION_NOE 肺癌<|>RELATION_NOE 死亡率<|>RELATION_NOE 变化<|>RELATION_NOE 趋势<|>RELATION_NOE 分析<|>RELATION_S
根据<|>RELATION_NOE 启东市<|>RELATION_NOE 1972<|>RELATION_NOE —<|>RELATION_NOE 20<|>RELATION_NOE 11<|>RELATION_NOE 年<|>RELATION_NOE 癌症<|>RELATION_NOE 死亡<|>RELATION_NOE 登记<|>RELATION_NOE 数据库<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_S 肺癌<|>RELATION_NOE 粗<|>RELATION_NOE 死亡率<|>RELATION_NOE (<|>RELATION_NOE CR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 中国<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE (<|>RELATION_NOE CASR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 世界<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE (<|>RELATION_NOE WASR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 35<|>RELATION_NOE －<|>RELATION_NOE 64<|>RELATION_NOE 岁<|>RELATION_NOE 截缩<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 74<|>RELATION_NOE 岁<|>RELATION_NOE 累积<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 累积<|>RELATION_NOE 死亡<|>RELATION_NOE 风险<|>RELATION_NOE 及<|>RELATION_NOE 占<|>RELATION_NOE 全部<|>RELATION_NOE 癌症<|>RELATION_NOE 的<|>RELATION_NOE 百分率<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 做<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 时间<|>RELATION_NOE 趋势<|>RELATION_NOE 。<|>RELATION_NOE
1972<|>RELATION_NOE —<|>RELATION_NOE 20<|>RELATION_NOE 11<|>RELATION_NOE 年<|>RELATION_NOE 启东市<|>RELATION_NOE 肺癌<|>RELATION_NOE 年均<|>RELATION_NOE CR<|>RELATION_NOE 为<|>RELATION_NOE 31.15<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 45.68<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 16.95<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CASR<|>RELATION_NOE 为<|>RELATION_NOE 14.04<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE WASR<|>RELATION_NOE 为<|>RELATION_NOE 22.95<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 35-64<|>RELATION_NOE 岁<|>RELATION_NOE 截缩<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 31.82<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 74<|>RELATION_NOE 岁<|>RELATION_NOE 累积<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 2.9<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 累积<|>RELATION_NOE 死亡<|>RELATION_NOE 风险<|>RELATION_NOE 为<|>RELATION_NOE 2.8<|>RELATION_NOE 9%<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 全部<|>RELATION_NOE 癌症<|>RELATION_NOE 比例<|>RELATION_NOE 为<|>RELATION_NOE 20.50%<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 男性<|>RELATION_NOE 死亡率<|>RELATION_NOE 高于<|>RELATION_S 女性<|>RELATION_NOE ,<|>RELATION_NOE 性比值<|>RELATION_NOE 为<|>RELATION_NOE 2.69<|>RELATION_NOE :<|>RELATION_NOE 1.<|>RELATION_NOE 30<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 年龄组<|>RELATION_NOE 肺癌<|>RELATION_NOE 死亡率<|>RELATION_NOE 随<|>RELATION_NOE 年龄<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE 而<|>RELATION_NOE 上升<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
1972<|>RELATION_NOE 、<|>RELATION_NOE 1973-1977<|>RELATION_NOE 、<|>RELATION_NOE 1978-1982<|>RELATION_NOE 、<|>RELATION_NOE 1983-1987<|>RELATION_NOE 、<|>RELATION_NOE 1988-1992<|>RELATION_NOE 、<|>RELATION_NOE 1993-1997<|>RELATION_NOE 、<|>RELATION_NOE 19<|>RELATION_NOE 98<|>RELATION_NOE —<|>RELATION_NOE 2002<|>RELATION_NOE 、<|>RELATION_NOE 2003<|>RELATION_NOE —<|>RELATION_NOE 2007<|>RELATION_NOE 、<|>RELATION_NOE 2008<|>RELATION_NOE —<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 9<|>RELATION_NOE 个<|>RELATION_NOE 时期<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE CR<|>RELATION_NOE 、<|>RELATION_NOE CASR<|>RELATION_NOE 、<|>RELATION_NOE WASR<|>RELATION_NOE 、<|>RELATION_NOE 截缩<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 累积<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 累积<|>RELATION_NOE 死亡<|>RELATION_NOE 风险<|>RELATION_NOE 及<|>RELATION_NOE 占<|>RELATION_NOE 全<|>RELATION_NOE 癌百分率<|>RELATION_NOE 均<|>RELATION_NOE 有所<|>RELATION_NOE 上升<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 死亡率<|>RELATION_NOE 时间<|>RELATION_NOE 趋势<|>RELATION_NOE 分析<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 红细胞生成素<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 相关性<|>RELATION_NOE 贫血<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
评价<|>RELATION_S 重组<|>RELATION_NOE 人<|>RELATION_NOE 红细胞生成素<|>RELATION_NOE (<|>RELATION_NOE rhEPO<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 相关性<|>RELATION_NOE 贫血<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 相关性<|>RELATION_NOE 贫血<|>RELATION_NOE 患者<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 治疗组<|>RELATION_NOE 给予<|>RELATION_S rhEPO<|>RELATION_NOE 联合<|>RELATION_NOE 铁剂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 仅<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 相关性<|>RELATION_NOE 贫血<|>RELATION_NOE 患者<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 治疗组<|>RELATION_NOE 给予<|>RELATION_NOE rhEPO<|>RELATION_NOE 联合<|>RELATION_NOE 铁剂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 仅<|>RELATION_NOE 给予<|>RELATION_S 铁剂<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 剔除<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 出现<|>RELATION_NOE 乏力<|>RELATION_NOE 、<|>RELATION_NOE 头晕<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 局部<|>RELATION_NOE 注射<|>RELATION_NOE 部位<|>RELATION_NOE 疼痛<|>RELATION_NOE 及<|>RELATION_NOE 硬结<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 自行缓解<|>RELATION_NOE 。<|>RELATION_NOE
GP<|>RELATION_NOE 方案<|>RELATION_NOE 联合<|>RELATION_NOE 鸦胆子<|>RELATION_NOE 油乳<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 联合<|>RELATION_NOE 卡培<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 治疗<|>RELATION_S 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 术后<|>RELATION_NOE 单纯肺<|>RELATION_NOE 转移<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_S 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 联合<|>RELATION_NOE 卡培<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 治疗<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 术后<|>RELATION_NOE 单纯肺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 术后<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 提供<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE 。<|>RELATION_NOE
原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 术后<|>RELATION_NOE 单纯肺<|>RELATION_NOE 转移<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 及<|>RELATION_NOE 影像学<|>RELATION_NOE 证实<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 联合<|>RELATION_NOE 卡培<|>RELATION_NOE 他<|>RELATION_NOE 滨组<|>RELATION_NOE 与<|>RELATION_NOE FOLFOX4<|>RELATION_NOE 方案<|>RELATION_NOE 化疗组<|>RELATION_NOE 。<|>RELATION_NOE
支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 联合<|>RELATION_NOE 卡培<|>RELATION_NOE 他<|>RELATION_NOE 滨化疗<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_B 方法<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE FOLFOX4<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 一定<|>RELATION_NOE 程度<|>RELATION_NOE 上<|>RELATION_NOE 提高<|>RELATION_NOE 了<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 术后<|>RELATION_NOE 肺内<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 又<|>RELATION_NOE 对<|>RELATION_NOE 远处<|>RELATION_NOE 微<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 预防<|>RELATION_NOE 和<|>RELATION_NOE 控制<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 提高<|>RELATION_NOE 了<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 有效率<|>RELATION_NOE ,<|>RELATION_NOE 延长<|>RELATION_NOE 了<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE P53<|>RELATION_NOE 和<|>RELATION_NOE Ki-67<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
观察<|>RELATION_S P53<|>RELATION_NOE 和<|>RELATION_NOE Ki-67<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 状况<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 233<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE P53<|>RELATION_NOE 和<|>RELATION_NOE Ki-67<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
P53<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 关系<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE Ki-67<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE
P53<|>RELATION_NOE 在<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 95.0%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE Ki67<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 是否<|>RELATION_NOE 转移<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 关联<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE P53<|>RELATION_NOE 和<|>RELATION_NOE Ki67<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 低<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE 占<|>RELATION_NOE 了<|>RELATION_NOE 相当<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 可能<|>RELATION_NOE 共同<|>RELATION_NOE 参与<|>RELATION_NOE 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE ,<|>RELATION_NOE P53<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 可能<|>RELATION_NOE 更<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE Ki67<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 程度<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 时辰<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 专项<|>RELATION_NOE 护理<|>RELATION_NOE 改善<|>RELATION_S 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 预期性<|>RELATION_NOE 呕吐<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE
观察<|>RELATION_S 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE NP<|>RELATION_NOE )<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 时辰<|>RELATION_NOE 给<|>RELATION_NOE 药及<|>RELATION_NOE 护理<|>RELATION_NOE 改善<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预期性<|>RELATION_NOE 呕吐<|>RELATION_NOE (<|>RELATION_NOE ANY<|>RELATION_NOE )<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
NP<|>RELATION_NOE 方案<|>RELATION_NOE 时辰<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 专项<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 可<|>RELATION_NOE 降低<|>RELATION_S 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE ANY<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 改善<|>RELATION_NOE ANY<|>RELATION_NOE 等级<|>RELATION_NOE 指标<|>RELATION_NOE 及<|>RELATION_NOE 恶心<|>RELATION_NOE 问卷<|>RELATION_NOE 评分<|>RELATION_NOE 。<|>RELATION_NOE
胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
评估<|>RELATION_B 分析<|>RELATION_E 血清<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE (<|>RELATION_NOE ProGRP<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 化学发<|>RELATION_NOE 光法<|>RELATION_NOE 和<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 20<|>RELATION_NOE 10年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 4月<|>RELATION_NOE 期间<|>RELATION_NOE ,<|>RELATION_NOE 青岛<|>RELATION_NOE 大学<|>RELATION_NOE 医学院<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 初诊<|>RELATION_NOE SCLC<|>RELATION_NOE (<|>RELATION_NOE 局限期<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 广泛期<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 56<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 血清<|>RELATION_NOE ProGRP<|>RELATION_NOE 和<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE (<|>RELATION_NOE ROC<|>RELATION_NOE )<|>RELATION_NOE 曲线<|>RELATION_NOE 确定<|>RELATION_NOE ProGRP<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 诊断<|>RELATION_NOE SCLC<|>RELATION_NOE 的<|>RELATION_NOE 临界值<|>RELATION_NOE 及<|>RELATION_NOE 曲线下面积<|>RELATION_NOE (<|>RELATION_NOE ROC-AUC<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_NOE 2项<|>RELATION_NOE 指标<|>RELATION_NOE 诊断<|>RELATION_NOE SCLC<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 。<|>RELATION_NOE
125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE
首先<|>RELATION_NOE 根据<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 大小<|>RELATION_NOE 利用<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE (<|>RELATION_NOE TPS<|>RELATION_NOE )<|>RELATION_NOE 计算<|>RELATION_S 出<|>RELATION_NOE 治疗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 所<|>RELATION_NOE 需要<|>RELATION_NOE 的<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 的<|>RELATION_NOE 最佳<|>RELATION_NOE 数量<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 经<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿刺<|>RELATION_NOE 将<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 均匀<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 肿瘤<|>RELATION_NOE 内<|>RELATION_NOE 进行<|>RELATION_NOE 组织<|>RELATION_NOE 间<|>RELATION_NOE 放疗<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 1－<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 复查<|>RELATION_NOE CT1<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
经皮<|>RELATION_NOE 穿刺<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 组织<|>RELATION_NOE 间<|>RELATION_NOE 永久<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 为<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 满意<|>RELATION_NOE 、<|>RELATION_NOE 微创<|>RELATION_NOE 、<|>RELATION_NOE 低毒<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 进一步<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
中晚期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE EP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 整体<|>RELATION_B 护理<|>RELATION_I 体会<|>RELATION_E
观察<|>RELATION_S 整体<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 中晚期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE EP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
把<|>RELATION_NOE 63<|>RELATION_NOE 例<|>RELATION_NOE 以<|>RELATION_NOE EP<|>RELATION_NOE 方案<|>RELATION_NOE (<|>RELATION_NOE 足叶乙<|>RELATION_NOE 甙<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE ,<|>RELATION_NOE 卡铂<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 予<|>RELATION_NOE 整体<|>RELATION_NOE 优质<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 按<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 护理<|>RELATION_NOE 常规<|>RELATION_NOE 进行<|>RELATION_B 护理<|>RELATION_E 。<|>RELATION_NOE
观察组<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 静脉炎<|>RELATION_NOE 、<|>RELATION_NOE 肝肾<|>RELATION_NOE 损害<|>RELATION_NOE 发生率<|>RELATION_NOE (<|>RELATION_NOE 56.2<|>RELATION_NOE 5%<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 25.8<|>RELATION_NOE 1%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 6.02<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 整体<|>RELATION_NOE 护理<|>RELATION_NOE 应用<|>RELATION_NOE 于<|>RELATION_NOE 以<|>RELATION_NOE EP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 减少<|>RELATION_S 患者<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 静脉炎<|>RELATION_NOE 、<|>RELATION_NOE 肝肾<|>RELATION_NOE 损害<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 124<|>RELATION_NOE 例<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 用<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 进行<|>RELATION_B 治疗<|>RELATION_E ,<|>RELATION_NOE 对照组<|>RELATION_NOE 用<|>RELATION_NOE 异<|>RELATION_NOE 长春花碱<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 观察组<|>RELATION_NOE 用<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 进行<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 用<|>RELATION_NOE 异<|>RELATION_NOE 长春花碱<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 进行<|>RELATION_B 治疗<|>RELATION_E ;<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 一<|>RELATION_NOE 线<|>RELATION_NOE 的<|>RELATION_NOE
2002<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 上海市<|>RELATION_NOE 杨浦区<|>RELATION_NOE 居民<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 分析<|>RELATION_S
整理<|>RELATION_NOE 上海市<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病例<|>RELATION_NOE 登记<|>RELATION_NOE 和<|>RELATION_NOE 管理<|>RELATION_NOE 系统<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 杨浦区<|>RELATION_NOE 户籍<|>RELATION_NOE 人群<|>RELATION_NOE 肺癌<|>RELATION_NOE 病例<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 年<|>RELATION_NOE 平均<|>RELATION_NOE 变化<|>RELATION_NOE 百分比<|>RELATION_NOE (<|>RELATION_NOE APC<|>RELATION_NOE )<|>RELATION_NOE 模型<|>RELATION_NOE 分析<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 发病<|>RELATION_NOE 的<|>RELATION_NOE 时间<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 应片<|>RELATION_NOE jSPSS16.0<|>RELATION_NOE 软件<|>RELATION_NOE 、<|>RELATION_NOE Joinpoint<|>RELATION_NOE Regression<|>RELATION_NOE Program3.5.1<|>RELATION_NOE 统计<|>RELATION_NOE 软件<|>RELATION_NOE 进行<|>RELATION_NOE 生存<|>RELATION_NOE
肺癌<|>RELATION_NOE 男性<|>RELATION_NOE 平均<|>RELATION_NOE 粗<|>RELATION_NOE 发病率<|>RELATION_NOE 为<|>RELATION_NOE 77.36<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 女性<|>RELATION_NOE (<|>RELATION_NOE 39.31<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 男性<|>RELATION_NOE 标化<|>RELATION_NOE 发病率<|>RELATION_NOE 为<|>RELATION_NOE 25.23<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 女性<|>RELATION_NOE (<|>RELATION_NOE 13.47<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 男性<|>RELATION_NOE 平均<|>RELATION_NOE 粗<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 71.77<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 女性<|>RELATION_NOE (<|>RELATION_NOE 35.11<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 男性<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 21.72<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 女性<|>RELATION_NOE (<|>RELATION_NOE 11.08<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ;<|>RELATION_NOE
45<|>RELATION_NOE 岁<|>RELATION_NOE 以后<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 与<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发病率<|>RELATION_NOE 和<|>RELATION_NOE 死亡率<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 上升<|>RELATION_NOE 。<|>RELATION_NOE
四维<|>RELATION_NOE CT<|>RELATION_NOE 测定<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE
测量<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 分<|>RELATION_NOE 次内<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE NSCLC<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 内<|>RELATION_NOE 靶区<|>RELATION_NOE 的<|>RELATION_NOE 确定<|>RELATION_NOE 提供<|>RELATION_B 依据<|>RELATION_E 。<|>RELATION_NOE
增强<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 显示<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE 短径<|>RELATION_NOE ≥<|>RELATION_NOE Icm<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 自由<|>RELATION_NOE 呼吸<|>RELATION_NOE 状态<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 大<|>RELATION_NOE 孔径<|>RELATION_NOE CT<|>RELATION_NOE 模拟<|>RELATION_NOE 定位<|>RELATION_NOE 并<|>RELATION_NOE 获得<|>RELATION_NOE 四维<|>RELATION_NOE CT<|>RELATION_NOE (<|>RELATION_NOE 4D-CT<|>RELATION_NOE )<|>RELATION_NOE 图像<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 系统<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 勾画<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 呼吸<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE 4D-CT<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 显示<|>RELATION_NOE 清楚<|>RELATION_NOE 的<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 及<|>RELATION_NOE 同<|>RELATION_NOE 侧膈<|>RELATION_NOE 肌顶层<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 依据<|>RELATION_NOE 被<|>RELATION_NOE 勾画<|>RELATION_NOE 淋巴结<|>RELATION_NOE 所在<|>RELATION_NOE 的<|>RELATION_NOE 区域<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 分为<|>RELATION_NOE 上<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 下<|>RELATION_NOE 纵隔<|>RELATION_NOE 3<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 获得<|>RELATION_NOE 每个<|>RELATION_NOE 被<|>RELATION_NOE 勾画<|>RELATION_NOE 淋巴结<|>RELATION_NOE 在<|>RELATION_NOE 左右<|>RELATION_NOE 、<|>RELATION_NOE 前后<|>RELATION_NOE 和<|>RELATION_NOE 上下<|>RELATION_NOE 方向<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE 及<|>RELATION_NOE 三维<|>RELATION_NOE 运动<|>RELATION_NOE 矢量<|>RELATION_NOE 。<|>RELATION_NOE
比较<|>RELATION_NOE 同一<|>RELATION_NOE 区域<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 方向<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE 差异<|>RELATION_NOE 、<|>RELATION_NOE 不同<|>RELATION_NOE 区域<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 在<|>RELATION_NOE 相同<|>RELATION_NOE 方向<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE 差异<|>RELATION_NOE 和<|>RELATION_NOE 三维<|>RELATION_NOE 运动<|>RELATION_NOE 矢量<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 位移<|>RELATION_NOE 与<|>RELATION_NOE 同<|>RELATION_NOE 侧膈<|>RELATION_NOE 肌位移<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 自由<|>RELATION_NOE 呼吸<|>RELATION_NOE 状态<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 分<|>RELATION_NOE 次<|>RELATION_NOE 内在<|>RELATION_NOE 同一<|>RELATION_NOE 方向<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE 大小<|>RELATION_NOE 与<|>RELATION_NOE 所在<|>RELATION_NOE 纵隔<|>RELATION_NOE 的<|>RELATION_NOE 区域<|>RELATION_NOE 无关<|>RELATION_S ;<|>RELATION_NOE
各<|>RELATION_NOE 区域<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 在<|>RELATION_NOE 三维<|>RELATION_NOE 方向<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 上下<|>RELATION_NOE 方向<|>RELATION_NOE 大于<|>RELATION_NOE 左右<|>RELATION_NOE 和<|>RELATION_NOE 前后<|>RELATION_NOE 方向<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 这种<|>RELATION_NOE 差异<|>RELATION_NOE 在<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 下<|>RELATION_NOE 纵隔<|>RELATION_NOE 区域<|>RELATION_NOE 淋巴结<|>RELATION_NOE 表现<|>RELATION_NOE 更为<|>RELATION_NOE 显著<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 上下<|>RELATION_NOE 方向<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 区域<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE 均<|>RELATION_NOE 与<|>RELATION_NOE 同侧膈<|>RELATION_NOE 肌位移<|>RELATION_NOE 无关<|>RELATION_S ,<|>RELATION_NOE 即<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 以<|>RELATION_NOE 膈肌<|>RELATION_NOE 位<|>RELATION_NOE 移<|>RELATION_NOE 来<|>RELATION_NOE 预测<|>RELATION_NOE 或<|>RELATION_NOE 判断<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE miR-30c<|>RELATION_NOE 侧<|>RELATION_NOE 翼区<|>RELATION_NOE 的<|>RELATION_NOE 单<|>RELATION_NOE 核苷酸多态性<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 成熟<|>RELATION_NOE 进程<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
构建<|>RELATION_NOE 含有<|>RELATION_NOE 不同<|>RELATION_NOE 基因型<|>RELATION_NOE miR-30c<|>RELATION_NOE 侧<|>RELATION_NOE 翼区<|>RELATION_NOE 的<|>RELATION_NOE 报告基因<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE pG13-promoter-miR-30e-A<|>RELATION_NOE 和<|>RELATION_NOE pGL3-promoter-miR-30c-G<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 与<|>RELATION_NOE 内参<|>RELATION_NOE 质粒<|>RELATION_NOE pRL-SV40<|>RELATION_NOE 共<|>RELATION_NOE 转染<|>RELATION_NOE 于<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 人<|>RELATION_NOE 胚肾<|>RELATION_NOE 293A<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 中国仓鼠<|>RELATION_NOE 卵巢<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE CHO<|>RELATION_NOE 细胞<|>RELATION_NOE )<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_S 荧光素<|>RELATION_NOE 酶<|>RELATION_NOE 活性<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE Taqman<|>RELATION_NOE 基因<|>RELATION_NOE 分型<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 进行<|>RELATION_NOE 基因<|>RELATION_NOE 分型<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 不同<|>RELATION_NOE 基因型<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE pri-miR-30c<|>RELATION_NOE 、<|>RELATION_NOE pre-miR-30c<|>RELATION_NOE 、<|>RELATION_NOE 成熟<|>RELATION_NOE miR-30c<|>RELATION_NOE 以及<|>RELATION_NOE miR-30c<|>RELATION_NOE 宿主<|>RELATION_NOE 基因<|>RELATION_NOE 核<|>RELATION_NOE 转录因子<|>RELATION_NOE Y<|>RELATION_NOE (<|>RELATION_NOE NFYC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 转录<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
荩因分型<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE 昆示<|>RELATION_NOE ,<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE AA<|>RELATION_NOE 基因型<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE AG<|>RELATION_NOE 基因型<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE GG<|>RELATION_NOE 基因型<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE pri-miR-30c<|>RELATION_NOE 和<|>RELATION_NOE NFYC<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 各<|>RELATION_NOE 基因型<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 相对<|>RELATION_NOE 表达量<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 35<|>RELATION_NOE 和<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 93<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE miR-30c<|>RELATION_NOE 侧翼<|>RELATION_NOE Ⅸ<|>RELATION_NOE 的<|>RELATION_NOE 单<|>RELATION_NOE 核苷酸多态性<|>RELATION_NOE rs928508<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE G<|>RELATION_NOE )<|>RELATION_NOE 可以<|>RELATION_NOE 影响<|>RELATION_S pri-miR-30c<|>RELATION_NOE →<|>RELATION_NOE pre-miR-30c<|>RELATION_NOE →<|>RELATION_NOE 成熟<|>RELATION_NOE miR-30c<|>RELATION_NOE 的<|>RELATION_NOE 转化<|>RELATION_NOE 进程<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 不能<|>RELATION_NOE
5-<|>RELATION_NOE 氮杂<|>RELATION_NOE -2<|>RELATION_NOE '<|>RELATION_NOE -<|>RELATION_NOE 脱氧胞苷<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 抑<|>RELATION_NOE 癌基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
观察<|>RELATION_S 分泌型<|>RELATION_NOE 卷曲<|>RELATION_NOE 相关<|>RELATION_NOE 篮白1<|>RELATION_NOE (<|>RELATION_NOE SFRP1<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 抑<|>RELATION_NOE 甲基化<|>RELATION_NOE 制剂<|>RELATION_NOE 5-<|>RELATION_NOE 氮杂<|>RELATION_NOE -2<|>RELATION_NOE '<|>RELATION_NOE -<|>RELATION_NOE 脱氧胞苷<|>RELATION_NOE (<|>RELATION_NOE 5-Aza-CdR<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE SFRP1<|>RELATION_NOE 、<|>RELATION_NOE p16<|>RELATION_NOE 和<|>RELATION_NOE O<|>RELATION_NOE ^<|>RELATION_NOE 6-<|>RELATION_NOE 甲基<|>RELATION_NOE 鸟嘌呤<|>RELATION_NOE -DNA<|>RELATION_NOE 甲基<|>RELATION_NOE 转移酶<|>RELATION_NOE (<|>RELATION_NOE MGMT<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE sP<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 60<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE SFRPl<|>RELATION_NOE 基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 状态<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 肺良<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 组织<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 5-Aza-CdR<|>RELATION_NOE 处理<|>RELATION_NOE 肺癌<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE MSP<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE RT-PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 处理<|>RELATION_NOE 前后<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE SFRP1<|>RELATION_NOE 、<|>RELATION_NOE p16<|>RELATION_NOE 和<|>RELATION_NOE MGMT<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE 及<|>RELATION_NOE 相应<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
SFRP1<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
末用<|>RELATION_NOE 5-Aza-CdR<|>RELATION_NOE 处理<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE SFRPI<|>RELATION_NOE 、<|>RELATION_NOE p16<|>RELATION_NOE 和<|>RELATION_NOE MGMT<|>RELATION_NOE 基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 和<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 甚<|>RELATION_NOE 很<|>RELATION_NOE 低<|>RELATION_NOE ;<|>RELATION_NOE
应用<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 5-Aza-dCR<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE SFRP1<|>RELATION_NOE 、<|>RELATION_NOE p16<|>RELATION_NOE 和<|>RELATION_NOE MGMT<|>RELATION_NOE 基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 和<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_NOE 上调<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 经典<|>RELATION_NOE 人类<|>RELATION_NOE 白细胞抗原<|>RELATION_NOE I<|>RELATION_NOE (<|>RELATION_NOE HLA-I<|>RELATION_NOE )<|>RELATION_NOE 类<|>RELATION_NOE 抗原<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结癌<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 及其<|>RELATION_NOE 调控<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 各<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 抗原<|>RELATION_NOE 处理<|>RELATION_NOE 相关<|>RELATION_NOE 转运体1<|>RELATION_NOE (<|>RELATION_NOE TAPl<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 、<|>RELATION_NOE 潜伏膜<|>RELATION_NOE 蛋白2<|>RELATION_NOE (<|>RELATION_NOE LMP2<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 变量<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 目的<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 统计<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 经典<|>RELATION_NOE HLA-I<|>RELATION_NOE 类<|>RELATION_NOE 抗原<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE (<|>RELATION_NOE 15.35<|>RELATION_NOE ±<|>RELATION_NOE 6.24<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 肺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE (<|>RELATION_NOE 39.68<|>RELATION_NOE ±<|>RELATION_NOE 12.46<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.06<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE
经典<|>RELATION_NOE HLA-I<|>RELATION_NOE 类<|>RELATION_NOE 抗原<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结癌<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 中<|>RELATION_NOE TAPlmRNA<|>RELATION_NOE 、<|>RELATION_NOE LMP2mRNA<|>RELATION_NOE 表达率<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 肺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE (<|>RELATION_NOE ,<|>RELATION_NOE =<|>RELATION_NOE 5.01<|>RELATION_NOE 及<|>RELATION_NOE 5.39<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
经典<|>RELATION_NOE HLA-I<|>RELATION_NOE 类<|>RELATION_NOE 抗原<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_B 之一<|>RELATION_E 。<|>RELATION_NOE
TAPl<|>RELATION_NOE 、<|>RELATION_NOE LMP2mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 缺陷<|>RELATION_NOE 是<|>RELATION_NOE NSCLC<|>RELATION_NOE 原发灶<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 经典<|>RELATION_NOE HLA-I<|>RELATION_NOE 抗原<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_B 之一<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 淋巴结癌<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 表现<|>RELATION_NOE 更<|>RELATION_NOE 明显<|>RELATION_NOE 。<|>RELATION_NOE
蛋白<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激<|>RELATION_NOE 酶<|>RELATION_NOE 2<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 大肠<|>RELATION_NOE 癌细胞<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 肺转移<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_S 富<|>RELATION_NOE 含<|>RELATION_NOE 脯氨酸<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE Pyk2<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 大肠<|>RELATION_NOE 癌细胞<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 肺转移<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
利崩人<|>RELATION_NOE 大肠<|>RELATION_NOE 癌细胞株<|>RELATION_NOE SW480<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 止义<|>RELATION_NOE 及<|>RELATION_NOE 反义<|>RELATION_NOE eDNA<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 技术<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 构建<|>RELATION_NOE Pyk2<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE SW480-Pyk2<|>RELATION_NOE -<|>RELATION_NOE 和<|>RELATION_NOE SW480-Pyk2<|>RELATION_NOE -<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 未<|>RELATION_NOE 转染<|>RELATION_NOE 质粒<|>RELATION_NOE 和<|>RELATION_NOE 转染<|>RELATION_NOE 空<|>RELATION_NOE 质粒<|>RELATION_NOE 的<|>RELATION_NOE SW480<|>RELATION_NOE 细胞<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
Pyk2<|>RELATION_NOE 在<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 能够<|>RELATION_NOE 抑制<|>RELATION_S 大肠<|>RELATION_NOE 痈细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 肺转移<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
TLR4-siRNA<|>RELATION_NOE 对<|>RELATION_NOE 高氧<|>RELATION_NOE 诱导<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 炎性<|>RELATION_NOE 因子<|>RELATION_NOE 分泌<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
评价<|>RELATION_S Toll<|>RELATION_NOE 样<|>RELATION_NOE 受体4<|>RELATION_NOE (<|>RELATION_NOE TLR4<|>RELATION_NOE )<|>RELATION_NOE -<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 高氧<|>RELATION_NOE 诱导<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 炎性<|>RELATION_NOE 因子<|>RELATION_NOE 分泌<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 培养<|>RELATION_NOE 板<|>RELATION_NOE ,<|>RELATION_NOE 培养<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 4组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 高氧组<|>RELATION_NOE (<|>RELATION_NOE H<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE TLR4-siRNA<|>RELATION_NOE 转染组<|>RELATION_NOE (<|>RELATION_NOE TR<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 阴性<|>RELATION_NOE siRNA<|>RELATION_NOE 转染组<|>RELATION_NOE (<|>RELATION_NOE NR<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
TR<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE NR<|>RELATION_NOE 组<|>RELATION_NOE 分别<|>RELATION_NOE 将<|>RELATION_NOE TLR4-siRNA<|>RELATION_NOE 或<|>RELATION_NOE 阴性<|>RELATION_NOE siRNA<|>RELATION_NOE 转染<|>RELATION_NOE 至<|>RELATION_NOE 细胞<|>RELATION_NOE 内.<|>RELATION_NOE
七<|>RELATION_NOE 氟醚<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 抑制<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 迁移<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 培养<|>RELATION_NOE 板<|>RELATION_NOE ,<|>RELATION_NOE 培养<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 4组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE 、<|>RELATION_NOE 顺铂组<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE +<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组.<|>RELATION_NOE
采用<|>RELATION_NOE Transwell<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 细胞<|>RELATION_NOE 划痕<|>RELATION_NOE 实验<|>RELATION_NOE
与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE 、<|>RELATION_NOE 顺铂组<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE +<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 迁移<|>RELATION_NOE 能力<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 、<|>RELATION_NOE Ezrin<|>RELATION_NOE 和<|>RELATION_NOE Fascin<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
不同<|>RELATION_NOE 浓度<|>RELATION_NOE 七<|>RELATION_NOE 氟醚<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 黏附<|>RELATION_NOE 能力<|>RELATION_NOE 、<|>RELATION_NOE CD24<|>RELATION_NOE 和<|>RELATION_NOE CD44v6<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
取<|>RELATION_NOE 对<|>RELATION_NOE 数<|>RELATION_NOE 生长期<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 24<|>RELATION_NOE 孔<|>RELATION_NOE 培养<|>RELATION_NOE 板<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 4组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 1.7%<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE (<|>RELATION_NOE S1<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 3.4%<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE (<|>RELATION_NOE S2<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 5.1%<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE (<|>RELATION_NOE S3<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 锥形束<|>RELATION_NOE CT<|>RELATION_NOE 与<|>RELATION_NOE 计划<|>RELATION_NOE CT<|>RELATION_NOE 形变<|>RELATION_NOE 配<|>RELATION_NOE 准<|>RELATION_NOE 自动<|>RELATION_NOE 勾画<|>RELATION_NOE 危及器官<|>RELATION_NOE 可行性研究<|>RELATION_S
选取<|>RELATION_NOE 5例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 1<|>RELATION_NOE 套<|>RELATION_NOE 定位<|>RELATION_NOE cT<|>RELATION_NOE 图像<|>RELATION_NOE 和<|>RELATION_NOE 各<|>RELATION_NOE 10<|>RELATION_NOE 套<|>RELATION_NOE 摆位<|>RELATION_NOE 验证<|>RELATION_NOE KVCBCT<|>RELATION_NOE 图像<|>RELATION_NOE 进行<|>RELATION_NOE 形变<|>RELATION_NOE 配<|>RELATION_NOE 准<|>RELATION_NOE 自动<|>RELATION_NOE 勾画<|>RELATION_NOE 和<|>RELATION_NOE 手工<|>RELATION_NOE 勾画<|>RELATION_NOE 危及器官<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_S 形变<|>RELATION_NOE 配准<|>RELATION_NOE 和<|>RELATION_NOE 刚性<|>RELATION_NOE 配准<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE Dice<|>RELATION_NOE 相似<|>RELATION_NOE 性系数<|>RELATION_NOE (<|>RELATION_NOE DSC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 敏感性<|>RELATION_NOE 等<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 并行<|>RELATION_NOE 配对<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 。<|>RELATION_NOE
射波刀<|>RELATION_NOE 治疗<|>RELATION_S 腹膜后肿瘤<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
≥<|>RELATION_NOE 2级<|>RELATION_NOE 急性<|>RELATION_NOE 反应<|>RELATION_NOE 中<|>RELATION_NOE 乏力<|>RELATION_NOE 、<|>RELATION_NOE 厌食<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 肠炎<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 9<|>RELATION_NOE 、<|>RELATION_NOE 9<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 远期<|>RELATION_NOE 反应<|>RELATION_NOE 仅<|>RELATION_NOE 1例<|>RELATION_NOE 出现<|>RELATION_NOE 1级肠<|>RELATION_NOE 狭窄<|>RELATION_NOE 。<|>RELATION_NOE
肺内<|>RELATION_NOE 孤立<|>RELATION_NOE 灶<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE CT<|>RELATION_NOE 不同<|>RELATION_NOE 扫描<|>RELATION_NOE 方式<|>RELATION_NOE 比较<|>RELATION_S
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预防性<|>RELATION_NOE 全脑<|>RELATION_NOE 照射<|>RELATION_NOE 系统<|>RELATION_B 评价<|>RELATION_E
1<|>RELATION_NOE 年<|>RELATION_NOE 时<|>RELATION_NOE 霍普<|>RELATION_NOE 金斯<|>RELATION_NOE 语言<|>RELATION_NOE 学习<|>RELATION_NOE 测验<|>RELATION_NOE 即时<|>RELATION_NOE 记忆<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 延迟记忆<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.008<|>RELATION_NOE )<|>RELATION_NOE PCI<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 下降<|>RELATION_NOE 。<|>RELATION_NOE
甲氨蝶呤<|>RELATION_NOE 对<|>RELATION_NOE 映体<|>RELATION_NOE 耐药<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_B 分析<|>RELATION_E
探讨<|>RELATION_S 甲氨蝶呤<|>RELATION_NOE (<|>RELATION_NOE MTX<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 映体<|>RELATION_NOE 耐药<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 运动<|>RELATION_NOE 能力<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 说明<|>RELATION_NOE MTX<|>RELATION_NOE 对<|>RELATION_NOE 映体<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 转移<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE
transwell<|>RELATION_NOE 小室<|>RELATION_NOE 检测<|>RELATION_NOE D-<|>RELATION_NOE (<|>RELATION_NOE -<|>RELATION_NOE )<|>RELATION_NOE -MTX<|>RELATION_NOE /<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE L-<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE -MTX<|>RELATION_NOE /<|>RELATION_NOE A549<|>RELATION_NOE 以及<|>RELATION_NOE 亲本<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 浸润<|>RELATION_NOE 侵袭<|>RELATION_NOE 穿过<|>RELATION_NOE 人工<|>RELATION_NOE 基底膜<|>RELATION_NOE Matrigel<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 267-4-30<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 106<|>RELATION_NOE ±<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 134<|>RELATION_NOE ±<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
-<|>RELATION_NOE (<|>RELATION_NOE -<|>RELATION_NOE )<|>RELATION_NOE -MTX<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 耐药<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 运动<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 侵袭力<|>RELATION_NOE 均<|>RELATION_NOE 大于<|>RELATION_NOE L-<|>RELATION_NOE (<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
MTX<|>RELATION_NOE 耐药<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 说明<|>RELATION_NOE MTX<|>RELATION_NOE 对<|>RELATION_NOE 映体<|>RELATION_NOE 耐药<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 转移力<|>RELATION_NOE 有<|>RELATION_NOE 差异<|>RELATION_NOE
18F-<|>RELATION_NOE 氟化钠<|>RELATION_NOE PET-CT<|>RELATION_NOE 显像<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 术前骨<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
探讨<|>RELATION_S PET-CT18F<|>RELATION_NOE -<|>RELATION_NOE 氟化钠<|>RELATION_NOE (<|>RELATION_NOE NaF<|>RELATION_NOE )<|>RELATION_NOE 显像<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE
标准<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 107<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_NOE 腺癌<|>RELATION_NOE 为<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 类型<|>RELATION_NOE 肺癌<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 40.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 21.1%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 两者<|>RELATION_NOE 之间<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE 检验<|>RELATION_NOE 校正法<|>RELATION_NOE ,<|>RELATION_NOE χ<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 1.4<|>RELATION_NOE 65<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.2<|>RELATION_NOE 26<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
PET-CT<|>RELATION_NOE 骨显像<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 术前<|>RELATION_NOE 患者<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 灵敏性<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 98.7%<|>RELATION_NOE (<|>RELATION_NOE 74<|>RELATION_NOE /<|>RELATION_NOE 75<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 准确性<|>RELATION_NOE 为<|>RELATION_NOE 99.1%<|>RELATION_NOE (<|>RELATION_NOE 106<|>RELATION_NOE /<|>RELATION_NOE 107<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 为<|>RELATION_NOE 97.0%<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE /<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 74<|>RELATION_NOE /<|>RELATION_NOE 74<|>RELATION_NOE )<|>RELATION_NOE
8F-NaFPET-CT<|>RELATION_NOE 骨显像<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 评价<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 灵敏性<|>RELATION_B 和<|>RELATION_I 特异性<|>RELATION_I 高<|>RELATION_E ,<|>RELATION_NOE 假<|>RELATION_NOE 阳性<|>RELATION_NOE 及<|>RELATION_NOE 假阴性<|>RELATION_NOE 低<|>RELATION_NOE ;<|>RELATION_NOE
Ⅲ<|>RELATION_NOE A-N2<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 性切<|>RELATION_NOE 除<|>RELATION_NOE 术后<|>RELATION_NOE 的<|>RELATION_NOE 复发<|>RELATION_B 分析<|>RELATION_E
回顾<|>RELATION_NOE 北京大学<|>RELATION_NOE 第一<|>RELATION_NOE 医院<|>RELATION_NOE 2004年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 2008年<|>RELATION_NOE 12月<|>RELATION_NOE 期间<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE Ⅲ<|>RELATION_NOE A<|>RELATION_NOE ,<|>RELATION_NOE N2<|>RELATION_NOE 期<|>RELATION_NOE 的<|>RELATION_NOE 63<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 监测<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 计算<|>RELATION_S 术后<|>RELATION_NOE 复发率<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Cox<|>RELATION_NOE 比例<|>RELATION_NOE 风险<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE 分析<|>RELATION_NOE 复发<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE
A-N2<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 主要<|>RELATION_NOE 以<|>RELATION_NOE 转移性<|>RELATION_NOE 复发<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 危险因素<|>RELATION_NOE 包括<|>RELATION_NOE Lvl<|>RELATION_NOE 、<|>RELATION_NOE N2<|>RELATION_NOE 阳性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 站<|>RELATION_NOE 数<|>RELATION_NOE 、<|>RELATION_NOE N2<|>RELATION_NOE 阳性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数量<|>RELATION_NOE 和<|>RELATION_NOE 隆突<|>RELATION_NOE 下<|>RELATION_NOE 淋巴结<|>RELATION_NOE 是否<|>RELATION_NOE 转移<|>RELATION_NOE
探讨<|>RELATION_S 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下袖式<|>RELATION_NOE 支气管<|>RELATION_NOE 成形术<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE 、<|>RELATION_NOE 有效性<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 适应证<|>RELATION_NOE 和<|>RELATION_NOE 操作<|>RELATION_NOE 注意<|>RELATION_NOE 事项<|>RELATION_NOE
中<|>RELATION_NOE 位<|>RELATION_NOE 年龄<|>RELATION_NOE 62.4<|>RELATION_NOE 岁<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径<|>RELATION_NOE 2.3cm<|>RELATION_NOE 右<|>RELATION_NOE 肺上<|>RELATION_NOE 叶袖式<|>RELATION_NOE 支气管<|>RELATION_NOE 成<|>RELATION_NOE 形术5<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 左肺<|>RELATION_NOE 下<|>RELATION_NOE 叶袖式<|>RELATION_NOE 支气管<|>RELATION_NOE 成<|>RELATION_NOE 形术2<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 左肺<|>RELATION_NOE 上<|>RELATION_NOE 叶袖式<|>RELATION_NOE 支气管<|>RELATION_NOE 成<|>RELATION_NOE 形术<|>RELATION_NOE 1例<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 为<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 解剖<|>RELATION_NOE 性袖式<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 支气管<|>RELATION_NOE 成形术+<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 至少<|>RELATION_NOE 3组<|>RELATION_NOE 纵隔<|>RELATION_NOE 区域<|>RELATION_NOE 淋巴结<|>RELATION_NOE )<|>RELATION_NOE 采用<|>RELATION_NOE 双腔<|>RELATION_NOE 气管<|>RELATION_NOE 插管<|>RELATION_NOE 全身麻醉<|>RELATION_NOE ,<|>RELATION_NOE 侧<|>RELATION_NOE 卧位<|>RELATION_NOE ,<|>RELATION_NOE 肩<|>RELATION_NOE 下<|>RELATION_NOE 垫枕<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 观察口<|>RELATION_NOE 放置<|>RELATION_NOE 在<|>RELATION_NOE 右侧<|>RELATION_NOE 腋中线<|>RELATION_NOE 第7<|>RELATION_NOE 肋<|>RELATION_NOE 间<|>RELATION_NOE ,<|>RELATION_NOE 长<|>RELATION_NOE 1.5cm<|>RELATION_NOE ;<|>RELATION_NOE
辅助<|>RELATION_NOE 操作口<|>RELATION_NOE 选择<|>RELATION_NOE 在<|>RELATION_NOE 肩胛<|>RELATION_NOE 下<|>RELATION_NOE 角线<|>RELATION_NOE 第7<|>RELATION_NOE 肋<|>RELATION_NOE 间<|>RELATION_NOE ,<|>RELATION_NOE 长<|>RELATION_NOE 1.5cm<|>RELATION_NOE 支气管<|>RELATION_NOE 吻合<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 端端<|>RELATION_NOE 吻合<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 膜部<|>RELATION_NOE 单纯<|>RELATION_NOE 连续<|>RELATION_NOE 缝合<|>RELATION_NOE +<|>RELATION_NOE 软骨部<|>RELATION_NOE 单纯<|>RELATION_NOE 间断<|>RELATION_NOE 缝合<|>RELATION_NOE 的<|>RELATION_NOE 吻合<|>RELATION_NOE 方式<|>RELATION_NOE ,<|>RELATION_NOE 即<|>RELATION_NOE 先<|>RELATION_NOE 以<|>RELATION_NOE 4—0<|>RELATION_NOE 不可<|>RELATION_NOE 吸收<|>RELATION_NOE 缝线<|>RELATION_NOE 单纯<|>RELATION_NOE 连续<|>RELATION_NOE 缝合<|>RELATION_NOE 支气管<|>RELATION_NOE 后<|>RELATION_NOE 壁<|>RELATION_NOE 及<|>RELATION_NOE 膜部<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 以<|>RELATION_NOE 3-0<|>RELATION_NOE 可<|>RELATION_NOE 吸收<|>RELATION_NOE 缝线<|>RELATION_NOE 单纯<|>RELATION_NOE 间断<|>RELATION_NOE 缝合<|>RELATION_NOE 支气管<|>RELATION_NOE 前<|>RELATION_NOE 壁<|>RELATION_NOE ,<|>RELATION_NOE 完成<|>RELATION_NOE 全<|>RELATION_NOE 周<|>RELATION_NOE 吻合<|>RELATION_NOE 以<|>RELATION_NOE 周围<|>RELATION_NOE 带<|>RELATION_NOE 血<|>RELATION_NOE 供<|>RELATION_NOE 组织<|>RELATION_NOE 缝合<|>RELATION_NOE 覆盖<|>RELATION_NOE 支气管<|>RELATION_NOE 吻<|>RELATION_NOE 合口<|>RELATION_NOE 常规<|>RELATION_NOE 放置<|>RELATION_NOE 胸腔<|>RELATION_NOE 闭式<|>RELATION_NOE 引流管<|>RELATION_NOE
术中<|>RELATION_NOE 出血<|>RELATION_NOE 200ml<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 19.8<|>RELATION_NOE 枚<|>RELATION_NOE /<|>RELATION_NOE 例<|>RELATION_NOE 无中转开<|>RELATION_NOE 胸病<|>RELATION_NOE 例术<|>RELATION_NOE 后<|>RELATION_NOE 病理<|>RELATION_NOE 示<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 1例术<|>RELATION_NOE 后<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE T1aN0M0<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE T1bN0M0<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE T1bN1M0<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE T1bN2M0<|>RELATION_NOE 1例术<|>RELATION_NOE 后<|>RELATION_NOE 轻微<|>RELATION_NOE 并发症<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 一<|>RELATION_NOE 过<|>RELATION_NOE 性窦性<|>RELATION_NOE 心动过速<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 药物治疗<|>RELATION_NOE 后<|>RELATION_NOE 好转<|>RELATION_NOE 全<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 恢复<|>RELATION_NOE 顺利<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 放置<|>RELATION_NOE 胸腔<|>RELATION_NOE 引<|>RELATION_NOE 流管<|>RELATION_NOE 时间<|>RELATION_NOE 7<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 住院9<|>RELATION_NOE 天<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 3－<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 下袖式<|>RELATION_NOE 支气管<|>RELATION_NOE 成<|>RELATION_NOE 形术<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE ;<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 解剖性<|>RELATION_NOE 肺段<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_S 肺部疾病<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 结果<|>RELATION_NOE
年龄<|>RELATION_NOE 32<|>RELATION_NOE －<|>RELATION_NOE 81<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 53<|>RELATION_NOE 岁<|>RELATION_NOE 病变<|>RELATION_NOE 包括<|>RELATION_NOE 原发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 肺转移<|>RELATION_NOE 瘤1<|>RELATION_NOE 例<|>RELATION_NOE 切除<|>RELATION_NOE 部位<|>RELATION_NOE 包括<|>RELATION_NOE :<|>RELATION_NOE 右上<|>RELATION_NOE 肺后段<|>RELATION_NOE 3例<|>RELATION_NOE 、<|>RELATION_NOE 右上<|>RELATION_NOE 肺尖<|>RELATION_NOE 段<|>RELATION_NOE 4例<|>RELATION_NOE 、<|>RELATION_NOE 右上<|>RELATION_NOE 肺前段<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 右下<|>RELATION_NOE 肺背<|>RELATION_NOE 段<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 左上<|>RELATION_NOE 肺舌<|>RELATION_NOE 段<|>RELATION_NOE 5例<|>RELATION_NOE 、<|>RELATION_NOE 左上肺<|>RELATION_NOE 三<|>RELATION_NOE 段<|>RELATION_NOE 切除<|>RELATION_NOE 3例<|>RELATION_NOE 、<|>RELATION_NOE 左下肺<|>RELATION_NOE 背段<|>RELATION_NOE 2例3<|>RELATION_NOE 例<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 患者<|>RELATION_NOE 同时<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 左上<|>RELATION_NOE 肺舌<|>RELATION_NOE 段<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 同时<|>RELATION_NOE 行<|>RELATION_NOE 胸腺切除术<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE UICC<|>RELATION_NOE ,<|>RELATION_NOE 2009年<|>RELATION_NOE )<|>RELATION_NOE Ia<|>RELATION_NOE 期<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE Ib<|>RELATION_NOE 期<|>RELATION_NOE 2例<|>RELATION_NOE
术后<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 1-6d<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 数<|>RELATION_NOE 3d<|>RELATION_NOE 全<|>RELATION_NOE 组<|>RELATION_NOE 无<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE 围手术期<|>RELATION_NOE 并发症<|>RELATION_NOE 包括<|>RELATION_NOE :<|>RELATION_NOE 术中<|>RELATION_NOE 出血<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 出血<|>RELATION_NOE 600ml<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 完成<|>RELATION_NOE 止血<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 输血<|>RELATION_NOE ;<|>RELATION_NOE
持续<|>RELATION_NOE 漏气<|>RELATION_NOE (<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 时<|>RELATION_NOE 问<|>RELATION_NOE 35d<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 50%<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 溶液<|>RELATION_NOE 胸腔<|>RELATION_NOE 灌注<|>RELATION_NOE 后<|>RELATION_NOE 愈合<|>RELATION_NOE ;<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 解剖性<|>RELATION_NOE 肺段<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_S 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 及<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 技术<|>RELATION_NOE 上<|>RELATION_NOE 可行<|>RELATION_NOE ,<|>RELATION_NOE 手术时间<|>RELATION_NOE 可以<|>RELATION_NOE 接受<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 失血<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 短<|>RELATION_NOE
例<|>RELATION_NOE 中<|>RELATION_NOE 男<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女4<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 25<|>RELATION_NOE －<|>RELATION_NOE 76<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE (<|>RELATION_NOE 55<|>RELATION_NOE ±<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE 肿瘤<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_NOE 单<|>RELATION_NOE 发<|>RELATION_NOE 圆形<|>RELATION_NOE 钱币<|>RELATION_NOE 状结节<|>RELATION_NOE ,<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 2.4<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE ,<|>RELATION_NOE 病变<|>RELATION_NOE 位于<|>RELATION_NOE 右上叶<|>RELATION_NOE 、<|>RELATION_NOE 中叶<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 左上叶<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 左下叶<|>RELATION_NOE 3例<|>RELATION_NOE 所有<|>RELATION_NOE 病例<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 并<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标本<|>RELATION_NOE PAS<|>RELATION_NOE 染色<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 显示<|>RELATION_NOE 黑色素<|>RELATION_NOE 生成<|>RELATION_NOE 及<|>RELATION_NOE 肌源性<|>RELATION_NOE 标志物<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 上皮源性<|>RELATION_NOE 标志物<|>RELATION_NOE 阴性<|>RELATION_NOE 7例<|>RELATION_NOE 患者<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 复发<|>RELATION_NOE
透明<|>RELATION_NOE 细胞瘤<|>RELATION_NOE 是<|>RELATION_NOE 罕见<|>RELATION_NOE 的<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 独特<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 、<|>RELATION_NOE 影像<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_B 有赖于<|>RELATION_E 常规<|>RELATION_NOE 病理<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE ;<|>RELATION_NOE
免疫<|>RELATION_NOE 磁珠阴<|>RELATION_NOE 性法<|>RELATION_NOE 富集<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 建立<|>RELATION_S
,<|>RELATION_NOE 探讨<|>RELATION_S 该<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 富集<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 及其<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 将<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE 个<|>RELATION_NOE 4<|>RELATION_NOE ,<|>RELATION_NOE 6-<|>RELATION_NOE 二<|>RELATION_NOE 眯<|>RELATION_NOE -2<|>RELATION_NOE 苯吲哚<|>RELATION_NOE (<|>RELATION_NOE DAPI<|>RELATION_NOE )<|>RELATION_NOE 染色<|>RELATION_NOE 的<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞系<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 分别<|>RELATION_NOE 加入<|>RELATION_NOE 20ml<|>RELATION_NOE 心力衰竭<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE [<|>RELATION_NOE 约<|>RELATION_NOE 含<|>RELATION_NOE (<|>RELATION_NOE 1－<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE ×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 细胞<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠阴<|>RELATION_NOE 性法<|>RELATION_NOE 富集<|>RELATION_NOE 癌细胞<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 检测<|>RELATION_NOE 体外<|>RELATION_NOE 加入<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 回收率<|>RELATION_NOE 收集<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 7月<|>RELATION_NOE 江苏省<|>RELATION_NOE 苏北<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 呼吸科<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 胸腔积液<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 包括<|>RELATION_NOE 经<|>RELATION_NOE 活检<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 男<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 78<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE (<|>RELATION_NOE 63<|>RELATION_NOE ±<|>RELATION_NOE 9<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ;<|>RELATION_NOE
17<|>RELATION_NOE 例<|>RELATION_NOE 非肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 男8<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 25<|>RELATION_NOE －<|>RELATION_NOE 81<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE (<|>RELATION_NOE 53<|>RELATION_NOE ±<|>RELATION_NOE 18<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠阴<|>RELATION_NOE 性法<|>RELATION_NOE 及<|>RELATION_NOE 密度<|>RELATION_NOE 梯度<|>RELATION_NOE 离心法<|>RELATION_NOE 富集<|>RELATION_NOE 53<|>RELATION_NOE 份<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 标本<|>RELATION_NOE 并<|>RELATION_NOE 涂片<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 分别<|>RELATION_NOE 应用<|>RELATION_NOE 瑞姬<|>RELATION_NOE 染色<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 染色<|>RELATION_NOE 及<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE (<|>RELATION_NOE FISH<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 进行<|>RELATION_S 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 鉴定<|>RELATION_NOE
别<|>RELATION_NOE 加<|>RELATION_NOE 人<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE 个<|>RELATION_NOE 经<|>RELATION_NOE DAPI<|>RELATION_NOE 染色<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 回收率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 75%<|>RELATION_NOE 、<|>RELATION_NOE 78%<|>RELATION_NOE 、<|>RELATION_NOE 82%<|>RELATION_NOE 、<|>RELATION_NOE 85%<|>RELATION_NOE 和<|>RELATION_NOE 88%<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 回收率<|>RELATION_NOE 为<|>RELATION_NOE 81.6%<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠<|>RELATION_NOE 阴性<|>RELATION_NOE 法<|>RELATION_NOE 联合<|>RELATION_NOE 瑞姬<|>RELATION_NOE 染色<|>RELATION_NOE 检测<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 81%<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠<|>RELATION_NOE 阴性<|>RELATION_NOE 法<|>RELATION_NOE 联合<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 染色<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 表达<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 18<|>RELATION_NOE (<|>RELATION_NOE CK18<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
DAPI<|>RELATION_NOE 阳性<|>RELATION_NOE 、<|>RELATION_NOE 白细胞<|>RELATION_NOE 共同<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE CD45<|>RELATION_NOE )<|>RELATION_NOE 阴性<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠<|>RELATION_NOE 阴性<|>RELATION_NOE 法<|>RELATION_NOE 联合<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE (<|>RELATION_NOE FISH<|>RELATION_NOE )<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 86%<|>RELATION_NOE (<|>RELATION_NOE 31<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
密度<|>RELATION_NOE 梯度<|>RELATION_NOE 离心法<|>RELATION_NOE 联合<|>RELATION_NOE 瑞姬<|>RELATION_NOE 染色<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 61%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠<|>RELATION_NOE 阴性<|>RELATION_NOE 法<|>RELATION_NOE 联合<|>RELATION_NOE 瑞姬<|>RELATION_NOE 染色<|>RELATION_NOE 或<|>RELATION_NOE FISH<|>RELATION_NOE 与<|>RELATION_NOE 密度<|>RELATION_NOE 梯度<|>RELATION_NOE 离心法<|>RELATION_NOE 联合<|>RELATION_NOE 瑞姬<|>RELATION_NOE 染色<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 4.00<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 39<|>RELATION_NOE ;<|>RELATION_NOE
X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 5.8<|>RELATION_NOE 18<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 良性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠<|>RELATION_NOE 阴性<|>RELATION_NOE 法<|>RELATION_NOE 联合<|>RELATION_NOE 瑞姬<|>RELATION_NOE 染色<|>RELATION_NOE 或<|>RELATION_NOE FISH<|>RELATION_NOE 、<|>RELATION_NOE 密度<|>RELATION_NOE 梯度<|>RELATION_NOE 离心法<|>RELATION_NOE 联合<|>RELATION_NOE 瑞姬<|>RELATION_NOE 染色<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_B 检<|>RELATION_I 出<|>RELATION_E 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠<|>RELATION_NOE 阴性<|>RELATION_NOE 法<|>RELATION_NOE 联合<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 染色<|>RELATION_NOE 检卅<|>RELATION_NOE CK18<|>RELATION_NOE 及<|>RELATION_NOE DAPI<|>RELATION_NOE 阳性<|>RELATION_NOE 、<|>RELATION_NOE CD45<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE
用<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠阴<|>RELATION_NOE 性法<|>RELATION_NOE 富集<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 可行<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 该<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 联合<|>RELATION_NOE 瑞姬<|>RELATION_NOE 染色<|>RELATION_NOE 或<|>RELATION_NOE FISH<|>RELATION_NOE 对<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 具有<|>RELATION_S 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 良恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 鉴别<|>RELATION_NOE
而<|>RELATION_NOE 联合<|>RELATION_NOE CK18<|>RELATION_NOE 、<|>RELATION_NOE DAPI<|>RELATION_NOE 、<|>RELATION_NOE CD45<|>RELATION_NOE ,<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 染色<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 鉴别<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 间皮<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 还<|>RELATION_NOE 需<|>RELATION_NOE 寻找<|>RELATION_NOE 更<|>RELATION_NOE 特异<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 抗体<|>RELATION_NOE 标志物<|>RELATION_NOE
特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE (<|>RELATION_NOE IPF<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 特发性<|>RELATION_NOE 间质性肺炎<|>RELATION_NOE 中<|>RELATION_NOE 最<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 类型<|>RELATION_NOE ,<|>RELATION_NOE 病情<|>RELATION_NOE 呈<|>RELATION_NOE 进行性<|>RELATION_NOE 发展<|>RELATION_NOE ,<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 在<|>RELATION_NOE 其<|>RELATION_NOE 病程<|>RELATION_NOE 中<|>RELATION_NOE 可<|>RELATION_NOE 有<|>RELATION_NOE 诸多<|>RELATION_NOE 合并症<|>RELATION_NOE ,<|>RELATION_NOE 如<|>RELATION_NOE 肺癌<|>RELATION_NOE 实际上<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 与<|>RELATION_NOE 纤维化性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 最<|>RELATION_NOE 早<|>RELATION_NOE 于<|>RELATION_NOE 1939年<|>RELATION_NOE 即<|>RELATION_NOE 由<|>RELATION_NOE Friedrich<|>RELATION_NOE 阐述<|>RELATION_NOE ,<|>RELATION_NOE 其后<|>RELATION_NOE 不断<|>RELATION_NOE 有<|>RELATION_NOE 研究<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE IPF<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 普通<|>RELATION_NOE 人群<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 由于<|>RELATION_NOE IPF<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 后<|>RELATION_NOE 均<|>RELATION_NOE 缺乏<|>RELATION_NOE 有效<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 同时<|>RELATION_NOE 存在<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 更为<|>RELATION_NOE 不利<|>RELATION_NOE ,<|>RELATION_NOE 已<|>RELATION_NOE 引起<|>RELATION_NOE 人们<|>RELATION_NOE 的<|>RELATION_NOE 高度<|>RELATION_NOE 关注<|>RELATION_NOE
荧光素<|>RELATION_NOE 酶<|>RELATION_NOE 光成<|>RELATION_NOE 像<|>RELATION_NOE 实时<|>RELATION_NOE 监测<|>RELATION_NOE 诱导<|>RELATION_NOE 凋亡<|>RELATION_NOE 配体<|>RELATION_NOE 基因<|>RELATION_NOE 治疗<|>RELATION_S 裸鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞移植<|>RELATION_NOE 瘤<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE
应用<|>RELATION_NOE 人<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 诱导<|>RELATION_NOE 凋亡<|>RELATION_NOE 配体<|>RELATION_NOE (<|>RELATION_NOE hTRAIL<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 和<|>RELATION_NOE 萤火虫<|>RELATION_NOE 荧光素<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE luc<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 腺病毒<|>RELATION_NOE 双<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE (<|>RELATION_NOE ad-hTRAIL-luc<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE luc<|>RELATION_NOE 为<|>RELATION_NOE 报告基因<|>RELATION_NOE ,<|>RELATION_NOE 活<|>RELATION_NOE 体内<|>RELATION_NOE 监测<|>RELATION_S hTRAIL<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 作用<|>RELATION_NOE
皮下<|>RELATION_NOE 接种<|>RELATION_NOE 法<|>RELATION_NOE 建立<|>RELATION_S 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 瘤内<|>RELATION_NOE 多<|>RELATION_NOE 点<|>RELATION_NOE 注射<|>RELATION_NOE 腺病毒<|>RELATION_NOE 载体<|>RELATION_NOE ad-luc<|>RELATION_NOE .<|>RELATION_NOE
luc<|>RELATION_NOE 对照组<|>RELATION_NOE 注射<|>RELATION_NOE 磷酸盐<|>RELATION_NOE 缓冲液<|>RELATION_NOE (<|>RELATION_NOE PBS<|>RELATION_NOE )<|>RELATION_NOE 于<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 14<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 、<|>RELATION_NOE 28d<|>RELATION_NOE 动态<|>RELATION_NOE 测量<|>RELATION_NOE 各组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 利用<|>RELATION_NOE 高<|>RELATION_NOE 敏感<|>RELATION_NOE 、<|>RELATION_NOE 超<|>RELATION_NOE 低温<|>RELATION_NOE (<|>RELATION_NOE CCD<|>RELATION_NOE )<|>RELATION_NOE 照相机<|>RELATION_NOE 进行<|>RELATION_NOE 活体<|>RELATION_NOE 生物<|>RELATION_NOE 发光<|>RELATION_NOE 成像<|>RELATION_NOE 检测<|>RELATION_NOE luc<|>RELATION_NOE 活性<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 处死<|>RELATION_NOE 动物<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE (<|>RELATION_NOE 简称<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE hTRAIL<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE IHS<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
TUNEL<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 计算<|>RELATION_NOE 凋亡率<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE 组间<|>RELATION_NOE 比较<|>RELATION_NOE 采用<|>RELATION_NOE 方差分析<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 样<|>RELATION_NOE 本<|>RELATION_NOE 比较<|>RELATION_NOE 采用<|>RELATION_NOE 配对<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 对<|>RELATION_NOE ad-luc-hTRAIL<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 发光<|>RELATION_NOE 光子<|>RELATION_NOE 数<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 凋亡率<|>RELATION_NOE 3种<|>RELATION_NOE
1uc-hTRAIL<|>RELATION_NOE 与<|>RELATION_NOE ad-hTRAIL<|>RELATION_NOE 组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE 明显<|>RELATION_NOE 较<|>RELATION_NOE PBS<|>RELATION_NOE 组<|>RELATION_NOE 缓慢<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.71<|>RELATION_NOE 、<|>RELATION_NOE 2.72<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 28d<|>RELATION_NOE 后<|>RELATION_NOE 各组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE 8.4<|>RELATION_NOE ±<|>RELATION_NOE 42.3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE 1.5<|>RELATION_NOE ±<|>RELATION_NOE 23.9<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE 7.0<|>RELATION_NOE ±<|>RELATION_NOE 59.3<|>RELATION_NOE )<|>RELATION_NOE mm2<|>RELATION_NOE ,<|>RELATION_NOE ad-luc<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE PBS<|>RELATION_NOE 组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.07<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ad-luc-hTRAIL<|>RELATION_NOE 组<|>RELATION_NOE luc<|>RELATION_NOE 活性<|>RELATION_NOE 于<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 第7<|>RELATION_NOE 天<|>RELATION_NOE 达<|>RELATION_NOE 高峰<|>RELATION_NOE (<|>RELATION_NOE 1.37<|>RELATION_NOE ±<|>RELATION_NOE 1.04<|>RELATION_NOE )<|>RELATION_NOE 后<|>RELATION_NOE 快速<|>RELATION_NOE 下降<|>RELATION_NOE ad-luc-hTRAIL<|>RELATION_NOE 与<|>RELATION_NOE ad<|>RELATION_NOE .<|>RELATION_NOE
hTRAIL2<|>RELATION_NOE 组<|>RELATION_NOE 在<|>RELATION_NOE 注射<|>RELATION_NOE 载体<|>RELATION_NOE 后<|>RELATION_NOE 第7<|>RELATION_NOE 天<|>RELATION_NOE hTRAIL<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 达<|>RELATION_NOE 高峰<|>RELATION_NOE ,<|>RELATION_NOE IHS<|>RELATION_NOE 峰值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 6.25<|>RELATION_NOE ±<|>RELATION_NOE 2.06<|>RELATION_NOE 和<|>RELATION_NOE 6.5<|>RELATION_NOE ±<|>RELATION_NOE 2.89<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 峰值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 60.75<|>RELATION_NOE ±<|>RELATION_NOE 8.06<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 61.50<|>RELATION_NOE ±<|>RELATION_NOE 8.47<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ad-luc-hTRAIL<|>RELATION_NOE 组<|>RELATION_NOE lue<|>RELATION_NOE 表达量<|>RELATION_NOE (<|>RELATION_NOE 绝对<|>RELATION_NOE 光子<|>RELATION_NOE 数<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE IHS<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 三者<|>RELATION_NOE 间<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_NOE 线性<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE r<|>RELATION_NOE 光子<|>RELATION_NOE 影<|>RELATION_NOE IHs<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 42<|>RELATION_NOE ,<|>RELATION_NOE r<|>RELATION_NOE 光子<|>RELATION_NOE 数<|>RELATION_NOE /<|>RELATION_NOE 凋亡率<|>RELATION_NOE =<|>RELATION_NOE 0.8<|>RELATION_NOE 42<|>RELATION_NOE ,<|>RELATION_NOE rIHS<|>RELATION_NOE /<|>RELATION_NOE 凋亡率<|>RELATION_NOE =<|>RELATION_NOE 0.8<|>RELATION_NOE 87<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE
的<|>RELATION_NOE :<|>RELATION_NOE 基因<|>RELATION_NOE 可以<|>RELATION_NOE 有效<|>RELATION_NOE 地<|>RELATION_NOE 通过<|>RELATION_NOE ad-luc-hTRAIL<|>RELATION_NOE 转<|>RELATION_NOE 导入<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞移植<|>RELATION_NOE 瘤内<|>RELATION_NOE 并<|>RELATION_NOE 高<|>RELATION_NOE 水平<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 发挥<|>RELATION_NOE 生长<|>RELATION_NOE 抑制<|>RELATION_NOE 和<|>RELATION_NOE 促<|>RELATION_NOE 凋亡<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 体外<|>RELATION_NOE CCD<|>RELATION_NOE 照相机<|>RELATION_NOE 观察<|>RELATION_NOE lue<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 实时<|>RELATION_B 监测<|>RELATION_E hTRAIL<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 反映<|>RELATION_NOE hTRAIL<|>RELATION_NOE 基因治疗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE
高速<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 感<|>RELATION_NOE 兴趣区<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 灌注<|>RELATION_NOE 参数<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
荧光<|>RELATION_NOE PCR-<|>RELATION_NOE 优化<|>RELATION_NOE 寡<|>RELATION_NOE 核苷<|>RELATION_NOE 酸探<|>RELATION_NOE 针法<|>RELATION_NOE 与<|>RELATION_NOE Sanger<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 患者<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_B 分析<|>RELATION_E
对<|>RELATION_NOE 荧光<|>RELATION_NOE PCR-<|>RELATION_NOE 优化<|>RELATION_NOE 寡<|>RELATION_NOE 核苷<|>RELATION_NOE 酸探<|>RELATION_NOE 针法<|>RELATION_NOE 与<|>RELATION_NOE Sanger<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 患者<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 、<|>RELATION_NOE 符合率<|>RELATION_NOE 进行<|>RELATION_B 对比<|>RELATION_I 分析<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 荧光<|>RELATION_NOE PCR-<|>RELATION_NOE 优化<|>RELATION_NOE 寡<|>RELATION_NOE 核苷<|>RELATION_NOE 酸探<|>RELATION_NOE 针法<|>RELATION_NOE 检测<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 特点<|>RELATION_NOE
收集<|>RELATION_NOE 221<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 131<|>RELATION_NOE 例<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 标本<|>RELATION_NOE 所有<|>RELATION_NOE 标本<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 4%<|>RELATION_NOE 中性<|>RELATION_NOE 甲醛<|>RELATION_NOE 固定<|>RELATION_NOE 、<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 切片<|>RELATION_NOE 后<|>RELATION_NOE 评估<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 必要<|>RELATION_NOE 时行<|>RELATION_NOE 刮<|>RELATION_NOE 取<|>RELATION_NOE 富集<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 提取<|>RELATION_NOE 基因组<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 荧光<|>RELATION_NOE PCR-<|>RELATION_NOE 优化<|>RELATION_NOE 寡<|>RELATION_NOE 核苷<|>RELATION_NOE 酸探<|>RELATION_NOE 针法<|>RELATION_NOE 及<|>RELATION_NOE Sanger<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S 标本<|>RELATION_NOE 中<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 统计<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE
21<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 通过<|>RELATION_NOE 荧光<|>RELATION_NOE PCR-<|>RELATION_NOE 优化<|>RELATION_NOE 寡<|>RELATION_NOE 核苷<|>RELATION_NOE 酸探<|>RELATION_NOE 针法<|>RELATION_NOE 及<|>RELATION_NOE Sanger<|>RELATION_NOE 测<|>RELATION_NOE 序法<|>RELATION_NOE 检卅<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 6.3%<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE /<|>RELATION_NOE 221<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 4.5%<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE 221<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
131<|>RELATION_NOE 例<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 41.2%<|>RELATION_NOE (<|>RELATION_NOE 54<|>RELATION_NOE /<|>RELATION_NOE 131<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 40.5%<|>RELATION_NOE (<|>RELATION_NOE 53<|>RELATION_NOE /<|>RELATION_NOE 131<|>RELATION_NOE )<|>RELATION_NOE 不论<|>RELATION_NOE 何种<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 检测<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 均<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 检测<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 结直肠癌<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 第12<|>RELATION_NOE 位<|>RELATION_NOE 密码子<|>RELATION_NOE 突变<|>RELATION_NOE 比例<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 第13<|>RELATION_NOE 位<|>RELATION_NOE 密码子<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 总体<|>RELATION_NOE 符合率<|>RELATION_NOE 为<|>RELATION_NOE 97.4%<|>RELATION_NOE
光<|>RELATION_NOE PCR-<|>RELATION_NOE 优化<|>RELATION_NOE 寡<|>RELATION_NOE 核苷<|>RELATION_NOE 酸探<|>RELATION_NOE 针法<|>RELATION_NOE 检测<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 患者<|>RELATION_NOE KRAS<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检出率<|>RELATION_NOE 与<|>RELATION_NOE Sanger<|>RELATION_NOE 测序法<|>RELATION_NOE 相当<|>RELATION_S ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE Sanger<|>RELATION_NOE 测<|>RELATION_NOE 序法<|>RELATION_NOE 之外<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 备选<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE
探讨<|>RELATION_S 肿瘤<|>RELATION_NOE 可溶性<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE TSA<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 超抗原<|>RELATION_NOE 金黄色<|>RELATION_NOE 葡萄球菌<|>RELATION_NOE 肠毒素<|>RELATION_NOE C<|>RELATION_NOE (<|>RELATION_NOE SEC<|>RELATION_NOE )<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 毒性<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE (<|>RELATION_NOE CTLs<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 作用<|>RELATION_NOE
实验组<|>RELATION_NOE (<|>RELATION_NOE SEC<|>RELATION_NOE +<|>RELATION_NOE TSA<|>RELATION_NOE +<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE )<|>RELATION_NOE 分离<|>RELATION_S 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE TSA<|>RELATION_NOE 、<|>RELATION_NOE 超抗原<|>RELATION_NOE SEC<|>RELATION_NOE 联合<|>RELATION_NOE 作用<|>RELATION_NOE 诱导<|>RELATION_NOE 产生<|>RELATION_NOE CTLs<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 表型<|>RELATION_NOE 、<|>RELATION_NOE 杀瘤<|>RELATION_NOE 活性<|>RELATION_NOE 进行<|>RELATION_NOE 观察<|>RELATION_NOE 和<|>RELATION_NOE 测定<|>RELATION_NOE
TSA<|>RELATION_NOE 、<|>RELATION_NOE SEC<|>RELATION_NOE 联合<|>RELATION_NOE 刺激<|>RELATION_NOE 的<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 组<|>RELATION_NOE 增殖<|>RELATION_NOE 活性<|>RELATION_NOE 明显<|>RELATION_NOE 增强<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE CD3<|>RELATION_NOE 均<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE CDs<|>RELATION_NOE +<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 49.07%<|>RELATION_NOE 比<|>RELATION_NOE 27.5<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 经<|>RELATION_NOE 肺癌<|>RELATION_NOE TSA<|>RELATION_NOE 、<|>RELATION_NOE 超抗原<|>RELATION_NOE SEC<|>RELATION_NOE 联合<|>RELATION_NOE 刺激<|>RELATION_NOE 淋巴细胞组<|>RELATION_NOE 培养<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE CTLs<|>RELATION_NOE ,<|>RELATION_NOE 当<|>RELATION_NOE 效靶<|>RELATION_NOE 比<|>RELATION_NOE 为<|>RELATION_NOE 20<|>RELATION_NOE :<|>RELATION_NOE 1时<|>RELATION_NOE 对<|>RELATION_NOE CALU-6<|>RELATION_NOE 、<|>RELATION_NOE 自体<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE Hela<|>RELATION_NOE 细胞<|>RELATION_NOE 杀伤<|>RELATION_NOE 活性<|>RELATION_NOE
效应<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE CALU-6<|>RELATION_NOE 、<|>RELATION_NOE 自体<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 活性<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E Hela<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE
肿瘤抗原<|>RELATION_NOE 和<|>RELATION_NOE 超抗原<|>RELATION_NOE SEC<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE CTL<|>RELATION_NOE 能够<|>RELATION_B 产生<|>RELATION_E 高效<|>RELATION_NOE 特异性<|>RELATION_NOE 的<|>RELATION_NOE 杀瘤<|>RELATION_NOE 效应<|>RELATION_NOE
细胞角蛋白<|>RELATION_NOE 19-2G2<|>RELATION_NOE 和<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE 抗原<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 评估<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
应用<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 124<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE (<|>RELATION_NOE 腺癌<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 化疗1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 和<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CK-2G2<|>RELATION_NOE 和<|>RELATION_NOE Cyfra21-1<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 经<|>RELATION_NOE 正态性<|>RELATION_NOE 检验<|>RELATION_NOE ,<|>RELATION_NOE CK-2G2<|>RELATION_NOE 和<|>RELATION_NOE Cyfra21-1<|>RELATION_NOE 水平<|>RELATION_NOE 为<|>RELATION_NOE 偏态<|>RELATION_NOE 分布<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE M<|>RELATION_NOE (<|>RELATION_NOE QR<|>RELATION_NOE )<|>RELATION_NOE 表示<|>RELATION_NOE ,<|>RELATION_NOE 组间<|>RELATION_NOE 和<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 比较<|>RELATION_NOE 采用<|>RELATION_NOE 秩和检验<|>RELATION_NOE
血清标记物<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E
评价<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 糖类<|>RELATION_NOE 抗原<|>RELATION_NOE 125<|>RELATION_NOE (<|>RELATION_NOE CA125<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经原<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
以<|>RELATION_NOE 65<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 人为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 其<|>RELATION_NOE 血<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE
清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 有助于<|>RELATION_S 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE
伊立<|>RELATION_NOE 替康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 与<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_NOE 研究<|>RELATION_NOE
本次<|>RELATION_NOE 研究<|>RELATION_NOE 主要<|>RELATION_NOE 比较<|>RELATION_S 伊立<|>RELATION_NOE 替康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE (<|>RELATION_NOE IP<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE
61<|>RELATION_NOE 例<|>RELATION_NOE 符合<|>RELATION_NOE 入<|>RELATION_NOE 组<|>RELATION_NOE 条件<|>RELATION_NOE 的<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 分为<|>RELATION_NOE IP<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE EP<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 62.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 37.7%<|>RELATION_NOE )<|>RELATION_NOE IP<|>RELATION_NOE 组<|>RELATION_NOE 方案<|>RELATION_NOE :<|>RELATION_NOE 伊立<|>RELATION_NOE 替康<|>RELATION_NOE 80mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE －3<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ;<|>RELATION_NOE
EP<|>RELATION_NOE 纽<|>RELATION_NOE 方案<|>RELATION_NOE :<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 100mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第<|>RELATION_NOE l<|>RELATION_NOE －3<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE －3<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 周期<|>RELATION_NOE 共<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 评价<|>RELATION_NOE 为<|>RELATION_NOE 未<|>RELATION_NOE 获<|>RELATION_NOE 缓解<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 交换<|>RELATION_NOE 分组<|>RELATION_NOE 继续<|>RELATION_NOE 研究<|>RELATION_NOE
有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 完成<|>RELATION_NOE 预定<|>RELATION_NOE 的<|>RELATION_NOE 4周期<|>RELATION_NOE 化疗<|>RELATION_NOE 和<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE ,<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE (<|>RELATION_NOE ORR<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 82.0%<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE /<|>RELATION_NOE 61<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE IP<|>RELATION_NOE 组<|>RELATION_NOE ORR<|>RELATION_NOE 为<|>RELATION_NOE 74.2%<|>RELATION_NOE ,<|>RELATION_NOE EP<|>RELATION_NOE 组<|>RELATION_NOE ORR<|>RELATION_NOE 为<|>RELATION_NOE 66.7%<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 0.4<|>RELATION_NOE 15<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.5<|>RELATION_NOE 82<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE IP<|>RELATION_NOE 组<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 51.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE EP<|>RELATION_NOE 组<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE 8例<|>RELATION_NOE (<|>RELATION_NOE 26.7%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 5.0<|>RELATION_NOE 56<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE 交换组<|>RELATION_NOE 共<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 38.9%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE IP<|>RELATION_NOE +<|>RELATION_NOE EP8<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 25%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_NOE EP<|>RELATION_NOE +<|>RELATION_NOE IP10<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 50%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 1.1<|>RELATION_NOE 69<|>RELATION_NOE ,<|>RELATION_NOE 9=<|>RELATION_NOE 0.3<|>RELATION_NOE 67<|>RELATION_NOE )<|>RELATION_NOE 本<|>RELATION_NOE 研究<|>RELATION_NOE 无<|>RELATION_NOE 化疗<|>RELATION_NOE 相关<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE IP<|>RELATION_NOE 组<|>RELATION_NOE 主要<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 包括<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 75.6%<|>RELATION_NOE 、<|>RELATION_NOE 腹泻<|>RELATION_NOE 46.3%<|>RELATION_NOE 和<|>RELATION_NOE 呕吐<|>RELATION_NOE 41.5%<|>RELATION_NOE EP<|>RELATION_NOE 组<|>RELATION_NOE 主要<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 包括<|>RELATION_NOE 呕吐<|>RELATION_NOE 71.1%<|>RELATION_NOE 、<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 68.4%<|>RELATION_NOE 和<|>RELATION_NOE 贫血<|>RELATION_NOE 28.9%<|>RELATION_NOE 其中<|>RELATION_NOE ,<|>RELATION_NOE IP<|>RELATION_NOE 组<|>RELATION_NOE 腹泻<|>RELATION_NOE 发生率<|>RELATION_NOE 与<|>RELATION_NOE EP<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_B 差异<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE G3<|>RELATION_NOE 以上<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE
探讨<|>RELATION_S 老年<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 致<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_NOE 、<|>RELATION_NOE 病情<|>RELATION_NOE 观察<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 护理<|>RELATION_NOE
总结<|>RELATION_S 解放军<|>RELATION_NOE 113<|>RELATION_NOE 医院<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 导致<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 护理<|>RELATION_NOE
过<|>RELATION_NOE 对<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 及<|>RELATION_NOE 加强<|>RELATION_NOE 基础<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 均<|>RELATION_NOE 控制<|>RELATION_NOE 在<|>RELATION_NOE 1-2<|>RELATION_NOE 级<|>RELATION_NOE
据<|>RELATION_NOE 患者<|>RELATION_NOE 实际<|>RELATION_NOE 病情<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 照射<|>RELATION_NOE 剂量<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 及时<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_S 减轻<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 损伤<|>RELATION_NOE ,<|>RELATION_NOE 确保<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 顺利<|>RELATION_NOE 完成<|>RELATION_NOE
替吉<|>RELATION_NOE 奥单<|>RELATION_NOE 药<|>RELATION_NOE 治疗<|>RELATION_S 吉非替尼<|>RELATION_NOE 获得<|>RELATION_NOE 性耐药<|>RELATION_NOE 后<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE
确定<|>RELATION_NOE 为<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 获得<|>RELATION_NOE 性耐药<|>RELATION_NOE 的<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 替<|>RELATION_NOE 吉奥<|>RELATION_NOE 胶囊<|>RELATION_NOE 单药<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 具体<|>RELATION_NOE 用法<|>RELATION_NOE :<|>RELATION_NOE 40mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 每天<|>RELATION_NOE 2<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 口服<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 14d<|>RELATION_NOE ,<|>RELATION_NOE 休息<|>RELATION_NOE 7d<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 观察<|>RELATION_S 替吉奥<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 生存期<|>RELATION_NOE 和<|>RELATION_NOE 毒性<|>RELATION_NOE
吉奥<|>RELATION_NOE 单药<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 缓解率<|>RELATION_NOE 为<|>RELATION_NOE 20%<|>RELATION_NOE (<|>RELATION_NOE 3/15<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 为<|>RELATION_NOE 60%<|>RELATION_NOE (<|>RELATION_NOE 9/15<|>RELATION_NOE )<|>RELATION_NOE 客观<|>RELATION_NOE 缓解率<|>RELATION_NOE 和<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE PS<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 先前<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_B 相关性<|>RELATION_E 替吉奥<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 205d<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 9.174-400.826d<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 是<|>RELATION_NOE 270d<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 26<|>RELATION_NOE 2.6<|>RELATION_NOE 23<|>RELATION_NOE －<|>RELATION_NOE 277.377d<|>RELATION_NOE )<|>RELATION_NOE 替<|>RELATION_NOE 吉奥<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 较<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 患者<|>RELATION_NOE 长<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存期<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 239d<|>RELATION_NOE 和<|>RELATION_NOE 50d<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
PICC<|>RELATION_NOE 在<|>RELATION_NOE 肝癌<|>RELATION_NOE 肝移植术<|>RELATION_NOE 后<|>RELATION_NOE 预防<|>RELATION_NOE 性化<|>RELATION_NOE 疗中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 观察<|>RELATION_E
探讨<|>RELATION_S 肝癌<|>RELATION_NOE 肝移植术<|>RELATION_NOE 后<|>RELATION_NOE 预防<|>RELATION_NOE 性化疗<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_NOE PICC<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肝癌<|>RELATION_NOE 肝移植术<|>RELATION_NOE 后<|>RELATION_NOE 应用<|>RELATION_NOE PICC<|>RELATION_NOE 进行<|>RELATION_NOE 预防<|>RELATION_NOE 性化疗<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 置管<|>RELATION_NOE 、<|>RELATION_NOE 带管<|>RELATION_NOE 及<|>RELATION_NOE 拔管<|>RELATION_NOE 全<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 并发症<|>RELATION_NOE 及<|>RELATION_NOE 异常<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 同期<|>RELATION_NOE 66<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 应用<|>RELATION_NOE PICC<|>RELATION_NOE 进行<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_NOE 观察<|>RELATION_NOE ;<|>RELATION_NOE
同时<|>RELATION_NOE ,<|>RELATION_NOE 总结<|>RELATION_S 肝癌<|>RELATION_NOE 肝移植术<|>RELATION_NOE 后<|>RELATION_NOE 应用<|>RELATION_NOE PICC<|>RELATION_NOE 进行<|>RELATION_NOE 预防<|>RELATION_NOE 性化疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE
肺内<|>RELATION_NOE 及<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 同期<|>RELATION_NOE 接种<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 建立<|>RELATION_S 裸鼠<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸水<|>RELATION_NOE 模型<|>RELATION_NOE 研究<|>RELATION_NOE
通过<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肺内<|>RELATION_NOE 和<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 移植<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE
建立<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸水<|>RELATION_NOE 的<|>RELATION_NOE 动物模型<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 突变<|>RELATION_NOE 系<|>RELATION_NOE SPF<|>RELATION_NOE 级<|>RELATION_NOE Balb<|>RELATION_NOE /<|>RELATION_NOE c-nu<|>RELATION_NOE 雌性<|>RELATION_NOE 裸鼠<|>RELATION_NOE 分为<|>RELATION_NOE 3<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 30<|>RELATION_NOE 只<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 于<|>RELATION_NOE 皮下<|>RELATION_NOE 、<|>RELATION_NOE 肺内<|>RELATION_NOE 、<|>RELATION_NOE 肺内<|>RELATION_NOE 及<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 移植<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 小鼠<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 体质量<|>RELATION_NOE 、<|>RELATION_NOE 饲料<|>RELATION_NOE 消耗<|>RELATION_NOE 、<|>RELATION_NOE 恶病质<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 胸水<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE
鼠<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 数<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 肺内<|>RELATION_NOE 及<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 移植<|>RELATION_NOE 、<|>RELATION_NOE 肺内<|>RELATION_NOE 移植<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 皮下<|>RELATION_NOE 移植<|>RELATION_NOE 明显<|>RELATION_NOE 缩短<|>RELATION_NOE ,<|>RELATION_NOE 皮下<|>RELATION_NOE 移植<|>RELATION_NOE 生存期<|>RELATION_NOE 范围<|>RELATION_NOE 离散<|>RELATION_NOE 程度<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺内<|>RELATION_NOE 、<|>RELATION_NOE 肺内<|>RELATION_NOE 及<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 移植<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ;<|>RELATION_NOE
肺内<|>RELATION_NOE 、<|>RELATION_NOE 肺内<|>RELATION_NOE 及<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 移植<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 平均<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 无<|>RELATION_B 差异<|>RELATION_E ,<|>RELATION_NOE 平均<|>RELATION_NOE 有效<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 有<|>RELATION_NOE 差异<|>RELATION_NOE ;<|>RELATION_NOE
肺内<|>RELATION_NOE 、<|>RELATION_NOE 肺内<|>RELATION_NOE 及<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 移植<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 小鼠<|>RELATION_NOE 摄食<|>RELATION_NOE 减少<|>RELATION_NOE 、<|>RELATION_NOE 体质量<|>RELATION_NOE 下降<|>RELATION_NOE 和<|>RELATION_NOE 恶病质<|>RELATION_NOE 症状<|>RELATION_NOE 和<|>RELATION_NOE 体征<|>RELATION_NOE 较<|>RELATION_NOE 皮下<|>RELATION_NOE 移植<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 肺内<|>RELATION_NOE 及<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 移植<|>RELATION_NOE 比<|>RELATION_NOE 肺内<|>RELATION_NOE 移植<|>RELATION_NOE 更<|>RELATION_NOE 多<|>RELATION_NOE 兄4<|>RELATION_NOE 周<|>RELATION_NOE 内<|>RELATION_NOE 肺内<|>RELATION_NOE 及<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 移植<|>RELATION_NOE 胸水<|>RELATION_NOE 发生率<|>RELATION_NOE 93.3%<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 肺内<|>RELATION_NOE 移植<|>RELATION_NOE 仅<|>RELATION_NOE 20.0%<|>RELATION_NOE 出现<|>RELATION_NOE 胸水<|>RELATION_NOE
肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肺内<|>RELATION_NOE 和<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 同期<|>RELATION_NOE 移植<|>RELATION_NOE 模型<|>RELATION_NOE 可<|>RELATION_B 作为<|>RELATION_E 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸水<|>RELATION_NOE 的<|>RELATION_NOE 动物模型<|>RELATION_NOE
流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_B 到<|>RELATION_E 细胞周期<|>RELATION_NOE 发生<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE G1<|>RELATION_NOE 期细胞<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 增多<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE S<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 减少<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE
剂量<|>RELATION_NOE TPT<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 诱导<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 相关<|>RELATION_S ,<|>RELATION_NOE 该<|>RELATION_NOE 过程<|>RELATION_NOE 与<|>RELATION_NOE caspase-3<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 的<|>RELATION_NOE
肺部<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 的<|>RELATION_NOE 多<|>RELATION_NOE 层<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 特征性<|>RELATION_NOE 表现<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
SCT<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 检查<|>RELATION_NOE 即<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 正确者<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 19.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 被<|>RELATION_NOE 提示<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断者<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 56.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 结核<|>RELATION_NOE 球<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 25.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 15.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 错<|>RELATION_NOE |<|>RELATION_NOE 牙合<|>RELATION_NOE |<|>RELATION_NOE 构瘤<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 2.6%<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 肺炎性假瘤<|>RELATION_NOE MSCT<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 发现<|>RELATION_NOE 肿块<|>RELATION_NOE 位于<|>RELATION_NOE 肺<|>RELATION_NOE 的<|>RELATION_NOE 外周<|>RELATION_NOE 、<|>RELATION_NOE 局限性<|>RELATION_NOE 胸膜<|>RELATION_NOE 增<|>RELATION_NOE 厚<|>RELATION_NOE 粘连<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 边缘<|>RELATION_NOE 多发性<|>RELATION_NOE 空泡<|>RELATION_NOE 征<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 下<|>RELATION_NOE 缘散<|>RELATION_NOE 在<|>RELATION_NOE 结节<|>RELATION_NOE 征<|>RELATION_NOE 、<|>RELATION_NOE 桃尖征<|>RELATION_NOE 、<|>RELATION_NOE 平直征<|>RELATION_NOE 及<|>RELATION_NOE 均匀<|>RELATION_NOE 强化<|>RELATION_NOE 等<|>RELATION_NOE 征象<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺炎性假瘤<|>RELATION_NOE 的<|>RELATION_NOE MSCT<|>RELATION_NOE 诊断<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
合<|>RELATION_NOE 分析<|>RELATION_NOE 肺炎性假瘤<|>RELATION_NOE 特征性<|>RELATION_NOE 的<|>RELATION_NOE MSCT<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 其<|>RELATION_NOE 肺内<|>RELATION_NOE 感染<|>RELATION_NOE 病史<|>RELATION_NOE 有利于<|>RELATION_S 提高<|>RELATION_NOE 肺部<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 的<|>RELATION_NOE MSCT<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE
微创<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 67<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 体会<|>RELATION_NOE
7例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 顺利<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_NOE 或<|>RELATION_NOE 一侧<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 加<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 术术<|>RELATION_NOE 后<|>RELATION_NOE 切口<|>RELATION_NOE 疼痛<|>RELATION_NOE 明显<|>RELATION_NOE 较<|>RELATION_NOE 常规<|>RELATION_NOE 开<|>RELATION_NOE 胸者<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 咳嗽<|>RELATION_NOE 排痰<|>RELATION_NOE 有力<|>RELATION_NOE ,<|>RELATION_NOE 绝大多数<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 毋<|>RELATION_NOE 需<|>RELATION_NOE 镇痛剂<|>RELATION_NOE 止痛<|>RELATION_NOE 无<|>RELATION_NOE 手术<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 术后<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 3－<|>RELATION_NOE 10<|>RELATION_NOE (<|>RELATION_NOE 5.5<|>RELATION_NOE ±<|>RELATION_NOE 2.2<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 住院时间<|>RELATION_NOE 7－<|>RELATION_NOE 18<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE ±<|>RELATION_NOE 4.5<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE
视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 加<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 手术<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 可靠<|>RELATION_NOE ,<|>RELATION_NOE 创伤<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 彻底<|>RELATION_NOE ,<|>RELATION_NOE 符合<|>RELATION_S 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 手术<|>RELATION_NOE 原则<|>RELATION_NOE
质量<|>RELATION_NOE 反馈<|>RELATION_NOE 理论<|>RELATION_NOE 应用<|>RELATION_B 于<|>RELATION_E 肺癌<|>RELATION_NOE 围手术期<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 评价<|>RELATION_NOE
探讨<|>RELATION_S 质量<|>RELATION_NOE 反馈<|>RELATION_NOE 理论<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 围手术期<|>RELATION_NOE 患者<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
选取<|>RELATION_NOE 2009年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 于<|>RELATION_NOE 本院<|>RELATION_NOE 进行<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 各<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 进行<|>RELATION_NOE 常规<|>RELATION_NOE 模式<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 则<|>RELATION_NOE 在<|>RELATION_NOE 质量<|>RELATION_NOE 反馈<|>RELATION_NOE 理论<|>RELATION_NOE 的<|>RELATION_NOE 指导<|>RELATION_NOE 下<|>RELATION_NOE 进行<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 2组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 排痰<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 下<|>RELATION_NOE 床<|>RELATION_NOE 活动<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 满意度<|>RELATION_NOE 及<|>RELATION_NOE 术前<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE ,<|>RELATION_NOE 10d<|>RELATION_NOE 的<|>RELATION_NOE SAS<|>RELATION_NOE 、<|>RELATION_NOE SDS<|>RELATION_NOE 评分<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE
量<|>RELATION_NOE 反馈<|>RELATION_NOE 理论<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 围手术期<|>RELATION_NOE 患者<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 地<|>RELATION_I 改善<|>RELATION_E 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 指标<|>RELATION_NOE 及<|>RELATION_NOE 生存<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 更<|>RELATION_NOE 具<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE
糖原合成酶<|>RELATION_NOE 激酶<|>RELATION_NOE 3<|>RELATION_NOE β<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
RT-PCR<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 扩增<|>RELATION_NOE 目的<|>RELATION_NOE :<|>RELATION_NOE 基因<|>RELATION_NOE GSK<|>RELATION_NOE &<|>RELATION_NOE nbsp<|>RELATION_NOE ;<|>RELATION_NOE
分子克隆<|>RELATION_NOE 技术<|>RELATION_NOE 构建<|>RELATION_S 哺乳动物<|>RELATION_NOE 细胞<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE ;<|>RELATION_NOE
脂质体<|>RELATION_NOE Lipofectamine2000<|>RELATION_NOE 转染<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ;<|>RELATION_NOE
自<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 用于<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 评估<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 观察<|>RELATION_E
探讨<|>RELATION_S 自<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 评估<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 选择<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 32<|>RELATION_NOE 例行<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 资料<|>RELATION_NOE 患者<|>RELATION_NOE 术前<|>RELATION_NOE 常规<|>RELATION_NOE 行<|>RELATION_NOE 普通<|>RELATION_NOE 白光<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE WLB<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
自<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE AFB<|>RELATION_NOE )<|>RELATION_NOE 检查<|>RELATION_B 比较<|>RELATION_E WLB<|>RELATION_NOE 与<|>RELATION_NOE AFB<|>RELATION_NOE 检查<|>RELATION_NOE 肿瘤<|>RELATION_NOE 侵犯<|>RELATION_NOE 黏膜<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 黏膜<|>RELATION_NOE 活检<|>RELATION_NOE
判定<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 边界<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 决定<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 结果<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 行<|>RELATION_NOE 气管<|>RELATION_NOE 隆突<|>RELATION_NOE 重建术<|>RELATION_NOE ,<|>RELATION_NOE 8例<|>RELATION_NOE 行袖<|>RELATION_NOE 状<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 因<|>RELATION_NOE 发生<|>RELATION_NOE 气管<|>RELATION_NOE 内<|>RELATION_NOE 转移<|>RELATION_NOE 而<|>RELATION_NOE 选择<|>RELATION_NOE 其他<|>RELATION_NOE 治疗<|>RELATION_NOE 8例<|>RELATION_NOE 行袖<|>RELATION_NOE 状<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 3例<|>RELATION_NOE 为<|>RELATION_NOE WLB<|>RELATION_NOE 和<|>RELATION_NOE AFB<|>RELATION_NOE 共同<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 为<|>RELATION_NOE AFB<|>RELATION_NOE 单独<|>RELATION_NOE 发现<|>RELATION_NOE 4例<|>RELATION_NOE 无法<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 2例<|>RELATION_NOE 为<|>RELATION_NOE WLB<|>RELATION_NOE 和<|>RELATION_NOE AFB<|>RELATION_NOE 共同<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 为<|>RELATION_NOE AFB<|>RELATION_NOE 单独<|>RELATION_NOE 发现<|>RELATION_NOE AFB<|>RELATION_NOE 对<|>RELATION_NOE 支气管<|>RELATION_NOE 黏膜<|>RELATION_NOE 癌变<|>RELATION_NOE 敏感性<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE WLB<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE
微波<|>RELATION_NOE 消融<|>RELATION_NOE 和<|>RELATION_NOE 131<|>RELATION_NOE ^<|>RELATION_NOE I-<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞核<|>RELATION_NOE 人<|>RELATION_NOE 鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE
微波<|>RELATION_NOE 消融<|>RELATION_NOE (<|>RELATION_NOE MWA<|>RELATION_NOE )<|>RELATION_NOE 被<|>RELATION_NOE 认为<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 肺癌<|>RELATION_NOE 局部<|>RELATION_NOE 控制<|>RELATION_NOE 的<|>RELATION_NOE 新型<|>RELATION_NOE 微创<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE ,<|>RELATION_NOE 它<|>RELATION_NOE 通过<|>RELATION_NOE 超声<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 或<|>RELATION_NOE MRI<|>RELATION_NOE 引导<|>RELATION_NOE 经皮<|>RELATION_NOE 穿刺<|>RELATION_NOE 导入<|>RELATION_NOE 微波<|>RELATION_NOE 天线<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 微波<|>RELATION_NOE 产热<|>RELATION_NOE 机制<|>RELATION_NOE ,<|>RELATION_NOE 高温<|>RELATION_NOE 原位<|>RELATION_NOE 灭<|>RELATION_NOE 活<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 原发性<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 或<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 局部<|>RELATION_NOE 控制率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 对于<|>RELATION_NOE 瘤体<|>RELATION_NOE 负荷<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病灶<|>RELATION_NOE (<|>RELATION_NOE 如<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 在<|>RELATION_NOE 3cm<|>RELATION_NOE 以上<|>RELATION_NOE )<|>RELATION_NOE 或<|>RELATION_NOE 近<|>RELATION_NOE 肺门<|>RELATION_NOE 的<|>RELATION_NOE 中心型<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 多发<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 风险<|>RELATION_NOE 大<|>RELATION_NOE 、<|>RELATION_NOE 疗效<|>RELATION_NOE 欠佳<|>RELATION_NOE 以<|>RELATION_NOE 变性<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 坏死<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞核<|>RELATION_NOE 作为<|>RELATION_NOE 抗原<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 131<|>RELATION_NOE ^<|>RELATION_NOE I<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞核<|>RELATION_NOE 人<|>RELATION_NOE 鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE (<|>RELATION_NOE 131<|>RELATION_NOE ^<|>RELATION_NOE I-chTNT<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 该<|>RELATION_NOE 抗原<|>RELATION_NOE 结合<|>RELATION_NOE ,<|>RELATION_NOE 导致<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新型<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 治疗法<|>RELATION_NOE 该<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 又<|>RELATION_NOE 一<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE ,<|>RELATION_NOE 然而<|>RELATION_NOE 其<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 完全<|>RELATION_NOE 缓解率<|>RELATION_NOE 低<|>RELATION_NOE MWA<|>RELATION_NOE 扩大<|>RELATION_NOE 了<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死区<|>RELATION_NOE 而<|>RELATION_NOE 有效<|>RELATION_NOE 地<|>RELATION_NOE 增加<|>RELATION_NOE 了<|>RELATION_NOE 131<|>RELATION_NOE ^<|>RELATION_NOE I-chTNT<|>RELATION_NOE 治疗<|>RELATION_NOE 结合<|>RELATION_NOE 抗原<|>RELATION_NOE 的<|>RELATION_NOE 靶点<|>RELATION_NOE ,<|>RELATION_NOE 故<|>RELATION_NOE MWA<|>RELATION_NOE 联合<|>RELATION_NOE 131<|>RELATION_NOE ^<|>RELATION_NOE I-chTNT<|>RELATION_NOE 治疗<|>RELATION_NOE 可望<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_S 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE
康艾<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 康艾<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE (<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨+<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
一般<|>RELATION_NOE 状态<|>RELATION_NOE (<|>RELATION_NOE Kamofsky<|>RELATION_NOE )<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE (<|>RELATION_NOE QOL<|>RELATION_NOE )<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 改善<|>RELATION_NOE 治疗组<|>RELATION_NOE 均<|>RELATION_NOE 优于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE Th17<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE IL-17<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
收集<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 原发<|>RELATION_NOE 未<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 志愿者<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE (<|>RELATION_NOE FCM<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S Th17<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE
NSCLC<|>RELATION_NOE 组<|>RELATION_NOE IL-17<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 健康<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 21.11<|>RELATION_NOE ±<|>RELATION_NOE 7.87<|>RELATION_NOE )<|>RELATION_NOE pg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 17.64<|>RELATION_NOE ±<|>RELATION_NOE 5.07<|>RELATION_NOE )<|>RELATION_NOE Pg<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.2<|>RELATION_NOE 80<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 27<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE IL-17<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 与<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 活化<|>RELATION_NOE 受体<|>RELATION_NOE NKG2D<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血中<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE CD25HiCD127<|>RELATION_NOE Lo<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 较<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 明显<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血中<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 下调<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 活化<|>RELATION_NOE 受体<|>RELATION_NOE NKG2D<|>RELATION_NOE 的<|>RELATION_NOE 方式<|>RELATION_NOE ,<|>RELATION_NOE 参与<|>RELATION_S 了<|>RELATION_NOE 肿瘤<|>RELATION_NOE 免疫<|>RELATION_NOE 逃逸<|>RELATION_NOE 机制<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 评估<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 状态<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌组织<|>RELATION_NOE 内<|>RELATION_NOE 中介素<|>RELATION_NOE 及其<|>RELATION_NOE 受体<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
PCR<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 及其<|>RELATION_NOE 癌旁<|>RELATION_NOE 新鲜<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE IMD<|>RELATION_NOE 、<|>RELATION_NOE CRLR<|>RELATION_NOE 、<|>RELATION_NOE RAMPl<|>RELATION_NOE 、<|>RELATION_NOE RAMP2<|>RELATION_NOE 、<|>RELATION_NOE RAMP3<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE SPSS16.0<|>RELATION_NOE 统计<|>RELATION_NOE 软件<|>RELATION_NOE 分析<|>RELATION_S IMD<|>RELATION_NOE 及<|>RELATION_NOE 受体<|>RELATION_NOE 在<|>RELATION_NOE 癌组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
I<|>RELATION_NOE MD<|>RELATION_NOE 及其<|>RELATION_NOE 受体<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_B 增高<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 有<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 激活<|>RELATION_NOE 受体<|>RELATION_NOE RAMP3<|>RELATION_NOE 发挥<|>RELATION_NOE 促进<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 治疗<|>RELATION_NOE 新靶点<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 有<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 白细胞介素<|>RELATION_NOE 17<|>RELATION_NOE (<|>RELATION_NOE IL-17<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE pTNM<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 相互<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 102<|>RELATION_NOE 例<|>RELATION_NOE 癌组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE IL-17<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE pTNM<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 进行<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE IL-17<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 癌<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 73.5<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 75<|>RELATION_NOE /<|>RELATION_NOE 102<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 60.7<|>RELATION_NOE 8%<|>RELATION_NOE (<|>RELATION_NOE 62<|>RELATION_NOE /<|>RELATION_NOE 102<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 71.5<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE 73<|>RELATION_NOE /<|>RELATION_NOE 102<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 7.8<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 8/<|>RELATION_NOE 102<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 不明<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 失败<|>RELATION_NOE 后<|>RELATION_NOE 行厄洛替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
探讨<|>RELATION_S 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 不<|>RELATION_NOE 明但<|>RELATION_NOE 初始吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 有效<|>RELATION_NOE 而<|>RELATION_NOE 最终<|>RELATION_NOE 耐药<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 直接<|>RELATION_NOE 换<|>RELATION_NOE 用<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 与<|>RELATION_NOE 先<|>RELATION_NOE 化疗<|>RELATION_NOE 再行<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
40<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 无<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE OS<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.0<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 和<|>RELATION_NOE 12.0<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
尼美<|>RELATION_NOE 舒利<|>RELATION_NOE 联合<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 及<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E
探讨<|>RELATION_S 环氧化酶2<|>RELATION_NOE (<|>RELATION_NOE COX-2<|>RELATION_NOE )<|>RELATION_NOE 抑制剂<|>RELATION_NOE 尼美<|>RELATION_NOE 舒利<|>RELATION_NOE 和<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 两<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 可能<|>RELATION_NOE 产生<|>RELATION_NOE 的<|>RELATION_NOE 协同<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_S COX-2<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE C<|>RELATION_NOE (<|>RELATION_NOE VEGF-C<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 3<|>RELATION_NOE (<|>RELATION_NOE VEGFR-3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE survivin<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE -catenin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 荧光<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE
联合<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE COX-2<|>RELATION_NOE 、<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE VEGFR-3<|>RELATION_NOE 、<|>RELATION_NOE survivin<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE -catenin<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
尼美<|>RELATION_NOE 舒利<|>RELATION_NOE 单独<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_B 抑制<|>RELATION_E 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 移植瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE COX-2<|>RELATION_NOE 、<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE VEGFR-3<|>RELATION_NOE 、<|>RELATION_NOE survivin<|>RELATION_NOE 、<|>RELATION_NOE β<|>RELATION_NOE -catenin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
胸部<|>RELATION_NOE CT<|>RELATION_NOE 联合<|>RELATION_NOE VEGF-C<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 肺门<|>RELATION_NOE 和<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
观察<|>RELATION_S 胸部<|>RELATION_NOE 增强<|>RELATION_NOE 计算机<|>RELATION_NOE 断层<|>RELATION_NOE 显像<|>RELATION_NOE (<|>RELATION_NOE CT<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE C<|>RELATION_NOE (<|>RELATION_NOE VEGF-C<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 肺门<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
2008年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 3月<|>RELATION_NOE 北京大学<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 胸外<|>RELATION_NOE 二<|>RELATION_NOE 科<|>RELATION_NOE 87<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE 增强<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 接受<|>RELATION_NOE 标准<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 手术<|>RELATION_NOE 及<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 为<|>RELATION_NOE 判断<|>RELATION_NOE 淋巴结<|>RELATION_NOE 是否<|>RELATION_NOE 转移<|>RELATION_NOE 金标准<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 为<|>RELATION_NOE 75.0%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 为<|>RELATION_NOE 59.6%<|>RELATION_NOE ,<|>RELATION_NOE 准确性<|>RELATION_NOE 66.7%<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE VEGF-C<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 78.2%<|>RELATION_NOE (<|>RELATION_NOE 68<|>RELATION_NOE /<|>RELATION_NOE 87<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 强<|>RELATION_NOE 阳性<|>RELATION_NOE 占<|>RELATION_NOE 13.8%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 87<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 灵敏度<|>RELATION_NOE 为<|>RELATION_NOE 97.5%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 为<|>RELATION_NOE 38.3%<|>RELATION_NOE ,<|>RELATION_NOE 准确性<|>RELATION_NOE 为<|>RELATION_NOE 65.5%<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE Foxp3<|>RELATION_NOE +<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE Th17<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S 与<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE TGF-<|>RELATION_NOE β<|>RELATION_NOE 、<|>RELATION_NOE IL-17<|>RELATION_NOE 、<|>RELATION_NOE IL-23<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_S 健康<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE TGF-<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 晚期组<|>RELATION_NOE /<|>RELATION_NOE
中国<|>RELATION_NOE 2008年<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 发病<|>RELATION_NOE 、<|>RELATION_NOE 死亡<|>RELATION_NOE 和<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 估计<|>RELATION_B 及<|>RELATION_I 预测<|>RELATION_E
估计<|>RELATION_S 2008年<|>RELATION_NOE 中国<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 发病<|>RELATION_NOE 、<|>RELATION_NOE 死亡<|>RELATION_NOE 和<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 预测<|>RELATION_NOE 20<|>RELATION_NOE 年<|>RELATION_NOE 后<|>RELATION_NOE 其<|>RELATION_NOE 发病数<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 数<|>RELATION_NOE 。<|>RELATION_NOE
估计<|>RELATION_S 2008年<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 发病<|>RELATION_NOE 、<|>RELATION_NOE 死亡<|>RELATION_NOE 和<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 预测<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 15<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 25<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 30年<|>RELATION_NOE 发病数<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 数<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 2008年<|>RELATION_NOE 中国<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 新发<|>RELATION_NOE 病例<|>RELATION_NOE 数<|>RELATION_NOE 约<|>RELATION_NOE 16.9万<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 所有<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 例数<|>RELATION_NOE 的<|>RELATION_NOE 14.2%<|>RELATION_NOE ,<|>RELATION_NOE 世界<|>RELATION_NOE 人口<|>RELATION_NOE 标化<|>RELATION_NOE 发病率<|>RELATION_NOE 为<|>RELATION_NOE 21.6<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 居<|>RELATION_NOE 女性<|>RELATION_NOE 所有<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 第2<|>RELATION_NOE 位<|>RELATION_NOE 。<|>RELATION_NOE
2008年<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 数<|>RELATION_NOE 约<|>RELATION_NOE 4.5万<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 所有<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡<|>RELATION_NOE 例数<|>RELATION_NOE 的<|>RELATION_NOE 6.1%<|>RELATION_NOE ,<|>RELATION_NOE 世界<|>RELATION_NOE 人口<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 5.7<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 居<|>RELATION_NOE 全部<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 第6<|>RELATION_NOE 位<|>RELATION_NOE 。<|>RELATION_NOE
2008年<|>RELATION_NOE 中国<|>RELATION_NOE 15<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 成年人<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 5年<|>RELATION_NOE 患病<|>RELATION_NOE 数<|>RELATION_NOE 约<|>RELATION_NOE 63.0万<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 所有<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 患病<|>RELATION_NOE 数<|>RELATION_NOE 的<|>RELATION_NOE 26.1%<|>RELATION_NOE ,<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 患病率<|>RELATION_NOE 为<|>RELATION_NOE 120.8<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 居<|>RELATION_NOE 女性<|>RELATION_NOE 所有<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 首<|>RELATION_NOE 位<|>RELATION_NOE 。<|>RELATION_NOE
乳腺癌<|>RELATION_NOE 居<|>RELATION_NOE 中国<|>RELATION_NOE 女性<|>RELATION_NOE 癌症<|>RELATION_NOE 第2<|>RELATION_NOE 位<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 首<|>RELATION_NOE 位<|>RELATION_NOE 肺癌<|>RELATION_NOE 基本<|>RELATION_B 持平<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 发病<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 情况<|>RELATION_NOE 在<|>RELATION_NOE 未来<|>RELATION_NOE 20<|>RELATION_NOE 年<|>RELATION_NOE 将<|>RELATION_NOE 越来越<|>RELATION_NOE 严重<|>RELATION_NOE ,<|>RELATION_NOE 重点<|>RELATION_NOE 防控<|>RELATION_NOE 人群<|>RELATION_NOE 为<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 70<|>RELATION_NOE 岁<|>RELATION_NOE 女性<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE AKAP95<|>RELATION_NOE 和<|>RELATION_NOE cyelinE2<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E 及<|>RELATION_NOE 与<|>RELATION_NOE Cx43<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 关联性<|>RELATION_NOE 分析<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE AKAP95<|>RELATION_NOE 和<|>RELATION_NOE cyelinE2<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE Cx43<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 关联性<|>RELATION_B 分析<|>RELATION_E
1.<|>RELATION_NOE AKAP95<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 82.3<|>RELATION_NOE 5%<|>RELATION_NOE 和<|>RELATION_NOE 33.3<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
3.<|>RELATION_NOE Cx43<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 60.7<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_S 其<|>RELATION_NOE 在<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE (<|>RELATION_NOE 80.00%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Cx43<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学分型<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 是否<|>RELATION_NOE 发生<|>RELATION_NOE 转移<|>RELATION_NOE 之间<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肝脏<|>RELATION_NOE 、<|>RELATION_NOE 胰腺<|>RELATION_NOE 、<|>RELATION_NOE 脾脏<|>RELATION_NOE 、<|>RELATION_NOE 唾液<|>RELATION_NOE 腺<|>RELATION_NOE 可见<|>RELATION_NOE ”<|>RELATION_NOE F-FECH<|>RELATION_NOE 生理性<|>RELATION_NOE 摄取<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肝脏<|>RELATION_NOE 、<|>RELATION_NOE 胰腺<|>RELATION_NOE 生理性<|>RELATION_NOE 摄取<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE SUVmax<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 10.1<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE 和<|>RELATION_NOE 6.1<|>RELATION_NOE ±<|>RELATION_NOE 1.1<|>RELATION_NOE 。<|>RELATION_NOE
30<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 发现<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 有<|>RELATION_NOE 前列腺<|>RELATION_NOE 以外<|>RELATION_NOE 组织<|>RELATION_NOE 器官<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE PET<|>RELATION_NOE 异常<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 33.3%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 6例<|>RELATION_NOE 为<|>RELATION_NOE 炎性<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 结核<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 松果体<|>RELATION_NOE 生殖细胞瘤<|>RELATION_NOE 。<|>RELATION_NOE
准确<|>RELATION_NOE 分析<|>RELATION_NOE 患者<|>RELATION_NOE 生理性<|>RELATION_NOE 摄取<|>RELATION_NOE 及<|>RELATION_NOE 非<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 相关<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 摄取<|>RELATION_NOE 对<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 至关重要<|>RELATION_S ,<|>RELATION_NOE 造成<|>RELATION_NOE ^<|>RELATION_NOE 18F-FECH<|>RELATION_NOE 假<|>RELATION_NOE 阳性<|>RELATION_NOE 的<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 主要<|>RELATION_NOE 是<|>RELATION_NOE 炎性<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
尾加<|>RELATION_NOE 压素Ⅱ<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
检测<|>RELATION_S 尾加<|>RELATION_NOE 压素Ⅱ<|>RELATION_NOE (<|>RELATION_NOE U<|>RELATION_NOE Ⅱ<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
揭示<|>RELATION_NOE U<|>RELATION_NOE Ⅱ<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 观察<|>RELATION_S 45<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 中<|>RELATION_NOE U<|>RELATION_NOE Ⅱ<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE U<|>RELATION_NOE Ⅱ<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE TNM<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE U<|>RELATION_NOE Ⅱ<|>RELATION_NOE 主要<|>RELATION_NOE 分布<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 细胞质<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 呈棕<|>RELATION_NOE 黄色<|>RELATION_NOE 颗粒<|>RELATION_NOE ;<|>RELATION_NOE
Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE U<|>RELATION_NOE Ⅱ<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE 85.7%<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E I<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE 16.7%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
U<|>RELATION_NOE Ⅱ<|>RELATION_NOE 广泛<|>RELATION_NOE 存在<|>RELATION_NOE 于<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 腺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 细胞质<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE U<|>RELATION_NOE Ⅱ<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE TNM<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E 。<|>RELATION_NOE
国产<|>RELATION_NOE 替<|>RELATION_NOE 吉奥<|>RELATION_NOE 胶囊<|>RELATION_NOE 联合<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 治疗<|>RELATION_S 老年人<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 肺转移<|>RELATION_NOE
探讨<|>RELATION_S 国产<|>RELATION_NOE 替<|>RELATION_NOE 吉奥<|>RELATION_NOE 胶囊<|>RELATION_NOE 联合<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 有效性<|>RELATION_NOE 与<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
国产<|>RELATION_NOE 替<|>RELATION_NOE 吉奥<|>RELATION_NOE 胶囊<|>RELATION_NOE 联合<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 并<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 具有<|>RELATION_S 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 耐受性<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 改善<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
PESC<|>RELATION_NOE 易<|>RELATION_NOE 早期<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 预后<|>RELATION_NOE 不<|>RELATION_NOE 佳<|>RELATION_NOE ,<|>RELATION_NOE 综合治疗<|>RELATION_NOE 有助于<|>RELATION_S 延长<|>RELATION_NOE 患者<|>RELATION_NOE 生存期<|>RELATION_NOE 。<|>RELATION_NOE
2例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 获<|>RELATION_NOE 手术<|>RELATION_NOE 成功<|>RELATION_NOE ,<|>RELATION_NOE 无中转开胸<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 手术<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 手术时间<|>RELATION_NOE 252.5min<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 出血量<|>RELATION_NOE 150ml<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 5d<|>RELATION_NOE 。<|>RELATION_NOE
围手术期<|>RELATION_NOE 未<|>RELATION_NOE 输血<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 轻<|>RELATION_NOE 。<|>RELATION_NOE
机器人<|>RELATION_NOE 辅助<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 左肺<|>RELATION_NOE 下<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE 初步<|>RELATION_B 证明<|>RELATION_E 是<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE ,<|>RELATION_NOE 相<|>RELATION_NOE 较<|>RELATION_NOE 于<|>RELATION_NOE VATS<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 更<|>RELATION_NOE 逼真<|>RELATION_NOE 的<|>RELATION_NOE 视野<|>RELATION_NOE ,<|>RELATION_NOE 更<|>RELATION_NOE 灵活<|>RELATION_NOE 稳定<|>RELATION_NOE 的<|>RELATION_NOE 操作<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 具备<|>RELATION_NOE 更<|>RELATION_NOE 宽泛<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 适应证<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 新<|>RELATION_NOE 一代<|>RELATION_NOE 微创<|>RELATION_NOE 胸部<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 选择<|>RELATION_NOE 。<|>RELATION_NOE
机器人<|>RELATION_NOE 辅助<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 技术<|>RELATION_NOE 应用<|>RELATION_B 于<|>RELATION_E 胸外科<|>RELATION_NOE 初步<|>RELATION_NOE 经验<|>RELATION_NOE
评价<|>RELATION_S 人工智能<|>RELATION_NOE 机器人<|>RELATION_NOE 外科手术<|>RELATION_NOE 系统<|>RELATION_NOE 在<|>RELATION_NOE 普胸<|>RELATION_NOE 外科手术<|>RELATION_NOE 领域<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
2009年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 共<|>RELATION_NOE 使用<|>RELATION_NOE 达芬奇<|>RELATION_NOE 外科手术<|>RELATION_NOE 系统<|>RELATION_NOE 完成<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 普胸<|>RELATION_NOE 外科手术<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 8例<|>RELATION_NOE 肺部<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 食管癌<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 1例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 第16<|>RELATION_NOE 天<|>RELATION_NOE 行<|>RELATION_NOE 支气管<|>RELATION_NOE 瘘修<|>RELATION_NOE 补术<|>RELATION_NOE ,<|>RELATION_NOE 修补<|>RELATION_NOE 成功<|>RELATION_NOE 后<|>RELATION_NOE 出院<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 单<|>RELATION_NOE 中心<|>RELATION_NOE 四肢<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 预后<|>RELATION_NOE 及<|>RELATION_NOE 生存<|>RELATION_NOE 状况<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 19<|>RELATION_NOE 98年<|>RELATION_NOE 至<|>RELATION_NOE 2008<|>RELATION_NOE 年<|>RELATION_NOE 间<|>RELATION_NOE 单<|>RELATION_NOE 中心<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 311<|>RELATION_NOE 例<|>RELATION_NOE 四肢<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病历<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 基本<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 、<|>RELATION_NOE Coxregression<|>RELATION_NOE 等<|>RELATION_NOE 统计学<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_NOE 各<|>RELATION_NOE 变量<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 肿瘤<|>RELATION_NOE 广泛<|>RELATION_NOE 或<|>RELATION_NOE 根治性<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 可以<|>RELATION_NOE 挽救<|>RELATION_NOE 约<|>RELATION_NOE 60%<|>RELATION_NOE 青少年<|>RELATION_NOE 四肢<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生命<|>RELATION_NOE ,<|>RELATION_NOE 肺转移<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 规范化<|>RELATION_NOE 疗<|>RELATION_NOE 严重<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
SOCS3<|>RELATION_NOE 和<|>RELATION_NOE Pyk2<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 相关性<|>RELATION_NOE 研究<|>RELATION_NOE
分别<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 染色<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S SOCS3<|>RELATION_NOE 和<|>RELATION_NOE Pyk2<|>RELATION_NOE 在<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 人<|>RELATION_NOE 支气管<|>RELATION_NOE 上皮细胞<|>RELATION_NOE HBE<|>RELATION_NOE 和<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE NSCLC<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE SOCS3<|>RELATION_NOE 基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
A549<|>RELATION_NOE 细胞<|>RELATION_NOE 经<|>RELATION_NOE 蛋白<|>RELATION_NOE 酶体<|>RELATION_NOE 抑制剂<|>RELATION_NOE β<|>RELATION_NOE -1actacystin<|>RELATION_NOE 预处理<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 加入<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 试剂<|>RELATION_NOE 5-aza-2<|>RELATION_NOE '<|>RELATION_NOE -<|>RELATION_NOE 脱氧胞苷<|>RELATION_NOE (<|>RELATION_NOE 5-aza<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 或<|>RELATION_NOE 转染<|>RELATION_NOE SOCS3<|>RELATION_NOE 突变<|>RELATION_NOE 质粒<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE Pvk2<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE Pyk2Tyr402<|>RELATION_NOE 和<|>RELATION_NOE ERK1<|>RELATION_NOE /<|>RELATION_NOE 2磷<|>RELATION_NOE 酸化<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
11<|>RELATION_NOE 例<|>RELATION_NOE RPLS<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 病<|>RELATION_NOE 因为<|>RELATION_NOE 妊娠<|>RELATION_NOE 高血压<|>RELATION_NOE 综合征<|>RELATION_NOE 、<|>RELATION_NOE 先兆子痫<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 孕<|>RELATION_NOE 38<|>RELATION_NOE 周<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 慢性<|>RELATION_NOE 肾功能不全<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 恶性高血压<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 头痛<|>RELATION_NOE 、<|>RELATION_NOE 视觉障碍<|>RELATION_NOE 、<|>RELATION_NOE 精神<|>RELATION_NOE 行为<|>RELATION_NOE 异常<|>RELATION_NOE 、<|>RELATION_NOE 共济失调<|>RELATION_NOE 、<|>RELATION_NOE 癫痫发作<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
神经<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 大脑半球<|>RELATION_NOE 后部<|>RELATION_NOE 广泛性<|>RELATION_NOE 白质<|>RELATION_NOE 异常<|>RELATION_NOE ,<|>RELATION_NOE 如<|>RELATION_NOE 顶枕<|>RELATION_NOE 颞叶<|>RELATION_NOE ,<|>RELATION_NOE 也<|>RELATION_NOE 可<|>RELATION_NOE 累及<|>RELATION_NOE 脑干<|>RELATION_NOE 、<|>RELATION_NOE 小脑<|>RELATION_NOE 、<|>RELATION_NOE 丘脑<|>RELATION_NOE 及<|>RELATION_NOE 其他<|>RELATION_NOE 部位<|>RELATION_NOE 。<|>RELATION_NOE
肝癌<|>RELATION_NOE 模型<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 残余肿瘤侵袭<|>RELATION_NOE 转移<|>RELATION_NOE 潜能<|>RELATION_NOE 变化<|>RELATION_NOE 规律<|>RELATION_NOE 及其<|>RELATION_NOE 机制<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_S
用<|>RELATION_NOE MHCC97L<|>RELATION_NOE 细胞<|>RELATION_NOE 构建<|>RELATION_S 人<|>RELATION_NOE 肝癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 原位<|>RELATION_NOE 移植<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 成瘤<|>RELATION_NOE 后<|>RELATION_NOE 化疗组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 以<|>RELATION_NOE 10mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 腹腔<|>RELATION_NOE 注射<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 注射<|>RELATION_NOE 0.9%<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE ,<|>RELATION_NOE 每周<|>RELATION_NOE 1次<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 3<|>RELATION_NOE 次<|>RELATION_NOE 。<|>RELATION_NOE
另<|>RELATION_NOE 将<|>RELATION_NOE 化疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 残余<|>RELATION_NOE 肝癌<|>RELATION_NOE 组织<|>RELATION_NOE 再接种<|>RELATION_NOE 于<|>RELATION_NOE 新<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肝脏<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 形成<|>RELATION_NOE 化疗<|>RELATION_NOE 预处理<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_B 和<|>RELATION_I 检测<|>RELATION_E 残余<|>RELATION_NOE 肝癌<|>RELATION_NOE 在<|>RELATION_NOE 新<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 体内<|>RELATION_NOE 化疔<|>RELATION_NOE 后<|>RELATION_NOE
将<|>RELATION_NOE 残癌<|>RELATION_NOE 组织<|>RELATION_NOE 再接种<|>RELATION_NOE 于<|>RELATION_NOE 新<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肝脏<|>RELATION_NOE 内<|>RELATION_NOE 42d<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 预处理<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 对照组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE 24.59<|>RELATION_NOE ±<|>RELATION_NOE 49<|>RELATION_NOE 1.60<|>RELATION_NOE )<|>RELATION_NOE l<|>RELATION_NOE /<|>RELATION_NOE mm<|>RELATION_NOE ^<|>RELATION_NOE 3<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 38<|>RELATION_NOE 49.72<|>RELATION_NOE ±<|>RELATION_NOE 82<|>RELATION_NOE 7.09<|>RELATION_NOE )<|>RELATION_NOE mm<|>RELATION_NOE ^<|>RELATION_NOE 3<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 预处理<|>RELATION_NOE 组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE E-eadherin<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_NOE 下调<|>RELATION_NOE ,<|>RELATION_NOE N-eadherin<|>RELATION_NOE 和<|>RELATION_NOE vimentin<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_NOE 增强<|>RELATION_NOE ,<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE ,<|>RELATION_NOE 表明<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 残癌<|>RELATION_NOE 组织<|>RELATION_NOE 发生<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
体内<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 残余<|>RELATION_NOE 肝癌<|>RELATION_NOE 生长<|>RELATION_NOE 减慢<|>RELATION_S ,<|>RELATION_NOE 肺转移<|>RELATION_NOE 能力<|>RELATION_NOE 显著<|>RELATION_NOE 增强<|>RELATION_NOE ,<|>RELATION_NOE 残癌<|>RELATION_NOE 组织<|>RELATION_NOE 发生<|>RELATION_NOE EMT<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 体内<|>RELATION_NOE 实验<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Wistar<|>RELATION_NOE 大鼠<|>RELATION_NOE 60<|>RELATION_NOE 只<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 正常<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 哮喘<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 烟雾<|>RELATION_NOE 暴露<|>RELATION_NOE 哮喘<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE SB203580<|>RELATION_NOE 干预组<|>RELATION_NOE 各<|>RELATION_NOE 15<|>RELATION_NOE 只<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_S 大鼠<|>RELATION_NOE 肺组织<|>RELATION_NOE 糖<|>RELATION_NOE 皮质<|>RELATION_NOE 激素<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE GR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 热休克<|>RELATION_NOE 蛋白<|>RELATION_NOE 90<|>RELATION_NOE (<|>RELATION_NOE HSP90<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE p38MAPKmRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE Western<|>RELATION_NOE 印迹<|>RELATION_NOE
烟雾<|>RELATION_NOE 暴露<|>RELATION_NOE 哮喘<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE SB203580<|>RELATION_NOE 干预组<|>RELATION_NOE 大鼠<|>RELATION_NOE 肺组织<|>RELATION_NOE GRmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.6<|>RELATION_NOE 71<|>RELATION_NOE ±<|>RELATION_NOE 0.002<|>RELATION_NOE 和<|>RELATION_NOE 0.595-4-0.061<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 65<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE GR<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.700<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 33<|>RELATION_NOE 和<|>RELATION_NOE 0.6284-0.091<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 48<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
盐酸埃克替尼<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_S 盐酸埃克替尼<|>RELATION_NOE 对<|>RELATION_NOE 不同<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
运用0<|>RELATION_NOE －<|>RELATION_NOE 40<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 盐酸埃克替尼<|>RELATION_NOE 和<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 分别<|>RELATION_NOE 处理<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE HCC827<|>RELATION_NOE 、<|>RELATION_NOE H1650<|>RELATION_NOE 、<|>RELATION_NOE H1975<|>RELATION_NOE 、<|>RELATION_NOE A549<|>RELATION_NOE 及<|>RELATION_NOE 人<|>RELATION_NOE 表皮<|>RELATION_NOE 癌细胞系<|>RELATION_NOE A431<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE 比色法<|>RELATION_NOE 观察<|>RELATION_S 细胞增殖<|>RELATION_NOE 活力<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 应用<|>RELATION_NOE 免疫印迹法<|>RELATION_NOE
与<|>RELATION_NOE H1650<|>RELATION_NOE 、<|>RELATION_NOE H1975<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞系<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 盐酸埃克替尼<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 抑制<|>RELATION_E A431<|>RELATION_NOE 和<|>RELATION_NOE HCC827<|>RELATION_NOE 细胞系<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.009<|>RELATION_NOE 、<|>RELATION_NOE 0.005<|>RELATION_NOE 、<|>RELATION_NOE 0.000<|>RELATION_NOE 和<|>RELATION_NOE 0.001<|>RELATION_NOE 、<|>RELATION_NOE 0.001<|>RELATION_NOE 、<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
盐酸埃克替尼<|>RELATION_NOE 可以<|>RELATION_NOE 通过<|>RELATION_NOE 抑制<|>RELATION_S 人<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 磷酸化<|>RELATION_NOE 活性<|>RELATION_NOE 使<|>RELATION_NOE 磷酸化<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE B<|>RELATION_NOE (<|>RELATION_NOE AKT<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 胞外<|>RELATION_NOE 信号<|>RELATION_NOE 调节<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE ERK<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE
ERK<|>RELATION_NOE 通路<|>RELATION_NOE 以及<|>RELATION_NOE survivin<|>RELATION_NOE 通路<|>RELATION_NOE 的<|>RELATION_NOE 激活<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 控制<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 或<|>RELATION_NOE EGFR<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 并<|>RELATION_NOE 促进<|>RELATION_NOE 其<|>RELATION_NOE 凋亡<|>RELATION_NOE 。<|>RELATION_NOE
超声<|>RELATION_NOE 造影<|>RELATION_NOE 可<|>RELATION_NOE 清晰<|>RELATION_NOE 显示<|>RELATION_NOE 病灶<|>RELATION_NOE 内<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 活<|>RELATION_NOE 性区<|>RELATION_NOE ,<|>RELATION_NOE 区别<|>RELATION_NOE 坏死区<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_NOE 穿刺<|>RELATION_NOE 取材<|>RELATION_NOE 部位<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 穿刺<|>RELATION_NOE 取材<|>RELATION_NOE 的<|>RELATION_NOE 成功率<|>RELATION_NOE 与<|>RELATION_NOE 准确率<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 中<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值.<|>RELATION_NOE
高压氧<|>RELATION_NOE 联合<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抑制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.37%<|>RELATION_NOE 、<|>RELATION_NOE 8.9<|>RELATION_NOE 2%<|>RELATION_NOE 、<|>RELATION_NOE 21.8<|>RELATION_NOE 8%<|>RELATION_NOE 、<|>RELATION_NOE 48.7<|>RELATION_NOE 1%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 顺铂组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
FCM<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 经<|>RELATION_NOE 高压氧<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE GO<|>RELATION_NOE ~<|>RELATION_NOE G1<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 减少<|>RELATION_NOE ,<|>RELATION_NOE s<|>RELATION_NOE 期<|>RELATION_NOE 细胞增多<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 极<|>RELATION_NOE 显著性<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
单病区组<|>RELATION_NOE 肺癌<|>RELATION_NOE 外科<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 质控<|>RELATION_B 分析<|>RELATION_E
回顾性<|>RELATION_B 总结<|>RELATION_E 2007年<|>RELATION_NOE 112<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 美国<|>RELATION_NOE 国立<|>RELATION_NOE 综合<|>RELATION_NOE 癌症<|>RELATION_NOE 网络<|>RELATION_NOE (<|>RELATION_NOE NCCN<|>RELATION_NOE ,<|>RELATION_NOE National<|>RELATION_NOE Comprehensive<|>RELATION_NOE Cancer<|>RELATION_NOE Network<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 美国<|>RELATION_NOE 外<|>RELATION_NOE 科学院<|>RELATION_NOE 肿瘤<|>RELATION_NOE 研究组<|>RELATION_NOE (<|>RELATION_NOE ACOSOG<|>RELATION_NOE ,<|>RELATION_NOE American<|>RELATION_NOE College<|>RELATION_NOE of<|>RELATION_NOE Surgeons'Oncology<|>RELATION_NOE Group<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 国际<|>RELATION_NOE 肺癌<|>RELATION_NOE 研究会<|>RELATION_NOE (<|>RELATION_NOE IASLC<|>RELATION_NOE ,<|>RELATION_NOE International<|>RELATION_NOE Association<|>RELATION_NOE for<|>RELATION_NOE the<|>RELATION_NOE Study<|>RELATION_NOE of<|>RELATION_NOE Lung<|>RELATION_NOE Cancer<|>RELATION_NOE )<|>RELATION_NOE 定义<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 外科<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 质量<|>RELATION_NOE 标准<|>RELATION_NOE 作为<|>RELATION_NOE 质控<|>RELATION_NOE 依据<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 外科<|>RELATION_NOE 质量<|>RELATION_NOE 控制<|>RELATION_NOE 工作<|>RELATION_NOE 。<|>RELATION_NOE
中位<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 数目<|>RELATION_NOE 27<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 63<|>RELATION_NOE 枚<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结切除<|>RELATION_NOE 数目<|>RELATION_NOE 16.5<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 0-43<|>RELATION_NOE 枚<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 第一<|>RELATION_NOE 站<|>RELATION_NOE 淋巴结<|>RELATION_NOE 切检<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 数目<|>RELATION_NOE 是<|>RELATION_NOE 10.5<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 26<|>RELATION_NOE 枚<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
第二<|>RELATION_NOE 站<|>RELATION_NOE 淋巴结<|>RELATION_NOE 最<|>RELATION_NOE 常<|>RELATION_NOE 清扫<|>RELATION_NOE 的<|>RELATION_NOE 部位<|>RELATION_NOE 是<|>RELATION_NOE 4R<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 和<|>RELATION_NOE 7组<|>RELATION_NOE 淋巴结<|>RELATION_NOE ,<|>RELATION_NOE 第一<|>RELATION_NOE 站<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE 最<|>RELATION_NOE 常<|>RELATION_NOE 清扫<|>RELATION_NOE 的<|>RELATION_NOE 部位<|>RELATION_NOE 10<|>RELATION_NOE 和<|>RELATION_NOE 12<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
质量<|>RELATION_NOE 控制<|>RELATION_NOE 工作<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 外科<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 核心<|>RELATION_B 内容<|>RELATION_E ,<|>RELATION_NOE 实行<|>RELATION_NOE 符合<|>RELATION_NOE 国际<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 是<|>RELATION_NOE 开展<|>RELATION_NOE 高<|>RELATION_NOE 质量<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE 的<|>RELATION_NOE 前提<|>RELATION_NOE ,<|>RELATION_NOE 建议<|>RELATION_NOE 肺癌<|>RELATION_NOE 外科手术<|>RELATION_NOE 质控<|>RELATION_NOE 应<|>RELATION_NOE 遵循<|>RELATION_NOE 严格<|>RELATION_NOE 的<|>RELATION_NOE 国际<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 以期<|>RELATION_NOE 提高<|>RELATION_NOE 分期<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2009年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 9月<|>RELATION_NOE 422<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 检查术<|>RELATION_NOE 前<|>RELATION_NOE 未经<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 且<|>RELATION_NOE 术后<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 胸部<|>RELATION_NOE 增强<|>RELATION_NOE CT<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 683<|>RELATION_NOE 个<|>RELATION_NOE 纵隔<|>RELATION_NOE /<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 人<|>RELATION_NOE 组<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 335<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 87<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 是<|>RELATION_NOE 纵隔<|>RELATION_NOE /<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 活检<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新<|>RELATION_NOE 手段<|>RELATION_NOE ,<|>RELATION_NOE 基于<|>RELATION_NOE EBUS<|>RELATION_NOE 成像<|>RELATION_NOE 分类<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 超声<|>RELATION_NOE 图像<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 指导<|>RELATION_S 淋巴结<|>RELATION_NOE 穿刺<|>RELATION_NOE 顺序<|>RELATION_NOE ,<|>RELATION_NOE 预测<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 良恶性<|>RELATION_NOE 。<|>RELATION_NOE
趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体4<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_S 趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体4<|>RELATION_NOE (<|>RELATION_NOE CXCR4<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 90<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE CXCR4<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 39<|>RELATION_NOE 例伴<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移者<|>RELATION_NOE 。<|>RELATION_NOE
CXCR4<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺正常<|>RELATION_NOE 组织<|>RELATION_NOE 表达<|>RELATION_NOE 较<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE CXCR4<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 高<|>RELATION_NOE 达<|>RELATION_NOE 61.1%<|>RELATION_NOE (<|>RELATION_NOE 55<|>RELATION_NOE /<|>RELATION_NOE 90<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CXCR4<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE ;<|>RELATION_NOE
VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 和<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 无<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
CXCR4<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 侵袭<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
吸烟<|>RELATION_NOE 患<|>RELATION_NOE 或<|>RELATION_NOE 未<|>RELATION_NOE 患<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 移动<|>RELATION_NOE 抑制<|>RELATION_NOE 因子<|>RELATION_NOE 表达<|>RELATION_S
通过<|>RELATION_NOE 检测<|>RELATION_S 吸烟<|>RELATION_NOE 患<|>RELATION_NOE 或<|>RELATION_NOE 未<|>RELATION_NOE 患<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 移动<|>RELATION_NOE 抑制<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE MIF<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 进一步<|>RELATION_NOE 了解<|>RELATION_NOE COPD<|>RELATION_NOE 易<|>RELATION_NOE 患<|>RELATION_NOE 机制<|>RELATION_NOE 提供<|>RELATION_NOE 基础<|>RELATION_NOE 研究<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
肺组织<|>RELATION_NOE 来源于<|>RELATION_NOE 因<|>RELATION_NOE 肺癌<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 分<|>RELATION_NOE 吸烟<|>RELATION_NOE 患<|>RELATION_NOE COPD<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 未<|>RELATION_NOE 患<|>RELATION_NOE COPD<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 吸烟<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 3组<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 肺组织<|>RELATION_NOE 内<|>RELATION_NOE MIF<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 吸<|>RELATION_NOE 光度值<|>RELATION_NOE 吸烟<|>RELATION_NOE 患<|>RELATION_NOE COPD<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 0.2<|>RELATION_NOE 77<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_S 吸烟<|>RELATION_NOE 未<|>RELATION_NOE 患<|>RELATION_NOE COPD<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 0.1<|>RELATION_NOE 99<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 34<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE
吸烟<|>RELATION_NOE 患<|>RELATION_NOE COPD<|>RELATION_NOE 者<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE MIF<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 气流<|>RELATION_NOE 受限<|>RELATION_NOE 程度<|>RELATION_NOE 呈<|>RELATION_B 正<|>RELATION_I 相关<|>RELATION_E ,<|>RELATION_NOE 提示<|>RELATION_NOE MIF<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 吸烟<|>RELATION_NOE 致<|>RELATION_NOE COPD<|>RELATION_NOE 发病<|>RELATION_NOE 机制<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
二十<|>RELATION_NOE 碳五烯酸<|>RELATION_NOE 联合<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A-549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
细胞<|>RELATION_NOE 荧光<|>RELATION_NOE 染色<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE EPA<|>RELATION_NOE 联合<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷组<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 细胞<|>RELATION_NOE 数量<|>RELATION_NOE 多于<|>RELATION_S 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 单独<|>RELATION_NOE 作用<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
80<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 为<|>RELATION_NOE 6.9<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中9<|>RELATION_NOE 2.9%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 14<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 34.4%<|>RELATION_NOE (<|>RELATION_NOE 31<|>RELATION_NOE /<|>RELATION_NOE 90<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 了<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤分期<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 功能<|>RELATION_NOE 状态<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_S 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
早期<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 保<|>RELATION_NOE 乳术<|>RELATION_NOE 后<|>RELATION_NOE 瘤床<|>RELATION_NOE 同步<|>RELATION_NOE 加量<|>RELATION_NOE 短<|>RELATION_NOE 疗程<|>RELATION_NOE 放疗<|>RELATION_NOE 临床<|>RELATION_B 观察<|>RELATION_E
常规组<|>RELATION_NOE 与<|>RELATION_NOE 短程组1<|>RELATION_NOE 、<|>RELATION_NOE 2级<|>RELATION_NOE 急性<|>RELATION_NOE 皮肤<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 46.9%<|>RELATION_NOE 与<|>RELATION_NOE 45.1%<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 0.73<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.6<|>RELATION_NOE 95<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 16.3%<|>RELATION_NOE 与<|>RELATION_NOE 13.7%<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 0.73<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.6<|>RELATION_NOE 95<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1级<|>RELATION_NOE 皮肤<|>RELATION_NOE 及<|>RELATION_NOE 皮下组织<|>RELATION_NOE 晚期<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 16.9%<|>RELATION_NOE 与<|>RELATION_NOE 17.1%<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 0.00<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 54<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
基于<|>RELATION_NOE 自主<|>RELATION_NOE 呼吸<|>RELATION_NOE 控制<|>RELATION_NOE 三维<|>RELATION_NOE CT<|>RELATION_NOE 分析<|>RELATION_S 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 四维<|>RELATION_NOE CT<|>RELATION_NOE 各<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 伪影<|>RELATION_NOE
基于<|>RELATION_NOE 自主<|>RELATION_NOE 呼吸<|>RELATION_NOE 控制<|>RELATION_NOE (<|>RELATION_NOE ABC<|>RELATION_NOE )<|>RELATION_NOE 辅助<|>RELATION_NOE 三维<|>RELATION_NOE cT<|>RELATION_NOE (<|>RELATION_NOE 3DCT<|>RELATION_NOE )<|>RELATION_NOE 探讨<|>RELATION_S 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 四维<|>RELATION_NOE cT<|>RELATION_NOE (<|>RELATION_NOE 4DCT<|>RELATION_NOE )<|>RELATION_NOE 各<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE (<|>RELATION_NOE GTV<|>RELATION_NOE )<|>RELATION_NOE 伪影<|>RELATION_NOE 大小<|>RELATION_NOE 及<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
19<|>RELATION_NOE 例<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 依次<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE 自由<|>RELATION_NOE 呼吸<|>RELATION_NOE 3DCT<|>RELATION_NOE (<|>RELATION_NOE CTFB<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 4DCT<|>RELATION_NOE 及<|>RELATION_NOE ABC<|>RELATION_NOE 辅助<|>RELATION_NOE 平静<|>RELATION_NOE 吸气<|>RELATION_NOE 末<|>RELATION_NOE 屏气<|>RELATION_NOE (<|>RELATION_NOE cTEIH<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 屏气<|>RELATION_NOE (<|>RELATION_NOE cTEEH<|>RELATION_NOE )<|>RELATION_NOE 3DCT<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 计算<|>RELATION_S 基于<|>RELATION_NOE cTFB<|>RELATION_NOE 勾画<|>RELATION_NOE 所得<|>RELATION_NOE GTV<|>RELATION_NOE (<|>RELATION_NOE GTVFB<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 基于<|>RELATION_NOE 4DCT<|>RELATION_NOE 各<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE 勾画<|>RELATION_NOE 所得<|>RELATION_NOE GTV<|>RELATION_NOE 与<|>RELATION_NOE 参照<|>RELATION_NOE GTV<|>RELATION_NOE (<|>RELATION_NOE GTVtef<|>RELATION_NOE )<|>RELATION_NOE 间<|>RELATION_NOE 相对<|>RELATION_NOE 变异<|>RELATION_NOE (<|>RELATION_NOE Devref<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 重要性<|>RELATION_B 研究<|>RELATION_E
评估<|>RELATION_S 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE (<|>RELATION_NOE 恩度<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 不可<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 有效性<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
3<|>RELATION_NOE 、<|>RELATION_NOE 4级中性<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 3级<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 和<|>RELATION_NOE 肺炎<|>RELATION_NOE 各<|>RELATION_NOE 4例<|>RELATION_NOE 。<|>RELATION_NOE
剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方<|>RELATION_NOE 图<|>RELATION_NOE 参数<|>RELATION_NOE 对<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE 预测<|>RELATION_B 分析<|>RELATION_E
应用<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE ROC<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方<|>RELATION_NOE 图<|>RELATION_NOE 参数<|>RELATION_NOE (<|>RELATION_NOE DVH<|>RELATION_NOE )<|>RELATION_NOE 预测<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE RP<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_B 分析<|>RELATION_E ,<|>RELATION_NOE 探究<|>RELATION_NOE DVH<|>RELATION_NOE 参数<|>RELATION_NOE 预测<|>RELATION_NOE RP<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE (<|>RELATION_NOE ACC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 敏感性<|>RELATION_NOE (<|>RELATION_NOE SEN<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE (<|>RELATION_NOE SPE<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
勾画者<|>RELATION_NOE 及<|>RELATION_NOE 勾画<|>RELATION_NOE 标准<|>RELATION_NOE 对<|>RELATION_NOE 基于<|>RELATION_NOE 4D-CT<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 靶区<|>RELATION_NOE 勾画<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
选择<|>RELATION_NOE 12<|>RELATION_NOE 例行<|>RELATION_NOE 4D-CT<|>RELATION_NOE 模拟<|>RELATION_NOE 定位<|>RELATION_NOE 扫描<|>RELATION_NOE 的<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 勾画<|>RELATION_NOE 标准<|>RELATION_NOE 制定<|>RELATION_NOE 前后<|>RELATION_NOE ,<|>RELATION_NOE 6<|>RELATION_NOE 名<|>RELATION_NOE 放疗<|>RELATION_NOE 医生<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE 4D-CT<|>RELATION_NOE 的<|>RELATION_NOE 吸气<|>RELATION_NOE 末<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE (<|>RELATION_NOE O<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE (<|>RELATION_NOE 50%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 3D-CT<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 勾画<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE GTV0<|>RELATION_NOE 、<|>RELATION_NOE GTV50<|>RELATION_NOE 和<|>RELATION_NOE GTV3D<|>RELATION_NOE ,<|>RELATION_NOE GTV0<|>RELATION_NOE 和<|>RELATION_NOE GTV50<|>RELATION_NOE 分别<|>RELATION_NOE 融合<|>RELATION_NOE 得到<|>RELATION_NOE 勾画<|>RELATION_NOE 标准<|>RELATION_NOE 制定<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 内<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE IGTVIN<|>RELATION_NOE ,<|>RELATION_NOE EX<|>RELATION_NOE 在<|>RELATION_NOE 4D-CT<|>RELATION_NOE 的<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 密度<|>RELATION_NOE 投影<|>RELATION_NOE (<|>RELATION_NOE MIP<|>RELATION_NOE )<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 勾画<|>RELATION_NOE 内<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE IGTVMIP<|>RELATION_NOE 对<|>RELATION_NOE 勾画<|>RELATION_NOE 标准<|>RELATION_NOE 制定<|>RELATION_NOE 前后<|>RELATION_NOE 同一<|>RELATION_NOE 勾画者<|>RELATION_NOE 及<|>RELATION_NOE 勾画者<|>RELATION_NOE 之间<|>RELATION_NOE 靶区<|>RELATION_NOE 勾画<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_B 分析<|>RELATION_E 我院<|>RELATION_NOE 门诊<|>RELATION_NOE 及<|>RELATION_NOE 病房<|>RELATION_NOE 共<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 、<|>RELATION_NOE 诊断<|>RELATION_NOE 方法<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 体征<|>RELATION_NOE :<|>RELATION_NOE 刺激性<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 血丝痰<|>RELATION_NOE 、<|>RELATION_NOE 持续性<|>RELATION_NOE 胸痛<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 56%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 合并<|>RELATION_NOE 血性<|>RELATION_NOE 胸水<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 20%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 症状<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 24%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
诊断<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 痰脱落<|>RELATION_NOE 细胞<|>RELATION_NOE 病检<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 30%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 胸水<|>RELATION_NOE 脱落<|>RELATION_NOE 细胞<|>RELATION_NOE 病检<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 20%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 8%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 刷片<|>RELATION_NOE 活检<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 12%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 病检<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 30%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 恶性<|>RELATION_NOE 纤维<|>RELATION_NOE 组织细胞<|>RELATION_NOE 瘤术<|>RELATION_NOE 后<|>RELATION_NOE 肺转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 短期<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_S cT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿刺<|>RELATION_NOE 放射性<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 肿瘤<|>RELATION_NOE 内<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE 恶性<|>RELATION_NOE 纤维<|>RELATION_NOE 组织细胞瘤<|>RELATION_NOE (<|>RELATION_NOE MFH<|>RELATION_NOE )<|>RELATION_NOE 术后肺<|>RELATION_NOE 转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 短期<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE MFH<|>RELATION_NOE 术后<|>RELATION_NOE 肺转移瘤<|>RELATION_NOE 患者<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 28<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE cT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 肿瘤<|>RELATION_NOE 内<|>RELATION_NOE 放射性<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE ,<|>RELATION_NOE 处方<|>RELATION_NOE 剂量<|>RELATION_NOE 80Gy<|>RELATION_NOE ,<|>RELATION_NOE 粒子<|>RELATION_NOE 活度<|>RELATION_NOE 0.7mCi<|>RELATION_NOE (<|>RELATION_NOE 2.59<|>RELATION_NOE ×<|>RELATION_NOE 107Bq<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 及<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 在<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 手术<|>RELATION_NOE 前后<|>RELATION_NOE 及<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
探讨<|>RELATION_S 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 在<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 手术<|>RELATION_NOE 前后<|>RELATION_NOE 及<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 肺转移<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 患者<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 甲状腺<|>RELATION_NOE 组织<|>RELATION_NOE 结构<|>RELATION_NOE 及<|>RELATION_NOE 功能<|>RELATION_NOE 正常者<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 检测<|>RELATION_S 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 及<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE ,<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 肺转移<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 患者<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 甲状腺<|>RELATION_NOE 组织<|>RELATION_NOE 结构<|>RELATION_NOE 及<|>RELATION_NOE 功能<|>RELATION_NOE 正常者<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 及<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE ,<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 血清<|>RELATION_NOE 甲状腺<|>RELATION_NOE 球<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE SPSS13.0<|>RELATION_NOE 统计学<|>RELATION_NOE 软件<|>RELATION_NOE 包<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 计量<|>RELATION_NOE 资料<|>RELATION_NOE 数据<|>RELATION_NOE 比较<|>RELATION_NOE 应用<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE ,<|>RELATION_NOE VEGF<|>RELATION_NOE 、<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 与<|>RELATION_NOE 甲状腺<|>RELATION_NOE 球<|>RELATION_NOE 蛋白<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 采用<|>RELATION_NOE Peamon<|>RELATION_NOE 等级<|>RELATION_NOE 相关<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
局部<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE 手术<|>RELATION_NOE 前<|>RELATION_NOE VEGF<|>RELATION_NOE 、<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE 9.4<|>RELATION_NOE ±<|>RELATION_NOE 56.3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 35.2<|>RELATION_NOE ±<|>RELATION_NOE 6.8<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE 9.3<|>RELATION_NOE ±<|>RELATION_NOE 36.7<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 25.7<|>RELATION_NOE ±<|>RELATION_NOE 4.7<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 406.5<|>RELATION_NOE ±<|>RELATION_NOE 59.2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 31.2<|>RELATION_NOE ±<|>RELATION_NOE 7.6<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 组内<|>RELATION_NOE 比较<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 手术<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 组间<|>RELATION_NOE 比较<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
VEGF<|>RELATION_NOE 、<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 在<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 术前<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 评估<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 项<|>RELATION_NOE 重要<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 对<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 断层<|>RELATION_NOE 显像<|>RELATION_NOE 阳性<|>RELATION_NOE 肺结节<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE 回顾性研究<|>RELATION_S
探寻<|>RELATION_NOE CT<|>RELATION_NOE 影像学<|>RELATION_NOE 特征<|>RELATION_NOE 能否<|>RELATION_NOE 帮助<|>RELATION_NOE 鉴别<|>RELATION_S 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 断层<|>RELATION_NOE 显像<|>RELATION_NOE (<|>RELATION_NOE PET<|>RELATION_NOE )<|>RELATION_NOE 阳性<|>RELATION_NOE 肺部<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE 及<|>RELATION_NOE 良性<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 。<|>RELATION_NOE
2005年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 2月<|>RELATION_NOE 间<|>RELATION_NOE 93<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 病理学<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 术前<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 及<|>RELATION_NOE PET<|>RELATION_NOE 影像学<|>RELATION_NOE 特征<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 得出<|>RELATION_NOE 对<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 印象性<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 影像学<|>RELATION_NOE 特征<|>RELATION_NOE 行<|>RELATION_NOE 多<|>RELATION_NOE 元<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 。<|>RELATION_NOE
神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 诊疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 价值<|>RELATION_E
SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_NOE 是<|>RELATION_NOE 患者<|>RELATION_NOE 总<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 分期<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 血清<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
NSE<|>RELATION_NOE 是<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 评估<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 理想<|>RELATION_B 肿瘤标记物<|>RELATION_E 。<|>RELATION_NOE
内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 在<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
探讨<|>RELATION_S 内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 在<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
102<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 恶性<|>RELATION_NOE 胸膜<|>RELATION_NOE 间皮瘤<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 恶性淋巴瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 结核性<|>RELATION_NOE 胸膜炎<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜炎性<|>RELATION_NOE 反应<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 结节病<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 未能<|>RELATION_NOE 确诊<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 异常<|>RELATION_NOE 4例<|>RELATION_NOE 。<|>RELATION_NOE
内科<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 对于<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 易<|>RELATION_NOE 操作<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 在<|>RELATION_NOE 直视<|>RELATION_NOE 下<|>RELATION_NOE 取<|>RELATION_NOE 到<|>RELATION_NOE 理想<|>RELATION_NOE 的<|>RELATION_NOE 胸膜<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_S 诊断<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 。<|>RELATION_NOE
肺功能<|>RELATION_NOE 综合<|>RELATION_NOE 评分<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 风险<|>RELATION_NOE 预测<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_B 探讨<|>RELATION_E
将<|>RELATION_NOE 其中<|>RELATION_NOE 术后<|>RELATION_NOE 发生<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 的<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其余<|>RELATION_NOE 同期<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 无<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 的<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 发现<|>RELATION_NOE 观察组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 在<|>RELATION_NOE 肺功能<|>RELATION_NOE 单项<|>RELATION_NOE 指标<|>RELATION_NOE 肺<|>RELATION_NOE 一氧化碳<|>RELATION_NOE 弥散量<|>RELATION_NOE 占<|>RELATION_NOE 预计<|>RELATION_NOE 值<|>RELATION_NOE 百分比<|>RELATION_NOE (<|>RELATION_NOE DLC0<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 摄氧量<|>RELATION_NOE 占<|>RELATION_NOE 预计<|>RELATION_NOE 值<|>RELATION_NOE 百分比<|>RELATION_NOE (<|>RELATION_NOE VOh2max<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 静息<|>RELATION_NOE 与<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 运动<|>RELATION_NOE 时<|>RELATION_NOE 经<|>RELATION_NOE 皮侧<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 差值<|>RELATION_NOE (<|>RELATION_NOE △<|>RELATION_NOE SaO2<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 肺段数<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 的<|>RELATION_NOE 肺功能<|>RELATION_NOE 综合<|>RELATION_NOE 评分为<|>RELATION_NOE (<|>RELATION_NOE 6.2<|>RELATION_NOE ±<|>RELATION_NOE 1.7<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 9.<|>RELATION_NOE 6士<|>RELATION_NOE 2.2<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 体质<|>RELATION_NOE 指数<|>RELATION_NOE 、<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 失<|>RELATION_NOE 血量<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 及<|>RELATION_NOE 第1<|>RELATION_NOE 秒<|>RELATION_NOE 用力<|>RELATION_NOE 呼气<|>RELATION_NOE 容积<|>RELATION_NOE 占<|>RELATION_NOE 预计<|>RELATION_NOE 值<|>RELATION_NOE 百分比<|>RELATION_NOE (<|>RELATION_NOE FEV<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 发生<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE 是<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE ,<|>RELATION_NOE DLC0<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE VO2max<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE ASaO2<|>RELATION_NOE %<|>RELATION_NOE 及<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 肺段数<|>RELATION_NOE 是<|>RELATION_NOE 其<|>RELATION_NOE 主要<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 术前<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 肺功能<|>RELATION_NOE 综合<|>RELATION_NOE 评分<|>RELATION_NOE 对<|>RELATION_NOE 预测术<|>RELATION_NOE 后<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 发生<|>RELATION_NOE 风险<|>RELATION_NOE 具有<|>RELATION_B 重要<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
PET-CT<|>RELATION_NOE 和<|>RELATION_NOE CT<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 射频<|>RELATION_NOE 消融术<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 价值<|>RELATION_E
参<|>RELATION_NOE 麦<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 对<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_S 参麦<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 对<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
参麦<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 提高<|>RELATION_S 机体<|>RELATION_NOE 免疫力<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
凋亡<|>RELATION_NOE 抑制蛋白<|>RELATION_NOE XIAP<|>RELATION_NOE 和<|>RELATION_NOE survivin<|>RELATION_NOE 在<|>RELATION_NOE 良恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 鉴别<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_S
探讨<|>RELATION_S 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE X<|>RELATION_NOE 染色体<|>RELATION_NOE 连锁<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 抑制蛋白<|>RELATION_NOE (<|>RELATION_NOE XIAP<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE survivingmRNA<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 判断<|>RELATION_NOE 良恶性<|>RELATION_NOE 胸水<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE reversetranscription-polymerasechainraction<|>RELATION_NOE ,<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 40<|>RELATION_NOE 例<|>RELATION_NOE 癌性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 标本<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE 结核性<|>RELATION_NOE 胸膜炎<|>RELATION_NOE 和<|>RELATION_NOE 8例<|>RELATION_NOE 心力衰竭<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE XIAPmRNA<|>RELATION_NOE 和<|>RELATION_NOE survivinmRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
胸水<|>RELATION_NOE XIAPmRNA<|>RELATION_NOE 检测<|>RELATION_NOE 联合<|>RELATION_NOE 胸水<|>RELATION_NOE CEA<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 90%<|>RELATION_NOE (<|>RELATION_NOE 36<|>RELATION_NOE /<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胸水<|>RELATION_NOE survivinmRNA<|>RELATION_NOE 检测<|>RELATION_NOE 联合<|>RELATION_NOE 胸水<|>RELATION_NOE CEA<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 80.1%<|>RELATION_NOE (<|>RELATION_NOE 33<|>RELATION_NOE /<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S 单独<|>RELATION_NOE 胸腔积液<|>RELATION_NOE CEA<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胸水<|>RELATION_NOE CEA<|>RELATION_NOE ,<|>RELATION_NOE XIAPmRNA<|>RELATION_NOE 和<|>RELATION_NOE survivinmRNA<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 59.4%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 93.8%<|>RELATION_NOE (<|>RELATION_NOE 30<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE 结核性<|>RELATION_NOE 胸膜炎<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 8例<|>RELATION_NOE 心力衰竭<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 标本<|>RELATION_NOE XIAPmRNA<|>RELATION_NOE 和<|>RELATION_NOE survivinmRNA<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 分别<|>RELATION_NOE 40.6%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 6.3%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胸水<|>RELATION_NOE 中<|>RELATION_NOE XIAPmRNA<|>RELATION_NOE 和<|>RELATION_NOE survivinmRNA<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 良恶性<|>RELATION_NOE 胸水<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 一个<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 进而<|>RELATION_NOE 为<|>RELATION_NOE 鉴别良<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 提供<|>RELATION_B 依据<|>RELATION_E 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 呼<|>RELATION_NOE 出气<|>RELATION_NOE 冷凝液<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S
研究<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE nonsmall-celllungcancer<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 呼<|>RELATION_NOE 出气<|>RELATION_NOE 冷凝液<|>RELATION_NOE (<|>RELATION_NOE exhaledbreathCondensate<|>RELATION_NOE ,<|>RELATION_NOE EBC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE EBC<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE (<|>RELATION_NOE SP<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 对照<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 免疫法<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 60.7%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 60.7%<|>RELATION_NOE 和<|>RELATION_NOE 90.0%<|>RELATION_NOE ,<|>RELATION_NOE EBC<|>RELATION_NOE 中<|>RELATION_NOE 为<|>RELATION_NOE 42.4%<|>RELATION_NOE 和<|>RELATION_NOE 93.4%<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 检测<|>RELATION_NOE 途径<|>RELATION_NOE 无<|>RELATION_NOE 显著性<|>RELATION_NOE 差异<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE EBC<|>RELATION_NOE 中<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_B 用于<|>RELATION_E 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 病情<|>RELATION_NOE 监测<|>RELATION_NOE 。<|>RELATION_NOE
赖氨酸<|>RELATION_NOE 氧化酶<|>RELATION_NOE 下调<|>RELATION_NOE 对<|>RELATION_NOE 乏氧<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 迁移<|>RELATION_NOE 和<|>RELATION_NOE E-<|>RELATION_NOE 钙黏素<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
应用<|>RELATION_NOE 针对<|>RELATION_NOE 人<|>RELATION_NOE LOX<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 转染<|>RELATION_NOE 常氧<|>RELATION_NOE (<|>RELATION_NOE 19%<|>RELATION_NOE 0<|>RELATION_NOE :<|>RELATION_NOE )<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE 将<|>RELATION_NOE 细胞<|>RELATION_NOE 置乏氧<|>RELATION_NOE (<|>RELATION_NOE 0.5%<|>RELATION_NOE O2<|>RELATION_NOE )<|>RELATION_NOE 培养箱<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE 乏氧<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE 采用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE LOXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE 印迹法<|>RELATION_NOE 评价<|>RELATION_NOE LOX<|>RELATION_NOE 和<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏素<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Transwell<|>RELATION_NOE 小室<|>RELATION_NOE 评价<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 迁移<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE 应用<|>RELATION_NOE 针对<|>RELATION_NOE 人<|>RELATION_NOE LOX<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 转染<|>RELATION_NOE 常氧<|>RELATION_NOE (<|>RELATION_NOE 19%<|>RELATION_NOE 0<|>RELATION_NOE :<|>RELATION_NOE )<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE 将<|>RELATION_NOE 细胞<|>RELATION_NOE 置乏氧<|>RELATION_NOE (<|>RELATION_NOE 0.5%<|>RELATION_NOE O2<|>RELATION_NOE )<|>RELATION_NOE 培养箱<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE 乏氧<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE 采用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE LOXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE 印迹法<|>RELATION_NOE 评价<|>RELATION_NOE LOX<|>RELATION_NOE 和<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏素<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Transwell<|>RELATION_NOE 小室<|>RELATION_NOE 评价<|>RELATION_S 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 迁移<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 乏氧<|>RELATION_NOE 对照<|>RELATION_NOE siRNA<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 设定<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE LOXsiRNA<|>RELATION_NOE 转染<|>RELATION_NOE 后<|>RELATION_NOE 乏氧<|>RELATION_NOE NCI-H460<|>RELATION_NOE 细胞<|>RELATION_NOE LOXmRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.24<|>RELATION_NOE ±<|>RELATION_NOE 0.03<|>RELATION_NOE 和<|>RELATION_NOE 0.29<|>RELATION_NOE ±<|>RELATION_NOE 0.03<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭力<|>RELATION_NOE 和<|>RELATION_NOE 迁移力<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.57<|>RELATION_NOE ±<|>RELATION_NOE 0.03<|>RELATION_NOE 和<|>RELATION_NOE 0.49<|>RELATION_NOE ±<|>RELATION_NOE 0.02<|>RELATION_NOE ,<|>RELATION_NOE E-<|>RELATION_NOE 钙黏素<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 为<|>RELATION_NOE 2.17<|>RELATION_NOE ±<|>RELATION_NOE 0.21<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 2006年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 天津<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 17<|>RELATION_NOE 7例<|>RELATION_NOE x<|>RELATION_NOE 线<|>RELATION_NOE 或<|>RELATION_NOE CT<|>RELATION_NOE 怀疑<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 初诊<|>RELATION_NOE 患者<|>RELATION_NOE 行^<|>RELATION_NOE 18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 及<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 片段<|>RELATION_NOE (<|>RELATION_NOE CYFR21-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 1周<|>RELATION_NOE 内<|>RELATION_NOE 完成<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE
^<|>RELATION_NOE 18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 和<|>RELATION_NOE 准确性<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 89.7%<|>RELATION_NOE ,<|>RELATION_NOE 78.1%<|>RELATION_NOE 和<|>RELATION_NOE 87.6%<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 联合<|>RELATION_NOE 诊断<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 82.1%<|>RELATION_NOE ,<|>RELATION_NOE 68.8%<|>RELATION_NOE 和<|>RELATION_NOE 79.7%<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_NOE 诊断<|>RELATION_NOE 分别<|>RELATION_NOE 是<|>RELATION_NOE 96.6%<|>RELATION_NOE ,<|>RELATION_NOE 56.3%<|>RELATION_NOE 和<|>RELATION_NOE 89.3%<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 找到<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 行视力<|>RELATION_NOE 、<|>RELATION_NOE 眼压<|>RELATION_NOE 、<|>RELATION_NOE 裂隙灯<|>RELATION_NOE 显微镜检查<|>RELATION_NOE 及<|>RELATION_NOE 散瞳<|>RELATION_NOE 眼底<|>RELATION_NOE 检查<|>RELATION_NOE 。<|>RELATION_NOE
荧光素<|>RELATION_NOE 眼底<|>RELATION_NOE 血管<|>RELATION_NOE 造影<|>RELATION_NOE (<|>RELATION_NOE FFA<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 吲哚<|>RELATION_NOE 青绿<|>RELATION_NOE 血管<|>RELATION_NOE 造影<|>RELATION_NOE (<|>RELATION_NOE ICGA<|>RELATION_NOE )<|>RELATION_NOE 检查<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 12<|>RELATION_NOE 只<|>RELATION_NOE 眼<|>RELATION_NOE ;<|>RELATION_NOE
玻璃体<|>RELATION_NOE 重度<|>RELATION_NOE 混浊<|>RELATION_NOE ,<|>RELATION_NOE 眼底<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 窥见者<|>RELATION_NOE 4<|>RELATION_NOE 只<|>RELATION_NOE 眼<|>RELATION_NOE 。<|>RELATION_NOE
脉络膜<|>RELATION_NOE 脱离<|>RELATION_NOE 32<|>RELATION_NOE 只<|>RELATION_NOE 眼<|>RELATION_NOE 和<|>RELATION_NOE 睫状体<|>RELATION_NOE 3<|>RELATION_NOE 只<|>RELATION_NOE 眼中<|>RELATION_NOE ,<|>RELATION_NOE 眼底<|>RELATION_NOE 单个<|>RELATION_NOE 病灶<|>RELATION_NOE 26<|>RELATION_NOE 只<|>RELATION_NOE 眼<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 及<|>RELATION_NOE 以上<|>RELATION_NOE 病灶<|>RELATION_NOE 9<|>RELATION_NOE 只<|>RELATION_NOE 眼<|>RELATION_NOE 。<|>RELATION_NOE
睫状体<|>RELATION_NOE 和<|>RELATION_NOE 虹膜<|>RELATION_NOE 转移<|>RELATION_NOE 癌<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 睫状体<|>RELATION_NOE 和<|>RELATION_NOE 虹膜<|>RELATION_NOE 上<|>RELATION_NOE 菜<|>RELATION_NOE 花样<|>RELATION_NOE 肉<|>RELATION_NOE 红色<|>RELATION_NOE 或<|>RELATION_NOE 灰白色<|>RELATION_NOE 肿物<|>RELATION_NOE ,<|>RELATION_NOE 表面<|>RELATION_NOE 呈<|>RELATION_NOE 不规则<|>RELATION_NOE 形<|>RELATION_NOE ,<|>RELATION_NOE 肿物<|>RELATION_NOE 内<|>RELATION_NOE 血管<|>RELATION_NOE 丰富<|>RELATION_NOE 。<|>RELATION_NOE
脉络膜<|>RELATION_NOE 转移<|>RELATION_NOE 癌<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 眼底<|>RELATION_NOE 后极部<|>RELATION_NOE 不规则<|>RELATION_NOE 形<|>RELATION_NOE 、<|>RELATION_NOE 圆形<|>RELATION_NOE 灰黄色<|>RELATION_NOE 或<|>RELATION_NOE 灰白<|>RELATION_NOE 色扁<|>RELATION_NOE 平隆<|>RELATION_NOE 起<|>RELATION_NOE 肿物<|>RELATION_NOE ;<|>RELATION_NOE
优质<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 本院<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_S 外科<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 将<|>RELATION_NOE 本院<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 外科<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_S 优质<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 的<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 满意度<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE
观察组<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE 在<|>RELATION_NOE 总体<|>RELATION_NOE 健康<|>RELATION_NOE 、<|>RELATION_NOE 躯体<|>RELATION_NOE 疼痛<|>RELATION_NOE 、<|>RELATION_NOE 活力<|>RELATION_NOE 等<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 优于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
优质<|>RELATION_NOE 护理<|>RELATION_NOE 能够<|>RELATION_NOE 显著<|>RELATION_B 改善<|>RELATION_E 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 治疗<|>RELATION_S 复发<|>RELATION_NOE 进展<|>RELATION_NOE 肺腺癌<|>RELATION_NOE
主要<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 为<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 脱发<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 导向<|>RELATION_NOE 经皮<|>RELATION_NOE 切割针<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 活组织检查<|>RELATION_NOE 对<|>RELATION_NOE 肺小<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 不同<|>RELATION_NOE 治疗<|>RELATION_NOE 手段<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE 及<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_B 研究<|>RELATION_E
探讨<|>RELATION_NOE 不同<|>RELATION_NOE 治疗<|>RELATION_NOE 手段<|>RELATION_NOE 的<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 分别<|>RELATION_NOE 进行<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE (<|>RELATION_NOE ProGRP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 评价<|>RELATION_S 治疗效果<|>RELATION_NOE 与<|>RELATION_NOE 标志<|>RELATION_NOE 物<|>RELATION_NOE 血清<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 电化学发光<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE 3组<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE ProGRP<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 进行<|>RELATION_B 联合<|>RELATION_I 检测<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 数据<|>RELATION_NOE 整理<|>RELATION_NOE 和<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE Survivin<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 机制<|>RELATION_NOE
探讨<|>RELATION_S 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE EGF<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE NIC-H446<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 凋亡<|>RELATION_NOE 抑制<|>RELATION_NOE 因子<|>RELATION_NOE Survivin<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 及其<|>RELATION_NOE 调控<|>RELATION_NOE Survivin<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
逆转<|>RELATION_NOE 录<|>RELATION_NOE 一<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 印迹<|>RELATION_NOE (<|>RELATION_NOE Westernblot<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 测定<|>RELATION_S EGF<|>RELATION_NOE 对<|>RELATION_NOE NIC-H446<|>RELATION_NOE 细胞<|>RELATION_NOE Survivin<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 测定<|>RELATION_S EGF<|>RELATION_NOE 对<|>RELATION_NOE NIC-H446<|>RELATION_NOE 细胞<|>RELATION_NOE p38<|>RELATION_NOE 丝<|>RELATION_NOE 裂原<|>RELATION_NOE 活化激酶<|>RELATION_NOE (<|>RELATION_NOE p38MAPK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 磷酸化<|>RELATION_NOE p38MAPK<|>RELATION_NOE (<|>RELATION_NOE p-p38MAPK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE c-Jun<|>RELATION_NOE 氨基端<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE JNK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 磷酸化<|>RELATION_NOE JNK<|>RELATION_NOE (<|>RELATION_NOE p-JNK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 外<|>RELATION_NOE 信号<|>RELATION_NOE 调节<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE ERK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 磷酸化<|>RELATION_NOE ERK<|>RELATION_NOE (<|>RELATION_NOE p-ERK<|>RELATION_NOE )<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
EGF<|>RELATION_NOE +<|>RELATION_NOE SB203580<|>RELATION_NOE 组<|>RELATION_NOE Survivin<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.56<|>RELATION_NOE ±<|>RELATION_NOE 0.17<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE p-p38MAPK<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.41<|>RELATION_NOE ±<|>RELATION_NOE 0.11<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E EGF<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 0.92<|>RELATION_NOE ±<|>RELATION_NOE 0.21<|>RELATION_NOE 、<|>RELATION_NOE 0.72<|>RELATION_NOE ±<|>RELATION_NOE 0.19<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
EGF<|>RELATION_NOE 通过<|>RELATION_NOE 活化<|>RELATION_NOE p38MAPK<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 上调<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 中<|>RELATION_NOE Survivin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 促进<|>RELATION_S 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 发展<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
伊立<|>RELATION_NOE 替康<|>RELATION_NOE 治疗<|>RELATION_S 27<|>RELATION_NOE 例<|>RELATION_NOE 结肠癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 体会<|>RELATION_NOE
毒性<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 为<|>RELATION_NOE 腹泻<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 22.2<|>RELATION_NOE 2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 37.04%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 急性<|>RELATION_NOE 胆碱<|>RELATION_NOE 能<|>RELATION_NOE 综合征<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 25.9<|>RELATION_NOE 2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 66.6<|>RELATION_NOE 7%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
伊立<|>RELATION_NOE 替康<|>RELATION_NOE 双<|>RELATION_NOE 周<|>RELATION_NOE 疗法<|>RELATION_NOE 对于<|>RELATION_NOE 结肠癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 治疗无效<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 疗效<|>RELATION_NOE 确切<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 其<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体4<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 及其<|>RELATION_NOE 脑转<|>RELATION_NOE 移癌<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 和<|>RELATION_I 意义<|>RELATION_E
检测<|>RELATION_S 趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体4<|>RELATION_NOE (<|>RELATION_NOE CXCR4<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 及其<|>RELATION_NOE 脑转移<|>RELATION_NOE 癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 41<|>RELATION_NOE 例<|>RELATION_NOE 肺源<|>RELATION_NOE 性脑<|>RELATION_NOE 转移<|>RELATION_NOE 癌组织<|>RELATION_NOE 、<|>RELATION_NOE 16<|>RELATION_NOE 例源性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE CXCR4<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE CD34<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
脑转移<|>RELATION_NOE 癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺原<|>RELATION_NOE 发灶<|>RELATION_NOE 。<|>RELATION_NOE
DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S 华法林<|>RELATION_NOE 用药<|>RELATION_NOE 剂量<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE
评估<|>RELATION_B 分析<|>RELATION_E DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_NOE 华法林<|>RELATION_NOE 用药<|>RELATION_NOE 剂量<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE ——<|>RELATION_NOE 细胞<|>RELATION_NOE 色素<|>RELATION_NOE 氧化酶<|>RELATION_NOE P4502C9<|>RELATION_NOE (<|>RELATION_NOE CYP2C9<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 维生素<|>RELATION_NOE K<|>RELATION_NOE 环氧化物<|>RELATION_NOE 还原<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE VKORCl<|>RELATION_NOE )<|>RELATION_NOE 多态性<|>RELATION_NOE 指导<|>RELATION_NOE 华法林<|>RELATION_NOE 临床<|>RELATION_NOE 用药<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 7月<|>RELATION_NOE 武汉<|>RELATION_NOE 大学<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 肿瘤科<|>RELATION_NOE 使用<|>RELATION_NOE 华法林<|>RELATION_NOE 经<|>RELATION_NOE 影像学<|>RELATION_NOE 和<|>RELATION_NOE 病理学<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 140<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 检测<|>RELATION_NOE CYP2C9<|>RELATION_NOE 和<|>RELATION_NOE VKORCI<|>RELATION_NOE 基因<|>RELATION_NOE 且<|>RELATION_NOE 使用<|>RELATION_NOE 华法林<|>RELATION_NOE (<|>RELATION_NOE 试验组<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 检测2<|>RELATION_NOE 个<|>RELATION_NOE 基因<|>RELATION_NOE 采取<|>RELATION_NOE 经验<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 分为<|>RELATION_NOE 2<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 已<|>RELATION_NOE 知<|>RELATION_NOE CYP2C9<|>RELATION_NOE 和<|>RELATION_NOE VKORCl<|>RELATION_NOE 基因<|>RELATION_NOE 序列<|>RELATION_NOE ,<|>RELATION_NOE 设计<|>RELATION_NOE 针对<|>RELATION_NOE CYP2C9<|>RELATION_NOE 和<|>RELATION_NOE VKORCl<|>RELATION_NOE 基因<|>RELATION_NOE 多<|>RELATION_NOE 态<|>RELATION_NOE 性位点<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 引物<|>RELATION_NOE ,<|>RELATION_NOE PCR<|>RELATION_NOE 扩增<|>RELATION_NOE 包含<|>RELATION_NOE CYP2C9<|>RELATION_NOE 和<|>RELATION_NOE VKORCl<|>RELATION_NOE 基因<|>RELATION_NOE 多<|>RELATION_NOE 态<|>RELATION_NOE 性位点<|>RELATION_NOE 的<|>RELATION_NOE DNA<|>RELATION_NOE 片段<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 验证<|>RELATION_NOE ;<|>RELATION_NOE
PCR<|>RELATION_NOE 产物<|>RELATION_NOE 凝胶<|>RELATION_NOE 电泳<|>RELATION_NOE 和<|>RELATION_NOE DNA<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 针对<|>RELATION_NOE CYP2C9<|>RELATION_NOE 和<|>RELATION_NOE VKORCl<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 引物<|>RELATION_NOE 可<|>RELATION_NOE 鉴别<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 基因型<|>RELATION_NOE (<|>RELATION_NOE CYP2C9<|>RELATION_NOE $<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE CYP2C9<|>RELATION_NOE $<|>RELATION_NOE 2<|>RELATION_NOE 和<|>RELATION_NOE CYP2C9<|>RELATION_NOE $<|>RELATION_NOE 3<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 基因型<|>RELATION_NOE 检测<|>RELATION_NOE 指导<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE INR<|>RELATION_NOE 值<|>RELATION_NOE 85.7%<|>RELATION_NOE 在<|>RELATION_NOE 第2<|>RELATION_NOE 周<|>RELATION_NOE 达到<|>RELATION_NOE 目标<|>RELATION_NOE 治疗<|>RELATION_NOE 范围<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 48.6%<|>RELATION_NOE ,<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 21.9<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
第4<|>RELATION_NOE 周<|>RELATION_NOE 试验组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE INR<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE 达到<|>RELATION_NOE 目标<|>RELATION_NOE 治疗<|>RELATION_NOE 范围<|>RELATION_NOE (<|>RELATION_NOE 100%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 65<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE INR<|>RELATION_NOE 值<|>RELATION_NOE 达到<|>RELATION_NOE 目标<|>RELATION_NOE 治疗<|>RELATION_NOE 范围<|>RELATION_NOE (<|>RELATION_NOE 92.9%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
但<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 发生<|>RELATION_NOE 出血<|>RELATION_NOE 和<|>RELATION_NOE 血栓<|>RELATION_NOE 形成<|>RELATION_NOE 事件<|>RELATION_NOE 。<|>RELATION_NOE
设计<|>RELATION_NOE 针对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 华法林<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 引物<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE PCR<|>RELATION_NOE 扩增<|>RELATION_NOE 及<|>RELATION_NOE DNA<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 分析<|>RELATION_NOE 能<|>RELATION_NOE 快速<|>RELATION_NOE 、<|>RELATION_NOE 准确<|>RELATION_NOE 有效<|>RELATION_NOE 检测<|>RELATION_NOE CYP2C9<|>RELATION_NOE 和<|>RELATION_NOE VKORC1<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE ,<|>RELATION_NOE 可靠<|>RELATION_NOE 地<|>RELATION_NOE 指导<|>RELATION_NOE 华法林<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 使用<|>RELATION_NOE .<|>RELATION_NOE
贝伐<|>RELATION_NOE 单抗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 转移性<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
42<|>RELATION_NOE 例<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE CR<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 稳定<|>RELATION_NOE (<|>RELATION_NOE SD<|>RELATION_NOE )<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 进展<|>RELATION_NOE (<|>RELATION_NOE PD<|>RELATION_NOE )<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 51.9%<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE /<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 66.7%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
可能<|>RELATION_NOE 与<|>RELATION_NOE 贝伐<|>RELATION_NOE 单抗<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE :<|>RELATION_NOE 59<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 3级<|>RELATION_NOE 咯血<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 3级<|>RELATION_NOE 血栓栓塞<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 常见<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 或<|>RELATION_NOE 2级<|>RELATION_NOE 的<|>RELATION_NOE 鼻出血<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE 、<|>RELATION_NOE 高血压<|>RELATION_NOE 、<|>RELATION_NOE 蛋白尿<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 程度<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE 患者<|>RELATION_NOE 可以<|>RELATION_NOE 耐受<|>RELATION_NOE 。<|>RELATION_NOE
1例<|>RELATION_NOE 右上<|>RELATION_NOE 叶<|>RELATION_NOE 支气管<|>RELATION_NOE 袖形<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 半<|>RELATION_NOE 年<|>RELATION_NOE 因<|>RELATION_NOE 吻<|>RELATION_NOE 合口<|>RELATION_NOE 瘢痕<|>RELATION_NOE 增生<|>RELATION_NOE 导致<|>RELATION_NOE 右余<|>RELATION_NOE 肺不张<|>RELATION_NOE 而<|>RELATION_NOE 行右<|>RELATION_NOE 余<|>RELATION_NOE 肺切除术<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 根治<|>RELATION_NOE 程度<|>RELATION_NOE 和<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独寺<|>RELATION_NOE 预测<|>RELATION_NOE 因子<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 改良<|>RELATION_NOE 的<|>RELATION_NOE 颈胸<|>RELATION_NOE 前<|>RELATION_NOE 入<|>RELATION_NOE 路<|>RELATION_NOE 治疗<|>RELATION_S 肺上沟瘤<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 2005年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 3例<|>RELATION_NOE 肺上沟瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 改良<|>RELATION_NOE 的<|>RELATION_NOE 颈胸<|>RELATION_NOE 前<|>RELATION_NOE 入<|>RELATION_NOE 路<|>RELATION_NOE 切口<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 第1<|>RELATION_NOE －3<|>RELATION_NOE 肋骨<|>RELATION_NOE 全部<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 切除<|>RELATION_NOE 1/5<|>RELATION_NOE 椎体<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 胸椎<|>RELATION_NOE 横<|>RELATION_NOE 突<|>RELATION_NOE 切除<|>RELATION_NOE I<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 胸椎<|>RELATION_NOE 横<|>RELATION_NOE 突<|>RELATION_NOE 切除<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 胸1<|>RELATION_NOE 神经根<|>RELATION_NOE 及<|>RELATION_NOE 星状神经节<|>RELATION_NOE 切除<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
3例<|>RELATION_NOE 患者<|>RELATION_NOE 于<|>RELATION_NOE 术后<|>RELATION_NOE 换<|>RELATION_NOE 药<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 见<|>RELATION_NOE 有<|>RELATION_NOE 轻度<|>RELATION_NOE 反常<|>RELATION_NOE 呼吸<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 无<|>RELATION_NOE 呼吸困难<|>RELATION_NOE ,<|>RELATION_NOE 耐<|>RELATION_NOE 受<|>RELATION_NOE 良好<|>RELATION_NOE ,<|>RELATION_NOE 继续<|>RELATION_NOE 胸壁<|>RELATION_NOE 加压<|>RELATION_NOE 包扎<|>RELATION_NOE 14d<|>RELATION_NOE 后<|>RELATION_NOE 等待<|>RELATION_NOE 纵隔<|>RELATION_NOE 固定<|>RELATION_NOE ,<|>RELATION_NOE 反常<|>RELATION_NOE 呼吸<|>RELATION_NOE 消失<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE :<|>RELATION_NOE 鳞癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 切缘<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE
VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE CD24<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
采用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 138<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE CD24<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE CD24mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE CD24mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达量<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE CD24<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 间<|>RELATION_NOE 有<|>RELATION_B 明显<|>RELATION_I 相关性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE CD24<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE Ⅲ<|>RELATION_NOE A<|>RELATION_NOE 期<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 短期<|>RELATION_NOE 预后<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 两者<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 无病生存<|>RELATION_NOE 时间<|>RELATION_NOE 呈<|>RELATION_NOE 负<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE
VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE CD24<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 异常<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 标志物<|>RELATION_NOE 。<|>RELATION_NOE
脂质体<|>RELATION_NOE 紫杉<|>RELATION_NOE 醇周<|>RELATION_NOE 疗法<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 25<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_S 脂质体<|>RELATION_NOE 紫杉<|>RELATION_NOE 醇周<|>RELATION_NOE 疗法<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
25<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 脂质体<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 60mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 8<|>RELATION_NOE ,<|>RELATION_NOE 15<|>RELATION_NOE 顺铂<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 21<|>RELATION_NOE 天<|>RELATION_NOE 1<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 4.6<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 周<|>RELATION_NOE 疗法<|>RELATION_NOE 是<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 进一步<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
腹腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_S 腹腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 手术<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 和<|>RELATION_NOE 地位<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 1997年<|>RELATION_NOE 1月<|>RELATION_NOE 到<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 肇庆市<|>RELATION_NOE 第一<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科行<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 152<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 103<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
所<|>RELATION_NOE 患<|>RELATION_NOE 胸部<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 构成<|>RELATION_NOE 特点<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 102<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE stage<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE stagema<|>RELATION_NOE 期<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 肺大疱<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺良<|>RELATION_NOE 性肿物<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 7例<|>RELATION_NOE 。<|>RELATION_NOE
尝试<|>RELATION_NOE 用<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 系统<|>RELATION_NOE 、<|>RELATION_NOE 部分<|>RELATION_NOE 内镜<|>RELATION_NOE 器械<|>RELATION_NOE 及<|>RELATION_NOE 普通<|>RELATION_NOE 的<|>RELATION_NOE 开胸<|>RELATION_NOE 器械<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 即<|>RELATION_NOE 在<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 操作<|>RELATION_NOE 时<|>RELATION_NOE 做<|>RELATION_NOE 一<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 将<|>RELATION_NOE 手指<|>RELATION_NOE 或<|>RELATION_NOE 一<|>RELATION_NOE 只<|>RELATION_NOE 手伸人<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 协助<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 操作<|>RELATION_NOE 器械<|>RELATION_NOE 作<|>RELATION_NOE 探查<|>RELATION_NOE 、<|>RELATION_NOE 解剖<|>RELATION_NOE 分离<|>RELATION_NOE 、<|>RELATION_NOE 切割<|>RELATION_NOE 或<|>RELATION_NOE 钳夹<|>RELATION_NOE 等<|>RELATION_NOE 操作<|>RELATION_NOE ,<|>RELATION_NOE 来<|>RELATION_NOE 完成<|>RELATION_NOE 一些<|>RELATION_NOE 较<|>RELATION_NOE 复杂<|>RELATION_NOE 的<|>RELATION_NOE 腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
合并<|>RELATION_NOE 部分<|>RELATION_NOE 心房<|>RELATION_NOE 切除<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE 102<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
颈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 阴性<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 术前<|>RELATION_NOE 中央区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_B 因素<|>RELATION_I 分析<|>RELATION_E
探讨<|>RELATION_S 颈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 阴性<|>RELATION_NOE (<|>RELATION_NOE eN0<|>RELATION_NOE )<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 癌术<|>RELATION_NOE 前<|>RELATION_NOE 中央区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
进一步<|>RELATION_NOE 分别<|>RELATION_NOE 取<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径5<|>RELATION_NOE 、<|>RELATION_NOE 6.7<|>RELATION_NOE 及<|>RELATION_NOE 8mm<|>RELATION_NOE 为<|>RELATION_NOE 截断值<|>RELATION_NOE 进行<|>RELATION_NOE 分层<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 结果<|>RELATION_NOE 发现<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE I<|>RELATION_NOE ><|>RELATION_NOE 5mm<|>RELATION_NOE 者术<|>RELATION_NOE 前<|>RELATION_NOE 中央区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE 为<|>RELATION_NOE 38.5%<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE <<|>RELATION_NOE 5mm<|>RELATION_NOE 者术<|>RELATION_NOE 前<|>RELATION_NOE 中央区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE 为<|>RELATION_NOE 4.3%<|>RELATION_NOE (<|>RELATION_NOE 1/23<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE :<|>RELATION_NOE 0.006<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
cNn<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 具有<|>RELATION_S 一定<|>RELATION_NOE 的<|>RELATION_NOE 术前<|>RELATION_NOE 中央区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE ≥<|>RELATION_NOE 5mm<|>RELATION_NOE 的<|>RELATION_NOE cN0<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 癌术<|>RELATION_NOE 前<|>RELATION_NOE 中央区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 应行<|>RELATION_NOE 中央区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 。<|>RELATION_NOE
神经丝<|>RELATION_NOE 蛋白<|>RELATION_NOE 轻链<|>RELATION_NOE 多肽<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
链菌<|>RELATION_NOE 素抗<|>RELATION_NOE 生物素<|>RELATION_NOE 蛋白<|>RELATION_NOE 一<|>RELATION_NOE 过氧化物酶<|>RELATION_NOE (<|>RELATION_NOE SP<|>RELATION_NOE )<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 108<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE NEFL<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 108<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 观察<|>RELATION_NOE 。<|>RELATION_NOE
NEFL<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 在<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 阳性<|>RELATION_NOE 和<|>RELATION_NOE 阴性<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 9.4%<|>RELATION_NOE 和<|>RELATION_NOE 32.7%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE x20.25.t<|>RELATION_NOE =<|>RELATION_NOE 8.74<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤分期<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE
NEFL<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_B 关系<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE
TTF-1<|>RELATION_NOE 在<|>RELATION_NOE I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 与<|>RELATION_NOE 预后<|>RELATION_NOE
探讨<|>RELATION_S 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE TTF-1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 及其<|>RELATION_NOE 预后<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 129<|>RELATION_NOE 例<|>RELATION_NOE I<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE TTF-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE TTF-1<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.005<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 预后<|>RELATION_I 因素<|>RELATION_E 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 与<|>RELATION_NOE 结缔组织<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 自身<|>RELATION_NOE 抗体<|>RELATION_NOE 特点<|>RELATION_NOE 比较<|>RELATION_S
探讨<|>RELATION_S 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 结缔组织<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 抗核抗体<|>RELATION_NOE 谱<|>RELATION_NOE (<|>RELATION_NOE ANAs<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 类风湿因子<|>RELATION_NOE (<|>RELATION_NOE RF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表现<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫印迹法<|>RELATION_NOE 检测<|>RELATION_NOE ANAs<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 散射<|>RELATION_NOE 比浊法<|>RELATION_NOE 检测<|>RELATION_S RF<|>RELATION_NOE ,<|>RELATION_NOE 对照<|>RELATION_NOE 分析<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 结缔组织<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 血清<|>RELATION_NOE ANAs<|>RELATION_NOE 、<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE ANAs<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE [<|>RELATION_NOE 46.7%<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE /<|>RELATION_NOE 90<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE [<|>RELATION_NOE 8.3%<|>RELATION_NOE (<|>RELATION_NOE 3/36<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 70<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 抗核抗体<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE [<|>RELATION_NOE 64.4%<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE
结缔组织<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE ANAs<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE [<|>RELATION_NOE 66.0%<|>RELATION_NOE (<|>RELATION_NOE 33<|>RELATION_NOE /<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 各<|>RELATION_NOE 年龄组<|>RELATION_NOE 间<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
结缔组织<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE RF<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 高于<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
ANAs<|>RELATION_NOE 不<|>RELATION_B 能<|>RELATION_I 用于<|>RELATION_I 鉴别<|>RELATION_E 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 结缔组织<|>RELATION_NOE 疾病<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 人群<|>RELATION_NOE 。<|>RELATION_NOE
首发<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 多<|>RELATION_NOE 为<|>RELATION_NOE 肺<|>RELATION_NOE (<|>RELATION_NOE 41.1%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 鼻<|>RELATION_NOE (<|>RELATION_NOE 38.2%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 眼(<|>RELATION_NOE 11.7%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 头痛<|>RELATION_NOE (<|>RELATION_NOE 11.7%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 耳<|>RELATION_NOE (<|>RELATION_NOE 8.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 非特异<|>RELATION_NOE 症状<|>RELATION_NOE 如<|>RELATION_NOE 发热<|>RELATION_NOE (<|>RELATION_NOE 26.4%<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 亦<|>RELATION_NOE 不少<|>RELATION_NOE 见<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 入院<|>RELATION_NOE 前<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肺结核<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺脓肿<|>RELATION_NOE ,<|>RELATION_NOE 误诊率<|>RELATION_NOE 为<|>RELATION_NOE 20.5%<|>RELATION_NOE ;<|>RELATION_NOE
人院<|>RELATION_NOE 后<|>RELATION_NOE 给予<|>RELATION_NOE 激素<|>RELATION_NOE 和<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 正规<|>RELATION_NOE 诱导<|>RELATION_NOE 缓解<|>RELATION_NOE 及<|>RELATION_NOE 维持<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 难<|>RELATION_NOE 治型<|>RELATION_NOE 给予<|>RELATION_NOE 血浆置换<|>RELATION_NOE 、<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE 丙种球<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE IVIG<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 抗<|>RELATION_NOE CD20<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE 利<|>RELATION_NOE 妥昔<|>RELATION_NOE 单抗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 疗效<|>RELATION_NOE 好<|>RELATION_NOE 。<|>RELATION_NOE
康莱特<|>RELATION_NOE 注射液<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 康莱特<|>RELATION_NOE 注射液<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
康莱特<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 减轻<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 保护<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 富集<|>RELATION_NOE 液相<|>RELATION_NOE 芯片<|>RELATION_NOE 检测<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 建立<|>RELATION_S
建立<|>RELATION_S 灵敏<|>RELATION_NOE 、<|>RELATION_NOE 特异<|>RELATION_NOE 、<|>RELATION_NOE 简便易行<|>RELATION_NOE 、<|>RELATION_NOE 高通量<|>RELATION_NOE 血浆<|>RELATION_NOE 检测<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 热点<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 富集<|>RELATION_NOE 液相<|>RELATION_NOE 芯片法<|>RELATION_NOE (<|>RELATION_NOE MEL<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
设计<|>RELATION_S EGFR<|>RELATION_NOE 外显子<|>RELATION_NOE 19E746-750<|>RELATION_NOE 缺失<|>RELATION_NOE 和<|>RELATION_NOE 外显子<|>RELATION_NOE 21L858R<|>RELATION_NOE 突变<|>RELATION_NOE 及<|>RELATION_NOE 野生型<|>RELATION_NOE 的<|>RELATION_NOE 特异探针<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 偶联<|>RELATION_NOE 到<|>RELATION_NOE 不同<|>RELATION_NOE 荧光<|>RELATION_NOE 编码<|>RELATION_NOE 微球<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 生物素<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 探针<|>RELATION_NOE 反<|>RELATION_NOE 向<|>RELATION_NOE 序列<|>RELATION_NOE 交叉<|>RELATION_NOE 试验<|>RELATION_NOE 验证<|>RELATION_NOE 探针<|>RELATION_NOE 偶联<|>RELATION_NOE 效果<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 突变<|>RELATION_NOE 富集<|>RELATION_NOE PCR<|>RELATION_NOE 产物<|>RELATION_NOE 互补<|>RELATION_NOE 配对<|>RELATION_NOE 杂交<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 经<|>RELATION_NOE 液相<|>RELATION_NOE 芯片<|>RELATION_NOE 仪<|>RELATION_NOE 检测<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 血浆<|>RELATION_NOE 检测<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE MEL<|>RELATION_NOE 技术<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2008年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 4月<|>RELATION_NOE 在<|>RELATION_NOE 广州<|>RELATION_NOE 医学院<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 201<|>RELATION_NOE 例<|>RELATION_NOE 11IB<|>RELATION_NOE 或<|>RELATION_NOE Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 突变<|>RELATION_NOE 富集<|>RELATION_NOE PCR<|>RELATION_NOE 和<|>RELATION_NOE MEL<|>RELATION_NOE 平行<|>RELATION_NOE 检测<|>RELATION_S EGFR<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 筛选<|>RELATION_NOE 经<|>RELATION_NOE 2种<|>RELATION_NOE 方法<|>RELATION_NOE 鉴定<|>RELATION_NOE 过<|>RELATION_NOE 的<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE PCR<|>RELATION_NOE 产物<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 直接<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 验证<|>RELATION_NOE MEL<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 与<|>RELATION_NOE 特异性<|>RELATION_NOE 。<|>RELATION_NOE
201<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE MEL<|>RELATION_NOE 共<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE EGFR<|>RELATION_NOE 外显子<|>RELATION_NOE 19E746-750<|>RELATION_NOE 缺失<|>RELATION_NOE 和<|>RELATION_NOE 外显子<|>RELATION_NOE 21L858R<|>RELATION_NOE 突变<|>RELATION_NOE 112<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 55.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 突变<|>RELATION_NOE 富集<|>RELATION_NOE PCR<|>RELATION_NOE 检出率<|>RELATION_NOE [<|>RELATION_NOE 58.2%<|>RELATION_NOE (<|>RELATION_NOE 117<|>RELATION_NOE /<|>RELATION_NOE 201<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 3.20<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 符合率<|>RELATION_NOE 为<|>RELATION_NOE 97.5%<|>RELATION_NOE (<|>RELATION_NOE 196<|>RELATION_NOE /<|>RELATION_NOE 201<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 组1<|>RELATION_NOE 、<|>RELATION_NOE 核糖<|>RELATION_NOE 核苷酸<|>RELATION_NOE 还原<|>RELATION_NOE 酶亚<|>RELATION_NOE 单位<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 含铂<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
通过<|>RELATION_NOE 对<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_S 切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 组1<|>RELATION_NOE (<|>RELATION_NOE ERCC1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 核糖<|>RELATION_NOE 核苷酸<|>RELATION_NOE 还原<|>RELATION_NOE 酶亚<|>RELATION_NOE 单位<|>RELATION_NOE (<|>RELATION_NOE RRM1<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE 含铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 中<|>RELATION_NOE 所<|>RELATION_NOE 起<|>RELATION_NOE 的<|>RELATION_NOE 指导<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
80<|>RELATION_NOE 例<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 2周期<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 均<|>RELATION_NOE 用<|>RELATION_NOE 分支<|>RELATION_NOE DNA<|>RELATION_NOE 一<|>RELATION_NOE 液相<|>RELATION_NOE 芯片法<|>RELATION_NOE 检测<|>RELATION_S ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 均<|>RELATION_NOE 采用<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨+<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE GP<|>RELATION_NOE )<|>RELATION_NOE 方案<|>RELATION_NOE ;<|>RELATION_NOE
80<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE :<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 均<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 为<|>RELATION_NOE 80.O<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE ERCC1<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 为<|>RELATION_NOE 60.9%<|>RELATION_NOE ,<|>RELATION_NOE ERCC1<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 50.0%<|>RELATION_NOE ,<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 均<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 4例<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 33.3%<|>RELATION_NOE ,<|>RELATION_NOE 4组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 7.81<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 疗效<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 其他<|>RELATION_NOE 3组<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE 亦<|>RELATION_NOE 高于<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
表达<|>RELATION_NOE 绿色<|>RELATION_NOE 荧光<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 单纯疱疹<|>RELATION_NOE 病毒<|>RELATION_NOE 检测<|>RELATION_S 循环<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 将<|>RELATION_NOE HSV<|>RELATION_NOE ^<|>RELATION_NOE GFP<|>RELATION_NOE 与<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤细胞系<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 观察<|>RELATION_S 表达<|>RELATION_NOE 荧光<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE 、<|>RELATION_NOE 1000<|>RELATION_NOE 和<|>RELATION_NOE 10000<|>RELATION_NOE 个<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE PG<|>RELATION_NOE 细胞<|>RELATION_NOE 加入<|>RELATION_NOE 到<|>RELATION_NOE 2ml<|>RELATION_NOE 全<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 分离液<|>RELATION_NOE 清除<|>RELATION_S 红细胞<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 富集<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE HSV<|>RELATION_NOE ^<|>RELATION_NOE GFP<|>RELATION_NOE 感染<|>RELATION_NOE 收集<|>RELATION_NOE 到<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 确定<|>RELATION_NOE 荧光<|>RELATION_NOE 细胞<|>RELATION_NOE 数量<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S HSV<|>RELATION_NOE ^<|>RELATION_NOE GFP<|>RELATION_NOE 检测<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE HSV<|>RELATION_NOE ^<|>RELATION_NOE GFP<|>RELATION_NOE 检测<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 在<|>RELATION_NOE 仅<|>RELATION_NOE 加入<|>RELATION_NOE 了<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 2ml<|>RELATION_NOE 全<|>RELATION_NOE 血中<|>RELATION_NOE 检测<|>RELATION_NOE 出<|>RELATION_NOE 阳性<|>RELATION_NOE 结果<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 脑放疗<|>RELATION_NOE 联合<|>RELATION_NOE 替<|>RELATION_NOE 莫唑胺<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌脑<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 荟萃<|>RELATION_NOE 分析<|>RELATION_NOE
通过<|>RELATION_NOE 荟萃<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_S 全<|>RELATION_NOE 脑放疗<|>RELATION_NOE (<|>RELATION_NOE WBRT<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 替<|>RELATION_NOE 莫唑胺<|>RELATION_NOE (<|>RELATION_NOE TMZ<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 脑转移<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
比较<|>RELATION_S 外科手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 与<|>RELATION_NOE 同<|>RELATION_NOE 分期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 在<|>RELATION_NOE 流行病学<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 疗效<|>RELATION_NOE 以及<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
排除<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 与<|>RELATION_NOE 腺癌<|>RELATION_NOE 混杂<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 共<|>RELATION_NOE 纳入<|>RELATION_NOE 337<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 298<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
Ⅰ期<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 与<|>RELATION_NOE 同<|>RELATION_NOE 分期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 相比<|>RELATION_NOE 在<|>RELATION_NOE 流行病学<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 特点<|>RELATION_NOE 和<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE 方式<|>RELATION_NOE 方面<|>RELATION_NOE 均<|>RELATION_NOE 具有<|>RELATION_B 特殊性<|>RELATION_E ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 加<|>RELATION_NOE 系统<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 是<|>RELATION_NOE 其<|>RELATION_NOE 首选<|>RELATION_NOE 合理<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 预后<|>RELATION_NOE 良好<|>RELATION_NOE 。<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌术<|>RELATION_NOE 后<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_S 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 因素<|>RELATION_NOE 之间<|>RELATION_NOE 关系<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 术后<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2009年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月经<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 且<|>RELATION_NOE 经过<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 383<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 及<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
突变<|>RELATION_NOE 在<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 以及<|>RELATION_NOE 年龄<|>RELATION_NOE <<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 所<|>RELATION_NOE 占<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 是<|>RELATION_NOE 63.9<|>RELATION_NOE 1%<|>RELATION_NOE 、<|>RELATION_NOE 61.5<|>RELATION_NOE 4%<|>RELATION_NOE 、<|>RELATION_NOE 88.7<|>RELATION_NOE 6%<|>RELATION_NOE 和<|>RELATION_NOE 62.1<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 男性<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 非腺癌<|>RELATION_NOE 及<|>RELATION_NOE 年龄<|>RELATION_NOE ≥<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 6.057-105.560<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE －0.0<|>RELATION_NOE 17<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
19<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 无病生存<|>RELATION_NOE 期<|>RELATION_NOE 分别<|>RELATION_NOE 是<|>RELATION_NOE 15<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 和<|>RELATION_NOE 13<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 0.9<|>RELATION_NOE 62<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 还<|>RELATION_NOE 与<|>RELATION_NOE 切除<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 修复<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE ERCC1<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 抗原<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 及<|>RELATION_NOE Cyril-1<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE x<|>RELATION_NOE 。<|>RELATION_NOE
=<|>RELATION_NOE 5.4<|>RELATION_NOE 36<|>RELATION_NOE －1<|>RELATION_NOE 6.8<|>RELATION_NOE 39<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000-0.023<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ERCCl<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 抗原<|>RELATION_NOE 及<|>RELATION_NOE c<|>RELATION_NOE 咖<|>RELATION_NOE 21.1<|>RELATION_NOE 升高<|>RELATION_NOE 多<|>RELATION_B 见于<|>RELATION_E EGFR<|>RELATION_NOE 野生型<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 升高<|>RELATION_NOE 则<|>RELATION_NOE
EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 在<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 及<|>RELATION_NOE 年龄<|>RELATION_NOE <<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 更<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE 。<|>RELATION_NOE
放射性<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_S 影响<|>RELATION_NOE 放射性<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
三<|>RELATION_NOE 氧化二砷<|>RELATION_NOE 联合<|>RELATION_NOE 动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞<|>RELATION_NOE 治疗<|>RELATION_S 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_S 三<|>RELATION_NOE 氧化二砷<|>RELATION_NOE (<|>RELATION_NOE As2O3<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞<|>RELATION_NOE 对<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
A<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 治疗组<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肝脏<|>RELATION_NOE 原<|>RELATION_NOE 发病<|>RELATION_NOE 灶行<|>RELATION_NOE 周期性<|>RELATION_NOE 肝动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞术<|>RELATION_NOE (<|>RELATION_NOE TACE<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE TACE<|>RELATION_NOE 后<|>RELATION_NOE 3d<|>RELATION_NOE 开始<|>RELATION_NOE 给予<|>RELATION_NOE As2O3<|>RELATION_NOE 持续<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 5h<|>RELATION_NOE (<|>RELATION_NOE 10mg<|>RELATION_NOE /<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 14d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 疗程<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 问<|>RELATION_NOE 隔<|>RELATION_NOE 2<|>RELATION_NOE 周<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 进行<|>RELATION_NOE 3－<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ;<|>RELATION_NOE
观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 、<|>RELATION_NOE 获益率<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 等<|>RELATION_NOE 指标<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 瘤大<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 灶数<|>RELATION_NOE 与<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
As203<|>RELATION_NOE 联合<|>RELATION_NOE 动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 治疗<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_B 治疗<|>RELATION_I 方法<|>RELATION_E 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 在<|>RELATION_NOE 尘肺<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 运用<|>RELATION_S
探讨<|>RELATION_S 采用<|>RELATION_NOE cT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 术<|>RELATION_NOE 诊断<|>RELATION_NOE 尘肺<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 可行性<|>RELATION_NOE 和<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
尘肺<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 110<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 80.9%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 腺癌<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_S 尘肺<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 尘肺<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_NOE 重要<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
纳米<|>RELATION_NOE 与<|>RELATION_NOE 微米<|>RELATION_NOE 二<|>RELATION_NOE 氧化钛<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 毒性<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_S
比较<|>RELATION_S 纳米<|>RELATION_NOE 二<|>RELATION_NOE 氧化钛<|>RELATION_NOE 和<|>RELATION_NOE 微米<|>RELATION_NOE 二<|>RELATION_NOE 氧化钛<|>RELATION_NOE 对<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺<|>RELATION_NOE 上皮细胞<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 毒性作用<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 纳米<|>RELATION_NOE (<|>RELATION_NOE 粒径<|>RELATION_NOE 4nm<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 微米<|>RELATION_NOE (<|>RELATION_NOE 粒径1<|>RELATION_NOE μ<|>RELATION_NOE m<|>RELATION_NOE )<|>RELATION_NOE 二氧化钛<|>RELATION_NOE 处理<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 倒置<|>RELATION_NOE 相差<|>RELATION_NOE 显微镜<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 形态<|>RELATION_NOE ,<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CCK-8<|>RELATION_NOE 和<|>RELATION_NOE 台盼<|>RELATION_NOE 蓝<|>RELATION_NOE 排斥法<|>RELATION_NOE 测定<|>RELATION_S 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 活性<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE
在<|>RELATION_NOE 本<|>RELATION_NOE 实验<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 纳米<|>RELATION_NOE 二<|>RELATION_NOE 氧化钛<|>RELATION_NOE 和<|>RELATION_NOE 微米<|>RELATION_NOE 二<|>RELATION_NOE 氧化钛<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 没有<|>RELATION_B 显示<|>RELATION_E 明显<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 毒性作用<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 131I<|>RELATION_NOE 显像<|>RELATION_NOE 及<|>RELATION_NOE Tg<|>RELATION_NOE 值<|>RELATION_NOE 监测<|>RELATION_NOE ^<|>RELATION_NOE 131I<|>RELATION_NOE 治疗<|>RELATION_S 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 探讨<|>RELATION_NOE
比较<|>RELATION_S ^<|>RELATION_NOE 131I<|>RELATION_NOE 显像肺<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 呈<|>RELATION_NOE 弥漫性<|>RELATION_NOE 摄取<|>RELATION_NOE 和<|>RELATION_NOE 局灶性<|>RELATION_NOE 摄取<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 有效率<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 肺外<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 有效率<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 131I<|>RELATION_NOE 显像<|>RELATION_NOE 结合<|>RELATION_NOE Tg<|>RELATION_NOE 是<|>RELATION_NOE 评价<|>RELATION_NOE DTC<|>RELATION_NOE 肺<|>RELATION_NOE 转移<|>RELATION_NOE ^<|>RELATION_NOE 131I<|>RELATION_NOE 治疗<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 标准<|>RELATION_E ,<|>RELATION_NOE 他<|>RELATION_NOE 异常<|>RELATION_NOE 升高<|>RELATION_NOE 和<|>RELATION_NOE 肺外<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE DTC<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 楔<|>RELATION_NOE 形成<|>RELATION_NOE 形术<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 术中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
回顾性<|>RELATION_B 分析<|>RELATION_E 96<|>RELATION_NOE 例<|>RELATION_NOE 支气管<|>RELATION_NOE 楔<|>RELATION_NOE 形成<|>RELATION_NOE 形术<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 了<|>RELATION_NOE 围手术期<|>RELATION_NOE 病死率<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 残端<|>RELATION_NOE 癌细胞阳<|>RELATION_NOE 性率<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 吻合口瘘<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
96<|>RELATION_NOE 例<|>RELATION_NOE 支气管<|>RELATION_NOE 楔<|>RELATION_NOE 形成<|>RELATION_NOE 形术<|>RELATION_NOE 患者<|>RELATION_NOE 无<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 支气管<|>RELATION_NOE 吻合口瘘<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 7例<|>RELATION_NOE 出现<|>RELATION_NOE 支气管<|>RELATION_NOE 残端<|>RELATION_NOE 癌细胞<|>RELATION_NOE 阳性<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 楔<|>RELATION_NOE 形成<|>RELATION_NOE 形术<|>RELATION_NOE 根治<|>RELATION_NOE 肺癌<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 可行<|>RELATION_NOE 的<|>RELATION_NOE ,<|>RELATION_NOE 不仅<|>RELATION_NOE 能<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 限度<|>RELATION_NOE 地<|>RELATION_NOE 保留<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE ,<|>RELATION_NOE 还<|>RELATION_NOE 能<|>RELATION_NOE 降低<|>RELATION_S 术后<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 为<|>RELATION_NOE 部分<|>RELATION_NOE 肺功能<|>RELATION_NOE 差<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 机会<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 外科<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
外科<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺切除<|>RELATION_NOE 加<|>RELATION_NOE 部分<|>RELATION_NOE 胸壁<|>RELATION_NOE 切除<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 右<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 加隆<|>RELATION_NOE 凸<|>RELATION_NOE 成<|>RELATION_NOE 形<|>RELATION_NOE 6例<|>RELATION_NOE 、<|>RELATION_NOE 左全<|>RELATION_NOE 肺切除<|>RELATION_NOE 加隆<|>RELATION_NOE 凸<|>RELATION_NOE 成<|>RELATION_NOE 形<|>RELATION_NOE 4例<|>RELATION_NOE 、<|>RELATION_NOE 右上<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 加上<|>RELATION_NOE 腔静脉<|>RELATION_NOE 部分<|>RELATION_NOE 置换<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 右<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 加上<|>RELATION_NOE 腔静脉<|>RELATION_NOE 部分<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 成<|>RELATION_NOE 形<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 左全<|>RELATION_NOE 肺切除<|>RELATION_NOE 加<|>RELATION_NOE 主动脉<|>RELATION_NOE 部分<|>RELATION_NOE 切除<|>RELATION_NOE 成形<|>RELATION_NOE 3例<|>RELATION_NOE 、<|>RELATION_NOE 左全<|>RELATION_NOE 肺切除<|>RELATION_NOE 加<|>RELATION_NOE 部分<|>RELATION_NOE 左<|>RELATION_NOE 心房<|>RELATION_NOE 切除<|>RELATION_NOE 6例<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 病例<|>RELATION_NOE 围手术期<|>RELATION_NOE 无<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 21<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 乳糜胸<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肺不张<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 心率<|>RELATION_NOE 失常<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 喉返神经<|>RELATION_NOE 损伤<|>RELATION_NOE 3例<|>RELATION_NOE 。<|>RELATION_NOE
扩大<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 可以<|>RELATION_NOE 达<|>RELATION_B 到<|>RELATION_E 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 根治<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 能<|>RELATION_NOE 延长<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 但是<|>RELATION_NOE 要<|>RELATION_NOE 严格<|>RELATION_NOE 把握<|>RELATION_NOE 手术<|>RELATION_NOE 指征<|>RELATION_NOE 。<|>RELATION_NOE
比较<|>RELATION_S 奥<|>RELATION_NOE 氮平<|>RELATION_NOE 联合<|>RELATION_NOE 昂丹司琼<|>RELATION_NOE 与<|>RELATION_NOE 单用<|>RELATION_NOE 昂丹司琼<|>RELATION_NOE 预防<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE (<|>RELATION_NOE CINV<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
84<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 研究组<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 均<|>RELATION_NOE 在<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 30min<|>RELATION_NOE 给予<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 昂丹司琼<|>RELATION_NOE 8mg<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 自<|>RELATION_NOE 化疗<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 早晨<|>RELATION_NOE 开始<|>RELATION_NOE I<|>RELATION_NOE :<|>RELATION_NOE 1服<|>RELATION_NOE 奥<|>RELATION_NOE 氮平<|>RELATION_NOE 10mg<|>RELATION_NOE ,<|>RELATION_NOE 连<|>RELATION_NOE 用<|>RELATION_NOE 8d<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 化疗<|>RELATION_NOE 第1<|>RELATION_NOE 周期<|>RELATION_NOE 的<|>RELATION_NOE 止吐<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 1991-2011<|>RELATION_NOE 年<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 110<|>RELATION_NOE 例<|>RELATION_NOE 甲状<|>RELATION_NOE 舌管<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 5例经术<|>RELATION_NOE 后<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 甲状<|>RELATION_NOE 舌管癌<|>RELATION_NOE ,<|>RELATION_NOE 乳头状癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
5例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 2例<|>RELATION_NOE 接受<|>RELATION_NOE Sistrunk<|>RELATION_NOE 术<|>RELATION_NOE (<|>RELATION_NOE 切除<|>RELATION_NOE 肿瘤<|>RELATION_NOE 、<|>RELATION_NOE 甲状<|>RELATION_NOE 舌管<|>RELATION_NOE 及<|>RELATION_NOE 部分<|>RELATION_NOE 舌骨<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE Sistrunk<|>RELATION_NOE 术<|>RELATION_NOE +<|>RELATION_NOE 甲状腺结节<|>RELATION_NOE 切除术<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 合并<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE Sistrunk<|>RELATION_NOE 术<|>RELATION_NOE +<|>RELATION_NOE 甲状腺<|>RELATION_NOE 全<|>RELATION_NOE 切除<|>RELATION_NOE 术+<|>RELATION_NOE 中央区<|>RELATION_NOE 淋巴<|>RELATION_NOE 清扫术<|>RELATION_NOE ,<|>RELATION_NOE 1例鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE Sistrunk<|>RELATION_NOE 术+<|>RELATION_NOE 受侵<|>RELATION_NOE 组织<|>RELATION_NOE 扩大<|>RELATION_NOE 切除术<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 14-45<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 73<|>RELATION_NOE 岁<|>RELATION_NOE 甲状<|>RELATION_NOE 舌管<|>RELATION_NOE 鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 于<|>RELATION_NOE 术后<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 生存<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 同步<|>RELATION_NOE EP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
随<|>RELATION_NOE 访<|>RELATION_NOE 2<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 失访<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 失访<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降<|>RELATION_NOE 、<|>RELATION_NOE 贫血<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 及<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 发生率<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 同步<|>RELATION_NOE EP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 远期<|>RELATION_NOE 生存率<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 局部<|>RELATION_NOE 复发率<|>RELATION_NOE 及<|>RELATION_NOE 远处<|>RELATION_NOE 转移率<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 老年<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE Meta<|>RELATION_B 分析<|>RELATION_E
探讨<|>RELATION_S 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE rs3918242<|>RELATION_NOE 位点<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
伊立<|>RELATION_NOE 替康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 与<|>RELATION_NOE 足叶<|>RELATION_NOE 乙甙<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 广泛期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 对比<|>RELATION_B 研究<|>RELATION_E
比较<|>RELATION_B 探究<|>RELATION_E 伊立<|>RELATION_NOE 替康<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE IP<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 足叶<|>RELATION_NOE 乙甙<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE EP<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 广泛期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 毒副反应<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 毒副反应<|>RELATION_NOE 有<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 腹泻<|>RELATION_NOE 、<|>RELATION_NOE 白细胞计数<|>RELATION_NOE 减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板计数<|>RELATION_NOE 减少<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 腹泻<|>RELATION_NOE IP<|>RELATION_NOE 组<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 33.3%<|>RELATION_NOE ,<|>RELATION_NOE EP<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 6.7%<|>RELATION_NOE ,<|>RELATION_NOE 白细胞减少<|>RELATION_NOE IP<|>RELATION_NOE 组<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 77.7%<|>RELATION_NOE ,<|>RELATION_NOE EP<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 93-3<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 血小板减少<|>RELATION_NOE IP<|>RELATION_NOE 组<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 29.6%<|>RELATION_NOE ,<|>RELATION_NOE EP<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 76.7%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 显著性<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 同型<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 作为<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 初步<|>RELATION_B 探讨<|>RELATION_E
检测<|>RELATION_S 同型<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 在<|>RELATION_NOE 多种<|>RELATION_NOE 常见<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 初步<|>RELATION_NOE 研究<|>RELATION_NOE 其<|>RELATION_NOE 作为<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 可能性<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 血清<|>RELATION_NOE 同型<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 11.40<|>RELATION_NOE ±<|>RELATION_NOE 3.13<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 同型<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 均<|>RELATION_NOE 升高<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 13.89<|>RELATION_NOE ±<|>RELATION_NOE 4.95<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE －<|>RELATION_NOE (<|>RELATION_NOE 21.40<|>RELATION_NOE ±<|>RELATION_NOE 9.38<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE (<|>RELATION_NOE 17.01<|>RELATION_NOE ±<|>RELATION_NOE 9.32<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 另外<|>RELATION_NOE 4种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE AFP<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CA199<|>RELATION_NOE )<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 血清<|>RELATION_NOE 同型<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 中<|>RELATION_NOE 具有<|>RELATION_NOE 更<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 预测率<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 同型<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 升高<|>RELATION_NOE 具有<|>RELATION_NOE 普遍性<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 按照<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 使用<|>RELATION_NOE 的<|>RELATION_NOE cutoff<|>RELATION_NOE 值<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 用<|>RELATION_NOE 作为<|>RELATION_S 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 食管癌<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 肺切除<|>RELATION_NOE 并<|>RELATION_NOE 心包<|>RELATION_NOE 开<|>RELATION_NOE 窗术<|>RELATION_NOE 患者<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_B 与<|>RELATION_I 护理<|>RELATION_E
探讨<|>RELATION_B 预防<|>RELATION_E 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 并<|>RELATION_NOE 心包<|>RELATION_NOE 开<|>RELATION_NOE 窗术<|>RELATION_NOE 患者<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 选取<|>RELATION_NOE 行全肺<|>RELATION_NOE 切除<|>RELATION_NOE 并<|>RELATION_NOE 心包<|>RELATION_NOE 开<|>RELATION_NOE 窗术<|>RELATION_NOE 患者<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 干预组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 给<|>RELATION_NOE 与<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 干预组<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 存在<|>RELATION_NOE 心律失常<|>RELATION_NOE 高危<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 制订<|>RELATION_NOE 活动<|>RELATION_NOE 计划<|>RELATION_NOE 、<|>RELATION_NOE 预防<|>RELATION_NOE 便秘<|>RELATION_NOE 、<|>RELATION_NOE 严密<|>RELATION_NOE 观察<|>RELATION_NOE 病情<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 引流管<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
经过<|>RELATION_NOE 实施<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 干预组<|>RELATION_NOE 患者<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE (<|>RELATION_NOE 10%<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 33.3%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 严密<|>RELATION_NOE 观察<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病情<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 高危<|>RELATION_NOE 患者<|>RELATION_NOE 早期<|>RELATION_NOE 给予<|>RELATION_NOE 预防性<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 有效<|>RELATION_B 降低<|>RELATION_E 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 心律失常<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
放化<|>RELATION_NOE 疗<|>RELATION_NOE 联合<|>RELATION_NOE 西妥昔<|>RELATION_NOE 单抗<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
西妥昔<|>RELATION_NOE 单抗组<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 23<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 21<|>RELATION_NOE －<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 21<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 19-23<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺部疾病<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 水平<|>RELATION_NOE 测定<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
肺炎<|>RELATION_NOE 、<|>RELATION_NOE 肺结核<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 急性<|>RELATION_NOE 加重<|>RELATION_NOE 、<|>RELATION_NOE 急性<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 及<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 血浆<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺炎<|>RELATION_NOE 组<|>RELATION_NOE 血浆<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 水平<|>RELATION_NOE 低于<|>RELATION_S 肺结核<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 急性<|>RELATION_NOE 加重<|>RELATION_NOE 、<|>RELATION_NOE 急性<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 、<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺结核<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 急性<|>RELATION_NOE 加重<|>RELATION_NOE 、<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组间<|>RELATION_NOE 血浆<|>RELATION_NOE Ⅱ<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 水平<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
急性<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肺结核<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 急性<|>RELATION_NOE 加重<|>RELATION_NOE 、<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 血浆<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 水平<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺炎<|>RELATION_NOE 、<|>RELATION_NOE 肺结核<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 急性<|>RELATION_NOE 加重<|>RELATION_NOE 、<|>RELATION_NOE 急性<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 、<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 均<|>RELATION_NOE 可<|>RELATION_NOE 引起<|>RELATION_S 凝血<|>RELATION_NOE 机制<|>RELATION_NOE 的<|>RELATION_NOE 异常<|>RELATION_NOE ,<|>RELATION_NOE 导致<|>RELATION_NOE 血浆<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 急性<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 中<|>RELATION_NOE 最为<|>RELATION_NOE 明显<|>RELATION_NOE 。<|>RELATION_NOE
相关<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 苦<|>RELATION_NOE 参碱<|>RELATION_NOE 诱导<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞凋亡<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
Bcl-2<|>RELATION_NOE 基因表达<|>RELATION_NOE 降低<|>RELATION_NOE 、<|>RELATION_NOE Bax<|>RELATION_NOE 基因表达<|>RELATION_NOE 增高<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 苦<|>RELATION_NOE 参碱<|>RELATION_NOE 诱导<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_B 重要<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
肝细胞<|>RELATION_NOE 生长因子<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 纯化<|>RELATION_NOE 和<|>RELATION_NOE 基本<|>RELATION_NOE 活性<|>RELATION_NOE 研究<|>RELATION_S
通过<|>RELATION_NOE 构建<|>RELATION_NOE 肝细胞<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE HGF<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 重组<|>RELATION_NOE 原<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 转化<|>RELATION_NOE 大肠杆菌<|>RELATION_NOE ,<|>RELATION_NOE 制备<|>RELATION_S HGF<|>RELATION_NOE 重组<|>RELATION_NOE 蛋白<|>RELATION_NOE 并<|>RELATION_NOE 初步<|>RELATION_NOE 证实<|>RELATION_NOE 其<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
职业<|>RELATION_NOE 暴露<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_B 分析<|>RELATION_E
对<|>RELATION_NOE 唐山市<|>RELATION_NOE 21<|>RELATION_NOE 10<|>RELATION_NOE 名<|>RELATION_NOE 有<|>RELATION_NOE 从事<|>RELATION_NOE 石棉<|>RELATION_NOE 、<|>RELATION_NOE 煤焦油<|>RELATION_NOE 、<|>RELATION_NOE 烟尘<|>RELATION_NOE 、<|>RELATION_NOE 重金属<|>RELATION_NOE 、<|>RELATION_NOE 橡胶<|>RELATION_NOE 等<|>RELATION_NOE 相关<|>RELATION_NOE 职业<|>RELATION_NOE 且<|>RELATION_NOE 年龄<|>RELATION_NOE ≥<|>RELATION_NOE 20<|>RELATION_NOE 岁<|>RELATION_NOE 的<|>RELATION_NOE 居民<|>RELATION_NOE 进行<|>RELATION_NOE 问卷调查<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 一般<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 工作<|>RELATION_NOE 年限<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 和<|>RELATION_NOE 吸烟<|>RELATION_NOE 程度<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 另外<|>RELATION_NOE 收集<|>RELATION_NOE 37<|>RELATION_NOE 8例<|>RELATION_NOE 医院<|>RELATION_NOE 就诊<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 有<|>RELATION_NOE 职业<|>RELATION_NOE 暴露史<|>RELATION_NOE 149<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 一般<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 肺外<|>RELATION_NOE 病变<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 胸部<|>RELATION_NOE 影像学<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 伴随<|>RELATION_NOE 疾病<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 情况<|>RELATION_NOE 等<|>RELATION_NOE 与<|>RELATION_NOE 其他<|>RELATION_NOE 职业<|>RELATION_NOE 患者<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
调查<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 年限<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 程度<|>RELATION_NOE 以及<|>RELATION_NOE 从事<|>RELATION_NOE 职业<|>RELATION_NOE 暴露<|>RELATION_NOE 的<|>RELATION_NOE 工作<|>RELATION_NOE 年限<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 患病<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 因素<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
职业<|>RELATION_NOE 暴露<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE 吸烟<|>RELATION_NOE 程度<|>RELATION_NOE 重<|>RELATION_NOE 、<|>RELATION_NOE 年长者<|>RELATION_NOE 和<|>RELATION_NOE 职业<|>RELATION_NOE 暴露<|>RELATION_NOE 年限<|>RELATION_NOE 高者<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 多<|>RELATION_NOE 为<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺气肿<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 以<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 后期<|>RELATION_NOE 肿瘤<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 为<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE 。<|>RELATION_NOE
自<|>RELATION_NOE 研发<|>RELATION_NOE 变形<|>RELATION_NOE 配<|>RELATION_NOE 准<|>RELATION_NOE 软件<|>RELATION_NOE 在<|>RELATION_NOE 四维<|>RELATION_NOE CT<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 确定<|>RELATION_NOE 靶体<|>RELATION_NOE 积<|>RELATION_NOE 的<|>RELATION_NOE 初步<|>RELATION_B 临床<|>RELATION_I 验证<|>RELATION_E
肺癌<|>RELATION_NOE 病例<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 呼吸<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE 4DCT<|>RELATION_NOE 图像<|>RELATION_NOE 序列<|>RELATION_NOE 的<|>RELATION_NOE CTV<|>RELATION_NOE defm<|>RELATION_NOE 与<|>RELATION_NOE CTV<|>RELATION_NOE manu<|>RELATION_NOE 体积<|>RELATION_NOE 偏差<|>RELATION_NOE 平均值<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE －<|>RELATION_NOE 2.59<|>RELATION_NOE ±<|>RELATION_NOE 5.02<|>RELATION_NOE )%<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 手术<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 靶区<|>RELATION_NOE 变化<|>RELATION_NOE 的<|>RELATION_NOE 锥形束<|>RELATION_B CT<|>RELATION_I 观察<|>RELATION_E
不同<|>RELATION_NOE 追踪<|>RELATION_NOE 方式<|>RELATION_NOE 对<|>RELATION_NOE 射波刀<|>RELATION_NOE 治疗<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 射波刀<|>RELATION_NOE 治疗<|>RELATION_S 肺部肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 64<|>RELATION_NOE 例<|>RELATION_NOE 72<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 原发瘤<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 41<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE 瘤<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE 31<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 。<|>RELATION_NOE
伽玛刀<|>RELATION_NOE 立体<|>RELATION_NOE 定向<|>RELATION_NOE 放疗<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_B 及<|>RELATION_I 生存<|>RELATION_I 质量<|>RELATION_I 分析<|>RELATION_E
呼吸困难<|>RELATION_NOE 和<|>RELATION_NOE 咳嗽<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 改善<|>RELATION_NOE ,<|>RELATION_NOE 躯体<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 疲倦<|>RELATION_NOE 、<|>RELATION_NOE 食欲<|>RELATION_NOE 减退<|>RELATION_NOE 和<|>RELATION_NOE 失眠<|>RELATION_NOE 无<|>RELATION_NOE 加重<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺癌<|>RELATION_NOE CT<|>RELATION_NOE 征象<|>RELATION_NOE 与<|>RELATION_NOE 病理学<|>RELATION_NOE 对照<|>RELATION_B 分析<|>RELATION_E
不同<|>RELATION_NOE 组织<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 分叶征<|>RELATION_NOE 、<|>RELATION_NOE 毛刺征<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 凹陷征<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 集束征<|>RELATION_NOE 、<|>RELATION_NOE 晕征<|>RELATION_NOE 等<|>RELATION_NOE CT<|>RELATION_NOE 征象<|>RELATION_NOE 方面<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
本<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 骨髓<|>RELATION_NOE 源性<|>RELATION_NOE 抑制<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE MDSC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 及<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE MDSC<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 参与<|>RELATION_NOE 形成<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 抑制<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 患者<|>RELATION_NOE 高<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE MDSC<|>RELATION_NOE 既<|>RELATION_NOE 受<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 诱导<|>RELATION_NOE ,<|>RELATION_NOE 又<|>RELATION_NOE 与<|>RELATION_NOE 炎症<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE
中<|>RELATION_NOE 位<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 5.79<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 生存期<|>RELATION_NOE 为<|>RELATION_NOE 3.5-26.8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 8.6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 超过<|>RELATION_NOE 1年<|>RELATION_NOE ,<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 30.6%<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 超过<|>RELATION_NOE 2<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 2年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 8.3%<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 局部<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 术前<|>RELATION_NOE 心包<|>RELATION_NOE 探查<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 探讨<|>RELATION_E
探讨<|>RELATION_S 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 心包<|>RELATION_NOE 探查<|>RELATION_NOE 的<|>RELATION_NOE 安全<|>RELATION_NOE 和<|>RELATION_NOE 可靠性<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 其<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
2008年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE 中心型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 实施<|>RELATION_NOE 术前<|>RELATION_NOE 电视<|>RELATION_NOE 辅助<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 心包<|>RELATION_NOE 探查术<|>RELATION_NOE 。<|>RELATION_NOE
胸脏<|>RELATION_NOE 镜<|>RELATION_NOE 心包<|>RELATION_NOE 探查<|>RELATION_NOE 后<|>RELATION_NOE 行<|>RELATION_NOE 肺切除术<|>RELATION_NOE 并<|>RELATION_NOE 心包<|>RELATION_NOE 内<|>RELATION_NOE 处理<|>RELATION_NOE 肺动脉<|>RELATION_NOE 8例<|>RELATION_NOE (<|>RELATION_NOE 合并<|>RELATION_NOE 心包<|>RELATION_NOE 部分<|>RELATION_NOE 切除<|>RELATION_NOE 2例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺静脉<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 心包<|>RELATION_NOE 外<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 9例<|>RELATION_NOE ;<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 技术<|>RELATION_NOE 除<|>RELATION_NOE 可<|>RELATION_NOE 广泛<|>RELATION_NOE 应用<|>RELATION_NOE 于<|>RELATION_NOE 肺楔形<|>RELATION_NOE 切除<|>RELATION_NOE 、<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 等<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 提高<|>RELATION_NOE 中晚<|>RELATION_NOE 期<|>RELATION_NOE 局部<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 切除率<|>RELATION_NOE 和<|>RELATION_NOE 生存率<|>RELATION_NOE ,<|>RELATION_NOE 电视<|>RELATION_NOE 辅助<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 心包<|>RELATION_NOE 探查<|>RELATION_NOE 可<|>RELATION_NOE 减少<|>RELATION_S 剖胸<|>RELATION_NOE 探查术<|>RELATION_NOE 的<|>RELATION_NOE 必要<|>RELATION_NOE 。<|>RELATION_NOE
瘤体<|>RELATION_NOE 直径<|>RELATION_NOE 超过<|>RELATION_NOE 10<|>RELATION_NOE 厘米<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 方法<|>RELATION_NOE 探讨<|>RELATION_S
13<|>RELATION_NOE 例<|>RELATION_NOE 该型<|>RELATION_NOE 肺癌<|>RELATION_NOE 经<|>RELATION_NOE 改良<|>RELATION_NOE 前<|>RELATION_NOE 外侧<|>RELATION_NOE 剖胸<|>RELATION_NOE 入<|>RELATION_NOE 路<|>RELATION_NOE 完成<|>RELATION_NOE 了<|>RELATION_NOE 心包<|>RELATION_NOE 内<|>RELATION_NOE 全<|>RELATION_NOE 肺<|>RELATION_NOE 扩大<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 顺利<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 恢复<|>RELATION_NOE 平稳<|>RELATION_NOE 。<|>RELATION_NOE
MiR-34b<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 在<|>RELATION_NOE HGF-Met<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE
microRNAs<|>RELATION_NOE (<|>RELATION_NOE miRNAs<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 内源性<|>RELATION_NOE 非编码<|>RELATION_NOE 小<|>RELATION_NOE RNA<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 大多数<|>RELATION_NOE miRNAs<|>RELATION_NOE 表达<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_S miRNAs<|>RELATION_NOE 抑制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE miR-34b<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 参数<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 细胞<|>RELATION_NOE 转染<|>RELATION_NOE 技术<|>RELATION_NOE 获得<|>RELATION_NOE miR-34b<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 检测<|>RELATION_S 细胞凋亡<|>RELATION_NOE 与<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 。<|>RELATION_NOE
运用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 探索<|>RELATION_S miR-34b<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 下游<|>RELATION_NOE 蛋白<|>RELATION_NOE c-Met<|>RELATION_NOE 、<|>RELATION_NOE p53<|>RELATION_NOE 以及<|>RELATION_NOE Mdm2<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
miR-34b<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中低<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 负<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
miR-34b<|>RELATION_NOE 影响<|>RELATION_S 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 、<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 发挥<|>RELATION_NOE 抑制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE TCF21<|>RELATION_NOE 基因表达<|>RELATION_NOE 及其<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
探讨<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE TCF21<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及其<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
97<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_NOE 出<|>RELATION_NOE TCF21<|>RELATION_NOE 基网<|>RELATION_NOE mRNA<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 23.7<|>RELATION_NOE 1%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 66.6<|>RELATION_NOE 7%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
探讨<|>RELATION_S 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 全<|>RELATION_NOE 肺切<|>RELATION_NOE 除<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE 和<|>RELATION_NOE 有效性<|>RELATION_NOE 。<|>RELATION_NOE
2009年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 6月<|>RELATION_NOE 共<|>RELATION_NOE 施行<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 46<|>RELATION_NOE －<|>RELATION_NOE 83<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 62.2<|>RELATION_NOE 岁<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 全部<|>RELATION_NOE 通过<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 切口<|>RELATION_NOE 完成<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_NOE 撑<|>RELATION_NOE 开<|>RELATION_NOE 肋问<|>RELATION_NOE ,<|>RELATION_NOE 完全<|>RELATION_NOE 在<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 视野<|>RELATION_NOE 下<|>RELATION_NOE 使用<|>RELATION_NOE 腔镜<|>RELATION_NOE 器械<|>RELATION_NOE 进行<|>RELATION_NOE 解剖性<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 和<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 安全<|>RELATION_NOE 可行<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 未<|>RELATION_B 增加<|>RELATION_E 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 围手术期<|>RELATION_NOE 风险<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 总结<|>RELATION_NOE 经验<|>RELATION_NOE 并<|>RELATION_NOE 加以<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2007年<|>RELATION_NOE 4月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 11月<|>RELATION_NOE 期间<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 手指<|>RELATION_NOE 软组织肉瘤<|>RELATION_NOE 保指<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 采取<|>RELATION_NOE 肿瘤<|>RELATION_NOE 广泛<|>RELATION_NOE 切除<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 创面<|>RELATION_NOE 覆盖<|>RELATION_NOE 选用<|>RELATION_NOE 第一<|>RELATION_NOE 掌背<|>RELATION_NOE 动脉<|>RELATION_NOE 皮瓣<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 第二<|>RELATION_NOE 掌背<|>RELATION_NOE 动脉<|>RELATION_NOE 皮瓣<|>RELATION_NOE 修复<|>RELATION_NOE 4例<|>RELATION_NOE ;<|>RELATION_NOE
术后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 14<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 至<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 9例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 无<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 1例术<|>RELATION_NOE 后<|>RELATION_NOE 14<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 肺转移<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 1例肺<|>RELATION_NOE 转移<|>RELATION_NOE 带<|>RELATION_NOE 瘤<|>RELATION_NOE 生存<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 乳头<|>RELATION_NOE 状<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 颈部<|>RELATION_NOE 中央组<|>RELATION_NOE (<|>RELATION_NOE Ⅵ区<|>RELATION_NOE )<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_S 了<|>RELATION_NOE 甲状腺<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 全切<|>RELATION_NOE 加<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 颈部<|>RELATION_NOE 中央组<|>RELATION_NOE (<|>RELATION_NOE Ⅵ区<|>RELATION_NOE )<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE 。<|>RELATION_NOE
中央组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 36.7%<|>RELATION_NOE (<|>RELATION_NOE 79<|>RELATION_NOE /<|>RELATION_NOE 215<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 包括<|>RELATION_NOE :<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 每<|>RELATION_NOE 增加<|>RELATION_NOE 1岁<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 是<|>RELATION_NOE 原来<|>RELATION_NOE 的<|>RELATION_NOE 0.9<|>RELATION_NOE 35<|>RELATION_NOE 倍<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE (<|>RELATION_NOE 女性<|>RELATION_NOE 患者<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 为<|>RELATION_NOE 男性<|>RELATION_NOE 的<|>RELATION_NOE 0.202<|>RELATION_NOE 倍<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 数目<|>RELATION_NOE 和<|>RELATION_NOE 总<|>RELATION_NOE 直径<|>RELATION_NOE 。<|>RELATION_NOE
乳头<|>RELATION_NOE 状<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 可<|>RELATION_B 发生<|>RELATION_E 中央组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 当<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 年轻人<|>RELATION_NOE 或<|>RELATION_NOE 男性<|>RELATION_NOE ,<|>RELATION_NOE 癌肿<|>RELATION_NOE 呈<|>RELATION_NOE 多<|>RELATION_NOE 灶性<|>RELATION_NOE 或<|>RELATION_NOE 总<|>RELATION_NOE 直径<|>RELATION_NOE 超过<|>RELATION_NOE 0.5cm<|>RELATION_NOE 时<|>RELATION_NOE 转移<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE 。<|>RELATION_NOE
帕瑞昔布钠<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 老年<|>RELATION_NOE 病人<|>RELATION_NOE 术后<|>RELATION_NOE 炎性<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
择期<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 病人<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 性别<|>RELATION_NOE 不<|>RELATION_NOE 限<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 65<|>RELATION_NOE －<|>RELATION_NOE 78<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 体重<|>RELATION_NOE 52<|>RELATION_NOE －<|>RELATION_NOE 81kg<|>RELATION_NOE ,<|>RELATION_NOE ASA<|>RELATION_NOE 分级<|>RELATION_NOE Ⅱ<|>RELATION_NOE 或<|>RELATION_NOE Ⅲ<|>RELATION_NOE 级<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 病人<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 2组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 帕瑞昔布<|>RELATION_NOE 钠组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
麻醉<|>RELATION_NOE 诱导<|>RELATION_NOE 后<|>RELATION_NOE 气管<|>RELATION_NOE 插<|>RELATION_NOE 管<|>RELATION_NOE ,<|>RELATION_NOE 机械通气<|>RELATION_NOE ,<|>RELATION_NOE 麻醉<|>RELATION_NOE 维持<|>RELATION_NOE :<|>RELATION_NOE 静脉<|>RELATION_NOE 输<|>RELATION_NOE 注瑞<|>RELATION_NOE 芬太尼<|>RELATION_NOE 和<|>RELATION_NOE 异丙酚<|>RELATION_NOE ,<|>RELATION_NOE 吸入<|>RELATION_NOE 七<|>RELATION_NOE 氟醚<|>RELATION_NOE ,<|>RELATION_NOE 间断<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 维库溴铵<|>RELATION_NOE ,<|>RELATION_NOE 维持<|>RELATION_NOE 脑电<|>RELATION_NOE 双频<|>RELATION_NOE 指数<|>RELATION_NOE 值<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 50<|>RELATION_NOE 。<|>RELATION_NOE
2组术<|>RELATION_NOE 后<|>RELATION_NOE 采用<|>RELATION_NOE 病人<|>RELATION_NOE 自控<|>RELATION_NOE 静脉<|>RELATION_NOE 镇痛<|>RELATION_NOE ,<|>RELATION_NOE 镇痛<|>RELATION_NOE 药物<|>RELATION_NOE 为<|>RELATION_NOE 吗啡<|>RELATION_NOE ,<|>RELATION_NOE 维持<|>RELATION_NOE 静息<|>RELATION_NOE 时<|>RELATION_NOE VAS<|>RELATION_NOE 评分<|>RELATION_NOE ≤<|>RELATION_NOE 3分<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 吗啡<|>RELATION_NOE 用量<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE 时<|>RELATION_NOE Ramsay<|>RELATION_NOE 镇静<|>RELATION_NOE 评分<|>RELATION_NOE 。<|>RELATION_NOE
分别<|>RELATION_NOE 于<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 术毕<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 和<|>RELATION_NOE 48h<|>RELATION_NOE 时<|>RELATION_NOE 采集<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 血样<|>RELATION_NOE ,<|>RELATION_NOE 测定<|>RELATION_NOE 血浆<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE IL-8<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 于<|>RELATION_NOE 上述<|>RELATION_NOE 时点<|>RELATION_NOE 采集<|>RELATION_NOE 桡动脉<|>RELATION_NOE 血样<|>RELATION_NOE ,<|>RELATION_NOE 测定<|>RELATION_NOE PaO2<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 肺泡<|>RELATION_NOE -<|>RELATION_NOE 动脉<|>RELATION_NOE 氧分压<|>RELATION_NOE 差<|>RELATION_NOE 及<|>RELATION_NOE 氧合<|>RELATION_NOE 指数<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_S 术后<|>RELATION_NOE 2d<|>RELATION_NOE 内<|>RELATION_NOE 肺部<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 组<|>RELATION_NOE 吗啡<|>RELATION_NOE 用量<|>RELATION_NOE 、<|>RELATION_NOE Ramsav<|>RELATION_NOE 镇静<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 血浆<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 、<|>RELATION_NOE IL-8<|>RELATION_NOE 浓度<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE -<|>RELATION_NOE 动脉<|>RELATION_NOE 氧分压<|>RELATION_NOE 差<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 肺部<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 氧合<|>RELATION_NOE 指数<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 一线<|>RELATION_NOE 厄<|>RELATION_NOE 罗替尼<|>RELATION_NOE 或<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 随机<|>RELATION_B 对照<|>RELATION_I 研究<|>RELATION_E
64<|>RELATION_NOE 例<|>RELATION_NOE 经病<|>RELATION_NOE 理学<|>RELATION_NOE 确诊<|>RELATION_NOE 且<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE 外显子<|>RELATION_NOE 缺<|>RELATION_NOE 失<|>RELATION_NOE 或<|>RELATION_NOE L858R<|>RELATION_NOE 点突变<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 厄洛替尼组<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 服用<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE (<|>RELATION_NOE 150mg<|>RELATION_NOE ,<|>RELATION_NOE 口服<|>RELATION_NOE ,<|>RELATION_NOE 每天<|>RELATION_NOE 1<|>RELATION_NOE 次<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 直至<|>RELATION_NOE 病情<|>RELATION_NOE 进展<|>RELATION_NOE 或<|>RELATION_NOE 出现<|>RELATION_NOE 严重<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ;<|>RELATION_NOE
药物<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 多<|>RELATION_NOE 为<|>RELATION_NOE I<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 度<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 因<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 需<|>RELATION_NOE 停药者<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 发现<|>RELATION_NOE 药物<|>RELATION_NOE 相关<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
厄洛替尼组<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 皮疹<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 71.4%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 腹泻<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 31.o<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肝功能<|>RELATION_NOE 异常<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 23.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 66.7%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 或<|>RELATION_NOE 呕吐<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 47.6%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 贫血<|>RELATION_NOE 9例<|>RELATION_NOE (<|>RELATION_NOE 42.9%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血小板<|>RELATION_NOE 下降<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 33.3%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 便秘<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 33.3%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 周围神经炎<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 23.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 较<|>RELATION_NOE 厄<|>RELATION_NOE 洛替尼组<|>RELATION_NOE 有<|>RELATION_NOE 更<|>RELATION_NOE 多<|>RELATION_NOE 的<|>RELATION_NOE 3－<|>RELATION_NOE 4<|>RELATION_NOE 级<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 71.4%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 16.7%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE X<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 1.69<|>RELATION_NOE ,<|>RELATION_NOE P-o<|>RELATION_NOE .<|>RELATION_NOE
厄洛替尼<|>RELATION_NOE 用于<|>RELATION_NOE 治疗<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE 优于<|>RELATION_S 化疗组<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 期<|>RELATION_NOE 无<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 相对<|>RELATION_NOE 减少<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE EGFR<|>RELATION_NOE 敏感<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 合理<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
测定<|>RELATION_S 宣威<|>RELATION_NOE 肺癌<|>RELATION_NOE 高发<|>RELATION_NOE 地区<|>RELATION_NOE 使用<|>RELATION_NOE 的<|>RELATION_NOE C1<|>RELATION_NOE 烟煤<|>RELATION_NOE 及<|>RELATION_NOE 燃烧<|>RELATION_NOE 产物<|>RELATION_NOE 中<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 云南省<|>RELATION_NOE 宣威<|>RELATION_NOE 地区<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 高发<|>RELATION_NOE 与<|>RELATION_NOE C1<|>RELATION_NOE 烟煤<|>RELATION_NOE 中<|>RELATION_NOE 自然<|>RELATION_NOE 产出<|>RELATION_NOE 的<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
从<|>RELATION_NOE 昆明<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 第三<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE (<|>RELATION_NOE 云南省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE )<|>RELATION_NOE 病理科<|>RELATION_NOE 调取<|>RELATION_NOE 宣威<|>RELATION_NOE 地区<|>RELATION_NOE (<|>RELATION_NOE 当地<|>RELATION_NOE 出生<|>RELATION_NOE 并<|>RELATION_NOE 居住<|>RELATION_NOE 生活<|>RELATION_NOE 3代<|>RELATION_NOE 以上<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 非吸烟<|>RELATION_NOE 女性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 14<|>RELATION_NOE 份<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 扫描<|>RELATION_NOE 电镜<|>RELATION_NOE (<|>RELATION_NOE SEM<|>RELATION_NOE )<|>RELATION_NOE 观察<|>RELATION_NOE C1<|>RELATION_NOE 烟煤<|>RELATION_NOE 和<|>RELATION_NOE 燃烧<|>RELATION_NOE 后<|>RELATION_NOE 底灰<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 颗粒物<|>RELATION_NOE 形态<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 配带<|>RELATION_NOE 的<|>RELATION_NOE 能谱仪<|>RELATION_NOE (<|>RELATION_NOE SEN-EDX<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_S 其<|>RELATION_NOE 显微组<|>RELATION_NOE 分<|>RELATION_NOE 的<|>RELATION_NOE 依存<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 透射<|>RELATION_NOE 电镜<|>RELATION_NOE (<|>RELATION_NOE TEM<|>RELATION_NOE )<|>RELATION_NOE 观察<|>RELATION_NOE 底灰<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 煤烟尘<|>RELATION_NOE 和<|>RELATION_NOE 宣威<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 颗粒物<|>RELATION_NOE 形态<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 配带<|>RELATION_NOE 的<|>RELATION_NOE 能谱仪<|>RELATION_NOE (<|>RELATION_NOE TEM-EDX<|>RELATION_NOE )<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE c1<|>RELATION_NOE 烟煤<|>RELATION_NOE 燃烧<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 煤烟尘<|>RELATION_NOE 和<|>RELATION_NOE 宣威<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 癌组织<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 发现<|>RELATION_NOE 有<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 颗粒物<|>RELATION_NOE 存在<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 底灰<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 颗粒物<|>RELATION_NOE 粒径<|>RELATION_NOE 主要<|>RELATION_NOE 分布<|>RELATION_NOE 在<|>RELATION_NOE 120-500nm<|>RELATION_NOE 之间<|>RELATION_NOE ,<|>RELATION_NOE 形态各异<|>RELATION_NOE ,<|>RELATION_NOE 大小<|>RELATION_NOE 不一<|>RELATION_NOE ,<|>RELATION_NOE 赋存<|>RELATION_NOE 有铁<|>RELATION_NOE 、<|>RELATION_NOE 铝<|>RELATION_NOE 、<|>RELATION_NOE 钙和钾<|>RELATION_NOE 等<|>RELATION_NOE 元素<|>RELATION_NOE ;<|>RELATION_NOE
煤烟尘<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 颗粒物<|>RELATION_NOE 多<|>RELATION_NOE 呈<|>RELATION_NOE 纳米<|>RELATION_NOE 级别<|>RELATION_NOE ,<|>RELATION_NOE 颗粒物<|>RELATION_NOE 直径<|>RELATION_NOE 多<|>RELATION_NOE 分布<|>RELATION_NOE 在<|>RELATION_NOE 37<|>RELATION_NOE －<|>RELATION_NOE 80nm<|>RELATION_NOE 之间<|>RELATION_NOE ,<|>RELATION_NOE 形态各异<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 成纤维状<|>RELATION_NOE ,<|>RELATION_NOE 表面<|>RELATION_NOE 不<|>RELATION_NOE 光滑<|>RELATION_NOE ,<|>RELATION_NOE 含有铁<|>RELATION_NOE 、<|>RELATION_NOE 钾<|>RELATION_NOE 、<|>RELATION_NOE 钙<|>RELATION_NOE 、<|>RELATION_NOE 铝和硫<|>RELATION_NOE 等<|>RELATION_NOE 元素<|>RELATION_NOE 。<|>RELATION_NOE
宣威<|>RELATION_NOE 地区<|>RELATION_NOE 富<|>RELATION_NOE 含<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 的<|>RELATION_NOE C1<|>RELATION_NOE 烟煤<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 死亡率<|>RELATION_NOE 空间<|>RELATION_NOE 分布<|>RELATION_NOE 上<|>RELATION_NOE 吻合<|>RELATION_S ,<|>RELATION_NOE 燃烧<|>RELATION_NOE 产物<|>RELATION_NOE (<|>RELATION_NOE 煤烟尘<|>RELATION_NOE 和<|>RELATION_NOE 底灰<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 颗粒物<|>RELATION_NOE 富集<|>RELATION_NOE ,<|>RELATION_NOE 颗粒物<|>RELATION_NOE 形态<|>RELATION_NOE 和<|>RELATION_NOE 显微组<|>RELATION_NOE 分<|>RELATION_NOE 上<|>RELATION_NOE 具有<|>RELATION_NOE 继承性<|>RELATION_NOE 。<|>RELATION_NOE
宣威<|>RELATION_NOE 地区<|>RELATION_NOE C1<|>RELATION_NOE 烟煤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 颗粒物<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_NOE “<|>RELATION_NOE C1<|>RELATION_NOE 烟煤<|>RELATION_NOE 燃烧<|>RELATION_NOE 后<|>RELATION_NOE 二氧化硅<|>RELATION_NOE 颗粒物<|>RELATION_NOE 进入<|>RELATION_NOE 室内<|>RELATION_NOE 空气<|>RELATION_NOE 中<|>RELATION_NOE 随<|>RELATION_NOE 悬浮<|>RELATION_NOE 颗粒物<|>RELATION_NOE 吸入<|>RELATION_NOE 肺部<|>RELATION_NOE ”<|>RELATION_NOE 的<|>RELATION_NOE 迁移<|>RELATION_NOE 富集<|>RELATION_NOE 路线<|>RELATION_NOE 。<|>RELATION_NOE
了解<|>RELATION_S 石棉<|>RELATION_NOE 暴露<|>RELATION_NOE 与<|>RELATION_NOE 职业性<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 间皮瘤<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 现行<|>RELATION_NOE 的<|>RELATION_NOE 石棉<|>RELATION_NOE 致<|>RELATION_NOE 职业性<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 间皮瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 修订<|>RELATION_NOE 提供<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 系统<|>RELATION_NOE 综述<|>RELATION_NOE 和<|>RELATION_NOE 文献<|>RELATION_NOE 检索<|>RELATION_NOE 的<|>RELATION_NOE 信息<|>RELATION_NOE 收集<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 凡<|>RELATION_NOE 满足<|>RELATION_NOE 职业性<|>RELATION_NOE 石棉<|>RELATION_NOE 暴露<|>RELATION_NOE 人员<|>RELATION_NOE 且<|>RELATION_NOE 有<|>RELATION_NOE 肺癌<|>RELATION_NOE 死亡<|>RELATION_NOE 或<|>RELATION_NOE 发病<|>RELATION_NOE 的<|>RELATION_NOE 队列研究<|>RELATION_NOE 资料<|>RELATION_NOE 均<|>RELATION_NOE 被<|>RELATION_NOE 纳入<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 收集<|>RELATION_NOE 国际<|>RELATION_NOE 上<|>RELATION_NOE 其他<|>RELATION_NOE 国家<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 信息<|>RELATION_NOE 。<|>RELATION_NOE
接触<|>RELATION_NOE 石棉<|>RELATION_NOE 原料<|>RELATION_NOE 的<|>RELATION_NOE 队列<|>RELATION_NOE 中<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 温石棉<|>RELATION_NOE 暴露<|>RELATION_NOE (<|>RELATION_NOE 47.6%<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 另外<|>RELATION_NOE 有<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 队列<|>RELATION_NOE (<|>RELATION_NOE 33.3%<|>RELATION_NOE ,<|>RELATION_NOE 7<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 未<|>RELATION_NOE 给<|>RELATION_NOE 出<|>RELATION_NOE 石棉<|>RELATION_NOE 暴露<|>RELATION_NOE 的<|>RELATION_NOE 类型<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 15<|>RELATION_NOE 篇<|>RELATION_NOE 文献<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 13<|>RELATION_NOE 篇<|>RELATION_NOE 文献<|>RELATION_NOE 得出<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE 是<|>RELATION_NOE 石棉<|>RELATION_NOE 暴露<|>RELATION_NOE 使<|>RELATION_NOE 患<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 危险<|>RELATION_NOE f<|>RELATION_NOE 生<|>RELATION_NOE 增加<|>RELATION_NOE (<|>RELATION_NOE 肺癌<|>RELATION_NOE SMR<|>RELATION_NOE 为<|>RELATION_NOE 1.6-6.52<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 进行<|>RELATION_NOE meta<|>RELATION_NOE 分析<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE 为<|>RELATION_NOE meta-SMR<|>RELATION_NOE =<|>RELATION_NOE 2.09<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI1.73-2.52<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 石棉<|>RELATION_NOE 纤维<|>RELATION_NOE 累计<|>RELATION_NOE 接触<|>RELATION_NOE 年限<|>RELATION_NOE 分级<|>RELATION_NOE 与<|>RELATION_NOE 间皮瘤<|>RELATION_NOE SMR<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 分析<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 队列研究<|>RELATION_NOE 显示<|>RELATION_NOE 当<|>RELATION_NOE 石棉<|>RELATION_NOE 纤维<|>RELATION_NOE 累计<|>RELATION_NOE 接触<|>RELATION_NOE 年限<|>RELATION_NOE <<|>RELATION_NOE 1<|>RELATION_NOE 年<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 患<|>RELATION_NOE 间皮瘤<|>RELATION_NOE 的<|>RELATION_NOE 危险性<|>RELATION_NOE 增加<|>RELATION_NOE (<|>RELATION_NOE SMR<|>RELATION_NOE 为<|>RELATION_NOE 18.0<|>RELATION_NOE －<|>RELATION_NOE 20.0<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 新版<|>RELATION_NOE 石棉<|>RELATION_NOE 致<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 间皮瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE 修订<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 重点<|>RELATION_B 讨论<|>RELATION_E 累计<|>RELATION_NOE 接触<|>RELATION_NOE 工龄<|>RELATION_NOE 和<|>RELATION_NOE 潜隐期<|>RELATION_NOE 的<|>RELATION_NOE 年限<|>RELATION_NOE 规定<|>RELATION_NOE 问题<|>RELATION_NOE 。<|>RELATION_NOE
气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检<|>RELATION_NOE 对<|>RELATION_NOE 肺门<|>RELATION_NOE 纵隔<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
探讨<|>RELATION_S 气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE (<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺门<|>RELATION_NOE 纵隔<|>RELATION_NOE 肿物<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 共<|>RELATION_NOE 穿刺<|>RELATION_NOE 淋巴结<|>RELATION_NOE 16<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 1.95<|>RELATION_NOE 次/例<|>RELATION_NOE ,<|>RELATION_NOE 穿刺<|>RELATION_NOE 成功率<|>RELATION_NOE 100%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 4R<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE 7组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 分别<|>RELATION_NOE 占<|>RELATION_NOE 穿刺<|>RELATION_NOE 总数<|>RELATION_NOE 的<|>RELATION_NOE 43%<|>RELATION_NOE 和<|>RELATION_NOE 34%<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断率<|>RELATION_NOE 为<|>RELATION_NOE 94.11%<|>RELATION_NOE ;<|>RELATION_NOE
除<|>RELATION_NOE 穿刺<|>RELATION_NOE 部位<|>RELATION_NOE 少许<|>RELATION_NOE 出血<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 其他<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 气胸<|>RELATION_NOE 、<|>RELATION_NOE 纵隔气肿<|>RELATION_NOE 、<|>RELATION_NOE 大<|>RELATION_NOE 血管<|>RELATION_NOE 损伤<|>RELATION_NOE 等<|>RELATION_NOE 严重<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 作为<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 微创<|>RELATION_NOE ,<|>RELATION_NOE 便利<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 风险<|>RELATION_NOE 的<|>RELATION_NOE 操作<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 纵隔<|>RELATION_NOE 和<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 以及<|>RELATION_NOE 肿块<|>RELATION_NOE 的<|>RELATION_NOE 穿刺<|>RELATION_NOE 诊断<|>RELATION_NOE 有着<|>RELATION_B 较<|>RELATION_I 高<|>RELATION_I 的<|>RELATION_I 实用<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经<|>RELATION_NOE 支气管<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检<|>RELATION_NOE 对<|>RELATION_NOE 肺内<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
评价<|>RELATION_S 气管<|>RELATION_NOE 内<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE 经<|>RELATION_NOE 支气管<|>RELATION_NOE 针吸活检<|>RELATION_NOE (<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺内良<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 上海市<|>RELATION_NOE 胸科<|>RELATION_NOE 医院<|>RELATION_NOE 于<|>RELATION_NOE 2009年<|>RELATION_NOE 10月<|>RELATION_NOE 9日<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 30日<|>RELATION_NOE 行<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE 78<|>RELATION_NOE 例<|>RELATION_NOE 肺内<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 显示<|>RELATION_NOE 气管<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 周围<|>RELATION_NOE 肺内<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 采用<|>RELATION_NOE 现场<|>RELATION_NOE 细胞学<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 必要<|>RELATION_NOE 时<|>RELATION_NOE 联合<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检测<|>RELATION_NOE 进一步<|>RELATION_S 完善<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 诊断<|>RELATION_NOE 75<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 61<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺炎<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 肺结核<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE 获得<|>RELATION_NOE 了<|>RELATION_NOE 特异<|>RELATION_NOE 的<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE 依据<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 仅<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 良性<|>RELATION_NOE 而<|>RELATION_NOE 未<|>RELATION_NOE 获得<|>RELATION_NOE 特异<|>RELATION_NOE 的<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE 依据<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 为<|>RELATION_NOE 假<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 项<|>RELATION_NOE 微创<|>RELATION_NOE 、<|>RELATION_NOE 安全<|>RELATION_NOE 的<|>RELATION_NOE 检查<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 气管<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 周围<|>RELATION_NOE 的<|>RELATION_NOE 肺内良<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE 有着<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检查<|>RELATION_NOE 结果<|>RELATION_NOE 有助于<|>RELATION_S 明确<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 来源<|>RELATION_NOE 和<|>RELATION_NOE 类型<|>RELATION_NOE 。<|>RELATION_NOE
良恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 鉴别<|>RELATION_NOE 中<|>RELATION_NOE SP70<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
探讨<|>RELATION_S SP70<|>RELATION_NOE 抗原<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 鉴别<|>RELATION_NOE 癌性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 癌性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 2月经<|>RELATION_NOE 临床<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 108<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 癌性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 122<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 双<|>RELATION_NOE 抗体<|>RELATION_NOE 夹心<|>RELATION_NOE ELISA<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE SP70<|>RELATION_NOE 抗原<|>RELATION_NOE 进行<|>RELATION_B 检测<|>RELATION_E ;<|>RELATION_NOE
采用<|>RELATION_NOE 直接<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光法<|>RELATION_NOE 对<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 脱落<|>RELATION_NOE 细胞<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE SP70<|>RELATION_NOE 抗原<|>RELATION_NOE 进行<|>RELATION_B 检测<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE HE<|>RELATION_NOE 染色法<|>RELATION_NOE 的<|>RELATION_NOE 脱落<|>RELATION_NOE 细胞<|>RELATION_NOE 学<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 各组<|>RELATION_NOE 问阳<|>RELATION_NOE 性率<|>RELATION_NOE 比较<|>RELATION_NOE 采用<|>RELATION_NOE 矿<|>RELATION_NOE 检验<|>RELATION_NOE 或<|>RELATION_NOE Fisher<|>RELATION_NOE 确切<|>RELATION_NOE 概率<|>RELATION_NOE 法<|>RELATION_NOE 。<|>RELATION_NOE
测定<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 及<|>RELATION_NOE 脱落<|>RELATION_NOE 细胞<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE SP70<|>RELATION_NOE 抗原<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_S 癌性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 。<|>RELATION_NOE
肺结核<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 并存<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 影像<|>RELATION_NOE 研究<|>RELATION_S
再<|>RELATION_NOE 将<|>RELATION_NOE Ⅰ<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 定为<|>RELATION_NOE Ⅰ<|>RELATION_NOE a<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE Ⅱ<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 定为<|>RELATION_NOE Ⅱ<|>RELATION_NOE a<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 2组<|>RELATION_NOE 的<|>RELATION_NOE 中心型<|>RELATION_NOE 肺癌<|>RELATION_NOE 分别<|>RELATION_NOE 定<|>RELATION_NOE 为<|>RELATION_NOE Ⅰ<|>RELATION_NOE b<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE Ⅱ<|>RELATION_NOE b<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_B 总结<|>RELATION_E 肺结核<|>RELATION_NOE 及<|>RELATION_NOE 肺癌<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 影像<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 将<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 肺结核<|>RELATION_NOE 出现<|>RELATION_NOE 的<|>RELATION_NOE 先后<|>RELATION_NOE 进行<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE 和<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 期间<|>RELATION_NOE 继发<|>RELATION_NOE 肺结核<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 与<|>RELATION_NOE 普通<|>RELATION_NOE 活动性<|>RELATION_NOE 肺结核<|>RELATION_NOE 具有<|>RELATION_B 同样<|>RELATION_I 特征<|>RELATION_E ;<|>RELATION_NOE
分析<|>RELATION_NOE 肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 形态<|>RELATION_NOE 、<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 及<|>RELATION_NOE 动态<|>RELATION_NOE 观察<|>RELATION_NOE 等<|>RELATION_NOE 均<|>RELATION_NOE 有助于<|>RELATION_S 诊断<|>RELATION_NOE 及<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 。<|>RELATION_NOE
60<|>RELATION_NOE 例<|>RELATION_NOE 活动性<|>RELATION_NOE 结核<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 体层<|>RELATION_NOE 摄影<|>RELATION_NOE -CT<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 分析<|>RELATION_S
回顾性<|>RELATION_B 分析<|>RELATION_E 60<|>RELATION_NOE 例<|>RELATION_NOE 被<|>RELATION_NOE PET-CT<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 结核病<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 影像<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 误诊<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 以期<|>RELATION_NOE 提高<|>RELATION_NOE 结核病<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确率<|>RELATION_NOE 并<|>RELATION_NOE 降低<|>RELATION_NOE 误诊率<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 提供<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 帮助<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 检查<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 氟代<|>RELATION_NOE 脱氧葡萄糖<|>RELATION_NOE (<|>RELATION_NOE ^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE )<|>RELATION_NOE 后<|>RELATION_NOE 行<|>RELATION_NOE PET-CT<|>RELATION_NOE 全身<|>RELATION_NOE 显像<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 感<|>RELATION_NOE 兴趣<|>RELATION_NOE 区<|>RELATION_NOE 划定<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_S 病灶<|>RELATION_NOE 标准<|>RELATION_NOE 摄取值<|>RELATION_NOE (<|>RELATION_NOE SUV<|>RELATION_NOE )<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 值<|>RELATION_NOE 及<|>RELATION_NOE 平均值<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 活动性<|>RELATION_NOE 结核<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
肝癌<|>RELATION_NOE 、<|>RELATION_NOE 脾脏<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 、<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 、<|>RELATION_NOE 喉癌<|>RELATION_NOE 、<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE PET-CT<|>RELATION_NOE 影像<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 误诊<|>RELATION_NOE 原因<|>RELATION_NOE :<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 结核<|>RELATION_NOE 病灶<|>RELATION_NOE 93.3%<|>RELATION_NOE (<|>RELATION_NOE 28<|>RELATION_NOE /<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 呈<|>RELATION_NOE 高<|>RELATION_NOE 代谢<|>RELATION_NOE 结节<|>RELATION_NOE 或<|>RELATION_NOE 团块状<|>RELATION_NOE 。<|>RELATION_NOE
误诊<|>RELATION_NOE 为<|>RELATION_NOE 恶性淋巴瘤<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结结核<|>RELATION_NOE 病<|>RELATION_NOE 以<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 对称<|>RELATION_NOE 性累<|>RELATION_NOE 及<|>RELATION_NOE 最为<|>RELATION_NOE 常见<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 85.7%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 14<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
只有<|>RELATION_NOE 对<|>RELATION_NOE 结核病<|>RELATION_NOE 的<|>RELATION_NOE 常见<|>RELATION_NOE 发生<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 分布<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 病灶<|>RELATION_NOE 影像<|>RELATION_NOE 特征<|>RELATION_NOE 进行<|>RELATION_NOE 全面<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE HRCT<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 密切<|>RELATION_NOE 结合<|>RELATION_NOE 实验室<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 才<|>RELATION_NOE 能<|>RELATION_NOE 全面<|>RELATION_NOE 掌握<|>RELATION_NOE 结核<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病变<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 细微<|>RELATION_NOE 差别<|>RELATION_NOE ,<|>RELATION_NOE 尽量<|>RELATION_NOE 减少<|>RELATION_NOE 漏<|>RELATION_NOE 、<|>RELATION_NOE 误诊率<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
化学<|>RELATION_NOE 合成<|>RELATION_NOE 一<|>RELATION_NOE 系列<|>RELATION_NOE 磷脂<|>RELATION_NOE 酰聚<|>RELATION_NOE 乙二醇<|>RELATION_NOE 单甲醚<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 超声<|>RELATION_NOE 薄<|>RELATION_NOE 膜法<|>RELATION_NOE 制备<|>RELATION_S 脂质体<|>RELATION_NOE 和<|>RELATION_NOE 载药<|>RELATION_NOE 脂质体<|>RELATION_NOE ,<|>RELATION_NOE 测定<|>RELATION_NOE 它们<|>RELATION_NOE 的<|>RELATION_NOE 药物<|>RELATION_NOE 包封率<|>RELATION_NOE 和<|>RELATION_NOE 粒径<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 考察<|>RELATION_S 磷脂<|>RELATION_NOE 酰聚<|>RELATION_NOE 乙二醇<|>RELATION_NOE 单甲醚<|>RELATION_NOE 脂质体<|>RELATION_NOE 和<|>RELATION_NOE 载药<|>RELATION_NOE 磷脂<|>RELATION_NOE 酰聚<|>RELATION_NOE 乙二醇<|>RELATION_NOE 单甲醚<|>RELATION_NOE 脂质体<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 共<|>RELATION_NOE 聚焦<|>RELATION_NOE 显微镜<|>RELATION_NOE 观察<|>RELATION_S 脂质体<|>RELATION_NOE 在<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 定位<|>RELATION_NOE 。<|>RELATION_NOE
Ⅲ<|>RELATION_NOE A-N2<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 外科<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_B 分析<|>RELATION_E
Cox<|>RELATION_NOE 模型<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴<|>RELATION_NOE 血管<|>RELATION_NOE 侵犯<|>RELATION_NOE (<|>RELATION_NOE LVI<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N2<|>RELATION_NOE 阳性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数目<|>RELATION_NOE 和<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 站数<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_S 。<|>RELATION_NOE
按<|>RELATION_NOE 年龄<|>RELATION_NOE 分层<|>RELATION_NOE 分析<|>RELATION_NOE 提示<|>RELATION_NOE ,<|>RELATION_NOE 上述<|>RELATION_NOE 预后<|>RELATION_NOE 危险因素<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 在<|>RELATION_NOE 年龄<|>RELATION_NOE ≥<|>RELATION_NOE 55<|>RELATION_NOE 岁<|>RELATION_NOE 者<|>RELATION_NOE 中<|>RELATION_NOE 尤为<|>RELATION_NOE 显著<|>RELATION_NOE 。<|>RELATION_NOE
ADx-EGFR<|>RELATION_NOE 实时<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Sanger<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 体细胞<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 收集<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 石蜡<|>RELATION_NOE 切片<|>RELATION_NOE 208<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE ADx-EGFR<|>RELATION_NOE 实时<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE SangerDNA<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 外显子<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 类型<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 其<|>RELATION_NOE 突变率<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE
208<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE ADx-EGFR<|>RELATION_NOE 实时<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 成功<|>RELATION_NOE 检测<|>RELATION_NOE 208<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 突变<|>RELATION_NOE 检出率<|>RELATION_NOE 为<|>RELATION_NOE 19.2%<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 主要<|>RELATION_NOE 以<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 缺<|>RELATION_NOE 失<|>RELATION_NOE 和<|>RELATION_NOE 外显子<|>RELATION_NOE 21<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE L858R<|>RELATION_NOE 的<|>RELATION_NOE 点突变<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 占<|>RELATION_NOE 4.8%<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE 208<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 11.6%<|>RELATION_NOE (<|>RELATION_NOE 23<|>RELATION_NOE /<|>RELATION_NOE 208<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 类型<|>RELATION_NOE 少见<|>RELATION_NOE 。<|>RELATION_NOE
对于<|>RELATION_NOE 甲醛<|>RELATION_NOE 固定<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 组织<|>RELATION_NOE 而言<|>RELATION_NOE ,<|>RELATION_NOE ADx-EGFR<|>RELATION_NOE 实时<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 成功率<|>RELATION_NOE 和<|>RELATION_NOE 突变<|>RELATION_NOE 检出率<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S SangerDNA<|>RELATION_NOE 测序法<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 成为<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 检测<|>RELATION_NOE 肿瘤<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_S 22<|>RELATION_NOE 例<|>RELATION_NOE 行<|>RELATION_NOE 肺切除术<|>RELATION_NOE 同期<|>RELATION_NOE 联合<|>RELATION_NOE 非<|>RELATION_NOE 体外循环<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 旁路<|>RELATION_NOE 移植术<|>RELATION_NOE (<|>RELATION_NOE OPCAB<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 合并<|>RELATION_NOE 严重<|>RELATION_NOE 冠心病<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病历<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 总结<|>RELATION_NOE 同期<|>RELATION_NOE 手术<|>RELATION_NOE 临床<|>RELATION_NOE 经验<|>RELATION_NOE 。<|>RELATION_NOE
临床<|>RELATION_NOE 肿瘤分期<|>RELATION_NOE 大部分<|>RELATION_NOE 为<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE ,<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 病变<|>RELATION_NOE 程度<|>RELATION_NOE 以<|>RELATION_NOE 两<|>RELATION_NOE 支<|>RELATION_NOE 或<|>RELATION_NOE 三<|>RELATION_NOE 支<|>RELATION_NOE 血管<|>RELATION_NOE 狭窄<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 心<|>RELATION_NOE 肺<|>RELATION_NOE 功能<|>RELATION_NOE 基本<|>RELATION_NOE 正常<|>RELATION_NOE 。<|>RELATION_NOE
搭桥<|>RELATION_NOE 后<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 正中<|>RELATION_NOE 切口<|>RELATION_NOE 完成<|>RELATION_NOE 同期<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 切除<|>RELATION_NOE 4例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 9例经<|>RELATION_NOE 后<|>RELATION_NOE 外侧<|>RELATION_NOE 切口<|>RELATION_NOE 完成<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 2例经<|>RELATION_NOE 后<|>RELATION_NOE 外侧<|>RELATION_NOE 切口<|>RELATION_NOE 完成<|>RELATION_NOE 单<|>RELATION_NOE 支<|>RELATION_NOE 乳内<|>RELATION_NOE 动脉<|>RELATION_NOE 至<|>RELATION_NOE 左前<|>RELATION_NOE 降支<|>RELATION_NOE 搭桥<|>RELATION_NOE 及<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
围手术期<|>RELATION_NOE 无<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 及<|>RELATION_NOE 新发<|>RELATION_NOE 心肌梗死<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 为<|>RELATION_NOE 良性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 常见<|>RELATION_NOE 并发症<|>RELATION_NOE :<|>RELATION_NOE 心律失常<|>RELATION_NOE 、<|>RELATION_NOE 肺不张<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 。<|>RELATION_NOE
随<|>RELATION_NOE 访<|>RELATION_NOE 自<|>RELATION_NOE 术后<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 至<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 患者<|>RELATION_NOE 因<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
同期<|>RELATION_NOE 肺切除术<|>RELATION_NOE 联合<|>RELATION_NOE OPCAB<|>RELATION_NOE 治疗<|>RELATION_S 肺部肿瘤<|>RELATION_NOE 合并<|>RELATION_NOE 冠心病<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 。<|>RELATION_NOE
肺鳞状细胞癌<|>RELATION_NOE 450<|>RELATION_NOE 例<|>RELATION_NOE 预后<|>RELATION_NOE 分析<|>RELATION_S
探讨<|>RELATION_S 肺鳞状细胞癌<|>RELATION_NOE 综合治疗<|>RELATION_NOE 策略<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 分析<|>RELATION_NOE 预后<|>RELATION_NOE 及<|>RELATION_NOE 影响<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_NOE 回归<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 影像<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 状态<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 18.9<|>RELATION_NOE 69<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 44.0<|>RELATION_NOE 69<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE χ2<|>RELATION_NOE =<|>RELATION_NOE 63.0<|>RELATION_NOE 25<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 独立<|>RELATION_B 的<|>RELATION_I 预后<|>RELATION_I 影响<|>RELATION_I 因素<|>RELATION_E 。<|>RELATION_NOE
术<|>RELATION_NOE 前<|>RELATION_NOE 影像<|>RELATION_NOE 提示<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 多<|>RELATION_NOE 组<|>RELATION_NOE 肿大<|>RELATION_NOE 融合<|>RELATION_NOE 怀疑<|>RELATION_NOE 转移<|>RELATION_NOE 者<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 应该<|>RELATION_NOE 慎行<|>RELATION_NOE 。<|>RELATION_NOE
成纤维细胞<|>RELATION_NOE 生长因子<|>RELATION_NOE 2逆转<|>RELATION_NOE 上皮<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_B 机制<|>RELATION_E
探讨<|>RELATION_S 成纤维细胞<|>RELATION_NOE 生长因子<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE FGF2<|>RELATION_NOE )<|>RELATION_NOE 逆转<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE -<|>RELATION_NOE β1<|>RELATION_NOE (<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE )<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 细胞<|>RELATION_NOE 划痕<|>RELATION_NOE 和<|>RELATION_NOE Transwell<|>RELATION_NOE 侵袭<|>RELATION_NOE 试验<|>RELATION_NOE 检测<|>RELATION_S 细胞运动<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 和<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE
TGF-<|>RELATION_NOE β1<|>RELATION_NOE 作用<|>RELATION_NOE 72h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 发生<|>RELATION_NOE EMT<|>RELATION_NOE ,<|>RELATION_NOE 细胞运动<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 增强<|>RELATION_NOE (<|>RELATION_NOE 200.0<|>RELATION_NOE ±<|>RELATION_NOE 12.5<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
微电场<|>RELATION_NOE 网<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE PC9<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞膜<|>RELATION_NOE 通透性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
利用<|>RELATION_NOE 微电场<|>RELATION_NOE 网<|>RELATION_NOE 发生仪<|>RELATION_NOE 对<|>RELATION_NOE 细胞株<|>RELATION_NOE PC9<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 在<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 25<|>RELATION_NOE 、<|>RELATION_NOE 40V<|>RELATION_NOE /<|>RELATION_NOE cm<|>RELATION_NOE 电场<|>RELATION_NOE 强度<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 作用<|>RELATION_NOE 1h<|>RELATION_NOE 和<|>RELATION_NOE 2h<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S PC9<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 和<|>RELATION_NOE 细胞膜<|>RELATION_NOE 通透性<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
此时<|>RELATION_NOE ,<|>RELATION_NOE 微电场<|>RELATION_NOE 网组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 荧光<|>RELATION_NOE 染<|>RELATION_NOE 色阳<|>RELATION_NOE 性率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE PC9<|>RELATION_NOE 细胞<|>RELATION_NOE 荧光<|>RELATION_NOE 染<|>RELATION_NOE 色阳<|>RELATION_NOE 性率<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 15.4<|>RELATION_NOE ±<|>RELATION_NOE 2.9<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 荧光<|>RELATION_NOE 染<|>RELATION_NOE 色阳<|>RELATION_NOE 性率<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 18.1<|>RELATION_NOE ±<|>RELATION_NOE 2.1<|>RELATION_NOE )%<|>RELATION_NOE 。<|>RELATION_NOE
当<|>RELATION_NOE 电场<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 10V<|>RELATION_NOE /<|>RELATION_NOE cm<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 2h<|>RELATION_NOE 以内<|>RELATION_NOE ,<|>RELATION_NOE 微电场<|>RELATION_NOE 网<|>RELATION_NOE 增加<|>RELATION_NOE PC9<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞膜<|>RELATION_NOE 通透性<|>RELATION_NOE 是<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 73<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 、<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 癌旁<|>RELATION_NOE 和<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 非肿瘤性<|>RELATION_NOE 肺组织<|>RELATION_NOE 的<|>RELATION_NOE KAI1<|>RELATION_NOE 和<|>RELATION_NOE TIMP-1<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE ,<|>RELATION_NOE 检验<|>RELATION_NOE 和<|>RELATION_NOE Pearson<|>RELATION_NOE 分析<|>RELATION_NOE 临床<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE KAI1<|>RELATION_NOE 检出率<|>RELATION_NOE 与<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE TIMP-1<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE 与<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 三者<|>RELATION_NOE 检出率<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE ;<|>RELATION_NOE
BiPAP<|>RELATION_NOE 联合<|>RELATION_NOE CPAP<|>RELATION_NOE 通气<|>RELATION_NOE 用于<|>RELATION_S 单肺通气<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE
观察<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 开胸<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 患者<|>RELATION_NOE 单肺通气<|>RELATION_NOE 中行<|>RELATION_NOE BiPAP<|>RELATION_NOE 联合<|>RELATION_NOE cPAP<|>RELATION_NOE 通气<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 血流动力学<|>RELATION_NOE 、<|>RELATION_NOE 动脉<|>RELATION_NOE 氧分压<|>RELATION_NOE 、<|>RELATION_NOE 气道<|>RELATION_NOE 压力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
B<|>RELATION_NOE 组<|>RELATION_NOE VCV<|>RELATION_NOE 通气<|>RELATION_NOE 模式<|>RELATION_NOE ,<|>RELATION_NOE 双<|>RELATION_NOE 肺通气<|>RELATION_NOE 潮气量<|>RELATION_NOE (<|>RELATION_NOE VT<|>RELATION_NOE )<|>RELATION_NOE 8ml<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE 呼吸频率<|>RELATION_NOE (<|>RELATION_NOE RR<|>RELATION_NOE )<|>RELATION_NOE 12-14<|>RELATION_NOE 次<|>RELATION_NOE /<|>RELATION_NOE min<|>RELATION_NOE 。<|>RELATION_NOE
分别<|>RELATION_NOE 于<|>RELATION_NOE OLV<|>RELATION_NOE 前<|>RELATION_NOE (<|>RELATION_NOE T1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE OLV30min<|>RELATION_NOE (<|>RELATION_NOE T2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE OLV120min<|>RELATION_NOE (<|>RELATION_NOE T3<|>RELATION_NOE )<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 时间点<|>RELATION_NOE 观察<|>RELATION_NOE 患者<|>RELATION_NOE 气道<|>RELATION_NOE 峰值<|>RELATION_NOE 压<|>RELATION_NOE (<|>RELATION_NOE Ppeak<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 平均<|>RELATION_NOE 气道压<|>RELATION_NOE (<|>RELATION_NOE Pmean<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 动脉<|>RELATION_NOE 血气分析<|>RELATION_NOE 、<|>RELATION_NOE 心率<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 平均<|>RELATION_NOE 动脉压<|>RELATION_NOE (<|>RELATION_NOE MAP<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
瑶药<|>RELATION_NOE 定心藤<|>RELATION_NOE 挥发<|>RELATION_NOE 油<|>RELATION_NOE 对<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 和<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 活性<|>RELATION_I 研究<|>RELATION_E
超临界<|>RELATION_NOE C02<|>RELATION_NOE 法<|>RELATION_NOE 提取<|>RELATION_NOE 挥发<|>RELATION_NOE 油<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 半数<|>RELATION_NOE 抑制<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IC50<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 评价<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 活性<|>RELATION_NOE 强度<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 盐法<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE 观察<|>RELATION_S 定心藤<|>RELATION_NOE 挥发<|>RELATION_NOE 油<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
紫杉<|>RELATION_NOE 醇+<|>RELATION_NOE 顺铂<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_S 小细胞肺癌<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
顺铂<|>RELATION_NOE 70mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE ,<|>RELATION_NOE 第<|>RELATION_NOE 11－3<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 3<|>RELATION_NOE －<|>RELATION_NOE 4<|>RELATION_NOE 周<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 连<|>RELATION_NOE 用<|>RELATION_NOE 2－<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
本组<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 可<|>RELATION_NOE 评价<|>RELATION_NOE 毒副反应<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 度<|>RELATION_NOE 以上<|>RELATION_NOE 白细胞<|>RELATION_NOE 及<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 47.4%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 57.9%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 非<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒副反应<|>RELATION_NOE 是<|>RELATION_NOE 乏力<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 周围神经<|>RELATION_NOE 毒性<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 度<|>RELATION_NOE 以上<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 是<|>RELATION_NOE 乏力<|>RELATION_NOE 55.3%<|>RELATION_NOE (<|>RELATION_NOE 21<|>RELATION_NOE /<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 31.6%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
自发<|>RELATION_NOE 荧光<|>RELATION_NOE 实时<|>RELATION_NOE 成像<|>RELATION_NOE 技术<|>RELATION_NOE 与<|>RELATION_NOE 普通<|>RELATION_NOE 光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 在<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 癌前<|>RELATION_NOE 病变<|>RELATION_NOE 方面<|>RELATION_NOE 效果<|>RELATION_B 的<|>RELATION_I 比较<|>RELATION_E
比较<|>RELATION_S 自发<|>RELATION_NOE 荧光<|>RELATION_NOE 实时<|>RELATION_NOE 成像<|>RELATION_NOE 技术<|>RELATION_NOE (<|>RELATION_NOE AFI<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 普通<|>RELATION_NOE 光<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE WLB<|>RELATION_NOE )<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 癌前<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 及<|>RELATION_NOE 特异度<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 中<|>RELATION_NOE 常规<|>RELATION_NOE 应用<|>RELATION_NOE AFI<|>RELATION_NOE 技术<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE ReviewManager5.0N<|>RELATION_NOE 算<|>RELATION_NOE AFI<|>RELATION_NOE 与<|>RELATION_NOE WLB<|>RELATION_NOE 在<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 癌前<|>RELATION_NOE 病变<|>RELATION_NOE 方面<|>RELATION_NOE 总<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 、<|>RELATION_NOE 特异度<|>RELATION_NOE 、<|>RELATION_NOE 相对危险度<|>RELATION_NOE (<|>RELATION_NOE RR<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
探索<|>RELATION_S 铜陵<|>RELATION_NOE 地区<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 蝎形<|>RELATION_NOE 探针<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 冷冻<|>RELATION_NOE 组织<|>RELATION_NOE 进行<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 18<|>RELATION_NOE －<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 特征<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
42<|>RELATION_NOE 份<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 24<|>RELATION_NOE 份<|>RELATION_NOE 检测<|>RELATION_NOE 出<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 检出率<|>RELATION_NOE 57.1<|>RELATION_NOE 4%<|>RELATION_NOE 。<|>RELATION_NOE
突变<|>RELATION_NOE 类型<|>RELATION_NOE 主要<|>RELATION_NOE 包括<|>RELATION_NOE L858R<|>RELATION_NOE 点突变<|>RELATION_NOE (<|>RELATION_NOE 41.6<|>RELATION_NOE 7%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 19-delE746-A450<|>RELATION_NOE 缺<|>RELATION_NOE 失<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 41.6<|>RELATION_NOE 7%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE L858R<|>RELATION_NOE +<|>RELATION_NOE 19-del<|>RELATION_NOE (<|>RELATION_NOE 12.50%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE G719X<|>RELATION_NOE 点突变<|>RELATION_NOE (<|>RELATION_NOE 4.17%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
吸烟<|>RELATION_NOE <<|>RELATION_NOE 400<|>RELATION_NOE 年<|>RELATION_NOE 支<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 70.3<|>RELATION_NOE 7%<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 吸烟<|>RELATION_NOE ≥<|>RELATION_NOE 400<|>RELATION_NOE 年<|>RELATION_NOE 支<|>RELATION_NOE 突变率<|>RELATION_NOE (<|>RELATION_NOE 33.3<|>RELATION_NOE 3%<|>RELATION_NOE )<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.02<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肿瘤<|>RELATION_NOE 病理学<|>RELATION_NOE 类型<|>RELATION_NOE 为<|>RELATION_NOE 腺癌<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 60.6<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE /<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 鳞癌<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 40.00%<|>RELATION_NOE (<|>RELATION_NOE 2/5<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 多<|>RELATION_NOE 见于<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 或<|>RELATION_NOE 少<|>RELATION_NOE 吸烟<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
支气管动脉<|>RELATION_NOE 介入<|>RELATION_NOE 治疗<|>RELATION_NOE 与<|>RELATION_NOE 静脉<|>RELATION_NOE 化疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
通过<|>RELATION_NOE 分析<|>RELATION_S 支气管动脉<|>RELATION_NOE 介入<|>RELATION_NOE 治疗<|>RELATION_NOE 与<|>RELATION_NOE 静脉<|>RELATION_NOE 化疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 最佳<|>RELATION_NOE 治疗<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE 接受<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 75<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 介入<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 化疗<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
介入<|>RELATION_NOE 治疗<|>RELATION_NOE 患者<|>RELATION_NOE 中行<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 加<|>RELATION_NOE 栓塞<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
支气管动脉<|>RELATION_NOE 介入<|>RELATION_NOE 治疗<|>RELATION_NOE 中央型<|>RELATION_NOE 、<|>RELATION_NOE 多血供型<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 小<|>RELATION_NOE 细胞型<|>RELATION_NOE 肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 明显<|>RELATION_B 优于<|>RELATION_E 静脉<|>RELATION_NOE 化疗<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 周围型<|>RELATION_NOE 、<|>RELATION_NOE 乏血供型<|>RELATION_NOE 、<|>RELATION_NOE 小细胞型<|>RELATION_NOE 肺癌<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
支气管动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 加<|>RELATION_NOE 栓塞<|>RELATION_NOE 疗效<|>RELATION_NOE 明显<|>RELATION_B 优于<|>RELATION_E 支气管动脉<|>RELATION_NOE 化疗<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
支气管动脉<|>RELATION_NOE 介入<|>RELATION_NOE 和<|>RELATION_NOE 静脉<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 类型<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 根据<|>RELATION_NOE 肺癌<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 认为<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 介入<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 手段<|>RELATION_NOE 之一<|>RELATION_NOE ,<|>RELATION_NOE 如<|>RELATION_NOE 无<|>RELATION_NOE 栓塞<|>RELATION_NOE 禁忌证<|>RELATION_NOE 应<|>RELATION_NOE 首选<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 加<|>RELATION_NOE 栓塞<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 无<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 腹部<|>RELATION_NOE 、<|>RELATION_NOE 腰部<|>RELATION_NOE 疼痛<|>RELATION_NOE 为<|>RELATION_NOE 主要<|>RELATION_NOE 症状<|>RELATION_NOE (<|>RELATION_NOE 57.1%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
14<|>RELATION_NOE 例<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 瘤中<|>RELATION_NOE ,<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 肾癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 结肠癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 喉癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 及<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
肾癌<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 间隔<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 存活<|>RELATION_NOE 时间<|>RELATION_NOE 较<|>RELATION_NOE 长<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 病例<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 胰腺<|>RELATION_NOE 外<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 出现<|>RELATION_NOE 周围<|>RELATION_NOE 血管<|>RELATION_NOE 侵犯<|>RELATION_NOE 。<|>RELATION_NOE
胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 瘤少见<|>RELATION_NOE ,<|>RELATION_NOE 常<|>RELATION_NOE 有<|>RELATION_NOE 多发病灶<|>RELATION_NOE 及<|>RELATION_NOE 胰腺<|>RELATION_NOE 外<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
肾癌<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 主要<|>RELATION_B 为<|>RELATION_E 稍<|>RELATION_NOE 高<|>RELATION_NOE 密度<|>RELATION_NOE 、<|>RELATION_NOE 明显<|>RELATION_NOE 强化<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 转移瘤<|>RELATION_NOE
人类<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 翻译<|>RELATION_NOE 延长<|>RELATION_NOE 因子<|>RELATION_NOE 1A2<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 胰腺癌<|>RELATION_NOE SW1990<|>RELATION_NOE 细胞体<|>RELATION_NOE 外<|>RELATION_NOE 侵袭<|>RELATION_NOE 及<|>RELATION_NOE 体内<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_S 人类<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 翻译<|>RELATION_NOE 延长<|>RELATION_NOE 因子<|>RELATION_NOE 1A2<|>RELATION_NOE (<|>RELATION_NOE EEFlA2<|>RELATION_NOE )<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 胰腺癌<|>RELATION_NOE SW1990<|>RELATION_NOE 细胞体<|>RELATION_NOE 外<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 肺转移<|>RELATION_NOE 潜能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 携带<|>RELATION_NOE EEFlA2<|>RELATION_NOE 的<|>RELATION_NOE 慢病毒感染<|>RELATION_NOE 人<|>RELATION_NOE 胰腺癌<|>RELATION_NOE SW1990<|>RELATION_NOE 细胞<|>RELATION_NOE 建立<|>RELATION_NOE EEFlA2<|>RELATION_NOE 稳定<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE SW1990<|>RELATION_NOE /<|>RELATION_NOE EEFlA2<|>RELATION_NOE 细胞株<|>RELATION_NOE 及<|>RELATION_NOE 空<|>RELATION_NOE 质粒<|>RELATION_NOE 对照<|>RELATION_NOE 的<|>RELATION_NOE SW1990<|>RELATION_NOE /<|>RELATION_NOE GFP<|>RELATION_NOE 细胞株<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 亲本<|>RELATION_NOE SW1990<|>RELATION_NOE 细胞<|>RELATION_NOE 作为<|>RELATION_NOE 空白<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 实时<|>RELATION_NOE PCR<|>RELATION_NOE 和<|>RELATION_NOE 蛋白质<|>RELATION_NOE 印迹法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 细胞<|>RELATION_NOE EEFlA2mRAN<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 裸鼠尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 癌细胞<|>RELATION_NOE 方法<|>RELATION_NOE 构建<|>RELATION_S 肺转移<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 8<|>RELATION_NOE 周<|>RELATION_NOE 后<|>RELATION_NOE 观察<|>RELATION_NOE 并<|>RELATION_NOE 计数<|>RELATION_NOE 肺<|>RELATION_NOE 表面<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 结节<|>RELATION_NOE 。<|>RELATION_NOE
穿膜<|>RELATION_NOE 细胞数<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 60<|>RELATION_NOE ±<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_NOE 多于<|>RELATION_NOE SW1990<|>RELATION_NOE /<|>RELATION_NOE GFP<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 33<|>RELATION_NOE ±<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 和<|>RELATION_NOE 亲本<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE ±<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 31.33<|>RELATION_NOE 、<|>RELATION_NOE 34.78<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
EEFlA2<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 可以<|>RELATION_NOE 明显<|>RELATION_B 增强<|>RELATION_E 胰腺癌<|>RELATION_NOE SW1990<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 肺转移<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
胰岛素<|>RELATION_NOE 注射器<|>RELATION_NOE 与<|>RELATION_NOE 1ml<|>RELATION_NOE 注射器<|>RELATION_NOE 用于<|>RELATION_NOE 升血<|>RELATION_NOE 药物<|>RELATION_NOE 皮下注射<|>RELATION_NOE 升血<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_S
探讨<|>RELATION_S 胰岛素<|>RELATION_NOE 注射器<|>RELATION_NOE 用于<|>RELATION_NOE 升血<|>RELATION_NOE 药物<|>RELATION_NOE 皮下注射<|>RELATION_NOE 的<|>RELATION_NOE 升<|>RELATION_NOE 血<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
方便<|>RELATION_NOE 抽样<|>RELATION_NOE 选取<|>RELATION_NOE 134<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 需<|>RELATION_NOE 皮下注射<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 粒细胞<|>RELATION_NOE 集落<|>RELATION_NOE 刺激<|>RELATION_NOE 因子<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 11年<|>RELATION_NOE 6-10<|>RELATION_NOE 月<|>RELATION_NOE 使用<|>RELATION_NOE 1ml<|>RELATION_NOE 注射器<|>RELATION_NOE 注射<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE 设<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 使用<|>RELATION_NOE 胰岛素<|>RELATION_NOE 注射器<|>RELATION_NOE 注射<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 64<|>RELATION_NOE 例设<|>RELATION_NOE 为<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 注射<|>RELATION_NOE 剂量<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 200<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 注射<|>RELATION_NOE 3d<|>RELATION_NOE 后<|>RELATION_NOE 采<|>RELATION_NOE 血<|>RELATION_NOE 观察<|>RELATION_NOE 白细胞<|>RELATION_NOE (<|>RELATION_NOE WBC<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE (<|>RELATION_NOE NE<|>RELATION_NOE )<|>RELATION_NOE 值<|>RELATION_NOE 。<|>RELATION_NOE
胰岛素<|>RELATION_NOE 注射器<|>RELATION_NOE 用于<|>RELATION_S 皮下注射<|>RELATION_NOE 升血<|>RELATION_NOE 药物<|>RELATION_NOE ,<|>RELATION_NOE 药液<|>RELATION_NOE 损耗<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 升血<|>RELATION_NOE 效果<|>RELATION_NOE 好<|>RELATION_NOE 于<|>RELATION_NOE 1ml<|>RELATION_NOE 注射器<|>RELATION_NOE 。<|>RELATION_NOE
江苏省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 低发区<|>RELATION_NOE 绿茶<|>RELATION_NOE 和<|>RELATION_NOE 大蒜<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 保护<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_B 对照<|>RELATION_I 研究<|>RELATION_E
开展<|>RELATION_NOE 以<|>RELATION_NOE 人群<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 面对面<|>RELATION_NOE 询问<|>RELATION_NOE 收集<|>RELATION_S 主要<|>RELATION_NOE 人口学<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 可能<|>RELATION_NOE 有关<|>RELATION_NOE 的<|>RELATION_NOE 行为<|>RELATION_NOE 、<|>RELATION_NOE 环境<|>RELATION_NOE 和<|>RELATION_NOE 饮食<|>RELATION_NOE 等<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
不<|>RELATION_NOE 食用<|>RELATION_NOE 大蒜<|>RELATION_NOE 与<|>RELATION_NOE 吸烟<|>RELATION_NOE 存在<|>RELATION_NOE 相加<|>RELATION_NOE 交互<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 超额<|>RELATION_NOE 相对危险度<|>RELATION_NOE (<|>RELATION_NOE RERI<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 交互<|>RELATION_NOE 作用<|>RELATION_NOE 归因<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE AP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 交互<|>RELATION_NOE 作用<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE SI<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.86<|>RELATION_NOE 、<|>RELATION_NOE 0.26<|>RELATION_NOE 和<|>RELATION_NOE 1.61<|>RELATION_NOE ;<|>RELATION_NOE
饮用<|>RELATION_NOE 绿茶<|>RELATION_NOE 和<|>RELATION_NOE 食用<|>RELATION_NOE 大蒜<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 保护因素<|>RELATION_S 。<|>RELATION_NOE
肺灌<|>RELATION_NOE 注显<|>RELATION_NOE 像<|>RELATION_NOE 在<|>RELATION_NOE 保护<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 功能<|>RELATION_NOE 肺中<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
比较<|>RELATION_S 解剖<|>RELATION_NOE 图像<|>RELATION_NOE 及<|>RELATION_NOE 功能<|>RELATION_NOE 图像<|>RELATION_NOE 引导<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 的<|>RELATION_NOE 区别<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 通过<|>RELATION_NOE SPECT<|>RELATION_NOE 肺灌<|>RELATION_NOE 注显<|>RELATION_NOE 像<|>RELATION_NOE 指导<|>RELATION_NOE 调<|>RELATION_NOE 强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCI<|>RELATION_NOE 。<|>RELATION_NOE
C<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 放疗<|>RELATION_NOE 前行<|>RELATION_NOE 肺功能<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 将<|>RELATION_NOE 肺灌注<|>RELATION_NOE 图像<|>RELATION_NOE 传<|>RELATION_NOE 至<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 系统<|>RELATION_NOE 进行<|>RELATION_NOE 图像<|>RELATION_NOE 融合<|>RELATION_NOE 制定<|>RELATION_NOE 两<|>RELATION_NOE 套<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE (<|>RELATION_NOE planl<|>RELATION_NOE 和<|>RELATION_NOE plan2<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE planl<|>RELATION_NOE 没有<|>RELATION_NOE 考虑<|>RELATION_NOE SPECT<|>RELATION_NOE 肺灌注<|>RELATION_NOE 图像<|>RELATION_NOE 仅<|>RELATION_NOE 根据<|>RELATION_NOE 解剖<|>RELATION_NOE 信息<|>RELATION_NOE 进行<|>RELATION_NOE 设计<|>RELATION_NOE ,<|>RELATION_NOE plan2<|>RELATION_NOE 考虑<|>RELATION_NOE SPECT<|>RELATION_NOE 肺灌注<|>RELATION_NOE 图像<|>RELATION_NOE 提供<|>RELATION_NOE 的<|>RELATION_NOE 肺功能<|>RELATION_NOE 信息<|>RELATION_NOE 进行<|>RELATION_NOE 优化<|>RELATION_NOE ,<|>RELATION_NOE 尽可能<|>RELATION_NOE 降低<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 的<|>RELATION_NOE 照射<|>RELATION_NOE 剂量<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S plan2<|>RELATION_NOE 与<|>RELATION_NOE planl<|>RELATION_NOE 在<|>RELATION_NOE 保护<|>RELATION_NOE 功能<|>RELATION_NOE 肺<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 差别<|>RELATION_NOE 。<|>RELATION_NOE
核素<|>RELATION_NOE 肺灌<|>RELATION_NOE 注显<|>RELATION_NOE 像<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 评价<|>RELATION_E 放疗<|>RELATION_NOE 前<|>RELATION_NOE 肿瘤<|>RELATION_NOE 对<|>RELATION_NOE 局部<|>RELATION_NOE 肺动脉<|>RELATION_NOE 血流<|>RELATION_NOE 灌注<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 及<|>RELATION_NOE 减少<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 的<|>RELATION_NOE 受<|>RELATION_NOE 照射<|>RELATION_NOE 剂量<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿刺<|>RELATION_NOE ^<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 肺转<|>RELATION_NOE 移癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE
11<|>RELATION_NOE 例<|>RELATION_NOE 次<|>RELATION_NOE 出现<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 气胸<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3例次<|>RELATION_NOE 较<|>RELATION_NOE 重<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 胸腔<|>RELATION_NOE 穿刺<|>RELATION_NOE 后<|>RELATION_NOE 好转<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 轻者<|>RELATION_NOE 密切<|>RELATION_NOE 随诊<|>RELATION_NOE 观察<|>RELATION_NOE 直至<|>RELATION_NOE 气体<|>RELATION_NOE 吸收<|>RELATION_NOE ;<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 共<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 533<|>RELATION_NOE 枚<|>RELATION_NOE 淋巴结<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 证实<|>RELATION_NOE 恶性<|>RELATION_NOE 192<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 341<|>RELATION_NOE 枚<|>RELATION_NOE (<|>RELATION_NOE 炎性<|>RELATION_NOE 增生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 或<|>RELATION_NOE 正常<|>RELATION_NOE 淋巴结<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 以<|>RELATION_NOE ^<|>RELATION_NOE 18F-FDGSUV<|>RELATION_NOE ≥<|>RELATION_NOE 2.5<|>RELATION_NOE 和<|>RELATION_NOE ^<|>RELATION_NOE 18F-FLTSUV<|>RELATION_NOE ≥<|>RELATION_NOE 2.0<|>RELATION_NOE 为<|>RELATION_NOE 诊断<|>RELATION_NOE 恶性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 阈值<|>RELATION_NOE ^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 和<|>RELATION_NOE ^<|>RELATION_NOE 18F-FIJTPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 对<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 良<|>RELATION_NOE 恶性<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 及<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 91.6<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE 176<|>RELATION_NOE /<|>RELATION_NOE 192<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 80.9<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 276<|>RELATION_NOE /<|>RELATION_NOE 341<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 84.80%<|>RELATION_NOE (<|>RELATION_NOE 452<|>RELATION_NOE /<|>RELATION_NOE 533<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 73.03%<|>RELATION_NOE (<|>RELATION_NOE 176<|>RELATION_NOE /<|>RELATION_NOE 241<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 94.5<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 276<|>RELATION_NOE /<|>RELATION_NOE 292<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 81.2<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 156<|>RELATION_NOE /<|>RELATION_NOE 192<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 92.9<|>RELATION_NOE 6%<|>RELATION_NOE (<|>RELATION_NOE 317<|>RELATION_NOE /<|>RELATION_NOE 341<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 88.7<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 473<|>RELATION_NOE /<|>RELATION_NOE 533<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 86.6<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE 156<|>RELATION_NOE /<|>RELATION_NOE 180<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 89.80%<|>RELATION_NOE (<|>RELATION_NOE 317<|>RELATION_NOE /<|>RELATION_NOE 353<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 灵敏度<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE ,<|>RELATION_NOE =<|>RELATION_NOE 8.8<|>RELATION_NOE 97<|>RELATION_NOE 、<|>RELATION_NOE 21.7<|>RELATION_NOE 22<|>RELATION_NOE 和<|>RELATION_NOE 11.4<|>RELATION_NOE 95<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 准确性<|>RELATION_NOE 和<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 3.<|>RELATION_NOE 604<|>RELATION_NOE 和<|>RELATION_NOE 3.7<|>RELATION_NOE 12<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 诊断<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 良<|>RELATION_NOE 恶性<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 高于<|>RELATION_S ^<|>RELATION_NOE 18F-FLT<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 特异性<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE FLT<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 联合<|>RELATION_NOE 诊断<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE 诊断<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
肺部<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE (<|>RELATION_NOE 简称<|>RELATION_NOE 鳞癌<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE SUV<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE 12.57<|>RELATION_NOE ±<|>RELATION_NOE 4.34<|>RELATION_NOE 、<|>RELATION_NOE 10.66<|>RELATION_NOE ±<|>RELATION_NOE 2.90<|>RELATION_NOE 和<|>RELATION_NOE 8.19<|>RELATION_NOE ±<|>RELATION_NOE 6.01<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE SUV<|>RELATION_NOE (<|>RELATION_NOE 3.01<|>RELATION_NOE ±<|>RELATION_NOE 3.62<|>RELATION_NOE )<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 20.83<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 肺癌<|>RELATION_NOE suV<|>RELATION_NOE 从<|>RELATION_NOE 大<|>RELATION_NOE 到<|>RELATION_NOE 小<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 鳞癌<|>RELATION_NOE 与<|>RELATION_NOE 腺癌<|>RELATION_NOE suV<|>RELATION_NOE 一<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
SUV<|>RELATION_NOE …<|>RELATION_NOE 的<|>RELATION_NOE ROCAUC<|>RELATION_NOE 为<|>RELATION_NOE 0.8<|>RELATION_NOE 63<|>RELATION_NOE ,<|>RELATION_NOE SUV<|>RELATION_NOE 界值<|>RELATION_NOE 2.99<|>RELATION_NOE 和<|>RELATION_NOE 2.50<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 89.0%<|>RELATION_NOE (<|>RELATION_NOE 73<|>RELATION_NOE /<|>RELATION_NOE 82<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 75.0%<|>RELATION_NOE (<|>RELATION_NOE 30<|>RELATION_NOE /<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 91.5%<|>RELATION_NOE (<|>RELATION_NOE 75<|>RELATION_NOE /<|>RELATION_NOE 82<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 65.0%<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE /<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE SUV2.99<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 比值比<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE )<|>RELATION_NOE 优于<|>RELATION_S SUV2.50<|>RELATION_NOE 的<|>RELATION_NOE OR<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.42<|>RELATION_NOE 和<|>RELATION_NOE 3.93<|>RELATION_NOE ;<|>RELATION_NOE
SUV<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 5.42<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 7.27.P<|>RELATION_NOE =<|>RELATION_NOE 0.02<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 毛刺征<|>RELATION_NOE (<|>RELATION_NOE 鲫=<|>RELATION_NOE 7.70<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 分叶征<|>RELATION_NOE (<|>RELATION_NOE DR<|>RELATION_NOE =<|>RELATION_NOE 12.38<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 与<|>RELATION_NOE 良性<|>RELATION_NOE 病灶<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 有<|>RELATION_B 统计学<|>RELATION_I 意义<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_I 因素<|>RELATION_E 。<|>RELATION_NOE
SUV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 有<|>RELATION_B 较<|>RELATION_I 高<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
“<|>RELATION_NOE F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 联合<|>RELATION_NOE HRCT<|>RELATION_NOE 诊断<|>RELATION_NOE 肺实性<|>RELATION_NOE 病灶<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE SUV<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径<|>RELATION_NOE 、<|>RELATION_NOE 毛刺征<|>RELATION_NOE 和<|>RELATION_NOE 分叶<|>RELATION_NOE 征<|>RELATION_NOE 为<|>RELATION_NOE 其<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
SPECT<|>RELATION_NOE 定性<|>RELATION_NOE 和<|>RELATION_NOE 半定量分析法<|>RELATION_NOE 在<|>RELATION_NOE ”<|>RELATION_NOE Tc<|>RELATION_NOE ”<|>RELATION_NOE -3P<|>RELATION_NOE ±<|>RELATION_NOE RGD<|>RELATION_NOE ,<|>RELATION_NOE SPECT<|>RELATION_NOE 显像<|>RELATION_NOE 诊断<|>RELATION_NOE SPN<|>RELATION_NOE 方面<|>RELATION_NOE 具有<|>RELATION_B 高<|>RELATION_I 灵敏度<|>RELATION_I 和<|>RELATION_I 一致性<|>RELATION_E 。<|>RELATION_NOE
应用<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 应用<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 试验组<|>RELATION_NOE 37<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 为<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 、<|>RELATION_NOE 脱发<|>RELATION_NOE 、<|>RELATION_NOE 肌肉<|>RELATION_NOE 关节<|>RELATION_NOE 酸痛<|>RELATION_NOE 、<|>RELATION_NOE 消化道<|>RELATION_NOE 症状<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 严重<|>RELATION_NOE 过敏反应<|>RELATION_NOE ,<|>RELATION_NOE 试验组<|>RELATION_NOE 低血压<|>RELATION_NOE 、<|>RELATION_NOE 面部<|>RELATION_NOE 潮红<|>RELATION_NOE 、<|>RELATION_NOE 感觉异常<|>RELATION_NOE 、<|>RELATION_NOE 肌肉<|>RELATION_NOE 关节痛<|>RELATION_NOE 、<|>RELATION_NOE 皮疹<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE [<|>RELATION_NOE 0<|>RELATION_NOE 比<|>RELATION_NOE 9.7%<|>RELATION_NOE (<|>RELATION_NOE 3/31<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5.4%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 19.4%<|>RELATION_NOE (<|>RELATION_NOE 6/31<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 10.8%<|>RELATION_NOE (<|>RELATION_NOE 4/37<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 22.6%<|>RELATION_NOE (<|>RELATION_NOE 7/31<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 13.5%<|>RELATION_NOE (<|>RELATION_NOE 5/37<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 38.7%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5.4%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 25.8%<|>RELATION_NOE (<|>RELATION_NOE 8<|>RELATION_NOE ,<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE 或<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
超声检查<|>RELATION_NOE 在<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
超声检查<|>RELATION_NOE 在<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 具有<|>RELATION_B 重要<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
探讨<|>RELATION_S 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 放疗<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
体外<|>RELATION_NOE 化学<|>RELATION_NOE 合成<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 序列<|>RELATION_NOE 特异性<|>RELATION_NOE 双链<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE dsRNA<|>RELATION_NOE )<|>RELATION_NOE 结合<|>RELATION_NOE 脂质体<|>RELATION_NOE Lipofectamine2000<|>RELATION_NOE 转染<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE SPC-A1<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE real-timePCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Wesemblot<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S 转染<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE EGFRmRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 集落<|>RELATION_NOE 抑制<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_NOE EGFR<|>RELATION_NOE 序列<|>RELATION_NOE 特异性<|>RELATION_NOE dsRNA<|>RELATION_NOE (<|>RELATION_NOE dsRNA-EGFR<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 放疗<|>RELATION_NOE 增敏<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 测定<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 重量<|>RELATION_NOE ,<|>RELATION_NOE 绘制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_S 肿瘤<|>RELATION_NOE 抑制率<|>RELATION_NOE 。<|>RELATION_NOE
放疗<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE dsRNA-unrelated<|>RELATION_NOE 联合<|>RELATION_NOE 放疗组<|>RELATION_NOE 和<|>RELATION_NOE dsRNA-EGFR<|>RELATION_NOE 联合<|>RELATION_NOE 放疗组<|>RELATION_NOE 的<|>RELATION_NOE 集落<|>RELATION_NOE 抑制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 9.3%<|>RELATION_NOE 、<|>RELATION_NOE 12.5%<|>RELATION_NOE 和<|>RELATION_NOE 65.5%<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 21.3%<|>RELATION_NOE 、<|>RELATION_NOE 24.4%<|>RELATION_NOE 和<|>RELATION_NOE 64.2%<|>RELATION_NOE ,<|>RELATION_NOE dsRNA-EGFR<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 抑制<|>RELATION_E 体外<|>RELATION_NOE 、<|>RELATION_NOE 体内<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 可溶性<|>RELATION_NOE 程序性<|>RELATION_NOE 死亡<|>RELATION_NOE 配体<|>RELATION_NOE 1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 对<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
观察<|>RELATION_S 可溶性<|>RELATION_NOE 程序性<|>RELATION_NOE 死亡<|>RELATION_NOE 配体<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE sPD-L1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 特性<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 生物学<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 膜型<|>RELATION_NOE PD-L1<|>RELATION_NOE (<|>RELATION_NOE mPD-L1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 人<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 表面<|>RELATION_NOE 程序性<|>RELATION_NOE 死亡<|>RELATION_NOE 受体<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE PD-1<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE
CCK-8<|>RELATION_NOE 体外<|>RELATION_NOE 实验<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 活化<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE +<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE +<|>RELATION_NOE mIgG<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 活化<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE +<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE +<|>RELATION_NOE α<|>RELATION_NOE -PD-L1<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE A<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.924-0.09<|>RELATION_NOE 和<|>RELATION_NOE 1.284-0.13<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
活化<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE +<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 上<|>RELATION_NOE 清<|>RELATION_NOE +<|>RELATION_NOE d-PD-L1<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 活化<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE +<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 上<|>RELATION_NOE 清<|>RELATION_NOE +<|>RELATION_NOE mIgG<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE A<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.92<|>RELATION_NOE ±<|>RELATION_NOE 0.03<|>RELATION_NOE 和<|>RELATION_NOE 0.68<|>RELATION_NOE ±<|>RELATION_NOE 0.03<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE mPD-L1<|>RELATION_NOE 和<|>RELATION_NOE sPD-L1<|>RELATION_NOE 均<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 抑制<|>RELATION_E T<|>RELATION_NOE 淋巴细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 发挥<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 的<|>RELATION_NOE 负性<|>RELATION_NOE 调节<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 可能<|>RELATION_NOE 导致<|>RELATION_NOE 肿瘤抗原特异性<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 失活<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 逃逸<|>RELATION_NOE 。<|>RELATION_NOE
生物钟<|>RELATION_NOE 基因<|>RELATION_NOE Per2<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
研究<|>RELATION_S 生物钟<|>RELATION_NOE 基因<|>RELATION_NOE Per2<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色法<|>RELATION_NOE 检测<|>RELATION_S 60<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE Per2<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
Gal-3<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 和<|>RELATION_NOE pTNM<|>RELATION_NOE 分期<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
SB203580<|>RELATION_NOE 增强<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 对<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE PC-9<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E
采用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MIT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S SB203580<|>RELATION_NOE 和<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 对<|>RELATION_NOE PC-9<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 技术<|>RELATION_NOE 采用<|>RELATION_NOE 四甲基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MIT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE SB203580<|>RELATION_NOE 和<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 对<|>RELATION_NOE PC-9<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S p38<|>RELATION_NOE 、<|>RELATION_NOE 磷酸化<|>RELATION_NOE p38<|>RELATION_NOE (<|>RELATION_NOE P-p38<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
细胞免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE p-p38<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中低表达<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE PC-9<|>RELATION_NOE 细胞<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 细胞<|>RELATION_NOE 角质<|>RELATION_NOE 蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 和<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 意义<|>RELATION_E
探讨<|>RELATION_S 血清<|>RELATION_NOE 细胞<|>RELATION_NOE 角质<|>RELATION_NOE 蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE (<|>RELATION_NOE ProGRP<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 敏感度<|>RELATION_NOE 3项<|>RELATION_NOE 联合<|>RELATION_NOE 达<|>RELATION_NOE 72.6<|>RELATION_NOE 7%<|>RELATION_NOE ,<|>RELATION_NOE 特异度<|>RELATION_NOE CYb'RA21-1<|>RELATION_NOE 最高<|>RELATION_NOE 为<|>RELATION_NOE 97.4<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 准确度<|>RELATION_NOE 为<|>RELATION_NOE 3<|>RELATION_NOE 项<|>RELATION_NOE 联合<|>RELATION_NOE 最高<|>RELATION_NOE (<|>RELATION_NOE 76.2<|>RELATION_NOE 6%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 区分<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 和<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 有<|>RELATION_B 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ProGRP<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 区分<|>RELATION_NOE 不同<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效率<|>RELATION_NOE 。<|>RELATION_NOE
CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 呵<|>RELATION_NOE 鉴别<|>RELATION_S 肺部良<|>RELATION_NOE 恶性<|>RELATION_NOE 疾病<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 分型<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 意义<|>RELATION_NOE ;<|>RELATION_NOE
ProGRP<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 学分型<|>RELATION_NOE 具有<|>RELATION_B 较<|>RELATION_I 高<|>RELATION_I 的<|>RELATION_I 诊断<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
119<|>RELATION_NOE 例<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 激素<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE hormone<|>RELATION_NOE receptor<|>RELATION_NOE ,<|>RELATION_NOE HR<|>RELATION_NOE )<|>RELATION_NOE +<|>RELATION_NOE /<|>RELATION_NOE 人<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE human<|>RELATION_NOE epithelial<|>RELATION_NOE growth<|>RELATION_NOE factor<|>RELATION_NOE receptor<|>RELATION_NOE ,<|>RELATION_NOE HER2<|>RELATION_NOE )<|>RELATION_NOE -<|>RELATION_NOE 、<|>RELATION_NOE HR<|>RELATION_NOE +<|>RELATION_NOE /<|>RELATION_NOE HER2<|>RELATION_NOE +<|>RELATION_NOE 、<|>RELATION_NOE HR-<|>RELATION_NOE /<|>RELATION_NOE HER2<|>RELATION_NOE +<|>RELATION_NOE 和<|>RELATION_NOE 三阴性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE (<|>RELATION_NOE triple<|>RELATION_NOE negative<|>RELATION_NOE breast<|>RELATION_NOE cancer<|>RELATION_NOE ,<|>RELATION_NOE TNBC<|>RELATION_NOE )<|>RELATION_NOE 各<|>RELATION_NOE 亚型<|>RELATION_NOE 所<|>RELATION_NOE 占<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 35.3%<|>RELATION_NOE 、<|>RELATION_NOE 17.6%<|>RELATION_NOE 、<|>RELATION_NOE 21.8%<|>RELATION_NOE 、<|>RELATION_NOE 25.2%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 三阴性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 与<|>RELATION_NOE 其他<|>RELATION_NOE 亚型<|>RELATION_NOE 相比<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE Ⅲ<|>RELATION_NOE 级<|>RELATION_NOE 发生率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
本组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 为<|>RELATION_NOE 60<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 9-141<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中位肺<|>RELATION_NOE 转移<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 29<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 3-99<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE 肺<|>RELATION_NOE 转移<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 是<|>RELATION_NOE 33<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 6-98<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 是<|>RELATION_NOE 72.9%<|>RELATION_NOE 、<|>RELATION_NOE 54.1%<|>RELATION_NOE 、<|>RELATION_NOE 35.1%<|>RELATION_NOE 和<|>RELATION_NOE 14.4%<|>RELATION_NOE 。<|>RELATION_NOE
三阴性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 多发肺<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 、<|>RELATION_NOE 肺转移<|>RELATION_NOE 时间<|>RELATION_NOE ≤<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 及<|>RELATION_NOE 是否<|>RELATION_NOE 曾<|>RELATION_NOE 接受<|>RELATION_NOE 系统<|>RELATION_NOE 化疗<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 危险因素<|>RELATION_E 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 我院<|>RELATION_NOE 2000年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 640<|>RELATION_NOE 例<|>RELATION_NOE 肝移植术<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病历<|>RELATION_NOE 及<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 总结<|>RELATION_NOE 肝移植术<|>RELATION_NOE 后<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 患病率<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 肝移植术<|>RELATION_NOE 后<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 伯基特<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE (<|>RELATION_NOE 肝移植术<|>RELATION_NOE 后<|>RELATION_NOE 淋巴组织<|>RELATION_NOE 增殖性<|>RELATION_NOE 疾病<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 、<|>RELATION_NOE 急性<|>RELATION_NOE 髓性<|>RELATION_NOE 白血病<|>RELATION_NOE (<|>RELATION_NOE AMI<|>RELATION_NOE 。<|>RELATION_NOE
)<|>RELATION_NOE 、<|>RELATION_NOE 膀胱癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 乙状结肠癌<|>RELATION_NOE 、<|>RELATION_NOE 直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 肾透明<|>RELATION_NOE 细胞癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE 以及<|>RELATION_NOE 肝癌<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
肝移植术<|>RELATION_NOE 前<|>RELATION_NOE 原发<|>RELATION_NOE 疾病<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 抑制<|>RELATION_NOE 强度<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 以及<|>RELATION_NOE 不同<|>RELATION_NOE 人<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 特点<|>RELATION_NOE 等<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 我<|>RELATION_NOE 中心<|>RELATION_NOE 肝移植术<|>RELATION_NOE 后<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患病率<|>RELATION_NOE 低于<|>RELATION_S 欧<|>RELATION_NOE 美<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 第四<|>RELATION_NOE 军医<|>RELATION_NOE 大学<|>RELATION_NOE 唐都<|>RELATION_NOE 医院<|>RELATION_NOE 呼吸<|>RELATION_NOE 内科<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 9月<|>RELATION_NOE 支气管镜室<|>RELATION_NOE 使用<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE 14<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 863<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 60.6<|>RELATION_NOE 9%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 559<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 39.3<|>RELATION_NOE 1%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
分析<|>RELATION_NOE 了<|>RELATION_NOE 14<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE 镜下<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 活检<|>RELATION_NOE
白光<|>RELATION_NOE 下<|>RELATION_NOE 正常<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 黏膜<|>RELATION_NOE 轻度<|>RELATION_NOE 充血<|>RELATION_NOE 、<|>RELATION_NOE 肿胀者<|>RELATION_NOE )<|>RELATION_NOE 而<|>RELATION_NOE 荧光镜<|>RELATION_NOE 下<|>RELATION_NOE 异常者<|>RELATION_NOE ,<|>RELATION_NOE 活检<|>RELATION_NOE 发现<|>RELATION_NOE 中<|>RELATION_NOE 一<|>RELATION_NOE 重度<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 增生<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 对于<|>RELATION_NOE 气管<|>RELATION_NOE 内<|>RELATION_NOE 明显<|>RELATION_NOE 可见<|>RELATION_NOE 并<|>RELATION_NOE 怀疑<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 不<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 黏膜<|>RELATION_NOE 荧光<|>RELATION_NOE 改变<|>RELATION_NOE 的<|>RELATION_NOE 程度<|>RELATION_NOE 可能<|>RELATION_NOE 有助于<|>RELATION_S 良<|>RELATION_NOE 、<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 镜<|>RELATION_NOE 下<|>RELATION_NOE 鉴别<|>RELATION_NOE 。<|>RELATION_NOE
拓扑<|>RELATION_NOE 替康<|>RELATION_NOE 诱导<|>RELATION_S 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE HTB-56<|>RELATION_NOE 凋亡<|>RELATION_NOE 早期<|>RELATION_NOE 线粒体<|>RELATION_NOE 膜电位<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE
探讨<|>RELATION_S 拓扑<|>RELATION_NOE 替康<|>RELATION_NOE 诱导<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE HTB-56<|>RELATION_NOE 凋亡<|>RELATION_NOE 早期<|>RELATION_NOE 线粒体<|>RELATION_NOE 膜电位<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE HTB-56<|>RELATION_NOE 细胞株<|>RELATION_NOE ,<|>RELATION_NOE JC-1<|>RELATION_NOE 荧光<|>RELATION_NOE 染色<|>RELATION_NOE 标记<|>RELATION_NOE 线粒体<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 早期<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 拓扑<|>RELATION_NOE 替康<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE HTB<|>RELATION_NOE .<|>RELATION_NOE
56<|>RELATION_NOE 细胞<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 细胞<|>RELATION_NOE 线粒体膜<|>RELATION_NOE 电位<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 琼脂糖<|>RELATION_NOE 凝胶<|>RELATION_NOE 电泳<|>RELATION_NOE 检测<|>RELATION_S 拓扑<|>RELATION_NOE 替康<|>RELATION_NOE 作用<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 引起<|>RELATION_NOE HTB-56<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
4h<|>RELATION_NOE 后<|>RELATION_NOE 细胞<|>RELATION_NOE 线粒体膜<|>RELATION_NOE 电位<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 8h<|>RELATION_NOE 后<|>RELATION_NOE 细胞膜<|>RELATION_NOE 电位<|>RELATION_NOE 明显<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 下降<|>RELATION_NOE 程度<|>RELATION_NOE 随<|>RELATION_NOE 时间<|>RELATION_NOE 延长<|>RELATION_NOE 而<|>RELATION_NOE 增大<|>RELATION_NOE 。<|>RELATION_NOE
小<|>RELATION_NOE 剂量<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 局部<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_S 高龄<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_S 小<|>RELATION_NOE 剂量<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 局部<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 高龄<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
HBsAg<|>RELATION_NOE 阴性<|>RELATION_NOE 或<|>RELATION_NOE 抗<|>RELATION_NOE -HBc<|>RELATION_NOE 阳<|>RELATION_NOE 性者<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 辅助<|>RELATION_NOE 化学<|>RELATION_NOE 治疗<|>RELATION_S 中<|>RELATION_NOE 乙型<|>RELATION_NOE 肝炎病毒<|>RELATION_NOE 的<|>RELATION_NOE 再<|>RELATION_NOE 激活<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2003年<|>RELATION_NOE 1月<|>RELATION_NOE 到<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 接受<|>RELATION_NOE 辅助<|>RELATION_NOE 化学<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 32<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 入<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_S HBV<|>RELATION_NOE 血清<|>RELATION_NOE 学<|>RELATION_NOE 标志物<|>RELATION_NOE 和<|>RELATION_NOE 生物<|>RELATION_NOE 化学<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 接受<|>RELATION_NOE 以<|>RELATION_NOE 顺铂<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 化学<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
36<|>RELATION_NOE 7例<|>RELATION_NOE HBsAg<|>RELATION_NOE 阴性<|>RELATION_NOE 或<|>RELATION_NOE 抗<|>RELATION_NOE -HBc<|>RELATION_NOE 阳性<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 3.8<|>RELATION_NOE 1%<|>RELATION_NOE )<|>RELATION_NOE 进展<|>RELATION_NOE 为<|>RELATION_NOE 乙型肝炎<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_S 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE
探讨<|>RELATION_S 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 手术时间<|>RELATION_NOE 明显<|>RELATION_B 增加<|>RELATION_E ,<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 明显<|>RELATION_NOE 减少<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
VATS<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 可<|>RELATION_NOE 彻底<|>RELATION_B 清扫<|>RELATION_E 淋巴结<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 创伤<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 轻<|>RELATION_NOE 、<|>RELATION_NOE 恢复<|>RELATION_NOE 较<|>RELATION_NOE 快<|>RELATION_NOE 及<|>RELATION_NOE 生存率<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 早期<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE 术式<|>RELATION_NOE 。<|>RELATION_NOE
电子<|>RELATION_NOE 支气管镜<|>RELATION_NOE 替代<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 在<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_E
评价<|>RELATION_S 电子<|>RELATION_NOE 支气管镜<|>RELATION_NOE 替代<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 对<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 病因<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
98<|>RELATION_NOE 例<|>RELATION_NOE 经过<|>RELATION_NOE 一<|>RELATION_NOE 系列<|>RELATION_NOE 常规<|>RELATION_NOE 检查<|>RELATION_NOE 仍<|>RELATION_NOE 不能<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 渗出性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 电子<|>RELATION_NOE 支气管镜<|>RELATION_NOE 胸腔<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 诊断<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 非霍奇金<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 恶性<|>RELATION_NOE 胸膜<|>RELATION_NOE 间皮瘤<|>RELATION_NOE 5<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 结核性<|>RELATION_NOE 胸膜炎<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 特异性<|>RELATION_NOE 炎性<|>RELATION_NOE 反应<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 确诊<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 确诊率<|>RELATION_NOE 为<|>RELATION_NOE 90.8<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 89<|>RELATION_NOE /<|>RELATION_NOE 98<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
局部<|>RELATION_NOE 麻醉<|>RELATION_NOE 下行<|>RELATION_NOE 电子<|>RELATION_NOE 支气管镜<|>RELATION_NOE 替代<|>RELATION_NOE 胸腔镜检查<|>RELATION_NOE 具有<|>RELATION_S 创伤<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 诊断率<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 操作<|>RELATION_NOE 简便<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE 等<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 中<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 外源性<|>RELATION_NOE p21waf1<|>RELATION_NOE 基因<|>RELATION_NOE 转染<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
p21waf1<|>RELATION_NOE 转染组<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 空<|>RELATION_NOE 载体组<|>RELATION_NOE 和<|>RELATION_NOE 未<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
p21waf1<|>RELATION_NOE 基因<|>RELATION_NOE 转染<|>RELATION_NOE 可以<|>RELATION_NOE 抑制<|>RELATION_S 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 并<|>RELATION_NOE 能<|>RELATION_NOE 诱导<|>RELATION_NOE 其<|>RELATION_NOE 发生<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 基因治疗<|>RELATION_NOE 提供<|>RELATION_NOE 一<|>RELATION_NOE 条<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 途径<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 选择<|>RELATION_NOE 我院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 股骨颈骨折<|>RELATION_NOE 患者<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 术前<|>RELATION_NOE 积极<|>RELATION_NOE 做好<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 卫生<|>RELATION_NOE 宣教<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 消除<|>RELATION_NOE 患者<|>RELATION_NOE 不良<|>RELATION_NOE 情绪<|>RELATION_NOE ,<|>RELATION_NOE 使<|>RELATION_NOE 其<|>RELATION_NOE 积极<|>RELATION_NOE 配合<|>RELATION_NOE 治疗<|>RELATION_NOE ;<|>RELATION_NOE
术后<|>RELATION_NOE 加强<|>RELATION_NOE 基础<|>RELATION_NOE 护理<|>RELATION_NOE 及<|>RELATION_NOE 康复<|>RELATION_NOE 指导<|>RELATION_NOE ,<|>RELATION_NOE 预防<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 促进<|>RELATION_S 康复<|>RELATION_NOE 。<|>RELATION_NOE
良好<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 保证<|>RELATION_NOE 老年<|>RELATION_NOE 股骨颈骨折<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 成功<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 顺利<|>RELATION_NOE 康复<|>RELATION_NOE 极为<|>RELATION_B 重要<|>RELATION_E 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 因素<|>RELATION_I 分析<|>RELATION_E
通过<|>RELATION_NOE 分析<|>RELATION_B 比较<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 化疗<|>RELATION_NOE 对于<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
化疗<|>RELATION_NOE 前<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 方面<|>RELATION_NOE 疲乏<|>RELATION_NOE 、<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 项目<|>RELATION_NOE 得分<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 伴<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 占<|>RELATION_NOE 58%<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE SAS<|>RELATION_NOE 得分<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 49.7<|>RELATION_NOE ±<|>RELATION_NOE 5.8<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ;<|>RELATION_NOE
化疗2<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 得分<|>RELATION_NOE 较<|>RELATION_NOE 前<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 食欲<|>RELATION_NOE 丧失<|>RELATION_NOE 、<|>RELATION_NOE 失眠<|>RELATION_NOE 得分<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 比较<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_NOE 差异<|>RELATION_NOE ;<|>RELATION_NOE
化疗4<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 角色<|>RELATION_NOE 、<|>RELATION_NOE 躯体<|>RELATION_NOE 、<|>RELATION_NOE 情绪<|>RELATION_NOE 、<|>RELATION_NOE 社会<|>RELATION_NOE 功能<|>RELATION_NOE 得分<|>RELATION_NOE 明显<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 便秘<|>RELATION_NOE 、<|>RELATION_NOE 食欲不振及<|>RELATION_NOE 经济<|>RELATION_NOE 困难<|>RELATION_NOE 条目<|>RELATION_NOE 得分<|>RELATION_NOE 明显<|>RELATION_NOE 上升<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 前2<|>RELATION_NOE 周期<|>RELATION_NOE 相比<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_NOE 差异<|>RELATION_NOE ;<|>RELATION_NOE
焦虑<|>RELATION_NOE 症状<|>RELATION_NOE 与<|>RELATION_NOE 疲乏<|>RELATION_NOE 、<|>RELATION_NOE 便秘<|>RELATION_NOE 及<|>RELATION_NOE 失眠<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 在<|>RELATION_NOE 化疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 患者<|>RELATION_NOE 躯体<|>RELATION_NOE 症状<|>RELATION_NOE 得到<|>RELATION_NOE 缓解<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 生命<|>RELATION_NOE 质量<|>RELATION_NOE 有所<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 因此<|>RELATION_NOE 护理<|>RELATION_NOE 人员<|>RELATION_NOE 应当<|>RELATION_NOE 及时<|>RELATION_NOE 准确<|>RELATION_NOE 评价<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 情绪<|>RELATION_NOE 改变<|>RELATION_NOE 并<|>RELATION_NOE 针对性<|>RELATION_NOE 地<|>RELATION_NOE 加强<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
外<|>RELATION_NOE 周血<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 与<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
动态<|>RELATION_NOE 监测<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 与<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 可<|>RELATION_NOE 指导<|>RELATION_S 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 有助于<|>RELATION_NOE 评估<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_NOE 基于<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE RT-qPCR<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S miRNA<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 进行<|>RELATION_NOE 定量<|>RELATION_NOE 研究<|>RELATION_NOE ;<|>RELATION_NOE
20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 9月<|>RELATION_NOE 收集<|>RELATION_NOE 苏州<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 第一<|>RELATION_NOE 医院<|>RELATION_NOE 住院<|>RELATION_NOE 及<|>RELATION_NOE 门诊<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 61<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 及<|>RELATION_NOE 健康<|>RELATION_NOE 对照<|>RELATION_NOE 各<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 各组<|>RELATION_NOE 间<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 匹配<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 为<|>RELATION_NOE 64<|>RELATION_NOE (<|>RELATION_NOE 40-85<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ;<|>RELATION_NOE
20a<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 27<|>RELATION_NOE 1.64<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE mill-21<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 223<|>RELATION_NOE 2.51<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-205<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 45.13<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-29a<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 19.98<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-25<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 31<|>RELATION_NOE 3.19<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-126<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 32<|>RELATION_NOE .<|>RELATION_NOE 38<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.叭<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 其中<|>RELATION_NOE miR-29a<|>RELATION_NOE (<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 3.27<|>RELATION_NOE ±<|>RELATION_NOE 2.44<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE 3.19<|>RELATION_NOE ±<|>RELATION_NOE 0.32<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 0.99<|>RELATION_NOE ±<|>RELATION_NOE 2.31<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-25<|>RELATION_NOE (<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 3.88<|>RELATION_NOE ±<|>RELATION_NOE 0.62<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE 3.42<|>RELATION_NOE ±<|>RELATION_NOE 0.51<|>RELATION_NOE ,<|>RELATION_NOE 肺癌组<|>RELATION_NOE 1.79<|>RELATION_NOE ±<|>RELATION_NOE 0.37<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-126<|>RELATION_NOE (<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 3.19<|>RELATION_NOE ±<|>RELATION_NOE 1.77<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE 2.67<|>RELATION_NOE ±<|>RELATION_NOE 1.55<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 0.96<|>RELATION_NOE ±<|>RELATION_NOE 0.84<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 恶性化<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_NOE 下调<|>RELATION_NOE 趋势<|>RELATION_NOE ;<|>RELATION_NOE
当<|>RELATION_NOE 全身<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE 特别<|>RELATION_NOE 是<|>RELATION_NOE 骨转移<|>RELATION_NOE )<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE miR-31<|>RELATION_NOE (<|>RELATION_NOE 无<|>RELATION_NOE 转移<|>RELATION_NOE 1.16<|>RELATION_NOE ±<|>RELATION_NOE 0.40<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 转移<|>RELATION_NOE 1.03<|>RELATION_NOE ±<|>RELATION_NOE 0.24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 下降<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 配对<|>RELATION_NOE PBMC<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE mill-126<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 69<|>RELATION_NOE 0.58<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-129<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 26.66<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-145<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 48.57<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-205<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 30<|>RELATION_NOE 8.61<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE mill-25<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 21<|>RELATION_NOE 8.57<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE miR-31<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 48.05<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 其中<|>RELATION_NOE miR-25<|>RELATION_NOE (<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 6.54<|>RELATION_NOE ±<|>RELATION_NOE 0.63<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE 5.82<|>RELATION_NOE ±<|>RELATION_NOE 0.51<|>RELATION_NOE ,<|>RELATION_NOE 肺癌组<|>RELATION_NOE 3.97<|>RELATION_NOE ±<|>RELATION_NOE 0.55<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE mill-31<|>RELATION_NOE (<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 4.26<|>RELATION_NOE ±<|>RELATION_NOE 0.43<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病组<|>RELATION_NOE 4.08<|>RELATION_NOE ±<|>RELATION_NOE 0.37<|>RELATION_NOE ,<|>RELATION_NOE 肺癌组<|>RELATION_NOE 3.43<|>RELATION_NOE ±<|>RELATION_NOE 0.38<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 恶性化<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_NOE 下调<|>RELATION_NOE 趋势<|>RELATION_NOE ;<|>RELATION_NOE
当<|>RELATION_NOE 全身<|>RELATION_NOE 转移<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE miR-21<|>RELATION_NOE (<|>RELATION_NOE 无<|>RELATION_NOE 转移<|>RELATION_NOE 5.11<|>RELATION_NOE ±<|>RELATION_NOE 0.24<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 转移<|>RELATION_NOE 5.28<|>RELATION_NOE ±<|>RELATION_NOE 0.24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 上升<|>RELATION_NOE ;<|>RELATION_NOE
miRNA<|>RELATION_NOE 可能<|>RELATION_NOE 参与<|>RELATION_NOE 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 多<|>RELATION_NOE 个<|>RELATION_NOE 步骤<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 局部<|>RELATION_NOE 浸润<|>RELATION_NOE 、<|>RELATION_NOE 渗出<|>RELATION_NOE 血管<|>RELATION_NOE 或<|>RELATION_NOE 在<|>RELATION_NOE 远处<|>RELATION_NOE 的<|>RELATION_NOE 初步<|>RELATION_NOE 生存<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 生长<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 也<|>RELATION_NOE 可能<|>RELATION_NOE 影响<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
X<|>RELATION_NOE 线<|>RELATION_NOE 照射<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 后<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 机制<|>RELATION_NOE 探讨<|>RELATION_S
探讨<|>RELATION_S X<|>RELATION_NOE 线<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 存活<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE (<|>RELATION_NOE A549<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S X<|>RELATION_NOE 线<|>RELATION_NOE 照射<|>RELATION_NOE 前后<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE MTT<|>RELATION_NOE 黏附<|>RELATION_NOE 实验<|>RELATION_NOE 、<|>RELATION_NOE Transwell<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 迁移<|>RELATION_NOE 实验<|>RELATION_NOE
照射<|>RELATION_NOE 后<|>RELATION_NOE Vimentin<|>RELATION_NOE 、<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE 、<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 均<|>RELATION_NOE 上调<|>RELATION_NOE (<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 1.37<|>RELATION_NOE 、<|>RELATION_NOE 2.37<|>RELATION_NOE 、<|>RELATION_NOE 1.80<|>RELATION_NOE 、<|>RELATION_NOE 1.50<|>RELATION_NOE 倍<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 也<|>RELATION_NOE 相应<|>RELATION_NOE 上调<|>RELATION_NOE (<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 1.60<|>RELATION_NOE 、<|>RELATION_NOE 1.80<|>RELATION_NOE 、<|>RELATION_NOE 1.<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 1.20<|>RELATION_NOE 倍<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE E-Cadherin<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 则<|>RELATION_NOE 下调<|>RELATION_NOE (<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 59.4%<|>RELATION_NOE 、<|>RELATION_NOE 74.6%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
X<|>RELATION_NOE 线<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE 较<|>RELATION_NOE 照射<|>RELATION_NOE 前<|>RELATION_NOE 明显<|>RELATION_NOE 增强<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 放射<|>RELATION_NOE 诱导<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE 表达<|>RELATION_NOE 进而<|>RELATION_NOE 促进<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 问质化<|>RELATION_NOE 改变<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 还<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 放射<|>RELATION_NOE 诱导<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 表达<|>RELATION_NOE 增强<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 有<|>RELATION_NOE 症状<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 临床<|>RELATION_B 特点<|>RELATION_I 分析<|>RELATION_E
分析<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 发生<|>RELATION_NOE 有<|>RELATION_NOE 症状<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE (<|>RELATION_NOE SRILI<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
SRILI<|>RELATION_NOE 症状<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 咳嗽<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 气短<|>RELATION_NOE (<|>RELATION_NOE 69%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE (<|>RELATION_NOE 48%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 最高<|>RELATION_NOE 体温<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 数<|>RELATION_NOE 38.3<|>RELATION_NOE ℃<|>RELATION_NOE 。<|>RELATION_NOE
SRILI<|>RELATION_NOE 出现<|>RELATION_NOE 在<|>RELATION_NOE 放疗<|>RELATION_NOE 开始<|>RELATION_NOE 后<|>RELATION_NOE 平均<|>RELATION_NOE 8.3<|>RELATION_NOE 周<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 气<|>RELATION_NOE 短<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE 、<|>RELATION_NOE 呼吸音<|>RELATION_NOE 粗糙<|>RELATION_NOE ,<|>RELATION_NOE 放射<|>RELATION_NOE 野内<|>RELATION_NOE 或<|>RELATION_NOE 少数<|>RELATION_NOE 野外<|>RELATION_NOE 实变<|>RELATION_NOE 、<|>RELATION_NOE 斑片<|>RELATION_NOE 、<|>RELATION_NOE 条索影<|>RELATION_NOE ,<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE 比例<|>RELATION_NOE 稍<|>RELATION_NOE 高<|>RELATION_NOE 。<|>RELATION_NOE
局部<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 评价<|>RELATION_S 射波刀<|>RELATION_NOE 治疗<|>RELATION_NOE 外周型<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 局部<|>RELATION_NOE 疗效<|>RELATION_NOE 价值<|>RELATION_NOE
声<|>RELATION_NOE 触诊<|>RELATION_NOE 组织<|>RELATION_NOE 量化<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 肝局<|>RELATION_NOE 灶性<|>RELATION_NOE 小<|>RELATION_NOE 病变<|>RELATION_NOE 定性<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE 初步<|>RELATION_B 研究<|>RELATION_E
初步<|>RELATION_B 探讨<|>RELATION_E 声<|>RELATION_NOE 触诊<|>RELATION_NOE 组织<|>RELATION_NOE 量化<|>RELATION_NOE (<|>RELATION_NOE VTQ<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 肝局<|>RELATION_NOE 灶性<|>RELATION_NOE 小<|>RELATION_NOE 病变<|>RELATION_NOE 定性<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
恶性病灶<|>RELATION_NOE SWV<|>RELATION_NOE 值<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 良性<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.56<|>RELATION_NOE ±<|>RELATION_NOE 0.67<|>RELATION_NOE )<|>RELATION_NOE m<|>RELATION_NOE /<|>RELATION_NOE s<|>RELATION_NOE 对<|>RELATION_NOE (<|>RELATION_NOE 1.70<|>RELATION_NOE ±<|>RELATION_NOE 0.55<|>RELATION_NOE )<|>RELATION_NOE m<|>RELATION_NOE /<|>RELATION_NOE s<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE 性肝<|>RELATION_NOE 癌组<|>RELATION_NOE 中<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 肝转移者<|>RELATION_NOE SWV<|>RELATION_NOE 值<|>RELATION_NOE 高于<|>RELATION_NOE 胃肠道<|>RELATION_NOE 肿瘤<|>RELATION_NOE 肝转移者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 良<|>RELATION_NOE 、<|>RELATION_NOE 恶性病灶<|>RELATION_NOE 的<|>RELATION_NOE 硬度<|>RELATION_NOE 均<|>RELATION_NOE 大于<|>RELATION_NOE 正常<|>RELATION_NOE 肝组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血浆<|>RELATION_NOE 组织因子<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 意义<|>RELATION_E
检测<|>RELATION_S 组织因子<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 高凝<|>RELATION_NOE 状态<|>RELATION_NOE 、<|>RELATION_NOE 血栓栓塞性<|>RELATION_NOE 疾病<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 检测<|>RELATION_S 61<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 14<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 对照者<|>RELATION_NOE 血浆<|>RELATION_NOE 组织因子<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 比较<|>RELATION_NOE 各组<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 。<|>RELATION_NOE
按<|>RELATION_NOE 组织因子<|>RELATION_NOE 水平<|>RELATION_NOE 分为<|>RELATION_NOE 低<|>RELATION_NOE 组织因子组<|>RELATION_NOE (<|>RELATION_NOE 103.73-476.22ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 高<|>RELATION_NOE 组织因子组<|>RELATION_NOE (<|>RELATION_NOE 47<|>RELATION_NOE 6.22<|>RELATION_NOE －<|>RELATION_NOE 1003.00ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 组织因子<|>RELATION_NOE 水平<|>RELATION_NOE 随着<|>RELATION_NOE 肿瘤分期<|>RELATION_NOE 的<|>RELATION_NOE 升高<|>RELATION_NOE 而<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 组织因子<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 有<|>RELATION_B 密切<|>RELATION_I 联系<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE m<|>RELATION_NOE 栓<|>RELATION_NOE 栓塞性<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 及<|>RELATION_NOE 生存率<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 病情<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_NOE 有<|>RELATION_NOE 局限性<|>RELATION_NOE 。<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 组织因子<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 有<|>RELATION_NOE 密切<|>RELATION_NOE 联系<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE m<|>RELATION_NOE 栓<|>RELATION_NOE 栓塞性<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 及<|>RELATION_NOE 生存率<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关<|>RELATION_E ,<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 病情<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_NOE 有<|>RELATION_NOE 局限性<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_S 开<|>RELATION_NOE 胸术<|>RELATION_NOE 后<|>RELATION_NOE 乳糜胸<|>RELATION_NOE 的<|>RELATION_NOE 形成<|>RELATION_NOE 原因<|>RELATION_NOE 、<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 综合治疗<|>RELATION_NOE
术后<|>RELATION_NOE 当天<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 再<|>RELATION_NOE 开<|>RELATION_NOE 胸结<|>RELATION_NOE 扎<|>RELATION_NOE 胸导管<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 2例<|>RELATION_NOE 采用<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 乳糜液<|>RELATION_NOE 漏<|>RELATION_NOE 出<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 次<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 平均<|>RELATION_NOE 住院<|>RELATION_NOE 天<|>RELATION_NOE 数<|>RELATION_NOE 11.0d<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 治疗<|>RELATION_S 胸外科<|>RELATION_NOE 疾病<|>RELATION_NOE 28<|>RELATION_NOE 2例<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
采用<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 技术<|>RELATION_NOE 治疗<|>RELATION_S 胸外科<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 282<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺大<|>RELATION_NOE 疱切<|>RELATION_NOE 除术<|>RELATION_NOE 162<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 外伤性<|>RELATION_NOE 机化<|>RELATION_NOE 性血<|>RELATION_NOE 胸廓<|>RELATION_NOE 清术<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺囊肿<|>RELATION_NOE 切除术<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 脓胸廓<|>RELATION_NOE 清<|>RELATION_NOE 纤维<|>RELATION_NOE 板剥<|>RELATION_NOE 脱术<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 结节性<|>RELATION_NOE 病灶切除术<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 肺楔<|>RELATION_NOE 形<|>RELATION_NOE 切除术<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 自发性<|>RELATION_NOE 血气胸<|>RELATION_NOE 肺<|>RELATION_NOE 大疱<|>RELATION_NOE 切除<|>RELATION_NOE 加<|>RELATION_NOE 止血术<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜肿瘤<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 食管<|>RELATION_NOE 平滑肌瘤<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 异物<|>RELATION_NOE 取出术<|>RELATION_NOE 3例<|>RELATION_NOE 。<|>RELATION_NOE
手术时间<|>RELATION_NOE 30<|>RELATION_NOE －<|>RELATION_NOE 180min<|>RELATION_NOE ,<|>RELATION_NOE 出血量<|>RELATION_NOE 20<|>RELATION_NOE －<|>RELATION_NOE 650ml<|>RELATION_NOE ,<|>RELATION_NOE 胸腔<|>RELATION_NOE 闭式<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 3－<|>RELATION_NOE 16d<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 3.9%<|>RELATION_NOE ,<|>RELATION_NOE 全<|>RELATION_NOE 组<|>RELATION_NOE 无<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 微创<|>RELATION_NOE 手术<|>RELATION_NOE 创伤<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 出血<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 广泛<|>RELATION_NOE 的<|>RELATION_NOE 胸外科<|>RELATION_NOE 适应证<|>RELATION_NOE 。<|>RELATION_NOE
舒适<|>RELATION_NOE 护理<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 围术期<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
围术期<|>RELATION_NOE 舒适<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 能<|>RELATION_NOE 确保<|>RELATION_S 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 顺利<|>RELATION_NOE 完成<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 进而<|>RELATION_NOE 大大<|>RELATION_NOE 提高<|>RELATION_NOE 了<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 获得<|>RELATION_NOE 随访<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 随访期<|>RELATION_NOE 内<|>RELATION_NOE 无<|>RELATION_NOE 1例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 发生<|>RELATION_NOE 多<|>RELATION_NOE 发骨<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 肺转移<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 死亡<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肺转移<|>RELATION_NOE 进展<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 心脏<|>RELATION_NOE 疾病<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 或<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE
观察<|>RELATION_S 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 或<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
PC<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 卡铂<|>RELATION_NOE 按<|>RELATION_NOE 曲线下面积<|>RELATION_NOE (<|>RELATION_NOE AUC<|>RELATION_NOE )<|>RELATION_NOE =<|>RELATION_NOE 5<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 水平<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
GC<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 吉西<|>RELATION_NOE 他滨<|>RELATION_NOE 1000mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 卡铂<|>RELATION_NOE 按<|>RELATION_NOE AUC<|>RELATION_NOE =<|>RELATION_NOE 5<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 水平<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
GC<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE Ⅲ<|>RELATION_NOE -<|>RELATION_NOE Ⅳ<|>RELATION_NOE 级<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板减少<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E PC<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 或<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 相近<|>RELATION_S ,<|>RELATION_NOE 但<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 可能<|>RELATION_NOE 更<|>RELATION_NOE 安全<|>RELATION_NOE 。<|>RELATION_NOE
转录因子<|>RELATION_NOE SOX4<|>RELATION_NOE 在<|>RELATION_NOE 云南<|>RELATION_NOE 宣威<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 和<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
应用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 96<|>RELATION_NOE 例<|>RELATION_NOE 宣威<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE SOX4mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE SOX4<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
SOX4mRNA<|>RELATION_NOE 在<|>RELATION_NOE 宣威<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.53<|>RELATION_NOE ±<|>RELATION_NOE 1.65<|>RELATION_NOE 和<|>RELATION_NOE 1.43<|>RELATION_NOE ±<|>RELATION_NOE 1.14<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.003<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
SOX4<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 以及<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE SOX4<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 以及<|>RELATION_NOE 分期晚<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 较<|>RELATION_NOE 短<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 为<|>RELATION_NOE 影响<|>RELATION_NOE 宣威<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 因素<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
SOX4mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 宣威<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 升高<|>RELATION_E ;<|>RELATION_NOE
SOX4<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 判断<|>RELATION_NOE 宣威<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
Robol<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE sP<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 80<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 和<|>RELATION_NOE 52<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE R0130l<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE
Robol<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 脑转移<|>RELATION_NOE 瘤组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.9%<|>RELATION_NOE (<|>RELATION_NOE 1/52<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 13.8%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 80<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 40.3%<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE /<|>RELATION_NOE 72<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Robol<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 瘤组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 依次<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE Robol<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 瘤中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 脑转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 呈<|>RELATION_B 负<|>RELATION_I 相关<|>RELATION_E 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 血流量<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 微血管<|>RELATION_NOE 超微<|>RELATION_NOE 结构<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_B 初探<|>RELATION_E
初步<|>RELATION_B 探讨<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 血流量<|>RELATION_NOE (<|>RELATION_NOE BF<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 微血管<|>RELATION_NOE 超微<|>RELATION_NOE 结构<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 手术<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE CT<|>RELATION_NOE 灌注<|>RELATION_NOE 检查<|>RELATION_NOE 和<|>RELATION_NOE 病理学<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE BF<|>RELATION_NOE 值<|>RELATION_NOE 将<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 高<|>RELATION_NOE 灌注组<|>RELATION_NOE 和<|>RELATION_NOE 低<|>RELATION_NOE 灌注组<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_S 高<|>RELATION_NOE 灌注组<|>RELATION_NOE 和<|>RELATION_NOE 低<|>RELATION_NOE 灌注组<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 病变<|>RELATION_NOE 微血管<|>RELATION_NOE 超微<|>RELATION_NOE 结构<|>RELATION_NOE 的<|>RELATION_NOE 表现<|>RELATION_NOE 以及<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 灌注组<|>RELATION_NOE 有<|>RELATION_NOE 9例<|>RELATION_NOE (<|>RELATION_NOE 64.3%<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 或<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 高灌<|>RELATION_NOE 注组<|>RELATION_NOE 有<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 28.6%<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 或<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 灌注组<|>RELATION_NOE 和<|>RELATION_NOE 高灌注组<|>RELATION_NOE 转移率<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 28<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 的<|>RELATION_NOE BF<|>RELATION_NOE 值<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 微血管<|>RELATION_NOE 超微<|>RELATION_NOE 结构<|>RELATION_NOE 的<|>RELATION_NOE 异常<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 并<|>RELATION_NOE 有助于<|>RELATION_NOE 评价<|>RELATION_NOE NSCLC<|>RELATION_NOE 发生<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_NOE 。<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE -<|>RELATION_NOE 细胞<|>RELATION_NOE 外<|>RELATION_NOE 信号<|>RELATION_NOE 调节<|>RELATION_NOE 激酶<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 下调<|>RELATION_S 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 微小<|>RELATION_NOE RNA145<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE
分别<|>RELATION_NOE 以<|>RELATION_NOE EGF<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE EGFR<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE AG1478<|>RELATION_NOE 或<|>RELATION_NOE ERK1<|>RELATION_NOE /<|>RELATION_NOE 2抑<|>RELATION_NOE 制剂<|>RELATION_NOE U0126<|>RELATION_NOE 处理<|>RELATION_NOE H1975<|>RELATION_NOE 、<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE BEAS<|>RELATION_NOE ~<|>RELATION_NOE B<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 各<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE miR-145<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_S 胃<|>RELATION_NOE 小细胞癌<|>RELATION_NOE (<|>RELATION_NOE SCC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 其<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 的<|>RELATION_NOE 总体<|>RELATION_NOE 生存期<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 5.5<|>RELATION_NOE 65<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 体重变化<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 3.6<|>RELATION_NOE 88<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 根治<|>RELATION_NOE 程度<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 11.7<|>RELATION_NOE 47<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE 是否<|>RELATION_NOE 复发<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 17.9<|>RELATION_NOE 66<|>RELATION_NOE )<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胃<|>RELATION_NOE SCC<|>RELATION_NOE 是<|>RELATION_NOE 胃恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 罕见<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 误诊率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 病情<|>RELATION_NOE 进展<|>RELATION_NOE 迅速<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 根治性<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 肿瘤<|>RELATION_NOE 可以<|>RELATION_NOE 显著<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 手术<|>RELATION_NOE 为主<|>RELATION_NOE 的<|>RELATION_NOE 综合治疗<|>RELATION_NOE 仍<|>RELATION_NOE 是<|>RELATION_NOE 胃<|>RELATION_NOE SCC<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 治疗<|>RELATION_NOE 手段<|>RELATION_NOE 。<|>RELATION_NOE
Hsa-miR-26a<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 及其<|>RELATION_NOE 在<|>RELATION_NOE 肺发育<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
利用<|>RELATION_NOE miRNA<|>RELATION_NOE 靶标<|>RELATION_NOE 基因<|>RELATION_NOE 数据库<|>RELATION_NOE miRGen2.0<|>RELATION_NOE 进行<|>RELATION_S hsa-miR-26a<|>RELATION_NOE 的<|>RELATION_NOE 靶基因<|>RELATION_NOE 预测<|>RELATION_NOE ,<|>RELATION_NOE 选取<|>RELATION_NOE PicTar<|>RELATION_NOE 和<|>RELATION_NOE TargetScanS<|>RELATION_NOE 的<|>RELATION_NOE 交集<|>RELATION_NOE 并<|>RELATION_NOE 合并<|>RELATION_NOE DIANALAB-TarBase6.0<|>RELATION_NOE 数据库<|>RELATION_NOE 的<|>RELATION_NOE 已<|>RELATION_NOE 验证<|>RELATION_NOE 靶标<|>RELATION_NOE 对<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE
已<|>RELATION_NOE 有<|>RELATION_NOE 研究<|>RELATION_NOE 提示<|>RELATION_NOE hsa-miR-26a<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 器官<|>RELATION_NOE 发育<|>RELATION_NOE 、<|>RELATION_NOE 免疫系统<|>RELATION_NOE 等<|>RELATION_NOE 生物学过程<|>RELATION_NOE 具有<|>RELATION_B 重要<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
miR-26a<|>RELATION_NOE 调控<|>RELATION_NOE 的<|>RELATION_NOE 靶基因<|>RELATION_NOE 生物学<|>RELATION_NOE 功能<|>RELATION_NOE 主要<|>RELATION_NOE 包括<|>RELATION_NOE 转录<|>RELATION_NOE 调控<|>RELATION_NOE 、<|>RELATION_NOE 蛋白质修饰<|>RELATION_NOE 、<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 等<|>RELATION_NOE 基本<|>RELATION_NOE 生物学过程<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE 活性<|>RELATION_NOE 等<|>RELATION_NOE 分子<|>RELATION_NOE 功能<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE 存在<|>RELATION_NOE 于<|>RELATION_NOE 细胞<|>RELATION_NOE 各个<|>RELATION_NOE 组<|>RELATION_NOE 分<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 细胞膜<|>RELATION_NOE 、<|>RELATION_NOE 细胞质<|>RELATION_NOE 、<|>RELATION_NOE 细胞核<|>RELATION_NOE 中<|>RELATION_NOE ;<|>RELATION_NOE
信号<|>RELATION_NOE 转导<|>RELATION_NOE 通路<|>RELATION_NOE 显著<|>RELATION_B 富集<|>RELATION_I 于<|>RELATION_E Wnt<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE ,<|>RELATION_NOE 丝裂原<|>RELATION_NOE 活化<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE ,<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE 一<|>RELATION_NOE B<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE ,<|>RELATION_NOE p53<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE ,<|>RELATION_NOE 细胞周期<|>RELATION_NOE 、<|>RELATION_NOE 黏附<|>RELATION_NOE 功能<|>RELATION_NOE 等<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 以及<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 、<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 、<|>RELATION_NOE 直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 肾癌<|>RELATION_NOE 、<|>RELATION_NOE 神经胶质瘤<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 疾病<|>RELATION_NOE 通路<|>RELATION_NOE 中<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
